_id,compound_id,inchl_key,generic_name,trade_name,orphan_designation,umls_id,parsed_text,designated_date,designation_status,approval_status,approved_labeled_indication,marketing_approval_date,exclusivity_end_date,exclusivity_protected_indication
PIBARDGJJAGJAJ-NQIIRXRSSA-N,118323590,PIBARDGJJAGJAJ-NQIIRXRSSA-N,"(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide",,Treatment of paroxysmal nocturnal hemoglobinuria,C0024790,Paroxysmal nocturnal hemoglobinuria,11/2/17,Designated,Not FDA Approved for Orphan Indication,,,,
CIWBSHSKHKDKBQ-JLAZNSOCSA-N,54670067,CIWBSHSKHKDKBQ-JLAZNSOCSA-N,ascorbic acid,,Treatment of Charcot-Marie-Tooth disease type 1A.,C0270911,Charcot-Marie-Tooth Disease Type 1A,5/11/09,Designated,Not FDA Approved for Orphan Indication,,,,
GJPICJJJRGTNOD-UHFFFAOYSA-N,104865,GJPICJJJRGTNOD-UHFFFAOYSA-N,bosentan,Tracleer,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,10/6/00,Designated/Approved,,Treatment of pulmonary arterial hypertension., 11/20/2001 , 11/20/2008 ,
GJPICJJJRGTNOD-UHFFFAOYSA-N,104865,GJPICJJJRGTNOD-UHFFFAOYSA-N,bosentan,Tracleer,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,10/6/00,Designated/Approved,,"Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability", 09/05/2017 , 09/05/2024 ,"Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability"
VOVIALXJUBGFJZ-KWVAZRHASA-N,5281004,VOVIALXJUBGFJZ-KWVAZRHASA-N,budesonide,,Treatment of patients with eosinophilic esophagitis,C0341106,Eosinophilic esophagitis,12/20/06,Designated,Not FDA Approved for Orphan Indication,,,,
PQAPVTKIEGUPRN-UHFFFAOYSA-N,11455910,PQAPVTKIEGUPRN-UHFFFAOYSA-N,"N-[4-[[2-(1,1-Dimethylethyl)phenyl]sulfonyl]phenyl]-2,3,4-trihydroxy-5-[[2-(1-methylethyl)phenyl]methyl]benzamide",,Treatment of retinoblastoma,C0035335,Retinoblastoma,9/14/20,Designated,Not FDA Approved for Orphan Indication,,,,
CPKVUHPKYQGHMW-UHFFFAOYSA-N,410087,CPKVUHPKYQGHMW-UHFFFAOYSA-N,povidone iodine,,Treatment of endophthalmitis,C0014236,Endophthalmitis,11/27/17,Designated,Not FDA Approved for Orphan Indication,,,,
WRFHGDPIDHPWIQ-UHFFFAOYSA-N,10257882,WRFHGDPIDHPWIQ-UHFFFAOYSA-N,sparsentan,,Treatment of immunoglobulin A (IgA) nephropathy,C0022658,Nephropathy,1/11/21,Designated,Not FDA Approved for Orphan Indication,,,,
GFJCILQBXUTOGN-UHFFFAOYSA-N,15942270,GFJCILQBXUTOGN-UHFFFAOYSA-N,"((4-(3-benzyl-4-hydroxybenzyl)-3,5-dimethylphenoxy)methyl)phosphonic acid",,Treatment of X-linked adrenoleukodystrophy,C0162309,X-Linked Adrenoleukodystrophy,12/5/16,Designated,Not FDA Approved for Orphan Indication,,,,
WEQLWGNDNRARGE-DJIMGWMZSA-N,14580381,WEQLWGNDNRARGE-DJIMGWMZSA-N,(+)-alpha-dihydrotetrabenazine,,Treatment of Huntington's disease.,C0020179,Huntington's Disease,12/5/18,Designated,Not FDA Approved for Orphan Indication,,,,
PFTAWBLQPZVEMU-ZFWWWQNUSA-N,182232,PFTAWBLQPZVEMU-ZFWWWQNUSA-N,(+)-Epicatechin,,Treatment of Duchenne and Becker muscular dystrophy,C3542021,Duchenne and Becker Muscular Dystrophy,4/6/20,Designated,Not FDA Approved for Orphan Indication,,,,
ZFPZEYHRWGMJCV-ZHALLVOQSA-N,9926832,ZFPZEYHRWGMJCV-ZHALLVOQSA-N,"(-)-(3aR,4S,7aR)-4-Hydroxy-4-m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester",,Treatment of Fragile X syndrome,C0016667,Fragile X Syndrome,10/12/11,Designated,Not FDA Approved for Orphan Indication,,,,
ZRJBHWIHUMBLCN-MEBBXXQBSA-N,6565233,ZRJBHWIHUMBLCN-MEBBXXQBSA-N,(-)-huperzine A,,Treatment of Lennox-Gastaut Syndrome,C0238111,Lennox-Gastaut syndrome,6/15/20,Designated,Not FDA Approved for Orphan Indication,,,,
ZRJBHWIHUMBLCN-QDEBKDIKSA-N,5912039,ZRJBHWIHUMBLCN-QDEBKDIKSA-N,(-)-huperzine A,,Treatment of Lennox-Gastaut Syndrome,C0238111,Lennox-Gastaut syndrome,6/15/20,Designated,Not FDA Approved for Orphan Indication,,,,
ZRJBHWIHUMBLCN-HNWKQCISSA-N,71308731,ZRJBHWIHUMBLCN-HNWKQCISSA-N,(-)-huperzine A,,Treatment of Lennox-Gastaut Syndrome,C0238111,Lennox-Gastaut syndrome,6/15/20,Designated,Not FDA Approved for Orphan Indication,,,,
ZRJBHWIHUMBLCN-JYXJEATCSA-N,44461111,ZRJBHWIHUMBLCN-JYXJEATCSA-N,(-)-huperzine A,,Treatment of Lennox-Gastaut Syndrome,C0238111,Lennox-Gastaut syndrome,6/15/20,Designated,Not FDA Approved for Orphan Indication,,,,
ZRJBHWIHUMBLCN-UHFFFAOYSA-N,1253,ZRJBHWIHUMBLCN-UHFFFAOYSA-N,(-)-huperzine A,,Treatment of Lennox-Gastaut Syndrome,C0238111,Lennox-Gastaut syndrome,6/15/20,Designated,Not FDA Approved for Orphan Indication,,,,
ZRJBHWIHUMBLCN-YQEJDHNASA-N,854026,ZRJBHWIHUMBLCN-YQEJDHNASA-N,(-)-huperzine A,,Treatment of Lennox-Gastaut Syndrome,C0238111,Lennox-Gastaut syndrome,6/15/20,Designated,Not FDA Approved for Orphan Indication,,,,
ZRJBHWIHUMBLCN-ZUZCIYMTSA-N,449069,ZRJBHWIHUMBLCN-ZUZCIYMTSA-N,(-)-huperzine A,,Treatment of Lennox-Gastaut Syndrome,C0238111,Lennox-Gastaut syndrome,6/15/20,Designated,Not FDA Approved for Orphan Indication,,,,
ZRJBHWIHUMBLCN-SEQYCRGISA-N,907504,ZRJBHWIHUMBLCN-SEQYCRGISA-N,(-)-huperzine A,,Treatment of Lennox-Gastaut Syndrome,C0238111,Lennox-Gastaut syndrome,6/15/20,Designated,Not FDA Approved for Orphan Indication,,,,
DVZQUMSQEGOYMX-UHFFFAOYSA-N,122540907,DVZQUMSQEGOYMX-UHFFFAOYSA-N,(1-hydroxy-2-oxopiperidin-3-yl)phosphonic acid,,Treatment of Glioblastoma,C0017636,Glioblastoma,8/9/18,Designated,Not FDA Approved for Orphan Indication,,,,
OEBIHOVSAMBXIB-SJKOYZFVSA-N,129103609,OEBIHOVSAMBXIB-SJKOYZFVSA-N,"(13E,14E,22R,6R)-35-fluoro-6-methyl-7-aza-1(5,3)-pyrazolo[1,5-a]pyrimidina-3(3,2)-pyridina-2(1,2)-pyrrolidinacyclooctaphan-8-one",,Treatment of solid tumors with neurotrophic tyrosine receptor kinase (NTRK)-fusion proteins,C0280100,solid tumors,9/24/18,Designated,Not FDA Approved for Orphan Indication,,,,
JQUBXCDDRXAMLF-IXPVHAAZSA-N,16735504,JQUBXCDDRXAMLF-IXPVHAAZSA-N,"(2R,3R,4S)-2-(2-chloro-6-(3-chlorobenzylamino)-9H-purin-9-yl)tetrahydrothiophene-3,4-diol",,Treatment of Primary Biliary Cholangitis,C0008312,Primary Biliary Cholangitis,2/1/21,Designated,Not FDA Approved for Orphan Indication,,,,
UFPFGVNKHCLJJO-SSKFGXFMSA-N,24737642,UFPFGVNKHCLJJO-SSKFGXFMSA-N,"(2S)-N-[(1S)-1-cyclohexyl-2-[(2S)-2-[4-(4-fluorobenzoyl)-1,3-thiazol-2-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide",,Treatment of multiple myeloma,C0026764,Multiple Myeloma,6/28/17,Designated,Not FDA Approved for Orphan Indication,,,,
HCZQIIVHWYFIPW-UKKRHICBSA-N,9859470,HCZQIIVHWYFIPW-UKKRHICBSA-N,"(2S,3R,4R,5S)-2-(hydroxymethyl)-1-pentylpiperidine-3,4,5-triol",,Treatment of GM2 gangliosidosis,C0268274,GM2 Gangliosidosis,8/1/19,Designated,Not FDA Approved for Orphan Indication,,,,
PIBARDGJJAGJAJ-NQIIRXRSSA-N,118323590,PIBARDGJJAGJAJ-NQIIRXRSSA-N,"(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide",,Treatment of C3 glomerulopathy (C3G),C4521256,Glomerulopathy,12/14/17,Designated,Not FDA Approved for Orphan Indication,,,,
PDWGVXJIDIRQME-DCNFBYMVSA-N,71812122,PDWGVXJIDIRQME-DCNFBYMVSA-N,"(3R,3aS,9R,9aS,9bS)-3-((dimethylamino)methyl)-9-hydroxy-6,9-dimethyl-3,3a,4,5,7,8,9,9a-octahydroazuleno[4,5-b]furan-2(9bH)-one fumarate",,Treatment of glioblastoma multiforme,C0017636,Glioblastoma multiforme,11/8/17,Designated,Not FDA Approved for Orphan Indication,,,,
HWSLMIXAPNOWGU-AWEZNQCLSA-N,22869857,HWSLMIXAPNOWGU-AWEZNQCLSA-N,"(3S)-(+)-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indol-2-one",,Treatment of Fragile X Syndrome.,C0016667,Fragile X Syndrome,12/9/15,Designated,Not FDA Approved for Orphan Indication,,,,
UOKSXAOZBSWROR-DOELHFPHSA-N,146048056,UOKSXAOZBSWROR-DOELHFPHSA-N,(E)-N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)oct-2-enediamide phosphate,,Treatment of Pancreatic cancer,C0235974,PANCREATIC CANCER,8/26/19,Designated,Not FDA Approved for Orphan Indication,,,,
XDAOLTSRNUSPPH-XMMPIXPASA-N,6480466,XDAOLTSRNUSPPH-XMMPIXPASA-N,"(R)-2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazole",,Treatment of pulmonary tuberculosis.,C0041327,Pulmonary tuberculosis,7/12/07,Designated,Not FDA Approved for Orphan Indication,,,,
OLDWOVJAXRWCGT-FBHGDYMESA-N,124081779,OLDWOVJAXRWCGT-FBHGDYMESA-N,"(R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine dihydrochloride",,Treatment of cholangiocarcinoma.,C0206698,Cholangiocarcinoma,11/19/15,Designated,Not FDA Approved for Orphan Indication,,,,
GFVBDLIBPSGFDL-ZOWNYOTGSA-N,131801108,GFVBDLIBPSGFDL-ZOWNYOTGSA-N,(R)-Azasetron besylate,,Prevention of platinum-induced ototoxicity in pediatric patients,C0235280,Ototoxicity,8/16/17,Designated,Not FDA Approved for Orphan Indication,,,,
SJHNWSAWWOAWJH-MRXNPFEDSA-N,118224491,SJHNWSAWWOAWJH-MRXNPFEDSA-N,"(R)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide",,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,4/5/21,Designated,Not FDA Approved for Orphan Indication,,,,
FSVJFNAIGNNGKK-KRWDZBQOSA-N,445900,FSVJFNAIGNNGKK-KRWDZBQOSA-N,(R)-praziquantel,,Treatment of schistosomiasis,C0036323,Schistosomiasis,6/27/17,Designated,Not FDA Approved for Orphan Indication,,,,
KXMZDGSRSGHMMK-VWLOTQADSA-N,46215462,KXMZDGSRSGHMMK-VWLOTQADSA-N,"(S)-1-(6,7-Dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)-1H-1,2,4-triazole-3,5-diamine",,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,11/5/14,Designated,Not FDA Approved for Orphan Indication,,,,
QUMWKKVIZAIAHU-LBPRGKRZSA-N,70675172,QUMWKKVIZAIAHU-LBPRGKRZSA-N,"(S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile",,Treatment of pemphigus vulgaris,C0030809,Pemphigus Vulgaris,1/26/15,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
HVFWCHDZDIRYBZ-MQZJHDQISA-N,72710874,HVFWCHDZDIRYBZ-MQZJHDQISA-N,"(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride",,Treatment of inherited mitochondrial respiratory chain diseases,C1325653,mitochondrial respiratory chain,11/17/14,Designated,Not FDA Approved for Orphan Indication,,,,
RSIWALKZYXPAGW-NSHDSACASA-N,58111426,RSIWALKZYXPAGW-NSHDSACASA-N,"(S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one",,Treatment of Hodgkin lymphoma,C0019829,Hodgkin Lymphoma,4/29/15,Designated,Not FDA Approved for Orphan Indication,,,,
MGTLGARADRIKNV-GFCCVEGCSA-N,56846912,MGTLGARADRIKNV-GFCCVEGCSA-N,(s)-perillyl alcohol temozolomide carbamate,,Treatment of intracranially located metastases from breast cancer,"C0027627,C0678222","Metastases , Breast cancer",2/28/17,Designated,Not FDA Approved for Orphan Indication,,,,
MGTLGARADRIKNV-GFCCVEGCSA-N,56846912,MGTLGARADRIKNV-GFCCVEGCSA-N,(s)-perillyl alcohol temozolomide carbamate,,Treatment of nasopharyngeal carcinoma,C2931822,Nasopharyngeal carcinoma,7/27/17,Designated,Not FDA Approved for Orphan Indication,,,,
NEBUOXBYNAHKFV-UHFFFAOYSA-N,51357549,NEBUOXBYNAHKFV-UHFFFAOYSA-N,"1'-{[5-(trifluoromethyl)-2-furyl]methyl}spiro[furo[2,3-f][1,3]benzodioxole-7,3'-indol]-2'(1'H)-one",,Treatment of erythromelalgia,C0014804,Erythromelalgia,11/19/12,Designated,Not FDA Approved for Orphan Indication,,,,
AAFJXZWCNVJTMK-GUCUJZIJSA-N,15942827,AAFJXZWCNVJTMK-GUCUJZIJSA-N,"1,2:5,6-dianhydrogalactitol",,Treatment of ovarian cancer.,C4721610,Ovarian Cancer,4/19/16,Designated,Not FDA Approved for Orphan Indication,,,,
AAFJXZWCNVJTMK-GUCUJZIJSA-N,15942827,AAFJXZWCNVJTMK-GUCUJZIJSA-N,"1,2:5,6-dianhydrogalactitol",,Treatment of medulloblastoma.,C0025149,Medulloblastoma,3/10/16,Designated,Not FDA Approved for Orphan Indication,,,,
SKDNPCDRIUQGAL-XTJCVSPVSA-N,89584363,SKDNPCDRIUQGAL-XTJCVSPVSA-N,"1-(((Z)-hexadec-1-en-1-yl)oxy)-3-((2-oxido-1,3,2-oxazaphospholidin-2-yl)oxy)propan-2-yl (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate",,Treatment of Rhizomelic Chondrodysplasia Punctata,C0282529,Rhizomelic chondrodysplasia punctata,8/8/19,Designated,Not FDA Approved for Orphan Indication,,,,
TZOWVYPYWJLZTK-IMTBSYHQSA-N,57524523,TZOWVYPYWJLZTK-IMTBSYHQSA-N,1-(2-chlorophenyl)-1-(S)-hydroxy-2-(S)-carbamoyloxy-propane,,Treatment of infantile spasms,C3887898,Infantile spasms,3/20/17,Designated,Not FDA Approved for Orphan Indication,,,,
TZOWVYPYWJLZTK-IMTBSYHQSA-N,57524523,TZOWVYPYWJLZTK-IMTBSYHQSA-N,1-(2-chlorophenyl)-1-(S)-hydroxy-2-(S)-carbamoyloxy-propane,,Treatment of status epilepticus,C0038220,Status Epilepticus,7/7/16,Designated,Not FDA Approved for Orphan Indication,,,,
RDALZZCKQFLGJP-UHFFFAOYSA-N,73051434,RDALZZCKQFLGJP-UHFFFAOYSA-N,"1-(4-(benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide",,Treatment of multiple myeloma,C0026764,Multiple Myeloma,7/8/15,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
VCPMZDWBEWTGNW-UHFFFAOYSA-N,4988454,VCPMZDWBEWTGNW-UHFFFAOYSA-N,"1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one",,Management of postherpetic neuralgia,C0032768,Postherpetic neuralgia,9/26/13,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
OQDQIFQRNZIEEJ-UHFFFAOYSA-N,68677842,OQDQIFQRNZIEEJ-UHFFFAOYSA-N,1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid,,Treatment of systemic sclerosis,C0036421,Systemic sclerosis,3/31/15,Designated,Not FDA Approved for Orphan Indication,,,,
LOLPPWBBNUVNQZ-UHFFFAOYSA-N,135398495,LOLPPWBBNUVNQZ-UHFFFAOYSA-N,1-Cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,11/12/09,Designated,Not FDA Approved for Orphan Indication,,,,
ZOAIEFWMQLYMTF-PEHXSSJGSA-N,11570943,ZOAIEFWMQLYMTF-PEHXSSJGSA-N,18-(p-[124I]-iodophenyl)octadecyl phosphocholine,,Diagnostic for the management of glioma,C0017638,Glioma,4/30/14,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
AUFUWRKPQLGTGF-QRMSVCKNSA-N,60004399,AUFUWRKPQLGTGF-QRMSVCKNSA-N,"2',3',5'-tri-o-acetyluridine",,Treatment of mitochondrial disease,C0751651,Mitochondrial disease,1/13/03,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
AUFUWRKPQLGTGF-ZRJCITRHSA-N,6547277,AUFUWRKPQLGTGF-ZRJCITRHSA-N,"2',3',5'-tri-o-acetyluridine",,Treatment of mitochondrial disease,C0751651,Mitochondrial disease,1/13/03,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
AUFUWRKPQLGTGF-ZZVYKPCYSA-N,990800,AUFUWRKPQLGTGF-ZZVYKPCYSA-N,"2',3',5'-tri-o-acetyluridine",,Treatment of mitochondrial disease,C0751651,Mitochondrial disease,1/13/03,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
AUFUWRKPQLGTGF-RWDKGTSBSA-N,44629990,AUFUWRKPQLGTGF-RWDKGTSBSA-N,"2',3',5'-tri-o-acetyluridine",,Treatment of mitochondrial disease,C0751651,Mitochondrial disease,1/13/03,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
AUFUWRKPQLGTGF-UHFFFAOYSA-N,254731,AUFUWRKPQLGTGF-UHFFFAOYSA-N,"2',3',5'-tri-o-acetyluridine",,Treatment of mitochondrial disease,C0751651,Mitochondrial disease,1/13/03,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
AUFUWRKPQLGTGF-FMKGYKFTSA-N,20058,AUFUWRKPQLGTGF-FMKGYKFTSA-N,"2',3',5'-tri-o-acetyluridine",,Treatment of mitochondrial disease,C0751651,Mitochondrial disease,1/13/03,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
CKTSBUTUHBMZGZ-SHYZEUOFSA-N,13711,CKTSBUTUHBMZGZ-SHYZEUOFSA-N,2'-deoxycytidine,,As a host-protective agent in the treatment of acute myelogenous leukemia.,C0023467,Acute myelogenous leukemia,9/9/96,Designated,Not FDA Approved for Orphan Indication,,,,
VUAXHMVRKOTJKP-UHFFFAOYSA-N,11684,VUAXHMVRKOTJKP-UHFFFAOYSA-N,"2,2-dimethylbutanoic acid",,Treatment of propionic acidemia,C0268579,Propionic acidemia,12/10/20,Designated,Not FDA Approved for Orphan Indication,,,,
VUAXHMVRKOTJKP-UHFFFAOYSA-N,11684,VUAXHMVRKOTJKP-UHFFFAOYSA-N,"2,2-dimethylbutanoic acid",,Treatment of methylmalonic acidemia,C0268583,Methylmalonic acidemia,12/10/20,Designated,Not FDA Approved for Orphan Indication,,,,
UFBJCMHMOXMLKC-UHFFFAOYSA-N,1493,UFBJCMHMOXMLKC-UHFFFAOYSA-N,"2,4 dinitrophenol",,Treatment of Amyotrophic Lateral Sclerosis,C0002736,Amyotrophic Lateral Sclerosis,9/8/20,Designated,Not FDA Approved for Orphan Indication,,,,
UFBJCMHMOXMLKC-UHFFFAOYSA-N,1493,UFBJCMHMOXMLKC-UHFFFAOYSA-N,"2,4-dinitrophenol",,Treatment of Huntington disease,C0020179,Huntington Disease,2/11/19,Designated,Not FDA Approved for Orphan Indication,,,,
OMPATGZMNFWVOH-UHFFFAOYSA-N,24986824,OMPATGZMNFWVOH-UHFFFAOYSA-N,"2-(3,5-difluoro-3'-methoxybiphenyl-4-ylamino)nicotinic acid",,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,8/16/18,Designated,Not FDA Approved for Orphan Indication,,,,
XLXXBYJYWULGGD-UHFFFAOYSA-N,69619483,XLXXBYJYWULGGD-UHFFFAOYSA-N,"2-(4-(2,4-dichlorophenethyl)-3,6-dioxo-1-(2-(thiophen-2-yl)ethyl)piperazin-2-yl)-N-(2-(5-methoxy-1H-indol-3-yl)ethyl) acetamide",,Prevention of platinum-induced ototoxicity in pediatric patients,C0235280,Ototoxicity,12/14/17,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ORQGHAJIWGGFJK-UHFFFAOYSA-N,132260161,ORQGHAJIWGGFJK-UHFFFAOYSA-N,"2-(4-oxo-3-((5-(trifluoromethyl)benzo[d]thiazol-2-yl)methyl)-3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid",,Treatment of Galactosemia,C0016952,Galactosemia,5/23/19,Designated,Not FDA Approved for Orphan Indication,,,,
ORQGHAJIWGGFJK-UHFFFAOYSA-N,132260161,ORQGHAJIWGGFJK-UHFFFAOYSA-N,"2-(4-oxo-3-((5-(trifluoromethyl)benzo[d]thiazol-2-yl)methyl)-3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid",,Treatment of phosphomannomutase 2 deficiency,C0349653,Phosphomannomutase 2 deficiency,9/21/20,Designated,Not FDA Approved for Orphan Indication,,,,
XRPSUWYWZUQALB-UHFFFAOYSA-N,86298861,XRPSUWYWZUQALB-UHFFFAOYSA-N,2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo[d]oxazol-6-yl)acetamide,,Treatment of cystic fibrosis,C0010674,Cystic Fibrosis,5/13/15,Designated,Not FDA Approved for Orphan Indication,,,,
HYHJFNXFVPGMBI-UHFFFAOYSA-N,100773,HYHJFNXFVPGMBI-UHFFFAOYSA-N,2-chloroethyl-3-sarcosinamide-1-nitrosourea,,Treatment for malignant gliomas,C0555198,malignant gliomas,8/3/01,Designated,Not FDA Approved for Orphan Indication,,,,
HYHJFNXFVPGMBI-UHFFFAOYSA-N,100773,HYHJFNXFVPGMBI-UHFFFAOYSA-N,2-chloroethyl-3-sarcosinamide-1-nitrosourea,,Treatment for malignant glioma,C0555198,Malignant Glioma,11/15/01,Designated,Not FDA Approved for Orphan Indication,,,,
GOWDQYRMBCOOJR-JHMJKTBASA-M,145711124,GOWDQYRMBCOOJR-JHMJKTBASA-M,"2-hydroxy-N,N,N-trimethylethan-1-aminium (Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoate",,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,9/11/19,Designated,Not FDA Approved for Orphan Indication,,,,
WWVANQJRLPIHNS-ZKWXMUAHSA-N,128878,WWVANQJRLPIHNS-ZKWXMUAHSA-N,2-iminobiotin,,Treatment of perinatal asphyxia.,C0559477,Perinatal asphyxia,2/24/09,Designated,Not FDA Approved for Orphan Indication,,,,
AJFWITSBVLLDCC-UHFFFAOYSA-N,91820639,AJFWITSBVLLDCC-UHFFFAOYSA-N,"2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione",,Treatment of inherited mitochondrial respiratory chain disease,"C0012634,C1325653","Disease , mitochondrial respiratory chain",4/16/18,Designated,Not FDA Approved for Orphan Indication,,,,
CQOQDQWUFQDJMK-SSTWWWIQSA-N,66414,CQOQDQWUFQDJMK-SSTWWWIQSA-N,2-methoxyestradiol,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,4/4/05,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
CQOQDQWUFQDJMK-SSTWWWIQSA-N,66414,CQOQDQWUFQDJMK-SSTWWWIQSA-N,2-methoxyestradiol,,Treatment of multiforme glioblastoma,C0017636,Glioblastoma,6/16/06,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
CQOQDQWUFQDJMK-SSTWWWIQSA-N,66414,CQOQDQWUFQDJMK-SSTWWWIQSA-N,2-methoxyestradiol,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,7/10/01,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
CQOQDQWUFQDJMK-SSTWWWIQSA-N,66414,CQOQDQWUFQDJMK-SSTWWWIQSA-N,2-methoxyestradiol,,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,4/11/05,Designated,Not FDA Approved for Orphan Indication,,,,
WTPZYIZNHQOCOQ-VQIWEWKSSA-N,78324948,WTPZYIZNHQOCOQ-VQIWEWKSSA-N,2-{4-[(9R)-9-Hydroxy-2-(3-hydroxy-3-methylbutyloxy)-9-(trifluoromethyl)-9H-fluoren-4-yl]-1H-pyrazol-1-yl}-2-methylpropanamide monohydrate,,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,1/23/18,Designated,Not FDA Approved for Orphan Indication,,,,
NKDFYOWSKOHCCO-YPVLXUMRSA-N,5459840,NKDFYOWSKOHCCO-YPVLXUMRSA-N,20-hydroxyecdysone,,Treatment of Duchenne Muscular Dystrophy,C0013264,DUCHENNE MUSCULAR DYSTROPHY,5/10/18,Designated,Not FDA Approved for Orphan Indication,,,,
FCKJYANJHNLEEP-SRLFHJKTSA-N,6434253,FCKJYANJHNLEEP-SRLFHJKTSA-N,"24,25 dihydroxycholecalciferol",,Treatment of uremic osteodystrophy.,C0543799,uremic osteodystrophy,2/27/87,Designated,Not FDA Approved for Orphan Indication,,,,
XMAYWYJOQHXEEK-ZEQKJWHPSA-N,47576,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,"2S,4R ketoconazole",,Treatment of endogenous Cushing's syndrome,C0010481,Cushing's Syndrome,3/9/12,Designated,Not FDA Approved for Orphan Indication,,,,
OYTKINVCDFNREN-UHFFFAOYSA-N,5918,OYTKINVCDFNREN-UHFFFAOYSA-N,"3,4-diaminopyridine",,Treatment of congenital myasthenic syndrome (CMS),C0751882,congenital myasthenic syndrome,3/30/17,Designated,Not FDA Approved for Orphan Indication,,,,
WONYMNWUJVKVII-UHFFFAOYSA-N,160565,WONYMNWUJVKVII-UHFFFAOYSA-N,"3,5-diiodothyropropionic acid",,Treatment of monocarboxylate transporter (MCT) 8 deficiency (Allan-Herndon-Dudley syndrome),C0795889,Allan-Herndon-Dudley syndrome,7/28/20,Designated,Not FDA Approved for Orphan Indication,,,,
WONYMNWUJVKVII-UHFFFAOYSA-N,160565,WONYMNWUJVKVII-UHFFFAOYSA-N,"3,5-diiodothyropropionic acid",,Treatment of Allan-Herndon-Dudley syndrome,C0795889,Allan-Herndon-Dudley syndrome,5/14/13,Designated,Not FDA Approved for Orphan Indication,,,,
LOMMPXLFBTZENJ-ZACQAIPSSA-N,117947097,LOMMPXLFBTZENJ-ZACQAIPSSA-N,"3-(((1S,2S,3R)-2,3-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile",,Treatment of von Hippel-Lindau disease,C0019562,von Hippel-Lindau Disease,6/24/20,Designated,Not FDA Approved for Orphan Indication,,,,
IWMJORKECAFMRX-USANWJRDSA-N,137254226,IWMJORKECAFMRX-USANWJRDSA-N,3-(1-butyloxy)ethyl-3-deacetyl-bacteriopurpurin-18-N-butylimide methyl ester,,Treatment of glioma,C0017638,Glioma,12/6/17,Designated,Not FDA Approved for Orphan Indication,,,,
BVJRNKXVSYLNFD-UHFFFAOYSA-N,60199173,BVJRNKXVSYLNFD-UHFFFAOYSA-N,"3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride",,Treatment of diffuse large B-cell lymphoma,C1332201,Diffuse Large B-Cell Lymphoma,9/19/16,Designated,Not FDA Approved for Orphan Indication,,,,
BVJRNKXVSYLNFD-UHFFFAOYSA-N,60199173,BVJRNKXVSYLNFD-UHFFFAOYSA-N,"3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride",,Treatment of hepatocellular carcinoma (HCC),C2239176,HEPATOCELLULAR CARCINOMA,7/3/17,Designated,Not FDA Approved for Orphan Indication,,,,
XMYKNCNAZKMVQN-WCIBSUBMSA-N,5468049,XMYKNCNAZKMVQN-WCIBSUBMSA-N,3-aminopyridine-2-carboxaldehyde thiosemicarbazone,,Treatment of stage 1B to IV cervical cancer,C4048328,cervical cancer,11/8/17,Designated,Not FDA Approved for Orphan Indication,,,,
XMYKNCNAZKMVQN-UHFFFAOYSA-N,3006315,XMYKNCNAZKMVQN-UHFFFAOYSA-N,3-aminopyridine-2-carboxaldehyde thiosemicarbazone,,Treatment of stage 1B to IV cervical cancer,C4048328,cervical cancer,11/8/17,Designated,Not FDA Approved for Orphan Indication,,,,
XMYKNCNAZKMVQN-NYYWCZLTSA-N,9571836,XMYKNCNAZKMVQN-NYYWCZLTSA-N,3-aminopyridine-2-carboxaldehyde thiosemicarbazone,,Treatment of stage 1B to IV cervical cancer,C4048328,cervical cancer,11/8/17,Designated,Not FDA Approved for Orphan Indication,,,,
PRRZDZJYSJLDBS-UHFFFAOYSA-N,70684,PRRZDZJYSJLDBS-UHFFFAOYSA-N,3-bromo-2-oxopropanoic acid,,Treatment of stage IIb-IV melanoma,C0025202,melanoma,5/1/20,Designated,Not FDA Approved for Orphan Indication,,,,
PRRZDZJYSJLDBS-UHFFFAOYSA-M,6994776,PRRZDZJYSJLDBS-UHFFFAOYSA-M,3-bromopyruvate,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,4/29/14,Designated,Not FDA Approved for Orphan Indication,,,,
PRRZDZJYSJLDBS-UHFFFAOYSA-M,6994776,PRRZDZJYSJLDBS-UHFFFAOYSA-M,3-bromopyruvate,,Treatment of liver and intrahepatic bile duct cancer,C0279000,Liver and Intrahepatic Bile Duct Cancer,3/5/13,Designated,Not FDA Approved for Orphan Indication,,,,
CNSJWSLXKSJQFE-UHFFFAOYSA-M,46944243,CNSJWSLXKSJQFE-UHFFFAOYSA-M,3-pentylbenzenacetic acid sodium salt,,Treatment of idiopathic pulmonary fibrosis.,C1800706,Idiopathic Pulmonary Fibrosis,2/11/15,Designated,Not FDA Approved for Orphan Indication,,,,
ZXRVKCBLGJOCEE-UHFFFAOYSA-N,3448,ZXRVKCBLGJOCEE-UHFFFAOYSA-N,"4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol",,Treatment of Angelman syndrome.,C0162635,Angelman Syndrome,9/6/16,Designated,Not FDA Approved for Orphan Indication,,,,
MUDCDMMNYVJLEB-UHFFFAOYSA-N,9871944,MUDCDMMNYVJLEB-UHFFFAOYSA-N,"4,5-dibromorhodamine 123",,Treatment of chronic myelogenous leukemia,C0023473,Chronic myelogenous leukemia,4/10/03,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
WCXAUCDLLSWGQS-UHFFFAOYSA-N,126485502,WCXAUCDLLSWGQS-UHFFFAOYSA-N,"4-(((3-chloro-1,4-dioxo-1,4 dihydronaphthalen-2-yl)amino)methyl)-N-(pyridine-3-yl)benzamide",,Treatment of Multiple Myeloma,C0026764,Multiple Myeloma,2/28/19,Designated,Not FDA Approved for Orphan Indication,,,,
RMGPNQKZEPTAOC-QMMMGPOBSA-N,54274194,RMGPNQKZEPTAOC-QMMMGPOBSA-N,4-((L-valyl)oxy)butanoic acid,,Treatment of Narcolepsy,C0027404,Narcolepsy,6/12/19,Designated,Not FDA Approved for Orphan Indication,,,,
LQBVNQSMGBZMKD-UHFFFAOYSA-N,49846579,LQBVNQSMGBZMKD-UHFFFAOYSA-N,"4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide",,Treatment of diffuse large B-cell lymphoma.,C1332201,Diffuse Large B-Cell Lymphoma,3/27/14,Designated,Not FDA Approved for Orphan Indication,,,,
NUKYPUAOHBNCPY-UHFFFAOYSA-N,1727,NUKYPUAOHBNCPY-UHFFFAOYSA-N,4-Aminopyridine,,Treatment chronic functional motor and sensory deficits from Guillain-Barre syndrome,C0018378,Guillain-Barre Syndrome,12/14/05,Designated,Not FDA Approved for Orphan Indication,,,,
WUBBRNOQWQTFEX-UHFFFAOYSA-N,4649,WUBBRNOQWQTFEX-UHFFFAOYSA-N,4-aminosalicylic acid,,Treatment of mild to moderate ulcerative colitis in patients intolerant to sulfasalazine.,C0009324,Ulcerative Colitis,12/13/89,Designated,Not FDA Approved for Orphan Indication,,,,
WUBBRNOQWQTFEX-UHFFFAOYSA-N,4649,WUBBRNOQWQTFEX-UHFFFAOYSA-N,4-aminosalicylic acid,,Treatment of acute flares in pediatric patients with ileo-cecal Crohn's disease,C0010346,Crohn's Disease,4/26/06,Designated,Not FDA Approved for Orphan Indication,,,,
ZJUUIXYKTPSIOH-LEZJFEBPSA-N,16126905,ZJUUIXYKTPSIOH-LEZJFEBPSA-N,4-demethyl-4-cholesteryloxycarbonylpenclomedine,,Treatment of non-small cell lung cancer with CNS metastases,"C0686377,C3539721","CNS metastases , Non-Small Cell Lung Cancer",9/19/17,Designated,Not FDA Approved for Orphan Indication,,,,
HSHNITRMYYLLCV-UHFFFAOYSA-N,5280567,HSHNITRMYYLLCV-UHFFFAOYSA-N,4-Methylumbelliferone,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,3/13/20,Designated,Not FDA Approved for Orphan Indication,,,,
HSHNITRMYYLLCV-UHFFFAOYSA-N,5280567,HSHNITRMYYLLCV-UHFFFAOYSA-N,4-Methylumbelliferone,,Treatment of Esophageal Carcinoma,C0152018,Esophageal carcinoma,4/20/20,Designated,Not FDA Approved for Orphan Indication,,,,
HSHNITRMYYLLCV-UHFFFAOYSA-N,5280567,HSHNITRMYYLLCV-UHFFFAOYSA-N,4-Methylumbelliferone,,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,3/30/20,Designated,Not FDA Approved for Orphan Indication,,,,
XAKLYHGHEFMDAP-UNMCSNQZSA-N,57887037,XAKLYHGHEFMDAP-UNMCSNQZSA-N,5(S)-(2'-hydroxy ethoxy)-20(S)-Camptothecin,,Treatment of osteosarcoma (bone cancer),C0279530,Bone Cancer,6/15/07,Designated,Not FDA Approved for Orphan Indication,,,,
JYHHQTRVJFMEGR-UHFFFAOYSA-N,57411069,JYHHQTRVJFMEGR-UHFFFAOYSA-N,"5,5-dimethyl-3-[2-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione",,Treatment of fragile X syndrome,C0016667,Fragile X Syndrome,6/12/17,Designated,Not FDA Approved for Orphan Indication,,,,
LJIRBXZDQGQUOO-KVTDHHQDSA-N,99681,LJIRBXZDQGQUOO-KVTDHHQDSA-N,"5,6-dihydro-5-azacytidine",,Treatment of malignant mesothelioma.,C0345967,Malignant mesothelioma,5/11/92,Designated,Not FDA Approved for Orphan Indication,,,,
FVWAMONNJGNNHY-UHFFFAOYSA-N,44472513,FVWAMONNJGNNHY-UHFFFAOYSA-N,"5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine hydrochloride",,Treatment of progressive supranuclear palsy.,C0038868,Progressive supranuclear palsy,4/18/11,Designated,Not FDA Approved for Orphan Indication,,,,
STWVLEKJQQRGMO-GUYCJALGSA-N,126642132,STWVLEKJQQRGMO-GUYCJALGSA-N,"5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1H-1,2,4-triazol-3-amine",,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,2/25/19,Designated,Not FDA Approved for Orphan Indication,,,,
STWVLEKJQQRGMO-GUYCJALGSA-N,126642132,STWVLEKJQQRGMO-GUYCJALGSA-N,"5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1H-1,2,4-triazol-3-amine",,Treatment of sarcoidosis,C0036202,Sarcoidosis,1/14/20,Designated,Not FDA Approved for Orphan Indication,,,,
ZGXJTSGNIOSYLO-UHFFFAOYSA-N,137,ZGXJTSGNIOSYLO-UHFFFAOYSA-N,5-aminolevulinic acid,Gleolan,Visualization of malignant tissue during surgery for malignant glioma (WHO grades III and IV),C0555198,Malignant Glioma,1/15/13,Designated/Approved,,Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery, 06/06/2017 , 06/06/2024 ,Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery
ZGXJTSGNIOSYLO-UHFFFAOYSA-N,137,ZGXJTSGNIOSYLO-UHFFFAOYSA-N,5-aminolevulinic acid,,Diagnostic for the visualization of tumor tissue in patients undergoing surgical resection for meningioma,C0025286,Meningioma,11/12/20,Designated,Not FDA Approved for Orphan Indication,,,,
ZGXJTSGNIOSYLO-UHFFFAOYSA-N,137,ZGXJTSGNIOSYLO-UHFFFAOYSA-N,5-Aminolevulinic Acid,,Treatment of malignant glioma,C0555198,Malignant Glioma,3/29/21,Designated,Not FDA Approved for Orphan Indication,,,,
XAUDJQYHKZQPEU-KVQBGUIXSA-N,451668,XAUDJQYHKZQPEU-KVQBGUIXSA-N,5-aza-2'-deoxycytidine,,Treatment of acute leukemia.,C0085669,Acute leukemia,8/3/87,Designated,Not FDA Approved for Orphan Indication,,,,
NOEGNKMFWQHSLB-UHFFFAOYSA-N,237332,NOEGNKMFWQHSLB-UHFFFAOYSA-N,5-hydroxymethyl-2-furfuraldehyde,,Treatment of sickle cell disease,C0002895,Sickle Cell Disease,5/26/06,Designated,Not FDA Approved for Orphan Indication,,,,
XIJXHOVKJAXCGJ-UHFFFAOYSA-N,14326905,XIJXHOVKJAXCGJ-UHFFFAOYSA-N,5-iodo-2-pyrimidinone-2'-deoxyribose,,Treatment of malginant glioma,C0017638,Glioma,5/26/06,Designated,Not FDA Approved for Orphan Indication,,,,
XIJXHOVKJAXCGJ-XLPZGREQSA-N,9840777,XIJXHOVKJAXCGJ-XLPZGREQSA-N,5-iodo-2-pyrimidinone-2'-deoxyribose,,Treatment of malginant glioma,C0017638,Glioma,5/26/06,Designated,Not FDA Approved for Orphan Indication,,,,
YGCADXGQGUPFOA-UHFFFAOYSA-N,154925881,YGCADXGQGUPFOA-UHFFFAOYSA-N,5-methyl cromolyn,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,9/23/20,Designated,Not FDA Approved for Orphan Indication,,,,
BOIAUNVCOPGNOT-STOTURBNSA-N,71461381,BOIAUNVCOPGNOT-STOTURBNSA-N,"6'-(R)-Methyl-5-O-(5-amino-5,6-dideoxy-a-L-talofuranosyl)- paromamine sulfate",,Treatment of Rett syndrome,C0035372,Rett Syndrome,11/3/16,Designated,Not FDA Approved for Orphan Indication,,,,
ZYRLHJIMTROTBO-UHFFFAOYSA-N,24770514,ZYRLHJIMTROTBO-UHFFFAOYSA-N,"6,8-bis(benzylthio)octanoic acid",,Treatment of Peripheral T-cell Lymphoma (PTCL),C0079774,Peripheral T-Cell Lymphoma,2/28/18,Designated,Not FDA Approved for Orphan Indication,,,,
ZYRLHJIMTROTBO-UHFFFAOYSA-N,24770514,ZYRLHJIMTROTBO-UHFFFAOYSA-N,"6,8-bis(benzylthio)octanoic acid",,Treatment of Burkitts Lymphoma (BL),C0006413,Burkitts Lymphoma,1/25/18,Designated,Not FDA Approved for Orphan Indication,,,,
XIIOFHFUYBLOLW-UHFFFAOYSA-N,134436906,XIIOFHFUYBLOLW-UHFFFAOYSA-N,"6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile",,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,10/10/18,Designated,Not FDA Approved for Orphan Indication,,,,
JTQBMTFVGGUDPN-UHFFFAOYSA-N,25400580,JTQBMTFVGGUDPN-UHFFFAOYSA-N,"6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-bensoxazin-4-one",,Treatment of Netherton syndrome,"C0265962,C0265962","Netherton Syndrome , Netherton Syndrome",6/18/15,Designated,Not FDA Approved for Orphan Indication,,,,
NICJCIQSJJKZAH-AWEZNQCLSA-N,148189,NICJCIQSJJKZAH-AWEZNQCLSA-N,6-hydroxymethylacylfulvene,,Treatment of histologically confirmed advanced or metastatic pancreatic cancer.,C0346976,metastatic pancreatic cancer,4/6/99,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
CLEFVPILGAPOTG-NSHDSACASA-N,146591762,CLEFVPILGAPOTG-NSHDSACASA-N,6-{(1S)-1-[(2-Amino-6-fluoroquinolin-3-yl)oxy]ethyl}-5-(1H-pyrazol-1-yl)pyridin-2(1H)-one,,Treatment for Sickle Cell Disease.,C0002895,Sickle Cell Disease,9/18/20,Designated,Not FDA Approved for Orphan Indication,,,,
VLULRUCCHYVXOH-UHFFFAOYSA-N,73777259,VLULRUCCHYVXOH-UHFFFAOYSA-N,"7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one",,Treatment of malignant glioma,C0555198,Malignant Glioma,6/4/18,Designated,Not FDA Approved for Orphan Indication,,,,
FFBDFADSZUINTG-UHFFFAOYSA-N,1329,FFBDFADSZUINTG-UHFFFAOYSA-N,"8 Cyclopentyl 1,3-dipropylxanthine",,Treatment of cystic fibrosis.,C0010674,Cystic Fibrosis,3/24/97,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
FMMOOAYVCKXGMF-XMCVDNGOSA-N,124037379,FMMOOAYVCKXGMF-XMCVDNGOSA-N,"9-cis, 12-cis-11,11-d2-linoleic acid ethyl ester",,Treatment of Friedreich's Ataxia,C0016719,Friedreich's Ataxia,5/23/16,Designated,Not FDA Approved for Orphan Indication,,,,
SHGAZHPCJJPHSC-ZVCIMWCZSA-N,449171,SHGAZHPCJJPHSC-ZVCIMWCZSA-N,9-cis-retinoic acid,,Prevention of retinal detachment due to proliferative vitreoretinopathy.,"C0035305,C0344290","Retinal Detachment , Vitreoretinopathy",1/2/97,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
RTRQQBHATOEIAF-UUOKFMHZSA-N,17513,RTRQQBHATOEIAF-UUOKFMHZSA-N,acadesine,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,3/3/11,Designated,Not FDA Approved for Orphan Indication,,,,
RTRQQBHATOEIAF-UUOKFMHZSA-N,17513,RTRQQBHATOEIAF-UUOKFMHZSA-N,acadesine,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,5/4/11,Designated,Not FDA Approved for Orphan Indication,,,,
WDENQIQQYWYTPO-IBGZPJMESA-N,71226662,WDENQIQQYWYTPO-IBGZPJMESA-N,acalabrutinib,CALQUENCE,Treatment of mantle cell lymphoma.,C4721414,Mantle cell lymphoma,9/21/15,Designated/Approved,,treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, 10/31/2017 , 10/31/2024 ,treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy
WDENQIQQYWYTPO-IBGZPJMESA-N,71226662,WDENQIQQYWYTPO-IBGZPJMESA-N,acalabrutinib,,Treatment of Waldenstrom macroglobulinemia.,C0024419,Waldenstrom Macroglobulinemia,10/22/15,Designated,Not FDA Approved for Orphan Indication,,,,
WDENQIQQYWYTPO-IBGZPJMESA-N,71226662,WDENQIQQYWYTPO-IBGZPJMESA-N,acalabrutinib,,Treatment of chronic lymphocytic leukemia (CLL).,C0023434,Chronic Lymphocytic Leukemia,5/13/15,Designated/Approved,,CALQUENCE is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)., 11/21/2019 , 11/21/2026 ,Indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
AFCGFAGUEYAMAO-UHFFFAOYSA-N,71158,AFCGFAGUEYAMAO-UHFFFAOYSA-N,acamprosate,,Treatment of fragile X syndrome,C0016667,Fragile X Syndrome,3/25/13,Designated,Not FDA Approved for Orphan Indication,,,,
KBGAYAKRZNYFFG-BOHATCBPSA-N,14017587,KBGAYAKRZNYFFG-BOHATCBPSA-N,aceneuramic acid,,Treatment of hereditary inclusion body myopathy,C1853926,Hereditary inclusion body myopathy,9/23/11,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
MDQMFOHHSFMREL-YIYMUJAPSA-N,134819826,MDQMFOHHSFMREL-YIYMUJAPSA-N,acetyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-cysteinyl-D-glutaminyl-D-cysteinyl-D-arginyl-D-arginyl-D-lysyl-Dasparaginylamide disulfide,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,2/18/11,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
RDHQFKQIGNGIED-MRVPVSSYSA-N,7045767,RDHQFKQIGNGIED-MRVPVSSYSA-N,acetyl-l-carnitine,,Treatment of Fragile X syndrome,C0016667,Fragile X Syndrome,7/24/12,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PWKSKIMOESPYIA-BYPYZUCNSA-N,12035,PWKSKIMOESPYIA-BYPYZUCNSA-N,Acetylcysteine,,Intravenous treatment of patients presenting with moderate to severe acetaminophen overdose.,C0572025,Acetaminophen overdose,8/13/87,Designated,Not FDA Approved for Orphan Indication,,,,
PWKSKIMOESPYIA-BYPYZUCNSA-N,12035,PWKSKIMOESPYIA-BYPYZUCNSA-N,acetylcysteine,Acetadote,For the intravenous treatment of moderate to severe acetaminophen overdose,C0572025,Acetaminophen overdose,10/19/01,Designated/Approved,,"For the use of Acetadote(registered TM) Injection, administered intravenously within 8 to 10 hours after ingestion of a potentially heptotoxic quantity of acetaminophen, to prevent or lessen hepatic injur", 01/23/2004 , 01/23/2011 ,
MDFXJBQEWLCGHP-MFOYZWKCSA-N,5391612,MDFXJBQEWLCGHP-MFOYZWKCSA-N,Aconiazide,,Treatment of tuberculosis.,C0041296,Tuberculosis,6/20/88,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
MKUXAQIIEYXACX-UHFFFAOYSA-N,135398513,MKUXAQIIEYXACX-UHFFFAOYSA-N,acyclovir,,Treatment of herpetic keratitis.,C0022568,Keratitis,5/3/16,Designated,Not FDA Approved for Orphan Indication,,,,
MKUXAQIIEYXACX-UHFFFAOYSA-N,135398513,MKUXAQIIEYXACX-UHFFFAOYSA-N,acyclovir,,Treatment of herpetic keratitis,C0019357,Herpetic keratitis,9/16/10,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
MKUXAQIIEYXACX-UHFFFAOYSA-N,135398513,MKUXAQIIEYXACX-UHFFFAOYSA-N,acyclovir,Avaclyr,Treatment of acute herpetic keratitis caused by Herpes Simplex Virus type 1 and 2,C0019357,Herpetic keratitis,12/13/10,Designated/Approved,,AVACLYR is a sterile topical antiviral indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in patients with herpes simplex (HSV-1 and HSV-2) virus., 03/29/2019 , 03/29/2026 ,AVACLYR is a sterile topical antiviral indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in patients with herpes simplex (HSV-1 and HSV-2) virus.
OIRDTQYFTABQOQ-KQYNXXCUSA-N,60961,OIRDTQYFTABQOQ-KQYNXXCUSA-N,Adenosine,,For use in conjunction with BCNU in the treatment of brain tumors.,C0006118,Brain Tumors,8/1/89,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
UAHFGYDRQSXQEB-LEBBXHLNSA-N,16197727,UAHFGYDRQSXQEB-LEBBXHLNSA-N,afamelanotide,,Treatment of solar urticaria,C0263610,Solar urticaria,12/11/09,Designated,Not FDA Approved for Orphan Indication,,,,
UAHFGYDRQSXQEB-LEBBXHLNSA-N,16197727,UAHFGYDRQSXQEB-LEBBXHLNSA-N,afamelanotide,,Treatment of familial benign chronic pemphigus (Hailey-Hailey disease),C0085106,Familial Benign Chronic Pemphigus,5/14/14,Designated,Not FDA Approved for Orphan Indication,,,,
UAHFGYDRQSXQEB-LEBBXHLNSA-N,16197727,UAHFGYDRQSXQEB-LEBBXHLNSA-N,afamelanotide,SCENESSE,Treatment of erythropoietic porphyrias,C0162530,Erythropoietic Porphyrias,7/17/08,Designated/Approved,,SCENESSE is indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP), 10/08/2019 , 10/08/2026 ,Indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP).
UAHFGYDRQSXQEB-LEBBXHLNSA-N,16197727,UAHFGYDRQSXQEB-LEBBXHLNSA-N,afamelanotide,,Treatment of cutaneous variants of porphyria (which includes treatment and prevention of cutaneous manifestations of disease),C0032708,Porphyria,2/4/16,Designated,Not FDA Approved for Orphan Indication,,,,
ULXXDDBFHOBEHA-CWDCEQMOSA-N,10184653,ULXXDDBFHOBEHA-CWDCEQMOSA-N,afatinib,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,7/9/19,Designated,Not FDA Approved for Orphan Indication,,,,
ULXXDDBFHOBEHA-CWDCEQMOSA-N,10184653,ULXXDDBFHOBEHA-CWDCEQMOSA-N,afatinib,,Treatment of malignant brain and central nervous system tumors,C0085136,central nervous system tumors,6/4/14,Designated,Not FDA Approved for Orphan Indication,,,,
ULXXDDBFHOBEHA-CWDCEQMOSA-N,10184653,ULXXDDBFHOBEHA-CWDCEQMOSA-N,afatinib,Gilotrif,Treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).,C0007131,Non-Small Cell Lung Cancer,12/3/12,Designated/Approved,,First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test., 07/12/2013 , 07/12/2020 ,First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
ULXXDDBFHOBEHA-CWDCEQMOSA-N,10184653,ULXXDDBFHOBEHA-CWDCEQMOSA-N,afatinib,Gilotrif,Treatment of non-small cell lung cancer with squamous histology.,C0007131,non-small cell lung cancer,8/3/15,Designated/Approved,,"Treatment of patients with metastatic, squamous, non-small cell lung cancer progressing after platinum-based chemotherapy", 04/15/2016 , 04/15/2023 ,"Treatment of patients with metastatic, squamous, non-small cell lung cancer progressing after platinum-based chemotherapy"
ULXXDDBFHOBEHA-CWDCEQMOSA-N,10184653,ULXXDDBFHOBEHA-CWDCEQMOSA-N,afatinib,Gilotrif,Treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).,C0007131,Non-Small Cell Lung Cancer,12/3/12,Designated/Approved,,GILOTRIF is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test., 01/12/2018 , 01/12/2025 ,GILOTRIF is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations other than exon 19 deletions or exon 21 (L858R) substiution mutationas as detected by an FDA-approved test.
HXHWSAZORRCQMX-UHFFFAOYSA-N,2082,HXHWSAZORRCQMX-UHFFFAOYSA-N,Albendazole,Albenza,Treatment of hydatid disease (cystic echinococcosis due to E. granulosus larvae or alveolar echinococcosis due to E. multilocularis larvae).,"C0013502,C0152069,C4553297","Hydatid disease , Alveolar echinococcosis , Hydatid Disease",1/17/96,Designated/Approved,,"Treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.", 06/11/1996 , 06/11/2003 ,
HXHWSAZORRCQMX-UHFFFAOYSA-N,2082,HXHWSAZORRCQMX-UHFFFAOYSA-N,Albendazole,Albenza,"Treatment of neurocysticercosis due to Taenia solium as: 1) chemotherapy of parenchymal, subarachnoidal and racemose (cysts in spinal fluid) neurocysticercosis in symptomatic cases and 2) prophylaxis of epilepsy and other sequelae in asymptomatic neurocys","C0010709,C0014544,C0338437","Cysts , Epilepsy , Neurocysticercosis",1/18/96,Designated/Approved,,"Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium.", 06/11/1996 , 06/11/2003 ,
NDAUXUAQIAJITI-UHFFFAOYSA-N,2083,NDAUXUAQIAJITI-UHFFFAOYSA-N,Albuterol,,Prevention of paralysis due to spinal cord injury,"C0037929,C0522224","Spinal Cord Injury , Paralysis",3/12/02,Designated,Not FDA Approved for Orphan Indication,,,,
OBMJQRLIQQTJLR-USGQOSEYSA-N,9810709,OBMJQRLIQQTJLR-USGQOSEYSA-N,aldoxorubicin,,Treatment of glioblastoma multiforme,C0017636,Glioblastoma multiforme,9/24/14,Designated,Not FDA Approved for Orphan Indication,,,,
OBMJQRLIQQTJLR-USGQOSEYSA-N,9810709,OBMJQRLIQQTJLR-USGQOSEYSA-N,aldoxorubicin,,Treatment of small cell lung cancer,C3540630,Small Cell Lung Cancer,9/24/14,Designated,Not FDA Approved for Orphan Indication,,,,
OBMJQRLIQQTJLR-USGQOSEYSA-N,9810709,OBMJQRLIQQTJLR-USGQOSEYSA-N,aldoxorubicin,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,9/24/14,Designated,Not FDA Approved for Orphan Indication,,,,
OBMJQRLIQQTJLR-USGQOSEYSA-N,9810709,OBMJQRLIQQTJLR-USGQOSEYSA-N,Aldoxorubicin,,Treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,6/29/11,Designated,Not FDA Approved for Orphan Indication,,,,
OBMJQRLIQQTJLR-USGQOSEYSA-N,9810709,OBMJQRLIQQTJLR-USGQOSEYSA-N,Aldoxorubicin,,Treatment of adenocarcinoma of the pancreas.,C0281361,adenocarcinoma of the pancreas,4/18/11,Designated,Not FDA Approved for Orphan Indication,,,,
KDGFLJKFZUIJMX-UHFFFAOYSA-N,49806720,KDGFLJKFZUIJMX-UHFFFAOYSA-N,alectinib,Alecensa,Treatment of ALK-positive non-small cell lung cancer,C3539721,Non-Small Cell Lung Cancer,1/27/15,Designated/Approved,,"ALECENSA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.", 11/06/2017 , 11/06/2024 ,"Treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small-cell lung cancer (NSCLC) as detected by an FDA-approved test, excluding patients who have progressed on or are intolerant to crizotinib."
KDGFLJKFZUIJMX-UHFFFAOYSA-N,49806720,KDGFLJKFZUIJMX-UHFFFAOYSA-N,alectinib,Alecensa,Treatment of ALK-positive non-small cell lung cancer,C3539721,Non-Small Cell Lung Cancer,1/27/15,Designated/Approved,,"ALECENSA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.", 12/11/2015 , 12/11/2022 ,"Treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), who have progressed on or are intolerant to crizotinib"
OGSPWJRAVKPPFI-UHFFFAOYSA-N,2088,OGSPWJRAVKPPFI-UHFFFAOYSA-N,alendronate,,Treatment of osteogenesis imperfecta in pediatric patients 4 years of age and older,C0029434,Osteogenesis Imperfecta,3/31/03,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
CAKRAHQRJGUPIG-UHFFFAOYSA-L,91997073,CAKRAHQRJGUPIG-UHFFFAOYSA-L,Alendronate disodium,,Treatment of the bone manifestations of Gaucher disease,C0017205,Gaucher Disease,2/13/01,Designated,Not FDA Approved for Orphan Indication,,,,
LMWOPQOPFYJQLI-UHFFFAOYSA-L,14157383,LMWOPQOPFYJQLI-UHFFFAOYSA-L,Alendronate disodium,,Treatment of the bone manifestations of Gaucher disease,C0017205,Gaucher Disease,2/13/01,Designated,Not FDA Approved for Orphan Indication,,,,
IDBPHNDTYPBSNI-UHFFFAOYSA-N,51263,IDBPHNDTYPBSNI-UHFFFAOYSA-N,Alfentanil,,Treatment of painful HIV-associated neuropathy,"C0019682,C0442874","HIV , Neuropathy",8/9/05,Designated,Not FDA Approved for Orphan Indication,,,,
IDBPHNDTYPBSNI-UHFFFAOYSA-N,51263,IDBPHNDTYPBSNI-UHFFFAOYSA-N,Alfentanil,,Management of postherpetic neuralgia,C0032768,Postherpetic neuralgia,7/8/05,Designated,Not FDA Approved for Orphan Indication,,,,
ZMJWRJKGPUDEOX-LMXUULCNSA-A,16197725,ZMJWRJKGPUDEOX-LMXUULCNSA-A,alicaforsen,,Treatment of pouchitis.,C0376620,Pouchitis,6/24/08,Designated,Not FDA Approved for Orphan Indication,,,,
POHUROFYRXELIO-YUMQZZPRSA-N,121488179,POHUROFYRXELIO-YUMQZZPRSA-N,Alidornase alfa,,Treatment of sarcoidosis,C0036202,Sarcoidosis,7/21/20,Designated,Not FDA Approved for Orphan Indication,,,,
ZLHFILGSQDJULK-UHFFFAOYSA-N,24771867,ZLHFILGSQDJULK-UHFFFAOYSA-N,alisertib,,Treatment of small cell lung cancer,C3540630,Small Cell Lung Cancer,7/12/13,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ZLHFILGSQDJULK-UHFFFAOYSA-N,24771867,ZLHFILGSQDJULK-UHFFFAOYSA-N,alisertib,,Treatment of peripheral T-cell lymphoma,C0079774,Peripheral T-Cell Lymphoma,5/14/12,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
SHGAZHPCJJPHSC-ZVCIMWCZSA-N,449171,SHGAZHPCJJPHSC-ZVCIMWCZSA-N,Alitretinoin,Panretin,Treatment of AIDS-related Kaposi's sarcoma.,C0276535,AIDS-related Kaposi's sarcoma,3/24/98,Designated/Approved,,Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma., 02/02/1999 , 02/02/2006 ,
SHGAZHPCJJPHSC-ZVCIMWCZSA-N,449171,SHGAZHPCJJPHSC-ZVCIMWCZSA-N,alitretinoin,,Treatment of systemic (non-cutaneous) kaposi sarcoma,C0036220,Kaposi Sarcoma,1/12/21,Designated,Not FDA Approved for Orphan Indication,,,,
SHGAZHPCJJPHSC-ZVCIMWCZSA-N,449171,SHGAZHPCJJPHSC-ZVCIMWCZSA-N,Alitretinoin,,Treatment of acute promyelocytic leukemia,C0023487,Acute Promyelocytic Leukemia,4/10/92,Designated,Not FDA Approved for Orphan Indication,,,,
MBMBGCFOFBJSGT-KUBAVDMBSA-N,445580,MBMBGCFOFBJSGT-KUBAVDMBSA-N,"all-cis-docosa-4,7,10,13,16,19-hexaenoic acid",,Treatment of retinitis pigmentosa,C0035334,Retinitis Pigmentosa,5/21/14,Designated,Not FDA Approved for Orphan Indication,,,,
POJWUDADGALRAB-UHFFFAOYSA-N,204,POJWUDADGALRAB-UHFFFAOYSA-N,allantoin,,Treatment of skin blistering and erosions associated with inherited epidermolysis bullosa,"C0014527,C2220104","Epidermolysis Bullosa , Skin blistering",11/21/02,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
AURFZBICLPNKBZ-FFWOKMQNSA-N,134688930,AURFZBICLPNKBZ-FFWOKMQNSA-N,allopregnanolone,,Treatment of status epilepticus,C0038220,Status Epilepticus,4/20/14,Designated,Not FDA Approved for Orphan Indication,,,,
AURFZBICLPNKBZ-JITSNLRCSA-N,21139953,AURFZBICLPNKBZ-JITSNLRCSA-N,allopregnanolone,,Treatment of status epilepticus,C0038220,Status Epilepticus,4/20/14,Designated,Not FDA Approved for Orphan Indication,,,,
AURFZBICLPNKBZ-LOPWJTSLSA-N,9883500,AURFZBICLPNKBZ-LOPWJTSLSA-N,allopregnanolone,,Treatment of status epilepticus,C0038220,Status Epilepticus,4/20/14,Designated,Not FDA Approved for Orphan Indication,,,,
AURFZBICLPNKBZ-MHPDUSGUSA-N,6708605,AURFZBICLPNKBZ-MHPDUSGUSA-N,allopregnanolone,,Treatment of status epilepticus,C0038220,Status Epilepticus,4/20/14,Designated,Not FDA Approved for Orphan Indication,,,,
AURFZBICLPNKBZ-SRJHXTLLSA-N,104881,AURFZBICLPNKBZ-SRJHXTLLSA-N,allopregnanolone,,Treatment of status epilepticus,C0038220,Status Epilepticus,4/20/14,Designated,Not FDA Approved for Orphan Indication,,,,
AURFZBICLPNKBZ-JMTGGFPBSA-N,22833567,AURFZBICLPNKBZ-JMTGGFPBSA-N,allopregnanolone,,Treatment of status epilepticus,C0038220,Status Epilepticus,4/20/14,Designated,Not FDA Approved for Orphan Indication,,,,
AURFZBICLPNKBZ-YZRLXODZSA-N,31402,AURFZBICLPNKBZ-YZRLXODZSA-N,allopregnanolone,,Treatment of status epilepticus,C0038220,Status Epilepticus,4/20/14,Designated,Not FDA Approved for Orphan Indication,,,,
AURFZBICLPNKBZ-SUZPBREPSA-N,16760287,AURFZBICLPNKBZ-SUZPBREPSA-N,allopregnanolone,,Treatment of status epilepticus,C0038220,Status Epilepticus,4/20/14,Designated,Not FDA Approved for Orphan Indication,,,,
AURFZBICLPNKBZ-UHFFFAOYSA-N,262961,AURFZBICLPNKBZ-UHFFFAOYSA-N,allopregnanolone,,Treatment of status epilepticus,C0038220,Status Epilepticus,4/20/14,Designated,Not FDA Approved for Orphan Indication,,,,
AURFZBICLPNKBZ-FZCSVUEKSA-N,92787,AURFZBICLPNKBZ-FZCSVUEKSA-N,allopregnanolone,,Treatment of status epilepticus,C0038220,Status Epilepticus,4/20/14,Designated,Not FDA Approved for Orphan Indication,,,,
AURFZBICLPNKBZ-SYBPFIFISA-N,92786,AURFZBICLPNKBZ-SYBPFIFISA-N,allopregnanolone,,Treatment of status epilepticus,C0038220,Status Epilepticus,4/20/14,Designated,Not FDA Approved for Orphan Indication,,,,
AURFZBICLPNKBZ-FFWOKMQNSA-N,134688930,AURFZBICLPNKBZ-FFWOKMQNSA-N,allopregnanolone,,"Treatment of Neimann-Pick disease, type C",C0028064,neimann-pick disease,7/12/13,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
AURFZBICLPNKBZ-JITSNLRCSA-N,21139953,AURFZBICLPNKBZ-JITSNLRCSA-N,allopregnanolone,,"Treatment of Neimann-Pick disease, type C",C0028064,neimann-pick disease,7/12/13,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
AURFZBICLPNKBZ-LOPWJTSLSA-N,9883500,AURFZBICLPNKBZ-LOPWJTSLSA-N,allopregnanolone,,"Treatment of Neimann-Pick disease, type C",C0028064,neimann-pick disease,7/12/13,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
AURFZBICLPNKBZ-MHPDUSGUSA-N,6708605,AURFZBICLPNKBZ-MHPDUSGUSA-N,allopregnanolone,,"Treatment of Neimann-Pick disease, type C",C0028064,neimann-pick disease,7/12/13,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
AURFZBICLPNKBZ-SRJHXTLLSA-N,104881,AURFZBICLPNKBZ-SRJHXTLLSA-N,allopregnanolone,,"Treatment of Neimann-Pick disease, type C",C0028064,neimann-pick disease,7/12/13,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
AURFZBICLPNKBZ-JMTGGFPBSA-N,22833567,AURFZBICLPNKBZ-JMTGGFPBSA-N,allopregnanolone,,"Treatment of Neimann-Pick disease, type C",C0028064,neimann-pick disease,7/12/13,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
AURFZBICLPNKBZ-YZRLXODZSA-N,31402,AURFZBICLPNKBZ-YZRLXODZSA-N,allopregnanolone,,"Treatment of Neimann-Pick disease, type C",C0028064,neimann-pick disease,7/12/13,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
AURFZBICLPNKBZ-SUZPBREPSA-N,16760287,AURFZBICLPNKBZ-SUZPBREPSA-N,allopregnanolone,,"Treatment of Neimann-Pick disease, type C",C0028064,neimann-pick disease,7/12/13,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
AURFZBICLPNKBZ-UHFFFAOYSA-N,262961,AURFZBICLPNKBZ-UHFFFAOYSA-N,allopregnanolone,,"Treatment of Neimann-Pick disease, type C",C0028064,neimann-pick disease,7/12/13,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
AURFZBICLPNKBZ-FZCSVUEKSA-N,92787,AURFZBICLPNKBZ-FZCSVUEKSA-N,allopregnanolone,,"Treatment of Neimann-Pick disease, type C",C0028064,neimann-pick disease,7/12/13,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
AURFZBICLPNKBZ-SYBPFIFISA-N,92786,AURFZBICLPNKBZ-SYBPFIFISA-N,allopregnanolone,,"Treatment of Neimann-Pick disease, type C",C0028064,neimann-pick disease,7/12/13,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
KFQUAMTWOJHPEJ-DAGMQNCNSA-N,135407110,KFQUAMTWOJHPEJ-DAGMQNCNSA-N,Allopurinol riboside,,1. Treatment of Chagas' disease 2. Treatment of cutaneous and visceral leishmaniasis,"C0023290,C0041234","Visceral leishmaniasis , Chagas' disease",12/4/85,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PTJRZVJXXNYNLN-UHFFFAOYSA-M,70691471,PTJRZVJXXNYNLN-UHFFFAOYSA-M,Allopurinol sodium,Aloprim for Injection,"Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.","C0006826,C0023418,C0024299,C0280099","MALIGNANCIES , leukemia , Lymphoma , Solid Tumor",10/16/92,Designated/Approved,,"Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.", 05/17/1996 , 05/17/2003 ,
PTJRZVJXXNYNLN-UHFFFAOYSA-N,135534565,PTJRZVJXXNYNLN-UHFFFAOYSA-N,Allopurinol sodium,Aloprim for Injection,"Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.","C0006826,C0023418,C0024299,C0280099","MALIGNANCIES , leukemia , Lymphoma , Solid Tumor",10/16/92,Designated/Approved,,"Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.", 05/17/1996 , 05/17/2003 ,
PTJRZVJXXNYNLN-UHFFFAOYSA-M,70691471,PTJRZVJXXNYNLN-UHFFFAOYSA-M,Allopurinol sodium,Aloprim for Injection,"Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.","C0006826,C0023418,C0024299,C0280099","MALIGNANCIES , leukemia , Lymphoma , Solid Tumor",10/16/92,Designated/Approved,,"Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.", 05/17/1996 , 05/17/2003 ,
STUWGJZDJHPWGZ-LBPRGKRZSA-N,56649450,STUWGJZDJHPWGZ-LBPRGKRZSA-N,alpelisib,,Treatment of PIK3CA-related overgrowth spectrum,C1849265,Overgrowth,11/18/19,Designated,Not FDA Approved for Orphan Indication,,,,
WHNFPRLDDSXQCL-UAZQEYIDSA-N,44273719,WHNFPRLDDSXQCL-UAZQEYIDSA-N,Alpha-melanocyte stimulating hormone,,Prevention and treatment of intrinsic acute renal failure due to ischemia.,C1828256,Acute renal failure due to ischemia,8/19/97,Designated,Not FDA Approved for Orphan Indication,,,,
LTVDFSLWFKLJDQ-IEOSBIPESA-N,2734086,LTVDFSLWFKLJDQ-IEOSBIPESA-N,Alpha-tocopherol quinone,,Treatment of inherited mitochondrial respiratory chain diseases,C1325653,mitochondrial respiratory chain,3/28/06,Designated,Not FDA Approved for Orphan Indication,,,,
LNOVHERIIMJMDG-XZXLULOTSA-N,46184405,LNOVHERIIMJMDG-XZXLULOTSA-N,alpha-tocotrienol quinone,,Treatment of inherited mitochondrial respiratory chain diseases,C1325653,mitochondrial respiratory chain,10/21/10,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
GMVPRGQOIOIIMI-DWKJAMRDSA-N,5280723,GMVPRGQOIOIIMI-DWKJAMRDSA-N,Alprostadil,,"Treatment of severe peripheral arterial occlusive disease (critical limb ischemia) in patients where other procedures, grafts or angioplasty, are not indicated.","C1142264,C1306889","critical limb ischemia , Peripheral arterial occlusive disease",10/20/93,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
GNNDEPIMDAZHRQ-UHFFFAOYSA-N,54576299,GNNDEPIMDAZHRQ-UHFFFAOYSA-N,altiratinib,,Treatment of glioblastoma multiforme.,C0017636,Glioblastoma multiforme,8/19/14,Designated,Not FDA Approved for Orphan Indication,,,,
UUVWYPNAQBNQJQ-UHFFFAOYSA-N,2123,UUVWYPNAQBNQJQ-UHFFFAOYSA-N,Altretamine,Hexalen,Treatment of advanced adenocarcinoma of the ovary.,"C0948216,C5204526","Adenocarcinoma of the Ovary , Advanced Adenocarcinoma",2/9/84,Designated/Approved,,Single agent palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent based combination., 12/26/1990 , 12/26/1997 ,
BIIVYFLTOXDAOV-YVEFUNNKSA-N,5287969,BIIVYFLTOXDAOV-YVEFUNNKSA-N,alvocidib,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,4/21/14,Designated,Not FDA Approved for Orphan Indication,,,,
BIIVYFLTOXDAOV-YVEFUNNKSA-N,5287969,BIIVYFLTOXDAOV-YVEFUNNKSA-N,Alvocidib,,Teatment of B-cell chronic lymphocytic leukemia (B-CLL) or prolymphocytic leukemia arising from CLL.,"C0023434,C0023486","B-cell chronic lymphocytic leukemia , Prolymphocytic Leukemia",4/13/07,Designated,Not FDA Approved for Orphan Indication,,,,
WOLHOYHSEKDWQH-UHFFFAOYSA-N,64150,WOLHOYHSEKDWQH-UHFFFAOYSA-N,Amantadine HCl,,Treatment of levodopa-induced dyskinesia,C0013384,Dyskinesia,7/20/15,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
WOLHOYHSEKDWQH-UHFFFAOYSA-N,64150,WOLHOYHSEKDWQH-UHFFFAOYSA-N,Amantadine hydrochloride,Gocovri,Treatment of levodopa-induced dyskinesia,C0013384,Dyskinesia,4/9/15,Designated/Approved,,treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy with or without concomitant dopminergic medications, 08/24/2017 , 08/24/2024 ,treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy with or without concomitant dopminergic medications
OUJTZYPIHDYQMC-LJQANCHMSA-N,6918493,OUJTZYPIHDYQMC-LJQANCHMSA-N,ambrisentan,Letairis,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,7/16/04,Designated/Approved,,Treatment of pulmonary arterial hypertension (WHO group I) in patients with WHO class II or III symptoms to improve exercise capacity and delay clinical worsening, 06/15/2007 , 06/15/2014 ,
OUJTZYPIHDYQMC-LJQANCHMSA-N,6918493,OUJTZYPIHDYQMC-LJQANCHMSA-N,ambrisentan,,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,12/23/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
JBDGDEWWOUBZPM-UHFFFAOYSA-N,2132,JBDGDEWWOUBZPM-UHFFFAOYSA-N,ambroxol,,Treatment of Gaucher disease,C0017205,Gaucher Disease,6/29/11,Designated,Not FDA Approved for Orphan Indication,,,,
OYTKINVCDFNREN-UHFFFAOYSA-N,5918,OYTKINVCDFNREN-UHFFFAOYSA-N,amifampridine,Ruzurgi,Treatment of Lambert-Eaton myasthenic syndrome.,C0022972,Lambert-Eaton Myasthenic Syndrome,12/18/90,Designated/Approved,,RUZURGI is indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to less than 17 years of age., 05/06/2019 , 05/06/2026 ,Treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to less than 17 years of age.
KAICRBBQCRKMPO-UHFFFAOYSA-N,9920716,KAICRBBQCRKMPO-UHFFFAOYSA-N,amifampridine phosphate,,Treatment of congenital myasthenic syndromes,C0751882,congenital myasthenic syndromes,3/3/15,Designated,Not FDA Approved for Orphan Indication,,,,
KAICRBBQCRKMPO-UHFFFAOYSA-N,9920716,KAICRBBQCRKMPO-UHFFFAOYSA-N,amifampridine phosphate,,Treatment of myasthenia gravis,C0026896,Myasthenia Gravis,8/31/16,Designated,Not FDA Approved for Orphan Indication,,,,
KAICRBBQCRKMPO-UHFFFAOYSA-N,9920716,KAICRBBQCRKMPO-UHFFFAOYSA-N,amifampridine phosphate,FIRDAPSE,Treatment of Lambert-Eaton Myasthenic Syndrome,C0022972,Lambert-Eaton Myasthenic Syndrome,11/12/09,Designated/Approved,,FIRDAPSE is indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults., 11/28/2018 , 11/28/2025 ,FIRDAPSE is indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.
JKOQGQFVAUAYPM-UHFFFAOYSA-N,2141,JKOQGQFVAUAYPM-UHFFFAOYSA-N,Amifostine,,For use as a chemoprotective agent for cyclophosphamide in the treatment of advanced ovarian carcinoma.,C4721610,Ovarian carcinoma,5/30/90,Designated,Not FDA Approved for Orphan Indication,,,,
JKOQGQFVAUAYPM-UHFFFAOYSA-N,2141,JKOQGQFVAUAYPM-UHFFFAOYSA-N,Amifostine,Ethyol,For use as a chemoprotective agent for cisplatin in the treatment of advanced ovarian carcinoma.,C4721610,Ovarian carcinoma,5/30/90,Designated/Approved,,To reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer., 12/08/1995 , 12/08/2002 ,
JKOQGQFVAUAYPM-UHFFFAOYSA-N,2141,JKOQGQFVAUAYPM-UHFFFAOYSA-N,Amifostine,Ethyol,Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.,C0043352,Xerostomia,5/12/98,Designated/Approved,,"Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands.", 06/24/1999 , 06/24/2006 ,
JKOQGQFVAUAYPM-UHFFFAOYSA-N,2141,JKOQGQFVAUAYPM-UHFFFAOYSA-N,Amifostine,,For the reduction of the incidence and severity of toxicities associated with cisplatin administration.,C0600688,toxicities,11/24/98,Designated,Not FDA Approved for Orphan Indication,,,,
JKOQGQFVAUAYPM-UHFFFAOYSA-N,2141,JKOQGQFVAUAYPM-UHFFFAOYSA-N,Amifostine,,For use as a chemoprotective agent for cisplatin in the treatment of metastatic melanoma.,C0278883,Metastatic melanoma,5/30/90,Designated,Not FDA Approved for Orphan Indication,,,,
JKOQGQFVAUAYPM-UHFFFAOYSA-N,2141,JKOQGQFVAUAYPM-UHFFFAOYSA-N,Amifostine,,Treatment of myelodysplastic syndromes.,C3463824,Myelodysplastic Syndromes,10/4/99,Designated,Not FDA Approved for Orphan Indication,,,,
HIBICIOPDUTNRR-XTHCGPPUSA-L,86619108,HIBICIOPDUTNRR-XTHCGPPUSA-L,amikacin sulfate,,Management of cystic fibrosis patients with Pseudomonas aeruginosa lung infections,"C0010674,C0033809,C3714514","Cystic Fibrosis , Pseudomonas aeruginosa , Infections",1/5/15,Designated,Not FDA Approved for Orphan Indication,,,,
HIBICIOPDUTNRR-XTHCGPPUSA-N,5458175,HIBICIOPDUTNRR-XTHCGPPUSA-N,amikacin sulfate,,Management of cystic fibrosis patients with Pseudomonas aeruginosa lung infections,"C0010674,C0033809,C3714514","Cystic Fibrosis , Pseudomonas aeruginosa , Infections",1/5/15,Designated,Not FDA Approved for Orphan Indication,,,,
LKCWBDHBTVXHDL-RMDFUYIESA-N,37768,LKCWBDHBTVXHDL-RMDFUYIESA-N,amikacin sulfate,,Management of cystic fibrosis patients with Pseudomonas aeruginosa lung infections,"C0010674,C0033809,C3714514","Cystic Fibrosis , Pseudomonas aeruginosa , Infections",1/5/15,Designated,Not FDA Approved for Orphan Indication,,,,
FXKSEJFHKVNEFI-GCZBSULCSA-N,38351,FXKSEJFHKVNEFI-GCZBSULCSA-N,amikacin sulfate,,Management of cystic fibrosis patients with Pseudomonas aeruginosa lung infections,"C0010674,C0033809,C3714514","Cystic Fibrosis , Pseudomonas aeruginosa , Infections",1/5/15,Designated,Not FDA Approved for Orphan Indication,,,,
SLXKOJJOQWFEFD-UHFFFAOYSA-N,564,SLXKOJJOQWFEFD-UHFFFAOYSA-N,Aminocaproic acid,,For the topical treatment of traumatic hyphema of the eye.,C0339335,Traumatic hyphema,1/6/95,Designated,Not FDA Approved for Orphan Indication,,,,
ZLHFONARZHCSET-UHFFFAOYSA-N,123608,ZLHFONARZHCSET-UHFFFAOYSA-N,aminolevulinic acid hydrochloride,,Treatment of esophageal dysplasia,C0586354,Esophageal dysplasia,3/20/07,Designated,Not FDA Approved for Orphan Indication,,,,
ZLHFONARZHCSET-UHFFFAOYSA-N,123608,ZLHFONARZHCSET-UHFFFAOYSA-N,Aminolevulinic acid hydrochloride,,Treatment of malignant glioma,C0555198,Malignant Glioma,9/9/20,Designated,Not FDA Approved for Orphan Indication,,,,
WUBBRNOQWQTFEX-UHFFFAOYSA-M,54690315,WUBBRNOQWQTFEX-UHFFFAOYSA-M,Aminosalicylate sodium,,Treatment of Crohn's disease.,C0010346,Crohn's Disease,4/6/93,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
FVVDKUPCWXUVNP-UHFFFAOYSA-N,16051922,FVVDKUPCWXUVNP-UHFFFAOYSA-N,Aminosalicylate sodium,,Treatment of Crohn's disease.,C0010346,Crohn's Disease,4/6/93,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
GMUQJDAYXZXBOT-UHFFFAOYSA-M,16211148,GMUQJDAYXZXBOT-UHFFFAOYSA-M,Aminosalicylate sodium,,Treatment of Crohn's disease.,C0010346,Crohn's Disease,4/6/93,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
WUBBRNOQWQTFEX-UHFFFAOYSA-N,4649,WUBBRNOQWQTFEX-UHFFFAOYSA-N,Aminosalicylate sodium,,Treatment of Crohn's disease.,C0010346,Crohn's Disease,4/6/93,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
FVVDKUPCWXUVNP-UHFFFAOYSA-M,2724368,FVVDKUPCWXUVNP-UHFFFAOYSA-M,Aminosalicylate sodium,,Treatment of Crohn's disease.,C0010346,Crohn's Disease,4/6/93,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
WUBBRNOQWQTFEX-UHFFFAOYSA-N,4649,WUBBRNOQWQTFEX-UHFFFAOYSA-N,Aminosalicylic acid,Paser Granules,Treatment of tuberculosis infections,C0041296,Tuberculosis,2/19/92,Designated/Approved,,Treatment of tuberculosis, 06/30/1994 , 06/30/2001 ,
UOZODPSAJZTQNH-LSWIJEOBSA-N,165580,UOZODPSAJZTQNH-LSWIJEOBSA-N,Aminosidine,,Treatment of tuberculosis.,C0041296,Tuberculosis,5/14/93,Designated,Not FDA Approved for Orphan Indication,,,,
UOZODPSAJZTQNH-LSWIJEOBSA-N,165580,UOZODPSAJZTQNH-LSWIJEOBSA-N,Aminosidine,,Treatment of visceral leishmaniasis (kala-azar).,C0023290,Visceral leishmaniasis,9/9/94,Designated,Not FDA Approved for Orphan Indication,,,,
UOZODPSAJZTQNH-LSWIJEOBSA-N,165580,UOZODPSAJZTQNH-LSWIJEOBSA-N,Aminosidine,,Treatment of Mycobacterium avium complex.,C0026914,Mycobacterium avium Complex,11/15/93,Designated,Not FDA Approved for Orphan Indication,,,,
UOZODPSAJZTQNH-LSWIJEOBSA-N,165580,UOZODPSAJZTQNH-LSWIJEOBSA-N,aminosidine,,Treatment of visceral leishmaniasis,C0023290,Visceral leishmaniasis,3/29/05,Designated,Not FDA Approved for Orphan Indication,,,,
IYIKLHRQXLHMJQ-UHFFFAOYSA-N,2157,IYIKLHRQXLHMJQ-UHFFFAOYSA-N,Amiodarone,,Treatment of incessant ventricular tachycardia.,C0042514,Ventricular tachycardia,8/17/93,Designated,Not FDA Approved for Orphan Indication,,,,
ITPDYQOUSLNIHG-UHFFFAOYSA-N,441325,ITPDYQOUSLNIHG-UHFFFAOYSA-N,Amiodarone HCl,Cordarone,For the acute treatment and prophylaxis of life-threatening ventricular tachycardia or ventricular fibrillation.,"C0042510,C0042514","Ventricular Fibrillation , Ventricular tachycardia",3/16/94,Designated/Approved,,For initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy., 08/03/1995 , 08/03/2002 ,
KRMDCWKBEZIMAB-UHFFFAOYSA-N,2160,KRMDCWKBEZIMAB-UHFFFAOYSA-N,Amitriptyline,,Treatment of Erythromelalgia,C0014804,Erythromelalgia,5/27/20,Designated,Not FDA Approved for Orphan Indication,,,,
ZKKLPDLKUGTPME-UHFFFAOYSA-N,15251598,ZKKLPDLKUGTPME-UHFFFAOYSA-N,Ammonium tetrathiomolybdate,,Treatment of Wilson's disease.,C0019202,Wilson's Disease,1/31/94,Designated,Not FDA Approved for Orphan Indication,,,,
ZKKLPDLKUGTPME-UHFFFAOYSA-N,15251598,ZKKLPDLKUGTPME-UHFFFAOYSA-N,ammonium tetrathiomolybdate,,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,5/5/08,Designated,Not FDA Approved for Orphan Indication,,,,
JNZBHHQBPHSOMU-WNQIDUERSA-N,10216431,JNZBHHQBPHSOMU-WNQIDUERSA-N,Amonafide L-malate,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,12/20/06,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
APKFDSVGJQXUKY-INPOYWNPSA-N,5280965,APKFDSVGJQXUKY-INPOYWNPSA-N,amphotericin B,,Treatment of visceral leishmaniasis.,C0023290,Visceral leishmaniasis,9/15/10,Designated,Not FDA Approved for Orphan Indication,,,,
APKFDSVGJQXUKY-INPOYWNPSA-N,5280965,APKFDSVGJQXUKY-INPOYWNPSA-N,amphotericin B,,Treatment of visceral leishmaniasis.,C0023290,Visceral leishmaniasis,9/15/10,Designated,Not FDA Approved for Orphan Indication,,,,
APKFDSVGJQXUKY-VTPNKFOWSA-N,118705500,APKFDSVGJQXUKY-VTPNKFOWSA-N,Amphotericin B lipid complex,,Treatment of invasive candidiasis.,C1609535,Invasive Candidiasis,6/27/96,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
APKFDSVGJQXUKY-VTPNKFOWSA-N,118705500,APKFDSVGJQXUKY-VTPNKFOWSA-N,Amphotericin B lipid complex,Abelcet,Treatment of invasive fungal infections.,C1262313,Invasive Fungal Infections,12/5/91,Designated/Approved,,Treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B therapy., 10/18/1996 , 10/18/2003 ,
APKFDSVGJQXUKY-VTPNKFOWSA-N,118705500,APKFDSVGJQXUKY-VTPNKFOWSA-N,Amphotericin B lipid complex,,Treatment of invasive zygomycosis.,C0043541,Zygomycosis,5/6/96,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
APKFDSVGJQXUKY-VTPNKFOWSA-N,118705500,APKFDSVGJQXUKY-VTPNKFOWSA-N,Amphotericin B lipid complex,,Treatment of invasive protothecosis.,C0033735,Protothecosis,8/21/96,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
APKFDSVGJQXUKY-VTPNKFOWSA-N,118705500,APKFDSVGJQXUKY-VTPNKFOWSA-N,Amphotericin B lipid complex,,Treatment of invasive sporotrichosis.,C0038034,Sporotrichosis,9/23/96,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
APKFDSVGJQXUKY-VTPNKFOWSA-N,118705500,APKFDSVGJQXUKY-VTPNKFOWSA-N,Amphotericin B lipid complex,,Treatment of invasive coccidioidomycosis.,C0009186,Coccidioidomycosis,5/6/96,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
VJZITPJGSQKZMX-XDPRQOKASA-N,3035016,VJZITPJGSQKZMX-XDPRQOKASA-N,amrubicin,,Treatment of small cell lung cancer,C3540630,Small Cell Lung Cancer,3/10/08,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
XCPGHVQEEXUHNC-UHFFFAOYSA-N,2179,XCPGHVQEEXUHNC-UHFFFAOYSA-N,Amsacrine,,Treatment of acute adult leukemia.,"C0023418,C1547229","leukemia , Acute",12/7/84,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
WMGFVAGNIYUEEP-WUYNJSITSA-N,439207,WMGFVAGNIYUEEP-WUYNJSITSA-N,amylopectin,,Treatment of glycogen storage disease types Ia and Ib,C0017919,Glycogen Storage Disease,3/24/15,Designated,Not FDA Approved for Orphan Indication,,,,
OTBXOEAOVRKTNQ-UHFFFAOYSA-N,135409400,OTBXOEAOVRKTNQ-UHFFFAOYSA-N,Anagrelide,Agrylin,Treatment of essential thrombocythemia.,C0040028,ESSENTIAL THROMBOCYTHEMIA,1/27/88,Designated/Approved,,Treatment of patients with essential thrombocythemia to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms., 03/14/1997 , 03/14/2004 ,
OTBXOEAOVRKTNQ-UHFFFAOYSA-N,135409400,OTBXOEAOVRKTNQ-UHFFFAOYSA-N,Anagrelide,,Treatment of polycythemia vera.,C0032463,Polycythemia Vera,6/11/85,Designated,Not FDA Approved for Orphan Indication,,,,
OTBXOEAOVRKTNQ-UHFFFAOYSA-N,135409400,OTBXOEAOVRKTNQ-UHFFFAOYSA-N,Anagrelide,,Treatment of thrombocytosis in chronic myelogenous leukemia.,"C0023473,C0836924","Chronic myelogenous leukemia , Thrombocytosis",7/14/86,Designated,Not FDA Approved for Orphan Indication,,,,
HMLGSIZOMSVISS-UHFFFAOYSA-N,139595263,HMLGSIZOMSVISS-UHFFFAOYSA-N,anakinra,Kineret,Treatment of cryopyrin-associated periodic syndromes,C0039082,Syndromes,8/19/10,Designated/Approved,,Treatment of neonatal-onset multisystem inflammatory disease (NOMID), 12/21/2012 , 12/21/2019 ,
ZXFWJPKXEMFBOG-LWVMDMHWSA-N,118984442,ZXFWJPKXEMFBOG-LWVMDMHWSA-N,Anaritide acetate,,Treatment of patients with acute renal failure.,C0022660,Acute renal failure,8/27/92,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
XUHBBTKJWIBQMY-MHZLTWQESA-N,9831652,XUHBBTKJWIBQMY-MHZLTWQESA-N,Anatibant,,Treatment of patients having experienced a severe traumatic brain injury (Glasgow Coma Scale 3 to 8) in order to decrease early mortality and improve long-term functional and neurological outcome,C0876926,Traumatic Brain Injury,4/15/05,Designated,Not FDA Approved for Orphan Indication,,,,
PVHLMTREZMEJCG-GDTLVBQBSA-N,123805,PVHLMTREZMEJCG-GDTLVBQBSA-N,Angiotensin (1-7),,Treatment of recessive dystrophic epidermolysis bullosa (RDEB).,C0079474,Recessive dystrophic epidermolysis bullosa,9/1/16,Designated,Not FDA Approved for Orphan Indication,,,,
PVHLMTREZMEJCG-GDTLVBQBSA-N,123805,PVHLMTREZMEJCG-GDTLVBQBSA-N,Angiotensin (1-7),,Treatment of LAMA2-related muscular dystrophy,C0026850,Muscular Dystrophy,2/8/16,Designated,Not FDA Approved for Orphan Indication,,,,
PVHLMTREZMEJCG-GDTLVBQBSA-N,123805,PVHLMTREZMEJCG-GDTLVBQBSA-N,Angiotensin (1-7),,Treatment of limb-girdle muscular dystrophy,C0686353,Limb-girdle muscular dystrophy,11/26/13,Designated,Not FDA Approved for Orphan Indication,,,,
PVHLMTREZMEJCG-GDTLVBQBSA-N,123805,PVHLMTREZMEJCG-GDTLVBQBSA-N,angiotensin 1-7,,"To accelerate engraftment of hematopoietic cells (treatment of neutropenia, thrombocytopenia, lymphoma, and aneima)in hematopoietic stem cell transplants.","C0024299,C0027947,C0040034","Lymphoma , Neutropenia , Thrombocytopenia",6/17/10,Designated,Not FDA Approved for Orphan Indication,,,,
PVHLMTREZMEJCG-GDTLVBQBSA-N,123805,PVHLMTREZMEJCG-GDTLVBQBSA-N,Angiotensin 1-7,,Treatment of myelodysplastic syndrome,C3463824,MYELODYSPLASTIC SYNDROME,8/3/01,Designated,Not FDA Approved for Orphan Indication,,,,
PVHLMTREZMEJCG-GDTLVBQBSA-N,123805,PVHLMTREZMEJCG-GDTLVBQBSA-N,Angiotensin 1-7,,Treatment of neutropenia associated with autologous bone marrow transplantation.,C0027947,Neutropenia,2/16/00,Designated,Not FDA Approved for Orphan Indication,,,,
PVHLMTREZMEJCG-GDTLVBQBSA-N,123805,PVHLMTREZMEJCG-GDTLVBQBSA-N,angiotensin 1-7,,Treatment of sarcoma.,C1261473,Sarcoma,1/29/10,Designated,Not FDA Approved for Orphan Indication,,,,
PVHLMTREZMEJCG-GDTLVBQBSA-N,123805,PVHLMTREZMEJCG-GDTLVBQBSA-N,Angiotensin-(1-7),,Treatment of pulmonary arterial hypertension.,C3203102,PULMONARY ARTERIAL HYPERTENSION,9/13/11,Designated,Not FDA Approved for Orphan Indication,,,,
KHPXUQMNIQBQEV-UHFFFAOYSA-N,970,KHPXUQMNIQBQEV-UHFFFAOYSA-N,anhydrous enol-oxaloacetate,,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,3/7/18,Designated,Not FDA Approved for Orphan Indication,,,,
KSMZEXLVHXZPEF-UHFFFAOYSA-N,25017411,KSMZEXLVHXZPEF-UHFFFAOYSA-N,Anlotinib,,Treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,6/19/17,Designated,Not FDA Approved for Orphan Indication,,,,
UUAKQNIPIXQZFN-UHFFFAOYSA-N,57380530,UUAKQNIPIXQZFN-UHFFFAOYSA-N,anlotinib hydrochloride,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,12/31/15,Designated,Not FDA Approved for Orphan Indication,,,,
BLPUOQGPBJPXRL-FNORWQNLSA-N,641115,BLPUOQGPBJPXRL-FNORWQNLSA-N,Antiepilepsirine,,Treatment of drug resistant generalized tonic-clonic epilepsy in children and adults.,"C0014549,C3826394","Tonic-Clonic Epilepsy , Epilepsy in children",3/23/89,Designated,Not FDA Approved for Orphan Indication,,,,
LJTSIMVOOOLKOL-FNRDIUJOSA-N,24875259,LJTSIMVOOOLKOL-FNRDIUJOSA-N,antroquinonol,,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,7/23/15,Designated,Not FDA Approved for Orphan Indication,,,,
LJTSIMVOOOLKOL-FNRDIUJOSA-N,24875259,LJTSIMVOOOLKOL-FNRDIUJOSA-N,antroquinonol,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,1/21/15,Designated,Not FDA Approved for Orphan Indication,,,,
LJTSIMVOOOLKOL-FNRDIUJOSA-N,24875259,LJTSIMVOOOLKOL-FNRDIUJOSA-N,antroquinonol,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,4/30/15,Designated,Not FDA Approved for Orphan Indication,,,,
FYJROXRIVQPKRY-UHFFFAOYSA-N,45139106,FYJROXRIVQPKRY-UHFFFAOYSA-N,apatinib mesylate,,Treatment of gastric cancer,C0024623,Gastric Cancer,6/15/17,Designated,Not FDA Approved for Orphan Indication,,,,
NOFOAYPPHIUXJR-APNQCZIXSA-N,457964,NOFOAYPPHIUXJR-APNQCZIXSA-N,aphidicolin,,Treatment of Ebola virus infection,C0282687,Ebola Virus Infection,4/20/16,Designated,Not FDA Approved for Orphan Indication,,,,
GAJWNIKZLYZYSY-OKUPSQOASA-N,11527330,GAJWNIKZLYZYSY-OKUPSQOASA-N,apilimod dimesylate,,Treatment of follicular lymphoma,C0024301,follicular lymphoma,7/1/19,Designated,Not FDA Approved for Orphan Indication,,,,
VMWNQDUVQKEIOC-CYBMUJFWSA-N,6005,VMWNQDUVQKEIOC-CYBMUJFWSA-N,Apomorphine,,Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.,C0030567,Parkinson's Disease,7/17/95,Designated,Not FDA Approved for Orphan Indication,,,,
VMWNQDUVQKEIOC-CYBMUJFWSA-N,6005,VMWNQDUVQKEIOC-CYBMUJFWSA-N,Apomorphine,,For use as rescue treatment for early morning motor dysfunction in late-stage Parkinson's disease.,"C0030567,C0521654","Parkinson's Disease , Motor dysfunction",10/20/97,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
SKYZYDSNJIOXRL-BTQNPOSSSA-N,9410,SKYZYDSNJIOXRL-BTQNPOSSSA-N,Apomorphine HCl,Apokyn,Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.,C0030567,Parkinson's Disease,4/22/93,Designated/Approved,,"For the acute, intermittent treatment of hypomobility, ""off"" episodes (""end-of-dose-wearing-off"" and unpredictable :on/off"" episodes) associated with advanced Parkinson's disease", 04/20/2004 , 04/20/2011 ,
SKYZYDSNJIOXRL-BTQNPOSSSA-M,44358405,SKYZYDSNJIOXRL-BTQNPOSSSA-M,Apomorphine hydrochloride,,For the treatment of patients in a vegetative state or minimally conscious state for up to 12 months following a severe traumatic brain injury (traumatic or spontaneous),"C0751699,C0876926,C0917808","Minimally Conscious State , Traumatic Brain Injury , Vegetative State",5/23/06,Designated,Not FDA Approved for Orphan Indication,,,,
CXWQXGNFZLHLHQ-DPFCLETOSA-N,25058166,CXWQXGNFZLHLHQ-DPFCLETOSA-N,Apomorphine hydrochloride,,For the treatment of patients in a vegetative state or minimally conscious state for up to 12 months following a severe traumatic brain injury (traumatic or spontaneous),"C0751699,C0876926,C0917808","Minimally Conscious State , Traumatic Brain Injury , Vegetative State",5/23/06,Designated,Not FDA Approved for Orphan Indication,,,,
DQQCJDBYNZMPOA-FFXKMJQXSA-N,6852399,DQQCJDBYNZMPOA-FFXKMJQXSA-N,Apomorphine hydrochloride,,For the treatment of patients in a vegetative state or minimally conscious state for up to 12 months following a severe traumatic brain injury (traumatic or spontaneous),"C0751699,C0876926,C0917808","Minimally Conscious State , Traumatic Brain Injury , Vegetative State",5/23/06,Designated,Not FDA Approved for Orphan Indication,,,,
CXWQXGNFZLHLHQ-DPFCLETOSA-N,25058166,CXWQXGNFZLHLHQ-DPFCLETOSA-N,Apomorphine hydrochloride,,For the treatment of patients in a vegetative state or minimally conscious state for up to 12 months following a severe traumatic brain injury (traumatic or spontaneous),"C0751699,C0876926,C0917808","Minimally Conscious State , Traumatic Brain Injury , Vegetative State",5/23/06,Designated,Not FDA Approved for Orphan Indication,,,,
VMWNQDUVQKEIOC-CYBMUJFWSA-N,6005,VMWNQDUVQKEIOC-CYBMUJFWSA-N,Apomorphine hydrochloride,,For the treatment of patients in a vegetative state or minimally conscious state for up to 12 months following a severe traumatic brain injury (traumatic or spontaneous),"C0751699,C0876926,C0917808","Minimally Conscious State , Traumatic Brain Injury , Vegetative State",5/23/06,Designated,Not FDA Approved for Orphan Indication,,,,
SKYZYDSNJIOXRL-BTQNPOSSSA-N,9410,SKYZYDSNJIOXRL-BTQNPOSSSA-N,Apomorphine hydrochloride,,For the treatment of patients in a vegetative state or minimally conscious state for up to 12 months following a severe traumatic brain injury (traumatic or spontaneous),"C0751699,C0876926,C0917808","Minimally Conscious State , Traumatic Brain Injury , Vegetative State",5/23/06,Designated,Not FDA Approved for Orphan Indication,,,,
MAFITCMHQZUUQZ-VZUYHUTRSA-N,135390845,MAFITCMHQZUUQZ-VZUYHUTRSA-N,apomorphine palmitate,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,6/4/18,Designated,Not FDA Approved for Orphan Indication,,,,
IMOZEMNVLZVGJZ-QGZVFWFLSA-N,11561674,IMOZEMNVLZVGJZ-QGZVFWFLSA-N,apremilast,,Treatment of pediatric patients with ulcerative colitis,C0009324,Ulcerative Colitis,1/17/18,Designated,Not FDA Approved for Orphan Indication,,,,
IMOZEMNVLZVGJZ-QGZVFWFLSA-N,11561674,IMOZEMNVLZVGJZ-QGZVFWFLSA-N,apremilast,OTEZLA,Treatment of Behcet's disease,C0004943,Behcet Syndrome,1/17/13,Designated/Approved,,OTEZLA is indicated for the treatment of adult patients with oral ulcers associated with Beh祴s Disease., 07/19/2019 , 07/19/2026 ,For the treatment of adult patients with oral ulcers associated with Beh祴s disease
ZPNFWUPYTFPOJU-IAUBLLHJSA-N,129627711,ZPNFWUPYTFPOJU-IAUBLLHJSA-N,Aprotinin,Trasylol,"For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary c",C0019080,Blood loss,11/17/93,Designated/Approved,,, 12/29/1993 , 12/29/2000 ,
ZPNFWUPYTFPOJU-YSFZTAPISA-N,53487898,ZPNFWUPYTFPOJU-YSFZTAPISA-N,Aprotinin,Trasylol,"For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary c",C0019080,Blood loss,11/17/93,Designated/Approved,,, 12/29/1993 , 12/29/2000 ,
ZPNFWUPYTFPOJU-UHFFFAOYSA-N,22833874,ZPNFWUPYTFPOJU-UHFFFAOYSA-N,Aprotinin,Trasylol,"For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary c",C0019080,Blood loss,11/17/93,Designated/Approved,,, 12/29/1993 , 12/29/2000 ,
ZPNFWUPYTFPOJU-LPYSRVMUSA-N,16130295,ZPNFWUPYTFPOJU-LPYSRVMUSA-N,Aprotinin,Trasylol,"For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary c",C0019080,Blood loss,11/17/93,Designated/Approved,,, 12/29/1993 , 12/29/2000 ,
ZPNFWUPYTFPOJU-VKTQZXOTSA-N,146027575,ZPNFWUPYTFPOJU-VKTQZXOTSA-N,Aprotinin,Trasylol,"For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary c",C0019080,Blood loss,11/17/93,Designated/Approved,,, 12/29/1993 , 12/29/2000 ,
ZVEMACCDKBQNGX-KALODSIISA-N,23622962,ZVEMACCDKBQNGX-KALODSIISA-N,Arginine butyrate,,Treatment of sickle cell disease and beta thalassemia.,"C0002895,C0005283","Sickle Cell Disease , beta Thalassemia",5/25/94,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ZVEMACCDKBQNGX-KALODSIISA-N,23622962,ZVEMACCDKBQNGX-KALODSIISA-N,Arginine butyrate,,Treatment of beta-hemoglobinopathies and beta-thalassemia.,"C0005283,C0019045","BETA-THALASSEMIA , Hemoglobinopathies",4/7/92,Designated,Not FDA Approved for Orphan Indication,,,,
SGEIEGAXKLMUIZ-YZGLPLCXSA-N,92461203,SGEIEGAXKLMUIZ-YZGLPLCXSA-N,arimoclomol,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,3/29/05,Designated,Not FDA Approved for Orphan Indication,,,,
SGEIEGAXKLMUIZ-UHFFFAOYSA-N,53427024,SGEIEGAXKLMUIZ-UHFFFAOYSA-N,arimoclomol,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,3/29/05,Designated,Not FDA Approved for Orphan Indication,,,,
SGEIEGAXKLMUIZ-ZPTIMJQQSA-N,6507255,SGEIEGAXKLMUIZ-ZPTIMJQQSA-N,arimoclomol,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,3/29/05,Designated,Not FDA Approved for Orphan Indication,,,,
SGEIEGAXKLMUIZ-CYBMUJFWSA-N,208924,SGEIEGAXKLMUIZ-CYBMUJFWSA-N,arimoclomol,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,3/29/05,Designated,Not FDA Approved for Orphan Indication,,,,
SGEIEGAXKLMUIZ-XUVDNFPMSA-N,9568077,SGEIEGAXKLMUIZ-XUVDNFPMSA-N,arimoclomol,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,3/29/05,Designated,Not FDA Approved for Orphan Indication,,,,
SGEIEGAXKLMUIZ-YZGLPLCXSA-N,92461203,SGEIEGAXKLMUIZ-YZGLPLCXSA-N,arimoclomol,,Treatment of inclusion body myositis,C0238190,INCLUSION BODY MYOSITIS,11/2/17,Designated,Not FDA Approved for Orphan Indication,,,,
SGEIEGAXKLMUIZ-UHFFFAOYSA-N,53427024,SGEIEGAXKLMUIZ-UHFFFAOYSA-N,arimoclomol,,Treatment of inclusion body myositis,C0238190,INCLUSION BODY MYOSITIS,11/2/17,Designated,Not FDA Approved for Orphan Indication,,,,
SGEIEGAXKLMUIZ-ZPTIMJQQSA-N,6507255,SGEIEGAXKLMUIZ-ZPTIMJQQSA-N,arimoclomol,,Treatment of inclusion body myositis,C0238190,INCLUSION BODY MYOSITIS,11/2/17,Designated,Not FDA Approved for Orphan Indication,,,,
SGEIEGAXKLMUIZ-CYBMUJFWSA-N,208924,SGEIEGAXKLMUIZ-CYBMUJFWSA-N,arimoclomol,,Treatment of inclusion body myositis,C0238190,INCLUSION BODY MYOSITIS,11/2/17,Designated,Not FDA Approved for Orphan Indication,,,,
SGEIEGAXKLMUIZ-XUVDNFPMSA-N,9568077,SGEIEGAXKLMUIZ-XUVDNFPMSA-N,arimoclomol,,Treatment of inclusion body myositis,C0238190,INCLUSION BODY MYOSITIS,11/2/17,Designated,Not FDA Approved for Orphan Indication,,,,
XSENLDLUMVYRET-BTQNPOSSSA-N,72710735,XSENLDLUMVYRET-BTQNPOSSSA-N,arimoclomol citrate,,"Treatment of Neimann-Pick disease, type C",C0028064,neimann-pick disease,1/13/15,Designated,Not FDA Approved for Orphan Indication,,,,
CEUORZQYGODEFX-UHFFFAOYSA-N,60795,CEUORZQYGODEFX-UHFFFAOYSA-N,Aripiprazole,,Treatment of N-glycanase 1 (NGLY1) deficiency,C1425023,N-GLYCANASE 1,7/22/19,Designated,Not FDA Approved for Orphan Indication,,,,
CEUORZQYGODEFX-UHFFFAOYSA-N,60795,CEUORZQYGODEFX-UHFFFAOYSA-N,aripiprazole,Abilify,Treatment of Tourette's syndrome,C0040517,Tourette's Syndrome,1/25/06,Designated/Approved,,Treatment of pediatric patients with Tourette's, 12/12/2014 , 12/12/2021 ,Treatment of pediatric patients with Tourette's
RQNWIZPPADIBDY-UHFFFAOYSA-N,5359596,RQNWIZPPADIBDY-UHFFFAOYSA-N,arsenic,,"Treatment of acute myelocytic leukemia subtypes M0, M1, M2, M4, M5, M6 and M7",C0023467,Acute myelocytic leukemia,11/2/01,Designated,Not FDA Approved for Orphan Indication,,,,
QTLQKAJBUDWPIB-UHFFFAOYSA-N,14888,QTLQKAJBUDWPIB-UHFFFAOYSA-N,Arsenic trioxide,,Treatment of malignant glioma,C0555198,Malignant Glioma,3/4/05,Designated,Not FDA Approved for Orphan Indication,,,,
QTLQKAJBUDWPIB-UHFFFAOYSA-N,14888,QTLQKAJBUDWPIB-UHFFFAOYSA-N,arsenic trioxide,,Treatment of chronic myeloid leukemia,C0023473,Chronic myeloid leukemia,10/18/01,Designated,Not FDA Approved for Orphan Indication,,,,
QTLQKAJBUDWPIB-UHFFFAOYSA-N,14888,QTLQKAJBUDWPIB-UHFFFAOYSA-N,Arsenic trioxide,Trisenox,Treatment of acute promyelocytic leukemia.,C0023487,Acute Promyelocytic Leukemia,3/3/98,Designated/Approved,,In combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression., 01/12/2018 , 01/12/2025 ,In combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.
QTLQKAJBUDWPIB-UHFFFAOYSA-N,14888,QTLQKAJBUDWPIB-UHFFFAOYSA-N,Arsenic trioxide,,Treatment of multiple myeloma.,C0026764,Multiple Myeloma,4/28/00,Designated,Not FDA Approved for Orphan Indication,,,,
QTLQKAJBUDWPIB-UHFFFAOYSA-N,14888,QTLQKAJBUDWPIB-UHFFFAOYSA-N,arsenic trioxide,,Treatment of myelodysplastic syndrome.,C3463824,MYELODYSPLASTIC SYNDROME,7/17/00,Designated,Not FDA Approved for Orphan Indication,,,,
QTLQKAJBUDWPIB-UHFFFAOYSA-N,14888,QTLQKAJBUDWPIB-UHFFFAOYSA-N,arsenic trioxide,,Treatment of Graft-versus-host disease,C0018133,Graft-Versus-Host Disease,7/30/18,Designated,Not FDA Approved for Orphan Indication,,,,
QTLQKAJBUDWPIB-UHFFFAOYSA-N,14888,QTLQKAJBUDWPIB-UHFFFAOYSA-N,Arsenic trioxide,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,5/13/03,Designated,Not FDA Approved for Orphan Indication,,,,
QTLQKAJBUDWPIB-UHFFFAOYSA-N,14888,QTLQKAJBUDWPIB-UHFFFAOYSA-N,arsenic trioxide,,Treatment of liver cancer,C0220630,Liver Cancer,6/13/03,Designated,Not FDA Approved for Orphan Indication,,,,
QTLQKAJBUDWPIB-UHFFFAOYSA-N,14888,QTLQKAJBUDWPIB-UHFFFAOYSA-N,Arsenic trioxide,Trisenox,Treatment of acute promyelocytic leukemia.,C0023487,Acute Promyelocytic Leukemia,3/3/98,Designated/Approved,,"For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation of PML/RAR-alpha gene expression.", 09/25/2000 , 09/25/2007 ,
FDMUNKXWYMSZIR-NQWKWHCYSA-N,11531457,FDMUNKXWYMSZIR-NQWKWHCYSA-N,artemisone,,Treatment of malaria,C0024530,Malaria,7/19/17,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-PNDUOAGUSA-N,129009911,FIHJKUPKCHIPAT-PNDUOAGUSA-N,artesunate,,Immediate treatment of malaria,C0024530,Malaria,3/28/06,Designated/Approved,,Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen., 05/26/2020 , 05/26/2027 ,For the initial treatment of severe malaria in adult and pediatric patients to always be followed by a complete treatment course of an appropriate oral antimalarial regimen.
FIHJKUPKCHIPAT-XIIQFBLFSA-N,91746179,FIHJKUPKCHIPAT-XIIQFBLFSA-N,artesunate,,Immediate treatment of malaria,C0024530,Malaria,3/28/06,Designated/Approved,,Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen., 05/26/2020 , 05/26/2027 ,For the initial treatment of severe malaria in adult and pediatric patients to always be followed by a complete treatment course of an appropriate oral antimalarial regimen.
FIHJKUPKCHIPAT-WNZKYHKJSA-N,60196289,FIHJKUPKCHIPAT-WNZKYHKJSA-N,artesunate,,Immediate treatment of malaria,C0024530,Malaria,3/28/06,Designated/Approved,,Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen., 05/26/2020 , 05/26/2027 ,For the initial treatment of severe malaria in adult and pediatric patients to always be followed by a complete treatment course of an appropriate oral antimalarial regimen.
FIHJKUPKCHIPAT-RUYKMDFCSA-N,49769200,FIHJKUPKCHIPAT-RUYKMDFCSA-N,artesunate,,Immediate treatment of malaria,C0024530,Malaria,3/28/06,Designated/Approved,,Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen., 05/26/2020 , 05/26/2027 ,For the initial treatment of severe malaria in adult and pediatric patients to always be followed by a complete treatment course of an appropriate oral antimalarial regimen.
FIHJKUPKCHIPAT-MFMTXCBGSA-N,146160078,FIHJKUPKCHIPAT-MFMTXCBGSA-N,artesunate,,Immediate treatment of malaria,C0024530,Malaria,3/28/06,Designated/Approved,,Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen., 05/26/2020 , 05/26/2027 ,For the initial treatment of severe malaria in adult and pediatric patients to always be followed by a complete treatment course of an appropriate oral antimalarial regimen.
FIHJKUPKCHIPAT-RVBFJZMGSA-N,129317578,FIHJKUPKCHIPAT-RVBFJZMGSA-N,artesunate,,Immediate treatment of malaria,C0024530,Malaria,3/28/06,Designated/Approved,,Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen., 05/26/2020 , 05/26/2027 ,For the initial treatment of severe malaria in adult and pediatric patients to always be followed by a complete treatment course of an appropriate oral antimalarial regimen.
FIHJKUPKCHIPAT-DRVUCALVSA-N,126963478,FIHJKUPKCHIPAT-DRVUCALVSA-N,artesunate,,Immediate treatment of malaria,C0024530,Malaria,3/28/06,Designated/Approved,,Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen., 05/26/2020 , 05/26/2027 ,For the initial treatment of severe malaria in adult and pediatric patients to always be followed by a complete treatment course of an appropriate oral antimalarial regimen.
FIHJKUPKCHIPAT-AXFKQHSWSA-N,9821433,FIHJKUPKCHIPAT-AXFKQHSWSA-N,artesunate,,Immediate treatment of malaria,C0024530,Malaria,3/28/06,Designated/Approved,,Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen., 05/26/2020 , 05/26/2027 ,For the initial treatment of severe malaria in adult and pediatric patients to always be followed by a complete treatment course of an appropriate oral antimalarial regimen.
FIHJKUPKCHIPAT-OQYNCAMDSA-N,53486426,FIHJKUPKCHIPAT-OQYNCAMDSA-N,artesunate,,Immediate treatment of malaria,C0024530,Malaria,3/28/06,Designated/Approved,,Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen., 05/26/2020 , 05/26/2027 ,For the initial treatment of severe malaria in adult and pediatric patients to always be followed by a complete treatment course of an appropriate oral antimalarial regimen.
FIHJKUPKCHIPAT-RLQWWVEOSA-N,16394563,FIHJKUPKCHIPAT-RLQWWVEOSA-N,artesunate,,Immediate treatment of malaria,C0024530,Malaria,3/28/06,Designated/Approved,,Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen., 05/26/2020 , 05/26/2027 ,For the initial treatment of severe malaria in adult and pediatric patients to always be followed by a complete treatment course of an appropriate oral antimalarial regimen.
FIHJKUPKCHIPAT-UHFFFAOYSA-N,105031,FIHJKUPKCHIPAT-UHFFFAOYSA-N,artesunate,,Immediate treatment of malaria,C0024530,Malaria,3/28/06,Designated/Approved,,Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen., 05/26/2020 , 05/26/2027 ,For the initial treatment of severe malaria in adult and pediatric patients to always be followed by a complete treatment course of an appropriate oral antimalarial regimen.
FIHJKUPKCHIPAT-HXMLZIBGSA-N,156252,FIHJKUPKCHIPAT-HXMLZIBGSA-N,artesunate,,Immediate treatment of malaria,C0024530,Malaria,3/28/06,Designated/Approved,,Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen., 05/26/2020 , 05/26/2027 ,For the initial treatment of severe malaria in adult and pediatric patients to always be followed by a complete treatment course of an appropriate oral antimalarial regimen.
FIHJKUPKCHIPAT-JQXDXKTESA-N,5464098,FIHJKUPKCHIPAT-JQXDXKTESA-N,artesunate,,Immediate treatment of malaria,C0024530,Malaria,3/28/06,Designated/Approved,,Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen., 05/26/2020 , 05/26/2027 ,For the initial treatment of severe malaria in adult and pediatric patients to always be followed by a complete treatment course of an appropriate oral antimalarial regimen.
FIHJKUPKCHIPAT-NKHDUEHSSA-N,65664,FIHJKUPKCHIPAT-NKHDUEHSSA-N,artesunate,,Immediate treatment of malaria,C0024530,Malaria,3/28/06,Designated/Approved,,Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen., 05/26/2020 , 05/26/2027 ,For the initial treatment of severe malaria in adult and pediatric patients to always be followed by a complete treatment course of an appropriate oral antimalarial regimen.
FIHJKUPKCHIPAT-AHIGJZGOSA-N,6917864,FIHJKUPKCHIPAT-AHIGJZGOSA-N,artesunate,,Immediate treatment of malaria,C0024530,Malaria,3/28/06,Designated/Approved,,Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen., 05/26/2020 , 05/26/2027 ,For the initial treatment of severe malaria in adult and pediatric patients to always be followed by a complete treatment course of an appropriate oral antimalarial regimen.
FIHJKUPKCHIPAT-PNDUOAGUSA-N,129009911,FIHJKUPKCHIPAT-PNDUOAGUSA-N,artesunate,,Treatment of malaria,C0024530,Malaria,7/22/19,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-XIIQFBLFSA-N,91746179,FIHJKUPKCHIPAT-XIIQFBLFSA-N,artesunate,,Treatment of malaria,C0024530,Malaria,7/22/19,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-WNZKYHKJSA-N,60196289,FIHJKUPKCHIPAT-WNZKYHKJSA-N,artesunate,,Treatment of malaria,C0024530,Malaria,7/22/19,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-RUYKMDFCSA-N,49769200,FIHJKUPKCHIPAT-RUYKMDFCSA-N,artesunate,,Treatment of malaria,C0024530,Malaria,7/22/19,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-MFMTXCBGSA-N,146160078,FIHJKUPKCHIPAT-MFMTXCBGSA-N,artesunate,,Treatment of malaria,C0024530,Malaria,7/22/19,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-RVBFJZMGSA-N,129317578,FIHJKUPKCHIPAT-RVBFJZMGSA-N,artesunate,,Treatment of malaria,C0024530,Malaria,7/22/19,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-DRVUCALVSA-N,126963478,FIHJKUPKCHIPAT-DRVUCALVSA-N,artesunate,,Treatment of malaria,C0024530,Malaria,7/22/19,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-AXFKQHSWSA-N,9821433,FIHJKUPKCHIPAT-AXFKQHSWSA-N,artesunate,,Treatment of malaria,C0024530,Malaria,7/22/19,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-OQYNCAMDSA-N,53486426,FIHJKUPKCHIPAT-OQYNCAMDSA-N,artesunate,,Treatment of malaria,C0024530,Malaria,7/22/19,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-RLQWWVEOSA-N,16394563,FIHJKUPKCHIPAT-RLQWWVEOSA-N,artesunate,,Treatment of malaria,C0024530,Malaria,7/22/19,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-UHFFFAOYSA-N,105031,FIHJKUPKCHIPAT-UHFFFAOYSA-N,artesunate,,Treatment of malaria,C0024530,Malaria,7/22/19,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-HXMLZIBGSA-N,156252,FIHJKUPKCHIPAT-HXMLZIBGSA-N,artesunate,,Treatment of malaria,C0024530,Malaria,7/22/19,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-JQXDXKTESA-N,5464098,FIHJKUPKCHIPAT-JQXDXKTESA-N,artesunate,,Treatment of malaria,C0024530,Malaria,7/22/19,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-NKHDUEHSSA-N,65664,FIHJKUPKCHIPAT-NKHDUEHSSA-N,artesunate,,Treatment of malaria,C0024530,Malaria,7/22/19,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-AHIGJZGOSA-N,6917864,FIHJKUPKCHIPAT-AHIGJZGOSA-N,artesunate,,Treatment of malaria,C0024530,Malaria,7/22/19,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-PNDUOAGUSA-N,129009911,FIHJKUPKCHIPAT-PNDUOAGUSA-N,Artesunate,,Treatment of malaria,C0024530,Malaria,9/5/17,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-XIIQFBLFSA-N,91746179,FIHJKUPKCHIPAT-XIIQFBLFSA-N,Artesunate,,Treatment of malaria,C0024530,Malaria,9/5/17,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-WNZKYHKJSA-N,60196289,FIHJKUPKCHIPAT-WNZKYHKJSA-N,Artesunate,,Treatment of malaria,C0024530,Malaria,9/5/17,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-RUYKMDFCSA-N,49769200,FIHJKUPKCHIPAT-RUYKMDFCSA-N,Artesunate,,Treatment of malaria,C0024530,Malaria,9/5/17,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-MFMTXCBGSA-N,146160078,FIHJKUPKCHIPAT-MFMTXCBGSA-N,Artesunate,,Treatment of malaria,C0024530,Malaria,9/5/17,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-RVBFJZMGSA-N,129317578,FIHJKUPKCHIPAT-RVBFJZMGSA-N,Artesunate,,Treatment of malaria,C0024530,Malaria,9/5/17,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-DRVUCALVSA-N,126963478,FIHJKUPKCHIPAT-DRVUCALVSA-N,Artesunate,,Treatment of malaria,C0024530,Malaria,9/5/17,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-AXFKQHSWSA-N,9821433,FIHJKUPKCHIPAT-AXFKQHSWSA-N,Artesunate,,Treatment of malaria,C0024530,Malaria,9/5/17,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-OQYNCAMDSA-N,53486426,FIHJKUPKCHIPAT-OQYNCAMDSA-N,Artesunate,,Treatment of malaria,C0024530,Malaria,9/5/17,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-RLQWWVEOSA-N,16394563,FIHJKUPKCHIPAT-RLQWWVEOSA-N,Artesunate,,Treatment of malaria,C0024530,Malaria,9/5/17,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-UHFFFAOYSA-N,105031,FIHJKUPKCHIPAT-UHFFFAOYSA-N,Artesunate,,Treatment of malaria,C0024530,Malaria,9/5/17,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-HXMLZIBGSA-N,156252,FIHJKUPKCHIPAT-HXMLZIBGSA-N,Artesunate,,Treatment of malaria,C0024530,Malaria,9/5/17,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-JQXDXKTESA-N,5464098,FIHJKUPKCHIPAT-JQXDXKTESA-N,Artesunate,,Treatment of malaria,C0024530,Malaria,9/5/17,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-NKHDUEHSSA-N,65664,FIHJKUPKCHIPAT-NKHDUEHSSA-N,Artesunate,,Treatment of malaria,C0024530,Malaria,9/5/17,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-AHIGJZGOSA-N,6917864,FIHJKUPKCHIPAT-AHIGJZGOSA-N,Artesunate,,Treatment of malaria,C0024530,Malaria,9/5/17,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-PNDUOAGUSA-N,129009911,FIHJKUPKCHIPAT-PNDUOAGUSA-N,Artesunate,,Treatment of malaria.,C0024530,Malaria,7/19/99,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-XIIQFBLFSA-N,91746179,FIHJKUPKCHIPAT-XIIQFBLFSA-N,Artesunate,,Treatment of malaria.,C0024530,Malaria,7/19/99,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-WNZKYHKJSA-N,60196289,FIHJKUPKCHIPAT-WNZKYHKJSA-N,Artesunate,,Treatment of malaria.,C0024530,Malaria,7/19/99,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-RUYKMDFCSA-N,49769200,FIHJKUPKCHIPAT-RUYKMDFCSA-N,Artesunate,,Treatment of malaria.,C0024530,Malaria,7/19/99,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-MFMTXCBGSA-N,146160078,FIHJKUPKCHIPAT-MFMTXCBGSA-N,Artesunate,,Treatment of malaria.,C0024530,Malaria,7/19/99,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-RVBFJZMGSA-N,129317578,FIHJKUPKCHIPAT-RVBFJZMGSA-N,Artesunate,,Treatment of malaria.,C0024530,Malaria,7/19/99,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-DRVUCALVSA-N,126963478,FIHJKUPKCHIPAT-DRVUCALVSA-N,Artesunate,,Treatment of malaria.,C0024530,Malaria,7/19/99,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-AXFKQHSWSA-N,9821433,FIHJKUPKCHIPAT-AXFKQHSWSA-N,Artesunate,,Treatment of malaria.,C0024530,Malaria,7/19/99,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-OQYNCAMDSA-N,53486426,FIHJKUPKCHIPAT-OQYNCAMDSA-N,Artesunate,,Treatment of malaria.,C0024530,Malaria,7/19/99,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-RLQWWVEOSA-N,16394563,FIHJKUPKCHIPAT-RLQWWVEOSA-N,Artesunate,,Treatment of malaria.,C0024530,Malaria,7/19/99,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-UHFFFAOYSA-N,105031,FIHJKUPKCHIPAT-UHFFFAOYSA-N,Artesunate,,Treatment of malaria.,C0024530,Malaria,7/19/99,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-HXMLZIBGSA-N,156252,FIHJKUPKCHIPAT-HXMLZIBGSA-N,Artesunate,,Treatment of malaria.,C0024530,Malaria,7/19/99,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-JQXDXKTESA-N,5464098,FIHJKUPKCHIPAT-JQXDXKTESA-N,Artesunate,,Treatment of malaria.,C0024530,Malaria,7/19/99,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-NKHDUEHSSA-N,65664,FIHJKUPKCHIPAT-NKHDUEHSSA-N,Artesunate,,Treatment of malaria.,C0024530,Malaria,7/19/99,Designated,Not FDA Approved for Orphan Indication,,,,
FIHJKUPKCHIPAT-AHIGJZGOSA-N,6917864,FIHJKUPKCHIPAT-AHIGJZGOSA-N,Artesunate,,Treatment of malaria.,C0024530,Malaria,7/19/99,Designated,Not FDA Approved for Orphan Indication,,,,
VOVZXURTCKPRDQ-CQSZACIVSA-N,72165228,VOVZXURTCKPRDQ-CQSZACIVSA-N,asciminib,,Treatment of chronic myelogenous leukemia,C0023473,Chronic myelogenous leukemia,2/27/17,Designated,Not FDA Approved for Orphan Indication,,,,
CIWBSHSKHKDKBQ-JLAZNSOCSA-N,54670067,CIWBSHSKHKDKBQ-JLAZNSOCSA-N,ascorbic acid,,Treatment of cystic fibrosis,C0010674,Cystic Fibrosis,7/30/18,Designated,Not FDA Approved for Orphan Indication,,,,
CIWBSHSKHKDKBQ-JLAZNSOCSA-N,54670067,CIWBSHSKHKDKBQ-JLAZNSOCSA-N,ascorbic acid,Ascor,Treatment of scurvy,C0036474,Scurvy,8/31/07,Designated/Approved,,"for the treatment of scurvy in adult and pediatric patients age 5 months and older for whom oral administrtaion is not possible, insufficient or contraindicated", 10/02/2017 , 10/02/2024 ,"for the treatment of scurvy in adult and pediatric patients age 5 months and older for whom oral administrtaion is not possible, insufficient or contraindicated"
BSYNRYMUTXBXSQ-UHFFFAOYSA-N,2244,BSYNRYMUTXBXSQ-UHFFFAOYSA-N,aspirin,,Treatment of Kawasaki Disease,C0026691,Kawasaki Disease,9/18/20,Designated,Not FDA Approved for Orphan Indication,,,,
OOUGLTULBSNHNF-UHFFFAOYSA-N,11219835,OOUGLTULBSNHNF-UHFFFAOYSA-N,ataluren,,Treatment of spinal muscular atrophy,C0026847,Spinal Muscular Atrophy,3/10/08,Designated,Not FDA Approved for Orphan Indication,,,,
OOUGLTULBSNHNF-UHFFFAOYSA-N,11219835,OOUGLTULBSNHNF-UHFFFAOYSA-N,ataluren,,Treatment of aniridia,C0003076,Aniridia,9/1/15,Designated,Not FDA Approved for Orphan Indication,,,,
OOUGLTULBSNHNF-UHFFFAOYSA-N,11219835,OOUGLTULBSNHNF-UHFFFAOYSA-N,ataluren,,Treatment of mucopolysaccharidosis type I,C0023786,Mucopolysaccharidosis Type I,12/10/14,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
OOUGLTULBSNHNF-UHFFFAOYSA-N,11219835,OOUGLTULBSNHNF-UHFFFAOYSA-N,ataluren,,Treatment of Muscular Dystrophy resulting from premature stop mutations in the dystrohin gene,C0026850,Muscular Dystrophy,1/10/05,Designated,Not FDA Approved for Orphan Indication,,,,
OOUGLTULBSNHNF-UHFFFAOYSA-N,11219835,OOUGLTULBSNHNF-UHFFFAOYSA-N,ataluren,,For use in the treatment of cystic fibrosis resulting fron a nonsense (premature stopcodon) mutation in the cystic bibrosis transmembrane conductance regulatory gene,C0010674,Cystic Fibrosis,9/1/04,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
LUCXVPAZUDVVBT-UNTBIKODSA-N,54840,LUCXVPAZUDVVBT-UNTBIKODSA-N,Atomoxetine hydrochloride,,Treatment of Tourette's Syndrome,C0040517,Tourette's Syndrome,8/26/03,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
BSJMWHQBCZFXBR-UHFFFAOYSA-N,74989,BSJMWHQBCZFXBR-UHFFFAOYSA-N,Atovaquone,Mepron,Treatment of AIDS associated Pneumocystis Carinii Pneumonia.,"C0001175,C1535939","AIDS , Pneumocystis carinii Pneumonia",9/10/90,Designated/Approved,,For the acute oral treatment of mild to moderate Pneumocystis carinii pneumonia in patients who are intolerant to trimethoprim-sulfamethoxazole., 11/25/1992 , 11/25/1999 ,
BSJMWHQBCZFXBR-UHFFFAOYSA-N,74989,BSJMWHQBCZFXBR-UHFFFAOYSA-N,Atovaquone,Mepron,"Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients defined by a history of one or more episodes of PCP and/or a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm3.","C0019682,C1535939","HIV , Pneumocystis carinii Pneumonia",8/14/91,Designated/Approved,,Prevention of PCP in patients who are intolerant to trimethoprim-sulfamethoxazole., 01/05/1999 , 01/05/2006 ,
BSJMWHQBCZFXBR-UHFFFAOYSA-N,74989,BSJMWHQBCZFXBR-UHFFFAOYSA-N,Atovaquone,,Treatment and suppression of Toxoplasma gondii encephalitis.,C0085315,toxoplasma gondii encephalitis,3/16/93,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
BSJMWHQBCZFXBR-UHFFFAOYSA-N,74989,BSJMWHQBCZFXBR-UHFFFAOYSA-N,Atovaquone,,Primary prophylaxis of HIV-infected persons at high risk for developing Toxoplasma gondii encephalitis.,"C0019682,C0085315","HIV , toxoplasma gondii encephalitis",3/16/93,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
MOTJMGVDPWRKOC-QPVYNBJUSA-N,159594,MOTJMGVDPWRKOC-QPVYNBJUSA-N,Atrasentan,,Treatment of pediatric nephrotic syndrome,C0027726,Nephrotic Syndrome,9/29/16,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
IRPYFWIZKIOHQN-XTZHGVARSA-N,138402869,IRPYFWIZKIOHQN-XTZHGVARSA-N,auranofin,,Treatment of amebiasis,C0013370,amebiasis,4/30/10,Designated,Not FDA Approved for Orphan Indication,,,,
AUJRCFUBUPVWSZ-JMYRMHIVSA-M,124081048,AUJRCFUBUPVWSZ-JMYRMHIVSA-M,auranofin,,Treatment of amebiasis,C0013370,amebiasis,4/30/10,Designated,Not FDA Approved for Orphan Indication,,,,
AUJRCFUBUPVWSZ-BQWBZISASA-N,57417071,AUJRCFUBUPVWSZ-BQWBZISASA-N,auranofin,,Treatment of amebiasis,C0013370,amebiasis,4/30/10,Designated,Not FDA Approved for Orphan Indication,,,,
AUJRCFUBUPVWSZ-UHFFFAOYSA-N,6333901,AUJRCFUBUPVWSZ-UHFFFAOYSA-N,auranofin,,Treatment of amebiasis,C0013370,amebiasis,4/30/10,Designated,Not FDA Approved for Orphan Indication,,,,
AUJRCFUBUPVWSZ-XTZHGVARSA-M,6918453,AUJRCFUBUPVWSZ-XTZHGVARSA-M,auranofin,,Treatment of amebiasis,C0013370,amebiasis,4/30/10,Designated,Not FDA Approved for Orphan Indication,,,,
AUJRCFUBUPVWSZ-XTZHGVARSA-M,6918453,AUJRCFUBUPVWSZ-XTZHGVARSA-M,auranofin,,Treatment of amebiasis,C0013370,amebiasis,4/30/10,Designated,Not FDA Approved for Orphan Indication,,,,
IRPYFWIZKIOHQN-XTZHGVARSA-N,138402869,IRPYFWIZKIOHQN-XTZHGVARSA-N,auranofin,,Treatment of amebiasis,C0013370,amebiasis,4/30/10,Designated,Not FDA Approved for Orphan Indication,,,,
AUJRCFUBUPVWSZ-UHFFFAOYSA-M,24199313,AUJRCFUBUPVWSZ-UHFFFAOYSA-M,auranofin,,Treatment of amebiasis,C0013370,amebiasis,4/30/10,Designated,Not FDA Approved for Orphan Indication,,,,
PUKBOVABABRILL-YZNIXAGQSA-N,49841217,PUKBOVABABRILL-YZNIXAGQSA-N,avacopan,,Treatment of atypical hemolytic uremic syndrome,C2931788,Atypical Hemolytic Uremic Syndrome,11/17/14,Designated,Not FDA Approved for Orphan Indication,,,,
PUKBOVABABRILL-YZNIXAGQSA-N,49841217,PUKBOVABABRILL-YZNIXAGQSA-N,avacopan,,Treatment of C3 glomerulopathy,C4521256,Glomerulopathy,3/20/17,Designated,Not FDA Approved for Orphan Indication,,,,
PUKBOVABABRILL-YZNIXAGQSA-N,49841217,PUKBOVABABRILL-YZNIXAGQSA-N,avacopan,,"Treatment of anti-neutrophil cytoplasmic autoantibodies associated vasculitides (granulomatosis with polyangiitis or Wegener's granulomatosis), microscopic polyangiitis, and Churg-Strauss syndrome.","C0008728,C0042384,C2347126,C3495801,C4050407","Churg-Strauss Syndrome , Vasculitides , Microscopic Polyangiitis , Granulomatosis with polyangiitis , Wegener Granulomatosis",6/2/14,Designated,Not FDA Approved for Orphan Indication,,,,
DWYRIWUZIJHQKQ-SANMLTNESA-N,118023034,DWYRIWUZIJHQKQ-SANMLTNESA-N,avapritinib,,Treatment of mastocytosis,C0024899,Mastocytosis,1/21/16,Designated,Not FDA Approved for Orphan Indication,,,,
DWYRIWUZIJHQKQ-SANMLTNESA-N,118023034,DWYRIWUZIJHQKQ-SANMLTNESA-N,avapritinib,Ayvakit,Treatment of gastrointestinal stromal tumors,C0238198,Gastrointestinal Stromal Tumors,1/6/16,Designated/Approved,,"AYVAKIT is indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations", 01/09/2020 , 01/09/2027 ,
MISPBGHDNZYFNM-BTJKTKAUSA-N,9918581,MISPBGHDNZYFNM-BTJKTKAUSA-N,avatrombopag maleate,,Treatment of chemotherapy-induced thrombocytopenia,C0040034,Thrombocytopenia,12/19/19,Designated,Not FDA Approved for Orphan Indication,,,,
MISPBGHDNZYFNM-BTJKTKAUSA-N,9918581,MISPBGHDNZYFNM-BTJKTKAUSA-N,avatrombopag maleate,,Treatment of idiopathic thrombocytopenic purpura,C0398650,IDIOPATHIC THROMBOCYTOPENIC PURPURA,9/1/11,Designated/Approved,,DOPTELET is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment, 06/26/2019 , 06/26/2026 ,For the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment
HKEDBKXRDHFCFB-UHFFFAOYSA-N,3216,HKEDBKXRDHFCFB-UHFFFAOYSA-N,avicin d,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,3/24/15,Designated,Not FDA Approved for Orphan Indication,,,,
HKEDBKXRDHFCFB-LUAQNYIXSA-N,44566777,HKEDBKXRDHFCFB-LUAQNYIXSA-N,avicin d,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,3/24/15,Designated,Not FDA Approved for Orphan Indication,,,,
VBUWHHLIZKOSMS-RIWXPGAOSA-N,53314964,VBUWHHLIZKOSMS-RIWXPGAOSA-N,Aviptadil,,Treatment of sarcoidosis,C0036202,Sarcoidosis,7/23/20,Designated,Not FDA Approved for Orphan Indication,,,,
VBUWHHLIZKOSMS-RIWXPGAOSA-N,53314964,VBUWHHLIZKOSMS-RIWXPGAOSA-N,aviptadil,,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,2/22/05,Designated,Not FDA Approved for Orphan Indication,,,,
RITAVMQDGBJQJZ-FMIVXFBMSA-N,6450551,RITAVMQDGBJQJZ-FMIVXFBMSA-N,axitinib,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,5/31/07,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
NMUSYJAQQFHJEW-KVTDHHQDSA-N,9444,NMUSYJAQQFHJEW-KVTDHHQDSA-N,azacitidine,Vidaza,Treatament of myelodysplastic syndromes,C3463824,Myelodysplastic Syndromes,12/3/01,Designated/Approved,,"Treatment of patients with the following myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia and requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia", 05/19/2004 , 05/19/2011 ,
NMUSYJAQQFHJEW-KVTDHHQDSA-N,9444,NMUSYJAQQFHJEW-KVTDHHQDSA-N,Azacitidine,ONUREG,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,6/18/08,Designated/Approved,,ONUREG is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy, 09/01/2020 , 09/01/2027 ,ONUREG is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy
LMEKQMALGUDUQG-UHFFFAOYSA-N,2265,LMEKQMALGUDUQG-UHFFFAOYSA-N,Azathioprine,,Treatment of oral manifestations of graft-versus-host disease.,C0018133,Graft-Versus-Host Disease,9/14/99,Designated,Not FDA Approved for Orphan Indication,,,,
WZPBZJONDBGPKJ-HMTIBFNOSA-N,86741379,WZPBZJONDBGPKJ-HMTIBFNOSA-N,aztreonam,,Improvement of respiratory symptoms in patients with bronchiectasis and gram-negative bacteria in the airways.,"C0006267,C0037090","Bronchiectasis , Respiratory symptoms",5/15/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
WZPBZJONDBGPKJ-NACOFCMISA-N,22842006,WZPBZJONDBGPKJ-NACOFCMISA-N,aztreonam,,Improvement of respiratory symptoms in patients with bronchiectasis and gram-negative bacteria in the airways.,"C0006267,C0037090","Bronchiectasis , Respiratory symptoms",5/15/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
WZPBZJONDBGPKJ-PSGLRMFWSA-N,56842327,WZPBZJONDBGPKJ-PSGLRMFWSA-N,aztreonam,,Improvement of respiratory symptoms in patients with bronchiectasis and gram-negative bacteria in the airways.,"C0006267,C0037090","Bronchiectasis , Respiratory symptoms",5/15/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
WZPBZJONDBGPKJ-CAOOACKPSA-N,5466987,WZPBZJONDBGPKJ-CAOOACKPSA-N,aztreonam,,Improvement of respiratory symptoms in patients with bronchiectasis and gram-negative bacteria in the airways.,"C0006267,C0037090","Bronchiectasis , Respiratory symptoms",5/15/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
WZPBZJONDBGPKJ-FSPLSTOPSA-N,54117,WZPBZJONDBGPKJ-FSPLSTOPSA-N,aztreonam,,Improvement of respiratory symptoms in patients with bronchiectasis and gram-negative bacteria in the airways.,"C0006267,C0037090","Bronchiectasis , Respiratory symptoms",5/15/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
WZPBZJONDBGPKJ-UHFFFAOYSA-N,2274,WZPBZJONDBGPKJ-UHFFFAOYSA-N,aztreonam,,Improvement of respiratory symptoms in patients with bronchiectasis and gram-negative bacteria in the airways.,"C0006267,C0037090","Bronchiectasis , Respiratory symptoms",5/15/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
WZPBZJONDBGPKJ-IYZXUIDESA-N,5459211,WZPBZJONDBGPKJ-IYZXUIDESA-N,aztreonam,,Improvement of respiratory symptoms in patients with bronchiectasis and gram-negative bacteria in the airways.,"C0006267,C0037090","Bronchiectasis , Respiratory symptoms",5/15/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
WZPBZJONDBGPKJ-VEHQQRBSSA-N,5742832,WZPBZJONDBGPKJ-VEHQQRBSSA-N,aztreonam,,Improvement of respiratory symptoms in patients with bronchiectasis and gram-negative bacteria in the airways.,"C0006267,C0037090","Bronchiectasis , Respiratory symptoms",5/15/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
WZPBZJONDBGPKJ-HMTIBFNOSA-N,86741379,WZPBZJONDBGPKJ-HMTIBFNOSA-N,aztreonam,Cayston,Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis,C0010674,Cystic Fibrosis,3/12/02,Designated/Approved,,To improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa, 02/22/2010 , 02/22/2017 ,
WZPBZJONDBGPKJ-NACOFCMISA-N,22842006,WZPBZJONDBGPKJ-NACOFCMISA-N,aztreonam,Cayston,Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis,C0010674,Cystic Fibrosis,3/12/02,Designated/Approved,,To improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa, 02/22/2010 , 02/22/2017 ,
WZPBZJONDBGPKJ-PSGLRMFWSA-N,56842327,WZPBZJONDBGPKJ-PSGLRMFWSA-N,aztreonam,Cayston,Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis,C0010674,Cystic Fibrosis,3/12/02,Designated/Approved,,To improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa, 02/22/2010 , 02/22/2017 ,
WZPBZJONDBGPKJ-CAOOACKPSA-N,5466987,WZPBZJONDBGPKJ-CAOOACKPSA-N,aztreonam,Cayston,Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis,C0010674,Cystic Fibrosis,3/12/02,Designated/Approved,,To improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa, 02/22/2010 , 02/22/2017 ,
WZPBZJONDBGPKJ-FSPLSTOPSA-N,54117,WZPBZJONDBGPKJ-FSPLSTOPSA-N,aztreonam,Cayston,Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis,C0010674,Cystic Fibrosis,3/12/02,Designated/Approved,,To improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa, 02/22/2010 , 02/22/2017 ,
WZPBZJONDBGPKJ-UHFFFAOYSA-N,2274,WZPBZJONDBGPKJ-UHFFFAOYSA-N,aztreonam,Cayston,Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis,C0010674,Cystic Fibrosis,3/12/02,Designated/Approved,,To improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa, 02/22/2010 , 02/22/2017 ,
WZPBZJONDBGPKJ-IYZXUIDESA-N,5459211,WZPBZJONDBGPKJ-IYZXUIDESA-N,aztreonam,Cayston,Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis,C0010674,Cystic Fibrosis,3/12/02,Designated/Approved,,To improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa, 02/22/2010 , 02/22/2017 ,
WZPBZJONDBGPKJ-VEHQQRBSSA-N,5742832,WZPBZJONDBGPKJ-VEHQQRBSSA-N,aztreonam,Cayston,Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis,C0010674,Cystic Fibrosis,3/12/02,Designated/Approved,,To improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa, 02/22/2010 , 02/22/2017 ,
KPYSYYIEGFHWSV-UHFFFAOYSA-N,2284,KPYSYYIEGFHWSV-UHFFFAOYSA-N,baclofen,,Treatment of complex regional pain syndrome,C0458219,Complex regional pain syndrome,10/28/15,Designated,Not FDA Approved for Orphan Indication,,,,
KPYSYYIEGFHWSV-UHFFFAOYSA-N,2284,KPYSYYIEGFHWSV-UHFFFAOYSA-N,Baclofen,,Treatment of spasticity associated with cerebral palsy.,"C0007789,C0026838","Cerebral Palsy , Spasticity",9/26/94,Designated,Not FDA Approved for Orphan Indication,,,,
KPYSYYIEGFHWSV-UHFFFAOYSA-N,2284,KPYSYYIEGFHWSV-UHFFFAOYSA-N,baclofen,Lioresal Intrathecal,"Treatment of intractable spasticity caused by spinal cord injury, multiple sclerosis, and other spinal diseases (including spinal ischemia, spinal tumor, transverse myelitis, cervical spondylosis, and degenerative myelopathy).","C0022116,C0026769,C0026838,C0026976,C0037929,C0037930,C0037933,C0270780,C1384641","Ischemia , Multiple Sclerosis , Spasticity , Transverse myelitis , Spinal Cord Injury , Spinal tumor , Spinal Diseases , Degenerative myelopathy , Cervical spondylosis",11/10/87,Designated/Approved,,Management of severe spasticity of spinal cord origin in patients who are unresponsive to oral baclofen therapy or experience intolerable CNS side effects at effective doses., 06/25/1992 , 06/25/1999 ,
KPYSYYIEGFHWSV-UHFFFAOYSA-N,2284,KPYSYYIEGFHWSV-UHFFFAOYSA-N,baclofen,OZOBAX,Treatment of intractable spasticity due to multiple sclerosis or spinal cord injury.,"C0026769,C0026838,C0037929","Multiple Sclerosis , Spasticity , Spinal Cord Injury",12/16/91,Designated/Approved,,"OZOBAX is indicated for the treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity.", 09/18/2019 ,  ,
KPYSYYIEGFHWSV-UHFFFAOYSA-N,2284,KPYSYYIEGFHWSV-UHFFFAOYSA-N,baclofen,,Treatment of dystonia,C0013421,Dystonia,12/2/03,Designated,Not FDA Approved for Orphan Indication,,,,
KPYSYYIEGFHWSV-UHFFFAOYSA-N,2284,KPYSYYIEGFHWSV-UHFFFAOYSA-N,baclofen,,Prevention of baclofen withdrawal syndrome,C0038587,Withdrawal Syndrome,12/31/20,Designated,Not FDA Approved for Orphan Indication,,,,
KVHRYLNQDWXAGI-UHFFFAOYSA-N,46848915,KVHRYLNQDWXAGI-UHFFFAOYSA-N,Balipodect,,Treatment of CDKL5 deficiency disorder,C0012634,Disorder,6/19/19,Designated,Not FDA Approved for Orphan Indication,,,,
KVHRYLNQDWXAGI-UHFFFAOYSA-N,46848915,KVHRYLNQDWXAGI-UHFFFAOYSA-N,Balipodect,,Treatment of Fragile X Syndrome,C0016667,Fragile X Syndrome,6/13/19,Designated,Not FDA Approved for Orphan Indication,,,,
IBRSMMVMVMCYCS-UHFFFAOYSA-N,135430840,IBRSMMVMVMCYCS-UHFFFAOYSA-N,Balsalazide disodium,Colazal,Treatment of pediatric patients with ulcerative colitis,C0009324,Ulcerative Colitis,8/12/05,Designated/Approved,,Treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. Safety and Effectiveness of Colazal beyond 8 weeks in children (ages 5-17) and 12 weeks in adults have not been established., 12/20/2006 , 12/20/2013 ,
UANPKWBWEAQNQY-UHFFFAOYSA-N,136040192,UANPKWBWEAQNQY-UHFFFAOYSA-N,Balsalazide disodium,Colazal,Treatment of pediatric patients with ulcerative colitis,C0009324,Ulcerative Colitis,8/12/05,Designated/Approved,,Treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. Safety and Effectiveness of Colazal beyond 8 weeks in children (ages 5-17) and 12 weeks in adults have not been established., 12/20/2006 , 12/20/2013 ,
WLYZKTXOAMAVEO-UHFFFAOYSA-N,135515521,WLYZKTXOAMAVEO-UHFFFAOYSA-N,Balsalazide disodium,Colazal,Treatment of pediatric patients with ulcerative colitis,C0009324,Ulcerative Colitis,8/12/05,Designated/Approved,,Treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. Safety and Effectiveness of Colazal beyond 8 weeks in children (ages 5-17) and 12 weeks in adults have not been established., 12/20/2006 , 12/20/2013 ,
IPOKCKJONYRRHP-UHFFFAOYSA-N,54585,IPOKCKJONYRRHP-UHFFFAOYSA-N,Balsalazide disodium,Colazal,Treatment of pediatric patients with ulcerative colitis,C0009324,Ulcerative Colitis,8/12/05,Designated/Approved,,Treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. Safety and Effectiveness of Colazal beyond 8 weeks in children (ages 5-17) and 12 weeks in adults have not been established., 12/20/2006 , 12/20/2013 ,
XDCNKOBSQURQOZ-UHFFFAOYSA-L,135414247,XDCNKOBSQURQOZ-UHFFFAOYSA-L,Balsalazide disodium,Colazal,Treatment of pediatric patients with ulcerative colitis,C0009324,Ulcerative Colitis,8/12/05,Designated/Approved,,Treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. Safety and Effectiveness of Colazal beyond 8 weeks in children (ages 5-17) and 12 weeks in adults have not been established., 12/20/2006 , 12/20/2013 ,
CKMOQBVBEGCJGW-UHFFFAOYSA-L,135413496,CKMOQBVBEGCJGW-UHFFFAOYSA-L,Balsalazide disodium,Colazal,Treatment of pediatric patients with ulcerative colitis,C0009324,Ulcerative Colitis,8/12/05,Designated/Approved,,Treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. Safety and Effectiveness of Colazal beyond 8 weeks in children (ages 5-17) and 12 weeks in adults have not been established., 12/20/2006 , 12/20/2013 ,
TXGZJQLMVSIZEI-UQMAOPSPSA-N,400010,TXGZJQLMVSIZEI-UQMAOPSPSA-N,Bardoxolone,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,8/6/08,Designated,Not FDA Approved for Orphan Indication,,,,
TXGZJQLMVSIZEI-UQMAOPSPSA-N,400010,TXGZJQLMVSIZEI-UQMAOPSPSA-N,bardoxolone,,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,3/30/15,Designated,Not FDA Approved for Orphan Indication,,,,
WPTTVJLTNAWYAO-OYWPANLISA-N,133109022,WPTTVJLTNAWYAO-OYWPANLISA-N,bardoxolone methyl,,Treatment of autosomal dominant polycystic kidney disease,C0085413,Autosomal dominant polycystic kidney disease,6/3/19,Designated,Not FDA Approved for Orphan Indication,,,,
WPTTVJLTNAWYAO-ZREYCQBLSA-N,131632414,WPTTVJLTNAWYAO-ZREYCQBLSA-N,bardoxolone methyl,,Treatment of autosomal dominant polycystic kidney disease,C0085413,Autosomal dominant polycystic kidney disease,6/3/19,Designated,Not FDA Approved for Orphan Indication,,,,
WPTTVJLTNAWYAO-OROHISIGSA-N,24896135,WPTTVJLTNAWYAO-OROHISIGSA-N,bardoxolone methyl,,Treatment of autosomal dominant polycystic kidney disease,C0085413,Autosomal dominant polycystic kidney disease,6/3/19,Designated,Not FDA Approved for Orphan Indication,,,,
WPTTVJLTNAWYAO-UHFFFAOYSA-N,53315588,WPTTVJLTNAWYAO-UHFFFAOYSA-N,bardoxolone methyl,,Treatment of autosomal dominant polycystic kidney disease,C0085413,Autosomal dominant polycystic kidney disease,6/3/19,Designated,Not FDA Approved for Orphan Indication,,,,
WPTTVJLTNAWYAO-UFHYVYMVSA-N,49827815,WPTTVJLTNAWYAO-UFHYVYMVSA-N,bardoxolone methyl,,Treatment of autosomal dominant polycystic kidney disease,C0085413,Autosomal dominant polycystic kidney disease,6/3/19,Designated,Not FDA Approved for Orphan Indication,,,,
WPTTVJLTNAWYAO-FUARBKCBSA-N,70700216,WPTTVJLTNAWYAO-FUARBKCBSA-N,bardoxolone methyl,,Treatment of autosomal dominant polycystic kidney disease,C0085413,Autosomal dominant polycystic kidney disease,6/3/19,Designated,Not FDA Approved for Orphan Indication,,,,
WPTTVJLTNAWYAO-KPOXMGGZSA-N,400769,WPTTVJLTNAWYAO-KPOXMGGZSA-N,bardoxolone methyl,,Treatment of autosomal dominant polycystic kidney disease,C0085413,Autosomal dominant polycystic kidney disease,6/3/19,Designated,Not FDA Approved for Orphan Indication,,,,
WPTTVJLTNAWYAO-OYWPANLISA-N,133109022,WPTTVJLTNAWYAO-OYWPANLISA-N,bardoxolone methyl,,Treatment of Alport Syndrome,C1567741,Alport Syndrome,7/3/17,Designated,Not FDA Approved for Orphan Indication,,,,
WPTTVJLTNAWYAO-ZREYCQBLSA-N,131632414,WPTTVJLTNAWYAO-ZREYCQBLSA-N,bardoxolone methyl,,Treatment of Alport Syndrome,C1567741,Alport Syndrome,7/3/17,Designated,Not FDA Approved for Orphan Indication,,,,
WPTTVJLTNAWYAO-OROHISIGSA-N,24896135,WPTTVJLTNAWYAO-OROHISIGSA-N,bardoxolone methyl,,Treatment of Alport Syndrome,C1567741,Alport Syndrome,7/3/17,Designated,Not FDA Approved for Orphan Indication,,,,
WPTTVJLTNAWYAO-UHFFFAOYSA-N,53315588,WPTTVJLTNAWYAO-UHFFFAOYSA-N,bardoxolone methyl,,Treatment of Alport Syndrome,C1567741,Alport Syndrome,7/3/17,Designated,Not FDA Approved for Orphan Indication,,,,
WPTTVJLTNAWYAO-UFHYVYMVSA-N,49827815,WPTTVJLTNAWYAO-UFHYVYMVSA-N,bardoxolone methyl,,Treatment of Alport Syndrome,C1567741,Alport Syndrome,7/3/17,Designated,Not FDA Approved for Orphan Indication,,,,
WPTTVJLTNAWYAO-FUARBKCBSA-N,70700216,WPTTVJLTNAWYAO-FUARBKCBSA-N,bardoxolone methyl,,Treatment of Alport Syndrome,C1567741,Alport Syndrome,7/3/17,Designated,Not FDA Approved for Orphan Indication,,,,
WPTTVJLTNAWYAO-KPOXMGGZSA-N,400769,WPTTVJLTNAWYAO-KPOXMGGZSA-N,bardoxolone methyl,,Treatment of Alport Syndrome,C1567741,Alport Syndrome,7/3/17,Designated,Not FDA Approved for Orphan Indication,,,,
XUZMWHLSFXCVMG-UHFFFAOYSA-N,44205240,XUZMWHLSFXCVMG-UHFFFAOYSA-N,baricitinib,,Treatment of pediatric systemic lupus erythematosus,C0024141,SYSTEMIC LUPUS ERYTHEMATOSUS,11/2/17,Designated,Not FDA Approved for Orphan Indication,,,,
UPZWINBEAHDTLA-UHFFFAOYSA-N,11438771,UPZWINBEAHDTLA-UHFFFAOYSA-N,basimglurant,,Treatment of Fragile X Syndrome,C0016667,Fragile X Syndrome,3/9/12,Designated,Not FDA Approved for Orphan Indication,,,,
NBMKJKDGKREAPL-DVTGEIKXSA-N,20469,NBMKJKDGKREAPL-DVTGEIKXSA-N,beclomethasone,,Treatment of pediatriac patients with ulcerative colitis,C0009324,Ulcerative Colitis,3/4/09,Designated,Not FDA Approved for Orphan Indication,,,,
KUVIULQEHSCUHY-XYWKZLDCSA-N,21700,KUVIULQEHSCUHY-XYWKZLDCSA-N,beclomethasone dipropionate,,For oral administration in the treatment of intestinal graft-versus-host disease.,C0018133,Graft-Versus-Host Disease,3/27/98,Designated,Not FDA Approved for Orphan Indication,,,,
QUIJNHUBAXPXFS-XLJNKUFUSA-N,5388906,QUIJNHUBAXPXFS-XLJNKUFUSA-N,bedaquiline,SIRTURO,Treatment of active tuberculosis,C0041296,Active Tuberculosis,1/10/05,Designated/Approved,,SIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multi-drug resistant tuberculosis (MDR-TB). Reserve SIRTURO for use when an effective treatment regimen cannot otherwise be provided., 05/27/2020 , 05/27/2027 ,As part of combination therapy in the treatment of pediatric patients 5 years and older to less than 12 years of age and weighing at least 15 kg with pulmonary multi-drug resistant tuberculosis (MDR-TB)
QUIJNHUBAXPXFS-XLJNKUFUSA-N,5388906,QUIJNHUBAXPXFS-XLJNKUFUSA-N,bedaquiline,SIRTURO,Treatment of active tuberculosis,C0041296,Active Tuberculosis,1/10/05,Designated/Approved,,Part of combination therapy in adults (greater than or equal to 18 years) with pulmonary multi-drug resistant tuberculosis (MDR-TB)., 12/28/2012 , 12/28/2019 ,
QUIJNHUBAXPXFS-XLJNKUFUSA-N,5388906,QUIJNHUBAXPXFS-XLJNKUFUSA-N,Bedaquiline,,Treatment of Nontuberculosis Mycobacteria infection,"C0009450,C0026912","Infection , Mycobacteria",7/27/17,Designated,Not FDA Approved for Orphan Indication,,,,
QUIJNHUBAXPXFS-XLJNKUFUSA-N,5388906,QUIJNHUBAXPXFS-XLJNKUFUSA-N,bedaquiline,SIRTURO,Treatment of active tuberculosis,C0041296,Active Tuberculosis,1/10/05,Designated/Approved,,SIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adult and pediatric patients (12 to less than 18 years of age and weighing at least 30 kg) with pulmonary multi-drug resistant tuberculosis (MDR-TB). Reserve SIRTURO for use when an effective treatment regimen cannot otherwise be provided., 08/09/2019 , 08/09/2026 ,As part of combination therapy in the treatment of pediatric patients (12 to less than 18 years of age and weighing at least 30 kg) with pulmonary multi-drug resistant tuberculosis (MDR-TB)
NCNRHFGMJRPRSK-MDZDMXLPSA-N,6918638,NCNRHFGMJRPRSK-MDZDMXLPSA-N,Belinostat,Beleodaq,Treatment of peripheral T-cell lymphoma (PTCL).,C0079774,Peripheral T-Cell Lymphoma,9/3/09,Designated/Approved,,Treatment of patients with relapsed or refractory peripheral T-cell lymphoma, 07/03/2014 , 07/03/2021 ,Treatment of patients with relapsed or refractory peripheral T-cell lymphoma
ZEZFKUBILQRZCK-MJSCXXSSSA-N,6918502,ZEZFKUBILQRZCK-MJSCXXSSSA-N,beloranib,,Treatment of Prader-Willi syndrome,C0032897,Prader-Willi Syndrome,1/15/13,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
GKHIVNAUVKXIIY-UHFFFAOYSA-N,11950170,GKHIVNAUVKXIIY-UHFFFAOYSA-N,Belumosudil,,Treatment of systemic sclerosis,C0036421,Systemic sclerosis,9/4/20,Designated,Not FDA Approved for Orphan Indication,,,,
HYHMLYSLQUKXKP-UHFFFAOYSA-N,10472693,HYHMLYSLQUKXKP-UHFFFAOYSA-N,bempedoic acid,,Treatment of homozygous familial hypercholesterolemia,C0020445,FAMILIAL HYPERCHOLESTEROLEMIA,4/5/21,Designated,Not FDA Approved for Orphan Indication,,,,
YTKUWDBFDASYHO-UHFFFAOYSA-N,65628,YTKUWDBFDASYHO-UHFFFAOYSA-N,bendamustine,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,6/22/17,Designated,Not FDA Approved for Orphan Indication,,,,
ZHSKUOZOLHMKEA-UHFFFAOYSA-N,77082,ZHSKUOZOLHMKEA-UHFFFAOYSA-N,Bendamustine hydrochloride,Treanda,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,8/17/07,Designated/Approved,,Treatment of patients with chronic lymphocytic leukemia, 03/20/2008 , 03/20/2015 ,
ZHSKUOZOLHMKEA-UHFFFAOYSA-N,77082,ZHSKUOZOLHMKEA-UHFFFAOYSA-N,bendamustine hydrochloride,Treanda,"Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively","C0024301,C0024419,C0242647,C0349632,C0855139,C1955690","follicular lymphoma , lymphoplasmacytic lymphoma , Mucosa-associated lymphoma , Splenic marginal zone lymphoma , Nodal Marginal Zone Lymphoma , Extranodal marginal zone B-cell lymphoma",11/26/13,Designated/Approved,,Treatment of Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen., 10/31/2008 , 10/31/2015 ,
CULUWZNBISUWAS-UHFFFAOYSA-N,31593,CULUWZNBISUWAS-UHFFFAOYSA-N,benznidazole,,Treatment of Chagas disease,C0041234,Chagas Disease,4/14/14,Designated/Approved,,"Treatment of Chagas disease (American trypanosomiasis), caused by Trypanosoma cruzi, in pediatric patients 2 to 12 years of age.", 08/29/2017 , 08/29/2024 ,"Treatment of Chagas disease (American trypanosomiasis), caused by Trypanosoma cruzi, in pediatric patients 2 to 12 years of age."
CULUWZNBISUWAS-UHFFFAOYSA-N,31593,CULUWZNBISUWAS-UHFFFAOYSA-N,benznidazole,,Treatment of Chagas disease,C0041234,Chagas Disease,7/5/17,Designated,Not FDA Approved for Orphan Indication,,,,
WPYMKLBDIGXBTP-UHFFFAOYSA-M,242,WPYMKLBDIGXBTP-UHFFFAOYSA-M,benzoate,,Treatment of pediatric schizophrenia,C0036341,Schizophrenia,7/6/12,Designated,Not FDA Approved for Orphan Indication,,,,
HNNIWKQLJSNAEQ-UHFFFAOYSA-N,65464,HNNIWKQLJSNAEQ-UHFFFAOYSA-N,Benzydamine hydrochloride,,Prophylactic treatment of oral mucositis resulting from radiation therapy for head and neck cancer.,"C1568868,C3887461","Oral Mucositis , Head and Neck Cancer",5/18/98,Designated,Not FDA Approved for Orphan Indication,,,,
CTPOHARTNNSRSR-SEYXRHQNSA-N,45358438,CTPOHARTNNSRSR-SEYXRHQNSA-N,Beraprost,,"Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV).",C3203102,PULMONARY ARTERIAL HYPERTENSION,4/29/99,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
CTPOHARTNNSRSR-UHFFFAOYSA-N,2352,CTPOHARTNNSRSR-UHFFFAOYSA-N,Beraprost,,"Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV).",C3203102,PULMONARY ARTERIAL HYPERTENSION,4/29/99,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
CTPOHARTNNSRSR-APJZLKAGSA-N,6917951,CTPOHARTNNSRSR-APJZLKAGSA-N,Beraprost,,"Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV).",C3203102,PULMONARY ARTERIAL HYPERTENSION,4/29/99,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
CTPOHARTNNSRSR-OUKQBFOZSA-N,5282428,CTPOHARTNNSRSR-OUKQBFOZSA-N,Beraprost,,"Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV).",C3203102,PULMONARY ARTERIAL HYPERTENSION,4/29/99,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
CTPOHARTNNSRSR-NOQAJONNSA-N,10501053,CTPOHARTNNSRSR-NOQAJONNSA-N,beraprost sodium 314d,,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,12/22/11,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
YTCZZXIRLARSET-ZTWNIFTGSA-M,71587534,YTCZZXIRLARSET-ZTWNIFTGSA-M,beraprost sodium 314d,,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,12/22/11,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
UXNXMBYCBRBRFD-MUUNZHRXSA-N,137528262,UXNXMBYCBRBRFD-MUUNZHRXSA-N,berotralstat,ORLADEYO,Treatment of C1-inhibitor-dependent angioedema (including prevention and treatment of attacks),C0002994,Angioedema,11/1/17,Designated/Approved,,prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older, 12/03/2020 , 12/03/2027 ,prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older
FIGNGSHKNAHTSH-JJMFXPFOSA-N,9874592,FIGNGSHKNAHTSH-JJMFXPFOSA-N,Berubicin,,Treatment of malignant glioma,C0555198,Malignant Glioma,6/9/20,Designated,Not FDA Approved for Orphan Indication,,,,
WELIVEBWRWAGOM-UHFFFAOYSA-N,69532,WELIVEBWRWAGOM-UHFFFAOYSA-N,Beta alethine,,Treatment of multiple myeloma.,C0026764,Multiple Myeloma,3/24/97,Designated,Not FDA Approved for Orphan Indication,,,,
WELIVEBWRWAGOM-UHFFFAOYSA-N,69532,WELIVEBWRWAGOM-UHFFFAOYSA-N,Beta alethine,,Treatment of metastatic melanoma.,C0278883,Metastatic melanoma,3/24/97,Designated,Not FDA Approved for Orphan Indication,,,,
XVDFMHARQUBJRE-UHFFFAOYSA-N,68643,XVDFMHARQUBJRE-UHFFFAOYSA-N,Betahistine dihydrochloride,,Treatment of obesity associated with Prader Willi syndrome,"C0028754,C0032897","Obesity , Prader Willi syndrome",11/8/07,Designated,Not FDA Approved for Orphan Indication,,,,
KWIUHFFTVRNATP-UHFFFAOYSA-N,247,KWIUHFFTVRNATP-UHFFFAOYSA-N,Betaine,Cystadane,Treatment of homocystinuria.,C0019880,Homocystinuria,5/16/94,Designated/Approved,,Treatment of homocystinuria to decrease elevated homocysteine blood levels., 10/25/1996 , 10/25/2003 ,
UREBDLICKHMUKA-DVTGEIKXSA-N,9782,UREBDLICKHMUKA-DVTGEIKXSA-N,betamethasone,,Treatment of Ataxia Telangiectasia.,C0004135,Ataxia Telangiectasia,10/7/15,Designated,Not FDA Approved for Orphan Indication,,,,
YTIJUXVIZLYQTB-UHFFFAOYSA-N,16048622,YTIJUXVIZLYQTB-UHFFFAOYSA-N,Bethanidine sulfate,,Prevention of recurrence of primary ventricular fibrillation.,C0042510,Ventricular Fibrillation,11/24/89,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
WDLCALUKNKNIDF-UHFFFAOYSA-N,23615599,WDLCALUKNKNIDF-UHFFFAOYSA-N,Bethanidine sulfate,,Prevention of recurrence of primary ventricular fibrillation.,C0042510,Ventricular Fibrillation,11/24/89,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
YTIJUXVIZLYQTB-UHFFFAOYSA-N,16048622,YTIJUXVIZLYQTB-UHFFFAOYSA-N,Bethanidine sulfate,,Prevention of recurrence of primary ventricular fibrillation.,C0042510,Ventricular Fibrillation,11/24/89,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
NIVZHWNOUVJHKV-UHFFFAOYSA-N,2368,NIVZHWNOUVJHKV-UHFFFAOYSA-N,Bethanidine sulfate,,Prevention of recurrence of primary ventricular fibrillation.,C0042510,Ventricular Fibrillation,11/24/89,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
YTIJUXVIZLYQTB-UHFFFAOYSA-N,16048622,YTIJUXVIZLYQTB-UHFFFAOYSA-N,Bethanidine sulfate,,Prevention of recurrence of primary ventricular fibrillation.,C0042510,Ventricular Fibrillation,11/24/89,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
YTIJUXVIZLYQTB-UHFFFAOYSA-N,16048622,YTIJUXVIZLYQTB-UHFFFAOYSA-N,Bethanidine sulfate,,Treatment of primary ventricular fibrillation.,C0042510,Ventricular Fibrillation,9/20/88,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
WDLCALUKNKNIDF-UHFFFAOYSA-N,23615599,WDLCALUKNKNIDF-UHFFFAOYSA-N,Bethanidine sulfate,,Treatment of primary ventricular fibrillation.,C0042510,Ventricular Fibrillation,9/20/88,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
YTIJUXVIZLYQTB-UHFFFAOYSA-N,16048622,YTIJUXVIZLYQTB-UHFFFAOYSA-N,Bethanidine sulfate,,Treatment of primary ventricular fibrillation.,C0042510,Ventricular Fibrillation,9/20/88,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
NIVZHWNOUVJHKV-UHFFFAOYSA-N,2368,NIVZHWNOUVJHKV-UHFFFAOYSA-N,Bethanidine sulfate,,Treatment of primary ventricular fibrillation.,C0042510,Ventricular Fibrillation,9/20/88,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
YTIJUXVIZLYQTB-UHFFFAOYSA-N,16048622,YTIJUXVIZLYQTB-UHFFFAOYSA-N,Bethanidine sulfate,,Treatment of primary ventricular fibrillation.,C0042510,Ventricular Fibrillation,9/20/88,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
QGJZLNKBHJESQX-FZFNOLFKSA-N,64971,QGJZLNKBHJESQX-FZFNOLFKSA-N,Betulinic acid,,Topical treatment of metastatic melanoma,C0278883,Metastatic melanoma,8/9/07,Designated,Not FDA Approved for Orphan Indication,,,,
NAVMQTYZDKMPEU-UHFFFAOYSA-N,82146,NAVMQTYZDKMPEU-UHFFFAOYSA-N,Bexarotene,Targretin,Treatment of cutaneous T-cell lymphoma.,C0079773,cutaneous T-cell lymphoma,6/18/99,Designated/Approved,,Treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy., 12/29/1999 , 12/29/2006 ,
IIBYAHWJQTYFKB-UHFFFAOYSA-N,39042,IIBYAHWJQTYFKB-UHFFFAOYSA-N,bezafibrate,,For therapeutic treatment of Barth syndrome,C0574083,Barth Syndrome,7/24/13,Designated,Not FDA Approved for Orphan Indication,,,,
MTHORRSSURHQPZ-UHFFFAOYSA-N,71354,MTHORRSSURHQPZ-UHFFFAOYSA-N,Bindarit,,Treatment of lupus nephritis.,C0024143,Lupus Nephritis,2/3/98,Designated,Not FDA Approved for Orphan Indication,,,,
ACWZRVQXLIRSDF-UHFFFAOYSA-N,10288191,ACWZRVQXLIRSDF-UHFFFAOYSA-N,binimetinib,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,7/31/14,Designated,Not FDA Approved for Orphan Indication,,,,
ACWZRVQXLIRSDF-UHFFFAOYSA-N,10288191,ACWZRVQXLIRSDF-UHFFFAOYSA-N,binimetinib,,Treatment Stage IIB-IV melanoma.,C0025202,melanoma,11/19/13,Designated,Not FDA Approved for Orphan Indication,,,,
YBJHBAHKTGYVGT-ZKWXMUAHSA-N,171548,YBJHBAHKTGYVGT-ZKWXMUAHSA-N,Biotin,,Treatment of Charcot-Marie-Tooth disease,C0007959,Charcot-Marie-Tooth Disease,9/8/20,Designated,Not FDA Approved for Orphan Indication,,,,
SCTZUZTYRMOMKT-UHFFFAOYSA-N,216327,SCTZUZTYRMOMKT-UHFFFAOYSA-N,Bis(4-fluorophenyl)phenylacetamide,,Treatment of sickle cell disease.,C0002895,Sickle Cell Disease,3/2/00,Designated,Not FDA Approved for Orphan Indication,,,,
FSWNJZRQQVVVJT-UHFFFAOYSA-L,18442052,FSWNJZRQQVVVJT-UHFFFAOYSA-L,bis-choline tetrathiomolybdate,,Treatment of Amyotrophic Lateral Sclerosis (ALS),C0002736,Amyotrophic Lateral Sclerosis,6/5/17,Designated,Not FDA Approved for Orphan Indication,,,,
FSWNJZRQQVVVJT-UHFFFAOYSA-L,18442052,FSWNJZRQQVVVJT-UHFFFAOYSA-L,bis-choline tetrathiomolybdate,,Treatment of primary biliary cholangitis,C0008312,Primary Biliary Cholangitis,4/6/20,Designated,Not FDA Approved for Orphan Indication,,,,
KINULKKPVJYRON-PVNXHVEDSA-N,6917792,KINULKKPVJYRON-PVNXHVEDSA-N,bisantrene HCl,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,2/14/14,Designated,Not FDA Approved for Orphan Indication,,,,
YUUGYIUSCYNSQR-LBPRGKRZSA-N,24946690,YUUGYIUSCYNSQR-LBPRGKRZSA-N,bitopertin,,Treatment of ߭thalassemia,C0039730,thalassemia,8/16/17,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
OIRCOABEOLEUMC-GEJPAHFPSA-N,16129704,OIRCOABEOLEUMC-GEJPAHFPSA-N,bivalirudin,,For use as an anticoagulant in patients with or at risk of heparin-induced thrombocytopenia/heparin-induced thrombocytopenia thrombosis syndrome,"C0040034,C0272285,C0302148","Thrombocytopenia , Heparin-induced thrombocytopenia , Thrombosis",11/2/05,Designated,Not FDA Approved for Orphan Indication,,,,
OYVAGSVQBOHSSS-QRQYLRPSSA-O,456190,OYVAGSVQBOHSSS-QRQYLRPSSA-O,Bleomycin,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,12/20/10,Designated,Not FDA Approved for Orphan Indication,,,,
OYVAGSVQBOHSSS-UHFFFAOYSA-O,84068,OYVAGSVQBOHSSS-UHFFFAOYSA-O,Bleomycin,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,12/20/10,Designated,Not FDA Approved for Orphan Indication,,,,
OYVAGSVQBOHSSS-UAPAGMARSA-O,5460769,OYVAGSVQBOHSSS-UAPAGMARSA-O,Bleomycin,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,12/20/10,Designated,Not FDA Approved for Orphan Indication,,,,
OYVAGSVQBOHSSS-WXFSZRTFSA-O,5360373,OYVAGSVQBOHSSS-WXFSZRTFSA-O,Bleomycin,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,12/20/10,Designated,Not FDA Approved for Orphan Indication,,,,
OYVAGSVQBOHSSS-QRQYLRPSSA-O,456190,OYVAGSVQBOHSSS-QRQYLRPSSA-O,Bleomycin,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,2/9/99,Designated,Not FDA Approved for Orphan Indication,,,,
OYVAGSVQBOHSSS-UHFFFAOYSA-O,84068,OYVAGSVQBOHSSS-UHFFFAOYSA-O,Bleomycin,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,2/9/99,Designated,Not FDA Approved for Orphan Indication,,,,
OYVAGSVQBOHSSS-UAPAGMARSA-O,5460769,OYVAGSVQBOHSSS-UAPAGMARSA-O,Bleomycin,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,2/9/99,Designated,Not FDA Approved for Orphan Indication,,,,
OYVAGSVQBOHSSS-WXFSZRTFSA-O,5360373,OYVAGSVQBOHSSS-WXFSZRTFSA-O,Bleomycin,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,2/9/99,Designated,Not FDA Approved for Orphan Indication,,,,
OYVAGSVQBOHSSS-ITQDJCQPSA-O,122172957,OYVAGSVQBOHSSS-ITQDJCQPSA-O,Bleomycin sulfate,Blenoxane,Treatment of malignant pleural effusion.,C0080032,malignant pleural effusion,9/17/93,Designated/Approved,,Treatment of malignant pleural effusion., 02/20/1996 , 02/20/2003 ,
WUIABRMSWOKTOF-OYALTWQYSA-O,71587153,WUIABRMSWOKTOF-OYALTWQYSA-O,Bleomycin sulfate,Blenoxane,Treatment of malignant pleural effusion.,C0080032,malignant pleural effusion,9/17/93,Designated/Approved,,Treatment of malignant pleural effusion., 02/20/1996 , 02/20/2003 ,
WUIABRMSWOKTOF-FOBMNYSPSA-N,57336513,WUIABRMSWOKTOF-FOBMNYSPSA-N,Bleomycin sulfate,Blenoxane,Treatment of malignant pleural effusion.,C0080032,malignant pleural effusion,9/17/93,Designated/Approved,,Treatment of malignant pleural effusion., 02/20/1996 , 02/20/2003 ,
WUIABRMSWOKTOF-NUAMMRKQSA-N,54608728,WUIABRMSWOKTOF-NUAMMRKQSA-N,Bleomycin sulfate,Blenoxane,Treatment of malignant pleural effusion.,C0080032,malignant pleural effusion,9/17/93,Designated/Approved,,Treatment of malignant pleural effusion., 02/20/1996 , 02/20/2003 ,
OYVAGSVQBOHSSS-NHOVFDEISA-O,46930982,OYVAGSVQBOHSSS-NHOVFDEISA-O,Bleomycin sulfate,Blenoxane,Treatment of malignant pleural effusion.,C0080032,malignant pleural effusion,9/17/93,Designated/Approved,,Treatment of malignant pleural effusion., 02/20/1996 , 02/20/2003 ,
OYVAGSVQBOHSSS-UHFFFAOYSA-O,84068,OYVAGSVQBOHSSS-UHFFFAOYSA-O,Bleomycin sulfate,Blenoxane,Treatment of malignant pleural effusion.,C0080032,malignant pleural effusion,9/17/93,Designated/Approved,,Treatment of malignant pleural effusion., 02/20/1996 , 02/20/2003 ,
OYVAGSVQBOHSSS-WXFSZRTFSA-O,5360373,OYVAGSVQBOHSSS-WXFSZRTFSA-O,Bleomycin sulfate,Blenoxane,Treatment of malignant pleural effusion.,C0080032,malignant pleural effusion,9/17/93,Designated/Approved,,Treatment of malignant pleural effusion., 02/20/1996 , 02/20/2003 ,
WUIABRMSWOKTOF-PATWWPTKSA-N,46930981,WUIABRMSWOKTOF-PATWWPTKSA-N,Bleomycin sulfate,Blenoxane,Treatment of malignant pleural effusion.,C0080032,malignant pleural effusion,9/17/93,Designated/Approved,,Treatment of malignant pleural effusion., 02/20/1996 , 02/20/2003 ,
WUIABRMSWOKTOF-UHFFFAOYSA-N,21864427,WUIABRMSWOKTOF-UHFFFAOYSA-N,Bleomycin sulfate,Blenoxane,Treatment of malignant pleural effusion.,C0080032,malignant pleural effusion,9/17/93,Designated/Approved,,Treatment of malignant pleural effusion., 02/20/1996 , 02/20/2003 ,
WUIABRMSWOKTOF-OCBSMOPSSA-N,72466,WUIABRMSWOKTOF-OCBSMOPSSA-N,Bleomycin sulfate,Blenoxane,Treatment of malignant pleural effusion.,C0080032,malignant pleural effusion,9/17/93,Designated/Approved,,Treatment of malignant pleural effusion., 02/20/1996 , 02/20/2003 ,
GXJABQQUPOEUTA-RDJZCZTQSA-N,387447,GXJABQQUPOEUTA-RDJZCZTQSA-N,bortezomib,,Treatment of neurofibromatosis type 2 (NF2),C0027832,Neurofibromatosis Type 2,7/5/16,Designated,Not FDA Approved for Orphan Indication,,,,
GXJABQQUPOEUTA-RDJZCZTQSA-N,387447,GXJABQQUPOEUTA-RDJZCZTQSA-N,bortezomib,Velcade,Treatment of multiple myeloma,C0026764,Multiple Myeloma,1/15/03,Designated/Approved,,Treatment of multiple myeloma patients who have received at least one prior therapy, 03/25/2005 , 03/25/2012 ,
GXJABQQUPOEUTA-RDJZCZTQSA-N,387447,GXJABQQUPOEUTA-RDJZCZTQSA-N,bortezomib,Velcade,Treatment of multiple myeloma,C0026764,Multiple Myeloma,1/15/03,Designated/Approved,,Treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy, 05/13/2003 , 05/13/2010 ,
GXJABQQUPOEUTA-RDJZCZTQSA-N,387447,GXJABQQUPOEUTA-RDJZCZTQSA-N,bortezomib,,Treatment of follicular non-Hodgkin lymphoma,C0024301,follicular non-Hodgkin lymphoma,1/4/11,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
GXJABQQUPOEUTA-RDJZCZTQSA-N,387447,GXJABQQUPOEUTA-RDJZCZTQSA-N,bortezomib,,Treatment of acute lymphoblastic leukemia,C0023449,Acute lymphoblastic leukemia,2/3/15,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
GXJABQQUPOEUTA-RDJZCZTQSA-N,387447,GXJABQQUPOEUTA-RDJZCZTQSA-N,bortezomib,Velcade,Treatment of multiple myeloma,C0026764,Multiple Myeloma,1/15/03,Designated/Approved,,First-line therapy of multiple myeloma., 06/20/2008 , 06/20/2015 ,
GXJABQQUPOEUTA-RDJZCZTQSA-N,387447,GXJABQQUPOEUTA-RDJZCZTQSA-N,bortezomib,Velcade,Treatment of mantle cell lymphoma.,C4721414,Mantle cell lymphoma,5/30/12,Designated/Approved,,Treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy., 12/08/2006 , 12/08/2013 ,
GXJABQQUPOEUTA-RDJZCZTQSA-N,387447,GXJABQQUPOEUTA-RDJZCZTQSA-N,bortezomib,Velcade,Treatment of mantle cell lymphoma.,C4721414,Mantle cell lymphoma,5/30/12,Designated/Approved,,Treatment of patients with mantle cell lymphoma., 10/08/2014 , 10/08/2021 ,Treatment of patients with mantle cell lymphoma who have not received at least 1 prior therapy
GJPICJJJRGTNOD-UHFFFAOYSA-N,104865,GJPICJJJRGTNOD-UHFFFAOYSA-N,bosentan,,Reduction of the number (treatment) of new digital ulcers in patients with systemic sclerosis,"C0036421,C0041582","Systemic sclerosis , Ulcers",6/7/10,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
GJPICJJJRGTNOD-UHFFFAOYSA-N,104865,GJPICJJJRGTNOD-UHFFFAOYSA-N,bosentan,,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,9/30/08,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
UBPYILGKFZZVDX-UHFFFAOYSA-N,5328940,UBPYILGKFZZVDX-UHFFFAOYSA-N,bosutinib,Bosulif,Treatment of chronic myelogenous leukemia,C0023473,Chronic myelogenous leukemia,2/24/09,Designated/Approved,,BOSULIF is indicated for the treatment of adult patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+CML)., 12/19/2017 , 12/19/2024 ,Treatment of adult patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML).
UBPYILGKFZZVDX-UHFFFAOYSA-N,5328940,UBPYILGKFZZVDX-UHFFFAOYSA-N,bosutinib,Bosulif,Treatment of chronic myelogenous leukemia,C0023473,Chronic myelogenous leukemia,2/24/09,Designated/Approved,,"Treatment of adult patients with chronic, accelerated or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy", 09/04/2012 , 09/04/2019 ,
STWTUEAWRAIWJG-UHFFFAOYSA-N,135565042,STWTUEAWRAIWJG-UHFFFAOYSA-N,Branaplam,,treatment of Huntingtons disease,C0020179,huntingtons disease,10/19/20,Designated,Not FDA Approved for Orphan Indication,,,,
STWTUEAWRAIWJG-UHFFFAOYSA-N,135565042,STWTUEAWRAIWJG-UHFFFAOYSA-N,branaplam,,Treatment of spinal muscular atrophy (SMA),C0026847,Spinal Muscular Atrophy,1/23/18,Designated,Not FDA Approved for Orphan Indication,,,,
JPBOABGEVHVPNM-LPEULFRDSA-N,15965874,JPBOABGEVHVPNM-LPEULFRDSA-N,Brevenal,,Treatment of cystic fibrosis,C0010674,Cystic Fibrosis,4/2/18,Designated,Not FDA Approved for Orphan Indication,,,,
JPBOABGEVHVPNM-ANYVIMDKSA-N,11490752,JPBOABGEVHVPNM-ANYVIMDKSA-N,Brevenal,,Treatment of cystic fibrosis,C0010674,Cystic Fibrosis,4/2/18,Designated,Not FDA Approved for Orphan Indication,,,,
JPBOABGEVHVPNM-KGIMXCGWSA-N,11227586,JPBOABGEVHVPNM-KGIMXCGWSA-N,Brevenal,,Treatment of cystic fibrosis,C0010674,Cystic Fibrosis,4/2/18,Designated,Not FDA Approved for Orphan Indication,,,,
JPBOABGEVHVPNM-GFIBHCGLSA-N,46886836,JPBOABGEVHVPNM-GFIBHCGLSA-N,Brevenal,,Treatment of cystic fibrosis,C0010674,Cystic Fibrosis,4/2/18,Designated,Not FDA Approved for Orphan Indication,,,,
AILRADAXUVEEIR-UHFFFAOYSA-N,68165256,AILRADAXUVEEIR-UHFFFAOYSA-N,brigatinib,Alunbrig,"Treatment of anaplastic lymphoma kinase-positive (ALK+), c-ros 1 oncogene positive (ROS1+), or epidermal growth factor receptor positive (EGFR+) non-small cell lung cancer (NSCLC).","C0007131,C3539721","Non-Small Cell Lung Cancer , Non-Small Cell Lung Cancer",4/28/16,Designated/Approved,,ALUNBRIG (brigatinib) is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test., 05/22/2020 , 05/22/2027 ,"For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test, not including patients who have progressed on or are intolerant to crizotinib."
AILRADAXUVEEIR-UHFFFAOYSA-N,68165256,AILRADAXUVEEIR-UHFFFAOYSA-N,brigatinib,Alunbrig,"Treatment of anaplastic lymphoma kinase-positive (ALK+), c-ros 1 oncogene positive (ROS1+), or epidermal growth factor receptor positive (EGFR+) non-small cell lung cancer (NSCLC).","C0007131,C3539721","Non-Small Cell Lung Cancer , Non-Small Cell Lung Cancer",4/28/16,Designated/Approved,,Treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib, 04/28/2017 , 04/28/2024 ,Treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib
XYLJNLCSTIOKRM-UHFFFAOYSA-N,2435,XYLJNLCSTIOKRM-UHFFFAOYSA-N,brimonidine,,Treatment of ocular graft versus host disease,C5203917,Ocular Graft Versus Host Disease,8/3/17,Designated,Not FDA Approved for Orphan Indication,,,,
XYLJNLCSTIOKRM-UHFFFAOYSA-N,2435,XYLJNLCSTIOKRM-UHFFFAOYSA-N,Brimonidine,,Treatment of anterior ischemic optic neuropathy.,C0751711,Anterior Ischemic Optic Neuropathy,2/7/00,Designated,Not FDA Approved for Orphan Indication,,,,
WXJFKKQWPMNTIM-VWLOTQADSA-N,483477,WXJFKKQWPMNTIM-VWLOTQADSA-N,brincidofovir,,Treatment of Smallpox,C0037356,smallpox,6/5/18,Designated,Not FDA Approved for Orphan Indication,,,,
LTEJRLHKIYCEOX-OCCSQVGLSA-N,11154925,LTEJRLHKIYCEOX-OCCSQVGLSA-N,brivanib alaninate,,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,3/18/11,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
MSYKRHVOOPPJKU-BDAKNGLRSA-N,9837243,MSYKRHVOOPPJKU-BDAKNGLRSA-N,brivaracetam,,Treatment of symptomatic myoclonus,C0393619,Symptomatic myoclonus,10/5/05,Designated,Not FDA Approved for Orphan Indication,,,,
MSYKRHVOOPPJKU-BDAKNGLRSA-N,9837243,MSYKRHVOOPPJKU-BDAKNGLRSA-N,brivaracetam,,Treatment of Juvenile Absence Epilepsy,C4317339,Juvenile Absence Epilepsy,12/3/19,Designated,Not FDA Approved for Orphan Indication,,,,
MSYKRHVOOPPJKU-BDAKNGLRSA-N,9837243,MSYKRHVOOPPJKU-BDAKNGLRSA-N,brivaracetam,,Treatment of Childhood Absence Epilepsy,C0014553,childhood absence epilepsy,12/3/19,Designated,Not FDA Approved for Orphan Indication,,,,
ODZBBRURCPAEIQ-PIXDULNESA-N,446727,ODZBBRURCPAEIQ-PIXDULNESA-N,Brivudin,,Adjunct treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,11/15/07,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
OJGDCBLYJGHCIH-UHFFFAOYSA-N,2442,OJGDCBLYJGHCIH-UHFFFAOYSA-N,Bromhexine,,Treatment of mild to moderate keratoconjunctivitis sicca in patients with Sjogren's syndrome.,"C0022575,C1527336","Keratoconjunctivitis Sicca , Sjogren Syndrome",5/15/89,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
WOVKYSAHUYNSMH-RRKCRQDMSA-N,6035,WOVKYSAHUYNSMH-RRKCRQDMSA-N,Broxuridine,,Radiation sensitizer in the treatment of primary brain tumors.,C0750974,primary brain tumors,9/18/95,Designated,Not FDA Approved for Orphan Indication,,,,
MJQUEDHRCUIRLF-DDYLLZMUSA-N,134817197,MJQUEDHRCUIRLF-DDYLLZMUSA-N,bryostatin 1,,Treatment of Fragile X Syndrome.,C0016667,Fragile X Syndrome,3/31/15,Designated,Not FDA Approved for Orphan Indication,,,,
MJQUEDHRCUIRLF-IBMAKELESA-N,133635911,MJQUEDHRCUIRLF-IBMAKELESA-N,bryostatin 1,,Treatment of Fragile X Syndrome.,C0016667,Fragile X Syndrome,3/31/15,Designated,Not FDA Approved for Orphan Indication,,,,
MJQUEDHRCUIRLF-JGGKDZLHSA-N,124918436,MJQUEDHRCUIRLF-JGGKDZLHSA-N,bryostatin 1,,Treatment of Fragile X Syndrome.,C0016667,Fragile X Syndrome,3/31/15,Designated,Not FDA Approved for Orphan Indication,,,,
MJQUEDHRCUIRLF-PXXLITNBSA-N,122173102,MJQUEDHRCUIRLF-PXXLITNBSA-N,bryostatin 1,,Treatment of Fragile X Syndrome.,C0016667,Fragile X Syndrome,3/31/15,Designated,Not FDA Approved for Orphan Indication,,,,
MJQUEDHRCUIRLF-ZVHDYJKJSA-N,14078847,MJQUEDHRCUIRLF-ZVHDYJKJSA-N,bryostatin 1,,Treatment of Fragile X Syndrome.,C0016667,Fragile X Syndrome,3/31/15,Designated,Not FDA Approved for Orphan Indication,,,,
MJQUEDHRCUIRLF-JYXSRQLPSA-N,146159872,MJQUEDHRCUIRLF-JYXSRQLPSA-N,bryostatin 1,,Treatment of Fragile X Syndrome.,C0016667,Fragile X Syndrome,3/31/15,Designated,Not FDA Approved for Orphan Indication,,,,
MJQUEDHRCUIRLF-MDGOTRLRSA-N,16760328,MJQUEDHRCUIRLF-MDGOTRLRSA-N,bryostatin 1,,Treatment of Fragile X Syndrome.,C0016667,Fragile X Syndrome,3/31/15,Designated,Not FDA Approved for Orphan Indication,,,,
MJQUEDHRCUIRLF-SGXMQRQHSA-N,6473739,MJQUEDHRCUIRLF-SGXMQRQHSA-N,bryostatin 1,,Treatment of Fragile X Syndrome.,C0016667,Fragile X Syndrome,3/31/15,Designated,Not FDA Approved for Orphan Indication,,,,
MJQUEDHRCUIRLF-BXOMOELISA-N,6435419,MJQUEDHRCUIRLF-BXOMOELISA-N,bryostatin 1,,Treatment of Fragile X Syndrome.,C0016667,Fragile X Syndrome,3/31/15,Designated,Not FDA Approved for Orphan Indication,,,,
MJQUEDHRCUIRLF-DECOFNLXSA-N,5884629,MJQUEDHRCUIRLF-DECOFNLXSA-N,bryostatin 1,,Treatment of Fragile X Syndrome.,C0016667,Fragile X Syndrome,3/31/15,Designated,Not FDA Approved for Orphan Indication,,,,
MJQUEDHRCUIRLF-KOWVOJLTSA-N,5477635,MJQUEDHRCUIRLF-KOWVOJLTSA-N,bryostatin 1,,Treatment of Fragile X Syndrome.,C0016667,Fragile X Syndrome,3/31/15,Designated,Not FDA Approved for Orphan Indication,,,,
MJQUEDHRCUIRLF-VUHCRTQMSA-N,5458769,MJQUEDHRCUIRLF-VUHCRTQMSA-N,bryostatin 1,,Treatment of Fragile X Syndrome.,C0016667,Fragile X Syndrome,3/31/15,Designated,Not FDA Approved for Orphan Indication,,,,
MJQUEDHRCUIRLF-YCVQJEHTSA-N,44277532,MJQUEDHRCUIRLF-YCVQJEHTSA-N,bryostatin 1,,Treatment of Fragile X Syndrome.,C0016667,Fragile X Syndrome,3/31/15,Designated,Not FDA Approved for Orphan Indication,,,,
MJQUEDHRCUIRLF-MEBWOBETSA-N,22524140,MJQUEDHRCUIRLF-MEBWOBETSA-N,bryostatin 1,,Treatment of Fragile X Syndrome.,C0016667,Fragile X Syndrome,3/31/15,Designated,Not FDA Approved for Orphan Indication,,,,
MJQUEDHRCUIRLF-UHFFFAOYSA-N,433902,MJQUEDHRCUIRLF-UHFFFAOYSA-N,bryostatin 1,,Treatment of Fragile X Syndrome.,C0016667,Fragile X Syndrome,3/31/15,Designated,Not FDA Approved for Orphan Indication,,,,
MJQUEDHRCUIRLF-TVIXENOKSA-N,5280757,MJQUEDHRCUIRLF-TVIXENOKSA-N,bryostatin 1,,Treatment of Fragile X Syndrome.,C0016667,Fragile X Syndrome,3/31/15,Designated,Not FDA Approved for Orphan Indication,,,,
MJQUEDHRCUIRLF-ZVHDYJKJSA-N,14078847,MJQUEDHRCUIRLF-ZVHDYJKJSA-N,bryostatin-1,,For use in combination with paclitaxel in the treatment of esophageal cancer,C0014859,esophageal cancer,12/3/01,Designated,Not FDA Approved for Orphan Indication,,,,
MJQUEDHRCUIRLF-SGXMQRQHSA-N,6473739,MJQUEDHRCUIRLF-SGXMQRQHSA-N,bryostatin-1,,For use in combination with paclitaxel in the treatment of esophageal cancer,C0014859,esophageal cancer,12/3/01,Designated,Not FDA Approved for Orphan Indication,,,,
MJQUEDHRCUIRLF-TVIXENOKSA-N,5280757,MJQUEDHRCUIRLF-TVIXENOKSA-N,bryostatin-1,,For use in combination with paclitaxel in the treatment of esophageal cancer,C0014859,esophageal cancer,12/3/01,Designated,Not FDA Approved for Orphan Indication,,,,
VUAFHZCUKUDDBC-BYPYZUCNSA-N,656604,VUAFHZCUKUDDBC-BYPYZUCNSA-N,bucillamine,,Treatment of cystinuria,C0010691,Cystinuria,10/22/15,Designated,Not FDA Approved for Orphan Indication,,,,
VOVIALXJUBGFJZ-KWVAZRHASA-N,5281004,VOVIALXJUBGFJZ-KWVAZRHASA-N,budesonide,,Treat of ulcerative colitis in pediatric patients aged 0 through 16 years.,C0009324,Ulcerative Colitis,5/6/13,Designated,Not FDA Approved for Orphan Indication,,,,
VOVIALXJUBGFJZ-KWVAZRHASA-N,5281004,VOVIALXJUBGFJZ-KWVAZRHASA-N,budesonide,,Treatment of primary biliary cholangitis,C0008312,Primary Biliary Cholangitis,2/11/19,Designated,Not FDA Approved for Orphan Indication,,,,
VOVIALXJUBGFJZ-KWVAZRHASA-N,5281004,VOVIALXJUBGFJZ-KWVAZRHASA-N,budesonide,,Treatment of Autoimmune Hepatitis,C0241910,Autoimmune hepatitis,2/1/19,Designated,Not FDA Approved for Orphan Indication,,,,
VOVIALXJUBGFJZ-KWVAZRHASA-N,5281004,VOVIALXJUBGFJZ-KWVAZRHASA-N,budesonide,,To slow the progression of immunoglobulin A nephropathy & delay kidney failure in patients affected by the disease.,"C0017661,C0035078","Immunoglobulin A Nephropathy , Kidney Failure",5/17/10,Designated,Not FDA Approved for Orphan Indication,,,,
VOVIALXJUBGFJZ-KWVAZRHASA-N,5281004,VOVIALXJUBGFJZ-KWVAZRHASA-N,budesonide,,Treatment of eosinophilic esophagitis,C0341106,Eosinophilic esophagitis,5/8/18,Designated,Not FDA Approved for Orphan Indication,,,,
LEBVLXFERQHONN-UHFFFAOYSA-N,2474,LEBVLXFERQHONN-UHFFFAOYSA-N,bupivacaine,,Relief of persistent pain associated with postherpetic neuralgia,"C0030193,C0032768","Pain , Postherpetic neuralgia",6/18/08,Designated,Not FDA Approved for Orphan Indication,,,,
SIEYLFHKZGLBNX-UHFFFAOYSA-N,64737,SIEYLFHKZGLBNX-UHFFFAOYSA-N,bupivacaine hydrochloride,,treatment of pain associated with postherpetic neuralgia.,"C0030193,C0032768","Pain , Postherpetic neuralgia",5/31/16,Designated,Not FDA Approved for Orphan Indication,,,,
UAIXRPCCYXNJMQ-RZIPZOSSSA-N,45265653,UAIXRPCCYXNJMQ-RZIPZOSSSA-N,Buprenorphine hydrochloride,,Treatment of opiate addiction in opiate users.,C0524662,Opiate Addiction,6/15/94,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
UAIXRPCCYXNJMQ-RZIPZOSSSA-N,45265653,UAIXRPCCYXNJMQ-RZIPZOSSSA-N,Buprenorphine hydrochloride,,Treatment of opiate addiction in opiate users.,C0524662,Opiate Addiction,6/15/94,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
UAIXRPCCYXNJMQ-RZIPZOSSSA-N,45265653,UAIXRPCCYXNJMQ-RZIPZOSSSA-N,Buprenorphine hydrochloride,,Treatment of opiate addiction in opiate users.,C0524662,Opiate Addiction,6/15/94,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
UAIXRPCCYXNJMQ-RZIPZOSSSA-N,45265653,UAIXRPCCYXNJMQ-RZIPZOSSSA-N,Buprenorphine hydrochloride,,Treatment of opiate addiction in opiate users.,C0524662,Opiate Addiction,6/15/94,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
COVZYZSDYWQREU-UHFFFAOYSA-N,2478,COVZYZSDYWQREU-UHFFFAOYSA-N,Busulfan,,Intrathecal therapy for neoplastic meningitis,C0220654,neoplastic meningitis,3/5/01,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
COVZYZSDYWQREU-UHFFFAOYSA-N,2478,COVZYZSDYWQREU-UHFFFAOYSA-N,Busulfan,,Treatment of primary brain malignancies.,C0006826,MALIGNANCIES,7/7/97,Designated,Not FDA Approved for Orphan Indication,,,,
COVZYZSDYWQREU-UHFFFAOYSA-N,2478,COVZYZSDYWQREU-UHFFFAOYSA-N,Busulfan,,For use as preparative therapy for malignancies treated with bone marrow transplantation.,C0006826,MALIGNANCIES,4/21/94,Designated,Not FDA Approved for Orphan Indication,,,,
COVZYZSDYWQREU-UHFFFAOYSA-N,2478,COVZYZSDYWQREU-UHFFFAOYSA-N,Busulfan,Busulfex,As preparative therapy in the treatment of malignancies with bone marrow transplantation.,C0006826,MALIGNANCIES,7/28/94,Designated/Approved,,For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia., 02/04/1999 , 02/04/2006 ,
KJQFBVYMGADDTQ-UHFFFAOYSA-N,21157,KJQFBVYMGADDTQ-UHFFFAOYSA-N,Buthionine sulfoxamine,,For use in children as a modulator of chemotherapy for the treatment of pediatric patients with neuroblastoma,C0027819,Neuroblastoma,10/5/05,Designated,Not FDA Approved for Orphan Indication,,,,
KJQFBVYMGADDTQ-UHFFFAOYSA-N,21157,KJQFBVYMGADDTQ-UHFFFAOYSA-N,Buthionine sulfoxamine,,Use as a modulator of chemotherapy for the treatment of pediatric patients with primary malignant brain tumors,C0750979,Primary Malignant Brain Tumors,10/5/05,Designated,Not FDA Approved for Orphan Indication,,,,
WMBOCUXXNSOQHM-DHZHZOJOSA-N,5352899,WMBOCUXXNSOQHM-DHZHZOJOSA-N,butylidenephthalide,,Treatment of Malignant Glioma,C0555198,Malignant Glioma,8/5/15,Designated,Not FDA Approved for Orphan Indication,,,,
WMBOCUXXNSOQHM-UHFFFAOYSA-N,62368,WMBOCUXXNSOQHM-UHFFFAOYSA-N,butylidenephthalide,,Treatment of Malignant Glioma,C0555198,Malignant Glioma,8/5/15,Designated,Not FDA Approved for Orphan Indication,,,,
WMBOCUXXNSOQHM-FLIBITNWSA-N,642376,WMBOCUXXNSOQHM-FLIBITNWSA-N,butylidenephthalide,,Treatment of Malignant Glioma,C0555198,Malignant Glioma,8/5/15,Designated,Not FDA Approved for Orphan Indication,,,,
ONIQOQHATWINJY-UHFFFAOYSA-N,25102847,ONIQOQHATWINJY-UHFFFAOYSA-N,cabozantinib,Cometriq,"Treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer.","C0238461,C0238463","Anaplastic thyroid carcinoma , papillary thyroid cancer",11/29/10,Designated/Approved,,"Treatment of progressive, metastatic medullary thyroid cancer (MTC).", 11/29/2012 , 11/29/2019 ,
ONIQOQHATWINJY-UHFFFAOYSA-N,25102847,ONIQOQHATWINJY-UHFFFAOYSA-N,cabozantinib,CABOMETYX,Treatment of hepatocellular carcinoma.,C2239176,HEPATOCELLULAR CARCINOMA,3/2/17,Designated/Approved,,CABOMETYX is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib., 01/14/2019 , 01/14/2026 ,CABOMETYX is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
XWFCFMXQTBGXQW-GOSISDBHSA-N,44242317,XWFCFMXQTBGXQW-GOSISDBHSA-N,cadazolid,,Treatment of clostridium difficile infection in pediatric patients,C0343386,Clostridium difficile infection,8/8/17,Designated,Not FDA Approved for Orphan Indication,,,,
RYYVLZVUVIJVGH-UHFFFAOYSA-N,2519,RYYVLZVUVIJVGH-UHFFFAOYSA-N,Caffeine,Cafcit,Treatment of apnea of prematurity.,C0475715,Apnea of prematurity,9/20/88,Designated/Approved,,Short term treatment of apnea of prematurity in infants between 28 and less than 33 weeks gestational age., 09/21/1999 , 09/21/2006 ,
JWBPVFVNISJVEM-UHFFFAOYSA-M,23669229,JWBPVFVNISJVEM-UHFFFAOYSA-M,caffeine and sodium benzoate,,Treatment of seizure prolongation in patients undergoing electroconvulsive therapy,C0036572,Seizure,8/22/12,Designated,Not FDA Approved for Orphan Indication,,,,
IHRNYHWGJUMPFJ-UHFFFAOYSA-N,44562555,IHRNYHWGJUMPFJ-UHFFFAOYSA-N,Caflanone,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,9/25/19,Designated,Not FDA Approved for Orphan Indication,,,,
VSGNNIFQASZAOI-UHFFFAOYSA-L,6116,VSGNNIFQASZAOI-UHFFFAOYSA-L,Calcium acetate,Phos-Lo,Treatment of hyperphosphatemia in end stage renal failure.,"C0022661,C0085681","End stage renal failure , Hyperphosphatemia",12/22/88,Designated/Approved,,, 12/10/1990 , 12/10/1997 ,
VSGNNIFQASZAOI-UHFFFAOYSA-L,6116,VSGNNIFQASZAOI-UHFFFAOYSA-L,Calcium acetate,,Treatment of hyperphosphatemia in end stage renal disease.,"C0022661,C0085681","End stage renal disease , Hyperphosphatemia",6/27/89,Designated,Not FDA Approved for Orphan Indication,,,,
VTYYLEPIZMXCLO-UHFFFAOYSA-L,10112,VTYYLEPIZMXCLO-UHFFFAOYSA-L,Calcium carbonate,,Treatment of hyperphosphatemia in patients with end stage renal disease.,"C0022661,C0085681","End stage renal disease , Hyperphosphatemia",6/6/90,Designated,Not FDA Approved for Orphan Indication,,,,
XASIMHXSUQUHLV-UHFFFAOYSA-N,2536,XASIMHXSUQUHLV-UHFFFAOYSA-N,camostat,,Treatment of chronic pancreatitis,C0149521,Chronic pancreatitis,5/18/11,Designated,Not FDA Approved for Orphan Indication,,,,
QHMBSVQNZZTUGM-ZWKOTPCHSA-N,644019,QHMBSVQNZZTUGM-ZWKOTPCHSA-N,cannabidiol,EPIDIOLEX,Treatment of Lennox-Gastaut syndrome,C0238111,Lennox-Gastaut syndrome,2/27/14,Designated/Approved,,"treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex (TSC) in patients 1 year of age and older.", 07/31/2020 , 07/31/2027 ,treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients between 1 and 2 years of age
QHMBSVQNZZTUGM-ZWKOTPCHSA-N,644019,QHMBSVQNZZTUGM-ZWKOTPCHSA-N,cannabidiol,,Treatment of Graft versus Host Disease,C0018133,GRAFT VERSUS HOST DISEASE,11/29/16,Designated,Not FDA Approved for Orphan Indication,,,,
QHMBSVQNZZTUGM-ZWKOTPCHSA-N,644019,QHMBSVQNZZTUGM-ZWKOTPCHSA-N,cannabidiol,,Prevention of ischemia/reperfusion Injury resulting from solid organ transplantation,"C0022116,C0035126","Ischemia , Reperfusion Injury",11/5/18,Designated,Not FDA Approved for Orphan Indication,,,,
QHMBSVQNZZTUGM-ZWKOTPCHSA-N,644019,QHMBSVQNZZTUGM-ZWKOTPCHSA-N,cannabidiol,,Treatment of Epidermolysis Bullosa,C0014527,Epidermolysis Bullosa,4/20/20,Designated,Not FDA Approved for Orphan Indication,,,,
QHMBSVQNZZTUGM-ZWKOTPCHSA-N,644019,QHMBSVQNZZTUGM-ZWKOTPCHSA-N,cannabidiol,,Treatment of glioblastoma,C0017636,Glioblastoma,4/28/20,Designated,Not FDA Approved for Orphan Indication,,,,
QHMBSVQNZZTUGM-ZWKOTPCHSA-N,644019,QHMBSVQNZZTUGM-ZWKOTPCHSA-N,cannabidiol,,Treatment of glioma,C0017638,Glioma,9/24/14,Designated,Not FDA Approved for Orphan Indication,,,,
QHMBSVQNZZTUGM-ZWKOTPCHSA-N,644019,QHMBSVQNZZTUGM-ZWKOTPCHSA-N,cannabidiol,,Treatment of pediatric schizophrenia (pediatrics is defined as 0 through 16 years of age),C0036341,Schizophrenia,11/17/14,Designated,Not FDA Approved for Orphan Indication,,,,
QHMBSVQNZZTUGM-ZWKOTPCHSA-N,644019,QHMBSVQNZZTUGM-ZWKOTPCHSA-N,cannabidiol,,Treatment of Fragile X syndrome,C0016667,Fragile X Syndrome,2/23/16,Designated,Not FDA Approved for Orphan Indication,,,,
QHMBSVQNZZTUGM-ZWKOTPCHSA-N,644019,QHMBSVQNZZTUGM-ZWKOTPCHSA-N,cannabidiol,Epidiolex,Treatment of Lennox-Gastaut syndrome,C0238111,Lennox-Gastaut syndrome,2/27/14,Designated/Approved,,EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) in patients 2 years of age and older., 09/28/2018 , 09/28/2025 ,EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
QHMBSVQNZZTUGM-ZWKOTPCHSA-N,644019,QHMBSVQNZZTUGM-ZWKOTPCHSA-N,cannabidiol,Epidiolex,Treatment of Dravet syndrome,C0751122,Dravet Syndrome,11/14/13,Designated/Approved,,EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) in patients 2 years of age and older., 09/28/2018 , 09/28/2025 ,EPIDIOLEX is indicated for the treatment of seizures associated with Dravet syndrome (DS) in patients 2 years of age and older.
QHMBSVQNZZTUGM-ZWKOTPCHSA-N,644019,QHMBSVQNZZTUGM-ZWKOTPCHSA-N,cannabidiol,Epidiolex,Treatment of tuberous sclerosis complex.,C0041341,Tuberous Sclerosis Complex,4/19/16,Designated/Approved,,"treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older", 07/31/2020 , 07/31/2027 ,treatment of seizures associated with tuberous sclerosis complex (TSC) in patients 1 year of age and older
QHMBSVQNZZTUGM-ZWKOTPCHSA-N,644019,QHMBSVQNZZTUGM-ZWKOTPCHSA-N,cannabidiol,,Treatment of infantile spasms,C3887898,Infantile spasms,7/23/15,Designated,Not FDA Approved for Orphan Indication,,,,
QHMBSVQNZZTUGM-ZWKOTPCHSA-N,644019,QHMBSVQNZZTUGM-ZWKOTPCHSA-N,cannabidiol,EPIDIOLEX,Treatment of Dravet syndrome,C0751122,Dravet Syndrome,11/14/13,Designated/Approved,,"treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older.", 07/31/2020 , 07/31/2027 ,treatment of seizures associated with Dravet syndrome (DS) in patients between 1 and 2 years of age
QHMBSVQNZZTUGM-ZWKOTPCHSA-N,644019,QHMBSVQNZZTUGM-ZWKOTPCHSA-N,cannabidiol,,Treatment of Prader Willi Syndrome,C0032897,Prader Willi syndrome,8/21/20,Designated,Not FDA Approved for Orphan Indication,,,,
QHMBSVQNZZTUGM-ZWKOTPCHSA-N,644019,QHMBSVQNZZTUGM-ZWKOTPCHSA-N,cannabidiol,,Treatment of glioblastoma multiforme,C0017636,Glioblastoma multiforme,8/20/14,Designated,Not FDA Approved for Orphan Indication,,,,
QHMBSVQNZZTUGM-ZWKOTPCHSA-N,644019,QHMBSVQNZZTUGM-ZWKOTPCHSA-N,cannabidiol,,Treatment of neonatal hypoxic ischemic encephalopathy,C3898147,Neonatal Hypoxic Ischemic Encephalopathy,4/22/15,Designated,Not FDA Approved for Orphan Indication,,,,
QHMBSVQNZZTUGM-ZWKOTPCHSA-N,644019,QHMBSVQNZZTUGM-ZWKOTPCHSA-N,cannabidiol,,Treatment of childhood absence epilepsy,C0014553,childhood absence epilepsy,8/15/19,Designated,Not FDA Approved for Orphan Indication,,,,
QHMBSVQNZZTUGM-ZWKOTPCHSA-N,644019,QHMBSVQNZZTUGM-ZWKOTPCHSA-N,cannabidiol,,Treatment of Dravet syndrome,C0751122,Dravet Syndrome,7/1/14,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
QHMBSVQNZZTUGM-ZWKOTPCHSA-N,644019,QHMBSVQNZZTUGM-ZWKOTPCHSA-N,cannabidiol,,Prevention of Graft versus Host Disease (GVHD).,C0018133,GRAFT VERSUS HOST DISEASE,7/14/15,Designated,Not FDA Approved for Orphan Indication,,,,
QHMBSVQNZZTUGM-ZWKOTPCHSA-N,644019,QHMBSVQNZZTUGM-ZWKOTPCHSA-N,cannabidiol,,Treatment of Lennox-Gastaut syndrome,C0238111,Lennox-Gastaut syndrome,6/23/14,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
QHMBSVQNZZTUGM-ZWKOTPCHSA-N,644019,QHMBSVQNZZTUGM-ZWKOTPCHSA-N,cannabidiol,,Treatment of infantile spasms,C3887898,Infantile spasms,6/13/16,Designated,Not FDA Approved for Orphan Indication,,,,
QHMBSVQNZZTUGM-ZWKOTPCHSA-N,644019,QHMBSVQNZZTUGM-ZWKOTPCHSA-N,Cannabidiol,,Treatment of Angelman syndrome,C0162635,Angelman Syndrome,3/22/21,Designated,Not FDA Approved for Orphan Indication,,,,
QHMBSVQNZZTUGM-ZWKOTPCHSA-N,644019,QHMBSVQNZZTUGM-ZWKOTPCHSA-N,cannabidiol,,Treatment of Dravet syndrome,C0751122,Dravet Syndrome,12/21/17,Designated,Not FDA Approved for Orphan Indication,,,,
QHMBSVQNZZTUGM-ZWKOTPCHSA-N,644019,QHMBSVQNZZTUGM-ZWKOTPCHSA-N,cannabidiol,,Treatment of autoimmune hepatitis,C0241910,Autoimmune hepatitis,6/25/18,Designated,Not FDA Approved for Orphan Indication,,,,
REOZWEGFPHTFEI-JKSUJKDBSA-N,11601669,REOZWEGFPHTFEI-JKSUJKDBSA-N,cannabidivarin,,Treatment of Rett syndrome,C0035372,Rett Syndrome,11/30/16,Designated,Not FDA Approved for Orphan Indication,,,,
REOZWEGFPHTFEI-JKSUJKDBSA-N,11601669,REOZWEGFPHTFEI-JKSUJKDBSA-N,Cannabidivarin,,Treatment of Fragile X syndrome,C0016667,Fragile X Syndrome,6/6/17,Designated,Not FDA Approved for Orphan Indication,,,,
DHZBEENLJMYSHQ-XCVPVQRUSA-N,5944,DHZBEENLJMYSHQ-XCVPVQRUSA-N,cantharidin,,"Treatment of perforating diseases, including Kyrle's disease, reactive perforating collangenosis, perforating folliculitis and elastosis perforans serpiginosa","C0016436,C0221271,C0263382","Folliculitis , Elastosis perforans serpiginosa , Kyrle's disease",7/24/12,Designated,Not FDA Approved for Orphan Indication,,,,
JFVVPUGGRUGRBJ-AVRDEDQJSA-N,129851403,JFVVPUGGRUGRBJ-AVRDEDQJSA-N,cantrixil,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,4/20/15,Designated,Not FDA Approved for Orphan Indication,,,,
LIOLIMKSCNQPLV-UHFFFAOYSA-N,25145656,LIOLIMKSCNQPLV-UHFFFAOYSA-N,capmatinib,,Treatment of non-small cell lung cancer with MET genomic tumor aberrations,"C0027651,C3539721","Tumor , Non-Small Cell Lung Cancer",3/15/19,Designated/Approved,,Tabrecta (capmatinib) is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test., 05/06/2020 , 05/06/2027 ,For the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
YKPUWZUDDOIDPM-SOFGYWHQSA-N,1548943,YKPUWZUDDOIDPM-SOFGYWHQSA-N,capsaicin,,Treatment of erythromelalgia,C0014804,Erythromelalgia,10/23/02,Designated,Not FDA Approved for Orphan Indication,,,,
YKPUWZUDDOIDPM-SOFGYWHQSA-N,1548943,YKPUWZUDDOIDPM-SOFGYWHQSA-N,Capsaicin,,Treatment of postherpetic neuralgia.,C0032768,Postherpetic neuralgia,8/3/05,Designated,Not FDA Approved for Orphan Indication,,,,
YKPUWZUDDOIDPM-SOFGYWHQSA-N,1548943,YKPUWZUDDOIDPM-SOFGYWHQSA-N,capsaicin,,Treatment of intermetatarsal neuroma (Morton's Neuroma) that does not respond to conservative treatment and requires either neurectomy or neurolysis,C0311337,Intermetatarsal Neuroma,9/29/06,Designated,Not FDA Approved for Orphan Indication,,,,
YKPUWZUDDOIDPM-SOFGYWHQSA-N,1548943,YKPUWZUDDOIDPM-SOFGYWHQSA-N,capsaicin,,Treatment of painful HIV-associated neuropathy,"C0019682,C0442874","HIV , Neuropathy",5/2/03,Designated,Not FDA Approved for Orphan Indication,,,,
YKPUWZUDDOIDPM-SOFGYWHQSA-N,1548943,YKPUWZUDDOIDPM-SOFGYWHQSA-N,capsaicin,Qutenza,Management of neuropathic pain in patients with postherpetic neuralgia,"C0027796,C0032768","Neuropathic Pain , Postherpetic neuralgia",5/22/09,Designated/Approved,,Management of neuropathic pain associated with postherpetic neuralgia, 11/16/2009 , 11/16/2016 ,
OBZHEBDUNPOCJG-HLWLYVGMSA-N,134689748,OBZHEBDUNPOCJG-HLWLYVGMSA-N,carbenoxolone,,Treatment of Huntington's Disease,C0020179,Huntington's Disease,7/2/14,Designated,Not FDA Approved for Orphan Indication,,,,
OBZHEBDUNPOCJG-IBEOWVBCSA-N,134613184,OBZHEBDUNPOCJG-IBEOWVBCSA-N,carbenoxolone,,Treatment of Huntington's Disease,C0020179,Huntington's Disease,7/2/14,Designated,Not FDA Approved for Orphan Indication,,,,
OBZHEBDUNPOCJG-KNJYOZPASA-N,146036893,OBZHEBDUNPOCJG-KNJYOZPASA-N,carbenoxolone,,Treatment of Huntington's Disease,C0020179,Huntington's Disease,7/2/14,Designated,Not FDA Approved for Orphan Indication,,,,
OBZHEBDUNPOCJG-SMVPYXKTSA-N,56965767,OBZHEBDUNPOCJG-SMVPYXKTSA-N,carbenoxolone,,Treatment of Huntington's Disease,C0020179,Huntington's Disease,7/2/14,Designated,Not FDA Approved for Orphan Indication,,,,
OBZHEBDUNPOCJG-SZTGPWMUSA-N,46936354,OBZHEBDUNPOCJG-SZTGPWMUSA-N,carbenoxolone,,Treatment of Huntington's Disease,C0020179,Huntington's Disease,7/2/14,Designated,Not FDA Approved for Orphan Indication,,,,
OBZHEBDUNPOCJG-WZCASOPNSA-N,21913,OBZHEBDUNPOCJG-WZCASOPNSA-N,carbenoxolone,,Treatment of Huntington's Disease,C0020179,Huntington's Disease,7/2/14,Designated,Not FDA Approved for Orphan Indication,,,,
OBZHEBDUNPOCJG-ILYNEHRHSA-N,5311038,OBZHEBDUNPOCJG-ILYNEHRHSA-N,carbenoxolone,,Treatment of Huntington's Disease,C0020179,Huntington's Disease,7/2/14,Designated,Not FDA Approved for Orphan Indication,,,,
OBZHEBDUNPOCJG-WBXJDKIVSA-N,636403,OBZHEBDUNPOCJG-WBXJDKIVSA-N,carbenoxolone,,Treatment of Huntington's Disease,C0020179,Huntington's Disease,7/2/14,Designated,Not FDA Approved for Orphan Indication,,,,
CURLTUGMZLYLDI-UHFFFAOYSA-N,280,CURLTUGMZLYLDI-UHFFFAOYSA-N,carbon dioxide,,Treatment of trigeminal neuralgia,C0040997,Trigeminal Neuralgia,12/17/15,Designated,Not FDA Approved for Orphan Indication,,,,
UGFAIRIUMAVXCW-UHFFFAOYSA-N,281,UGFAIRIUMAVXCW-UHFFFAOYSA-N,carbon monoxide,,Treatment of idiopathic pulmonary fibrosis (IPF).,"C0034069,C1800706","IPF , Idiopathic Pulmonary Fibrosis",8/16/16,Designated,Not FDA Approved for Orphan Indication,,,,
UGFAIRIUMAVXCW-UHFFFAOYSA-N,281,UGFAIRIUMAVXCW-UHFFFAOYSA-N,carbon monoxide,,Prevention of Primary Graft Dysfunction in transplant recipients receiving a lung or heart+ lung transplant.,C0948031,Primary Graft Dysfunction,4/14/20,Designated,Not FDA Approved for Orphan Indication,,,,
UGFAIRIUMAVXCW-UHFFFAOYSA-N,281,UGFAIRIUMAVXCW-UHFFFAOYSA-N,carbon monoxide,,Treatment of sickle cell disease,C0002895,Sickle Cell Disease,9/28/12,Designated,Not FDA Approved for Orphan Indication,,,,
XSSYCIGJYCVRRK-NKWVEPMBSA-N,135538685,XSSYCIGJYCVRRK-NKWVEPMBSA-N,Carbovir,,Treatment of persons with AIDS and in patients with symptomatic HIV infection and a CD4 count less than 200/mm3.,"C0001175,C0019693","AIDS , HIV infection",12/13/89,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
XSSYCIGJYCVRRK-RQJHMYQMSA-N,135433604,XSSYCIGJYCVRRK-RQJHMYQMSA-N,Carbovir,,Treatment of persons with AIDS and in patients with symptomatic HIV infection and a CD4 count less than 200/mm3.,"C0001175,C0019693","AIDS , HIV infection",12/13/89,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
XSSYCIGJYCVRRK-UHFFFAOYSA-N,135403630,XSSYCIGJYCVRRK-UHFFFAOYSA-N,Carbovir,,Treatment of persons with AIDS and in patients with symptomatic HIV infection and a CD4 count less than 200/mm3.,"C0001175,C0019693","AIDS , HIV infection",12/13/89,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
WEUITFNOCGSIHW-UHFFFAOYSA-N,154732136,WEUITFNOCGSIHW-UHFFFAOYSA-N,carboxyamidotriazole orotate,,Treatment of malignant glioma,C0555198,Malignant Glioma,5/10/18,Designated,Not FDA Approved for Orphan Indication,,,,
BLMPQMFVWMYDKT-NZTKNTHTSA-N,11556711,BLMPQMFVWMYDKT-NZTKNTHTSA-N,carfilzomib,,Treatment of Acute Lymphoblastic Leukemia,C0023449,Acute lymphoblastic leukemia,1/21/21,Designated,Not FDA Approved for Orphan Indication,,,,
BLMPQMFVWMYDKT-NZTKNTHTSA-N,11556711,BLMPQMFVWMYDKT-NZTKNTHTSA-N,carfilzomib,Kyprolis,Treatment of multiple myeloma,C0026764,Multiple Myeloma,1/18/08,Designated/Approved,,Treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy., 07/20/2012 , 07/20/2019 ,
BLMPQMFVWMYDKT-NZTKNTHTSA-N,11556711,BLMPQMFVWMYDKT-NZTKNTHTSA-N,carfilzomib,KYPROLIS,Treatment of multiple myeloma,C0026764,Multiple Myeloma,1/18/08,Designated/Approved,,KYPROLIS is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with daratumumab and dexamethasone., 08/20/2020 ,  ,
LCQLHJZYVOQKHU-VKHMYHEASA-N,121396,LCQLHJZYVOQKHU-VKHMYHEASA-N,carglumic acid,Carbaglu,Treatment of N-acetylglutamate synthetase deficiency.,C0268543,N-acetylglutamate synthetase deficiency,1/20/98,Designated/Approved,,As an adjunctive therapy for the treatment of acute hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS) and as manitenance therapy for chronic hyperammonemia due to NAGS deficiency, 03/18/2010 , 03/18/2017 ,
LCQLHJZYVOQKHU-VKHMYHEASA-N,121396,LCQLHJZYVOQKHU-VKHMYHEASA-N,carglumic acid,Carbaglu,Treatment of organic acidemias,C1829844,Organic acidemias,6/17/14,Designated/Approved,,adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA) in pediatric and adult patients, 01/22/2021 ,  ,
OLBWFRRUHYQABZ-MRVPVSSYSA-N,6918474,OLBWFRRUHYQABZ-MRVPVSSYSA-N,carisbamate,,Treatment of Lennox-Gastaut syndrome,C0238111,Lennox-Gastaut syndrome,8/2/17,Designated,Not FDA Approved for Orphan Indication,,,,
OLBWFRRUHYQABZ-MRVPVSSYSA-N,6918474,OLBWFRRUHYQABZ-MRVPVSSYSA-N,carisbamate,,Management of patients with infantile spasms,C3887898,Infantile spasms,3/16/12,Designated,Not FDA Approved for Orphan Indication,,,,
DLGOEMSEDOSKAD-UHFFFAOYSA-N,2578,DLGOEMSEDOSKAD-UHFFFAOYSA-N,Carmustine,,Treatment of intracranial malignancies.,C0006826,MALIGNANCIES,7/3/00,Designated,Not FDA Approved for Orphan Indication,,,,
GPEYTRIZYSZRRK-MHZLTWQESA-N,100951591,GPEYTRIZYSZRRK-MHZLTWQESA-N,Ceclazepide,,Treatment of gastric neuroendocrine tumors (gastric NETs).,C0206754,Neuroendocrine Tumors,5/12/16,Designated,Not FDA Approved for Orphan Indication,,,,
XXJWYDDUDKYVKI-UHFFFAOYSA-N,9933475,XXJWYDDUDKYVKI-UHFFFAOYSA-N,cediranib,,Treatment of glioblastoma,C0017636,Glioblastoma,12/13/10,Designated,Not FDA Approved for Orphan Indication,,,,
YOBPSXOHCHDCMU-FDDQUTDISA-M,137705394,YOBPSXOHCHDCMU-FDDQUTDISA-M,Ceftriaxone sodium,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,3/28/06,Designated,Not FDA Approved for Orphan Indication,,,,
VAAUVRVFOQPIGI-ONNSZKPLSA-L,98042587,VAAUVRVFOQPIGI-ONNSZKPLSA-L,Ceftriaxone sodium,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,3/28/06,Designated,Not FDA Approved for Orphan Indication,,,,
VUGBLGCUPUUDOI-GNXCPKRQSA-N,87900910,VUGBLGCUPUUDOI-GNXCPKRQSA-N,Ceftriaxone sodium,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,3/28/06,Designated,Not FDA Approved for Orphan Indication,,,,
XKYJAZULGNDPLX-IXIFSOOLSA-N,87060529,XKYJAZULGNDPLX-IXIFSOOLSA-N,Ceftriaxone sodium,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,3/28/06,Designated,Not FDA Approved for Orphan Indication,,,,
XMCDZRXQAGFWAK-PMCOHIMVSA-L,60196280,XMCDZRXQAGFWAK-PMCOHIMVSA-L,Ceftriaxone sodium,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,3/28/06,Designated,Not FDA Approved for Orphan Indication,,,,
VAAUVRVFOQPIGI-DAMLXXHOSA-L,24867842,VAAUVRVFOQPIGI-DAMLXXHOSA-L,Ceftriaxone sodium,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,3/28/06,Designated,Not FDA Approved for Orphan Indication,,,,
FDRNWTJTHBSPMW-UYIJMJIKSA-L,12971800,FDRNWTJTHBSPMW-UYIJMJIKSA-L,Ceftriaxone sodium,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,3/28/06,Designated,Not FDA Approved for Orphan Indication,,,,
XKYJAZULGNDPLX-VKZZUTNHSA-N,9894479,XKYJAZULGNDPLX-VKZZUTNHSA-N,Ceftriaxone sodium,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,3/28/06,Designated,Not FDA Approved for Orphan Indication,,,,
YOBPSXOHCHDCMU-IXIFSOOLSA-L,86287429,YOBPSXOHCHDCMU-IXIFSOOLSA-L,Ceftriaxone sodium,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,3/28/06,Designated,Not FDA Approved for Orphan Indication,,,,
YOBPSXOHCHDCMU-OOUOULNMSA-M,77906400,YOBPSXOHCHDCMU-OOUOULNMSA-M,Ceftriaxone sodium,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,3/28/06,Designated,Not FDA Approved for Orphan Indication,,,,
YOBPSXOHCHDCMU-UHFFFAOYSA-M,53394792,YOBPSXOHCHDCMU-UHFFFAOYSA-M,Ceftriaxone sodium,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,3/28/06,Designated,Not FDA Approved for Orphan Indication,,,,
KTAVBOYXMBQFGR-MAODNAKNSA-J,11953897,KTAVBOYXMBQFGR-MAODNAKNSA-J,Ceftriaxone sodium,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,3/28/06,Designated,Not FDA Approved for Orphan Indication,,,,
FDRNWTJTHBSPMW-ZJTMPOFJSA-L,9601224,FDRNWTJTHBSPMW-ZJTMPOFJSA-L,Ceftriaxone sodium,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,3/28/06,Designated,Not FDA Approved for Orphan Indication,,,,
FDRNWTJTHBSPMW-JQVQFYFGSA-L,59844,FDRNWTJTHBSPMW-JQVQFYFGSA-L,Ceftriaxone sodium,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,3/28/06,Designated,Not FDA Approved for Orphan Indication,,,,
FDRNWTJTHBSPMW-PHCXSBOASA-L,11957491,FDRNWTJTHBSPMW-PHCXSBOASA-L,Ceftriaxone sodium,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,3/28/06,Designated,Not FDA Approved for Orphan Indication,,,,
FDRNWTJTHBSPMW-GNXCPKRQSA-L,5362369,FDRNWTJTHBSPMW-GNXCPKRQSA-L,Ceftriaxone sodium,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,3/28/06,Designated,Not FDA Approved for Orphan Indication,,,,
FDRNWTJTHBSPMW-BBJOQENWSA-L,9570985,FDRNWTJTHBSPMW-BBJOQENWSA-L,Ceftriaxone sodium,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,3/28/06,Designated,Not FDA Approved for Orphan Indication,,,,
VAAUVRVFOQPIGI-SPQHTLEESA-N,5479530,VAAUVRVFOQPIGI-SPQHTLEESA-N,Ceftriaxone sodium,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,3/28/06,Designated,Not FDA Approved for Orphan Indication,,,,
YOBPSXOHCHDCMU-IXIFSOOLSA-M,23709629,YOBPSXOHCHDCMU-IXIFSOOLSA-M,Ceftriaxone sodium,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,3/28/06,Designated,Not FDA Approved for Orphan Indication,,,,
YOBPSXOHCHDCMU-VKZZUTNHSA-M,23679441,YOBPSXOHCHDCMU-VKZZUTNHSA-M,Ceftriaxone sodium,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,3/28/06,Designated,Not FDA Approved for Orphan Indication,,,,
RZEKVGVHFLEQIL-UHFFFAOYSA-N,2662,RZEKVGVHFLEQIL-UHFFFAOYSA-N,Celecoxib,,Treatment of hemophilic arthropathy,C0263725,Hemophilic arthropathy,7/30/20,Designated,Not FDA Approved for Orphan Indication,,,,
JOATXPAWOHTVSZ-UHFFFAOYSA-N,2663,JOATXPAWOHTVSZ-UHFFFAOYSA-N,celiprolol,,Treatment of Ehlers-Danlos syndrome,C0013720,Ehlers-Danlos Syndrome,1/5/15,Designated,Not FDA Approved for Orphan Indication,,,,
YVPXVXANRNDGTA-WDYNHAJCSA-N,10206,YVPXVXANRNDGTA-WDYNHAJCSA-N,Cepharanthine,,Treatment of immune thrombocytopenia (ITP),"C0242584,C0398650","Immune thrombocytopenia , Immune Thrombocytopenia",9/22/20,Designated,Not FDA Approved for Orphan Indication,,,,
YVPXVXANRNDGTA-WDYNHAJCSA-N,10206,YVPXVXANRNDGTA-WDYNHAJCSA-N,Cepharanthine,,Treatment of Esophageal Cancer,C0014859,esophageal cancer,1/14/21,Designated,Not FDA Approved for Orphan Indication,,,,
BGLPECHZZQDNCD-UHFFFAOYSA-N,44595079,BGLPECHZZQDNCD-UHFFFAOYSA-N,cerdulatinib,,Treatment of peripheral T-cell lymphoma (PTCL).,C0079774,Peripheral T-Cell Lymphoma,9/21/18,Designated,Not FDA Approved for Orphan Indication,,,,
VERWOWGGCGHDQE-UHFFFAOYSA-N,57379345,VERWOWGGCGHDQE-UHFFFAOYSA-N,ceritinib,ZYKADIA,Treatment of patients with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase(ALK)-positive,"C0007131,C3539721","Non-Small Cell Lung Cancer , Non-Small Cell Lung Cancer",9/27/13,Designated/Approved,,Treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test, 05/26/2017 , 05/26/2024 ,Treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test
WHTVZRBIWZFKQO-UHFFFAOYSA-N,2719,WHTVZRBIWZFKQO-UHFFFAOYSA-N,chloroquine,,Treatment of glioblastoma multiforme.,C0017636,Glioblastoma multiforme,5/20/15,Designated,Not FDA Approved for Orphan Indication,,,,
QNTASHOAVRSLMD-FCARAQADSA-N,21763506,QNTASHOAVRSLMD-FCARAQADSA-N,"cholest-4-en-3-one, oxime",,Treatment of spinal muscular atrophy.,C0026847,Spinal Muscular Atrophy,2/17/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
QNTASHOAVRSLMD-SIWSWZRQSA-N,9930827,QNTASHOAVRSLMD-SIWSWZRQSA-N,"cholest-4-en-3-one, oxime",,Treatment of spinal muscular atrophy.,C0026847,Spinal Muscular Atrophy,2/17/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
QNTASHOAVRSLMD-GYKMGIIDSA-N,76971721,QNTASHOAVRSLMD-GYKMGIIDSA-N,"cholest-4-en-3-one, oxime",,Treatment of spinal muscular atrophy.,C0026847,Spinal Muscular Atrophy,2/17/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
SCZVLDHREVKTSH-UHFFFAOYSA-N,5280666,SCZVLDHREVKTSH-UHFFFAOYSA-N,chrysoeriol,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,6/22/17,Designated,Not FDA Approved for Orphan Indication,,,,
VDHAWDNDOKGFTD-MRXNPFEDSA-N,156419,VDHAWDNDOKGFTD-MRXNPFEDSA-N,cinacalcet,Sensipar,"Treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery",C0221002,Primary hyperparathyroidism,4/30/10,Designated/Approved,,0, 02/25/2011 , 02/25/2018 ,
YKPUWZUDDOIDPM-VURMDHGXSA-N,1548942,YKPUWZUDDOIDPM-VURMDHGXSA-N,civamide,,Treatment of postherpetic neuralgia.,C0032768,Postherpetic neuralgia,2/17/09,Designated,Not FDA Approved for Orphan Indication,,,,
PTOAARAWEBMLNO-KVQBGUIXSA-N,20279,PTOAARAWEBMLNO-KVQBGUIXSA-N,Cladribine,,Treatment of non-Hodgkin's lymphoma.,C0024305,Non-Hodgkin's Lymphoma,4/19/93,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
STJMRWALKKWQGH-UHFFFAOYSA-N,2783,STJMRWALKKWQGH-UHFFFAOYSA-N,clenbuterol,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,10/2/18,Designated,Not FDA Approved for Orphan Indication,,,,
CXOXHMZGEKVPMT-UHFFFAOYSA-N,2789,CXOXHMZGEKVPMT-UHFFFAOYSA-N,clobazam,Onfi,Treatment of Lennox-Gastaut Syndrome,C0238111,Lennox-Gastaut syndrome,12/18/07,Designated/Approved,,Adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome inpatients 2 years of age or older, 10/21/2011 , 10/21/2018 ,
WDDPHFBMKLOVOX-AYQXTPAHSA-N,119182,WDDPHFBMKLOVOX-AYQXTPAHSA-N,clofarabine,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,1/24/19,Designated,Not FDA Approved for Orphan Indication,,,,
DGBIGWXXNGSACT-UHFFFAOYSA-N,2802,DGBIGWXXNGSACT-UHFFFAOYSA-N,Clonazepam,,Treatment of hyperekplexia (startle disease).,C0234166,Hyperekplexia,8/4/94,Designated,Not FDA Approved for Orphan Indication,,,,
ACTIUHUUMQJHFO-UPTCCGCDSA-N,5281915,ACTIUHUUMQJHFO-UPTCCGCDSA-N,Coenzyme Q10,,Treatment of Huntington's disease,C0020179,Huntington's Disease,3/5/01,Designated,Not FDA Approved for Orphan Indication,,,,
IQWHCHZFYPIVRV-UHFFFAOYSA-I,216258,IQWHCHZFYPIVRV-UHFFFAOYSA-I,colistimethate sodium,,Treatment of respiratory infection in patients with Cystic Fibrosis,"C0010674,C0035243","Cystic Fibrosis , respiratory infection",3/19/20,Designated,Not FDA Approved for Orphan Indication,,,,
WDOGQTQEKVLZIJ-WAYWQWQTSA-L,21159388,WDOGQTQEKVLZIJ-WAYWQWQTSA-L,Combretastatin A4 Phosphate,,"Treatment of anaplastic thyroid cancer, medullary thyroid cancer, and stage IV papillary or follicular thyroid cancer","C0206682,C0238461,C0238462","follicular thyroid cancer , anaplastic thyroid cancer , Thyroid cancer, medullary",7/23/03,Designated,Not FDA Approved for Orphan Indication,,,,
WDOGQTQEKVLZIJ-WAYWQWQTSA-N,5351387,WDOGQTQEKVLZIJ-WAYWQWQTSA-N,Combretastatin A4 Phosphate,,"Treatment of anaplastic thyroid cancer, medullary thyroid cancer, and stage IV papillary or follicular thyroid cancer","C0206682,C0238461,C0238462","follicular thyroid cancer , anaplastic thyroid cancer , Thyroid cancer, medullary",7/23/03,Designated,Not FDA Approved for Orphan Indication,,,,
UTQHLYJFMFKSGI-ZUMWLQPESA-N,101205708,UTQHLYJFMFKSGI-ZUMWLQPESA-N,Contulakin-G,,Intrathecal treatment of neuropathic pain associated with spinal cord injury,"C0027796,C0037929","Neuropathic Pain , Spinal Cord Injury",7/7/05,Designated,Not FDA Approved for Orphan Indication,,,,
UTQHLYJFMFKSGI-UBINZTMLSA-N,56928166,UTQHLYJFMFKSGI-UBINZTMLSA-N,Contulakin-G,,Intrathecal treatment of neuropathic pain associated with spinal cord injury,"C0027796,C0037929","Neuropathic Pain , Spinal Cord Injury",7/7/05,Designated,Not FDA Approved for Orphan Indication,,,,
MWYDSXOGIBMAET-UHFFFAOYSA-N,135565596,MWYDSXOGIBMAET-UHFFFAOYSA-N,copanlisib,,Treatment of extranodal marginal zone lymphoma,C1367654,Marginal zone lymphoma,2/7/17,Designated,Not FDA Approved for Orphan Indication,,,,
QEEJLLNYQOBRRM-KSHGRFHLSA-N,16132344,QEEJLLNYQOBRRM-KSHGRFHLSA-N,Corticorelin ovine triflutate,Acthrel,For use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushings syndrome.,C0010481,CUSHINGS SYNDROME,11/24/89,Designated/Approved,,To differentiate between pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing's syndrome., 05/23/1996 , 05/23/2003 ,
ZOEFCCMDUURGSE-CQVUSSRSSA-N,16129617,ZOEFCCMDUURGSE-CQVUSSRSSA-N,cosyntropin,,Treatment of Duchenne muscular dystrophy.,C0013264,DUCHENNE MUSCULAR DYSTROPHY,7/6/17,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
KTEIFNKAUNYNJU-GFCCVEGCSA-N,11626560,KTEIFNKAUNYNJU-GFCCVEGCSA-N,crizotinib,Xalkori,Treatment of anaplastic large cell lymphoma,C0024302,large cell lymphoma,9/28/12,Designated/Approved,,"treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive", 01/14/2021 , 01/14/2028 ,"treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive."
RCBJUJRVBGYTEO-UHFFFAOYSA-N,71587716,RCBJUJRVBGYTEO-UHFFFAOYSA-N,CT-2584 Mesylate,,Treatment of adult soft tissue sarcoma.,C0220613,Adult Soft Tissue Sarcoma,4/16/99,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
OGMADIBCHLQMIP-UHFFFAOYSA-N,9082,OGMADIBCHLQMIP-UHFFFAOYSA-N,Cysteamine hydrochloride,Cystaran,Treatment of corneal cystine crystal accumulation in cystinosis patients.,C4316899,Cystinosis,8/19/97,Designated/Approved,,Treatment of corneal cystine crystal accumulation in patients with cystinosis, 10/02/2012 , 10/02/2019 ,
UIBPZXXSPHGPDS-UXLZJAPBSA-N,71587612,UIBPZXXSPHGPDS-UXLZJAPBSA-N,D-peptide of the sequence AKRHHGYKRKFH - NH2,,Treatment of cystic fibrosis,C0010674,Cystic Fibrosis,10/23/02,Designated,Not FDA Approved for Orphan Indication,,,,
LKDRXBCSQODPBY-OEXCPVAWSA-N,439312,LKDRXBCSQODPBY-OEXCPVAWSA-N,D-tagatose,,Treatment of Prader-Willi Syndrome,C0032897,Prader-Willi Syndrome,1/19/17,Designated,Not FDA Approved for Orphan Indication,,,,
XAUDJQYHKZQPEU-KVQBGUIXSA-N,451668,XAUDJQYHKZQPEU-KVQBGUIXSA-N,decitabine,Dacogen,Treatment of myelodysplastic syndromes.,C3463824,Myelodysplastic Syndromes,3/8/99,Designated/Approved,,"for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups", 05/02/2006 , 05/02/2013 ,
BOFQWVMAQOTZIW-UHFFFAOYSA-N,214348,BOFQWVMAQOTZIW-UHFFFAOYSA-N,deferasirox,Exjade; Jadenu Sprinkles,Treatment of chronic iron overload in alpha-thalassemia,"C0002312,C0282193","alpha-Thalassemia , Iron Overload",2/24/15,Designated/Approved,,Treatment of chronic iron overload in patients 10 years of age and older with non-transfusion dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and serum ferritin greater than 300 mcg/L., 01/23/2013 , 01/23/2020 ,Treatment of chronic iron overload in patients 10 years of age and older with non-transfusion dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and serum ferritin greater than 300 mcg/L.
BOFQWVMAQOTZIW-UHFFFAOYSA-N,214348,BOFQWVMAQOTZIW-UHFFFAOYSA-N,Deferasirox,Exjade; Jadenu Sprinkles,Treatment of chronic iron overload in patients with transfusion-dependent anemias,"C0002871,C0282193","Anemias , Iron Overload",11/21/02,Designated/Approved,,Treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age or older, 11/02/2005 , 11/02/2012 ,
JNWFIPVDEINBAI-UHFFFAOYSA-N,135565962,JNWFIPVDEINBAI-UHFFFAOYSA-N,Defibrotide,,Treatment of thrombotic thrombocytopenic purpura.,C0857305,Thrombocytopenic purpura,7/5/85,Designated,Not FDA Approved for Orphan Indication,,,,
FBHSPRKOSMHSIF-GRMWVWQJSA-N,189821,FBHSPRKOSMHSIF-GRMWVWQJSA-N,deflazacort,Emflaza,Treatment of Duchenne muscular dystrophy,C0013264,DUCHENNE MUSCULAR DYSTROPHY,8/16/13,Designated/Approved,,Treatment of Duchenne Muscular Dystrophy in patients 5 years of age and older, 02/09/2017 , 02/09/2024 ,Treatment of Duchenne Muscular Dystrophy in patients 5 years of age and older
FBHSPRKOSMHSIF-GRMWVWQJSA-N,189821,FBHSPRKOSMHSIF-GRMWVWQJSA-N,deflazacort,,Treatment of Duchenne muscular dystrophy,C0013264,DUCHENNE MUSCULAR DYSTROPHY,9/16/10,Designated,Not FDA Approved for Orphan Indication,,,,
FMGSKLZLMKYGDP-USOAJAOKSA-N,5881,FMGSKLZLMKYGDP-USOAJAOKSA-N,Dehydroepiandrosterone (DHEA),,Replacement therapy in individuals with adrenal insufficiency,C0001623,Adrenal Insufficiency,8/19/03,Designated,Not FDA Approved for Orphan Indication,,,,
VFLDPWHFBUODDF-FCXRPNKRSA-N,969516,VFLDPWHFBUODDF-FCXRPNKRSA-N,diferuloylmethane,,Treatment of cystic fibrosis,C0010674,Cystic Fibrosis,6/13/03,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
VHBABGAFHUKREU-ICKLFXEKSA-N,11977455,VHBABGAFHUKREU-ICKLFXEKSA-N,dihydroartemisinin and piperaquine,,"Treatment of uncomplicated malaria caused by ""Plasmodium falciparum,"" Plasmodium vivax,"" Plasmodium malariae,"" or ""Plasmodium ovale.""",C0024530,Malaria,1/8/07,Designated,Not FDA Approved for Orphan Indication,,,,
LDCRTTXIJACKKU-ONEGZZNKSA-N,637568,LDCRTTXIJACKKU-ONEGZZNKSA-N,dimethyl fumarate,,Treatment of Friedreich's Ataxia,C0016719,Friedreich's Ataxia,9/11/13,Designated,Not FDA Approved for Orphan Indication,,,,
LZXMUJCJAWVHPZ-UHFFFAOYSA-N,44557636,LZXMUJCJAWVHPZ-UHFFFAOYSA-N,dipraglurant,,Treatment of levodopa-induced dyskinesias,C1970038,Levodopa-induced dyskinesias,12/29/15,Designated,Not FDA Approved for Orphan Indication,,,,
ZLVMAMIPILWYHQ-INIZCTEOSA-N,71137,ZLVMAMIPILWYHQ-INIZCTEOSA-N,docarpamine,,Treatment of ascites due to all etiologies except cancer,"C0003962,C0006826","Ascites , Cancer",4/14/20,Designated,Not FDA Approved for Orphan Indication,,,,
RZHKDBRREKOZEW-AAXZNHDCSA-N,158782,RZHKDBRREKOZEW-AAXZNHDCSA-N,Edotreotide,,Treatment of somatostatin receptor-positive neuroendocrine gastroenteropancreatic tumors,C0027651,Tumors,7/28/05,Designated,Not FDA Approved for Orphan Indication,,,,
VLCYCQAOQCDTCN-UHFFFAOYSA-N,3009,VLCYCQAOQCDTCN-UHFFFAOYSA-N,eflornithine,,Treatment of neuroblastoma,C0027819,Neuroblastoma,11/23/10,Designated,Not FDA Approved for Orphan Indication,,,,
JOZGNYDSEBIJDH-UHFFFAOYSA-N,43157,JOZGNYDSEBIJDH-UHFFFAOYSA-N,eniluracil,,Treatment of hepatocellular carcinoma.,C2239176,HEPATOCELLULAR CARCINOMA,12/15/05,Designated,Not FDA Approved for Orphan Indication,,,,
XSMSNFMDVXXHGJ-UHFFFAOYSA-N,59473233,XSMSNFMDVXXHGJ-UHFFFAOYSA-N,entospletinib,,Prevention of chronic graft-versus-host disease,C0867389,Chronic graft-versus-host disease,8/10/17,Designated,Not FDA Approved for Orphan Indication,,,,
AXRCEOKUDYDWLF-UHFFFAOYSA-N,176167,AXRCEOKUDYDWLF-UHFFFAOYSA-N,enzastaurin,,Treatment of diffuse large B-cell lymphoma,C1332201,Diffuse Large B-Cell Lymphoma,3/4/09,Designated,Not FDA Approved for Orphan Indication,,,,
LMHIPJMTZHDKEW-XQYLJSSYSA-N,21158562,LMHIPJMTZHDKEW-XQYLJSSYSA-N,epoprostenol,,Treatment of Frostbite,C0016736,Frostbite,4/20/20,Designated,Not FDA Approved for Orphan Indication,,,,
WHVPOEPABJZBBY-XQYLJSSYSA-N,67548346,WHVPOEPABJZBBY-XQYLJSSYSA-N,epoprostenol,,Treatment of Frostbite,C0016736,Frostbite,4/20/20,Designated,Not FDA Approved for Orphan Indication,,,,
LMHIPJMTZHDKEW-XQYLJSSYSA-M,6364626,LMHIPJMTZHDKEW-XQYLJSSYSA-M,epoprostenol,,Treatment of Frostbite,C0016736,Frostbite,4/20/20,Designated,Not FDA Approved for Orphan Indication,,,,
KAQKFAOMNZTLHT-OZUDYXHBSA-N,5282411,KAQKFAOMNZTLHT-OZUDYXHBSA-N,epoprostenol,,Treatment of Frostbite,C0016736,Frostbite,4/20/20,Designated,Not FDA Approved for Orphan Indication,,,,
KGWDUNBJIMUFAP-KVVVOXFISA-N,5282489,KGWDUNBJIMUFAP-KVVVOXFISA-N,Ethanolamine oleate,Ethamolin,"Treatment of patients with esophageal varices that have recently bled, to prevent rebleeding.",C0014867,Esophageal Varices,3/22/84,Designated/Approved,,, 12/22/1988 , 12/22/1995 ,
NUKYPUAOHBNCPY-UHFFFAOYSA-N,1727,NUKYPUAOHBNCPY-UHFFFAOYSA-N,Fampridine,,"Treatment of chronic, incomplete spinal cord injury.",C4545488,Incomplete spinal cord injury,6/2/97,Designated,Not FDA Approved for Orphan Indication,,,,
NGOGFTYYXHNFQH-UHFFFAOYSA-N,3547,NGOGFTYYXHNFQH-UHFFFAOYSA-N,Fasudil,,Treatment of Frontotemporal Dementia,C0338451,Frontotemporal dementia,9/9/20,Designated,Not FDA Approved for Orphan Indication,,,,
LFVPBERIVUNMGV-UHFFFAOYSA-N,163751,LFVPBERIVUNMGV-UHFFFAOYSA-N,fasudil HCL,,Treatment of Huntingtons Disease,C0020179,huntingtons disease,8/25/20,Designated,Not FDA Approved for Orphan Indication,,,,
AKJHMTWEGVYYSE-FXILSDISSA-N,5288209,AKJHMTWEGVYYSE-FXILSDISSA-N,fenretinide,,Treatment of cutaneous T-cell lymphoma,C0079773,cutaneous T-cell lymphoma,9/4/13,Designated,Not FDA Approved for Orphan Indication,,,,
MIWWSGDADVMLTG-UHFFFAOYSA-N,68792,MIWWSGDADVMLTG-UHFFFAOYSA-N,fexinidazole,,Treatment of human African trypanosomiasis (HAT) or sleeping sickness,C0041228,African Trypanosomiasis,4/4/16,Designated,Not FDA Approved for Orphan Indication,,,,
VHZXNQKVFDBFIK-DTCRIMCDSA-N,69944058,VHZXNQKVFDBFIK-DTCRIMCDSA-N,fluasterone,,"Treatment of Cushing syndrome (including hyperglycemia, nonalcoholic fatty liver disease, and nonalcoholic steatosis)","C0010481,C0020456,C0400966,C2711227","Cushing Syndrome , Hyperglycemia , Nonalcoholic Fatty Liver Disease , Steatosis",3/28/18,Designated,Not FDA Approved for Orphan Indication,,,,
VHZXNQKVFDBFIK-WYTRLKPUSA-N,145705956,VHZXNQKVFDBFIK-WYTRLKPUSA-N,fluasterone,,"Treatment of Cushing syndrome (including hyperglycemia, nonalcoholic fatty liver disease, and nonalcoholic steatosis)","C0010481,C0020456,C0400966,C2711227","Cushing Syndrome , Hyperglycemia , Nonalcoholic Fatty Liver Disease , Steatosis",3/28/18,Designated,Not FDA Approved for Orphan Indication,,,,
VHZXNQKVFDBFIK-UHFFFAOYSA-N,21906940,VHZXNQKVFDBFIK-UHFFFAOYSA-N,fluasterone,,"Treatment of Cushing syndrome (including hyperglycemia, nonalcoholic fatty liver disease, and nonalcoholic steatosis)","C0010481,C0020456,C0400966,C2711227","Cushing Syndrome , Hyperglycemia , Nonalcoholic Fatty Liver Disease , Steatosis",3/28/18,Designated,Not FDA Approved for Orphan Indication,,,,
VHZXNQKVFDBFIK-NBBHSKLNSA-N,133967,VHZXNQKVFDBFIK-NBBHSKLNSA-N,fluasterone,,"Treatment of Cushing syndrome (including hyperglycemia, nonalcoholic fatty liver disease, and nonalcoholic steatosis)","C0010481,C0020456,C0400966,C2711227","Cushing Syndrome , Hyperglycemia , Nonalcoholic Fatty Liver Disease , Steatosis",3/28/18,Designated,Not FDA Approved for Orphan Indication,,,,
GIUYCYHIANZCFB-FJFJXFQQSA-N,30751,GIUYCYHIANZCFB-FJFJXFQQSA-N,Fludarabine phosphate,Fludara,"Treatment of chronic lymphocytic leukemia (CLL), including refractory CLL.","C0023434,C0278791","Chronic Lymphocytic Leukemia , Refractory CLL",4/18/89,Designated/Approved,,, 04/18/1991 , 04/18/1998 ,
SMANXXCATUTDDT-QPJJXVBHSA-N,941361,SMANXXCATUTDDT-QPJJXVBHSA-N,flunarizine,,Treatment of hemiplegic migraine,C0270862,Hemiplegic migraine,7/20/16,Designated,Not FDA Approved for Orphan Indication,,,,
GHASVSINZRGABV-UHFFFAOYSA-N,3385,GHASVSINZRGABV-UHFFFAOYSA-N,Fluorouracil,,"For use in combination with interferon alpha-2a, recombinant, for the treatment of esophageal carcinoma.",C0152018,Esophageal carcinoma,10/27/89,Designated,Not FDA Approved for Orphan Indication,,,,
RIKMMFOAQPJVMX-UHFFFAOYSA-N,3406,RIKMMFOAQPJVMX-UHFFFAOYSA-N,fomepizole,Antizole,Treatment of methanol or ethylene glycol poisoning.,C0413194,Ethylene glycol poisoning,12/22/88,Designated/Approved,,"Use for suspected or confirmed methanol poisoning, either alone or in combination with hemodialysis", 12/08/2000 , 12/08/2007 ,
RNBGYGVWRKECFJ-VRPWFDPXSA-N,172313,RNBGYGVWRKECFJ-VRPWFDPXSA-N,"Fructose-1,6-diphosphate",,Treatment of painful vaso-occlusive episodes associated with sickle cell disease.,C0002895,Sickle Cell Disease,5/29/98,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
RNBGYGVWRKECFJ-ZXXMMSQZSA-N,445557,RNBGYGVWRKECFJ-ZXXMMSQZSA-N,"Fructose-1,6-diphosphate",,Treatment of painful vaso-occlusive episodes associated with sickle cell disease.,C0002895,Sickle Cell Disease,5/29/98,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
RNBGYGVWRKECFJ-UHFFFAOYSA-N,718,RNBGYGVWRKECFJ-UHFFFAOYSA-N,"Fructose-1,6-diphosphate",,Treatment of painful vaso-occlusive episodes associated with sickle cell disease.,C0002895,Sickle Cell Disease,5/29/98,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
RNBGYGVWRKECFJ-JGWLITMVSA-N,46937007,RNBGYGVWRKECFJ-JGWLITMVSA-N,"Fructose-1,6-diphosphate",,Treatment of painful vaso-occlusive episodes associated with sickle cell disease.,C0002895,Sickle Cell Disease,5/29/98,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
RNBGYGVWRKECFJ-ARQDHWQXSA-N,10267,RNBGYGVWRKECFJ-ARQDHWQXSA-N,"Fructose-1,6-diphosphate",,Treatment of painful vaso-occlusive episodes associated with sickle cell disease.,C0002895,Sickle Cell Disease,5/29/98,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
UGJMXCAKCUNAIE-UHFFFAOYSA-N,3446,UGJMXCAKCUNAIE-UHFFFAOYSA-N,gabapentin,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,7/5/95,Designated,Not FDA Approved for Orphan Indication,,,,
PGTVWKLGGCQMBR-FLBATMFCSA-N,6918305,PGTVWKLGGCQMBR-FLBATMFCSA-N,ganaxolone,,Treatment of Protocadherin 19 (PCDH19) female epilepsy.,C0014544,Epilepsy,3/24/15,Designated,Not FDA Approved for Orphan Indication,,,,
HUCXKZBETONXFO-NJFMWZAGSA-N,5282199,HUCXKZBETONXFO-NJFMWZAGSA-N,geranylgeranylacetone,,Treatment of spinal and bulbar muscular atrophy,C1839259,Spinal and Bulbar Muscular Atrophy,6/26/20,Designated,Not FDA Approved for Orphan Indication,,,,
GYQYAJJFPNQOOW-UHFFFAOYSA-N,49803313,GYQYAJJFPNQOOW-UHFFFAOYSA-N,gilteritinib,XOSPATA,Treatment of acute myeloid leukemia (AML),C0023467,Acute myeloid leukemia,7/13/17,Designated/Approved,,XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test., 11/28/2018 , 11/28/2025 ,XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test.
MASNOZXLGMXCHN-ZLPAWPGGSA-N,16132283,MASNOZXLGMXCHN-ZLPAWPGGSA-N,glucagon,,Prevention of hypoglycemia in the congenital hyperinsulinism population,"C0020615,C3888018","Hypoglycemia , Congenital Hyperinsulinism",12/5/12,Designated,Not FDA Approved for Orphan Indication,,,,
HIZCTWCPHWUPFU-UHFFFAOYSA-N,61156,HIZCTWCPHWUPFU-UHFFFAOYSA-N,glycerol tribenzoate,,Treatment of Huntingtons disease,C0020179,huntingtons disease,9/10/19,Designated,Not FDA Approved for Orphan Indication,,,,
HIZCTWCPHWUPFU-UHFFFAOYSA-N,61156,HIZCTWCPHWUPFU-UHFFFAOYSA-N,glyceryl tribenzoate,,Treatment of nonketotic hyperglycinemia,C0751748,Nonketotic Hyperglycinemia,10/15/19,Designated,Not FDA Approved for Orphan Indication,,,,
GKMPTIBZVGZJDN-RJLNLWLESA-N,123133491,GKMPTIBZVGZJDN-RJLNLWLESA-N,H-(D)p-Benzoylphenylalanyl-(D)seryl-(D)tryptophanyl-(D)seryl-(D)pentafluorophenylalanyl-(D)cyclohexylalanyl-(D)arginyl-(D)arginyl-(D)arginyl-(D)glutaminyl-(D)arginyl-(D)arginine acetate salt,,For use in combination with cisplatin and pemetrexed for the treatment of patients with mesothelioma,C0025500,Mesothelioma,12/22/11,Designated,Not FDA Approved for Orphan Indication,,,,
SJUWEPZBTXEUMU-CTHHTMFSSA-N,132470909,SJUWEPZBTXEUMU-CTHHTMFSSA-N,halofuginone hydrobromide,,Treatment of Duchenne Muscular Dystrophy,C0013264,DUCHENNE MUSCULAR DYSTROPHY,10/13/11,Designated,Not FDA Approved for Orphan Indication,,,,
SJUWEPZBTXEUMU-UHFFFAOYSA-N,62893,SJUWEPZBTXEUMU-UHFFFAOYSA-N,halofuginone hydrobromide,,Treatment of Duchenne Muscular Dystrophy,C0013264,DUCHENNE MUSCULAR DYSTROPHY,10/13/11,Designated,Not FDA Approved for Orphan Indication,,,,
SJUWEPZBTXEUMU-LIOBNPLQSA-N,11591339,SJUWEPZBTXEUMU-LIOBNPLQSA-N,halofuginone hydrobromide,,Treatment of Duchenne Muscular Dystrophy,C0013264,DUCHENNE MUSCULAR DYSTROPHY,10/13/11,Designated,Not FDA Approved for Orphan Indication,,,,
SJUWEPZBTXEUMU-LDXVYITESA-N,400771,SJUWEPZBTXEUMU-LDXVYITESA-N,halofuginone hydrobromide,,Treatment of Duchenne Muscular Dystrophy,C0013264,DUCHENNE MUSCULAR DYSTROPHY,10/13/11,Designated,Not FDA Approved for Orphan Indication,,,,
DGTVQJOTEDTFMR-VYFXDUNUSA-N,126970648,DGTVQJOTEDTFMR-VYFXDUNUSA-N,Histrelin acetate,Supprelin Injection,Treatment of central precocious puberty.,C0342543,Central Precocious Puberty,8/10/88,Designated/Approved,,Treatment of central precocious puberty., 12/24/1991 , 12/24/1998 ,
BKEMVGVBBDMHKL-VYFXDUNUSA-N,56927879,BKEMVGVBBDMHKL-VYFXDUNUSA-N,Histrelin acetate,Supprelin Injection,Treatment of central precocious puberty.,C0342543,Central Precocious Puberty,8/10/88,Designated/Approved,,Treatment of central precocious puberty., 12/24/1991 , 12/24/1998 ,
HHXHVIJIIXKSOE-QILQGKCVSA-N,25077993,HHXHVIJIIXKSOE-QILQGKCVSA-N,Histrelin acetate,Supprelin Injection,Treatment of central precocious puberty.,C0342543,Central Precocious Puberty,8/10/88,Designated/Approved,,Treatment of central precocious puberty., 12/24/1991 , 12/24/1998 ,
OWAUGAMNPZHEOJ-YKZVIGSYSA-N,25084151,OWAUGAMNPZHEOJ-YKZVIGSYSA-N,Histrelin acetate,Supprelin Injection,Treatment of central precocious puberty.,C0342543,Central Precocious Puberty,8/10/88,Designated/Approved,,Treatment of central precocious puberty., 12/24/1991 , 12/24/1998 ,
VSNHCAURESNICA-UHFFFAOYSA-N,3657,VSNHCAURESNICA-UHFFFAOYSA-N,hydroxyurea,,"Treatment of symptomatic sickle cell disease in pediatric patients, less than 17 years of age.",C0002895,Sickle Cell Disease,3/16/15,Designated,Not FDA Approved for Orphan Indication,,,,
ALHBJBCQLJZYON-PFSRBDOWSA-N,71543365,ALHBJBCQLJZYON-PFSRBDOWSA-N,iadademstat,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,2/10/21,Designated,Not FDA Approved for Orphan Indication,,,,
XYFPWWZEPKGCCK-GOSISDBHSA-N,24821094,XYFPWWZEPKGCCK-GOSISDBHSA-N,ibrutinib,Imbruvica,Treatment of chronic lymphocytic leukemia (CLL),C0023434,Chronic Lymphocytic Leukemia,4/6/12,Designated/Approved,,Treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy, 02/12/2014 , 02/12/2021 ,Treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy
QURWXBZNHXJZBE-UAULPJDASA-N,137705994,QURWXBZNHXJZBE-UAULPJDASA-N,icatibant,Firazyr,Treatment of angioedema,C0002994,Angioedema,11/25/03,Designated/Approved,,Treatment of acute attacks of hereditary angioedema in adults 18 years of age and older, 08/25/2011 , 08/25/2018 ,
QURWXBZNHXJZBE-JNFYKTHFSA-N,90488794,QURWXBZNHXJZBE-JNFYKTHFSA-N,icatibant,Firazyr,Treatment of angioedema,C0002994,Angioedema,11/25/03,Designated/Approved,,Treatment of acute attacks of hereditary angioedema in adults 18 years of age and older, 08/25/2011 , 08/25/2018 ,
QURWXBZNHXJZBE-UHFFFAOYSA-N,14724482,QURWXBZNHXJZBE-UHFFFAOYSA-N,icatibant,Firazyr,Treatment of angioedema,C0002994,Angioedema,11/25/03,Designated/Approved,,Treatment of acute attacks of hereditary angioedema in adults 18 years of age and older, 08/25/2011 , 08/25/2018 ,
QURWXBZNHXJZBE-MCDGZUPGSA-N,71364,QURWXBZNHXJZBE-MCDGZUPGSA-N,icatibant,Firazyr,Treatment of angioedema,C0002994,Angioedema,11/25/03,Designated/Approved,,Treatment of acute attacks of hereditary angioedema in adults 18 years of age and older, 08/25/2011 , 08/25/2018 ,
QURWXBZNHXJZBE-SKXRKSCCSA-N,6918173,QURWXBZNHXJZBE-SKXRKSCCSA-N,icatibant,Firazyr,Treatment of angioedema,C0002994,Angioedema,11/25/03,Designated/Approved,,Treatment of acute attacks of hereditary angioedema in adults 18 years of age and older, 08/25/2011 , 08/25/2018 ,
IFSDAJWBUCMOAH-HNNXBMFYSA-N,11625818,IFSDAJWBUCMOAH-HNNXBMFYSA-N,idelalisib,,Treatment of nodal marginal zone lymphoma.,C0242647,Nodal marginal zone lymphoma,10/15/13,Designated,Not FDA Approved for Orphan Indication,,,,
HOMGKSMUEGBAAB-UHFFFAOYSA-N,3690,HOMGKSMUEGBAAB-UHFFFAOYSA-N,Ifosfamide,Ifex,Treatment of testicular cancer.,C0855197,Testicular Cancer,1/20/87,Designated/Approved,,"In combination with certain other approved antineoplastic agents, for third line chemotherapy in the treatment of germ cell testicular cancer.", 12/30/1988 , 12/30/1995 ,
WPHKIQPVPYJNAX-UHFFFAOYSA-N,46207586,WPHKIQPVPYJNAX-UHFFFAOYSA-N,ilorasertib,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,3/16/12,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
DOUYETYNHWVLEO-UHFFFAOYSA-N,57469,DOUYETYNHWVLEO-UHFFFAOYSA-N,Imiquimod,,Treatment of carcinoma in situ (CIS) of the urinary bladder,C0007099,Carcinoma in Situ,12/3/14,Designated,Not FDA Approved for Orphan Indication,,,,
QADPYRIHXKWUSV-UHFFFAOYSA-N,53235510,QADPYRIHXKWUSV-UHFFFAOYSA-N,Infigratinib,,Treatment of cholangiocarcinoma,C0206698,Cholangiocarcinoma,9/11/19,Designated,Not FDA Approved for Orphan Indication,,,,
XNACDNPGABUBFR-FKNPGSCZSA-N,56840904,XNACDNPGABUBFR-FKNPGSCZSA-N,iobenguane sulfate I-123,,"For the detection, localization, and staging of pheochromocytomas.",C0031511,Pheochromocytomas,10/21/05,Designated,Not FDA Approved for Orphan Indication,,,,
ULBPPCHRAVUQMC-RWOHWRPJSA-N,70697642,ULBPPCHRAVUQMC-RWOHWRPJSA-N,isofagomine tartrate,,Treatment of Gaucher disease,C0017205,Gaucher Disease,1/10/06,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ULBPPCHRAVUQMC-AWUBODBRSA-N,56841032,ULBPPCHRAVUQMC-AWUBODBRSA-N,isofagomine tartrate,,Treatment of Gaucher disease,C0017205,Gaucher Disease,1/10/06,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ULBPPCHRAVUQMC-MUMXBIPUSA-N,23581846,ULBPPCHRAVUQMC-MUMXBIPUSA-N,isofagomine tartrate,,Treatment of Gaucher disease,C0017205,Gaucher Disease,1/10/06,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
VHVPQPYKVGDNFY-DFMJLFEVSA-N,14179008,VHVPQPYKVGDNFY-DFMJLFEVSA-N,Itraconazole,,Treatment of basal cell carcinoma nevus syndrome.,"C0007117,C0027962","Basal cell carcinoma , Nevus",5/19/16,Designated,Not FDA Approved for Orphan Indication,,,,
VHVPQPYKVGDNFY-VXTATNQMSA-N,45039617,VHVPQPYKVGDNFY-VXTATNQMSA-N,Itraconazole,,Treatment of basal cell carcinoma nevus syndrome.,"C0007117,C0027962","Basal cell carcinoma , Nevus",5/19/16,Designated,Not FDA Approved for Orphan Indication,,,,
VHVPQPYKVGDNFY-TUJWMRSMSA-N,14179013,VHVPQPYKVGDNFY-TUJWMRSMSA-N,Itraconazole,,Treatment of basal cell carcinoma nevus syndrome.,"C0007117,C0027962","Basal cell carcinoma , Nevus",5/19/16,Designated,Not FDA Approved for Orphan Indication,,,,
VHVPQPYKVGDNFY-AVQIMAJZSA-N,6917738,VHVPQPYKVGDNFY-AVQIMAJZSA-N,Itraconazole,,Treatment of basal cell carcinoma nevus syndrome.,"C0007117,C0027962","Basal cell carcinoma , Nevus",5/19/16,Designated,Not FDA Approved for Orphan Indication,,,,
VHVPQPYKVGDNFY-UHFFFAOYSA-N,3793,VHVPQPYKVGDNFY-UHFFFAOYSA-N,Itraconazole,,Treatment of basal cell carcinoma nevus syndrome.,"C0007117,C0027962","Basal cell carcinoma , Nevus",5/19/16,Designated,Not FDA Approved for Orphan Indication,,,,
VHVPQPYKVGDNFY-ZPGVKDDISA-N,55283,VHVPQPYKVGDNFY-ZPGVKDDISA-N,Itraconazole,,Treatment of basal cell carcinoma nevus syndrome.,"C0007117,C0027962","Basal cell carcinoma , Nevus",5/19/16,Designated,Not FDA Approved for Orphan Indication,,,,
PURKAOJPTOLRMP-UHFFFAOYSA-N,16220172,PURKAOJPTOLRMP-UHFFFAOYSA-N,ivacaftor,Kalydeco,Treatment of patients with cystic fibrosis,C0010674,Cystic Fibrosis,12/20/06,Designated/Approved,,Treatment of cystic fibrosis (CF) in patients age 12 months and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data., 08/15/2018 , 08/15/2025 ,For the treatment of cystic fibrosis (CF) in patients age 12 months to less than 2 years who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data
WIJZXSAJMHAVGX-DHLKQENFSA-N,71657455,WIJZXSAJMHAVGX-DHLKQENFSA-N,ivosidenib,,Treatment of glioma.,C0017638,Glioma,5/1/18,Designated,Not FDA Approved for Orphan Indication,,,,
WIJZXSAJMHAVGX-DHLKQENFSA-N,71657455,WIJZXSAJMHAVGX-DHLKQENFSA-N,ivosidenib,,Treatment of myelodysplastic syndromes,C3463824,Myelodysplastic Syndromes,5/20/20,Designated,Not FDA Approved for Orphan Indication,,,,
KPYSYYIEGFHWSV-QMMMGPOBSA-N,44602,KPYSYYIEGFHWSV-QMMMGPOBSA-N,L-baclofen,,Treatment of intractable spasticity in children with cerebral palsy.,"C0007789,C0026838","Cerebral Palsy , Spasticity",1/30/92,Designated,Not FDA Approved for Orphan Indication,,,,
KPYSYYIEGFHWSV-MRVPVSSYSA-N,44600,KPYSYYIEGFHWSV-MRVPVSSYSA-N,L-baclofen,,Treatment of intractable spasticity in children with cerebral palsy.,"C0007789,C0026838","Cerebral Palsy , Spasticity",1/30/92,Designated,Not FDA Approved for Orphan Indication,,,,
SHZGCJCMOBCMKK-DHVFOXMCSA-N,17106,SHZGCJCMOBCMKK-DHVFOXMCSA-N,L-fucose,,Treatment of Leukocyte Adhesion Deficiency Type- II,C0272187,Leukocyte adhesion deficiency,6/8/20,Designated,Not FDA Approved for Orphan Indication,,,,
ZDXPYRJPNDTMRX-VKHMYHEASA-N,5961,ZDXPYRJPNDTMRX-VKHMYHEASA-N,L-glutamine,Endari,Treatment of sickle cell disease,C0002895,Sickle Cell Disease,8/1/01,Designated/Approved,,To reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older., 07/07/2017 , 07/07/2024 ,To reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.
BCFGMOOMADDAQU-UHFFFAOYSA-N,208908,BCFGMOOMADDAQU-UHFFFAOYSA-N,lapatinib,,Treatment of ErbB2 positive gastric cancer,C0024623,Gastric Cancer,5/29/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PVCULFYROUOVGJ-UHFFFAOYSA-N,3081349,PVCULFYROUOVGJ-UHFFFAOYSA-N,laromustine,,Treatment of acute myelogenous leukemia,C0023467,Acute myelogenous leukemia,10/21/04,Designated,Not FDA Approved for Orphan Indication,,,,
GOTYRUGSSMKFNF-UHFFFAOYSA-N,216326,GOTYRUGSSMKFNF-UHFFFAOYSA-N,lenalidomide,Revlimid,Treatment of nodal marginal zone lymphoma,C0242647,Nodal marginal zone lymphoma,1/4/17,Designated/Approved,,"REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL).", 05/28/2019 , 05/28/2026 ,In combination with a rituximab product for the treatment of adult patients with previously treated nodal marginal zone lymphoma
GOTYRUGSSMKFNF-UHFFFAOYSA-N,216326,GOTYRUGSSMKFNF-UHFFFAOYSA-N,lenalidomide,Revlimid,Treatment of splenic marginal zone lymphoma,C0349632,Splenic marginal zone lymphoma,1/4/17,Designated/Approved,,"REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL).", 05/28/2019 , 05/28/2026 ,In combination with a rituximab product for the treatment of adult patients with previously treated splenic marginal zone lymphoma
WOSKHXYHFSIKNG-UHFFFAOYSA-N,9823820,WOSKHXYHFSIKNG-UHFFFAOYSA-N,lenvatinib,,Treatment of stage IIB to Stage IV melanoma,C0025202,melanoma,3/26/14,Designated,Not FDA Approved for Orphan Indication,,,,
OXVFDZYQLGRLCD-USSMZTJJSA-N,45359068,OXVFDZYQLGRLCD-USSMZTJJSA-N,leriglitazone,,Treatment of Friedreichs ataxia,C0016719,FRIEDREICHS ATAXIA,8/1/19,Designated,Not FDA Approved for Orphan Indication,,,,
OXVFDZYQLGRLCD-UHFFFAOYSA-N,4147757,OXVFDZYQLGRLCD-UHFFFAOYSA-N,leriglitazone,,Treatment of Friedreichs ataxia,C0016719,FRIEDREICHS ATAXIA,8/1/19,Designated,Not FDA Approved for Orphan Indication,,,,
UGFHIPBXIWJXNA-UHFFFAOYSA-N,60652,UGFHIPBXIWJXNA-UHFFFAOYSA-N,liarozole,,Treatment of congenital ichthyosis,C0079154,congenital ichthyosis,6/18/04,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
MWWSFMDVAYGXBV-RUELKSSGSA-N,443939,MWWSFMDVAYGXBV-RUELKSSGSA-N,Liposomal doxorubicin hydrochloride,,Treatment of soft tissue sarcomas,C1261473,Soft Tissue Sarcomas,12/27/06,Designated,Not FDA Approved for Orphan Indication,,,,
BKRGVLQUQGGVSM-KBXCAEBGSA-N,28864,BKRGVLQUQGGVSM-KBXCAEBGSA-N,lisuride,,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,1/17/13,Designated,Not FDA Approved for Orphan Indication,,,,
OSPNFKYGOFXGBX-YWWKUQGPSA-N,145722609,OSPNFKYGOFXGBX-YWWKUQGPSA-N,Lucinactant,,Treatment of cystic fibrosis.,C0010674,Cystic Fibrosis,10/21/10,Designated,Not FDA Approved for Orphan Indication,,,,
JGCMEBMXRHSZKX-UHFFFAOYSA-N,16004692,JGCMEBMXRHSZKX-UHFFFAOYSA-N,macitentan,,Treatment of chronic thromboembolic pulmonary hypertension (CTEPH),C2363973,Chronic thromboembolic pulmonary hypertension,6/15/17,Designated,Not FDA Approved for Orphan Indication,,,,
STPKWKPURVSAJF-LJEWAXOPSA-N,9831643,STPKWKPURVSAJF-LJEWAXOPSA-N,maralixibat,,Treatment of alagille syndrome,C0085280,Alagille Syndrome,9/4/13,Designated,Not FDA Approved for Orphan Indication,,,,
WESWYMRNZNDGBX-YLCXCWDSSA-N,65329,WESWYMRNZNDGBX-YLCXCWDSSA-N,mefloquine HCL,Lariam,"For use in the treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax, and for the prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs","C0024535,C2930826","Plasmodium falciparum Malaria , Acute malaria",4/13/88,Designated/Approved,,Prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs, 05/03/1989 , 05/03/1996 ,
WESWYMRNZNDGBX-YLCXCWDSSA-N,65329,WESWYMRNZNDGBX-YLCXCWDSSA-N,mefloquine HCL,Lariam,"For use in the treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax, and for the prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs","C0024535,C2930826","Plasmodium falciparum Malaria , Acute malaria",4/13/88,Designated/Approved,,Treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax, 05/02/1989 , 05/02/1996 ,
DRLFMBDRBRZALE-UHFFFAOYSA-N,896,DRLFMBDRBRZALE-UHFFFAOYSA-N,melatonin,,Treatment of acute acetaminophen overdose,C0572025,Acetaminophen overdose,3/2/17,Designated,Not FDA Approved for Orphan Indication,,,,
OUUYBRCCFUEMLH-YDALLXLXSA-N,9927978,OUUYBRCCFUEMLH-YDALLXLXSA-N,melphalan hydrochloride,,Treatment of neuroendocrine tumors,C0206754,Neuroendocrine Tumors,5/22/09,Designated,Not FDA Approved for Orphan Indication,,,,
INWLQCZOYSRPNW-UHFFFAOYSA-N,4062,INWLQCZOYSRPNW-UHFFFAOYSA-N,mepivacaine,,Treatment of postherpetic neuralgia,C0032768,Postherpetic neuralgia,1/8/07,Designated,Not FDA Approved for Orphan Indication,,,,
XNXVOSBNFZWHBV-UHFFFAOYSA-N,521874,XNXVOSBNFZWHBV-UHFFFAOYSA-N,Methoxyamine hydrochloride,,Treatment of malignant glioma,C0555198,Malignant Glioma,10/22/20,Designated,Not FDA Approved for Orphan Indication,,,,
VLPIATFUUWWMKC-UHFFFAOYSA-N,4178,VLPIATFUUWWMKC-UHFFFAOYSA-N,mexiletine,,Treatment of nondystrophic myotonia,C2931139,Nondystrophic myotonia,9/2/10,Designated,Not FDA Approved for Orphan Indication,,,,
HBNPJJILLOYFJU-VMPREFPWSA-N,60663,HBNPJJILLOYFJU-VMPREFPWSA-N,mibefradil,,Treatment of glioblastoma multiforme.,C0017636,Glioblastoma multiforme,8/25/09,Designated,Not FDA Approved for Orphan Indication,,,,
DDLIGBOFAVUZHB-UHFFFAOYSA-N,4192,DDLIGBOFAVUZHB-UHFFFAOYSA-N,midazolam,NAYZILAM,"Rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity (e.g. acute repetitive seizures, seizure clusters)","C0036572,C1148454,C1959629","Seizures , seizure activity , Seizure",10/20/09,Designated/Approved,,"NAYZILAM is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patients usual seizure pattern in patients with epilepsy 12 years of age and older.", 05/17/2019 , 05/17/2026 ,"NAYZILAM is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patients usual seizure pattern in patients with epilepsy 12 years of age and older."
DDLIGBOFAVUZHB-UHFFFAOYSA-N,4192,DDLIGBOFAVUZHB-UHFFFAOYSA-N,midazolam,SEIZALAM,Treatment of status epilepticus,C0038220,Status Epilepticus,2/4/16,Designated/Approved,,SEIZALAM is indicated for the treatment of status epilepticus in adults., 09/14/2018 , 09/14/2025 ,SEIZALAM is indicated for the treatment of status epilepticus in adults.
PQLXHQMOHUQAKB-UHFFFAOYSA-N,3599,PQLXHQMOHUQAKB-UHFFFAOYSA-N,miltefosine,,Treatment of Acanthamoeba keratitis,C0000880,Acanthamoeba Keratitis,12/6/16,Designated,Not FDA Approved for Orphan Indication,,,,
XAYGBKHKBBXDAK-UHFFFAOYSA-N,59634741,XAYGBKHKBBXDAK-UHFFFAOYSA-N,mitapivat,,Treatment of sickle cell disease,C0002895,Sickle Cell Disease,11/12/20,Designated,Not FDA Approved for Orphan Indication,,,,
VFKZTMPDYBFSTM-GUCUJZIJSA-N,5284380,VFKZTMPDYBFSTM-GUCUJZIJSA-N,Mitolactol,,Treatment of invasive carcinoma of the uterine cervix,"C0302592,C1334274","Carcinoma of the Uterine Cervix , Invasive Carcinoma",1/23/89,Designated,Not FDA Approved for Orphan Indication,,,,
VFKZTMPDYBFSTM-GUCUJZIJSA-N,5284380,VFKZTMPDYBFSTM-GUCUJZIJSA-N,Mitolactol,,As adjuvant therapy in the treatment of primary brain tumors.,C0750974,primary brain tumors,7/12/95,Designated,Not FDA Approved for Orphan Indication,,,,
ZAHQPTJLOCWVPG-UHFFFAOYSA-N,51082,ZAHQPTJLOCWVPG-UHFFFAOYSA-N,Mitoxantrone HCl,Novantrone,"Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.",C0023467,Acute myelogenous leukemia,7/13/87,Designated/Approved,,, 12/23/1987 , 12/23/1994 ,
HRNLUBSXIHFDHP-UHFFFAOYSA-N,9865515,HRNLUBSXIHFDHP-UHFFFAOYSA-N,mocetinostat,,Treatment of diffuse large B-cell lymphoma,C1332201,Diffuse Large B-Cell Lymphoma,8/7/14,Designated,Not FDA Approved for Orphan Indication,,,,
RTGDFNSFWBGLEC-SYZQJQIISA-N,5281078,RTGDFNSFWBGLEC-SYZQJQIISA-N,Mycophenolate mofetil,,Treatment of myasthenia gravis,C0026896,Myasthenia Gravis,12/19/05,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
WXNXCEHXYPACJF-UHFFFAOYSA-N,1995,WXNXCEHXYPACJF-UHFFFAOYSA-N,N-acetyl-DL-leucine,,Treatment of Spinocerebellar Ataxia (SCA),"C0018790,C0087012","SCA , Spinocerebellar ataxia",6/6/18,Designated,Not FDA Approved for Orphan Indication,,,,
DRHXTSWSUAJOJZ-FMDGEEDCSA-N,5289024,DRHXTSWSUAJOJZ-FMDGEEDCSA-N,N-acetyl-glucosamine thiazoline,,Treatment of adult Tay-Sachs disease,C0039373,Tay-Sachs Disease,2/6/06,Designated,Not FDA Approved for Orphan Indication,,,,
NOWRLNPOENZFHP-ARHDFHRDSA-N,445212,NOWRLNPOENZFHP-ARHDFHRDSA-N,N-Methanocarbathymidine,,Treatment of neonatal herpes,C2931185,Neonatal herpes,10/15/14,Designated,Not FDA Approved for Orphan Indication,,,,
DQCKKXVULJGBQN-XFWGSAIBSA-N,5360515,DQCKKXVULJGBQN-XFWGSAIBSA-N,naltrexone,,Treatment of autoimmune hepatitis,C0241910,Autoimmune hepatitis,1/13/15,Designated,Not FDA Approved for Orphan Indication,,,,
NPAGDVCDWIYMMC-IZPLOLCNSA-N,9904,NPAGDVCDWIYMMC-IZPLOLCNSA-N,nandrolone,,Treatment of Duchenne and Becker Muscular Dystrophy,C3542021,Duchenne and Becker Muscular Dystrophy,6/13/17,Designated,Not FDA Approved for Orphan Indication,,,,
DPHUWDIXHNQOSY-UHFFFAOYSA-N,10331844,DPHUWDIXHNQOSY-UHFFFAOYSA-N,napabucasin,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,10/25/16,Designated,Not FDA Approved for Orphan Indication,,,,
YDZYKNJZCVIKPP-VWLOTQADSA-N,9870520,YDZYKNJZCVIKPP-VWLOTQADSA-N,netazepide,,Treatment of gastric carcinoids,C0007095,Carcinoids,9/10/09,Designated,Not FDA Approved for Orphan Indication,,,,
HHZIURLSWUIHRB-UHFFFAOYSA-N,644241,HHZIURLSWUIHRB-UHFFFAOYSA-N,nilotinib,Tasigna,Treatment of chronic myelogenous leukemia,C0023473,Chronic myelogenous leukemia,4/27/06,Designated/Approved,,TASIGNA (nilotinib) is indicated for the treatment of pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase and pediatric patients greater than or equal to 1 year of age with chronic phase Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) with resistance or intolerance to prior tyrosine-kinase inhibitor (TKI) therapy., 03/22/2018 , 03/22/2025 ,TASIGNA (nilotinib) is indicated for the treatment of pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase and pediatric patients greater than or equal to 1 year of age with chronic phase Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) with resistance or intolerance to prior tyrosine-kinase inhibitor (TKI) therapy.
UIAGMCDKSXEBJQ-UHFFFAOYSA-N,4497,UIAGMCDKSXEBJQ-UHFFFAOYSA-N,nimodipine,NYMALIZE,Treatment of subarachnoid hemorrhage.,C0038525,Subarachnoid Hemorrhage,9/16/11,Designated/Approved,,"Improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I-V).", 05/10/2013 , 05/10/2020 ,"Improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I-V)."
PCHKPVIQAHNQLW-CQSZACIVSA-N,24958200,PCHKPVIQAHNQLW-CQSZACIVSA-N,niraparib,Zejula,Treatment of ovarian cancer,C4721610,Ovarian Cancer,4/30/10,Designated/Approved,,"ZEJULA is indicated for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either, (1) a deleterious or suspected deleterious BRCA mutation, or (2) genomic instability and who have progressed more than six months after response to the last platinum-based chemotherapy", 10/23/2019 , 10/23/2026 ,"Indicated for the treatment of adult patients with advanced ovarian cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation, or genomic instability and who have progressed more than six months after response to the last platinum-based chemotherapy."
VFCRKLWBYMDAED-REWPJTCUSA-N,46224413,VFCRKLWBYMDAED-REWPJTCUSA-N,nirogacestat,,Treatment of desmoid tumor (aggressive fibromatosis),C0079218,Desmoid tumor,6/7/18,Designated,Not FDA Approved for Orphan Indication,,,,
MWUXSHHQAYIFBG-UHFFFAOYSA-N,145068,MWUXSHHQAYIFBG-UHFFFAOYSA-N,Nitric oxide,INOmax,Treatment of persistent pulmonary hypertension in the newborn.,C1135361,Persistent pulmonary hypertension,6/22/93,Designated/Approved,,"In conjunction with ventilatory support and other appropriate agents, in the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.", 12/23/1999 , 12/23/2006 ,
ZVAGBRFUYHSUHA-XEKNBVSESA-N,122362431,ZVAGBRFUYHSUHA-XEKNBVSESA-N,Obatoclax mesylate,,Treatment of myelodysplastic syndrome,C3463824,MYELODYSPLASTIC SYNDROME,11/6/06,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ZVAGBRFUYHSUHA-QUIKYCSHSA-N,56843157,ZVAGBRFUYHSUHA-QUIKYCSHSA-N,Obatoclax mesylate,,Treatment of myelodysplastic syndrome,C3463824,MYELODYSPLASTIC SYNDROME,11/6/06,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ZVAGBRFUYHSUHA-UHFFFAOYSA-N,70700268,ZVAGBRFUYHSUHA-UHFFFAOYSA-N,Obatoclax mesylate,,Treatment of myelodysplastic syndrome,C3463824,MYELODYSPLASTIC SYNDROME,11/6/06,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ZVAGBRFUYHSUHA-CFWFSBERSA-N,16727411,ZVAGBRFUYHSUHA-CFWFSBERSA-N,Obatoclax mesylate,,Treatment of myelodysplastic syndrome,C3463824,MYELODYSPLASTIC SYNDROME,11/6/06,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ZVAGBRFUYHSUHA-RKMKAUCSSA-N,71816154,ZVAGBRFUYHSUHA-RKMKAUCSSA-N,Obatoclax mesylate,,Treatment of myelodysplastic syndrome,C3463824,MYELODYSPLASTIC SYNDROME,11/6/06,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ZVAGBRFUYHSUHA-VLJPQPJMSA-N,46930996,ZVAGBRFUYHSUHA-VLJPQPJMSA-N,Obatoclax mesylate,,Treatment of myelodysplastic syndrome,C3463824,MYELODYSPLASTIC SYNDROME,11/6/06,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ZVAGBRFUYHSUHA-LZOXOEDVSA-N,16681698,ZVAGBRFUYHSUHA-LZOXOEDVSA-N,Obatoclax mesylate,,Treatment of myelodysplastic syndrome,C3463824,MYELODYSPLASTIC SYNDROME,11/6/06,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ZXERDUOLZKYMJM-ZWECCWDJSA-N,447715,ZXERDUOLZKYMJM-ZWECCWDJSA-N,obeticholic acid,OCALIVA,Treatment of primary biliary cirrhosis,C0008312,Primary Biliary Cirrhosis,4/9/08,Designated/Approved,,"Treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA", 05/27/2016 , 05/27/2023 ,"Treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA"
MIMNFCVQODTQDP-NDLVEFNKSA-N,118984458,MIMNFCVQODTQDP-NDLVEFNKSA-N,oblimersen,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,8/28/01,Designated,Not FDA Approved for Orphan Indication,,,,
IBXPAFBDJCXCDW-MHFPCNPESA-A,118984457,IBXPAFBDJCXCDW-MHFPCNPESA-A,oblimersen,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,8/28/01,Designated,Not FDA Approved for Orphan Indication,,,,
DEQANNDTNATYII-JPZSUCLZSA-N,138107728,DEQANNDTNATYII-JPZSUCLZSA-N,Octreotide,Sandostatin LAR,Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.,"C0016382,C0391970,C1443924","Flushing , Malignant carcinoid tumors , Severe diarrhea",8/24/98,Designated/Approved,,Supression of severe diarrhea and flushing associated with malignant carcinoid syndrome., 11/25/1998 , 11/25/2005 ,
DEQANNDTNATYII-LIXSYSMXSA-N,44311916,DEQANNDTNATYII-LIXSYSMXSA-N,Octreotide,Sandostatin LAR,Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.,"C0016382,C0391970,C1443924","Flushing , Malignant carcinoid tumors , Severe diarrhea",8/24/98,Designated/Approved,,Supression of severe diarrhea and flushing associated with malignant carcinoid syndrome., 11/25/1998 , 11/25/2005 ,
DEQANNDTNATYII-XOEBDJBESA-N,90488715,DEQANNDTNATYII-XOEBDJBESA-N,Octreotide,Sandostatin LAR,Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.,"C0016382,C0391970,C1443924","Flushing , Malignant carcinoid tumors , Severe diarrhea",8/24/98,Designated/Approved,,Supression of severe diarrhea and flushing associated with malignant carcinoid syndrome., 11/25/1998 , 11/25/2005 ,
DEQANNDTNATYII-FLDZURHUSA-N,86289069,DEQANNDTNATYII-FLDZURHUSA-N,Octreotide,Sandostatin LAR,Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.,"C0016382,C0391970,C1443924","Flushing , Malignant carcinoid tumors , Severe diarrhea",8/24/98,Designated/Approved,,Supression of severe diarrhea and flushing associated with malignant carcinoid syndrome., 11/25/1998 , 11/25/2005 ,
DEQANNDTNATYII-MEUDYGGUSA-N,44420813,DEQANNDTNATYII-MEUDYGGUSA-N,Octreotide,Sandostatin LAR,Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.,"C0016382,C0391970,C1443924","Flushing , Malignant carcinoid tumors , Severe diarrhea",8/24/98,Designated/Approved,,Supression of severe diarrhea and flushing associated with malignant carcinoid syndrome., 11/25/1998 , 11/25/2005 ,
DEQANNDTNATYII-RRCPSWKPSA-N,6400441,DEQANNDTNATYII-RRCPSWKPSA-N,Octreotide,Sandostatin LAR,Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.,"C0016382,C0391970,C1443924","Flushing , Malignant carcinoid tumors , Severe diarrhea",8/24/98,Designated/Approved,,Supression of severe diarrhea and flushing associated with malignant carcinoid syndrome., 11/25/1998 , 11/25/2005 ,
DEQANNDTNATYII-UHFFFAOYSA-N,383414,DEQANNDTNATYII-UHFFFAOYSA-N,Octreotide,Sandostatin LAR,Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.,"C0016382,C0391970,C1443924","Flushing , Malignant carcinoid tumors , Severe diarrhea",8/24/98,Designated/Approved,,Supression of severe diarrhea and flushing associated with malignant carcinoid syndrome., 11/25/1998 , 11/25/2005 ,
DEQANNDTNATYII-OULOTJBUSA-N,448601,DEQANNDTNATYII-OULOTJBUSA-N,Octreotide,Sandostatin LAR,Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.,"C0016382,C0391970,C1443924","Flushing , Malignant carcinoid tumors , Severe diarrhea",8/24/98,Designated/Approved,,Supression of severe diarrhea and flushing associated with malignant carcinoid syndrome., 11/25/1998 , 11/25/2005 ,
JRHNIQQUVJOPQC-AQNFWKISSA-N,216385,JRHNIQQUVJOPQC-AQNFWKISSA-N,odiparcil,,Treatment of mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome),C0026709,Mucopolysaccharidosis Type VI,8/3/17,Designated,Not FDA Approved for Orphan Indication,,,,
SWZXEVABPLUDIO-WSZYKNRRSA-N,25067547,SWZXEVABPLUDIO-WSZYKNRRSA-N,oprozomib,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,10/28/14,Designated,Not FDA Approved for Orphan Indication,,,,
QSLJIVKCVHQPLV-PEMPUTJUSA-N,5878,QSLJIVKCVHQPLV-PEMPUTJUSA-N,Oxandrolone,,Treatment of short stature associated with Turner's syndrome.,"C0013336,C0041408","Short stature , Turner's Syndrome",7/5/90,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
BEZZFPOZAYTVHN-UHFFFAOYSA-N,40854,BEZZFPOZAYTVHN-UHFFFAOYSA-N,oxfendazole,,Treatment of cysticercosis (including neurocysticercosis),"C0010678,C0338437","Cysticercosis , Neurocysticercosis",7/14/14,Designated,Not FDA Approved for Orphan Indication,,,,
FPOHNWQLNRZRFC-ZHACJKMWSA-N,6918837,FPOHNWQLNRZRFC-ZHACJKMWSA-N,panobinostat,Farydak,Treatment of multiple myeloma,C0026764,Multiple Myeloma,8/20/12,Designated/Approved,,"FARYDAK (panobinostat) in combination with bortezomib (BTZ) and dexamethasone (DEX) for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent", 02/23/2015 , 02/23/2022 ,"FARYDAK (panobinostat) in combination with bortezomib (BTZ) and dexamethasone (DEX) for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent"
VMZMNAABQBOLAK-DBILLSOUSA-N,9941444,VMZMNAABQBOLAK-DBILLSOUSA-N,pasireotide,Signifor,Treatment of Cushing's disease,C0010481,Cushing's disease,7/24/09,Designated/Approved,,SIGNIFOR LAR is indicated for the treatment of patients with Cushings disease for whom pituitary surgery is not an option or has not been curative., 06/29/2018 , 06/29/2025 ,Indicated for treatment of patients with Cushings disease for whom pituitary surgery is not an option or has not been curative.
HZLFFNCLTRVYJG-WWGOJCOQSA-N,25027363,HZLFFNCLTRVYJG-WWGOJCOQSA-N,patidegib,,Treatment of nevoid basal cell carcinoma syndrome (Gorlin syndrome),C0004779,Nevoid Basal Cell Carcinoma Syndrome,7/19/17,Designated,Not FDA Approved for Orphan Indication,,,,
CUIHSIWYWATEQL-UHFFFAOYSA-N,10113978,CUIHSIWYWATEQL-UHFFFAOYSA-N,pazopanib,,Treatment of ovarian cancer.,C4721610,Ovarian Cancer,5/6/13,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
QIOCQCYXBYUYLH-YACUFSJGSA-N,76900653,QIOCQCYXBYUYLH-YACUFSJGSA-N,Pelcitoclax,,Treatment of Small Cell Lung Cancer,C3540630,Small Cell Lung Cancer,9/23/20,Designated,Not FDA Approved for Orphan Indication,,,,
SZFPYBIJACMNJV-UHFFFAOYSA-N,148177,SZFPYBIJACMNJV-UHFFFAOYSA-N,perifosine,,Treatment of neuroblastoma,C0027819,Neuroblastoma,7/9/10,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
NDTYTMIUWGWIMO-UHFFFAOYSA-N,10819,NDTYTMIUWGWIMO-UHFFFAOYSA-N,perillyl alcohol,,Treatment of glioma,C0017638,Glioma,4/18/11,Designated,Not FDA Approved for Orphan Indication,,,,
DDBREPKUVSBGFI-UHFFFAOYSA-N,4763,DDBREPKUVSBGFI-UHFFFAOYSA-N,Phenobarbital,,Treatment of Neonatal seizures,C0159020,Neonatal seizures,2/26/20,Designated,Not FDA Approved for Orphan Indication,,,,
WRLGYAWRGXKSKG-UHFFFAOYSA-M,23674889,WRLGYAWRGXKSKG-UHFFFAOYSA-M,Phenobarbital Sodium,,Treatment of neonatal seizures,C0159020,Neonatal seizures,9/30/20,Designated,Not FDA Approved for Orphan Indication,,,,
WRLGYAWRGXKSKG-UHFFFAOYSA-M,23674889,WRLGYAWRGXKSKG-UHFFFAOYSA-M,Phenobarbital sodium,,Treatment of neonatal seizures,C0159020,Neonatal seizures,3/28/18,Designated,Not FDA Approved for Orphan Indication,,,,
SONNWYBIRXJNDC-VIFPVBQESA-N,6041,SONNWYBIRXJNDC-VIFPVBQESA-N,phenylephrine,,Treatment of Tetralogy of Fallot,C0039685,Tetralogy of Fallot,1/31/12,Designated,Not FDA Approved for Orphan Indication,,,,
VIUAUNHCRHHYNE-JTQLQIEISA-N,44187362,VIUAUNHCRHHYNE-JTQLQIEISA-N,pimasertib,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,1/29/10,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ISWRGOKTTBVCFA-UHFFFAOYSA-N,40632,ISWRGOKTTBVCFA-UHFFFAOYSA-N,pirfenidone,,Treatment of systemic sclerosis (including the associated interstitial lung disease),"C0036421,C0206062","Systemic sclerosis , Interstitial lung disease",11/19/13,Designated,Not FDA Approved for Orphan Indication,,,,
IOEMETRLOWNXGW-UHFFFAOYSA-N,54368,IOEMETRLOWNXGW-UHFFFAOYSA-N,Piritrexim isethionate,,"Treatment of infections caused by Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium-intracellulare.","C0026914,C0040557,C3714514","Mycobacterium avium-intracellulare , Toxoplasma gondii , Infections",6/13/88,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
NNACHAUCXXVJSP-UHFFFAOYSA-N,9948102,NNACHAUCXXVJSP-UHFFFAOYSA-N,pitolisant,WAKIX,Treatment of narcolepsy,C0027404,Narcolepsy,5/17/10,Designated/Approved,,treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy, 10/13/2020 , 10/13/2027 ,treatment of cataplexy in adult patients with narcolepsy
IEJSCSAMMLUINT-NRFANRHFSA-N,135430970,IEJSCSAMMLUINT-NRFANRHFSA-N,Plevitrexed,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,5/14/07,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
RVGRUAULSDPKGF-UHFFFAOYSA-N,24751,RVGRUAULSDPKGF-UHFFFAOYSA-N,Poloxamer 188,,Treatment of severe burns requiring hospitalization.,C0006434,Burns,2/22/90,Designated,Not FDA Approved for Orphan Indication,,,,
UVSMNLNDYGZFPF-UHFFFAOYSA-N,134780,UVSMNLNDYGZFPF-UHFFFAOYSA-N,pomalidomide,Pomalyst,Treatment of multiple myeloma,C0026764,Multiple Myeloma,1/15/03,Designated/Approved,,Treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy., 02/08/2013 , 02/08/2020 ,Treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
GBLBJPZSROAGMF-SIYOEGHHSA-N,129073603,GBLBJPZSROAGMF-SIYOEGHHSA-N,pralsetinib,Gavreto,"Treatment of RET-fusion, RET-mutation, and TRKC-positive poorly differentiated thyroid cancer, undifferentiated or anaplastic thyroid cancer, medullary thyroid cancer, and locally advanced or metastatic follicular or papillary thyroid cancer","C0238461,C0238462,C0238463,C1337013","anaplastic thyroid cancer , Thyroid cancer, medullary , papillary thyroid cancer , Differentiated Thyroid Cancer",5/26/20,Designated/Approved,,Treatment of (1) Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy; and; (2) Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate), 12/01/2020 , 12/01/2027 ,Treatment of (1) Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy; and; (2) Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)
AQHHHDLHHXJYJD-UHFFFAOYSA-N,4946,AQHHHDLHHXJYJD-UHFFFAOYSA-N,propranolol,HEMANGEOL,Treatment of proliferating infantile hemangiomas requiring systemic therapy,C0018916,Hemangiomas,9/5/08,Designated/Approved,,Treatment of proliferating infantile hemangioma requiring systemic therapy., 03/14/2014 , 03/14/2021 ,Treatment of proliferating infantile hemangioma requiring systemic therapy.
XNSAINXGIQZQOO-SRVKXCTJSA-N,638678,XNSAINXGIQZQOO-SRVKXCTJSA-N,Protirelin,,Prevention of infant respiratory distress syndrome associated with prematurity.,C0035220,infant respiratory distress syndrome,8/24/93,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
QMHSXPLYMTVAMK-UHFFFAOYSA-N,5281035,QMHSXPLYMTVAMK-UHFFFAOYSA-N,pyrvinium,,Treatment of familial adenomatous polyposis,C0032580,Familial Adenomatous Polyposis,1/5/15,Designated,Not FDA Approved for Orphan Indication,,,,
RONWGALEIBILOG-VMJVVOMYSA-N,56927704,RONWGALEIBILOG-VMJVVOMYSA-N,quinine Sulfate,,Treatment of malaria,C0024530,Malaria,6/3/04,Designated/Approved,,Treatment of uncomplicated Plasmodium falciparum malaria, 08/12/2005 , 08/12/2012 ,
ZHNFLHYOFXQIOW-LPYZJUEESA-N,16211610,ZHNFLHYOFXQIOW-LPYZJUEESA-N,quinine Sulfate,,Treatment of malaria,C0024530,Malaria,6/3/04,Designated/Approved,,Treatment of uncomplicated Plasmodium falciparum malaria, 08/12/2005 , 08/12/2012 ,
LOUPRKONTZGTKE-WZBLMQSHSA-N,3034034,LOUPRKONTZGTKE-WZBLMQSHSA-N,quinine Sulfate,,Treatment of malaria,C0024530,Malaria,6/3/04,Designated/Approved,,Treatment of uncomplicated Plasmodium falciparum malaria, 08/12/2005 , 08/12/2012 ,
AKYHKWQPZHDOBW-DSXUQNDKSA-N,11949689,AKYHKWQPZHDOBW-DSXUQNDKSA-N,quinine Sulfate,,Treatment of malaria,C0024530,Malaria,6/3/04,Designated/Approved,,Treatment of uncomplicated Plasmodium falciparum malaria, 08/12/2005 , 08/12/2012 ,
RONWGALEIBILOG-VMJVVOMYSA-N,56927704,RONWGALEIBILOG-VMJVVOMYSA-N,quinine Sulfate,,Treatment of malaria,C0024530,Malaria,6/3/04,Designated/Approved,,Treatment of uncomplicated Plasmodium falciparum malaria, 08/12/2005 , 08/12/2012 ,
QFJCIRLUMZQUOT-HPLJOQBZSA-N,5284616,QFJCIRLUMZQUOT-HPLJOQBZSA-N,rapamycin,,Treatment of tuberous sclerosis complex,C0041341,Tuberous Sclerosis Complex,3/20/07,Designated,Not FDA Approved for Orphan Indication,,,,
WVXNSAVVKYZVOE-UHFFFAOYSA-N,25066467,WVXNSAVVKYZVOE-UHFFFAOYSA-N,Rebastinib,,Treatment of Philadelphia chromosome positive chronic myeloid leukemia,C0279543,Philadelphia Chromosome Positive Chronic Myeloid Leukemia,9/3/09,Designated,Not FDA Approved for Orphan Indication,,,,
WVXNSAVVKYZVOE-UHFFFAOYSA-N,25066467,WVXNSAVVKYZVOE-UHFFFAOYSA-N,rebastinib,,Treatment of Facioscapulohumeral Muscular Dystrophy,C0238288,Facioscapulohumeral muscular dystrophy,5/23/18,Designated,Not FDA Approved for Orphan Indication,,,,
VRNHFZYMPDKTBS-WYUJEMNCSA-N,71652162,VRNHFZYMPDKTBS-WYUJEMNCSA-N,reltecimod,,Treatment of necrotizing soft tissue infections (NSTI),C0149778,Soft Tissue Infections,10/12/11,Designated,Not FDA Approved for Orphan Indication,,,,
YSGASDXSLKIKOD-UHFFFAOYSA-N,60511,YSGASDXSLKIKOD-UHFFFAOYSA-N,Remacemide,,Treatment of Huntington's disease.,C0020179,Huntington's Disease,3/6/00,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
KQDRVXQXKZXMHP-LLVKDONJSA-N,9838712,KQDRVXQXKZXMHP-LLVKDONJSA-N,reparixin,,Prevention of graft loss in pancreatic islet transplantation,C0877042,graft loss,9/25/12,Designated,Not FDA Approved for Orphan Indication,,,,
FECGNJPYVFEKOD-VMPITWQZSA-N,11609955,FECGNJPYVFEKOD-VMPITWQZSA-N,resminostat,,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,6/29/11,Designated,Not FDA Approved for Orphan Indication,,,,
OIRUWDYJGMHDHJ-AFXVCOSJSA-N,11685945,OIRUWDYJGMHDHJ-AFXVCOSJSA-N,retaspimycin hydrochloride,,Treatment of melanoma stages IIb through IV.,C0280209,melanoma stages,6/24/08,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
IWUCXVSUMQZMFG-AFCXAGJDSA-N,37542,IWUCXVSUMQZMFG-AFCXAGJDSA-N,ribavirin,REBETOL,Treatment of chronic hepatitis C in pediatric patients,C0524910,chronic hepatitis c,4/4/03,Designated/Approved,,Treatment of chronic hepatitis C among previously untreated pediatric patients at least three years of age or older., 07/29/2003 , 07/29/2010 ,
HNJWVTLAOZFLEK-OOWZQQDUSA-N,49848291,HNJWVTLAOZFLEK-OOWZQQDUSA-N,ribavirin elaidate,,"Treatment of follicular, medullary, and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer","C0238461,C0238463","Anaplastic thyroid carcinoma , papillary thyroid cancer",9/2/11,Designated,Not FDA Approved for Orphan Indication,,,,
ZWBTYMGEBZUQTK-SHULBWHJSA-N,137313637,ZWBTYMGEBZUQTK-SHULBWHJSA-N,Rifabutin,Mycobutin,Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.,"C0019693,C0026914","HIV infection , Mycobacterium avium Complex",12/18/89,Designated/Approved,,Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infections., 12/23/1992 , 12/23/1999 ,
ZWBTYMGEBZUQTK-HBZSWILLSA-N,137295261,ZWBTYMGEBZUQTK-HBZSWILLSA-N,Rifabutin,Mycobutin,Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.,"C0019693,C0026914","HIV infection , Mycobacterium avium Complex",12/18/89,Designated/Approved,,Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infections., 12/23/1992 , 12/23/1999 ,
ZWBTYMGEBZUQTK-DNEPJJHDSA-N,135925740,ZWBTYMGEBZUQTK-DNEPJJHDSA-N,Rifabutin,Mycobutin,Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.,"C0019693,C0026914","HIV infection , Mycobacterium avium Complex",12/18/89,Designated/Approved,,Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infections., 12/23/1992 , 12/23/1999 ,
ZWBTYMGEBZUQTK-OZKAIBRQSA-N,136257950,ZWBTYMGEBZUQTK-OZKAIBRQSA-N,Rifabutin,Mycobutin,Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.,"C0019693,C0026914","HIV infection , Mycobacterium avium Complex",12/18/89,Designated/Approved,,Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infections., 12/23/1992 , 12/23/1999 ,
ZWBTYMGEBZUQTK-WOYMMMRKSA-N,136053407,ZWBTYMGEBZUQTK-WOYMMMRKSA-N,Rifabutin,Mycobutin,Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.,"C0019693,C0026914","HIV infection , Mycobacterium avium Complex",12/18/89,Designated/Approved,,Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infections., 12/23/1992 , 12/23/1999 ,
ZWBTYMGEBZUQTK-OZFKZPMASA-N,135458645,ZWBTYMGEBZUQTK-OZFKZPMASA-N,Rifabutin,Mycobutin,Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.,"C0019693,C0026914","HIV infection , Mycobacterium avium Complex",12/18/89,Designated/Approved,,Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infections., 12/23/1992 , 12/23/1999 ,
ZWBTYMGEBZUQTK-AMWSOCTHSA-N,136117120,ZWBTYMGEBZUQTK-AMWSOCTHSA-N,Rifabutin,Mycobutin,Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.,"C0019693,C0026914","HIV infection , Mycobacterium avium Complex",12/18/89,Designated/Approved,,Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infections., 12/23/1992 , 12/23/1999 ,
ZWBTYMGEBZUQTK-ASBZJICESA-N,135950975,ZWBTYMGEBZUQTK-ASBZJICESA-N,Rifabutin,Mycobutin,Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.,"C0019693,C0026914","HIV infection , Mycobacterium avium Complex",12/18/89,Designated/Approved,,Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infections., 12/23/1992 , 12/23/1999 ,
ZWBTYMGEBZUQTK-PVLSIAFMSA-N,135398743,ZWBTYMGEBZUQTK-PVLSIAFMSA-N,Rifabutin,Mycobutin,Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.,"C0019693,C0026914","HIV infection , Mycobacterium avium Complex",12/18/89,Designated/Approved,,Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infections., 12/23/1992 , 12/23/1999 ,
ZWBTYMGEBZUQTK-SHULBWHJSA-N,137313637,ZWBTYMGEBZUQTK-SHULBWHJSA-N,Rifabutin,,Treatment of disseminated Mycobacterium avium complex disease.,C0026914,Mycobacterium avium Complex,12/18/89,Designated,Not FDA Approved for Orphan Indication,,,,
ZWBTYMGEBZUQTK-HBZSWILLSA-N,137295261,ZWBTYMGEBZUQTK-HBZSWILLSA-N,Rifabutin,,Treatment of disseminated Mycobacterium avium complex disease.,C0026914,Mycobacterium avium Complex,12/18/89,Designated,Not FDA Approved for Orphan Indication,,,,
ZWBTYMGEBZUQTK-DNEPJJHDSA-N,135925740,ZWBTYMGEBZUQTK-DNEPJJHDSA-N,Rifabutin,,Treatment of disseminated Mycobacterium avium complex disease.,C0026914,Mycobacterium avium Complex,12/18/89,Designated,Not FDA Approved for Orphan Indication,,,,
ZWBTYMGEBZUQTK-OZKAIBRQSA-N,136257950,ZWBTYMGEBZUQTK-OZKAIBRQSA-N,Rifabutin,,Treatment of disseminated Mycobacterium avium complex disease.,C0026914,Mycobacterium avium Complex,12/18/89,Designated,Not FDA Approved for Orphan Indication,,,,
ZWBTYMGEBZUQTK-WOYMMMRKSA-N,136053407,ZWBTYMGEBZUQTK-WOYMMMRKSA-N,Rifabutin,,Treatment of disseminated Mycobacterium avium complex disease.,C0026914,Mycobacterium avium Complex,12/18/89,Designated,Not FDA Approved for Orphan Indication,,,,
ZWBTYMGEBZUQTK-OZFKZPMASA-N,135458645,ZWBTYMGEBZUQTK-OZFKZPMASA-N,Rifabutin,,Treatment of disseminated Mycobacterium avium complex disease.,C0026914,Mycobacterium avium Complex,12/18/89,Designated,Not FDA Approved for Orphan Indication,,,,
ZWBTYMGEBZUQTK-AMWSOCTHSA-N,136117120,ZWBTYMGEBZUQTK-AMWSOCTHSA-N,Rifabutin,,Treatment of disseminated Mycobacterium avium complex disease.,C0026914,Mycobacterium avium Complex,12/18/89,Designated,Not FDA Approved for Orphan Indication,,,,
ZWBTYMGEBZUQTK-ASBZJICESA-N,135950975,ZWBTYMGEBZUQTK-ASBZJICESA-N,Rifabutin,,Treatment of disseminated Mycobacterium avium complex disease.,C0026914,Mycobacterium avium Complex,12/18/89,Designated,Not FDA Approved for Orphan Indication,,,,
ZWBTYMGEBZUQTK-PVLSIAFMSA-N,135398743,ZWBTYMGEBZUQTK-PVLSIAFMSA-N,Rifabutin,,Treatment of disseminated Mycobacterium avium complex disease.,C0026914,Mycobacterium avium Complex,12/18/89,Designated,Not FDA Approved for Orphan Indication,,,,
VDNLFJGJEQUWRB-UHFFFAOYSA-L,3856851,VDNLFJGJEQUWRB-UHFFFAOYSA-L,rose bengal disodium,,Treatment of ocular melanoma,C0558356,Ocular Melanoma,2/11/19,Designated,Not FDA Approved for Orphan Indication,,,,
YLXBBCDOUAHKIB-LJKCMNKDSA-N,121488160,YLXBBCDOUAHKIB-LJKCMNKDSA-N,Rosomidnar,,Treatment of diffuse large B-cell lymphoma.,C1332201,Diffuse Large B-Cell Lymphoma,3/10/16,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
YLXBBCDOUAHKIB-UHFFFAOYSA-N,119058033,YLXBBCDOUAHKIB-UHFFFAOYSA-N,Rosomidnar,,Treatment of diffuse large B-cell lymphoma.,C1332201,Diffuse Large B-Cell Lymphoma,3/10/16,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
HFNKQEVNSGCOJV-OAHLLOKOSA-N,25126798,HFNKQEVNSGCOJV-OAHLLOKOSA-N,ruxolitinib,Jakafi,Treatment of polycythemia vera,C0032463,Polycythemia Vera,3/26/10,Designated/Approved,,Treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea., 12/04/2014 , 12/04/2021 ,Treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.
MEFKEPWMEQBLKI-AIRLBKTGSA-P,56593143,MEFKEPWMEQBLKI-AIRLBKTGSA-P,S-adenosylmethionine,,Treatment of AIDS-myelopathy.,"C0001175,C0005956","AIDS , myelopathy",4/30/98,Designated,Not FDA Approved for Orphan Indication,,,,
MEFKEPWMEQBLKI-AIRLBKTGSA-O,24762165,MEFKEPWMEQBLKI-AIRLBKTGSA-O,S-adenosylmethionine,,Treatment of AIDS-myelopathy.,"C0001175,C0005956","AIDS , myelopathy",4/30/98,Designated,Not FDA Approved for Orphan Indication,,,,
MEFKEPWMEQBLKI-AIRLBKTGSA-O,24762165,MEFKEPWMEQBLKI-AIRLBKTGSA-O,S-adenosylmethionine,,Treatment of AIDS-myelopathy.,"C0001175,C0005956","AIDS , myelopathy",4/30/98,Designated,Not FDA Approved for Orphan Indication,,,,
MEFKEPWMEQBLKI-AIRLBKTGSA-N,34755,MEFKEPWMEQBLKI-AIRLBKTGSA-N,S-adenosylmethionine,,Treatment of AIDS-myelopathy.,"C0001175,C0005956","AIDS , myelopathy",4/30/98,Designated,Not FDA Approved for Orphan Indication,,,,
HYHSBSXUHZOYLX-WDSKDSINSA-M,7059524,HYHSBSXUHZOYLX-WDSKDSINSA-M,S-nitrosoglutathione,,Treatment of severe preeclampsia,C0341950,Severe Preeclampsia,12/28/12,Designated,Not FDA Approved for Orphan Indication,,,,
HYHSBSXUHZOYLX-WDSKDSINSA-N,104858,HYHSBSXUHZOYLX-WDSKDSINSA-N,S-nitrosoglutathione,,Treatment of severe preeclampsia,C0341950,Severe Preeclampsia,12/28/12,Designated,Not FDA Approved for Orphan Indication,,,,
OUKYUETWWIPKQR-UHFFFAOYSA-N,10302451,OUKYUETWWIPKQR-UHFFFAOYSA-N,saracatinib,,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,3/11/19,Designated,Not FDA Approved for Orphan Indication,,,,
DEVSOMFAQLZNKR-RJRFIUFISA-N,71481097,DEVSOMFAQLZNKR-RJRFIUFISA-N,selinexor,XPOVIO,Treatment of multiple myeloma,C0026764,Multiple Myeloma,1/5/15,Designated/Approved,,"XPOVIO is indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.", 07/03/2019 , 07/03/2026 ,"Indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody."
DEVSOMFAQLZNKR-RJRFIUFISA-N,71481097,DEVSOMFAQLZNKR-RJRFIUFISA-N,selinexor,,Treatment of diffuse large B-cell lymphoma,C1332201,Diffuse Large B-Cell Lymphoma,5/14/14,Designated/Approved,,"XPOVIO is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.", 06/22/2020 ,  ,
DEVSOMFAQLZNKR-RJRFIUFISA-N,71481097,DEVSOMFAQLZNKR-RJRFIUFISA-N,selinexor,,Treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,7/7/16,Designated,Not FDA Approved for Orphan Indication,,,,
BVLCEKWPOSAKSZ-YQMCHIOTSA-N,16132412,BVLCEKWPOSAKSZ-YQMCHIOTSA-N,Sermorelin acetate,Geref,Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.,"C0015544,C3898072","growth failure , Organic Growth Hormone Deficiency",9/14/88,Designated/Approved,,, 09/26/1997 , 09/26/2004 ,
QFJCIRLUMZQUOT-HPLJOQBZSA-N,5284616,QFJCIRLUMZQUOT-HPLJOQBZSA-N,sirolimus,,Treatment of tuberous sclerosis complex,C0041341,Tuberous Sclerosis Complex,8/26/19,Designated,Not FDA Approved for Orphan Indication,,,,
QFJCIRLUMZQUOT-HPLJOQBZSA-N,5284616,QFJCIRLUMZQUOT-HPLJOQBZSA-N,sirolimus,,Treatment of pachyonychia congenita,C0265334,Pachyonychia Congenita,3/18/13,Designated,Not FDA Approved for Orphan Indication,,,,
QFJCIRLUMZQUOT-HPLJOQBZSA-N,5284616,QFJCIRLUMZQUOT-HPLJOQBZSA-N,sirolimus,,"Treatment of chronic/refractory anterior noninfectious uveitis, noninfectious intermediate uveitis, noninfectious panuveitis and non-infectious, uveitis affecting the posterior of the eye (NICUPS).","C0009450,C0042164,C0042166,C0751437,C0751438,C4518725","Infectious , Uveitis , Intermediate uveitis , Anterior , Posterior , Noninfectious panuveitis",11/4/11,Designated,Not FDA Approved for Orphan Indication,,,,
VPZRWNZGLKXFOE-UHFFFAOYSA-M,5258,VPZRWNZGLKXFOE-UHFFFAOYSA-M,sodium 4-phenylbutyrate,,Treatment of spinal muscular atrophy,C0026847,Spinal Muscular Atrophy,10/18/11,Designated,Not FDA Approved for Orphan Indication,,,,
HJHVQCXHVMGZNC-XOSDQFCBSA-M,134694338,HJHVQCXHVMGZNC-XOSDQFCBSA-M,sodium fusidate,,Treatment of cystic fibrosis,C0010674,Cystic Fibrosis,2/13/20,Designated,Not FDA Approved for Orphan Indication,,,,
HJHVQCXHVMGZNC-UHFFFAOYSA-M,44134727,HJHVQCXHVMGZNC-UHFFFAOYSA-M,sodium fusidate,,Treatment of cystic fibrosis,C0010674,Cystic Fibrosis,2/13/20,Designated,Not FDA Approved for Orphan Indication,,,,
HJHVQCXHVMGZNC-LOPNDLIXSA-M,23706209,HJHVQCXHVMGZNC-LOPNDLIXSA-M,sodium fusidate,,Treatment of cystic fibrosis,C0010674,Cystic Fibrosis,2/13/20,Designated,Not FDA Approved for Orphan Indication,,,,
HJHVQCXHVMGZNC-XDELSAJESA-M,91873261,HJHVQCXHVMGZNC-XDELSAJESA-M,sodium fusidate,,Treatment of cystic fibrosis,C0010674,Cystic Fibrosis,2/13/20,Designated,Not FDA Approved for Orphan Indication,,,,
HJHVQCXHVMGZNC-DHUMWTJCSA-M,23690471,HJHVQCXHVMGZNC-DHUMWTJCSA-M,sodium fusidate,,Treatment of cystic fibrosis,C0010674,Cystic Fibrosis,2/13/20,Designated,Not FDA Approved for Orphan Indication,,,,
HJHVQCXHVMGZNC-JCJNLNMISA-M,23672955,HJHVQCXHVMGZNC-JCJNLNMISA-M,sodium fusidate,,Treatment of cystic fibrosis,C0010674,Cystic Fibrosis,2/13/20,Designated,Not FDA Approved for Orphan Indication,,,,
LPXPTNMVRIOKMN-UHFFFAOYSA-M,23668193,LPXPTNMVRIOKMN-UHFFFAOYSA-M,sodium nitrite,,Treatment of vaso-occlusive crisis associated with sickle cell disease,"C0002895,C0750151","Sickle Cell Disease , Vaso-Occlusive Crisis",4/2/07,Designated,Not FDA Approved for Orphan Indication,,,,
VPZRWNZGLKXFOE-UHFFFAOYSA-M,5258,VPZRWNZGLKXFOE-UHFFFAOYSA-M,sodium phenylbutyrate,Buphenyl,"Treatment of urea cycle disorders: carbamylphosphate synthetase deficiency, ornithine transcarbamylase deficiency, and arginiosuccinic acid synthetase deficiency.","C0154246,C0268542,C1291575","Urea Cycle Disorders , Deficiency, Ornithine Transcarbamylase , synthetase deficiency",11/22/93,Designated/Approved,,"Adjunctive therapy in the chronic managment of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase.", 04/30/1996 , 04/30/2003 ,
DAEPDZWVDSPTHF-UHFFFAOYSA-M,23662274,DAEPDZWVDSPTHF-UHFFFAOYSA-M,Sodium pyruvate,,Treatment of cystic fibrosis,C0010674,Cystic Fibrosis,3/31/03,Designated,Not FDA Approved for Orphan Indication,,,,
CUEDNFKBTFCOSV-UZVLBLASSA-L,16683012,CUEDNFKBTFCOSV-UZVLBLASSA-L,sodium stibogluconate,,Treatment of cutaneous leishmaniasis,C0023283,Cutaneous leishmaniasis,10/28/09,Designated,Not FDA Approved for Orphan Indication,,,,
AKHNMLFCWUSKQB-UHFFFAOYSA-L,24477,AKHNMLFCWUSKQB-UHFFFAOYSA-L,sodium thiosulfate,,Treatment of extravasation of meclorethamine hydrochloride into subcutaneous tissues.,C0015376,Extravasation,12/2/10,Designated,Not FDA Approved for Orphan Indication,,,,
TTZHDVOVKQGIBA-LVPOHEQUSA-N,73425384,TTZHDVOVKQGIBA-LVPOHEQUSA-N,sofosbuvir,Sovaldi,Treatment of pediatric chronic hepatitis C virus infection,"C0019196,C0524910","Hepatitis C Virus Infection , chronic hepatitis c",10/25/16,Designated/Approved,,SOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin, 08/28/2019 , 08/28/2026 ,For the treatment of chronic hepatitis C virus (HCV) genotype 2 or 3 infection in pediatric patients between 3 years of age and 12 years of age or weighing 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin.
TTZHDVOVKQGIBA-KVOQBTHKSA-N,72699160,TTZHDVOVKQGIBA-KVOQBTHKSA-N,sofosbuvir,Sovaldi,Treatment of pediatric chronic hepatitis C virus infection,"C0019196,C0524910","Hepatitis C Virus Infection , chronic hepatitis c",10/25/16,Designated/Approved,,SOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin, 08/28/2019 , 08/28/2026 ,For the treatment of chronic hepatitis C virus (HCV) genotype 2 or 3 infection in pediatric patients between 3 years of age and 12 years of age or weighing 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin.
TTZHDVOVKQGIBA-IECBXEDQSA-N,129010435,TTZHDVOVKQGIBA-IECBXEDQSA-N,sofosbuvir,Sovaldi,Treatment of pediatric chronic hepatitis C virus infection,"C0019196,C0524910","Hepatitis C Virus Infection , chronic hepatitis c",10/25/16,Designated/Approved,,SOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin, 08/28/2019 , 08/28/2026 ,For the treatment of chronic hepatitis C virus (HCV) genotype 2 or 3 infection in pediatric patients between 3 years of age and 12 years of age or weighing 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin.
TTZHDVOVKQGIBA-UHFFFAOYSA-N,91302628,TTZHDVOVKQGIBA-UHFFFAOYSA-N,sofosbuvir,Sovaldi,Treatment of pediatric chronic hepatitis C virus infection,"C0019196,C0524910","Hepatitis C Virus Infection , chronic hepatitis c",10/25/16,Designated/Approved,,SOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin, 08/28/2019 , 08/28/2026 ,For the treatment of chronic hepatitis C virus (HCV) genotype 2 or 3 infection in pediatric patients between 3 years of age and 12 years of age or weighing 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin.
TTZHDVOVKQGIBA-IAAJYNJHSA-N,45375806,TTZHDVOVKQGIBA-IAAJYNJHSA-N,sofosbuvir,Sovaldi,Treatment of pediatric chronic hepatitis C virus infection,"C0019196,C0524910","Hepatitis C Virus Infection , chronic hepatitis c",10/25/16,Designated/Approved,,SOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin, 08/28/2019 , 08/28/2026 ,For the treatment of chronic hepatitis C virus (HCV) genotype 2 or 3 infection in pediatric patients between 3 years of age and 12 years of age or weighing 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin.
TTZHDVOVKQGIBA-IQWMDFIBSA-N,45375808,TTZHDVOVKQGIBA-IQWMDFIBSA-N,sofosbuvir,Sovaldi,Treatment of pediatric chronic hepatitis C virus infection,"C0019196,C0524910","Hepatitis C Virus Infection , chronic hepatitis c",10/25/16,Designated/Approved,,SOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin, 08/28/2019 , 08/28/2026 ,For the treatment of chronic hepatitis C virus (HCV) genotype 2 or 3 infection in pediatric patients between 3 years of age and 12 years of age or weighing 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin.
LKVFMOMQYXIFRK-KSVAIKAXSA-N,91864495,LKVFMOMQYXIFRK-KSVAIKAXSA-N,solnatide,,Treatment of generalized systemic pseudohypoaldosteronism type 1 (also known as autosomal recessive PHA-I or PHA-IB),C0268436,Pseudohypoaldosteronism Type 1,2/8/16,Designated,Not FDA Approved for Orphan Indication,,,,
JACAAXNEHGBPOQ-LLVKDONJSA-N,164509,JACAAXNEHGBPOQ-LLVKDONJSA-N,talampanel,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,3/24/08,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
AJKIRUJIDFJUKJ-UHFFFAOYSA-N,29566,AJKIRUJIDFJUKJ-UHFFFAOYSA-N,taurolidine,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,5/16/16,Designated,Not FDA Approved for Orphan Indication,,,,
NSQSAUGJQHDYNO-UHFFFAOYSA-N,66558664,NSQSAUGJQHDYNO-UHFFFAOYSA-N,tazemetostat,,Treatment of malignant rhabdoid tumors (MRTs),C0206743,Rhabdoid Tumors,2/4/16,Designated,Not FDA Approved for Orphan Indication,,,,
BPEGJWRSRHCHSN-UHFFFAOYSA-N,5394,BPEGJWRSRHCHSN-UHFFFAOYSA-N,temozolomide,Temodar,Treatment of recurrent malignant glioma.,C4684861,Recurrent Malignant Glioma,10/5/98,Designated/Approved,,"Treatment of adult patients with refractory anaplastic astrocytoma, i.e., patients at first relapse who have experienced disease progression on a drug regimen containing a nitrosourea and procarbazine", 08/11/1999 , 08/11/2006 ,
SGOIRFVFHAKUTI-ZCFIWIBFSA-N,464205,SGOIRFVFHAKUTI-ZCFIWIBFSA-N,tenofovir,Viread,Treatment of pediatric HIV infection.,C0019693,HIV infection,3/17/09,Designated/Approved,,Treatment of HIV infection in combination with other antiretroviral agents in patients 12 to less than 18 years of age, 03/24/2010 , 03/24/2017 ,
VCMJCVGFSROFHV-VIEYUMQNSA-N,86280652,VCMJCVGFSROFHV-VIEYUMQNSA-N,tenofovir disoproxil fumarate,,Prevention of mother to child transmission of hepatitis B virus,"C0019169,C0282474","hepatitis B virus , Mother to Child Transmission",9/27/16,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
JFVZFKDSXNQEJW-CQSZACIVSA-N,5481350,JFVZFKDSXNQEJW-CQSZACIVSA-N,tenofovir disoproxil fumarate,,Prevention of mother to child transmission of hepatitis B virus,"C0019169,C0282474","hepatitis B virus , Mother to Child Transmission",9/27/16,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
VCMJCVGFSROFHV-PFEQFJNWSA-N,5486830,VCMJCVGFSROFHV-PFEQFJNWSA-N,tenofovir disoproxil fumarate,,Prevention of mother to child transmission of hepatitis B virus,"C0019169,C0282474","hepatitis B virus , Mother to Child Transmission",9/27/16,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
VCMJCVGFSROFHV-WZGZYPNHSA-N,6398764,VCMJCVGFSROFHV-WZGZYPNHSA-N,tenofovir disoproxil fumarate,,Prevention of mother to child transmission of hepatitis B virus,"C0019169,C0282474","hepatitis B virus , Mother to Child Transmission",9/27/16,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
AHYMHWXQRWRBKT-UHFFFAOYSA-N,25171648,AHYMHWXQRWRBKT-UHFFFAOYSA-N,tepotinib,Tepmetko,Treatment of non-small cell lung cancer with MET genomic tumor aberrations,"C0027651,C3539721","Tumor , Non-Small Cell Lung Cancer",10/26/20,Designated/Approved,,treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations, 02/03/2021 , 02/03/2028 ,treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations
MUMGGOZAMZWBJJ-DYKIIFRCSA-N,6013,MUMGGOZAMZWBJJ-DYKIIFRCSA-N,Testosterone,,For use as physiologic testosterone replacement in androgen deficient HIV+ patients with an associated weight loss.,"C0019682,C4084774","HIV , Weight loss",9/22/97,Designated,Not FDA Approved for Orphan Indication,,,,
GFFXZLZWLOBBLO-ASKVSEFXSA-N,6435808,GFFXZLZWLOBBLO-ASKVSEFXSA-N,Tezacitabine,,Treatment of adenocarcinoma of the esophagus and stomach,C0279628,adenocarcinoma of the esophagus,1/27/03,Designated,Not FDA Approved for Orphan Indication,,,,
NZVYCXVTEHPMHE-ZSUJOUNUSA-N,16130571,NZVYCXVTEHPMHE-ZSUJOUNUSA-N,thymalfasin,,Treatment of chronic active hepatitis B,C0744831,Chronic active hepatitis B,5/3/91,Designated,Not FDA Approved for Orphan Indication,,,,
YTGJWQPHMWSCST-UHFFFAOYSA-N,5483,YTGJWQPHMWSCST-UHFFFAOYSA-N,Tiopronin,Thiola,Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.,"C0010691,C0022650","Cystinuria , Nephrolithiasis",1/17/86,Designated/Approved,,"THIOLA is indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 20 kg and greater with severe homozygous cystinuria, who are not responsive to these measures alone.", 06/28/2019 , 06/28/2026 ,"Indicated in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in pediatric patients between 20 kg and 9 years of age with severe homozygous cystinuria, who are not responsive to these measures alone"
MDCUNMLZLNGCQA-HWOAGHQOSA-N,44201346,MDCUNMLZLNGCQA-HWOAGHQOSA-N,tiprelestat,,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,12/28/12,Designated,Not FDA Approved for Orphan Indication,,,,
ORYDPOVDJJZGHQ-UHFFFAOYSA-N,135413511,ORYDPOVDJJZGHQ-UHFFFAOYSA-N,tirapazamine,,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,11/30/15,Designated,Not FDA Approved for Orphan Indication,,,,
UOWZUVNAGUAEQC-UHFFFAOYSA-N,5803,UOWZUVNAGUAEQC-UHFFFAOYSA-N,Tiratricol,,For use in combination with levo-thyroxine to suppress thyroid stimulating hormone in patients with well-differentiated thyroid cancer who are intolerant to adequate doses of levo-thyroxine alone.,C1337013,Well-Differentiated Thyroid Cancer,8/13/91,Designated,Not FDA Approved for Orphan Indication,,,,
GYHCTFXIZSNGJT-UHFFFAOYSA-N,216237,GYHCTFXIZSNGJT-UHFFFAOYSA-N,tolvaptan,Jynarque,Treatment of autosomal dominant polycystic kidney disease,C0085413,Autosomal dominant polycystic kidney disease,4/6/12,Designated/Approved,,JYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD), 04/23/2018 , 04/23/2025 ,JYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD)
GYDJEQRTZSCIOI-UHFFFAOYSA-N,5526,GYDJEQRTZSCIOI-UHFFFAOYSA-N,tranexamic acid,Cyklokapron,"For use in patients with congenital coagulopathies undergoing surgical procedures, e.g. dental extractions",C0005779,coagulopathies,12/3/85,Designated/Approved/Withdrawn,,Treatment of patients with hemophilia for short term use (2 to 8 days) before and after tooth extraction to reduce or prevent hemorrhage abd reduce the need for replacement therapy, 12/30/1986 , 12/30/1993 ,
WBYWAXJHAXSJNI-VOTSOKGWSA-N,444539,WBYWAXJHAXSJNI-VOTSOKGWSA-N,Trans-Cinnamic Acid,,Treatment of Krabbe disease,C0023521,Krabbe Disease,2/3/21,Designated,Not FDA Approved for Orphan Indication,,,,
LUKBXSAWLPMMSZ-OWOJBTEDSA-N,445154,LUKBXSAWLPMMSZ-OWOJBTEDSA-N,trans-resveratrol,,Treatment of Friedreichs Ataxia (FRDA),C0016719,FRIEDREICHS ATAXIA,8/16/17,Designated,Not FDA Approved for Orphan Indication,,,,
HDTRYLNUVZCQOY-LIZSDCNHSA-N,7427,HDTRYLNUVZCQOY-LIZSDCNHSA-N,Trehalose,,"Treatment of mucopolysaccharidosis type III (MPS III), or Sanfilippo syndrome","C0026706,C0086647","Mucopolysaccharidosis type III , mps iii",4/29/20,Designated,Not FDA Approved for Orphan Indication,,,,
SHGAZHPCJJPHSC-YCNIQYBTSA-N,444795,SHGAZHPCJJPHSC-YCNIQYBTSA-N,Tretinoin,,Treatment of T-cell non-Hodgkin's lymphoma,C0079772,T-cell non-Hodgkin's lymphoma,4/11/03,Designated,Not FDA Approved for Orphan Indication,,,,
PJHKBYALYHRYSK-UHFFFAOYSA-N,69286,PJHKBYALYHRYSK-UHFFFAOYSA-N,Triheptanoin,,Treatment of glycogen storage disorder II (Pompe disease),"C0017919,C0017921","glycogen storage disorder , Pompe Disease",2/1/08,Designated,Not FDA Approved for Orphan Indication,,,,
PJHKBYALYHRYSK-UHFFFAOYSA-N,69286,PJHKBYALYHRYSK-UHFFFAOYSA-N,triheptanoin,Dojolvi,Treatment of fatty acid oxidation disorders,C1456270,fatty acid oxidation disorder,4/15/15,Designated/Approved,,DOJOLVI is indicated as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD)., 06/30/2020 , 06/30/2027 ,Indicated as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).
UHWVSEOVJBQKBE-UHFFFAOYSA-N,21109,UHWVSEOVJBQKBE-UHFFFAOYSA-N,Trimetazidine,,Treatment of acute-on-chronic liver failure,C3850141,Acute-On-Chronic Liver Failure,3/15/18,Designated,Not FDA Approved for Orphan Indication,,,,
UHWVSEOVJBQKBE-UHFFFAOYSA-N,21109,UHWVSEOVJBQKBE-UHFFFAOYSA-N,trimetazidine,,Treatment of dilated cardiomyopathy,C0007193,Dilated cardiomyopathy,10/30/18,Designated,Not FDA Approved for Orphan Indication,,,,
ZCJXQWYMBJYJNB-UHFFFAOYSA-N,336805,ZCJXQWYMBJYJNB-UHFFFAOYSA-N,Trimetrexate glucuronate,,Treatment of patients with advanced non-small cell carcinoma of the lung.,C0007131,Non-Small Cell Carcinoma of the Lung,1/13/88,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ZCJXQWYMBJYJNB-LRDBBFHQSA-N,54949,ZCJXQWYMBJYJNB-LRDBBFHQSA-N,Trimetrexate glucuronate,,Treatment of patients with advanced non-small cell carcinoma of the lung.,C0007131,Non-Small Cell Carcinoma of the Lung,1/13/88,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ODVKSTFPQDVPJZ-UHFFFAOYSA-N,105102,ODVKSTFPQDVPJZ-UHFFFAOYSA-N,Ulinastatin,,Treatment of Kawasaki Disease,C0026691,Kawasaki Disease,6/12/20,Designated,Not FDA Approved for Orphan Indication,,,,
IUVCFHHAEHNCFT-INIZCTEOSA-N,72950888,IUVCFHHAEHNCFT-INIZCTEOSA-N,umbralisib,Ukoniq,Treatment of extranodal marginal zone lymphoma,C1367654,Marginal zone lymphoma,4/11/19,Designated/Approved,,Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen., 02/05/2021 ,  ,
XXUPXHKCPIKWLR-JHUOEJJVSA-N,5282175,XXUPXHKCPIKWLR-JHUOEJJVSA-N,unoprostone isopropyl,,Treatment of retinitis pigmentosa,C0035334,Retinitis Pigmentosa,9/16/10,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
AUFUWRKPQLGTGF-FMKGYKFTSA-N,20058,AUFUWRKPQLGTGF-FMKGYKFTSA-N,uridine triacetate,,An antidote in the treatment of 5-fluorouracil or capecitabine poisoning,C0032343,Poisoning,5/1/09,Designated/Approved,,"For the emergency treatment of adult and pediatric patients following a fluorouracil or capecitabine overdose regardless of the presence of symptoms, or who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration", 12/11/2015 , 12/11/2022 ,"For the emergency treatment of adult and pediatric patients following a fluorouracil or capecitabine overdose regardless of the presence of symptoms, or who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration"
RUDATBOHQWOJDD-UZVSRGJWSA-N,31401,RUDATBOHQWOJDD-UZVSRGJWSA-N,Ursodeoxycholic acid,,"Treatment of Niemann-Pick disease, type C",C0220756,"Niemann-Pick Disease, Type C",4/26/18,Designated,Not FDA Approved for Orphan Indication,,,,
LQBVNQSMGBZMKD-UHFFFAOYSA-N,49846579,LQBVNQSMGBZMKD-UHFFFAOYSA-N,Venetoclax,,Treatment of acute lymphoblastic leukemia,C0023449,Acute lymphoblastic leukemia,10/26/20,Designated,Not FDA Approved for Orphan Indication,,,,
FVJCUZCRPIMVLB-UHFFFAOYSA-N,11528958,FVJCUZCRPIMVLB-UHFFFAOYSA-N,verdiperstat,,Treatment of multiple system atrophy (MSA).,C0393571,Multiple System Atrophy,2/15/19,Designated,Not FDA Approved for Orphan Indication,,,,
DJWUNCQRNNEAKC-UHFFFAOYSA-L,11192,DJWUNCQRNNEAKC-UHFFFAOYSA-L,Zinc acetate,Galzin,Treatment of Wilson's disease.,C0019202,Wilson's Disease,11/6/85,Designated/Approved,,For maintenance treatment of patients with Wilson's disease who have been initially treated with a chelating agent., 01/28/1997 , 01/28/2004 ,
YFGBQHOOROIVKG-FKBYEOEOSA-N,443363,YFGBQHOOROIVKG-FKBYEOEOSA-N,[met5]-enkephalin,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,1/24/13,Designated,Not FDA Approved for Orphan Indication,,,,
VERWOWGGCGHDQE-UHFFFAOYSA-N,57379345,VERWOWGGCGHDQE-UHFFFAOYSA-N,ceritinib,ZYKADIA,Treatment of patients with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase(ALK)-positive,"C0007131,C3539721","Non-Small Cell Lung Cancer , Non-Small Cell Lung Cancer",9/27/13,Designated/Approved,,ZYKADIA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic nonsmall cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib., 04/29/2014 , 04/29/2021 ,Treatment of patients with anaplastic lymphoma kinase (ALK) positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
PENDGIOBPJLVBT-WNGDBVLYSA-N,146157949,PENDGIOBPJLVBT-WNGDBVLYSA-N,cethromycin,,Prophylactic treatment of plague due to Yersinia pestis,C0032064,Plague,9/9/09,Designated,Not FDA Approved for Orphan Indication,,,,
PENDGIOBPJLVBT-COVUKVLKSA-N,11354711,PENDGIOBPJLVBT-COVUKVLKSA-N,cethromycin,,Prophylactic treatment of plague due to Yersinia pestis,C0032064,Plague,9/9/09,Designated,Not FDA Approved for Orphan Indication,,,,
PENDGIOBPJLVBT-AMXFZXBBSA-N,156417,PENDGIOBPJLVBT-AMXFZXBBSA-N,cethromycin,,Prophylactic treatment of plague due to Yersinia pestis,C0032064,Plague,9/9/09,Designated,Not FDA Approved for Orphan Indication,,,,
PENDGIOBPJLVBT-HMMOOPTJSA-N,5282045,PENDGIOBPJLVBT-HMMOOPTJSA-N,cethromycin,,Prophylactic treatment of plague due to Yersinia pestis,C0032064,Plague,9/9/09,Designated,Not FDA Approved for Orphan Indication,,,,
PENDGIOBPJLVBT-ONLVEXIXSA-N,447451,PENDGIOBPJLVBT-ONLVEXIXSA-N,cethromycin,,Prophylactic treatment of plague due to Yersinia pestis,C0032064,Plague,9/9/09,Designated,Not FDA Approved for Orphan Indication,,,,
RUDATBOHQWOJDD-BSWAIDMHSA-N,10133,RUDATBOHQWOJDD-BSWAIDMHSA-N,Chenodeoxycholic acid,,Treatment of cerebrotendinous xanthomatosis,C0238052,CEREBROTENDINOUS XANTHOMATOSIS,1/29/04,Designated,Not FDA Approved for Orphan Indication,,,,
RUDATBOHQWOJDD-BSWAIDMHSA-N,10133,RUDATBOHQWOJDD-BSWAIDMHSA-N,chenodiol,,Treatment of cerebrotendinous xanthomatosis,C0238052,CEREBROTENDINOUS XANTHOMATOSIS,3/22/10,Designated,Not FDA Approved for Orphan Indication,,,,
VDHAWDNDOKGFTD-MRXNPFEDSA-N,156419,VDHAWDNDOKGFTD-MRXNPFEDSA-N,cinacalcet,Sensipar,Treatment of hypercalcemia in patients with parathyroid carcinoma,C0687150,Parathyroid Carcinoma,5/12/03,Designated/Approved,,Treatment of hypercalcemia in patients with parathyroid carcinoma, 03/08/2004 , 03/08/2011 ,
PTOAARAWEBMLNO-KVQBGUIXSA-N,20279,PTOAARAWEBMLNO-KVQBGUIXSA-N,cladribine,,Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder,C0027873,Neuromyelitis Optica,3/19/15,Designated,Not FDA Approved for Orphan Indication,,,,
KDLRVYVGXIQJDK-BVGIQVCNSA-N,129627692,KDLRVYVGXIQJDK-BVGIQVCNSA-N,Clindamycin,,Prevention of Pneumocystis carinii pneumonia in AIDS patients.,C1535939,Pneumocystis carinii Pneumonia,10/28/88,Designated,Not FDA Approved for Orphan Indication,,,,
KDLRVYVGXIQJDK-NQQGAZBYSA-N,129009913,KDLRVYVGXIQJDK-NQQGAZBYSA-N,Clindamycin,,Prevention of Pneumocystis carinii pneumonia in AIDS patients.,C1535939,Pneumocystis carinii Pneumonia,10/28/88,Designated,Not FDA Approved for Orphan Indication,,,,
KDLRVYVGXIQJDK-PSUNAQLJSA-N,53245639,KDLRVYVGXIQJDK-PSUNAQLJSA-N,Clindamycin,,Prevention of Pneumocystis carinii pneumonia in AIDS patients.,C1535939,Pneumocystis carinii Pneumonia,10/28/88,Designated,Not FDA Approved for Orphan Indication,,,,
KDLRVYVGXIQJDK-NKPHASNASA-N,46783762,KDLRVYVGXIQJDK-NKPHASNASA-N,Clindamycin,,Prevention of Pneumocystis carinii pneumonia in AIDS patients.,C1535939,Pneumocystis carinii Pneumonia,10/28/88,Designated,Not FDA Approved for Orphan Indication,,,,
KDLRVYVGXIQJDK-ZNZDIMKLSA-N,27281318,KDLRVYVGXIQJDK-ZNZDIMKLSA-N,Clindamycin,,Prevention of Pneumocystis carinii pneumonia in AIDS patients.,C1535939,Pneumocystis carinii Pneumonia,10/28/88,Designated,Not FDA Approved for Orphan Indication,,,,
KDLRVYVGXIQJDK-ZUWRKQLMSA-N,45357041,KDLRVYVGXIQJDK-ZUWRKQLMSA-N,Clindamycin,,Prevention of Pneumocystis carinii pneumonia in AIDS patients.,C1535939,Pneumocystis carinii Pneumonia,10/28/88,Designated,Not FDA Approved for Orphan Indication,,,,
KDLRVYVGXIQJDK-UHFFFAOYSA-N,2786,KDLRVYVGXIQJDK-UHFFFAOYSA-N,Clindamycin,,Prevention of Pneumocystis carinii pneumonia in AIDS patients.,C1535939,Pneumocystis carinii Pneumonia,10/28/88,Designated,Not FDA Approved for Orphan Indication,,,,
KDLRVYVGXIQJDK-NOWPCOIGSA-N,29029,KDLRVYVGXIQJDK-NOWPCOIGSA-N,Clindamycin,,Prevention of Pneumocystis carinii pneumonia in AIDS patients.,C1535939,Pneumocystis carinii Pneumonia,10/28/88,Designated,Not FDA Approved for Orphan Indication,,,,
KDLRVYVGXIQJDK-AWPVFWJPSA-N,446598,KDLRVYVGXIQJDK-AWPVFWJPSA-N,Clindamycin,,Prevention of Pneumocystis carinii pneumonia in AIDS patients.,C1535939,Pneumocystis carinii Pneumonia,10/28/88,Designated,Not FDA Approved for Orphan Indication,,,,
ZCIGNRJZKPOIKD-CQXVEOKZSA-N,25151504,ZCIGNRJZKPOIKD-CQXVEOKZSA-N,cobicistat,Tybost,Treatment of human immunodeficiency virus type 1 (HIV-1) infection in pediatric patients,"C0009450,C0019704","Infection , Human immunodeficiency virus type 1",6/15/17,Designated/Approved,,TYBOST is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection in pediatric patients weighing at least 35 kg coadminstered with atazanavir or weighing at least 40 kg coadministered with darunavir., 10/03/2019 ,  ,
MTSXPVSZJVNPBE-OCOINPOZSA-M,16218873,MTSXPVSZJVNPBE-OCOINPOZSA-M,corifungin,,Treatment of visceral leishmaniasis,C0023290,Visceral leishmaniasis,7/6/11,Designated,Not FDA Approved for Orphan Indication,,,,
VLARUOGDXDTHEH-UHFFFAOYSA-L,27503,VLARUOGDXDTHEH-UHFFFAOYSA-L,Cromolyn sodium,Gastrocrom,Treatment of mastocytosis.,C0024899,Mastocytosis,3/8/84,Designated/Approved,,, 12/22/1989 , 12/22/1996 ,
PMATZTZNYRCHOR-RNWFWJGASA-N,138107778,PMATZTZNYRCHOR-RNWFWJGASA-N,Cyclosporine A,,Treatment of vernal keratoconjunctivitis,C0022577,Vernal keratoconjunctivitis,5/4/07,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-RYZPDLMBSA-N,123134270,PMATZTZNYRCHOR-RYZPDLMBSA-N,Cyclosporine A,,Treatment of vernal keratoconjunctivitis,C0022577,Vernal keratoconjunctivitis,5/4/07,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-NFOUMSERSA-N,16404350,PMATZTZNYRCHOR-NFOUMSERSA-N,Cyclosporine A,,Treatment of vernal keratoconjunctivitis,C0022577,Vernal keratoconjunctivitis,5/4/07,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-QVSDIVLPSA-N,5497195,PMATZTZNYRCHOR-QVSDIVLPSA-N,Cyclosporine A,,Treatment of vernal keratoconjunctivitis,C0022577,Vernal keratoconjunctivitis,5/4/07,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-UHFFFAOYSA-N,2909,PMATZTZNYRCHOR-UHFFFAOYSA-N,Cyclosporine A,,Treatment of vernal keratoconjunctivitis,C0022577,Vernal keratoconjunctivitis,5/4/07,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-NSJDOISKSA-N,71463825,PMATZTZNYRCHOR-NSJDOISKSA-N,Cyclosporine A,,Treatment of vernal keratoconjunctivitis,C0022577,Vernal keratoconjunctivitis,5/4/07,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-VPYFBNRVSA-N,49867938,PMATZTZNYRCHOR-VPYFBNRVSA-N,Cyclosporine A,,Treatment of vernal keratoconjunctivitis,C0022577,Vernal keratoconjunctivitis,5/4/07,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-IMVLJIQESA-N,5280754,PMATZTZNYRCHOR-IMVLJIQESA-N,Cyclosporine A,,Treatment of vernal keratoconjunctivitis,C0022577,Vernal keratoconjunctivitis,5/4/07,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-CGLBZJNRSA-N,5284373,PMATZTZNYRCHOR-CGLBZJNRSA-N,Cyclosporine A,,Treatment of vernal keratoconjunctivitis,C0022577,Vernal keratoconjunctivitis,5/4/07,Designated,Not FDA Approved for Orphan Indication,,,,
UFULAYFCSOUIOV-UHFFFAOYSA-N,6058,UFULAYFCSOUIOV-UHFFFAOYSA-N,Cysteamine,,Treatment of nephropathic cystinosis.,C0015624,Nephropathic cystinosis,5/1/86,Designated,Not FDA Approved for Orphan Indication,,,,
WQZGKKKJIJFFOK-QTVWNMPRSA-N,18950,WQZGKKKJIJFFOK-QTVWNMPRSA-N,D-mannose,,Treatment of Mannose Phosphate Isomerase Deficiency,"C1291601,C1417244","isomerase deficiency , mannose phosphate isomerase",1/14/19,Designated,Not FDA Approved for Orphan Indication,,,,
BFSMGDJOXZAERB-UHFFFAOYSA-N,44462760,BFSMGDJOXZAERB-UHFFFAOYSA-N,dabrafenib,,Treatment of patients with BRAF mutation positive non-small cell lung cancer,C3539721,Non-Small Cell Lung Cancer,10/20/14,Designated,Not FDA Approved for Orphan Indication,,,,
NUKYPUAOHBNCPY-UHFFFAOYSA-N,1727,NUKYPUAOHBNCPY-UHFFFAOYSA-N,dalfampridine,,Treatment of Transverse Myelitis,C0026976,Transverse myelitis,11/25/19,Designated,Not FDA Approved for Orphan Indication,,,,
KSRLIXGNPXAZHD-DFPPEFKWSA-N,136675526,KSRLIXGNPXAZHD-DFPPEFKWSA-N,Dantrolene sodium,,Treatment of the neuroleptic malignant syndrome.,C0027849,Neuroleptic Malignant Syndrome,12/14/87,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
KSRLIXGNPXAZHD-DFPPEFKWSA-N,136675526,KSRLIXGNPXAZHD-DFPPEFKWSA-N,Dantrolene sodium,,Treatment of the neuroleptic malignant syndrome.,C0027849,Neuroleptic Malignant Syndrome,12/14/87,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
KSRLIXGNPXAZHD-DFPPEFKWSA-M,71563341,KSRLIXGNPXAZHD-DFPPEFKWSA-M,Dantrolene sodium,,Treatment of the neuroleptic malignant syndrome.,C0027849,Neuroleptic Malignant Syndrome,12/14/87,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
OZOMQRBLCMDCEG-CHHVJCJISA-M,5353563,OZOMQRBLCMDCEG-CHHVJCJISA-M,Dantrolene sodium,,Treatment of the neuroleptic malignant syndrome.,C0027849,Neuroleptic Malignant Syndrome,12/14/87,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
OZOMQRBLCMDCEG-VIZOYTHASA-M,6604728,OZOMQRBLCMDCEG-VIZOYTHASA-M,Dantrolene sodium,,Treatment of the neuroleptic malignant syndrome.,C0027849,Neuroleptic Malignant Syndrome,12/14/87,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
KSRLIXGNPXAZHD-HAZZGOGXSA-N,23707296,KSRLIXGNPXAZHD-HAZZGOGXSA-N,Dantrolene sodium,,Treatment of the neuroleptic malignant syndrome.,C0027849,Neuroleptic Malignant Syndrome,12/14/87,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
BDZCLIOURDFSFQ-HAZZGOGXSA-N,16219293,BDZCLIOURDFSFQ-HAZZGOGXSA-N,Dantrolene sodium,,Treatment of the neuroleptic malignant syndrome.,C0027849,Neuroleptic Malignant Syndrome,12/14/87,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
LTWQNYPDAUSXBC-CDJGKPBYSA-L,9568637,LTWQNYPDAUSXBC-CDJGKPBYSA-L,Dantrolene sodium,,Treatment of the neuroleptic malignant syndrome.,C0027849,Neuroleptic Malignant Syndrome,12/14/87,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
KSRLIXGNPXAZHD-UHFFFAOYSA-M,32731,KSRLIXGNPXAZHD-UHFFFAOYSA-M,Dantrolene sodium,,Treatment of the neuroleptic malignant syndrome.,C0027849,Neuroleptic Malignant Syndrome,12/14/87,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
KSRLIXGNPXAZHD-HAZZGOGXSA-M,13271066,KSRLIXGNPXAZHD-HAZZGOGXSA-M,Dantrolene sodium,,Treatment of the neuroleptic malignant syndrome.,C0027849,Neuroleptic Malignant Syndrome,12/14/87,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
KSRLIXGNPXAZHD-DFPPEFKWSA-M,71563341,KSRLIXGNPXAZHD-DFPPEFKWSA-M,Dantrolene sodium,,Treatment of the neuroleptic malignant syndrome.,C0027849,Neuroleptic Malignant Syndrome,12/14/87,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
KSRLIXGNPXAZHD-HAZZGOGXSA-M,13271066,KSRLIXGNPXAZHD-HAZZGOGXSA-M,Dantrolene sodium,,Treatment of the neuroleptic malignant syndrome.,C0027849,Neuroleptic Malignant Syndrome,12/14/87,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ZBNZXTGUTAYRHI-UHFFFAOYSA-N,3062316,ZBNZXTGUTAYRHI-UHFFFAOYSA-N,dasatinib,Sprycel,Treatment of chronic myelogenous leukemia,C0023473,Chronic myelogenous leukemia,11/28/05,Designated/Approved,,Treatment of adults with chronic myeloid leukemia with resistance or intolerance to prior therapy including imatinib, 06/28/2006 , 06/28/2013 ,
DWLTUUXCVGVRAV-XWRHUKJGSA-N,9832404,DWLTUUXCVGVRAV-XWRHUKJGSA-N,davunetide,,Treatment of progressive supranuclear palsy.,C0038868,Progressive supranuclear palsy,12/7/09,Designated,Not FDA Approved for Orphan Indication,,,,
XAUDJQYHKZQPEU-KVQBGUIXSA-N,451668,XAUDJQYHKZQPEU-KVQBGUIXSA-N,decitabine,,Treatment of sickle cell anemia,C0002895,SICKLE CELL ANEMIA,9/9/02,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
BOFQWVMAQOTZIW-UHFFFAOYSA-N,214348,BOFQWVMAQOTZIW-UHFFFAOYSA-N,Deferasirox,Exjade; Jadenu Sprinkles,Treatment of chronic iron overload in patients with transfusion-dependent anemias,"C0002871,C0282193","Anemias , Iron Overload",11/21/02,Designated/Approved,,treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older, 05/18/2017 ,  ,
UREBDLICKHMUKA-CXSFZGCWSA-N,5743,UREBDLICKHMUKA-CXSFZGCWSA-N,dexamethasone,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,2/26/19,Designated,Not FDA Approved for Orphan Indication,,,,
FASDKYOPVNHBLU-SSDOTTSWSA-N,59868,FASDKYOPVNHBLU-SSDOTTSWSA-N,Dexpramipexole,,Treatment of hypereosinophilic syndrome (HES),"C0206141,C1540912","Hypereosinophilic syndrome , Hypereosinophilic syndrome",4/22/19,Designated,Not FDA Approved for Orphan Indication,,,,
BMKDZUISNHGIBY-ZETCQYMHSA-N,71384,BMKDZUISNHGIBY-ZETCQYMHSA-N,Dexrazoxane,Zinecard,For the prevention of cardiomyopathy associated with doxorubicin administration.,C0878544,Cardiomyopathy,12/17/91,Designated/Approved,,Cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative dose of 300mg/m2., 05/26/1995 , 05/26/2002 ,
TYNLGDBUJLVSMA-UHFFFAOYSA-N,26248,TYNLGDBUJLVSMA-UHFFFAOYSA-N,diacerein,,Treatment of epidermolysis bullosa,C0014527,Epidermolysis Bullosa,10/15/14,Designated,Not FDA Approved for Orphan Indication,,,,
WDJUZGPOPHTGOT-XUDUSOBPSA-N,441207,WDJUZGPOPHTGOT-XUDUSOBPSA-N,digitoxin,,Treatment of soft tissue sarcomas,C1261473,Soft Tissue Sarcomas,10/18/01,Designated,Not FDA Approved for Orphan Indication,,,,
PIQCTGMSNWUMAF-UHFFFAOYSA-N,135398510,PIQCTGMSNWUMAF-UHFFFAOYSA-N,dovitinib,,Treatment of adenoid cystic carcinoma,C0010606,Adenoid Cystic Carcinoma,9/26/13,Designated,Not FDA Approved for Orphan Indication,,,,
AOJJSUZBOXZQNB-TZSSRYMLSA-N,31703,AOJJSUZBOXZQNB-TZSSRYMLSA-N,doxorubicin,,Treatment of cutaneous T-cell lymphoma,C0079773,cutaneous T-cell lymphoma,4/6/15,Designated,Not FDA Approved for Orphan Indication,,,,
QXWYKJLNLSIPIN-JGVFFNPUSA-N,92974,QXWYKJLNLSIPIN-JGVFFNPUSA-N,droxidopa,NORTHERA,"Treatment of neurogenic symptomatic orthostatic hypotension in patients with primary autonomic failure, dopamine-beta-hydroxylase deficiency, and nondiabetic autonomic neuropathy.","C0020651,C0259749,C0393911,C1291314","ORTHOSTATIC HYPOTENSION , Autonomic neuropathy , Autonomic failure , hydroxylase deficiency",1/17/07,Designated/Approved,,"Treatment of orthostatic dizziness, lightheadedness, or the ""feeling that you are about to black out"" in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.", 02/18/2014 , 02/18/2021 ,"Treatment of orthostatic dizziness, lightheadedness, or the ""feeling that you are about to black out"" in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy."
VLCYCQAOQCDTCN-UHFFFAOYSA-N,3009,VLCYCQAOQCDTCN-UHFFFAOYSA-N,Eflornithine,,Treatment of anaplastic glioma,C4287997,Anaplastic Glioma,9/29/06,Designated,Not FDA Approved for Orphan Indication,,,,
SFVLTCAESLKEHH-WKAQUBQDSA-N,11764719,SFVLTCAESLKEHH-WKAQUBQDSA-N,elamipretide,,Treatment of primary mitochondrial myopathy,C0162670,MITOCHONDRIAL MYOPATHY,9/5/17,Designated,Not FDA Approved for Orphan Indication,,,,
JYSJVJJVLNYRKL-UHFFFAOYSA-N,53395169,JYSJVJJVLNYRKL-UHFFFAOYSA-N,Elcatonin,,Intrathecal treatment of intractable pain.,C0030200,intractable pain,9/25/95,Designated,Not FDA Approved for Orphan Indication,,,,
WJIGGYYSZBWCGC-MRXNPFEDSA-N,25221720,WJIGGYYSZBWCGC-MRXNPFEDSA-N,emixustat,,Treatment of Stargardt disease (STGD),"C1412063,C1855465","Stargardt disease , STGD",1/4/17,Designated,Not FDA Approved for Orphan Indication,,,,
ZMQMTKVVAMWKNY-YSXLEBCMSA-N,6918632,ZMQMTKVVAMWKNY-YSXLEBCMSA-N,emodepside,,"Treatment of onchocerhiasis (""river blindness"") caused by the filarial nematode onchocerca volvulus",C0029002,River Blindness,9/13/16,Designated,Not FDA Approved for Orphan Indication,,,,
XSMSNFMDVXXHGJ-UHFFFAOYSA-N,59473233,XSMSNFMDVXXHGJ-UHFFFAOYSA-N,entospletinib,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,4/14/14,Designated,Not FDA Approved for Orphan Indication,,,,
HAYYBYPASCDWEQ-UHFFFAOYSA-N,25141092,HAYYBYPASCDWEQ-UHFFFAOYSA-N,entrectinib,,Treatment of neuroblastoma,C0027819,Neuroblastoma,12/22/14,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
YZSIZVRFVQKMJU-RDGPPVDQSA-N,135565889,YZSIZVRFVQKMJU-RDGPPVDQSA-N,etarfolatide,,For the identification of ovarian carcinomas,C1140680,ovarian carcinomas,2/16/00,Designated,Not FDA Approved for Orphan Indication,,,,
JKOQGQFVAUAYPM-UHFFFAOYSA-N,2141,JKOQGQFVAUAYPM-UHFFFAOYSA-N,Ethiofos,,Use as a chemoprotective agent for cisplatin and cyclophosphamide in the treatment of ovarian cancer.,C4721610,Ovarian Cancer,8/1/89,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
RAJWOBJTTGJROA-QJISAEMRSA-N,440114,RAJWOBJTTGJROA-QJISAEMRSA-N,Etiocholanedione,,Treatment of Prader-Willi syndrome.,C0032897,Prader-Willi Syndrome,5/7/96,Designated,Not FDA Approved for Orphan Indication,,,,
HKVAMNSJSFKALM-GKUWKFKPSA-N,6442177,HKVAMNSJSFKALM-GKUWKFKPSA-N,everolimus,Afinitor,"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)","C0041341,C0205768,C0206633,C0751674,C1832033,C2247022","Tuberous Sclerosis Complex , Subependymal Giant Cell Astrocytoma , Angiomyolipoma , Lymphangioleiomyomatosis , Subependymal Giant Cell Astrocytoma , tuberous sclerosis complex",6/8/09,Designated/Approved,,Treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis who require therapeutic intervention but are not candidates for curative surgical resection, 10/29/2010 , 10/29/2017 ,
HKVAMNSJSFKALM-GKUWKFKPSA-N,6442177,HKVAMNSJSFKALM-GKUWKFKPSA-N,everolimus,,Treatment of gastric cancer,C0024623,Gastric Cancer,5/24/11,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
NGOGFTYYXHNFQH-UHFFFAOYSA-N,3547,NGOGFTYYXHNFQH-UHFFFAOYSA-N,fasudil,,Treatment of subarachnoid hemorrhage,C0038525,Subarachnoid Hemorrhage,9/5/19,Designated,Not FDA Approved for Orphan Indication,,,,
NGOGFTYYXHNFQH-UHFFFAOYSA-N,3547,NGOGFTYYXHNFQH-UHFFFAOYSA-N,Fasudil,,Treatment of Amyotrophic Lateral Sclerosis,C0002736,Amyotrophic Lateral Sclerosis,1/15/20,Designated,Not FDA Approved for Orphan Indication,,,,
AKJHMTWEGVYYSE-FXILSDISSA-N,5288209,AKJHMTWEGVYYSE-FXILSDISSA-N,fenretinide,,Treatment of peripheral T-cell lymphoma (including follicular T-cell lymphoma),"C0079774,C2700204","Peripheral T-Cell Lymphoma , Follicular T-cell lymphoma",12/22/17,Designated,Not FDA Approved for Orphan Indication,,,,
AINQERPKMNDVQT-UHFFFAOYSA-N,135565128,AINQERPKMNDVQT-UHFFFAOYSA-N,fimaporfin,,Treatment of cholangiocarcinoma,C0206698,Cholangiocarcinoma,9/27/17,Designated,Not FDA Approved for Orphan Indication,,,,
MKDNDKMECWBLOF-WDSKDSINSA-N,44473414,MKDNDKMECWBLOF-WDSKDSINSA-N,florilglutamic acid,,Diagnostic for the management of glioma,C0017638,Glioma,5/11/16,Designated,Not FDA Approved for Orphan Indication,,,,
CPEUVMUXAHMANV-UHFFFAOYSA-N,35802,CPEUVMUXAHMANV-UHFFFAOYSA-N,flubendazole,,Treatment of onchocerciasis caused by Onchocerca volvulus,C0029001,Onchocerciasis,10/25/13,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
SMANXXCATUTDDT-QPJJXVBHSA-N,941361,SMANXXCATUTDDT-QPJJXVBHSA-N,flunarizine,,Treatment of Alternating Hemiplegia,C0338488,Alternating hemiplegia,11/20/18,Designated,Not FDA Approved for Orphan Indication,,,,
UUOUOERPONYGOS-CLCRDYEYSA-N,91488,UUOUOERPONYGOS-CLCRDYEYSA-N,Fluocinolone,Retisert,Treatment uveitis involving the posterior segment of the eye.,C0042164,Uveitis,7/31/00,Designated/Approved,,Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, 04/08/2005 , 04/08/2012 ,
LRNSXWGEKABTMP-XWLNNSFXSA-N,10307231,LRNSXWGEKABTMP-XWLNNSFXSA-N,Folate Binding Protein Peptide: Glu-Ile-Trp-Thr-Phe-Ser-Thr-Lys-Val,,Treatment (including prevention of recurrence) of ovarian cancer,C4721610,Ovarian Cancer,6/8/16,Designated,Not FDA Approved for Orphan Indication,,,,
FIDMEHCRMLKKPZ-YSMBQZINSA-N,10186184,FIDMEHCRMLKKPZ-YSMBQZINSA-N,fosbretabulin tromethamine,,Treatment of neuroendocrine tumors,C0206754,Neuroendocrine Tumors,12/29/15,Designated,Not FDA Approved for Orphan Indication,,,,
XWLUWCNOOVRFPX-UHFFFAOYSA-N,56339,XWLUWCNOOVRFPX-UHFFFAOYSA-N,Fosphenytoin,Cerebyx,For the acute treatment of patients with status epilepticus of the grand mal type.,"C0014549,C0038220","Grand mal , Status Epilepticus",6/4/91,Designated/Approved,,For the control of generalized convulsive status epilepticus., 08/05/1996 , 08/05/2003 ,
ZQGJCHHKJNSPMS-UHFFFAOYSA-L,24828759,ZQGJCHHKJNSPMS-UHFFFAOYSA-L,fostamatinib disodium hexahydrate,,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,8/25/15,Designated/Approved,,TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment., 04/17/2018 , 04/17/2025 ,TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
PGTVWKLGGCQMBR-FLBATMFCSA-N,6918305,PGTVWKLGGCQMBR-FLBATMFCSA-N,Ganaxolone,,Treatment of infantile spasms.,C3887898,Infantile spasms,5/25/94,Designated,Not FDA Approved for Orphan Indication,,,,
JJICLMJFIKGAAU-UHFFFAOYSA-M,23700083,JJICLMJFIKGAAU-UHFFFAOYSA-M,Ganciclovir sodium,Cytovene,Treatment of cytomegalovirus retinitis in immunocompromised patients with AIDS.,"C0001175,C0206178","AIDS , Cytomegalovirus Retinitis",10/31/85,Designated/Approved/Withdrawn,,, 06/23/1989 , 06/23/1996 ,
IRSCQMHQWWYFCW-UHFFFAOYSA-N,135398740,IRSCQMHQWWYFCW-UHFFFAOYSA-N,Gancyclovir,,Treatment of severe human cytomegalovirus infections in specific immunosuppressed patient populations.,C0010823,Cytomegalovirus Infections,6/7/85,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
HUCXKZBETONXFO-NJFMWZAGSA-N,5282199,HUCXKZBETONXFO-NJFMWZAGSA-N,geranylgeranylacetone,,Prevention of Acute Radiation Syndrome,C0520799,Acute Radiation Syndrome,6/10/20,Designated,Not FDA Approved for Orphan Indication,,,,
FHEAIOHRHQGZPC-KIWGSFCNSA-N,3081884,FHEAIOHRHQGZPC-KIWGSFCNSA-N,glatiramer acetate,Copaxone,Treatment of multiple sclerosis,C0026769,Multiple Sclerosis,11/9/87,Designated/Approved,,For reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis., 12/20/1996 , 12/20/2003 ,
ZVVGTYQPRVEJOH-GGZXVAPBSA-N,85471918,ZVVGTYQPRVEJOH-GGZXVAPBSA-N,glecaprevir and pibrentasvir,MAVYRET,Treatment of pediatric patients with chronic hepatitis C virus infection,"C0019196,C0524910","Hepatitis C Virus Infection , chronic hepatitis c",1/9/17,Designated/Approved,,"MAVYRET is indicated for the treatment of adult and pediatric patients 12 years and older or weighing at least 45 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is also indicated for the treatment of adult and pediatric patients 12 years and older or weighing at least 45 kg with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/", 04/30/2019 , 04/30/2026 ,"For the treatment of pediatric patients 12 years and older or weighing at least 45 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A), and also for the treatment of pediatric patients 12 years and older or weighing at least 45 kg with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both."
NGCGMRBZPXEPOZ-HBBGHHHDSA-N,11980076,NGCGMRBZPXEPOZ-HBBGHHHDSA-N,Gonadorelin acetate,Lutrepulse,For induction of ovulation in women with hypothalamic amenorrhea due to a deficiency or absence in the quantity or pulse pattern of endogenous GnRH secretion.,"C0341862,C1689985","Hypothalamic amenorrhea , Absence",4/22/87,Designated/Approved,,, 10/10/1989 , 10/10/1996 ,
NTYJJOPFIAHURM-UHFFFAOYSA-N,774,NTYJJOPFIAHURM-UHFFFAOYSA-N,Histamine,,For use as an adjunct to cytokine therapy in the treatment of malignant melanoma.,C0025202,Malignant Melanoma,2/1/00,Designated,Not FDA Approved for Orphan Indication,,,,
HHXHVIJIIXKSOE-QILQGKCVSA-N,25077993,HHXHVIJIIXKSOE-QILQGKCVSA-N,Histrelin,,"Treatment of acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria.","C0162532,C0162565,C0342856","Variegate Porphyria , Acute intermittent porphyria , Coproporphyria",5/3/91,Designated,Not FDA Approved for Orphan Indication,,,,
BVOZFCOTOYGLGD-VPQOAABJSA-N,24847767,BVOZFCOTOYGLGD-VPQOAABJSA-N,hyaluronic acid,,Treatment of emphysema in patients due to alpha-1 antitrypsin deficiency,"C0034067,C0221757","Emphysema , ALPHA-1 ANTITRYPSIN DEFICIENCY",3/19/02,Designated,Not FDA Approved for Orphan Indication,,,,
DOMWKUIIPQCAJU-LJHIYBGHSA-N,169870,DOMWKUIIPQCAJU-LJHIYBGHSA-N,hydroxyprogesterone caproate,Makena,Prevention of preterm birth in singleton pregnancies,C0151526,Preterm Birth,1/25/07,Designated/Approved,,Makena auto-injector for subcutaneous injection is indicated to reduce the risk of preterm birth in women with singleton pregnancy who have a history of singleton spontaneous preterm birth., 02/14/2018 ,  ,
XYFPWWZEPKGCCK-GOSISDBHSA-N,24821094,XYFPWWZEPKGCCK-GOSISDBHSA-N,ibrutinib,Imbruvica,Treatment of splenic marginal zone lymphoma,C0349632,Splenic marginal zone lymphoma,2/5/15,Designated/Approved,,Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy., 01/18/2017 , 01/18/2024 ,Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.
XYFPWWZEPKGCCK-GOSISDBHSA-N,24821094,XYFPWWZEPKGCCK-GOSISDBHSA-N,ibrutinib,IMBRUVICA,Treatment of small lymphocytic lymphoma,C0023434,Small Lymphocytic Lymphoma,5/30/13,Designated/Approved,,Indicated for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and indicated for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) with 17p deletion., 05/06/2016 , 05/06/2023 ,For treatment of patients with small lymphocytic lymphoma (SLL)
XYFPWWZEPKGCCK-GOSISDBHSA-N,24821094,XYFPWWZEPKGCCK-GOSISDBHSA-N,ibrutinib,Imbruvica,Treatment of Waldenstrom's macroglobulinemia,C0024419,Waldenstrom's Macroglobulinemia,10/15/13,Designated/Approved,,Treatment of patients with Waldenstrom's macroglobulinemia, 01/29/2015 , 01/29/2022 ,Treatment of patients with Waldenstrom's macroglobulinemia
HWJPWWYTGBZDEG-UHFFFAOYSA-N,213043,HWJPWWYTGBZDEG-UHFFFAOYSA-N,iclaprim,,Treatment of Staphylococus aureus lung infections in patients with cystic fibrosis,C0010674,Cystic Fibrosis,9/14/17,Designated,Not FDA Approved for Orphan Indication,,,,
IFSDAJWBUCMOAH-HNNXBMFYSA-N,11625818,IFSDAJWBUCMOAH-HNNXBMFYSA-N,idelalisib,Zydelig,Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma,"C0023434,C0855095","Chronic Lymphocytic Leukemia , Small Lymphocytic Lymphoma",10/15/13,Designated/Approved,,"Zydelig is indicated, in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities; and Zydelig is indicated for the treatment of patients with relapsed small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies.", 07/23/2014 , 07/23/2021 ,"(1) Relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities; and (2) Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies."
IFSDAJWBUCMOAH-HNNXBMFYSA-N,11625818,IFSDAJWBUCMOAH-HNNXBMFYSA-N,idelalisib,Zydelig,Treatment of follicular lymphoma,C0024301,follicular lymphoma,9/26/13,Designated/Approved,,Zydelig is indicated for the treatment of patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) who have received at least two prior systemic therapies., 07/23/2014 , 07/23/2021 ,Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies.
IFSDAJWBUCMOAH-HNNXBMFYSA-N,11625818,IFSDAJWBUCMOAH-HNNXBMFYSA-N,idelalisib,,Treatment of extranodal marginal zone lymphoma,C1367654,Marginal zone lymphoma,10/15/13,Designated,Not FDA Approved for Orphan Indication,,,,
YLMAHDNUQAMNNX-UHFFFAOYSA-N,123596,YLMAHDNUQAMNNX-UHFFFAOYSA-N,imatinib mesylate,Gleevec,Treatment of gastrointestinal stromal tumors,C0238198,Gastrointestinal Stromal Tumors,11/1/01,Designated/Approved,,Adjuvant treatment of adult patients following complete resection Kit (CD 117) positive gastrointestinal stromal tumors (GIST)., 12/19/2008 , 12/19/2015 ,
XNACDNPGABUBFR-FKNPGSCZSA-N,56840904,XNACDNPGABUBFR-FKNPGSCZSA-N,Iobenguane Sulfate I-123,,"For scintigraphic detection, localization and staging of neuroblastoma.",C0027819,Neuroblastoma,10/17/05,Designated,Not FDA Approved for Orphan Indication,,,,
ACRHBAYQBXXRTO-OAQYLSRUSA-N,132999,ACRHBAYQBXXRTO-OAQYLSRUSA-N,ivabradine,CORLANOR,Treatment of pediatric patients (0 through 16 years of age) with dilated cardiomyopathy.,C0007193,Dilated cardiomyopathy,3/23/16,Designated/Approved,,"Corlanor is indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate.", 04/22/2019 , 04/22/2026 ,"Corlanor is indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate."
PURKAOJPTOLRMP-UHFFFAOYSA-N,16220172,PURKAOJPTOLRMP-UHFFFAOYSA-N,ivacaftor,Kalydeco,Treatment of patients with cystic fibrosis,C0010674,Cystic Fibrosis,12/20/06,Designated/Approved,,"Treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R.", 02/21/2014 , 02/21/2021 ,"Treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the CFTR gene: G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R."
YQEZLKZALYSWHR-UHFFFAOYSA-N,3821,YQEZLKZALYSWHR-UHFFFAOYSA-N,ketamine,,Treatment of Complex Regional Pain Syndrome,C0458219,Complex regional pain syndrome,2/1/19,Designated,Not FDA Approved for Orphan Indication,,,,
XUJNEKJLAYXESH-REOHCLBHSA-N,5862,XUJNEKJLAYXESH-REOHCLBHSA-N,L-cysteine,,For the prevention and lessening of photosensitivity in erythropoietic protoporphyria.,"C0162568,C0349506","Erythropoietic Protoporphyria , Photosensitivity",5/16/94,Designated,Not FDA Approved for Orphan Indication,,,,
GOTYRUGSSMKFNF-UHFFFAOYSA-N,216326,GOTYRUGSSMKFNF-UHFFFAOYSA-N,lenalidomide,Revlimid,Treatment of follicular lymphoma,C0024301,follicular lymphoma,9/17/13,Designated/Approved,,"REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated follicular lymphoma (FL).", 05/28/2019 , 05/28/2026 ,In combination with a rituximab product for the treatment of adult patients with previously treated follicular lymphoma (FL).
GOTYRUGSSMKFNF-UHFFFAOYSA-N,216326,GOTYRUGSSMKFNF-UHFFFAOYSA-N,lenalidomide,Revlimid,Treatment of mantle cell lymphoma,C4721414,Mantle cell lymphoma,4/27/09,Designated/Approved,,"Treatment of mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.", 06/05/2013 , 06/05/2020 ,"Treatment of mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib."
MWKYMZXCGYXLPL-ZDUSSCGKSA-N,57495353,MWKYMZXCGYXLPL-ZDUSSCGKSA-N,leniolisib,,"Treatment of activated P13Kdelta Syndrome/p110delta-activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency","C0021051,C0497156","Immunodeficiency , Lymphadenopathy",1/30/18,Designated,Not FDA Approved for Orphan Indication,,,,
VVIAGPKUTFNRDU-ABLWVSNPSA-N,135403648,VVIAGPKUTFNRDU-ABLWVSNPSA-N,Leucovorin,Leucovorin calcium,For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.,C4721579,Metastatic colorectal cancer,12/8/86,Designated/Approved,,For use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer., 12/12/1991 , 12/12/1998 ,
RGLRXNKKBLIBQS-XNHQSDQCSA-N,657180,RGLRXNKKBLIBQS-XNHQSDQCSA-N,Leuprolide acetate,Lupron Injection,Treatment of central precocious puberty,C0342543,Central Precocious Puberty,7/25/88,Designated/Approved,,Treatment of children with central precocious puberty, 04/16/1993 , 04/16/2000 ,
HPHUVLMMVZITSG-LURJTMIESA-N,5284583,HPHUVLMMVZITSG-LURJTMIESA-N,levetiracetam,,Treatment of neonatal seizures,C0159020,Neonatal seizures,4/30/10,Designated,Not FDA Approved for Orphan Indication,,,,
WHXMKTBCFHIYNQ-SECBINFHSA-N,3033825,WHXMKTBCFHIYNQ-SECBINFHSA-N,levosimendan,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,4/10/17,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
MBBCVAKAJPKAKM-UHFFFAOYSA-N,9853053,MBBCVAKAJPKAKM-UHFFFAOYSA-N,lomitapide,Juxtapid,Treatment of homozygous familial hypercholesterolemia,C0020445,FAMILIAL HYPERCHOLESTEROLEMIA,10/23/07,Designated/Approved,,"Adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).", 12/21/2012 , 12/21/2019 ,
DHMTURDWPRKSOA-RUZDIDTESA-N,148195,DHMTURDWPRKSOA-RUZDIDTESA-N,lonafarnib,,Treatment of Hepatitis Delta Virus (HDV)infection,"C0009450,C0011220","Infection , Hepatitis Delta Virus",11/19/13,Designated,Not FDA Approved for Orphan Indication,,,,
XTTZERNUQAFMOF-QMMMGPOBSA-N,11658860,XTTZERNUQAFMOF-QMMMGPOBSA-N,Lorcaserin,,Treatment of Dravet syndrome,C0751122,Dravet Syndrome,8/31/20,Designated,Not FDA Approved for Orphan Indication,,,,
PSIFNNKUMBGKDQ-UHFFFAOYSA-N,3961,PSIFNNKUMBGKDQ-UHFFFAOYSA-N,losartan,,Treatment of Marfan Syndrome,C0024796,Marfan Syndrome,12/12/11,Designated,Not FDA Approved for Orphan Indication,,,,
YDDMIZRDDREKEP-HWTBNCOESA-N,57327016,YDDMIZRDDREKEP-HWTBNCOESA-N,lurbinectedin,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,8/20/12,Designated,Not FDA Approved for Orphan Indication,,,,
MXDPZUIOZWKRAA-PRDSJKGBSA-K,132274234,MXDPZUIOZWKRAA-PRDSJKGBSA-K,lutetium Lu 177 dotatate,,Treatment of gastro-entero-pancreatic neuroendocrine tumors,C0206754,Neuroendocrine Tumors,1/12/09,Designated/Approved,,"Treatment of somatostatin receptor positive GEP-NETs including foregut, midgut, and hindgut neuroendocrine tumors in adults", 01/26/2018 , 01/26/2025 ,"Treatment of somatostatin receptor positive GEP-NETs including foregut, midgut, and hindgut neuroendocrine tumors in adults"
MXDPZUIOZWKRAA-PRDSJKGBSA-K,132274234,MXDPZUIOZWKRAA-PRDSJKGBSA-K,lutetium Lu 177 dotatate,,Treatment of gastro-entero-pancreatic neuroendocrine tumors,C0206754,Neuroendocrine Tumors,1/12/09,Designated/Approved,,"Treatment of somatostatin receptor positive GEP-NETs including foregut, midgut, and hindgut neuroendocrine tumors in adults", 01/26/2018 , 01/26/2025 ,"Treatment of somatostatin receptor positive GEP-NETs including foregut, midgut, and hindgut neuroendocrine tumors in adults"
WVDSKQXKCDZXLH-OHIDFYLOSA-N,71526737,WVDSKQXKCDZXLH-OHIDFYLOSA-N,macimorelin acetate,Macrelin,Diagnosis of growth hormone deficiency,C3714796,Growth hormone deficiency,5/14/07,Designated/Approved,,For the diagnosis of adult growth hormone deficiency, 12/20/2017 , 12/20/2024 ,For the diagnosis of adult growth hormone deficiency.
FBPFZTCFMRRESA-KVTDHHQDSA-N,6251,FBPFZTCFMRRESA-KVTDHHQDSA-N,MANNITOL,Bronchitol,For use to facilitate clearance of mucus in patients with bronchiectasis and in patients with cystic fibrosis at risk for bronchiectasis,"C0006267,C0010674","Bronchiectasis , Cystic Fibrosis",2/11/05,Designated/Approved,,as add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis. Use Bronchitol only for adults who have passed the Bronchitol Tolerance Test., 10/30/2020 , 10/30/2027 ,as add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis and who have passed the Bronchitol Tolerance Test
DRLFMBDRBRZALE-UHFFFAOYSA-N,896,DRLFMBDRBRZALE-UHFFFAOYSA-N,Melatonin,,Treatment of non-24-hour sleep-wake disorder in blind individuals without light perception,"C0456909,C0851578","Blind , Sleep-wake disorder",7/9/04,Designated,Not FDA Approved for Orphan Indication,,,,
DRLFMBDRBRZALE-UHFFFAOYSA-N,896,DRLFMBDRBRZALE-UHFFFAOYSA-N,Melatonin,,Treatment of circadian rhythm sleep disorders in blind people with no light perception.,"C0456909,C0877792","Blind , Circadian rhythm sleep disorders",11/15/93,Designated,Not FDA Approved for Orphan Indication,,,,
FBOZXECLQNJBKD-ZDUSSCGKSA-N,126941,FBOZXECLQNJBKD-ZDUSSCGKSA-N,methotrexate,,Treatment of ectopic pregnancy,C0032987,Ectopic Pregnancy,3/25/19,Designated,Not FDA Approved for Orphan Indication,,,,
QXKHYNVANLEOEG-UHFFFAOYSA-N,4114,QXKHYNVANLEOEG-UHFFFAOYSA-N,methoxsalen,,For the prevention of acute rejection of cardiac allografts,C3273245,Acute Rejection,5/12/94,Designated,Not FDA Approved for Orphan Indication,,,,
XDZAHHULFQIBFE-UHFFFAOYSA-N,24875489,XDZAHHULFQIBFE-UHFFFAOYSA-N,methylparaben suberohydroxamic acid phenyl ester,,Treatment of cutaneous T-cell lymphoma,C0079773,cutaneous T-cell lymphoma,4/15/13,Designated,Not FDA Approved for Orphan Indication,,,,
VAOCPAMSLUNLGC-UHFFFAOYSA-N,4173,VAOCPAMSLUNLGC-UHFFFAOYSA-N,metronidazole,,Treatment of pouchitis,C0376620,Pouchitis,4/26/11,Designated,Not FDA Approved for Orphan Indication,,,,
VLPIATFUUWWMKC-UHFFFAOYSA-N,4178,VLPIATFUUWWMKC-UHFFFAOYSA-N,mexiletine,,Treatment of myotonic disorders,C0553604,Myotonic Disorders,3/16/20,Designated,Not FDA Approved for Orphan Indication,,,,
BYBLEWFAAKGYCD-UHFFFAOYSA-N,4189,BYBLEWFAAKGYCD-UHFFFAOYSA-N,miconazole,,Treatment of fungal otitis externa (otomycosis),C0029895,Fungal otitis externa,5/22/14,Designated,Not FDA Approved for Orphan Indication,,,,
VKHAHZOOUSRJNA-GCNJZUOMSA-N,55245,VKHAHZOOUSRJNA-GCNJZUOMSA-N,mifepristone,,Treatment of ovarian cancer.,C4721610,Ovarian Cancer,1/14/16,Designated,Not FDA Approved for Orphan Indication,,,,
UQRORFVVSGFNRO-UTINFBMNSA-N,51634,UQRORFVVSGFNRO-UTINFBMNSA-N,Miglustat,,Treatment of Niemann-Pick Disease Type C,C0220756,niemann-pick disease type c,2/2/21,Designated,Not FDA Approved for Orphan Indication,,,,
PQLXHQMOHUQAKB-UHFFFAOYSA-N,3599,PQLXHQMOHUQAKB-UHFFFAOYSA-N,miltefosine,,Treatment of schistosomiasis,C0036323,Schistosomiasis,8/2/17,Designated,Not FDA Approved for Orphan Indication,,,,
WTJXVDPDEQKTCV-VQAITOIOSA-N,54685925,WTJXVDPDEQKTCV-VQAITOIOSA-N,Minocycline hydrochloride,,Treatment of sarcoidosis,C0036202,Sarcoidosis,3/28/06,Designated,Not FDA Approved for Orphan Indication,,,,
WOFMFGQZHJDGCX-ZULDAHANSA-N,441336,WOFMFGQZHJDGCX-ZULDAHANSA-N,mometasone furoate,,Treatment of eosinophilic esophagitis,C0341106,Eosinophilic esophagitis,6/26/19,Designated,Not FDA Approved for Orphan Indication,,,,
ARIWANIATODDMH-UHFFFAOYSA-N,14871,ARIWANIATODDMH-UHFFFAOYSA-N,Monolaurin,,Treatment of congenital primary ichthyosis.,C0020757,Ichthyosis,4/29/93,Designated,Not FDA Approved for Orphan Indication,,,,
WXNXCEHXYPACJF-UHFFFAOYSA-N,1995,WXNXCEHXYPACJF-UHFFFAOYSA-N,N-acetyl-DL-leucine,,Treatment of GM2 Gangliosidosis,C0268274,GM2 Gangliosidosis,3/26/18,Designated,Not FDA Approved for Orphan Indication,,,,
BLXXJMDCKKHMKV-UHFFFAOYSA-N,4409,BLXXJMDCKKHMKV-UHFFFAOYSA-N,nabumetone,,Treatment of pediatric juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,5/5/08,Designated,Not FDA Approved for Orphan Indication,,,,
DQCKKXVULJGBQN-XFWGSAIBSA-N,5360515,DQCKKXVULJGBQN-XFWGSAIBSA-N,naltrexone,,Treatment of Crohn's disease in pediatric patients,C0010346,Crohn's Disease,1/19/10,Designated,Not FDA Approved for Orphan Indication,,,,
PBZBXDCHQQCLGL-UHFFFAOYSA-M,138402875,PBZBXDCHQQCLGL-UHFFFAOYSA-M,Nedaplatin,,Treatment of Small Cell Lung Cancer,C3540630,Small Cell Lung Cancer,8/5/20,Designated,Not FDA Approved for Orphan Indication,,,,
KLNFSAOEKUDMFA-UHFFFAOYSA-M,154731013,KLNFSAOEKUDMFA-UHFFFAOYSA-M,Nedaplatin,,Treatment of Small Cell Lung Cancer,C3540630,Small Cell Lung Cancer,8/5/20,Designated,Not FDA Approved for Orphan Indication,,,,
RPPDZANZFFUGHG-UHFFFAOYSA-N,46738098,RPPDZANZFFUGHG-UHFFFAOYSA-N,Nedaplatin,,Treatment of Small Cell Lung Cancer,C3540630,Small Cell Lung Cancer,8/5/20,Designated,Not FDA Approved for Orphan Indication,,,,
ZAXCMPAWRCMABN-UHFFFAOYSA-N,25199925,ZAXCMPAWRCMABN-UHFFFAOYSA-N,Nedaplatin,,Treatment of Small Cell Lung Cancer,C3540630,Small Cell Lung Cancer,8/5/20,Designated,Not FDA Approved for Orphan Indication,,,,
GRHLMSBCOPRFNA-UHFFFAOYSA-M,131842090,GRHLMSBCOPRFNA-UHFFFAOYSA-M,Nedaplatin,,Treatment of Small Cell Lung Cancer,C3540630,Small Cell Lung Cancer,8/5/20,Designated,Not FDA Approved for Orphan Indication,,,,
NOSYGQGJJZNNMA-UHFFFAOYSA-N,9548889,NOSYGQGJJZNNMA-UHFFFAOYSA-N,Nedaplatin,,Treatment of Small Cell Lung Cancer,C3540630,Small Cell Lung Cancer,8/5/20,Designated,Not FDA Approved for Orphan Indication,,,,
KLNFSAOEKUDMFA-UHFFFAOYSA-N,24200453,KLNFSAOEKUDMFA-UHFFFAOYSA-N,Nedaplatin,,Treatment of Small Cell Lung Cancer,C3540630,Small Cell Lung Cancer,8/5/20,Designated,Not FDA Approved for Orphan Indication,,,,
GYAVMUDJCHAASE-UHFFFAOYSA-M,9796440,GYAVMUDJCHAASE-UHFFFAOYSA-M,Nedaplatin,,Treatment of Small Cell Lung Cancer,C3540630,Small Cell Lung Cancer,8/5/20,Designated,Not FDA Approved for Orphan Indication,,,,
KLNFSAOEKUDMFA-UHFFFAOYSA-N,24200453,KLNFSAOEKUDMFA-UHFFFAOYSA-N,Nedaplatin,,Treatment of Small Cell Lung Cancer,C3540630,Small Cell Lung Cancer,8/5/20,Designated,Not FDA Approved for Orphan Indication,,,,
ZAXCMPAWRCMABN-UHFFFAOYSA-N,25199925,ZAXCMPAWRCMABN-UHFFFAOYSA-N,Nedaplatin,,Treatment of Small Cell Lung Cancer,C3540630,Small Cell Lung Cancer,8/5/20,Designated,Not FDA Approved for Orphan Indication,,,,
PBZBXDCHQQCLGL-UHFFFAOYSA-M,138402875,PBZBXDCHQQCLGL-UHFFFAOYSA-M,nedaplatin,,Treatment of esophageal cancer,C0014859,esophageal cancer,8/31/20,Designated,Not FDA Approved for Orphan Indication,,,,
KLNFSAOEKUDMFA-UHFFFAOYSA-M,154731013,KLNFSAOEKUDMFA-UHFFFAOYSA-M,nedaplatin,,Treatment of esophageal cancer,C0014859,esophageal cancer,8/31/20,Designated,Not FDA Approved for Orphan Indication,,,,
RPPDZANZFFUGHG-UHFFFAOYSA-N,46738098,RPPDZANZFFUGHG-UHFFFAOYSA-N,nedaplatin,,Treatment of esophageal cancer,C0014859,esophageal cancer,8/31/20,Designated,Not FDA Approved for Orphan Indication,,,,
ZAXCMPAWRCMABN-UHFFFAOYSA-N,25199925,ZAXCMPAWRCMABN-UHFFFAOYSA-N,nedaplatin,,Treatment of esophageal cancer,C0014859,esophageal cancer,8/31/20,Designated,Not FDA Approved for Orphan Indication,,,,
GRHLMSBCOPRFNA-UHFFFAOYSA-M,131842090,GRHLMSBCOPRFNA-UHFFFAOYSA-M,nedaplatin,,Treatment of esophageal cancer,C0014859,esophageal cancer,8/31/20,Designated,Not FDA Approved for Orphan Indication,,,,
NOSYGQGJJZNNMA-UHFFFAOYSA-N,9548889,NOSYGQGJJZNNMA-UHFFFAOYSA-N,nedaplatin,,Treatment of esophageal cancer,C0014859,esophageal cancer,8/31/20,Designated,Not FDA Approved for Orphan Indication,,,,
KLNFSAOEKUDMFA-UHFFFAOYSA-N,24200453,KLNFSAOEKUDMFA-UHFFFAOYSA-N,nedaplatin,,Treatment of esophageal cancer,C0014859,esophageal cancer,8/31/20,Designated,Not FDA Approved for Orphan Indication,,,,
GYAVMUDJCHAASE-UHFFFAOYSA-M,9796440,GYAVMUDJCHAASE-UHFFFAOYSA-M,nedaplatin,,Treatment of esophageal cancer,C0014859,esophageal cancer,8/31/20,Designated,Not FDA Approved for Orphan Indication,,,,
KLNFSAOEKUDMFA-UHFFFAOYSA-N,24200453,KLNFSAOEKUDMFA-UHFFFAOYSA-N,nedaplatin,,Treatment of esophageal cancer,C0014859,esophageal cancer,8/31/20,Designated,Not FDA Approved for Orphan Indication,,,,
ZAXCMPAWRCMABN-UHFFFAOYSA-N,25199925,ZAXCMPAWRCMABN-UHFFFAOYSA-N,nedaplatin,,Treatment of esophageal cancer,C0014859,esophageal cancer,8/31/20,Designated,Not FDA Approved for Orphan Indication,,,,
JWNPDZNEKVCWMY-VQHVLOKHSA-N,9915743,JWNPDZNEKVCWMY-VQHVLOKHSA-N,neratinib,,Treatment of breast cancer patients with brain metastases,"C0220650,C0678222","brain metastases , Breast cancer",8/26/19,Designated,Not FDA Approved for Orphan Indication,,,,
ARFHIAQFJWUCFH-IZZDOVSWSA-N,6842999,ARFHIAQFJWUCFH-IZZDOVSWSA-N,nifurtimox,,Treatment of Chagas disease,C0041234,Chagas Disease,12/31/13,Designated,Not FDA Approved for Orphan Indication,,,,
HHZIURLSWUIHRB-UHFFFAOYSA-N,644241,HHZIURLSWUIHRB-UHFFFAOYSA-N,nilotinib,,Treatment of gastrointestinal stromal tumors.,C0238198,Gastrointestinal Stromal Tumors,3/20/07,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
MWUXSHHQAYIFBG-UHFFFAOYSA-N,145068,MWUXSHHQAYIFBG-UHFFFAOYSA-N,nitric oxide,,Treatment of cystic fibrosis,C0010674,Cystic Fibrosis,9/23/14,Designated,Not FDA Approved for Orphan Indication,,,,
XHWRWCSCBDLOLM-UHFFFAOYSA-N,135400184,XHWRWCSCBDLOLM-UHFFFAOYSA-N,nolatrexed,,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,10/18/01,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ZVAGBRFUYHSUHA-XEKNBVSESA-N,122362431,ZVAGBRFUYHSUHA-XEKNBVSESA-N,obatoclax mesylate,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,10/8/04,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ZVAGBRFUYHSUHA-QUIKYCSHSA-N,56843157,ZVAGBRFUYHSUHA-QUIKYCSHSA-N,obatoclax mesylate,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,10/8/04,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ZVAGBRFUYHSUHA-UHFFFAOYSA-N,70700268,ZVAGBRFUYHSUHA-UHFFFAOYSA-N,obatoclax mesylate,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,10/8/04,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ZVAGBRFUYHSUHA-CFWFSBERSA-N,16727411,ZVAGBRFUYHSUHA-CFWFSBERSA-N,obatoclax mesylate,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,10/8/04,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ZVAGBRFUYHSUHA-RKMKAUCSSA-N,71816154,ZVAGBRFUYHSUHA-RKMKAUCSSA-N,obatoclax mesylate,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,10/8/04,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ZVAGBRFUYHSUHA-VLJPQPJMSA-N,46930996,ZVAGBRFUYHSUHA-VLJPQPJMSA-N,obatoclax mesylate,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,10/8/04,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ZVAGBRFUYHSUHA-LZOXOEDVSA-N,16681698,ZVAGBRFUYHSUHA-LZOXOEDVSA-N,obatoclax mesylate,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,10/8/04,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
DEQANNDTNATYII-JPZSUCLZSA-N,138107728,DEQANNDTNATYII-JPZSUCLZSA-N,Octreotide,Sandostatin LAR,Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).,"C0011991,C0011993,C0027651","Diarrhea , Vipoma , Tumors",8/24/98,Designated/Approved,,Treatment of profuse watery diarrhea associated with VIPoma., 11/25/1998 , 11/25/2005 ,
DEQANNDTNATYII-LIXSYSMXSA-N,44311916,DEQANNDTNATYII-LIXSYSMXSA-N,Octreotide,Sandostatin LAR,Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).,"C0011991,C0011993,C0027651","Diarrhea , Vipoma , Tumors",8/24/98,Designated/Approved,,Treatment of profuse watery diarrhea associated with VIPoma., 11/25/1998 , 11/25/2005 ,
DEQANNDTNATYII-XOEBDJBESA-N,90488715,DEQANNDTNATYII-XOEBDJBESA-N,Octreotide,Sandostatin LAR,Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).,"C0011991,C0011993,C0027651","Diarrhea , Vipoma , Tumors",8/24/98,Designated/Approved,,Treatment of profuse watery diarrhea associated with VIPoma., 11/25/1998 , 11/25/2005 ,
DEQANNDTNATYII-FLDZURHUSA-N,86289069,DEQANNDTNATYII-FLDZURHUSA-N,Octreotide,Sandostatin LAR,Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).,"C0011991,C0011993,C0027651","Diarrhea , Vipoma , Tumors",8/24/98,Designated/Approved,,Treatment of profuse watery diarrhea associated with VIPoma., 11/25/1998 , 11/25/2005 ,
DEQANNDTNATYII-MEUDYGGUSA-N,44420813,DEQANNDTNATYII-MEUDYGGUSA-N,Octreotide,Sandostatin LAR,Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).,"C0011991,C0011993,C0027651","Diarrhea , Vipoma , Tumors",8/24/98,Designated/Approved,,Treatment of profuse watery diarrhea associated with VIPoma., 11/25/1998 , 11/25/2005 ,
DEQANNDTNATYII-RRCPSWKPSA-N,6400441,DEQANNDTNATYII-RRCPSWKPSA-N,Octreotide,Sandostatin LAR,Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).,"C0011991,C0011993,C0027651","Diarrhea , Vipoma , Tumors",8/24/98,Designated/Approved,,Treatment of profuse watery diarrhea associated with VIPoma., 11/25/1998 , 11/25/2005 ,
DEQANNDTNATYII-UHFFFAOYSA-N,383414,DEQANNDTNATYII-UHFFFAOYSA-N,Octreotide,Sandostatin LAR,Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).,"C0011991,C0011993,C0027651","Diarrhea , Vipoma , Tumors",8/24/98,Designated/Approved,,Treatment of profuse watery diarrhea associated with VIPoma., 11/25/1998 , 11/25/2005 ,
DEQANNDTNATYII-OULOTJBUSA-N,448601,DEQANNDTNATYII-OULOTJBUSA-N,Octreotide,Sandostatin LAR,Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).,"C0011991,C0011993,C0027651","Diarrhea , Vipoma , Tumors",8/24/98,Designated/Approved,,Treatment of profuse watery diarrhea associated with VIPoma., 11/25/1998 , 11/25/2005 ,
FDLYAMZZIXQODN-UHFFFAOYSA-N,23725625,FDLYAMZZIXQODN-UHFFFAOYSA-N,olaparib,Lynparza,Treatment of ovarian cancer,C4721610,Ovarian Cancer,10/16/13,Designated/Approved,,"Lynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either: a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FD", 05/08/2020 , 05/08/2027 ,"LYNPARZA is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinumbased chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by genomic instability."
FDLYAMZZIXQODN-UHFFFAOYSA-N,23725625,FDLYAMZZIXQODN-UHFFFAOYSA-N,olaparib,Lynparza,Treatment of primary peritoneal cancer,C1514428,Primary Peritoneal Cancer,5/15/18,Designated/Approved,,"Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum based chemotherapy. Select patients with gBRCAm advanced epithelial ovarian, fallopian tube or primary peritoneal cancer for therapy based on FDA-approved companion diagnostic for Lynparza.", 12/19/2018 , 12/19/2025 ,Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced primary peritoneal cancer who are in complete or partial response to first-line platinum based chemotherapy.
SUFPWYYDCOKDLL-UHFFFAOYSA-N,91885568,SUFPWYYDCOKDLL-UHFFFAOYSA-N,olorofim,,Treatment of invasive aspergillosis,C0238013,Invasive aspergillosis,1/16/20,Designated,Not FDA Approved for Orphan Indication,,,,
QSLJIVKCVHQPLV-PEMPUTJUSA-N,5878,QSLJIVKCVHQPLV-PEMPUTJUSA-N,Oxandrolone,,Treatment of patients with Duchenne's muscular dystrophy and Becker's muscular dystrophy.,"C0013264,C0917713","Duchenne's Muscular Dystrophy , Becker's Muscular Dystrophy",4/22/97,Designated,Not FDA Approved for Orphan Indication,,,,
XNOPRXBHLZRZKH-DSZYJQQASA-N,439302,XNOPRXBHLZRZKH-DSZYJQQASA-N,oxytocin,,Treatment of Prader-Willi syndrome,C0032897,Prader-Willi Syndrome,11/24/14,Designated,Not FDA Approved for Orphan Indication,,,,
RCINICONZNJXQF-MZXODVADSA-N,36314,RCINICONZNJXQF-MZXODVADSA-N,paclitaxel,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,5/1/09,Designated,Not FDA Approved for Orphan Indication,,,,
ZPUHVPYXSITYDI-ZYOSQDPASA-N,134715513,ZPUHVPYXSITYDI-ZYOSQDPASA-N,paclitaxel poliglumex,,Treatment of glioblastoma multiforme,C0017636,Glioblastoma multiforme,9/20/12,Designated,Not FDA Approved for Orphan Indication,,,,
DIKSYHCCYVYKRO-UHFFFAOYSA-N,54684617,DIKSYHCCYVYKRO-UHFFFAOYSA-N,paquinimod,,Treatment of systemic sclerosis,C0036421,Systemic sclerosis,1/17/14,Designated,Not FDA Approved for Orphan Indication,,,,
LMYRWZFENFIFIT-UHFFFAOYSA-N,6269,LMYRWZFENFIFIT-UHFFFAOYSA-N,Para-toluenesulfonamide,,Treatment of adenoid cystic carcinoma,C0010606,Adenoid Cystic Carcinoma,1/30/17,Designated,Not FDA Approved for Orphan Indication,,,,
VMZMNAABQBOLAK-DBILLSOUSA-N,9941444,VMZMNAABQBOLAK-DBILLSOUSA-N,pasireotide,Signifor,Treatment of Cushing's disease,C0010481,Cushing's disease,7/24/09,Designated/Approved,,Treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative, 12/14/2012 , 12/14/2019 ,
CUIHSIWYWATEQL-UHFFFAOYSA-N,10113978,CUIHSIWYWATEQL-UHFFFAOYSA-N,pazopanib,Votrient,Treatment of soft tissue sarcomas,C1261473,Soft Tissue Sarcomas,10/20/09,Designated/Approved,,Advanced soft tissue sarcoma (STS) who have received prior chemotherapy, 04/26/2012 , 04/26/2019 ,
CUIHSIWYWATEQL-UHFFFAOYSA-N,10113978,CUIHSIWYWATEQL-UHFFFAOYSA-N,pazopanib,,Treatment of hereditary hemorrhagic telangiectasia,C0039445,hereditary hemorrhagic telangiectasia,10/9/19,Designated,Not FDA Approved for Orphan Indication,,,,
XDRYMKDFEDOLFX-UHFFFAOYSA-N,4735,XDRYMKDFEDOLFX-UHFFFAOYSA-N,pentamidine,,Treatment of liver and intrahepatic bile duct cancer,C0279000,Liver and Intrahepatic Bile Duct Cancer,8/12/13,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
FCCNSUIJIOOXEZ-SJYYZXOBSA-N,37720,FCCNSUIJIOOXEZ-SJYYZXOBSA-N,pentosan polysulfate,,Treatment of mucopolysaccharidosis type 1,C0026703,Mucopolysaccharidosis,4/28/20,Designated,Not FDA Approved for Orphan Indication,,,,
SSJGXNSABQPEKM-SBUIBGKBSA-N,56841989,SSJGXNSABQPEKM-SBUIBGKBSA-N,peptide YY,,Treatment of hepatocellular carcinoma.,C2239176,HEPATOCELLULAR CARCINOMA,4/18/11,Designated,Not FDA Approved for Orphan Indication,,,,
VPZRWNZGLKXFOE-UHFFFAOYSA-M,5258,VPZRWNZGLKXFOE-UHFFFAOYSA-M,Phenylbutyrate,,Treatment of acute promyelocytic leukemia.,C0023487,Acute Promyelocytic Leukemia,1/19/00,Designated,Not FDA Approved for Orphan Indication,,,,
OBKXEAXTFZPCHS-UHFFFAOYSA-N,4775,OBKXEAXTFZPCHS-UHFFFAOYSA-N,Phenylbutyrate,,Treatment of acute promyelocytic leukemia.,C0023487,Acute Promyelocytic Leukemia,1/19/00,Designated,Not FDA Approved for Orphan Indication,,,,
UVSMNLNDYGZFPF-UHFFFAOYSA-N,134780,UVSMNLNDYGZFPF-UHFFFAOYSA-N,pomalidomide,,Treatment of persons with myeloproliferative neoplasm-associated myelofibrosis and anemia who are red blood cell tranfusion dependent.,"C0002871,C0026987,C1292778","Anemia , Myelofibrosis , Myeloproliferative neoplasm",9/21/10,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PHXJVRSECIGDHY-UHFFFAOYSA-N,24826799,PHXJVRSECIGDHY-UHFFFAOYSA-N,ponatinib,Iclusig,Treatment of chronic myeloid leukemia,C0023473,Chronic myeloid leukemia,11/20/09,Designated/Approved,,"Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.", 12/14/2012 , 12/14/2019 ,
PHXJVRSECIGDHY-UHFFFAOYSA-N,24826799,PHXJVRSECIGDHY-UHFFFAOYSA-N,ponatinib,,Treatment of gastrointestinal stromal tumors (GIST).,C0238198,Gastrointestinal Stromal Tumors,3/12/15,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
HRHKSTOGXBBQCB-VFWICMBZSA-N,13116,HRHKSTOGXBBQCB-VFWICMBZSA-N,Porfiromycin,,Treatment of head and neck cancer.,C3887461,Head and Neck Cancer,9/19/95,Designated,Not FDA Approved for Orphan Indication,,,,
QEEAPRPFLLJWCF-UHFFFAOYSA-K,13344,QEEAPRPFLLJWCF-UHFFFAOYSA-K,Potassium citrate,Urocit-K,Prevention of uric acid nephrolithiasis.,C0558595,Uric acid nephrolithiasis,11/1/84,Designated/Approved,,, 08/30/1985 , 08/30/1992 ,
OGSBUKJUDHAQEA-WMCAAGNKSA-N,148121,OGSBUKJUDHAQEA-WMCAAGNKSA-N,pralatrexate,,Treatment of follicular lymphoma,C0024301,follicular lymphoma,10/20/08,Designated,Not FDA Approved for Orphan Indication,,,,
FSVJFNAIGNNGKK-UHFFFAOYSA-N,4891,FSVJFNAIGNNGKK-UHFFFAOYSA-N,Praziquantel,,Treatment of neurocysticercosis.,C0338437,Neurocysticercosis,4/18/88,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
HFVNWDWLWUCIHC-GUPDPFMOSA-N,34457,HFVNWDWLWUCIHC-GUPDPFMOSA-N,Prednimustine,,Treatment of malignant non-Hodgkin's lymphomas.,C0019829,hodgkin's lymphomas,6/17/85,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ORMHJJCIJXWHFH-UHFFFAOYSA-N,9925625,ORMHJJCIJXWHFH-UHFFFAOYSA-N,propofol hemisuccinate,,Treatment of acute repetitive seizures,C0036572,Seizures,8/19/16,Designated,Not FDA Approved for Orphan Indication,,,,
RZFNKJVCPDLQQA-UHFFFAOYSA-N,2725002,RZFNKJVCPDLQQA-UHFFFAOYSA-N,Quinacrine hydrochloride,,For prevention of recurrence of pneumothorax in patients at high risk of recurrence.,C0032326,Pneumothorax,10/17/84,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
GPKJTRJOBQGKQK-UHFFFAOYSA-N,237,GPKJTRJOBQGKQK-UHFFFAOYSA-N,Quinacrine hydrochloride,,For prevention of recurrence of pneumothorax in patients at high risk of recurrence.,C0032326,Pneumothorax,10/17/84,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
UKZANTJXIMWQCH-UHFFFAOYSA-N,5351141,UKZANTJXIMWQCH-UHFFFAOYSA-N,Quinacrine hydrochloride,,For prevention of recurrence of pneumothorax in patients at high risk of recurrence.,C0032326,Pneumothorax,10/17/84,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
UDKVBVICMUEIKS-UHFFFAOYSA-N,6239,UDKVBVICMUEIKS-UHFFFAOYSA-N,Quinacrine hydrochloride,,For prevention of recurrence of pneumothorax in patients at high risk of recurrence.,C0032326,Pneumothorax,10/17/84,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
CBQGYUDMJHNJBX-MOPGFXCFSA-N,5311403,CBQGYUDMJHNJBX-MOPGFXCFSA-N,reboxetine,,Treatment of narcolepsy,C0027404,Narcolepsy,10/15/18,Designated,Not FDA Approved for Orphan Indication,,,,
CBQGYUDMJHNJBX-UHFFFAOYSA-N,3022645,CBQGYUDMJHNJBX-UHFFFAOYSA-N,reboxetine,,Treatment of narcolepsy,C0027404,Narcolepsy,10/15/18,Designated,Not FDA Approved for Orphan Indication,,,,
CBQGYUDMJHNJBX-OALUTQOASA-N,65856,CBQGYUDMJHNJBX-OALUTQOASA-N,reboxetine,,Treatment of narcolepsy,C0027404,Narcolepsy,10/15/18,Designated,Not FDA Approved for Orphan Indication,,,,
CBQGYUDMJHNJBX-RTBURBONSA-N,127151,CBQGYUDMJHNJBX-RTBURBONSA-N,reboxetine,,Treatment of narcolepsy,C0027404,Narcolepsy,10/15/18,Designated,Not FDA Approved for Orphan Indication,,,,
BXNMTOQRYBFHNZ-UHFFFAOYSA-N,159603,BXNMTOQRYBFHNZ-UHFFFAOYSA-N,resiquimod,,Treatment of cutaneous T-cell lymphoma,C0079773,cutaneous T-cell lymphoma,5/24/17,Designated,Not FDA Approved for Orphan Indication,,,,
WDZCUPBHRAEYDL-YUUOHQKVSA-N,138404395,WDZCUPBHRAEYDL-YUUOHQKVSA-N,Rifapentine,,Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.,"C0001175,C0026914","AIDS , Mycobacterium avium Complex",3/12/96,Designated,Not FDA Approved for Orphan Indication,,,,
WDZCUPBHRAEYDL-RDKOBYJASA-N,137235501,WDZCUPBHRAEYDL-RDKOBYJASA-N,Rifapentine,,Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.,"C0001175,C0026914","AIDS , Mycobacterium avium Complex",3/12/96,Designated,Not FDA Approved for Orphan Indication,,,,
WDZCUPBHRAEYDL-LBJWSYCFSA-N,137091916,WDZCUPBHRAEYDL-LBJWSYCFSA-N,Rifapentine,,Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.,"C0001175,C0026914","AIDS , Mycobacterium avium Complex",3/12/96,Designated,Not FDA Approved for Orphan Indication,,,,
WDZCUPBHRAEYDL-USLNORDZSA-N,137030254,WDZCUPBHRAEYDL-USLNORDZSA-N,Rifapentine,,Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.,"C0001175,C0026914","AIDS , Mycobacterium avium Complex",3/12/96,Designated,Not FDA Approved for Orphan Indication,,,,
WDZCUPBHRAEYDL-QFWJEWEWSA-N,135887820,WDZCUPBHRAEYDL-QFWJEWEWSA-N,Rifapentine,,Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.,"C0001175,C0026914","AIDS , Mycobacterium avium Complex",3/12/96,Designated,Not FDA Approved for Orphan Indication,,,,
WDZCUPBHRAEYDL-FHDUCCPFSA-N,136122663,WDZCUPBHRAEYDL-FHDUCCPFSA-N,Rifapentine,,Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.,"C0001175,C0026914","AIDS , Mycobacterium avium Complex",3/12/96,Designated,Not FDA Approved for Orphan Indication,,,,
WDZCUPBHRAEYDL-METIDKAPSA-N,135932821,WDZCUPBHRAEYDL-METIDKAPSA-N,Rifapentine,,Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.,"C0001175,C0026914","AIDS , Mycobacterium avium Complex",3/12/96,Designated,Not FDA Approved for Orphan Indication,,,,
WDZCUPBHRAEYDL-PWXWUWFUSA-N,135925739,WDZCUPBHRAEYDL-PWXWUWFUSA-N,Rifapentine,,Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.,"C0001175,C0026914","AIDS , Mycobacterium avium Complex",3/12/96,Designated,Not FDA Approved for Orphan Indication,,,,
WDZCUPBHRAEYDL-HJTBMZGUSA-N,135749824,WDZCUPBHRAEYDL-HJTBMZGUSA-N,Rifapentine,,Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.,"C0001175,C0026914","AIDS , Mycobacterium avium Complex",3/12/96,Designated,Not FDA Approved for Orphan Indication,,,,
WDZCUPBHRAEYDL-BGZYVKEHSA-N,136246610,WDZCUPBHRAEYDL-BGZYVKEHSA-N,Rifapentine,,Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.,"C0001175,C0026914","AIDS , Mycobacterium avium Complex",3/12/96,Designated,Not FDA Approved for Orphan Indication,,,,
WDZCUPBHRAEYDL-LYDPARFQSA-N,135968625,WDZCUPBHRAEYDL-LYDPARFQSA-N,Rifapentine,,Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.,"C0001175,C0026914","AIDS , Mycobacterium avium Complex",3/12/96,Designated,Not FDA Approved for Orphan Indication,,,,
WDZCUPBHRAEYDL-NAFQJNKLSA-N,136238508,WDZCUPBHRAEYDL-NAFQJNKLSA-N,Rifapentine,,Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.,"C0001175,C0026914","AIDS , Mycobacterium avium Complex",3/12/96,Designated,Not FDA Approved for Orphan Indication,,,,
WDZCUPBHRAEYDL-QEDJKGLXSA-N,136073066,WDZCUPBHRAEYDL-QEDJKGLXSA-N,Rifapentine,,Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.,"C0001175,C0026914","AIDS , Mycobacterium avium Complex",3/12/96,Designated,Not FDA Approved for Orphan Indication,,,,
WDZCUPBHRAEYDL-PRHSTWAZSA-N,135659016,WDZCUPBHRAEYDL-PRHSTWAZSA-N,Rifapentine,,Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.,"C0001175,C0026914","AIDS , Mycobacterium avium Complex",3/12/96,Designated,Not FDA Approved for Orphan Indication,,,,
WDZCUPBHRAEYDL-GZAUEHORSA-N,135403821,WDZCUPBHRAEYDL-GZAUEHORSA-N,Rifapentine,,Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.,"C0001175,C0026914","AIDS , Mycobacterium avium Complex",3/12/96,Designated,Not FDA Approved for Orphan Indication,,,,
WDZCUPBHRAEYDL-YUUOHQKVSA-N,138404395,WDZCUPBHRAEYDL-YUUOHQKVSA-N,Rifapentine,Priftin,Treatment of pulmonary tuberculosis.,C0041327,Pulmonary tuberculosis,6/9/95,Designated/Approved,,, 06/22/1998 , 06/22/2005 ,
WDZCUPBHRAEYDL-RDKOBYJASA-N,137235501,WDZCUPBHRAEYDL-RDKOBYJASA-N,Rifapentine,Priftin,Treatment of pulmonary tuberculosis.,C0041327,Pulmonary tuberculosis,6/9/95,Designated/Approved,,, 06/22/1998 , 06/22/2005 ,
WDZCUPBHRAEYDL-LBJWSYCFSA-N,137091916,WDZCUPBHRAEYDL-LBJWSYCFSA-N,Rifapentine,Priftin,Treatment of pulmonary tuberculosis.,C0041327,Pulmonary tuberculosis,6/9/95,Designated/Approved,,, 06/22/1998 , 06/22/2005 ,
WDZCUPBHRAEYDL-USLNORDZSA-N,137030254,WDZCUPBHRAEYDL-USLNORDZSA-N,Rifapentine,Priftin,Treatment of pulmonary tuberculosis.,C0041327,Pulmonary tuberculosis,6/9/95,Designated/Approved,,, 06/22/1998 , 06/22/2005 ,
WDZCUPBHRAEYDL-QFWJEWEWSA-N,135887820,WDZCUPBHRAEYDL-QFWJEWEWSA-N,Rifapentine,Priftin,Treatment of pulmonary tuberculosis.,C0041327,Pulmonary tuberculosis,6/9/95,Designated/Approved,,, 06/22/1998 , 06/22/2005 ,
WDZCUPBHRAEYDL-FHDUCCPFSA-N,136122663,WDZCUPBHRAEYDL-FHDUCCPFSA-N,Rifapentine,Priftin,Treatment of pulmonary tuberculosis.,C0041327,Pulmonary tuberculosis,6/9/95,Designated/Approved,,, 06/22/1998 , 06/22/2005 ,
WDZCUPBHRAEYDL-METIDKAPSA-N,135932821,WDZCUPBHRAEYDL-METIDKAPSA-N,Rifapentine,Priftin,Treatment of pulmonary tuberculosis.,C0041327,Pulmonary tuberculosis,6/9/95,Designated/Approved,,, 06/22/1998 , 06/22/2005 ,
WDZCUPBHRAEYDL-PWXWUWFUSA-N,135925739,WDZCUPBHRAEYDL-PWXWUWFUSA-N,Rifapentine,Priftin,Treatment of pulmonary tuberculosis.,C0041327,Pulmonary tuberculosis,6/9/95,Designated/Approved,,, 06/22/1998 , 06/22/2005 ,
WDZCUPBHRAEYDL-HJTBMZGUSA-N,135749824,WDZCUPBHRAEYDL-HJTBMZGUSA-N,Rifapentine,Priftin,Treatment of pulmonary tuberculosis.,C0041327,Pulmonary tuberculosis,6/9/95,Designated/Approved,,, 06/22/1998 , 06/22/2005 ,
WDZCUPBHRAEYDL-BGZYVKEHSA-N,136246610,WDZCUPBHRAEYDL-BGZYVKEHSA-N,Rifapentine,Priftin,Treatment of pulmonary tuberculosis.,C0041327,Pulmonary tuberculosis,6/9/95,Designated/Approved,,, 06/22/1998 , 06/22/2005 ,
WDZCUPBHRAEYDL-LYDPARFQSA-N,135968625,WDZCUPBHRAEYDL-LYDPARFQSA-N,Rifapentine,Priftin,Treatment of pulmonary tuberculosis.,C0041327,Pulmonary tuberculosis,6/9/95,Designated/Approved,,, 06/22/1998 , 06/22/2005 ,
WDZCUPBHRAEYDL-NAFQJNKLSA-N,136238508,WDZCUPBHRAEYDL-NAFQJNKLSA-N,Rifapentine,Priftin,Treatment of pulmonary tuberculosis.,C0041327,Pulmonary tuberculosis,6/9/95,Designated/Approved,,, 06/22/1998 , 06/22/2005 ,
WDZCUPBHRAEYDL-QEDJKGLXSA-N,136073066,WDZCUPBHRAEYDL-QEDJKGLXSA-N,Rifapentine,Priftin,Treatment of pulmonary tuberculosis.,C0041327,Pulmonary tuberculosis,6/9/95,Designated/Approved,,, 06/22/1998 , 06/22/2005 ,
WDZCUPBHRAEYDL-PRHSTWAZSA-N,135659016,WDZCUPBHRAEYDL-PRHSTWAZSA-N,Rifapentine,Priftin,Treatment of pulmonary tuberculosis.,C0041327,Pulmonary tuberculosis,6/9/95,Designated/Approved,,, 06/22/1998 , 06/22/2005 ,
WDZCUPBHRAEYDL-GZAUEHORSA-N,135403821,WDZCUPBHRAEYDL-GZAUEHORSA-N,Rifapentine,Priftin,Treatment of pulmonary tuberculosis.,C0041327,Pulmonary tuberculosis,6/9/95,Designated/Approved,,, 06/22/1998 , 06/22/2005 ,
OWBFCJROIKNMGD-BQYQJAHWSA-N,6918736,OWBFCJROIKNMGD-BQYQJAHWSA-N,rigosertib,,Treatment of myelodysplastic syndromes,C3463824,Myelodysplastic Syndromes,9/3/09,Designated,Not FDA Approved for Orphan Indication,,,,
WPEWQEMJFLWMLV-UHFFFAOYSA-N,11315474,WPEWQEMJFLWMLV-UHFFFAOYSA-N,Rivoceranib,,Treatment of Adenoid Cystic Carcinoma,C0010606,Adenoid Cystic Carcinoma,2/2/21,Designated,Not FDA Approved for Orphan Indication,,,,
RZJQGNCSTQAWON-UHFFFAOYSA-N,5090,RZJQGNCSTQAWON-UHFFFAOYSA-N,rofecoxib,,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,3/16/04,Designated,Not FDA Approved for Orphan Indication,,,,
HFNKQEVNSGCOJV-OAHLLOKOSA-N,25126798,HFNKQEVNSGCOJV-OAHLLOKOSA-N,Ruxolitinib,,Treatment of acute lymphoblastic leukemia.,C0023449,Acute lymphoblastic leukemia,7/18/16,Designated,Not FDA Approved for Orphan Indication,,,,
MUSGYEMSJUFFHT-UWABRSFTSA-N,131634231,MUSGYEMSJUFFHT-UWABRSFTSA-N,"S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)",,Treatment of paroxysmal nocturnal hemoglobinuria (PNH),"C0024790,C1418558","Paroxysmal nocturnal hemoglobinuria , paroxysmal nocturnal hemoglobinuria",10/9/14,Designated,Not FDA Approved for Orphan Indication,,,,
ULRUOUDIQPERIJ-PQURJYPBSA-N,91668186,ULRUOUDIQPERIJ-PQURJYPBSA-N,sacituzumab govitecan,,Treatment of small cell lung cancer,C3540630,Small Cell Lung Cancer,11/27/13,Designated,Not FDA Approved for Orphan Indication,,,,
ULRUOUDIQPERIJ-PQURJYPBSA-N,91668186,ULRUOUDIQPERIJ-PQURJYPBSA-N,sacituzumab govitecan,,treatment of malignant glioma,C0555198,Malignant Glioma,10/8/20,Designated,Not FDA Approved for Orphan Indication,,,,
IYETZZCWLLUHIJ-UHFFFAOYSA-N,92913,IYETZZCWLLUHIJ-UHFFFAOYSA-N,Selegiline HCl,Eldepryl,"As an adjuvant to levodopa and carbidopa treatment of idiopathic Parkinson's disease (paralysis agitans), postencephalitic Parkinsonism, and symptomatic Parkinsonism.","C0030567,C0030568,C0030569","Idiopathic Parkinson's disease , Postencephalitic Parkinsonism , Symptomatic parkinsonism",11/7/84,Designated/Approved,,, 06/05/1989 , 06/05/1996 ,
IYETZZCWLLUHIJ-YDALLXLXSA-N,199604,IYETZZCWLLUHIJ-YDALLXLXSA-N,Selegiline HCl,Eldepryl,"As an adjuvant to levodopa and carbidopa treatment of idiopathic Parkinson's disease (paralysis agitans), postencephalitic Parkinsonism, and symptomatic Parkinsonism.","C0030567,C0030568,C0030569","Idiopathic Parkinson's disease , Postencephalitic Parkinsonism , Symptomatic parkinsonism",11/7/84,Designated/Approved,,, 06/05/1989 , 06/05/1996 ,
IYETZZCWLLUHIJ-UTONKHPSSA-N,26758,IYETZZCWLLUHIJ-UTONKHPSSA-N,Selegiline HCl,Eldepryl,"As an adjuvant to levodopa and carbidopa treatment of idiopathic Parkinson's disease (paralysis agitans), postencephalitic Parkinsonism, and symptomatic Parkinsonism.","C0030567,C0030568,C0030569","Idiopathic Parkinson's disease , Postencephalitic Parkinsonism , Symptomatic parkinsonism",11/7/84,Designated/Approved,,, 06/05/1989 , 06/05/1996 ,
CYOHGALHFOKKQC-UHFFFAOYSA-N,10127622,CYOHGALHFOKKQC-UHFFFAOYSA-N,selumetinib,,Treatment of Neurofibromatosis Type 1,C0027831,Neurofibromatosis type 1,2/14/18,Designated/Approved,,"KOSELUGO is indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN)", 04/10/2020 , 04/10/2027 ,"Indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN)."
VPVOXUSPXFPWBN-VKHMYHEASA-N,135398579,VPVOXUSPXFPWBN-VKHMYHEASA-N,sepiapterin,,Treatment of hyperphenylalaninemia,C0751435,Hyperphenylalaninemia,3/4/21,Designated,Not FDA Approved for Orphan Indication,,,,
HDHDTKMUACZDAA-PHNIDTBTSA-N,11993702,HDHDTKMUACZDAA-PHNIDTBTSA-N,setmelanotide,,Treatment of Bardet-Biedl syndrome,C0752166,Bardet-Biedl Syndrome,9/19/19,Designated,Not FDA Approved for Orphan Indication,,,,
QFJCIRLUMZQUOT-HPLJOQBZSA-N,5284616,QFJCIRLUMZQUOT-HPLJOQBZSA-N,sirolimus,,Treatment of sickle cell disease,C0002895,Sickle Cell Disease,3/13/18,Designated,Not FDA Approved for Orphan Indication,,,,
QFJCIRLUMZQUOT-HPLJOQBZSA-N,5284616,QFJCIRLUMZQUOT-HPLJOQBZSA-N,sirolimus,,Treatment of lymphangioleiomyomatosis,C0751674,Lymphangioleiomyomatosis,6/25/14,Designated,Not FDA Approved for Orphan Indication,,,,
QFJCIRLUMZQUOT-HPLJOQBZSA-N,5284616,QFJCIRLUMZQUOT-HPLJOQBZSA-N,sirolimus,,Treatment of lymphangioleiomyomatosis,C0751674,Lymphangioleiomyomatosis,11/17/14,Designated,Not FDA Approved for Orphan Indication,,,,
MDTNUYUCUYPIHE-UHFFFAOYSA-N,11477084,MDTNUYUCUYPIHE-UHFFFAOYSA-N,Sitaxsentan Sodium,,For the treatment of pulmonary arterial hypertension in the absence of chronic obstructive pulmonary disease or congestive heart failure.,"C0018802,C0024117,C3203102","Congestive heart failure , CHRONIC OBSTRUCTIVE PULMONARY DISEASE , PULMONARY ARTERIAL HYPERTENSION",11/2/04,Designated,Not FDA Approved for Orphan Indication,,,,
URGAHOPLAPQHLN-UHFFFAOYSA-N,19758701,URGAHOPLAPQHLN-UHFFFAOYSA-N,Sodium aluminosilicate,,Treatment of chronic hepatic encephalopathy,C4024937,Chronic hepatic encephalopathy,3/4/05,Designated,Not FDA Approved for Orphan Indication,,,,
LUPNKHXLFSSUGS-UHFFFAOYSA-M,517326,LUPNKHXLFSSUGS-UHFFFAOYSA-M,Sodium dichloroacetate,,Treatment of congenital lactic acidosis.,C4025276,Congenital lactic acidosis,12/31/97,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
XYGBKMMCQDZQOZ-UHFFFAOYSA-M,23663870,XYGBKMMCQDZQOZ-UHFFFAOYSA-M,sodium oxybate,Xyrem,Treatment of narcolepsy.,C0027404,Narcolepsy,11/7/94,Designated/Approved,,Xyrem is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy., 10/26/2018 , 10/26/2025 ,Xyrem is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in pediatric patients 7 years of age and older with narcolepsy.
VPZRWNZGLKXFOE-UHFFFAOYSA-M,5258,VPZRWNZGLKXFOE-UHFFFAOYSA-M,Sodium phenylbutyrate,,Treatment of spinal muscular atrophy,C0026847,Spinal Muscular Atrophy,1/25/07,Designated,Not FDA Approved for Orphan Indication,,,,
CUEDNFKBTFCOSV-UZVLBLASSA-L,16683012,CUEDNFKBTFCOSV-UZVLBLASSA-L,Sodium stibogluconate,,Treatment of cutaneous leishmaniasis,C0023283,Cutaneous leishmaniasis,6/16/06,Designated,Not FDA Approved for Orphan Indication,,,,
TTZHDVOVKQGIBA-LVPOHEQUSA-N,73425384,TTZHDVOVKQGIBA-LVPOHEQUSA-N,sofosbuvir,Sovaldi,Treatment of pediatric chronic hepatitis C virus infection,"C0019196,C0524910","Hepatitis C Virus Infection , chronic hepatitis c",10/25/16,Designated/Approved,,Treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin, 04/07/2017 , 04/07/2024 ,Treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin
TTZHDVOVKQGIBA-KVOQBTHKSA-N,72699160,TTZHDVOVKQGIBA-KVOQBTHKSA-N,sofosbuvir,Sovaldi,Treatment of pediatric chronic hepatitis C virus infection,"C0019196,C0524910","Hepatitis C Virus Infection , chronic hepatitis c",10/25/16,Designated/Approved,,Treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin, 04/07/2017 , 04/07/2024 ,Treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin
TTZHDVOVKQGIBA-IECBXEDQSA-N,129010435,TTZHDVOVKQGIBA-IECBXEDQSA-N,sofosbuvir,Sovaldi,Treatment of pediatric chronic hepatitis C virus infection,"C0019196,C0524910","Hepatitis C Virus Infection , chronic hepatitis c",10/25/16,Designated/Approved,,Treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin, 04/07/2017 , 04/07/2024 ,Treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin
TTZHDVOVKQGIBA-UHFFFAOYSA-N,91302628,TTZHDVOVKQGIBA-UHFFFAOYSA-N,sofosbuvir,Sovaldi,Treatment of pediatric chronic hepatitis C virus infection,"C0019196,C0524910","Hepatitis C Virus Infection , chronic hepatitis c",10/25/16,Designated/Approved,,Treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin, 04/07/2017 , 04/07/2024 ,Treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin
TTZHDVOVKQGIBA-IAAJYNJHSA-N,45375806,TTZHDVOVKQGIBA-IAAJYNJHSA-N,sofosbuvir,Sovaldi,Treatment of pediatric chronic hepatitis C virus infection,"C0019196,C0524910","Hepatitis C Virus Infection , chronic hepatitis c",10/25/16,Designated/Approved,,Treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin, 04/07/2017 , 04/07/2024 ,Treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin
TTZHDVOVKQGIBA-IQWMDFIBSA-N,45375808,TTZHDVOVKQGIBA-IQWMDFIBSA-N,sofosbuvir,Sovaldi,Treatment of pediatric chronic hepatitis C virus infection,"C0019196,C0524910","Hepatitis C Virus Infection , chronic hepatitis c",10/25/16,Designated/Approved,,Treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin, 04/07/2017 , 04/07/2024 ,Treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin
VZZJRYRQSPEMTK-CALCHBBNSA-N,24775005,VZZJRYRQSPEMTK-CALCHBBNSA-N,sonidegib,,Treatment of medulloblastoma,C0025149,Medulloblastoma,3/23/15,Designated,Not FDA Approved for Orphan Indication,,,,
MLDQJTXFUGDVEO-UHFFFAOYSA-N,216239,MLDQJTXFUGDVEO-UHFFFAOYSA-N,Sorafenib,Nexavar,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,4/20/06,Designated/Approved,,Treatment of unresectable hepatocellular carcinoma, 11/16/2007 , 11/16/2014 ,
IBLNKMRFIPWSOY-FNORWQNLSA-N,5311454,IBLNKMRFIPWSOY-FNORWQNLSA-N,Stiripentol,,Treatment of Primary Hyperoxaluria,C0020501,Primary Hyperoxaluria,2/22/21,Designated,Not FDA Approved for Orphan Indication,,,,
ACTRVOBWPAIOHC-XIXRPRMCSA-N,2724354,ACTRVOBWPAIOHC-XIXRPRMCSA-N,Succimer,,Prevention of cystine kidney stone formation in patients with homozygous cystinuria who are prone to stone development.,"C0010691,C0022650","Cystinuria , KIDNEY STONE",11/5/90,Designated,Not FDA Approved for Orphan Indication,,,,
YZPQNHUVIVIUCT-JTJNLBSYSA-F,121494085,YZPQNHUVIVIUCT-JTJNLBSYSA-F,Sucralfate,,Treatment of oral mucositis and stomatitis following radiation therapy for head and neck cancer.,"C0038362,C1568868,C1578499,C3887461","Oral mucositis , Oral Mucositis , Radiation Therapy , Head and Neck Cancer",7/15/93,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
TTZSNFLLYPYKIL-UHFFFAOYSA-N,52920501,TTZSNFLLYPYKIL-UHFFFAOYSA-N,surufatinib,,Treatment of pancreatic neuroendocrine tumors,C0206754,Neuroendocrine Tumors,11/21/19,Designated,Not FDA Approved for Orphan Indication,,,,
WOXKDUGGOYFFRN-IIBYNOLFSA-N,110635,WOXKDUGGOYFFRN-IIBYNOLFSA-N,tadalafil,Adcirca,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,12/18/06,Designated/Approved,,Treatment of pulmonary arterial hypertension (WHO Group I) to improve exercise ability, 05/22/2009 , 05/22/2016 ,
MUTNCGKQJGXKEM-UHFFFAOYSA-N,108143,MUTNCGKQJGXKEM-UHFFFAOYSA-N,tamibarotene,,Treatment of acute myeloid leukemia (AML),C0023467,Acute myeloid leukemia,8/16/17,Designated,Not FDA Approved for Orphan Indication,,,,
AYUNIORJHRXIBJ-TXHRRWQRSA-N,6505803,AYUNIORJHRXIBJ-TXHRRWQRSA-N,Tanespimycin,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,9/9/04,Designated,Not FDA Approved for Orphan Indication,,,,
PTOIAAWZLUQTIO-GXFFZTMASA-N,10220503,PTOIAAWZLUQTIO-GXFFZTMASA-N,tasimelteon,Hetlioz,Treatment of the sleep disorder in Smith-Magenis syndrome associated with diurnal melatonin secretion.,"C0795864,C0851578","Smith-Magenis syndrome , Sleep disorder",4/30/10,Designated/Approved,,Treatment of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in patients 16 years of age and older, 12/01/2020 , 12/01/2027 ,Treatment of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in patients 16 years of age and older.
QFLNTQDOVCLQKW-UHFFFAOYSA-N,54718618,QFLNTQDOVCLQKW-UHFFFAOYSA-N,tecarfarin,,Prevention of systemic thromboembolism of cardiac origin in patients with End Stage Renal Disease and atrial fibrillation,"C0004238,C0022661,C0040038","Atrial Fibrillation , End stage renal disease , Thromboembolism",3/7/19,Designated,Not FDA Approved for Orphan Indication,,,,
CSKDFZIMJXRJGH-VWLPUNTISA-N,16124688,CSKDFZIMJXRJGH-VWLPUNTISA-N,tecovirimat,,Treatment of orthopoxvirus infections.,"C0206580,C3714514","Orthopoxvirus , Infections",9/29/10,Designated,Not FDA Approved for Orphan Indication,,,,
OJICYBSWSZGRFB-UHFFFAOYSA-N,68234908,OJICYBSWSZGRFB-UHFFFAOYSA-N,Telacebec,,Treatment of Buruli ulcer,C0041582,Ulcer,1/13/21,Designated,Not FDA Approved for Orphan Indication,,,,
BPEGJWRSRHCHSN-UHFFFAOYSA-N,5394,BPEGJWRSRHCHSN-UHFFFAOYSA-N,Temozolomide,,Treatment of advanced metastatic melanoma.,C0278883,Metastatic melanoma,10/14/98,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PPJYSSNKSXAVDB-UHFFFAOYSA-N,65552,PPJYSSNKSXAVDB-UHFFFAOYSA-N,Tetraiodothyroacetic acid,,Suppression of thyroid stimulating hormone in patients with well-differentiated cancer of the thyroid gland.,C0549473,Cancer of the Thyroid,5/1/00,Designated,Not FDA Approved for Orphan Indication,,,,
WVTKBKWTSCPRNU-KYJUHHDHSA-N,73078,WVTKBKWTSCPRNU-KYJUHHDHSA-N,tetrandrine,,Treatment of acute myeloid leukemia.,C0023467,Acute myeloid leukemia,12/13/16,Designated,Not FDA Approved for Orphan Indication,,,,
WVTKBKWTSCPRNU-KYJUHHDHSA-N,73078,WVTKBKWTSCPRNU-KYJUHHDHSA-N,tetrandrine,,Treatment of chronic myeloid leukemia.,C0023473,Chronic myeloid leukemia,5/19/16,Designated,Not FDA Approved for Orphan Indication,,,,
UEJJHQNACJXSKW-UHFFFAOYSA-N,5426,UEJJHQNACJXSKW-UHFFFAOYSA-N,Thalidomide,,Treatment and maintenance of reactional lepromatous leprosy.,C0023348,Lepromatous leprosy,11/15/88,Designated,Not FDA Approved for Orphan Indication,,,,
UEJJHQNACJXSKW-UHFFFAOYSA-N,5426,UEJJHQNACJXSKW-UHFFFAOYSA-N,thalidomide,,Treatment of hereditary hemorrhagic telangiectasia,C0039445,hereditary hemorrhagic telangiectasia,7/19/17,Designated,Not FDA Approved for Orphan Indication,,,,
PRDJGNVQBVXXEO-UHFFFAOYSA-N,437740,PRDJGNVQBVXXEO-UHFFFAOYSA-N,thioureidobutyronitrile,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,7/14/15,Designated,Not FDA Approved for Orphan Indication,,,,
PRDJGNVQBVXXEO-UHFFFAOYSA-N,437740,PRDJGNVQBVXXEO-UHFFFAOYSA-N,thioureidobutyronitrile,,Treatment of retinoblastoma.,C0035335,Retinoblastoma,11/17/15,Designated,Not FDA Approved for Orphan Indication,,,,
NZVYCXVTEHPMHE-ZSUJOUNUSA-N,16130571,NZVYCXVTEHPMHE-ZSUJOUNUSA-N,Thymalfasin,,Treatment of stage IIb through Stage IV malignant melanoma,C0025202,Malignant Melanoma,3/13/06,Designated,Not FDA Approved for Orphan Indication,,,,
PSWFFKRAVBDQEG-YGQNSOCVSA-N,451417,PSWFFKRAVBDQEG-YGQNSOCVSA-N,thymopentin,,Treatment of sarcoidosis.,C0036202,Sarcoidosis,2/4/11,Designated,Not FDA Approved for Orphan Indication,,,,
UGPMCIBIHRSCBV-UHFFFAOYSA-N,45382195,UGPMCIBIHRSCBV-UHFFFAOYSA-N,thymosin beta 4,,Treatment of patients with neurotrophic keratopathy,C0339296,Neurotrophic keratopathy,12/31/13,Designated,Not FDA Approved for Orphan Indication,,,,
PMJIHLSCWIDGMD-UHFFFAOYSA-N,11313622,PMJIHLSCWIDGMD-UHFFFAOYSA-N,Tideglusib,,Treatment of myotonic dystrophy type 1 (DM1),"C0027126,C3250443","Myotonic Dystrophy , DM1",6/19/17,Designated,Not FDA Approved for Orphan Indication,,,,
HJLSLZFTEKNLFI-UHFFFAOYSA-N,5479,HJLSLZFTEKNLFI-UHFFFAOYSA-N,Tinidazole,Tindamax,Treatment of amebiasis,C0013370,amebiasis,8/20/03,Designated/Approved,,Treatment of intestinal amebiasis and amebic liver abcess caused by E. histolytica in both adults and pediatric patients older than three years of age. It is not indicated for the treatment of asymptomatic cyst passage., 05/17/2004 , 05/17/2011 ,
DWGQFQRWFYIINU-UHFFFAOYSA-N,134687437,DWGQFQRWFYIINU-UHFFFAOYSA-N,tinostamustine hydrochloride,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,4/2/18,Designated,Not FDA Approved for Orphan Indication,,,,
PLHJCIYEEKOWNM-HHHXNRCGSA-N,159324,PLHJCIYEEKOWNM-HHHXNRCGSA-N,tipifarnib,,Treatment of T-cell lymphoma,C0079772,T-Cell Lymphoma,4/6/20,Designated,Not FDA Approved for Orphan Indication,,,,
UCEQXRCJXIVODC-PMACEKPBSA-N,11494412,UCEQXRCJXIVODC-PMACEKPBSA-N,tivantinib,,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,10/16/13,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
LIRYPHYGHXZJBZ-UHFFFAOYSA-N,11707110,LIRYPHYGHXZJBZ-UHFFFAOYSA-N,trametinib,MEKINIST,Treatment of Stage IIb through Stage IV melanoma,C0278883,stage iv melanoma,12/20/10,Designated/Approved,,Treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA approved test., 05/29/2013 , 05/29/2020 ,Treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA approved test.
WBYWAXJHAXSJNI-VOTSOKGWSA-N,444539,WBYWAXJHAXSJNI-VOTSOKGWSA-N,Trans-Cinnamic Acid,,Treatment of GM2 gangliosidosis,C0268274,GM2 Gangliosidosis,11/24/20,Designated,Not FDA Approved for Orphan Indication,,,,
HDTRYLNUVZCQOY-LIZSDCNHSA-N,7427,HDTRYLNUVZCQOY-LIZSDCNHSA-N,trehalose,,Treatment of occulopharyngeal muscular dystrophy,C0026850,Muscular Dystrophy,10/25/13,Designated,Not FDA Approved for Orphan Indication,,,,
PAJMKGZZBBTTOY-ZFORQUDYSA-N,6918140,PAJMKGZZBBTTOY-ZFORQUDYSA-N,treprostinil,Remodulin;Orenitram,Treatment of pulmonary arterial hypertension.,C3203102,PULMONARY ARTERIAL HYPERTENSION,6/4/97,Designated/Approved,,Orenitram is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity., 10/18/2019 , 10/18/2026 ,Indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression.
NOYPYLRCIDNJJB-UHFFFAOYSA-N,5583,NOYPYLRCIDNJJB-UHFFFAOYSA-N,Trimetrexate,,Treatment of metastatic osteogenic sarcoma.,C0278512,Metastatic Osteogenic Sarcoma,8/10/00,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
VGGGPCQERPFHOB-RDBSUJKOSA-N,72172,VGGGPCQERPFHOB-RDBSUJKOSA-N,ubenimex,,Treatment of pulmonary arterial hypertension.,C3203102,PULMONARY ARTERIAL HYPERTENSION,11/19/15,Designated,Not FDA Approved for Orphan Indication,,,,
ACTIUHUUMQJHFO-AMJCLVIFSA-N,5354031,ACTIUHUUMQJHFO-AMJCLVIFSA-N,Ubiquinone,,Treatment of mitochondrial cytopathies.,C0162670,mitochondrial cytopathies,12/14/99,Designated,Not FDA Approved for Orphan Indication,,,,
ACTIUHUUMQJHFO-UPTCCGCDSA-N,5281915,ACTIUHUUMQJHFO-UPTCCGCDSA-N,Ubiquinone,,Treatment of mitochondrial cytopathies.,C0162670,mitochondrial cytopathies,12/14/99,Designated,Not FDA Approved for Orphan Indication,,,,
IUVCFHHAEHNCFT-INIZCTEOSA-N,72950888,IUVCFHHAEHNCFT-INIZCTEOSA-N,umbralisib,Ukoniq,Treatment of Follicular Lymphoma,C0024301,follicular lymphoma,3/4/20,Designated/Approved,,Treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy., 02/05/2021 ,  ,
AUFUWRKPQLGTGF-FMKGYKFTSA-N,20058,AUFUWRKPQLGTGF-FMKGYKFTSA-N,uridine triacetate,,Treatment of hereditary orotic aciduria,C0268130,OROTIC ACIDURIA,8/9/13,Designated/Approved,,Treatment of hereditary orotic aciduria, 09/04/2015 , 09/04/2022 ,Treatment of hereditary orotic aciduria
RUDATBOHQWOJDD-UZVSRGJWSA-N,31401,RUDATBOHQWOJDD-UZVSRGJWSA-N,Ursodiol,,Management of the clinical signs and symptoms associated with primary biliary cirrhosis.,C0008312,Primary Biliary Cirrhosis,2/19/91,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
BNJNAEJASPUJTO-DUOHOMBCSA-N,122706909,BNJNAEJASPUJTO-DUOHOMBCSA-N,vadastuximab talirine,,Treatment of acute myeloid leukemia.,C0023467,Acute myeloid leukemia,11/10/15,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
NIJJYAXOARWZEE-UHFFFAOYSA-N,3121,NIJJYAXOARWZEE-UHFFFAOYSA-N,Valproic acid,,Treatment of diffuse large B-cell lymphoma,C1332201,Diffuse Large B-Cell Lymphoma,3/30/17,Designated,Not FDA Approved for Orphan Indication,,,,
SWXOGPJRIDTIRL-CISAEKETSA-N,133566183,SWXOGPJRIDTIRL-CISAEKETSA-N,vapreotide,,Prevention of early postoperative complications following pancreatic resection.,C0032787,Postoperative Complications,3/6/00,Designated,Not FDA Approved for Orphan Indication,,,,
SWXOGPJRIDTIRL-HFQRKYADSA-N,5311370,SWXOGPJRIDTIRL-HFQRKYADSA-N,vapreotide,,Prevention of early postoperative complications following pancreatic resection.,C0032787,Postoperative Complications,3/6/00,Designated,Not FDA Approved for Orphan Indication,,,,
SWXOGPJRIDTIRL-KTJGOPLGSA-N,70689318,SWXOGPJRIDTIRL-KTJGOPLGSA-N,vapreotide,,Prevention of early postoperative complications following pancreatic resection.,C0032787,Postoperative Complications,3/6/00,Designated,Not FDA Approved for Orphan Indication,,,,
SWXOGPJRIDTIRL-DLRASJFKSA-N,45588099,SWXOGPJRIDTIRL-DLRASJFKSA-N,vapreotide,,Prevention of early postoperative complications following pancreatic resection.,C0032787,Postoperative Complications,3/6/00,Designated,Not FDA Approved for Orphan Indication,,,,
SWXOGPJRIDTIRL-UHFFFAOYSA-N,71306,SWXOGPJRIDTIRL-UHFFFAOYSA-N,vapreotide,,Prevention of early postoperative complications following pancreatic resection.,C0032787,Postoperative Complications,3/6/00,Designated,Not FDA Approved for Orphan Indication,,,,
SWXOGPJRIDTIRL-DOUNNPEJSA-N,6918026,SWXOGPJRIDTIRL-DOUNNPEJSA-N,vapreotide,,Prevention of early postoperative complications following pancreatic resection.,C0032787,Postoperative Complications,3/6/00,Designated,Not FDA Approved for Orphan Indication,,,,
LNOVHERIIMJMDG-XZXLULOTSA-N,46184405,LNOVHERIIMJMDG-XZXLULOTSA-N,vatiquinone,,Treatment of Friedreich's ataxia,C0016719,Friedreich's Ataxia,1/31/14,Designated,Not FDA Approved for Orphan Indication,,,,
JNAHVYVRKWKWKQ-CYBMUJFWSA-N,11960529,JNAHVYVRKWKWKQ-CYBMUJFWSA-N,veliparib,,Treatment of hepatocellular carcinoma in combination with DNA-damaging agents,C2239176,HEPATOCELLULAR CARCINOMA,11/20/09,Designated,Not FDA Approved for Orphan Indication,,,,
JNAHVYVRKWKWKQ-CYBMUJFWSA-N,11960529,JNAHVYVRKWKWKQ-CYBMUJFWSA-N,veliparib,,Treatment of epithelial ovarian cancer in combination with DNA-damaging agents,C4721610,Epithelial Ovarian Cancer,9/3/09,Designated,Not FDA Approved for Orphan Indication,,,,
WAEXFXRVDQXREF-UHFFFAOYSA-N,5311,WAEXFXRVDQXREF-UHFFFAOYSA-N,vorinostat,,"Treatment of advanced melanoma (stages IIb, IIc, III, and IV)",C4727838,Advanced Melanoma,10/13/16,Designated,Not FDA Approved for Orphan Indication,,,,
XZAFZXJXZHRNAQ-STQMWFEESA-N,9952884,XZAFZXJXZHRNAQ-STQMWFEESA-N,vosaroxin,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,10/28/09,Designated,Not FDA Approved for Orphan Indication,,,,
ZSSLCFLHEFXANG-GOSISDBHSA-N,25052630,ZSSLCFLHEFXANG-GOSISDBHSA-N,Zamicastat,,Treatment of pulmonary arterial hypertension (PAH) (pulmonary hypertension WHO Group 1),"C0020542,C3203102","Pulmonary Hypertension , PULMONARY ARTERIAL HYPERTENSION",7/15/19,Designated,Not FDA Approved for Orphan Indication,,,,
JDXCOXKBIGBZSK-PSNKNOTQSA-N,133083018,JDXCOXKBIGBZSK-PSNKNOTQSA-N,Zilucoplan,,Treatment of myasthenia gravis,C0026896,Myasthenia Gravis,8/26/19,Designated,Not FDA Approved for Orphan Indication,,,,
SGMZJAMFUVOLNK-UHFFFAOYSA-M,6209,SGMZJAMFUVOLNK-UHFFFAOYSA-M,Choline chloride,,"Treatment of choline deficiency, specifically the choline deficiency, hepatic steatosis, and cholestasis, associated with long-term parenteral nutrition.","C0008370,C0008412,C2711227","Cholestasis , Choline Deficiency , Hepatic steatosis",2/10/94,Designated,Not FDA Approved for Orphan Indication,,,,
QLMBAIRFQQLJJX-UHFFFAOYSA-N,54909,QLMBAIRFQQLJJX-UHFFFAOYSA-N,cicletanine hydrochloride,,Treatment for pulmonary arterial hypertension.,C3203102,PULMONARY ARTERIAL HYPERTENSION,6/24/08,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
CKLPLPZSUQEDRT-WPCRTTGESA-N,44469321,CKLPLPZSUQEDRT-WPCRTTGESA-N,cipargamin,,Treatment of malaria,C0024530,Malaria,5/1/20,Designated,Not FDA Approved for Orphan Indication,,,,
LFWCJABOXHSRGC-UHFFFAOYSA-N,6433095,LFWCJABOXHSRGC-UHFFFAOYSA-N,clazosentan,,Treatment of cerebral vasospasm following subarachnoid hemorrhage,"C0038525,C0265110","Subarachnoid Hemorrhage , Cerebral Vasospasm",2/16/06,Designated,Not FDA Approved for Orphan Indication,,,,
STJMRWALKKWQGH-UHFFFAOYSA-N,2783,STJMRWALKKWQGH-UHFFFAOYSA-N,Clenbuterol,,Treatment of Pompe disease (glycogen storage disease type II),"C0017921,C0342751","Pompe Disease , Pompe disease",1/9/17,Designated,Not FDA Approved for Orphan Indication,,,,
WDQPAMHFFCXSNU-UHFFFAOYSA-N,2794,WDQPAMHFFCXSNU-UHFFFAOYSA-N,clofazimine,,Treatment of Pulmonary Nontuberculous Mycobacterial Infections,C0026918,Mycobacterial infections,8/17/18,Designated,Not FDA Approved for Orphan Indication,,,,
SDDSJMXGJNWMJY-BRHAQHMBSA-N,16757521,SDDSJMXGJNWMJY-BRHAQHMBSA-N,cobiprostone,,Treatment of cystic fibrosis,C0010674,Cystic Fibrosis,11/14/02,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
IXYNFLOLUBKHQU-FZCWJHTDSA-N,121492440,IXYNFLOLUBKHQU-FZCWJHTDSA-N,cobitolimod,,Treatment of ulcerative colitis in pediatric patients,C0009324,Ulcerative Colitis,8/8/17,Designated,Not FDA Approved for Orphan Indication,,,,
IAKHMKGGTNLKSZ-INIZCTEOSA-N,6167,IAKHMKGGTNLKSZ-INIZCTEOSA-N,Colchicine,,For arresting the progression of neurologic disability caused by chronic progressive multiple sclerosis.,"C0231170,C0242656,C0393665","Disability , Progression , Chronic progressive multiple sclerosis",12/9/85,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
DYNHJHQFHQTFTP-UHFFFAOYSA-N,10366136,DYNHJHQFHQTFTP-UHFFFAOYSA-N,crenolanib,,Treatment of acute myelogenous leukemia,C0023467,Acute myelogenous leukemia,10/31/12,Designated,Not FDA Approved for Orphan Indication,,,,
KTEIFNKAUNYNJU-GFCCVEGCSA-N,11626560,KTEIFNKAUNYNJU-GFCCVEGCSA-N,crizotinib,Xalkori,"Treatment of ALK-positive, MET-positive, or ROS-positive non-small cell lung cancer",C3539721,Non-Small Cell Lung Cancer,9/13/10,Designated/Approved,,Treatment of patients with locally advanced or metastatic non-small cell lungcancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDAapprovedtest, 08/26/2011 , 08/26/2018 ,
UFULAYFCSOUIOV-UHFFFAOYSA-N,6058,UFULAYFCSOUIOV-UHFFFAOYSA-N,Cysteamine,Cystagon,Treatment of nephropathic cystinosis.,C0015624,Nephropathic cystinosis,1/25/91,Designated/Approved,,Treatment of nephropathic cystinosis in adults and children., 08/15/1994 , 08/15/2001 ,
WQZGKKKJIJFFOK-SVZMEOIVSA-N,6036,WQZGKKKJIJFFOK-SVZMEOIVSA-N,D-Galactose,,Treatment of Phosphoglucomutase 1 Deficiency,C2752015,PHOSPHOGLUCOMUTASE 1 DEFICIENCY,1/14/19,Designated,Not FDA Approved for Orphan Indication,,,,
PURKAOJPTOLRMP-ASMGOKTBSA-N,71470491,PURKAOJPTOLRMP-ASMGOKTBSA-N,D9-ivacaftor,,Treatment of cystic fibrosis (CF),C0010674,Cystic Fibrosis,1/18/17,Designated,Not FDA Approved for Orphan Indication,,,,
KSRLIXGNPXAZHD-DFPPEFKWSA-N,136675526,KSRLIXGNPXAZHD-DFPPEFKWSA-N,dantrolene sodium,,Treatment of heat stroke,C0038819,Heat Stroke,9/25/12,Designated,Not FDA Approved for Orphan Indication,,,,
KSRLIXGNPXAZHD-DFPPEFKWSA-N,136675526,KSRLIXGNPXAZHD-DFPPEFKWSA-N,dantrolene sodium,,Treatment of heat stroke,C0038819,Heat Stroke,9/25/12,Designated,Not FDA Approved for Orphan Indication,,,,
KSRLIXGNPXAZHD-DFPPEFKWSA-M,71563341,KSRLIXGNPXAZHD-DFPPEFKWSA-M,dantrolene sodium,,Treatment of heat stroke,C0038819,Heat Stroke,9/25/12,Designated,Not FDA Approved for Orphan Indication,,,,
OZOMQRBLCMDCEG-CHHVJCJISA-M,5353563,OZOMQRBLCMDCEG-CHHVJCJISA-M,dantrolene sodium,,Treatment of heat stroke,C0038819,Heat Stroke,9/25/12,Designated,Not FDA Approved for Orphan Indication,,,,
OZOMQRBLCMDCEG-VIZOYTHASA-M,6604728,OZOMQRBLCMDCEG-VIZOYTHASA-M,dantrolene sodium,,Treatment of heat stroke,C0038819,Heat Stroke,9/25/12,Designated,Not FDA Approved for Orphan Indication,,,,
KSRLIXGNPXAZHD-HAZZGOGXSA-N,23707296,KSRLIXGNPXAZHD-HAZZGOGXSA-N,dantrolene sodium,,Treatment of heat stroke,C0038819,Heat Stroke,9/25/12,Designated,Not FDA Approved for Orphan Indication,,,,
BDZCLIOURDFSFQ-HAZZGOGXSA-N,16219293,BDZCLIOURDFSFQ-HAZZGOGXSA-N,dantrolene sodium,,Treatment of heat stroke,C0038819,Heat Stroke,9/25/12,Designated,Not FDA Approved for Orphan Indication,,,,
LTWQNYPDAUSXBC-CDJGKPBYSA-L,9568637,LTWQNYPDAUSXBC-CDJGKPBYSA-L,dantrolene sodium,,Treatment of heat stroke,C0038819,Heat Stroke,9/25/12,Designated,Not FDA Approved for Orphan Indication,,,,
KSRLIXGNPXAZHD-UHFFFAOYSA-M,32731,KSRLIXGNPXAZHD-UHFFFAOYSA-M,dantrolene sodium,,Treatment of heat stroke,C0038819,Heat Stroke,9/25/12,Designated,Not FDA Approved for Orphan Indication,,,,
KSRLIXGNPXAZHD-HAZZGOGXSA-M,13271066,KSRLIXGNPXAZHD-HAZZGOGXSA-M,dantrolene sodium,,Treatment of heat stroke,C0038819,Heat Stroke,9/25/12,Designated,Not FDA Approved for Orphan Indication,,,,
KSRLIXGNPXAZHD-DFPPEFKWSA-M,71563341,KSRLIXGNPXAZHD-DFPPEFKWSA-M,dantrolene sodium,,Treatment of heat stroke,C0038819,Heat Stroke,9/25/12,Designated,Not FDA Approved for Orphan Indication,,,,
KSRLIXGNPXAZHD-HAZZGOGXSA-M,13271066,KSRLIXGNPXAZHD-HAZZGOGXSA-M,dantrolene sodium,,Treatment of heat stroke,C0038819,Heat Stroke,9/25/12,Designated,Not FDA Approved for Orphan Indication,,,,
ZBNZXTGUTAYRHI-UHFFFAOYSA-N,3062316,ZBNZXTGUTAYRHI-UHFFFAOYSA-N,Dasatinib,Sprycel,Treatment of Philadelphia-positive acute lymphoblastic leukemia,C1709527,Philadelphia-positive acute lymphoblastic leukemia,11/18/05,Designated/Approved,,Treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy, 06/28/2006 , 06/28/2013 ,
RZRMFQMNPDPAIX-AJTOSFMRSA-N,126961379,RZRMFQMNPDPAIX-AJTOSFMRSA-N,dasiglucagon,,Treatment of hypoglycemia in patients with congenital hyperinsulinism (CH),"C0020615,C3888018","Hypoglycemia , Congenital Hyperinsulinism",8/10/17,Designated,Not FDA Approved for Orphan Indication,,,,
UBQYURCVBFRUQT-UHFFFAOYSA-N,2973,UBQYURCVBFRUQT-UHFFFAOYSA-N,deferoxamine,,Treatment of sickle cell leg ulcers,C0023223,Leg Ulcers,3/15/19,Designated,Not FDA Approved for Orphan Indication,,,,
JNWFIPVDEINBAI-UHFFFAOYSA-N,135565962,JNWFIPVDEINBAI-UHFFFAOYSA-N,defibrotide,,Prevention of acute graft versus host disease,C0856825,Acute Graft Versus Host Disease,5/14/20,Designated,Not FDA Approved for Orphan Indication,,,,
ZYRLHJIMTROTBO-UHFFFAOYSA-N,24770514,ZYRLHJIMTROTBO-UHFFFAOYSA-N,Devimistat,,Treatment of soft tissues sarcoma.,C1261473,Sarcoma,10/26/20,Designated,Not FDA Approved for Orphan Indication,,,,
UREBDLICKHMUKA-CXSFZGCWSA-N,5743,UREBDLICKHMUKA-CXSFZGCWSA-N,dexamethasone,,Treatment of multiple myeloma (MM),"C0026764,C3538749","Multiple Myeloma , Myeloma",3/26/18,Designated/Approved,,HEMADY is indicated in combination with other anti-myeloma products for the treatment of adults with multiple myeloma, 10/03/2019 , 10/03/2026 ,Indicated in combination with other anti-myeloma products for the treatment of adults with multiple myeloma (MM).
BMKDZUISNHGIBY-ZETCQYMHSA-N,71384,BMKDZUISNHGIBY-ZETCQYMHSA-N,dexrazoxane,Totect(r),Treatment of anthracycline extravasation during chemotherapy,C0015376,Extravasation,3/25/04,Designated/Approved,,Treatment of extravasation resulting from IV anthracycline chemotherapy, 09/06/2007 , 09/06/2014 ,
WVYXNIXAMZOZFK-UHFFFAOYSA-N,42616,WVYXNIXAMZOZFK-UHFFFAOYSA-N,Diaziquone,,Treatment of primary brain malignancies (grade III and IV astrocytomas).,"C0004114,C0006826","Astrocytomas , MALIGNANCIES",11/10/83,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
HJKBJIYDJLVSAO-UHFFFAOYSA-L,31195,HJKBJIYDJLVSAO-UHFFFAOYSA-L,Disodium clodronate,,Treatment of hypercalcemia of malignancy.,C0149911,Hypercalcemia of malignancy,6/16/93,Designated,Not FDA Approved for Orphan Indication,,,,
XLZOVRYBVCMCGL-BPNVQINPSA-L,49867944,XLZOVRYBVCMCGL-BPNVQINPSA-L,disufenton sodium,,Treatment of glioblastoma multiforme,C0017636,Glioblastoma multiforme,8/22/16,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
XLZOVRYBVCMCGL-BPNVQINPSA-L,49867944,XLZOVRYBVCMCGL-BPNVQINPSA-L,disufenton sodium,,Treatment of glioblastoma multiforme,C0017636,Glioblastoma multiforme,8/22/16,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PIQCTGMSNWUMAF-UHFFFAOYSA-N,135398510,PIQCTGMSNWUMAF-UHFFFAOYSA-N,Dovitinib,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,10/3/06,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
VBGWSQKGUZHFPS-ZVYAWBDLSA-N,129628207,VBGWSQKGUZHFPS-ZVYAWBDLSA-N,ecallantide,Kalbitor,Treatment of angioedema,C0002994,Angioedema,2/4/03,Designated/Approved,,Treatment of acute attacks of hereditary angioedema in patients 16 years of age and older, 12/01/2009 , 12/01/2016 ,
VBGWSQKGUZHFPS-FHVLXVBRSA-N,118984459,VBGWSQKGUZHFPS-FHVLXVBRSA-N,ecallantide,Kalbitor,Treatment of angioedema,C0002994,Angioedema,2/4/03,Designated/Approved,,Treatment of acute attacks of hereditary angioedema in patients 16 years of age and older, 12/01/2009 , 12/01/2016 ,
VBGWSQKGUZHFPS-VGMMZINCSA-N,44152182,VBGWSQKGUZHFPS-VGMMZINCSA-N,ecallantide,Kalbitor,Treatment of angioedema,C0002994,Angioedema,2/4/03,Designated/Approved,,Treatment of acute attacks of hereditary angioedema in patients 16 years of age and older, 12/01/2009 , 12/01/2016 ,
AUJXLBOHYWTPFV-BLWRDSOESA-N,138402870,AUJXLBOHYWTPFV-BLWRDSOESA-N,echinomycin,,Treatment of graft-versus-host disease (GVHD),C0018133,Graft-Versus-Host Disease,1/5/17,Designated,Not FDA Approved for Orphan Indication,,,,
AUJXLBOHYWTPFV-UJILECMYSA-N,134692670,AUJXLBOHYWTPFV-UJILECMYSA-N,echinomycin,,Treatment of graft-versus-host disease (GVHD),C0018133,Graft-Versus-Host Disease,1/5/17,Designated,Not FDA Approved for Orphan Indication,,,,
AUJXLBOHYWTPFV-LDUXBRJQSA-N,91826096,AUJXLBOHYWTPFV-LDUXBRJQSA-N,echinomycin,,Treatment of graft-versus-host disease (GVHD),C0018133,Graft-Versus-Host Disease,1/5/17,Designated,Not FDA Approved for Orphan Indication,,,,
AUJXLBOHYWTPFV-MADNPERPSA-N,6917949,AUJXLBOHYWTPFV-MADNPERPSA-N,echinomycin,,Treatment of graft-versus-host disease (GVHD),C0018133,Graft-Versus-Host Disease,1/5/17,Designated,Not FDA Approved for Orphan Indication,,,,
AUJXLBOHYWTPFV-MXGHYKICSA-N,23724556,AUJXLBOHYWTPFV-MXGHYKICSA-N,echinomycin,,Treatment of graft-versus-host disease (GVHD),C0018133,Graft-Versus-Host Disease,1/5/17,Designated,Not FDA Approved for Orphan Indication,,,,
AUJXLBOHYWTPFV-RQLJINDISA-N,44448250,AUJXLBOHYWTPFV-RQLJINDISA-N,echinomycin,,Treatment of graft-versus-host disease (GVHD),C0018133,Graft-Versus-Host Disease,1/5/17,Designated,Not FDA Approved for Orphan Indication,,,,
AUJXLBOHYWTPFV-CVLRASHMSA-N,458034,AUJXLBOHYWTPFV-CVLRASHMSA-N,echinomycin,,Treatment of graft-versus-host disease (GVHD),C0018133,Graft-Versus-Host Disease,1/5/17,Designated,Not FDA Approved for Orphan Indication,,,,
AUJXLBOHYWTPFV-VITLIGDRSA-N,6857732,AUJXLBOHYWTPFV-VITLIGDRSA-N,echinomycin,,Treatment of graft-versus-host disease (GVHD),C0018133,Graft-Versus-Host Disease,1/5/17,Designated,Not FDA Approved for Orphan Indication,,,,
AUJXLBOHYWTPFV-UHFFFAOYSA-N,3197,AUJXLBOHYWTPFV-UHFFFAOYSA-N,echinomycin,,Treatment of graft-versus-host disease (GVHD),C0018133,Graft-Versus-Host Disease,1/5/17,Designated,Not FDA Approved for Orphan Indication,,,,
APFMVAHRFWBCDG-JUOYHRLASA-N,170317,APFMVAHRFWBCDG-JUOYHRLASA-N,ecopipam hydrochloride,,Treatment of pediatric patients with Tourette's syndrome.,C0040517,Tourette's Syndrome,9/29/10,Designated,Not FDA Approved for Orphan Indication,,,,
APFMVAHRFWBCDG-JUOYHRLASA-N,170317,APFMVAHRFWBCDG-JUOYHRLASA-N,ecopipam hydrochloride,,Symptomatic treatment of self injurious behaviors in patients with Lesch-Nyhan disease.,C0023374,Lesch-Nyhan Disease,7/21/09,Designated,Not FDA Approved for Orphan Indication,,,,
QELUYTUMUWHWMC-UHFFFAOYSA-N,4021,QELUYTUMUWHWMC-UHFFFAOYSA-N,edaravone,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,3/12/15,Designated,Not FDA Approved for Orphan Indication,,,,
VLCYCQAOQCDTCN-UHFFFAOYSA-N,3009,VLCYCQAOQCDTCN-UHFFFAOYSA-N,eflornithine,,Treatment of Familial Adenomatous Polyposis,C0032580,Familial Adenomatous Polyposis,2/4/11,Designated,Not FDA Approved for Orphan Indication,,,,
BKJIXTWSNXCKJH-UHFFFAOYSA-N,300471,BKJIXTWSNXCKJH-UHFFFAOYSA-N,Elesclomol,,Treatment of metastatic melanoma in combination with paclitaxel,C0278883,Metastatic melanoma,12/18/07,Designated,Not FDA Approved for Orphan Indication,,,,
SVOQIEJWJCQGDQ-UHFFFAOYSA-N,135449332,SVOQIEJWJCQGDQ-UHFFFAOYSA-N,eltrombopag,Promacta,Treatment of idiopathic thrombocytopenia purpura,C0398650,Idiopathic thrombocytopenia purpura,5/5/08,Designated/Approved,,"Treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy", 11/20/2008 , 11/20/2015 ,
DYLUUSLLRIQKOE-UHFFFAOYSA-N,89683805,DYLUUSLLRIQKOE-UHFFFAOYSA-N,enasidenib,Idhifa,Treatment of acute myelogenous leukemia,C0023467,Acute myelogenous leukemia,6/12/14,Designated/Approved,,Treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test, 08/01/2017 , 08/01/2024 ,Treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test
WSNVXWWLBYSQIM-DMHHVDOYSA-N,49855308,WSNVXWWLBYSQIM-DMHHVDOYSA-N,Encaleret sulfate,,Treatment for Autosomal Dominant Hypocalcemia (including ADh type 1 and ADH type 2).,C4048195,Autosomal dominant hypocalcemia,11/24/20,Designated,Not FDA Approved for Orphan Indication,,,,
NOJBHZIZNPMQRT-CBASKZFISA-N,51049993,NOJBHZIZNPMQRT-CBASKZFISA-N,Encaleret sulfate,,Treatment for Autosomal Dominant Hypocalcemia (including ADh type 1 and ADH type 2).,C4048195,Autosomal dominant hypocalcemia,11/24/20,Designated,Not FDA Approved for Orphan Indication,,,,
HAYYBYPASCDWEQ-UHFFFAOYSA-N,25141092,HAYYBYPASCDWEQ-UHFFFAOYSA-N,entrectinib,ROZLYTREK,"Treatment of TrkA-positive, TrkB-positive, TrkC-positive ROS1-positive or ALK-positive non-small cell lung cancer",C3539721,Non-Small Cell Lung Cancer,2/3/15,Designated/Approved,,ROZLYTREK is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive., 08/15/2019 , 08/15/2026 ,For the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.
GVUGOAYIVIDWIO-UFWWTJHBSA-N,16143379,GVUGOAYIVIDWIO-UFWWTJHBSA-N,Epidermal growth factor (human),,For promotion of cutaneous wound healing in extreme burn treatment protocols.,C0564444,Cutaneous wound,3/6/85,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
LMHIPJMTZHDKEW-XQYLJSSYSA-N,21158562,LMHIPJMTZHDKEW-XQYLJSSYSA-N,Epoprostenol,Flolan,Treatment of primary pulmonary hypertension.,C3203102,Primary Pulmonary Hypertension,9/25/85,Designated/Approved,,Long-term intravenous treatment of primary pulmonary hypertension in NYHA Class III and Class IV patients., 09/20/1995 , 09/20/2002 ,
WHVPOEPABJZBBY-XQYLJSSYSA-N,67548346,WHVPOEPABJZBBY-XQYLJSSYSA-N,Epoprostenol,Flolan,Treatment of primary pulmonary hypertension.,C3203102,Primary Pulmonary Hypertension,9/25/85,Designated/Approved,,Long-term intravenous treatment of primary pulmonary hypertension in NYHA Class III and Class IV patients., 09/20/1995 , 09/20/2002 ,
LMHIPJMTZHDKEW-XQYLJSSYSA-M,6364626,LMHIPJMTZHDKEW-XQYLJSSYSA-M,Epoprostenol,Flolan,Treatment of primary pulmonary hypertension.,C3203102,Primary Pulmonary Hypertension,9/25/85,Designated/Approved,,Long-term intravenous treatment of primary pulmonary hypertension in NYHA Class III and Class IV patients., 09/20/1995 , 09/20/2002 ,
KAQKFAOMNZTLHT-OZUDYXHBSA-N,5282411,KAQKFAOMNZTLHT-OZUDYXHBSA-N,Epoprostenol,Flolan,Treatment of primary pulmonary hypertension.,C3203102,Primary Pulmonary Hypertension,9/25/85,Designated/Approved,,Long-term intravenous treatment of primary pulmonary hypertension in NYHA Class III and Class IV patients., 09/20/1995 , 09/20/2002 ,
GWBBVOVXJZATQQ-UHFFFAOYSA-L,23894,GWBBVOVXJZATQQ-UHFFFAOYSA-L,Etidronate disodium,,Treatment of degenerative metabolic bone disease occurring in patients who require long term (6 months or greater) total parenteral nutrition.,C0005944,Metabolic Bone Disease,5/2/91,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
FCWSQAKOPTZCOD-SQYSSJHTSA-N,101163123,FCWSQAKOPTZCOD-SQYSSJHTSA-N,etoposide toniribate,,Treatment of biliary tract cancer,C0750952,Biliary Tract Cancer,2/11/19,Designated,Not FDA Approved for Orphan Indication,,,,
HKVAMNSJSFKALM-GKUWKFKPSA-N,6442177,HKVAMNSJSFKALM-GKUWKFKPSA-N,everolimus,Afinitor,"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)","C0041341,C0205768,C0206633,C0751674,C1832033,C2247022","Tuberous Sclerosis Complex , Subependymal Giant Cell Astrocytoma , Angiomyolipoma , Lymphangioleiomyomatosis , Subependymal Giant Cell Astrocytoma , tuberous sclerosis complex",6/8/09,Designated/Approved,,For the adjunctive treatment of adult and pediatric patients age 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures., 04/10/2018 , 04/10/2025 ,For the adjunctive treatment of adult and pediatric patients age 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures.
PCOBBVZJEWWZFR-UHFFFAOYSA-N,121892,PCOBBVZJEWWZFR-UHFFFAOYSA-N,ezogabine,,Treatment of KCNQ2 epileptic encephalopathy,C0543888,Epileptic encephalopathy,6/21/18,Designated,Not FDA Approved for Orphan Indication,,,,
BWCJZAGTBVMMTO-UHFFFAOYSA-N,139032792,BWCJZAGTBVMMTO-UHFFFAOYSA-N,Fenobam hydrochloride,,Treatment of fragile X syndrome,C0016667,Fragile X Syndrome,11/20/06,Designated,Not FDA Approved for Orphan Indication,,,,
AKJHMTWEGVYYSE-FXILSDISSA-N,5288209,AKJHMTWEGVYYSE-FXILSDISSA-N,Fenretinide,,Treatment of neuroblastoma,C0027819,Neuroblastoma,10/5/05,Designated,Not FDA Approved for Orphan Indication,,,,
KMUNHOKTIVSFRA-KXFIGUGUSA-N,135409256,KMUNHOKTIVSFRA-KXFIGUGUSA-N,filociclovir,,Treatment of active cytomegalovirus infections,C0010823,Cytomegalovirus Infections,11/29/10,Designated,Not FDA Approved for Orphan Indication,,,,
CXWRXYDTWCBSJF-DPTNTHPESA-N,59443782,CXWRXYDTWCBSJF-DPTNTHPESA-N,firtecan pegol,,Treatment of neuroblastoma.,C0027819,Neuroblastoma,4/18/11,Designated,Not FDA Approved for Orphan Indication,,,,
NCWZOASIUQVOFA-FWZJPQCDSA-N,11501341,NCWZOASIUQVOFA-FWZJPQCDSA-N,florbetaben F18,,Diagnostic for the management of amyloid light chain (AL) amyloidosis,C4509023,Light chain (AL) amyloidosis,4/7/20,Designated,Not FDA Approved for Orphan Indication,,,,
ZYULQCDNUYJBRI-HSGWXFLFSA-N,24989762,ZYULQCDNUYJBRI-HSGWXFLFSA-N,flubrobenguane (18F),,Diagnostic for the management of neuroendocrine tumors,C0206754,Neuroendocrine Tumors,6/4/19,Designated,Not FDA Approved for Orphan Indication,,,,
GIUYCYHIANZCFB-FJFJXFQQSA-N,30751,GIUYCYHIANZCFB-FJFJXFQQSA-N,Fludarabine phosphate,,Treatment and management of patients with non-Hodgkins lymphoma.,C0024305,Non-Hodgkins Lymphoma,4/18/89,Designated,Not FDA Approved for Orphan Indication,,,,
GHASVSINZRGABV-UHFFFAOYSA-N,3385,GHASVSINZRGABV-UHFFFAOYSA-N,Fluorouracil,,Treatment of glioblastoma multiforme.,C0017636,Glioblastoma multiforme,6/29/00,Designated,Not FDA Approved for Orphan Indication,,,,
WMWTYOKRWGGJOA-CENSZEJFSA-N,444036,WMWTYOKRWGGJOA-CENSZEJFSA-N,fluticasone propionate,,Treatment of pediatric and adult eosinophilic esophagitis,C0341106,Eosinophilic esophagitis,1/19/11,Designated,Not FDA Approved for Orphan Indication,,,,
WTCJDYDZHHFTEW-UHFFFAOYSA-N,24182261,WTCJDYDZHHFTEW-UHFFFAOYSA-N,gallium citrate,,Treatment of lung infections in patients with cystic fibrosis,C0010674,Cystic Fibrosis,6/24/19,Designated,Not FDA Approved for Orphan Indication,,,,
YEEGWNXDUZONAA-RYDPDVNUSA-K,65430,YEEGWNXDUZONAA-RYDPDVNUSA-K,gallium citrate,,Treatment of lung infections in patients with cystic fibrosis,C0010674,Cystic Fibrosis,6/24/19,Designated,Not FDA Approved for Orphan Indication,,,,
YEEGWNXDUZONAA-UHFFFAOYSA-K,34058,YEEGWNXDUZONAA-UHFFFAOYSA-K,gallium citrate,,Treatment of lung infections in patients with cystic fibrosis,C0010674,Cystic Fibrosis,6/24/19,Designated,Not FDA Approved for Orphan Indication,,,,
SJZRECIVHVDYJC-UHFFFAOYSA-N,10413,SJZRECIVHVDYJC-UHFFFAOYSA-N,Gamma hydroxybutyrate,,"Treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations and automatic behavior.","C0007384,C0027404,C0233773,C0456511,C1457887","Cataplexy , Narcolepsy , Hypnagogic hallucinations , Sleep Paralysis , Symptoms",12/3/87,Designated,Not FDA Approved for Orphan Indication,,,,
XGALLCVXEZPNRQ-UHFFFAOYSA-N,123631,XGALLCVXEZPNRQ-UHFFFAOYSA-N,gefitinib,Iressa,Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer,C3539721,Non-Small Cell Lung Cancer,8/26/14,Designated/Approved,,For the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test, 07/13/2015 , 07/13/2022 ,For the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test
SDUQYLNIPVEERB-QPPQHZFASA-N,60750,SDUQYLNIPVEERB-QPPQHZFASA-N,gemcitabine,,Treatment of upper tract urothelial carcinoma,C0007138,Urothelial carcinoma,12/30/15,Designated,Not FDA Approved for Orphan Indication,,,,
HEMJJKBWTPKOJG-UHFFFAOYSA-N,3463,HEMJJKBWTPKOJG-UHFFFAOYSA-N,gemfibrozil,,Treatment of neuronal ceroid lipofuscinoses,C0027877,neuronal ceroid lipofuscinoses,8/2/17,Designated,Not FDA Approved for Orphan Indication,,,,
DOAUQKRTILFGHV-PDCMDPCFSA-N,146170995,DOAUQKRTILFGHV-PDCMDPCFSA-N,glepaglutide,,Treatment of short bowel syndrome,C0036992,Short Bowel Syndrome,10/20/17,Designated,Not FDA Approved for Orphan Indication,,,,
FOHHNHSLJDZUGQ-UHFFFAOYSA-N,37393,FOHHNHSLJDZUGQ-UHFFFAOYSA-N,Halofantrine,Halfan,Treatment of mild to moderate acute malaria caused by susceptible strains of P. falciparum and P. vivax.,C2930826,Acute malaria,11/4/91,Designated/Approved,,Treatment of adults who can tolerate oral medication and who have mild to moderate malaria caused by Plasmodium falciparum or Plasmodium vivax., 07/24/1992 , 07/24/1999 ,
HQBGGOLLNATNQC-INZIHYEWSA-N,135564839,HQBGGOLLNATNQC-INZIHYEWSA-N,Heme arginate,,Treatment of myelodysplastic syndromes.,C3463824,Myelodysplastic Syndromes,3/1/94,Designated,Not FDA Approved for Orphan Indication,,,,
CZPDCEDNNVRQEX-INZIHYEWSA-L,154723996,CZPDCEDNNVRQEX-INZIHYEWSA-L,Heme arginate,,Treatment of myelodysplastic syndromes.,C3463824,Myelodysplastic Syndromes,3/1/94,Designated,Not FDA Approved for Orphan Indication,,,,
MGQITOFVXOEWNL-INZIHYEWSA-N,3086464,MGQITOFVXOEWNL-INZIHYEWSA-N,Heme arginate,,Treatment of myelodysplastic syndromes.,C3463824,Myelodysplastic Syndromes,3/1/94,Designated,Not FDA Approved for Orphan Indication,,,,
HQBGGOLLNATNQC-INZIHYEWSA-N,135564839,HQBGGOLLNATNQC-INZIHYEWSA-N,Heme arginate,,Treatment of symptomatic stage of acute porphyria.,C0162565,Acute Porphyria,3/10/88,Designated,Not FDA Approved for Orphan Indication,,,,
CZPDCEDNNVRQEX-INZIHYEWSA-L,154723996,CZPDCEDNNVRQEX-INZIHYEWSA-L,Heme arginate,,Treatment of symptomatic stage of acute porphyria.,C0162565,Acute Porphyria,3/10/88,Designated,Not FDA Approved for Orphan Indication,,,,
MGQITOFVXOEWNL-INZIHYEWSA-N,3086464,MGQITOFVXOEWNL-INZIHYEWSA-N,Heme arginate,,Treatment of symptomatic stage of acute porphyria.,C0162565,Acute Porphyria,3/10/88,Designated,Not FDA Approved for Orphan Indication,,,,
ZRJBHWIHUMBLCN-HNWKQCISSA-N,71308731,ZRJBHWIHUMBLCN-HNWKQCISSA-N,Huperzine A,,Treatment of Dravet syndrome,C0751122,Dravet Syndrome,4/12/17,Designated,Not FDA Approved for Orphan Indication,,,,
ZRJBHWIHUMBLCN-JRYCNTDSSA-N,4369233,ZRJBHWIHUMBLCN-JRYCNTDSSA-N,Huperzine A,,Treatment of Dravet syndrome,C0751122,Dravet Syndrome,4/12/17,Designated,Not FDA Approved for Orphan Indication,,,,
ZRJBHWIHUMBLCN-BMIGLBTASA-N,1633595,ZRJBHWIHUMBLCN-BMIGLBTASA-N,Huperzine A,,Treatment of Dravet syndrome,C0751122,Dravet Syndrome,4/12/17,Designated,Not FDA Approved for Orphan Indication,,,,
ZRJBHWIHUMBLCN-MEBBXXQBSA-N,6565233,ZRJBHWIHUMBLCN-MEBBXXQBSA-N,Huperzine A,,Treatment of Dravet syndrome,C0751122,Dravet Syndrome,4/12/17,Designated,Not FDA Approved for Orphan Indication,,,,
ZRJBHWIHUMBLCN-JYXJEATCSA-N,44461111,ZRJBHWIHUMBLCN-JYXJEATCSA-N,Huperzine A,,Treatment of Dravet syndrome,C0751122,Dravet Syndrome,4/12/17,Designated,Not FDA Approved for Orphan Indication,,,,
ZRJBHWIHUMBLCN-HZRLMBICSA-N,9794806,ZRJBHWIHUMBLCN-HZRLMBICSA-N,Huperzine A,,Treatment of Dravet syndrome,C0751122,Dravet Syndrome,4/12/17,Designated,Not FDA Approved for Orphan Indication,,,,
ZRJBHWIHUMBLCN-QDEBKDIKSA-N,5912039,ZRJBHWIHUMBLCN-QDEBKDIKSA-N,Huperzine A,,Treatment of Dravet syndrome,C0751122,Dravet Syndrome,4/12/17,Designated,Not FDA Approved for Orphan Indication,,,,
ZRJBHWIHUMBLCN-SEQYCRGISA-N,907504,ZRJBHWIHUMBLCN-SEQYCRGISA-N,Huperzine A,,Treatment of Dravet syndrome,C0751122,Dravet Syndrome,4/12/17,Designated,Not FDA Approved for Orphan Indication,,,,
ZRJBHWIHUMBLCN-UHFFFAOYSA-N,1253,ZRJBHWIHUMBLCN-UHFFFAOYSA-N,Huperzine A,,Treatment of Dravet syndrome,C0751122,Dravet Syndrome,4/12/17,Designated,Not FDA Approved for Orphan Indication,,,,
ZRJBHWIHUMBLCN-ZUZCIYMTSA-N,449069,ZRJBHWIHUMBLCN-ZUZCIYMTSA-N,Huperzine A,,Treatment of Dravet syndrome,C0751122,Dravet Syndrome,4/12/17,Designated,Not FDA Approved for Orphan Indication,,,,
ZRJBHWIHUMBLCN-YQEJDHNASA-N,854026,ZRJBHWIHUMBLCN-YQEJDHNASA-N,Huperzine A,,Treatment of Dravet syndrome,C0751122,Dravet Syndrome,4/12/17,Designated,Not FDA Approved for Orphan Indication,,,,
JYGXADMDTFJGBT-VWUMJDOOSA-N,5754,JYGXADMDTFJGBT-VWUMJDOOSA-N,hydrocortisone,,Prevention of bronchopulmonary dysplasia,C0006287,Bronchopulmonary Dysplasia,5/13/20,Designated,Not FDA Approved for Orphan Indication,,,,
ALEXXDVDDISNDU-JZYPGELDSA-N,5744,ALEXXDVDDISNDU-JZYPGELDSA-N,hydrocortisone acetate,,Treatment of pediatric ulcerative colitis,C2931173,Pediatric ulcerative colitis,6/27/17,Designated,Not FDA Approved for Orphan Indication,,,,
IXZOHGPZAQLIBH-NRFANRHFSA-N,67335295,IXZOHGPZAQLIBH-NRFANRHFSA-N,iberdomide,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,12/19/18,Designated,Not FDA Approved for Orphan Indication,,,,
XYFPWWZEPKGCCK-GOSISDBHSA-N,24821094,XYFPWWZEPKGCCK-GOSISDBHSA-N,ibrutinib,Imbruvica,Treatment of chronic lymphocytic leukemia (CLL),C0023434,Chronic Lymphocytic Leukemia,4/6/12,Designated/Approved,,Treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy and treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, 07/28/2014 , 07/28/2021 ,Treatment of chronic lymphocytic leukemia with 17p deletion who have not received at least one prior therapy
XYFPWWZEPKGCCK-GOSISDBHSA-N,24821094,XYFPWWZEPKGCCK-GOSISDBHSA-N,ibrutinib,Imbruvica,Treatment of chronic lymphocytic leukemia (CLL),C0023434,Chronic Lymphocytic Leukemia,4/6/12,Designated/Approved,,Indicated for the treatment of patients with chronic lymphocytic leukemia, 03/04/2016 , 03/04/2023 ,Indicated for the treatment of patients with chronic lymphocytic leukemia without 17p deletion who have not received at least one prior therapy (first line therapy).
XYFPWWZEPKGCCK-GOSISDBHSA-N,24821094,XYFPWWZEPKGCCK-GOSISDBHSA-N,ibrutinib,,Treatment of follicular lymphoma,C0024301,follicular lymphoma,9/8/14,Designated,Not FDA Approved for Orphan Indication,,,,
ZJVFLBOZORBYFE-UHFFFAOYSA-N,3671,ZJVFLBOZORBYFE-UHFFFAOYSA-N,Ibudilast,,Treatment of Glioblastoma,C0017636,Glioblastoma,10/2/18,Designated,Not FDA Approved for Orphan Indication,,,,
JGPMMRGNQUBGND-UHFFFAOYSA-N,3686,JGPMMRGNQUBGND-UHFFFAOYSA-N,idebenone,,Treatment of Friedreich's ataxia,C0016719,Friedreich's Ataxia,3/25/04,Designated,Not FDA Approved for Orphan Indication,,,,
JGPMMRGNQUBGND-UHFFFAOYSA-N,3686,JGPMMRGNQUBGND-UHFFFAOYSA-N,idebenone,,Treatment of Duchenne muscular dystrophy,C0013264,DUCHENNE MUSCULAR DYSTROPHY,2/16/07,Designated,Not FDA Approved for Orphan Indication,,,,
JGPMMRGNQUBGND-UHFFFAOYSA-N,3686,JGPMMRGNQUBGND-UHFFFAOYSA-N,idebenone,,Treatment of Leber's hereditary optic neuropathy.,C0917796,Leber's Hereditary Optic Neuropathy,10/31/06,Designated,Not FDA Approved for Orphan Indication,,,,
IFSDAJWBUCMOAH-HNNXBMFYSA-N,11625818,IFSDAJWBUCMOAH-HNNXBMFYSA-N,idelalisib,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,8/25/11,Designated,Not FDA Approved for Orphan Indication,,,,
XQFRJNBWHJMXHO-RRKCRQDMSA-N,5905,XQFRJNBWHJMXHO-RRKCRQDMSA-N,Idoxuridine,,Treatment of nonparenchymatous sarcomas.,C1261473,Sarcomas,4/8/96,Designated,Not FDA Approved for Orphan Indication,,,,
KTUFNOKKBVMGRW-UHFFFAOYSA-N,5291,KTUFNOKKBVMGRW-UHFFFAOYSA-N,imatinib,Gleevec,Treatment of Philadelphia-positive acute lymphoblastic leukemia,C1709527,Philadelphia-positive acute lymphoblastic leukemia,10/11/05,Designated/Approved,,Pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy, 01/25/2013 , 01/25/2020 ,Treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy
AMNXBQPRODZJQR-DITALETJSA-N,5745206,AMNXBQPRODZJQR-DITALETJSA-N,Implitapide,,Treatment of homozygous familial hypercholesterolemia,C0020445,FAMILIAL HYPERCHOLESTEROLEMIA,8/13/04,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
AMNXBQPRODZJQR-DITALETJSA-N,5745206,AMNXBQPRODZJQR-DITALETJSA-N,Implitapide,,Treatment of patients with Fredrickson type I or V hyperlipoproteinemia,C0023817,Fredrickson type I or V hyperlipoproteinemia,8/19/04,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
KLEGMTRDCCDFJK-XDQSQZFTSA-N,121492004,KLEGMTRDCCDFJK-XDQSQZFTSA-N,Inotersen,TEGSEDI,Treatment of transthyretin amyloidosis (ATTR amyloidosis),"C0002726,C2751492","Amyloidosis , Transthyretin Amyloidosis",7/24/12,Designated/Approved,,TEGSEDI is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults., 10/05/2018 , 10/05/2025 ,TEGSEDI is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
PDWUPXJEEYOOTR-IUAIQHPESA-N,135326,PDWUPXJEEYOOTR-IUAIQHPESA-N,Iobenguane I 123,Adreview,For the diagnosis of neuroblastomas,C0027819,Neuroblastomas,12/1/06,Designated/Approved,,To be used in the detection of primary or metastatic pheochromocytomas or neuroblastomas as an adjunct to other diagnostic tests, 09/19/2008 , 09/19/2015 ,
LWXUIUUOMSMZKJ-KLFWAVJMSA-M,72196309,LWXUIUUOMSMZKJ-KLFWAVJMSA-M,isavuconazonium sulfate,Cresemba,Treatment of invasive aspergillosis,C0238013,Invasive aspergillosis,5/6/13,Designated/Approved,,Treatment of invasive aspergillosis in patients 18 years of age and older, 03/06/2015 , 03/06/2022 ,Treatment of invasive aspergillosis in patients 18 years of age and older
VHVPQPYKVGDNFY-DFMJLFEVSA-N,14179008,VHVPQPYKVGDNFY-DFMJLFEVSA-N,itraconazole,,Treatment of coccidioidomycosis,C0009186,Coccidioidomycosis,11/17/20,Designated,Not FDA Approved for Orphan Indication,,,,
VHVPQPYKVGDNFY-VXTATNQMSA-N,45039617,VHVPQPYKVGDNFY-VXTATNQMSA-N,itraconazole,,Treatment of coccidioidomycosis,C0009186,Coccidioidomycosis,11/17/20,Designated,Not FDA Approved for Orphan Indication,,,,
VHVPQPYKVGDNFY-TUJWMRSMSA-N,14179013,VHVPQPYKVGDNFY-TUJWMRSMSA-N,itraconazole,,Treatment of coccidioidomycosis,C0009186,Coccidioidomycosis,11/17/20,Designated,Not FDA Approved for Orphan Indication,,,,
VHVPQPYKVGDNFY-AVQIMAJZSA-N,6917738,VHVPQPYKVGDNFY-AVQIMAJZSA-N,itraconazole,,Treatment of coccidioidomycosis,C0009186,Coccidioidomycosis,11/17/20,Designated,Not FDA Approved for Orphan Indication,,,,
VHVPQPYKVGDNFY-UHFFFAOYSA-N,3793,VHVPQPYKVGDNFY-UHFFFAOYSA-N,itraconazole,,Treatment of coccidioidomycosis,C0009186,Coccidioidomycosis,11/17/20,Designated,Not FDA Approved for Orphan Indication,,,,
VHVPQPYKVGDNFY-ZPGVKDDISA-N,55283,VHVPQPYKVGDNFY-ZPGVKDDISA-N,itraconazole,,Treatment of coccidioidomycosis,C0009186,Coccidioidomycosis,11/17/20,Designated,Not FDA Approved for Orphan Indication,,,,
PURKAOJPTOLRMP-UHFFFAOYSA-N,16220172,PURKAOJPTOLRMP-UHFFFAOYSA-N,ivacaftor,Kalydeco,Treatment of patients with cystic fibrosis,C0010674,Cystic Fibrosis,12/20/06,Designated/Approved,,Treatment of cystic fibrosis (CF) in patients age 2 years and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data., 07/31/2017 , 07/31/2024 ,"Treatment of cystic fibrosis (CF) in patients age 2 years and older who have one of the following mutations in the CFTR gene: 711+3A G, E831X, 2789+5G A, 3272-26A G, and 3849+10kbC T."
MBOMYENWWXQSNW-AWEZNQCLSA-N,56844015,MBOMYENWWXQSNW-AWEZNQCLSA-N,ixazomib citrate,Ninlaro,Treatment of multiple myeloma,C0026764,Multiple Myeloma,2/18/11,Designated/Approved,,Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy, 11/20/2015 , 11/20/2022 ,Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy
RHGKLRLOHDJJDR-BYPYZUCNSA-N,9750,RHGKLRLOHDJJDR-BYPYZUCNSA-N,L-Citrulline,,Treatment of Ornithine Transcarbamylase deficiency,C0268542,Ornithine Transcarbamylase Deficiency,11/3/20,Designated,Not FDA Approved for Orphan Indication,,,,
DYDCUQKUCUHJBH-REOHCLBHSA-N,449215,DYDCUQKUCUHJBH-REOHCLBHSA-N,L-cycloserine,,Treatment of Gaucher's disease.,C0017205,Gaucher's Disease,8/1/89,Designated,Not FDA Approved for Orphan Indication,,,,
LLEUXCDZPQOJMY-AAEUAGOBSA-N,100094,LLEUXCDZPQOJMY-AAEUAGOBSA-N,L-glutamyl-L-tryptophan,,Treatment of AIDS-related Kaposi's sarcoma.,C0276535,AIDS-related Kaposi's sarcoma,10/20/99,Designated,Not FDA Approved for Orphan Indication,,,,
PYZRQGJRPPTADH-UHFFFAOYSA-N,3878,PYZRQGJRPPTADH-UHFFFAOYSA-N,Lamotrigine,Lamictal,Treatment of Lennox-Gastaut syndrome.,C0238111,Lennox-Gastaut syndrome,8/23/95,Designated/Approved,,Adjunctive treatment of Lennox-Gastaut syndrome in pediatric and adult patients., 08/24/1998 , 08/24/2005 ,
PUDHBTGHUJUUFI-SCTWWAJVSA-N,6918011,PUDHBTGHUJUUFI-SCTWWAJVSA-N,lanreotide acetate,,Treatment of carcinoid syndrome,C0024586,Carcinoid syndrome,9/8/11,Designated/Approved,,"treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy", 09/15/2017 , 09/15/2024 ,"treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy"
PUDHBTGHUJUUFI-UHFFFAOYSA-N,71349,PUDHBTGHUJUUFI-UHFFFAOYSA-N,lanreotide acetate,,Treatment of carcinoid syndrome,C0024586,Carcinoid syndrome,9/8/11,Designated/Approved,,"treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy", 09/15/2017 , 09/15/2024 ,"treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy"
YCHYFHOSGQABSW-RTBURBONSA-N,3083542,YCHYFHOSGQABSW-RTBURBONSA-N,lenabasum,,Treatment of dermatomyositis,C0011633,Dermatomyositis,7/18/18,Designated,Not FDA Approved for Orphan Indication,,,,
GOTYRUGSSMKFNF-UHFFFAOYSA-N,216326,GOTYRUGSSMKFNF-UHFFFAOYSA-N,lenalidomide,,Treatment of diffuse large B-cell lymphoma,C1332201,Diffuse Large B-Cell Lymphoma,3/28/11,Designated,Not FDA Approved for Orphan Indication,,,,
GOTYRUGSSMKFNF-UHFFFAOYSA-N,216326,GOTYRUGSSMKFNF-UHFFFAOYSA-N,lenalidomide,Revlimid,Treatment of multiple myeloma,C0026764,Multiple Myeloma,9/20/01,Designated/Approved,,For use in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy, 06/29/2006 , 06/29/2013 ,
WOSKHXYHFSIKNG-UHFFFAOYSA-N,9823820,WOSKHXYHFSIKNG-UHFFFAOYSA-N,lenvatinib,Lenvima,"Treatment of follicullar, medullary, anaplastic, and metastatic or locally advanced papillary thyroid cancer",C0238463,papillary thyroid cancer,12/27/12,Designated/Approved,,"Treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine refractory differentiated thyroid cancer", 02/13/2015 , 02/13/2022 ,"Treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine refractory differentiated thyroid cancer"
WOSKHXYHFSIKNG-UHFFFAOYSA-N,9823820,WOSKHXYHFSIKNG-UHFFFAOYSA-N,lenvatinib,LENVIMA,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,3/27/14,Designated/Approved,,LENVIMA is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC), 08/15/2018 , 08/15/2025 ,LENVIMA is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)
UIARLYUEJFELEN-LROUJFHJSA-N,126565,UIARLYUEJFELEN-LROUJFHJSA-N,lestaurtinib,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,3/24/06,Designated,Not FDA Approved for Orphan Indication,,,,
PHIQHXFUZVPYII-ZCFIWIBFSA-N,10917,PHIQHXFUZVPYII-ZCFIWIBFSA-N,Levocarnitine,Carnitor,Treatment of primary and secondary carnitine deficiency of genetic origin.,C2025219,Secondary carnitine deficiency,7/26/84,Designated/Approved,,Treatment of primary systemic carnitine deficiency. (approved 12/27/85) Treatment of secondary carnitine deficiency. (approved 12/16/92), 12/16/1992 , 12/16/1999 ,
PHIQHXFUZVPYII-ZCFIWIBFSA-N,10917,PHIQHXFUZVPYII-ZCFIWIBFSA-N,Levocarnitine,Carnitor,Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.,"C0022661,C0342788","End stage renal disease , Carnitine Deficiency",9/6/88,Designated/Approved,,Prevention and treatment of carnitine deficiency in patients with end stage renal disease who are undergoing dialysis., 12/15/1999 , 12/15/2006 ,
VVIAGPKUTFNRDU-STQMWFEESA-N,135398559,VVIAGPKUTFNRDU-STQMWFEESA-N,Levoleucovorin,Fusilev,For use in conjunction with high-dose methotrexate in the treatment of osteosarcoma.,C0029463,Osteosarcoma,8/1/91,Designated/Approved,,Levoleucovorin rescue is indicated after high-dose methotrexate therapy in osteosarcoma. Levoleucovorin is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists, 03/07/2008 , 03/07/2015 ,
NSMXQKNUPPXBRG-SECBINFHSA-N,501254,NSMXQKNUPPXBRG-SECBINFHSA-N,Lisofylline,,Treatment of patients undergoing induction therapy for acute myeloid leukemia.,C0023467,Acute myeloid leukemia,6/10/99,Designated,Not FDA Approved for Orphan Indication,,,,
XGZVUEUWXADBQD-UHFFFAOYSA-L,11125,XGZVUEUWXADBQD-UHFFFAOYSA-L,lithium carbonate,,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,3/29/21,Designated,Not FDA Approved for Orphan Indication,,,,
OSPNFKYGOFXGBX-YWWKUQGPSA-N,145722609,OSPNFKYGOFXGBX-YWWKUQGPSA-N,Lucinactant,,Treatment of bronchopulmonary dysplasia in premature infants.,C0006287,Bronchopulmonary Dysplasia,10/21/05,Designated,Not FDA Approved for Orphan Indication,,,,
NGWSFRIPKNWYAO-SHTIJGAHSA-N,11347535,NGWSFRIPKNWYAO-SHTIJGAHSA-N,marizomib,,Treatment of malignant glioma.,C0555198,Malignant Glioma,9/21/15,Designated,Not FDA Approved for Orphan Indication,,,,
IMYZQPCYWPFTAG-UHFFFAOYSA-N,4032,IMYZQPCYWPFTAG-UHFFFAOYSA-N,Mecamylamine,,Treatment of Tourette's syndrome.,C0040517,Tourette's Syndrome,10/14/98,Designated,Not FDA Approved for Orphan Indication,,,,
DRLFMBDRBRZALE-UHFFFAOYSA-N,896,DRLFMBDRBRZALE-UHFFFAOYSA-N,melatonin,,Treatment of smith-magenis syndrome in combination with a beta-blocker,C0039082,Syndrome,11/3/16,Designated,Not FDA Approved for Orphan Indication,,,,
SGDBTWWWUNNDEQ-LBPRGKRZSA-N,460612,SGDBTWWWUNNDEQ-LBPRGKRZSA-N,Melphalan,Alkeran For Injection,Treatment of patients with multiple myeloma for whom oral therapy is inappropriate.,C0026764,Multiple Myeloma,2/24/92,Designated/Approved,,For the palliative treatment of patients with multiple myeloma for whom oral melphalan is not appropriate., 11/18/1992 , 11/18/1999 ,
XDPFHGWVCTXHDX-UHFFFAOYSA-M,23665888,XDPFHGWVCTXHDX-UHFFFAOYSA-M,menadione sodium bisulfite,,Treatment of autosomal dominant polycystic liver disease,C0158683,Polycystic liver disease,5/14/14,Designated,Not FDA Approved for Orphan Indication,,,,
XDPFHGWVCTXHDX-UHFFFAOYSA-M,23665888,XDPFHGWVCTXHDX-UHFFFAOYSA-M,Menadione Sodium Bisulfite,,For the treatment of autosomal dominant polycystic kidney disease,C0085413,Autosomal dominant polycystic kidney disease,5/14/14,Designated,Not FDA Approved for Orphan Indication,,,,
DKHGMERMDICWDU-GHDNBGIDSA-N,5282367,DKHGMERMDICWDU-GHDNBGIDSA-N,menatetrenone,,Treatment of hepatocellular carcinoma (HCC).,C2239176,HEPATOCELLULAR CARCINOMA,11/2/10,Designated,Not FDA Approved for Orphan Indication,,,,
DKHGMERMDICWDU-GHDNBGIDSA-N,5282367,DKHGMERMDICWDU-GHDNBGIDSA-N,menatetrenone,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,3/17/11,Designated,Not FDA Approved for Orphan Indication,,,,
INWLQCZOYSRPNW-UHFFFAOYSA-N,4062,INWLQCZOYSRPNW-UHFFFAOYSA-N,mepivacaine,,Treatment of painful HIV-associated neuropathy,"C0019682,C0442874","HIV , Neuropathy",10/18/06,Designated,Not FDA Approved for Orphan Indication,,,,
XOGTZOOQQBDUSI-UHFFFAOYSA-M,23662354,XOGTZOOQQBDUSI-UHFFFAOYSA-M,Mesna,Mesnex,For use as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.,C0085692,Hemorrhagic cystitis,11/14/85,Designated/Approved,,, 12/30/1988 , 12/30/1995 ,
XZWYZXLIPXDOLR-UHFFFAOYSA-N,4091,XZWYZXLIPXDOLR-UHFFFAOYSA-N,metformin,,Treatment of pediatric polycystic ovary syndrome,C0032460,Polycystic Ovary Syndrome,5/29/14,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
FBOZXECLQNJBKD-ZDUSSCGKSA-N,126941,FBOZXECLQNJBKD-ZDUSSCGKSA-N,methotrexate,,Treatment of acute lymphoblastic leukemia,C0023449,Acute lymphoblastic leukemia,8/20/09,Designated,Not FDA Approved for Orphan Indication,,,,
QXKHYNVANLEOEG-UHFFFAOYSA-N,4114,QXKHYNVANLEOEG-UHFFFAOYSA-N,Methoxsalen,,For use in conjunction with the UVAR photopheresis system to treat graft versus host disease.,C0018133,GRAFT VERSUS HOST DISEASE,10/14/98,Designated,Not FDA Approved for Orphan Indication,,,,
CXKWCBBOMKCUKX-UHFFFAOYSA-M,6099,CXKWCBBOMKCUKX-UHFFFAOYSA-M,methylene blue,,Treatment of methemoglobinemia,C0025637,Methemoglobinemia,7/24/12,Designated,Not FDA Approved for Orphan Indication,,,,
HBNPJJILLOYFJU-VMPREFPWSA-N,60663,HBNPJJILLOYFJU-VMPREFPWSA-N,mibefradil,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,6/15/07,Designated,Not FDA Approved for Orphan Indication,,,,
DDLIGBOFAVUZHB-UHFFFAOYSA-N,4192,DDLIGBOFAVUZHB-UHFFFAOYSA-N,midazolam,,Treatment of status epilepticus,C0038220,Status Epilepticus,2/18/16,Designated,Not FDA Approved for Orphan Indication,,,,
DDLIGBOFAVUZHB-UHFFFAOYSA-N,4192,DDLIGBOFAVUZHB-UHFFFAOYSA-N,midazolam,,Treatment of seizures induced by organophosporous insecticide poisoning.,"C0036572,C0413048","Seizures , Insecticide poisoning",2/8/16,Designated,Not FDA Approved for Orphan Indication,,,,
ZJIHMALTJRDNQI-OLALXQGDSA-N,11644097,ZJIHMALTJRDNQI-OLALXQGDSA-N,migalastat hydrochloride,GALAFOLD,Treatment of Fabry Disease,C0002986,Fabry Disease,2/25/04,Designated/Approved,,GALAFOLD is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data, 08/10/2018 , 08/10/2025 ,GALAFOLD is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data
UQRORFVVSGFNRO-UTINFBMNSA-N,51634,UQRORFVVSGFNRO-UTINFBMNSA-N,miglustat,,"Treatment of the neurological manifestations of Niemann-Pick disease,type C.","C0027854,C0028064","Neurological Manifestations , Niemann-Pick Disease",11/12/08,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
RYAYYVTWKAOAJF-QISPRATLSA-N,73297272,RYAYYVTWKAOAJF-QISPRATLSA-N,milademetan,,Treatment of liposarcoma,C0023827,liposarcoma,2/13/17,Designated,Not FDA Approved for Orphan Indication,,,,
DGVCEXQFNYYRQI-BTJKTKAUSA-N,46937352,DGVCEXQFNYYRQI-BTJKTKAUSA-N,milciclib maleate,,Treatment of thymic epithelial tumors.,C1368683,epithelial tumors,9/20/12,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
OJLOPKGSLYJEMD-URPKTTJQSA-N,5282381,OJLOPKGSLYJEMD-URPKTTJQSA-N,misoprostol,,Treatment of intrauterine fetal death not accompanied by complete expulsion of the products of conception in the second and third trimesters of pregnancy.,C0595939,Intrauterine Fetal Death,1/10/05,Designated,Not FDA Approved for Orphan Indication,,,,
KKZJGLLVHKMTCM-UHFFFAOYSA-N,4212,KKZJGLLVHKMTCM-UHFFFAOYSA-N,Mitoxantrone,Novantrone,Treatment of progressive-relapsing multiple sclerosis.,C0026769,Multiple Sclerosis,8/13/99,Designated/Approved,,"Reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly adnormal between relapses).", 10/13/2000 , 10/13/2007 ,
YFGHCGITMMYXAQ-UHFFFAOYSA-N,4236,YFGHCGITMMYXAQ-UHFFFAOYSA-N,Modafinil,Provigil,Treatment of excessive daytime sleepiness in narcolepsy.,"C0027404,C4551761","Narcolepsy , Excessive daytime sleepiness",3/15/93,Designated/Approved,,Improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy., 12/24/1998 , 12/24/2005 ,
GAKUNXBDVGLOFS-INJBRAEYSA-N,87183232,GAKUNXBDVGLOFS-INJBRAEYSA-N,mosedipimod,,Treatment of acute radiation syndrome,C0520799,Acute Radiation Syndrome,12/19/17,Designated,Not FDA Approved for Orphan Indication,,,,
GAKUNXBDVGLOFS-UHFFFAOYSA-N,53827958,GAKUNXBDVGLOFS-UHFFFAOYSA-N,mosedipimod,,Treatment of acute radiation syndrome,C0520799,Acute Radiation Syndrome,12/19/17,Designated,Not FDA Approved for Orphan Indication,,,,
GAKUNXBDVGLOFS-WCCXBCNRSA-N,87183063,GAKUNXBDVGLOFS-WCCXBCNRSA-N,mosedipimod,,Treatment of acute radiation syndrome,C0520799,Acute Radiation Syndrome,12/19/17,Designated,Not FDA Approved for Orphan Indication,,,,
GAKUNXBDVGLOFS-DUZKARGPSA-N,9960925,GAKUNXBDVGLOFS-DUZKARGPSA-N,mosedipimod,,Treatment of acute radiation syndrome,C0520799,Acute Radiation Syndrome,12/19/17,Designated,Not FDA Approved for Orphan Indication,,,,
VAZLWPAHMORDGR-UHFFFAOYSA-L,393405,VAZLWPAHMORDGR-UHFFFAOYSA-L,motexafin gadolinium,,For use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumors,"C0220650,C0280100","brain metastases , solid tumors",1/27/03,Designated,Not FDA Approved for Orphan Indication,,,,
KHDBHVDCUGRVLA-UHFFFAOYSA-L,23724967,KHDBHVDCUGRVLA-UHFFFAOYSA-L,motexafin gadolinium,,For use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumors,"C0220650,C0280100","brain metastases , solid tumors",1/27/03,Designated,Not FDA Approved for Orphan Indication,,,,
AARXZCZYLAFQQU-UHFFFAOYSA-N,12047567,AARXZCZYLAFQQU-UHFFFAOYSA-N,motexafin gadolinium,,For use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumors,"C0220650,C0280100","brain metastases , solid tumors",1/27/03,Designated,Not FDA Approved for Orphan Indication,,,,
AARXZCZYLAFQQU-UHFFFAOYSA-N,12047567,AARXZCZYLAFQQU-UHFFFAOYSA-N,motexafin gadolinium,,For use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumors,"C0220650,C0280100","brain metastases , solid tumors",1/27/03,Designated,Not FDA Approved for Orphan Indication,,,,
VAZLWPAHMORDGR-UHFFFAOYSA-L,393405,VAZLWPAHMORDGR-UHFFFAOYSA-L,motexafin gadolinium,,For use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumors,"C0220650,C0280100","brain metastases , solid tumors",1/27/03,Designated,Not FDA Approved for Orphan Indication,,,,
IDRGFNPZDVBSSE-UHFFFAOYSA-N,117909640,IDRGFNPZDVBSSE-UHFFFAOYSA-N,"N-(3-(2-(2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenylamino)quinazolin-8-yl)phenyl)acrylamide",,Treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC),"C0007131,C1414313,C3539721","Non-Small Cell Lung Cancer , EPIDERMAL GROWTH FACTOR RECEPTOR , Non-Small Cell Lung Cancer",9/5/17,Designated,Not FDA Approved for Orphan Indication,,,,
WXNXCEHXYPACJF-UHFFFAOYSA-N,1995,WXNXCEHXYPACJF-UHFFFAOYSA-N,N-acetyl-DL-leucine,,"Treatment of Niemann-Pick disease, type C",C0220756,"Niemann-Pick Disease, Type C",2/22/18,Designated,Not FDA Approved for Orphan Indication,,,,
PWKSKIMOESPYIA-BYPYZUCNSA-N,12035,PWKSKIMOESPYIA-BYPYZUCNSA-N,N-acetylcysteine,,Treatment of acute liver failure,C0162557,Acute liver failure,9/9/02,Designated,Not FDA Approved for Orphan Indication,,,,
LAMIXXKAWNLXOC-INIZCTEOSA-N,6918848,LAMIXXKAWNLXOC-INIZCTEOSA-N,N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide,,Treatment of meningioma,C0025286,Meningioma,1/13/12,Designated,Not FDA Approved for Orphan Indication,,,,
DPHUWDIXHNQOSY-UHFFFAOYSA-N,10331844,DPHUWDIXHNQOSY-UHFFFAOYSA-N,napabucasin,,Treatment of gastric cancer including gastroesophageal junction cancer.,C0024623,Gastric Cancer,6/20/16,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
JLYAXFNOILIKPP-KXQOOQHDSA-N,24978538,JLYAXFNOILIKPP-KXQOOQHDSA-N,navitoclax,,Treatment of myelofibrosis,C0026987,myelofibrosis,11/18/19,Designated,Not FDA Approved for Orphan Indication,,,,
OSZNNLWOYWAHSS-UHFFFAOYSA-M,5824,OSZNNLWOYWAHSS-UHFFFAOYSA-M,neostigmine methylsulfate,,Treatment of Myasthenia Gravis,C0026896,Myasthenia Gravis,2/17/12,Designated,Not FDA Approved for Orphan Indication,,,,
WWJFFVUVFNBJTN-VHDFTHOZSA-N,102515122,WWJFFVUVFNBJTN-VHDFTHOZSA-N,Nikkomycin Z,,Treatment of coccidioidomycosis,C0009186,Coccidioidomycosis,2/14/06,Designated,Not FDA Approved for Orphan Indication,,,,
WWJFFVUVFNBJTN-VHDFTHOZSA-N,102515122,WWJFFVUVFNBJTN-VHDFTHOZSA-N,Nikkomycin Z,,Treatment of coccidioidomycosis,C0009186,Coccidioidomycosis,2/14/06,Designated,Not FDA Approved for Orphan Indication,,,,
OUBCNLGXQFSTLU-UHFFFAOYSA-N,115355,OUBCNLGXQFSTLU-UHFFFAOYSA-N,Nitisinone,Orfadin,Treatment of tyrosinemia type 1.,C0268490,Tyrosinemia Type 1,5/16/95,Designated/Approved,,Adjunctive therapy to dietary restriction of tyrosine and phenylalanine in the treatment of hereditary tyrosinemia type 1, 01/18/2002 , 01/18/2009 ,
MWUXSHHQAYIFBG-UHFFFAOYSA-N,145068,MWUXSHHQAYIFBG-UHFFFAOYSA-N,nitric oxide,,Treatment of cystic fibrosis,C0010674,Cystic Fibrosis,9/11/13,Designated,Not FDA Approved for Orphan Indication,,,,
MWUXSHHQAYIFBG-UHFFFAOYSA-N,145068,MWUXSHHQAYIFBG-UHFFFAOYSA-N,nitric oxide,,Treatment of pulmonary arterial hypertension excluding persistent pulmonary hypertension of the newborn,"C0031190,C3203102","Persistent pulmonary hypertension of the newborn , PULMONARY ARTERIAL HYPERTENSION",1/25/17,Designated,Not FDA Approved for Orphan Indication,,,,
MIMNFCVQODTQDP-NDLVEFNKSA-N,118984458,MIMNFCVQODTQDP-NDLVEFNKSA-N,oblimersen,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,8/28/01,Designated,Not FDA Approved for Orphan Indication,,,,
IBXPAFBDJCXCDW-MHFPCNPESA-A,118984457,IBXPAFBDJCXCDW-MHFPCNPESA-A,oblimersen,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,8/28/01,Designated,Not FDA Approved for Orphan Indication,,,,
DEQANNDTNATYII-JPZSUCLZSA-N,138107728,DEQANNDTNATYII-JPZSUCLZSA-N,octreotide,,Treatment of neuroendocrine tumors,C0206754,Neuroendocrine Tumors,8/5/10,Designated,Not FDA Approved for Orphan Indication,,,,
DEQANNDTNATYII-LIXSYSMXSA-N,44311916,DEQANNDTNATYII-LIXSYSMXSA-N,octreotide,,Treatment of neuroendocrine tumors,C0206754,Neuroendocrine Tumors,8/5/10,Designated,Not FDA Approved for Orphan Indication,,,,
DEQANNDTNATYII-XOEBDJBESA-N,90488715,DEQANNDTNATYII-XOEBDJBESA-N,octreotide,,Treatment of neuroendocrine tumors,C0206754,Neuroendocrine Tumors,8/5/10,Designated,Not FDA Approved for Orphan Indication,,,,
DEQANNDTNATYII-FLDZURHUSA-N,86289069,DEQANNDTNATYII-FLDZURHUSA-N,octreotide,,Treatment of neuroendocrine tumors,C0206754,Neuroendocrine Tumors,8/5/10,Designated,Not FDA Approved for Orphan Indication,,,,
DEQANNDTNATYII-MEUDYGGUSA-N,44420813,DEQANNDTNATYII-MEUDYGGUSA-N,octreotide,,Treatment of neuroendocrine tumors,C0206754,Neuroendocrine Tumors,8/5/10,Designated,Not FDA Approved for Orphan Indication,,,,
DEQANNDTNATYII-RRCPSWKPSA-N,6400441,DEQANNDTNATYII-RRCPSWKPSA-N,octreotide,,Treatment of neuroendocrine tumors,C0206754,Neuroendocrine Tumors,8/5/10,Designated,Not FDA Approved for Orphan Indication,,,,
DEQANNDTNATYII-UHFFFAOYSA-N,383414,DEQANNDTNATYII-UHFFFAOYSA-N,octreotide,,Treatment of neuroendocrine tumors,C0206754,Neuroendocrine Tumors,8/5/10,Designated,Not FDA Approved for Orphan Indication,,,,
DEQANNDTNATYII-OULOTJBUSA-N,448601,DEQANNDTNATYII-OULOTJBUSA-N,octreotide,,Treatment of neuroendocrine tumors,C0206754,Neuroendocrine Tumors,8/5/10,Designated,Not FDA Approved for Orphan Indication,,,,
XULSCZPZVQIMFM-IPZQJPLYSA-N,10153627,XULSCZPZVQIMFM-IPZQJPLYSA-N,odevixibat,,Treatment of Biliary Atresia,C0005411,Biliary Atresia,1/16/19,Designated,Not FDA Approved for Orphan Indication,,,,
FDLYAMZZIXQODN-UHFFFAOYSA-N,23725625,FDLYAMZZIXQODN-UHFFFAOYSA-N,olaparib,Lynparza,Treatment of primary peritoneal cancer,C1514428,Primary Peritoneal Cancer,5/15/18,Designated/Approved,,"Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; and treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.", 08/17/2017 , 08/17/2024 ,Maintenance treatment of adult patients with recurrent primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
HYFHYPWGAURHIV-JFIAXGOJSA-N,285033,HYFHYPWGAURHIV-JFIAXGOJSA-N,omacetaxine mepesuccinate,Synribo,Treatment of chronic myelogenous leukemia,C0023473,Chronic myelogenous leukemia,3/10/06,Designated/Approved,,Treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI), 10/26/2012 , 10/26/2019 ,
USUZGMWDZDXMDG-CYBMUJFWSA-N,44139752,USUZGMWDZDXMDG-CYBMUJFWSA-N,osilodrostat,Isturisa,Treatment of Cushing's disease,C0010481,Cushing's disease,9/13/13,Designated/Approved,,ISTURISA is a cortisol synthesis inhibitor indicated for the treatment of adult patients with Cushings disease for whom pituitary surgery is not an option or has not been curative., 03/06/2020 , 03/06/2027 ,For the treatment of adult patients with Cushings disease for whom pituitary surgery is not an option or has not been curative.
RCINICONZNJXQF-MZXODVADSA-N,36314,RCINICONZNJXQF-MZXODVADSA-N,Paclitaxel,Taxol,Treatment of AIDS-related Kaposi's sarcoma.,C0276535,AIDS-related Kaposi's sarcoma,3/25/97,Designated/Approved,,For the second line treatment of AIDS-related Kaposi's sarcoma., 08/04/1997 , 08/04/2004 ,
SWMNGXODFOCPKQ-BTJKTKAUSA-N,154731101,SWMNGXODFOCPKQ-BTJKTKAUSA-N,Pafuramidine maleate,,Treatment of malaria,C0024530,Malaria,5/14/07,Designated,Not FDA Approved for Orphan Indication,,,,
SWMNGXODFOCPKQ-BTJKTKAUSA-N,154731101,SWMNGXODFOCPKQ-BTJKTKAUSA-N,Pafuramidine maleate,,Treatment of malaria,C0024530,Malaria,5/14/07,Designated,Not FDA Approved for Orphan Indication,,,,
SWMNGXODFOCPKQ-BTJKTKAUSA-N,154731101,SWMNGXODFOCPKQ-BTJKTKAUSA-N,Pafuramidine maleate,,Treatment of malaria,C0024530,Malaria,5/14/07,Designated,Not FDA Approved for Orphan Indication,,,,
YTFHCXIPDIHOIA-DHZHZOJOSA-N,10295295,YTFHCXIPDIHOIA-DHZHZOJOSA-N,palovarotene,,Treatment of fibrodysplasia ossificans progressiva,C0016037,fibrodysplasia ossificans progressiva,7/21/14,Designated,Not FDA Approved for Orphan Indication,,,,
ZQPDJCIXJHUERQ-QWRGUYRKSA-N,86677874,ZQPDJCIXJHUERQ-QWRGUYRKSA-N,parsaclisib,,Treatment of autoimmune hemolytic anemia,C0002880,Autoimmune hemolytic anemia,7/28/20,Designated,Not FDA Approved for Orphan Indication,,,,
VMZMNAABQBOLAK-DBILLSOUSA-N,9941444,VMZMNAABQBOLAK-DBILLSOUSA-N,pasireotide,,Treatment of acromegaly,C0001206,Acromegaly,8/25/09,Designated/Approved,,Treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option, 12/15/2014 , 12/15/2021 ,Treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option
FPVKHBSQESCIEP-JQCXWYLXSA-N,439693,FPVKHBSQESCIEP-JQCXWYLXSA-N,Pentostatin,,Treatment of peripheral T-cell lymphomas.,C0079774,Peripheral T-Cell Lymphomas,11/24/99,Designated,Not FDA Approved for Orphan Indication,,,,
BYPFEZZEUUWMEJ-UHFFFAOYSA-N,4740,BYPFEZZEUUWMEJ-UHFFFAOYSA-N,pentoxifylline,,Treatment of Behcet's disease,C0004943,Behcet Syndrome,6/14/12,Designated,Not FDA Approved for Orphan Indication,,,,
PRMWGUBFXWROHD-UHFFFAOYSA-N,9924495,PRMWGUBFXWROHD-UHFFFAOYSA-N,perampanel,,Treatment of Lennox-Gastaut Syndrome,C0238111,Lennox-Gastaut syndrome,12/7/12,Designated,Not FDA Approved for Orphan Indication,,,,
SZFPYBIJACMNJV-UHFFFAOYSA-N,148177,SZFPYBIJACMNJV-UHFFFAOYSA-N,perifosine,,Treatment of multiple myeloma.,C0026764,Multiple Myeloma,9/3/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
JGWRKYUXBBNENE-UHFFFAOYSA-N,25151352,JGWRKYUXBBNENE-UHFFFAOYSA-N,pexidartinib,TURALIO,Treatment of pigmented villonodular synovitis/giant cell tumor of the tendon sheath,"C0017525,C0039106","Giant Cell Tumor , Pigmented villonodular synovitis",2/14/14,Designated/Approved,,TURALIO is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery., 08/02/2019 , 08/02/2026 ,For the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery
WRLGYAWRGXKSKG-UHFFFAOYSA-M,23674889,WRLGYAWRGXKSKG-UHFFFAOYSA-M,phenobarbital sodium,,Treatment of status epilepticus,C0038220,Status Epilepticus,2/26/20,Designated,Not FDA Approved for Orphan Indication,,,,
SONNWYBIRXJNDC-VIFPVBQESA-N,6041,SONNWYBIRXJNDC-VIFPVBQESA-N,phenylephrine,,Treatment of ileal pouch anal anastomosis related fecal incontinence,C0015732,Fecal Incontinence,2/14/02,Designated,Not FDA Approved for Orphan Indication,,,,
YJGVMLPVUAXIQN-HAEOHBJNSA-N,72435,YJGVMLPVUAXIQN-HAEOHBJNSA-N,Picropodophyllin,,Treatment of glioma,C0017638,Glioma,7/27/17,Designated,Not FDA Approved for Orphan Indication,,,,
QCHFTSOMWOSFHM-WPRPVWTQSA-N,5910,QCHFTSOMWOSFHM-WPRPVWTQSA-N,Pilocarpine,Salagen,Treatment of xerostomia induced by radiation therapy for head and neck cancer.,"C0043352,C3887461","Xerostomia , Head and Neck Cancer",9/24/90,Designated/Approved,,Treatment of symptoms of xerostomia from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck., 03/22/1994 , 03/22/2001 ,
RNAICSBVACLLGM-GNAZCLTHSA-N,5909,RNAICSBVACLLGM-GNAZCLTHSA-N,Pilocarpine HCl,Salagen,Treatment of xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome patients.,"C0022575,C0043352,C1527336","Keratoconjunctivitis Sicca , Xerostomia , Sjogren Syndrome",2/28/92,Designated/Approved,,Treatment of dry mouth in patients with Sjogren's syndrome., 02/11/1998 , 02/11/2005 ,
HYAFETHFCAUJAY-UHFFFAOYSA-N,4829,HYAFETHFCAUJAY-UHFFFAOYSA-N,pioglitazone,,Treatment of sudden sensorineural hearing loss,C4275242,Sudden sensorineural hearing loss,12/12/19,Designated,Not FDA Approved for Orphan Indication,,,,
NNACHAUCXXVJSP-UHFFFAOYSA-N,9948102,NNACHAUCXXVJSP-UHFFFAOYSA-N,Pitolisant,WAKIX,Treatment of narcolepsy,C0027404,Narcolepsy,5/17/10,Designated/Approved,,WAKIX is indicated for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy, 08/14/2019 , 08/14/2026 ,For the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy
UUSZLLQJYRSZIS-LXNNNBEUSA-N,9812534,UUSZLLQJYRSZIS-LXNNNBEUSA-N,plitidepsin,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,9/30/04,Designated,Not FDA Approved for Orphan Indication,,,,
UVSMNLNDYGZFPF-UHFFFAOYSA-N,134780,UVSMNLNDYGZFPF-UHFFFAOYSA-N,pomalidomide,POMALYST,Treatment of Kaposi sarcoma,C0036220,Kaposi Sarcoma,4/4/18,Designated/Approved,,POMALYST (pomalidomide) is indicated for the treatment of adult patients with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART); and for the treatment of Kaposi sarcoma (KS) in adult patients who are HIV-negative., 05/14/2020 , 05/14/2027 ,Indicated for the treatment of adult patients with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART); and for the treatment of Kaposi sarcoma (KS) in adult patients who are HIV-negative.
PHXJVRSECIGDHY-UHFFFAOYSA-N,24826799,PHXJVRSECIGDHY-UHFFFAOYSA-N,ponatinib,Iclusig,Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL),C1709527,Philadelphia chromosome-positive acute lymphoblastic leukemia,11/20/09,Designated/Approved,,Treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy., 12/14/2012 , 12/14/2019 ,
RSQDGTJKZWTAGL-UHFFFAOYSA-N,137321858,RSQDGTJKZWTAGL-UHFFFAOYSA-N,Porfimer sodium,,For the photodynamic therapy of patients with transitional cell carcinoma in situ of the urinary bladder.,"C0334267,C4551642","Transitional cell carcinoma in situ , Carcinoma in situ of the Urinary Bladder",11/15/89,Designated,Not FDA Approved for Orphan Indication,,,,
RAGOYPUPXAKGKH-XAKZXMRKSA-N,468595,RAGOYPUPXAKGKH-XAKZXMRKSA-N,posaconazole,,Treatment of zygomycosis,C0043541,Zygomycosis,7/16/04,Designated,Not FDA Approved for Orphan Indication,,,,
OGSBUKJUDHAQEA-WMCAAGNKSA-N,148121,OGSBUKJUDHAQEA-WMCAAGNKSA-N,pralatrexate,,Treatment of advanced or metastatic transitional cell carcinoma of the urinary bladder,"C0279680,C3160869","Transitional Cell Carcinoma of the Urinary Bladder , Metastatic Transitional Cell Carcinoma",5/3/10,Designated,Not FDA Approved for Orphan Indication,,,,
AUBOIOCYVHATDV-QYLLOTSKSA-N,134693628,AUBOIOCYVHATDV-QYLLOTSKSA-N,pralmorelin hydrochloride,,As a diagnostic agent for the detection of growth hormone deficiency,C3714796,Growth hormone deficiency,10/18/12,Designated,Not FDA Approved for Orphan Indication,,,,
AQHHHDLHHXJYJD-UHFFFAOYSA-N,4946,AQHHHDLHHXJYJD-UHFFFAOYSA-N,Propranolol,,Treatment of retinopathy of prematurity,C0035344,Retinopathy of Prematurity,8/23/19,Designated,Not FDA Approved for Orphan Indication,,,,
GPKJTRJOBQGKQK-UHFFFAOYSA-N,237,GPKJTRJOBQGKQK-UHFFFAOYSA-N,quinacrine,,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,9/28/12,Designated,Not FDA Approved for Orphan Indication,,,,
RONWGALEIBILOG-VMJVVOMYSA-N,56927704,RONWGALEIBILOG-VMJVVOMYSA-N,quinine sulfate,,Treatment of malaria excluding Plasmodium faliparum,C0024530,Malaria,12/2/08,Designated,Not FDA Approved for Orphan Indication,,,,
ZHNFLHYOFXQIOW-LPYZJUEESA-N,16211610,ZHNFLHYOFXQIOW-LPYZJUEESA-N,quinine sulfate,,Treatment of malaria excluding Plasmodium faliparum,C0024530,Malaria,12/2/08,Designated,Not FDA Approved for Orphan Indication,,,,
LOUPRKONTZGTKE-WZBLMQSHSA-N,3034034,LOUPRKONTZGTKE-WZBLMQSHSA-N,quinine sulfate,,Treatment of malaria excluding Plasmodium faliparum,C0024530,Malaria,12/2/08,Designated,Not FDA Approved for Orphan Indication,,,,
AKYHKWQPZHDOBW-DSXUQNDKSA-N,11949689,AKYHKWQPZHDOBW-DSXUQNDKSA-N,quinine sulfate,,Treatment of malaria excluding Plasmodium faliparum,C0024530,Malaria,12/2/08,Designated,Not FDA Approved for Orphan Indication,,,,
RONWGALEIBILOG-VMJVVOMYSA-N,56927704,RONWGALEIBILOG-VMJVVOMYSA-N,quinine sulfate,,Treatment of malaria excluding Plasmodium faliparum,C0024530,Malaria,12/2/08,Designated,Not FDA Approved for Orphan Indication,,,,
BKXVVCILCIUCLG-UHFFFAOYSA-N,54900,BKXVVCILCIUCLG-UHFFFAOYSA-N,raloxifene hydrochloride,,Treatment of hereditary hemorrhagic telangiectasia,C0039445,hereditary hemorrhagic telangiectasia,8/20/10,Designated,Not FDA Approved for Orphan Indication,,,,
PRFBWBYKWZVQJF-RRABGKBLSA-M,23668369,PRFBWBYKWZVQJF-RRABGKBLSA-M,recilisib sodium,,Prevention of acute radiation syndrome,C0520799,Acute Radiation Syndrome,6/1/12,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
RWWYLEGWBNMMLJ-YSOARWBDSA-N,121304016,RWWYLEGWBNMMLJ-YSOARWBDSA-N,Remdesivir,,Treatment of Ebola virus disease,C0282687,Ebola Virus Disease,9/18/15,Designated,Not FDA Approved for Orphan Indication,,,,
LEEIJTHMHDMWLJ-CQSZACIVSA-N,11703255,LEEIJTHMHDMWLJ-CQSZACIVSA-N,resatorvid,,Treatment of acute-on-chronic liver failure,C3850141,Acute-On-Chronic Liver Failure,1/2/18,Designated,Not FDA Approved for Orphan Indication,,,,
FECGNJPYVFEKOD-VMPITWQZSA-N,11609955,FECGNJPYVFEKOD-VMPITWQZSA-N,resminostat,,Treatment of Hodgkin's lymphoma.,C0019829,hodgkin's lymphoma,9/16/11,Designated,Not FDA Approved for Orphan Indication,,,,
FTALBRSUTCGOEG-UHFFFAOYSA-N,5070,FTALBRSUTCGOEG-UHFFFAOYSA-N,Riluzole,,Treatment of Huntington's disease.,C0020179,Huntington's Disease,10/15/96,Designated,Not FDA Approved for Orphan Indication,,,,
CEFJVGZHQAGLHS-UHFFFAOYSA-N,71584930,CEFJVGZHQAGLHS-UHFFFAOYSA-N,Ripretinib,,Treatment of gastrointestinal stromal tumors (GIST),C0238198,Gastrointestinal Stromal Tumors,10/2/14,Designated/Approved,,"QINLOCK (ripretinib) is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.", 05/15/2020 , 05/15/2027 ,"Indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib."
TZSZZENYCISATO-WIOPSUGQSA-N,92045025,TZSZZENYCISATO-WIOPSUGQSA-N,rodatristat ethyl,,Treatment of pulmonary arterial hypertension (PAH).,C3203102,PULMONARY ARTERIAL HYPERTENSION,10/6/15,Designated,Not FDA Approved for Orphan Indication,,,,
RZJQGNCSTQAWON-UHFFFAOYSA-N,5090,RZJQGNCSTQAWON-UHFFFAOYSA-N,rofecoxib,,Treatment of hemophilic arthropathy (HA),C0263725,Hemophilic arthropathy,9/26/17,Designated,Not FDA Approved for Orphan Indication,,,,
OHRURASPPZQGQM-QPJBHPOGSA-N,154574495,OHRURASPPZQGQM-QPJBHPOGSA-N,romidepsin,Istodax,Treatment of non-Hodgkin T-cell lymphomas,C0079772,T-Cell Lymphomas,9/30/04,Designated/Approved,,Treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy, 11/05/2009 , 11/05/2016 ,
OHRURASPPZQGQM-WOADUJSRSA-N,129905275,OHRURASPPZQGQM-WOADUJSRSA-N,romidepsin,Istodax,Treatment of non-Hodgkin T-cell lymphomas,C0079772,T-Cell Lymphomas,9/30/04,Designated/Approved,,Treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy, 11/05/2009 , 11/05/2016 ,
OHRURASPPZQGQM-OYTWCIJESA-N,123135747,OHRURASPPZQGQM-OYTWCIJESA-N,romidepsin,Istodax,Treatment of non-Hodgkin T-cell lymphomas,C0079772,T-Cell Lymphomas,9/30/04,Designated/Approved,,Treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy, 11/05/2009 , 11/05/2016 ,
OHRURASPPZQGQM-MWQPNCDWSA-N,91110640,OHRURASPPZQGQM-MWQPNCDWSA-N,romidepsin,Istodax,Treatment of non-Hodgkin T-cell lymphomas,C0079772,T-Cell Lymphomas,9/30/04,Designated/Approved,,Treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy, 11/05/2009 , 11/05/2016 ,
OHRURASPPZQGQM-WDCUYUQDSA-N,56840936,OHRURASPPZQGQM-WDCUYUQDSA-N,romidepsin,Istodax,Treatment of non-Hodgkin T-cell lymphomas,C0079772,T-Cell Lymphomas,9/30/04,Designated/Approved,,Treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy, 11/05/2009 , 11/05/2016 ,
OHRURASPPZQGQM-UHFFFAOYSA-N,3425,OHRURASPPZQGQM-UHFFFAOYSA-N,romidepsin,Istodax,Treatment of non-Hodgkin T-cell lymphomas,C0079772,T-Cell Lymphomas,9/30/04,Designated/Approved,,Treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy, 11/05/2009 , 11/05/2016 ,
OHRURASPPZQGQM-QDBHDZETSA-N,57515973,OHRURASPPZQGQM-QDBHDZETSA-N,romidepsin,Istodax,Treatment of non-Hodgkin T-cell lymphomas,C0079772,T-Cell Lymphomas,9/30/04,Designated/Approved,,Treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy, 11/05/2009 , 11/05/2016 ,
OHRURASPPZQGQM-GCCNXGTGSA-N,5352062,OHRURASPPZQGQM-GCCNXGTGSA-N,romidepsin,Istodax,Treatment of non-Hodgkin T-cell lymphomas,C0079772,T-Cell Lymphomas,9/30/04,Designated/Approved,,Treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy, 11/05/2009 , 11/05/2016 ,
POGQSBRIGCQNEG-UHFFFAOYSA-N,129228,POGQSBRIGCQNEG-UHFFFAOYSA-N,rufinamide,Banzel,Treatment of Lennox-Gastaut Syndrome.,C0238111,Lennox-Gastaut syndrome,10/8/04,Designated/Approved,,Adjunctive therapy of seizures associated with Lennox-Gastaut syndrome., 11/14/2008 , 11/14/2015 ,
WUILNKCFCLNXOK-CFBAGHHKSA-N,5469318,WUILNKCFCLNXOK-CFBAGHHKSA-N,salirasib,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,12/18/06,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
FSYKKLYZXJSNPZ-UHFFFAOYSA-N,1088,FSYKKLYZXJSNPZ-UHFFFAOYSA-N,sarcosine,,Treatment of obsessive compulsive disorder in pediatric patients (0 to 16 years of age),C0028768,Obsessive compulsive disorder,10/12/11,Designated,Not FDA Approved for Orphan Indication,,,,
FCKJYANJHNLEEP-XRWYNYHCSA-N,5283748,FCKJYANJHNLEEP-XRWYNYHCSA-N,Secalciferol,,Treatment of familial hypophosphatemic rickets.,C3536983,Familial Hypophosphatemic Rickets,7/26/93,Designated,Not FDA Approved for Orphan Indication,,,,
QXWZQTURMXZVHJ-UHFFFAOYSA-N,9913767,QXWZQTURMXZVHJ-UHFFFAOYSA-N,selexipag,,Treatment of Chronic Thromboembolic Pulmonary Hypertension,C2363973,Chronic thromboembolic pulmonary hypertension,10/2/18,Designated,Not FDA Approved for Orphan Indication,,,,
DEVSOMFAQLZNKR-RJRFIUFISA-N,71481097,DEVSOMFAQLZNKR-RJRFIUFISA-N,selinexor,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,5/14/14,Designated,Not FDA Approved for Orphan Indication,,,,
QFJCIRLUMZQUOT-HPLJOQBZSA-N,5284616,QFJCIRLUMZQUOT-HPLJOQBZSA-N,sirolimus,,Treatment of tuberous sclerosis complex-related facial angiofibromas,"C0041341,C0265319","Tuberous Sclerosis Complex , Facial angiofibromas",2/13/17,Designated,Not FDA Approved for Orphan Indication,,,,
GMBQZIIUCVWOCD-UQHLGXRBSA-N,91439,GMBQZIIUCVWOCD-UQHLGXRBSA-N,smilagenin,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,7/21/11,Designated,Not FDA Approved for Orphan Indication,,,,
LUPNKHXLFSSUGS-UHFFFAOYSA-M,517326,LUPNKHXLFSSUGS-UHFFFAOYSA-M,sodium dichloroacetate,,Use as an antidote in the management of systemic monochloroacetic acid poisoning,C4707283,Systemic monochloroacetic acid poisoning,7/3/03,Designated,Not FDA Approved for Orphan Indication,,,,
LUPNKHXLFSSUGS-UHFFFAOYSA-M,517326,LUPNKHXLFSSUGS-UHFFFAOYSA-M,Sodium dichloroacetate,,Treatment of homozygous familial hypercholesterolemia.,C0020445,FAMILIAL HYPERCHOLESTEROLEMIA,6/11/90,Designated,Not FDA Approved for Orphan Indication,,,,
XYGBKMMCQDZQOZ-UHFFFAOYSA-M,23663870,XYGBKMMCQDZQOZ-UHFFFAOYSA-M,sodium oxybate,Xyrem,Treatment of narcolepsy.,C0027404,Narcolepsy,11/7/94,Designated/Approved,,Treatment of cataplexy associated with narcolepsy, 07/17/2002 , 07/17/2009 ,
AKHNMLFCWUSKQB-UHFFFAOYSA-L,24477,AKHNMLFCWUSKQB-UHFFFAOYSA-L,sodium thiosulfate,,Treatment of dermatomyositis,C0011633,Dermatomyositis,10/28/14,Designated,Not FDA Approved for Orphan Indication,,,,
AKHNMLFCWUSKQB-UHFFFAOYSA-L,24477,AKHNMLFCWUSKQB-UHFFFAOYSA-L,Sodium thiosulfate,,Prevention of platinum-induced ototoxicity in pediatric patients,C0235280,Ototoxicity,3/17/04,Designated,Not FDA Approved for Orphan Indication,,,,
TTZHDVOVKQGIBA-LVPOHEQUSA-N,73425384,TTZHDVOVKQGIBA-LVPOHEQUSA-N,sofosbuvir,Sovaldi,Treatment of pediatric chronic hepatitis C virus infection,"C0019196,C0524910","Hepatitis C Virus Infection , chronic hepatitis c",10/25/16,Designated/Approved,,SOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin, 08/28/2019 ,  ,
TTZHDVOVKQGIBA-KVOQBTHKSA-N,72699160,TTZHDVOVKQGIBA-KVOQBTHKSA-N,sofosbuvir,Sovaldi,Treatment of pediatric chronic hepatitis C virus infection,"C0019196,C0524910","Hepatitis C Virus Infection , chronic hepatitis c",10/25/16,Designated/Approved,,SOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin, 08/28/2019 ,  ,
TTZHDVOVKQGIBA-IECBXEDQSA-N,129010435,TTZHDVOVKQGIBA-IECBXEDQSA-N,sofosbuvir,Sovaldi,Treatment of pediatric chronic hepatitis C virus infection,"C0019196,C0524910","Hepatitis C Virus Infection , chronic hepatitis c",10/25/16,Designated/Approved,,SOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin, 08/28/2019 ,  ,
TTZHDVOVKQGIBA-UHFFFAOYSA-N,91302628,TTZHDVOVKQGIBA-UHFFFAOYSA-N,sofosbuvir,Sovaldi,Treatment of pediatric chronic hepatitis C virus infection,"C0019196,C0524910","Hepatitis C Virus Infection , chronic hepatitis c",10/25/16,Designated/Approved,,SOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin, 08/28/2019 ,  ,
TTZHDVOVKQGIBA-IAAJYNJHSA-N,45375806,TTZHDVOVKQGIBA-IAAJYNJHSA-N,sofosbuvir,Sovaldi,Treatment of pediatric chronic hepatitis C virus infection,"C0019196,C0524910","Hepatitis C Virus Infection , chronic hepatitis c",10/25/16,Designated/Approved,,SOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin, 08/28/2019 ,  ,
TTZHDVOVKQGIBA-IQWMDFIBSA-N,45375808,TTZHDVOVKQGIBA-IQWMDFIBSA-N,sofosbuvir,Sovaldi,Treatment of pediatric chronic hepatitis C virus infection,"C0019196,C0524910","Hepatitis C Virus Infection , chronic hepatitis c",10/25/16,Designated/Approved,,SOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin, 08/28/2019 ,  ,
MLDQJTXFUGDVEO-UHFFFAOYSA-N,216239,MLDQJTXFUGDVEO-UHFFFAOYSA-N,Sorafenib,Nexavar,Treatment of renal cell carcinoma.,C0007134,Renal Cell Carcinoma,10/8/04,Designated/Approved,,Treatment of patients with advanced renal cell carcinoma, 12/20/2005 , 12/20/2012 ,
VIDRYROWYFWGSY-UHFFFAOYSA-N,66245,VIDRYROWYFWGSY-UHFFFAOYSA-N,sotalol hydrochloride,,Treatment of life-threatening ventricular arrhythmias in pediatric patients,C3812282,Ventricular Arrhythmias,2/10/14,Designated,Not FDA Approved for Orphan Indication,,,,
ZPYIELFRIYUVQP-BHBJEIPNSA-N,72734342,ZPYIELFRIYUVQP-BHBJEIPNSA-N,squalamine lactate,,Treatment of ovarian cancer refractory or resistant to standard chemotherapy,"C0677936,C4721610","cancer refractory , Ovarian Cancer",5/11/01,Designated,Not FDA Approved for Orphan Indication,,,,
JMNXSNUXDHHTKQ-QVMSTPCGSA-N,3036507,JMNXSNUXDHHTKQ-QVMSTPCGSA-N,squalamine lactate,,Treatment of ovarian cancer refractory or resistant to standard chemotherapy,"C0677936,C4721610","cancer refractory , Ovarian Cancer",5/11/01,Designated,Not FDA Approved for Orphan Indication,,,,
IBLNKMRFIPWSOY-FNORWQNLSA-N,5311454,IBLNKMRFIPWSOY-FNORWQNLSA-N,stiripentol,Diacomit,Treatment of Dravet syndrome,C0751122,Dravet Syndrome,10/30/08,Designated/Approved,,DIACOMIT is indicated for the treatment of seizures associated with Dravet syndrome (DS) in patients 2 years of age and older taking clobazam., 08/20/2018 , 08/20/2025 ,DIACOMIT is indicated for the treatment of seizures associated with Dravet syndrome (DS) in patients 2 years of age and older taking clobazam.
QJJXYPPXXYFBGM-LFZNUXCKSA-N,445643,QJJXYPPXXYFBGM-LFZNUXCKSA-N,Tacrolimus,,Prophylaxis of graft-versus-host-disease.,C0018133,Graft-Versus-Host-Disease,4/6/98,Designated,Not FDA Approved for Orphan Indication,,,,
QJJXYPPXXYFBGM-LFZNUXCKSA-N,445643,QJJXYPPXXYFBGM-LFZNUXCKSA-N,tacrolimus,Envarsus XR,Prophylaxis of organ rejection in patients receiving allogeneic kidney transplant,C0815080,organ rejection,12/20/13,Designated/Approved,,Prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations in combination with other immunosuppressants, 07/10/2015 , 07/10/2022 ,Prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations in combination with other immunosuppressants
DQJDBUPLRMRBAB-WZTVWXICSA-N,24970412,DQJDBUPLRMRBAB-WZTVWXICSA-N,tafamidis meglumine,VYNDAQEL; VYNDAMAX,Treatment of symptomatic transthyretin (TTR) amyloid cardiomyopathy.,C0268407,Amyloid cardiomyopathy,2/17/12,Designated/Approved,,VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization., 05/03/2019 , 05/03/2026 ,VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
LBHLFPGPEGDCJG-UHFFFAOYSA-N,115358,LBHLFPGPEGDCJG-UHFFFAOYSA-N,tafenoquine,Krintafel,Treatment of malaria,C0024530,Malaria,1/15/13,Designated/Approved,,KRINTAFEL is indicated for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection., 07/20/2018 , 07/20/2025 ,KRINTAFEL is indicated for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection.
FKCMADOPPWWGNZ-YUMQZZPRSA-N,6918572,FKCMADOPPWWGNZ-YUMQZZPRSA-N,Talabostat,,Treatment of stages IIb through IV melanoma,C0025202,melanoma,3/20/17,Designated,Not FDA Approved for Orphan Indication,,,,
ONDYALNGTUAJDX-UHFFFAOYSA-N,54682876,ONDYALNGTUAJDX-UHFFFAOYSA-N,Tasquinimod,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,4/10/17,Designated,Not FDA Approved for Orphan Indication,,,,
XOAAWQZATWQOTB-UHFFFAOYSA-N,1123,XOAAWQZATWQOTB-UHFFFAOYSA-N,taurine,,Treatment of cystathionine beta-synthase deficient homocystinuria,C0019880,Homocystinuria,3/22/10,Designated,Not FDA Approved for Orphan Indication,,,,
AJKIRUJIDFJUKJ-UHFFFAOYSA-N,29566,AJKIRUJIDFJUKJ-UHFFFAOYSA-N,taurolidine,,Treatment of neuroblastoma,C0027819,Neuroblastoma,2/22/18,Designated,Not FDA Approved for Orphan Indication,,,,
MREOOEFUTWFQOC-UHFFFAOYSA-M,54715158,MREOOEFUTWFQOC-UHFFFAOYSA-M,Tegafur/gimeracil/oteracil,,Treatment of gastric cancer,C0024623,Gastric Cancer,7/20/06,Designated,Not FDA Approved for Orphan Indication,,,,
OMWCXCBGEFHCTN-FGYAAKKASA-N,46212391,OMWCXCBGEFHCTN-FGYAAKKASA-N,tegavivint,,Treatment of Desmoid Tumors,C0079218,desmoid tumors,4/11/18,Designated,Not FDA Approved for Orphan Indication,,,,
BJNLLBUOHPVGFT-CAYRISATSA-N,133065662,BJNLLBUOHPVGFT-CAYRISATSA-N,teicoplanin,,Treatment of Staphylococcus aureus lung infections in patients with cystic fibrosis,"C0010674,C0038172,C3714514","Cystic Fibrosis , Staphylococcus aureus , Infections",5/24/18,Designated,Not FDA Approved for Orphan Indication,,,,
BPEGJWRSRHCHSN-UHFFFAOYSA-N,5394,BPEGJWRSRHCHSN-UHFFFAOYSA-N,temozolomide,Temodar,Treatment of recurrent malignant glioma.,C4684861,Recurrent Malignant Glioma,10/5/98,Designated/Approved,,Treatment of adult patients with newly diagnosed glioblastoma multiforme concomitatly with radiotherapy and then as maintenance treatment, 03/15/2005 , 03/15/2012 ,
CBPNZQVSJQDFBE-RODMVNQKSA-N,154827473,CBPNZQVSJQDFBE-RODMVNQKSA-N,Temsirolimus,Torisel,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,12/16/04,Designated/Approved,,Treatment of advanced renal cell carcinoma, 05/30/2007 , 05/30/2014 ,
CBPNZQVSJQDFBE-NUTFMQKQSA-N,154575198,CBPNZQVSJQDFBE-NUTFMQKQSA-N,Temsirolimus,Torisel,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,12/16/04,Designated/Approved,,Treatment of advanced renal cell carcinoma, 05/30/2007 , 05/30/2014 ,
CBPNZQVSJQDFBE-LGVPMJLXSA-N,152772378,CBPNZQVSJQDFBE-LGVPMJLXSA-N,Temsirolimus,Torisel,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,12/16/04,Designated/Approved,,Treatment of advanced renal cell carcinoma, 05/30/2007 , 05/30/2014 ,
CBPNZQVSJQDFBE-HELDCPHESA-N,137295275,CBPNZQVSJQDFBE-HELDCPHESA-N,Temsirolimus,Torisel,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,12/16/04,Designated/Approved,,Treatment of advanced renal cell carcinoma, 05/30/2007 , 05/30/2014 ,
CBPNZQVSJQDFBE-VYCIWTNRSA-N,132274070,CBPNZQVSJQDFBE-VYCIWTNRSA-N,Temsirolimus,Torisel,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,12/16/04,Designated/Approved,,Treatment of advanced renal cell carcinoma, 05/30/2007 , 05/30/2014 ,
CBPNZQVSJQDFBE-QWRHTZMXSA-N,86287409,CBPNZQVSJQDFBE-QWRHTZMXSA-N,Temsirolimus,Torisel,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,12/16/04,Designated/Approved,,Treatment of advanced renal cell carcinoma, 05/30/2007 , 05/30/2014 ,
CBPNZQVSJQDFBE-DZCFMHCPSA-N,71296107,CBPNZQVSJQDFBE-DZCFMHCPSA-N,Temsirolimus,Torisel,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,12/16/04,Designated/Approved,,Treatment of advanced renal cell carcinoma, 05/30/2007 , 05/30/2014 ,
CBPNZQVSJQDFBE-VBSVFFBFSA-N,54608508,CBPNZQVSJQDFBE-VBSVFFBFSA-N,Temsirolimus,Torisel,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,12/16/04,Designated/Approved,,Treatment of advanced renal cell carcinoma, 05/30/2007 , 05/30/2014 ,
CBPNZQVSJQDFBE-MDHHOXSCSA-N,9876533,CBPNZQVSJQDFBE-MDHHOXSCSA-N,Temsirolimus,Torisel,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,12/16/04,Designated/Approved,,Treatment of advanced renal cell carcinoma, 05/30/2007 , 05/30/2014 ,
CBPNZQVSJQDFBE-GOFCWFHQSA-N,145712265,CBPNZQVSJQDFBE-GOFCWFHQSA-N,Temsirolimus,Torisel,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,12/16/04,Designated/Approved,,Treatment of advanced renal cell carcinoma, 05/30/2007 , 05/30/2014 ,
CBPNZQVSJQDFBE-KFZNZFKNSA-N,71312019,CBPNZQVSJQDFBE-KFZNZFKNSA-N,Temsirolimus,Torisel,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,12/16/04,Designated/Approved,,Treatment of advanced renal cell carcinoma, 05/30/2007 , 05/30/2014 ,
CBPNZQVSJQDFBE-ZJEVVSOISA-N,24847874,CBPNZQVSJQDFBE-ZJEVVSOISA-N,Temsirolimus,Torisel,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,12/16/04,Designated/Approved,,Treatment of advanced renal cell carcinoma, 05/30/2007 , 05/30/2014 ,
CBPNZQVSJQDFBE-DYFDTRMFSA-N,5938194,CBPNZQVSJQDFBE-DYFDTRMFSA-N,Temsirolimus,Torisel,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,12/16/04,Designated/Approved,,Treatment of advanced renal cell carcinoma, 05/30/2007 , 05/30/2014 ,
CBPNZQVSJQDFBE-UITOJQKMSA-N,129317846,CBPNZQVSJQDFBE-UITOJQKMSA-N,Temsirolimus,Torisel,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,12/16/04,Designated/Approved,,Treatment of advanced renal cell carcinoma, 05/30/2007 , 05/30/2014 ,
CBPNZQVSJQDFBE-AQHKCTBXSA-N,71433778,CBPNZQVSJQDFBE-AQHKCTBXSA-N,Temsirolimus,Torisel,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,12/16/04,Designated/Approved,,Treatment of advanced renal cell carcinoma, 05/30/2007 , 05/30/2014 ,
CBPNZQVSJQDFBE-FAYWIXGWSA-N,53486199,CBPNZQVSJQDFBE-FAYWIXGWSA-N,Temsirolimus,Torisel,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,12/16/04,Designated/Approved,,Treatment of advanced renal cell carcinoma, 05/30/2007 , 05/30/2014 ,
CBPNZQVSJQDFBE-UHFFFAOYSA-N,148191,CBPNZQVSJQDFBE-UHFFFAOYSA-N,Temsirolimus,Torisel,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,12/16/04,Designated/Approved,,Treatment of advanced renal cell carcinoma, 05/30/2007 , 05/30/2014 ,
CBPNZQVSJQDFBE-HGVVHKDOSA-N,23724530,CBPNZQVSJQDFBE-HGVVHKDOSA-N,Temsirolimus,Torisel,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,12/16/04,Designated/Approved,,Treatment of advanced renal cell carcinoma, 05/30/2007 , 05/30/2014 ,
CBPNZQVSJQDFBE-PXVOFZQNSA-N,18293306,CBPNZQVSJQDFBE-PXVOFZQNSA-N,Temsirolimus,Torisel,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,12/16/04,Designated/Approved,,Treatment of advanced renal cell carcinoma, 05/30/2007 , 05/30/2014 ,
CBPNZQVSJQDFBE-FUXHJELOSA-N,6918289,CBPNZQVSJQDFBE-FUXHJELOSA-N,Temsirolimus,Torisel,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,12/16/04,Designated/Approved,,Treatment of advanced renal cell carcinoma, 05/30/2007 , 05/30/2014 ,
BENFXAYNYRLAIU-QSVFAHTRSA-N,72081,BENFXAYNYRLAIU-QSVFAHTRSA-N,Terlipressin,,Treatment of bleeding esophageal varices.,C0014867,Esophageal Varices,3/6/86,Designated,Not FDA Approved for Orphan Indication,,,,
MKJIEFSOBYUXJB-UHFFFAOYSA-N,6018,MKJIEFSOBYUXJB-UHFFFAOYSA-N,Tetrabenazine,,Treatment of moderate/severe tardive dyskinesia.,C0686347,Tardive Dyskinesia,5/12/98,Designated,Not FDA Approved for Orphan Indication,,,,
IKPNWIGTWUZCKM-JEDNCBNOSA-N,135242,IKPNWIGTWUZCKM-JEDNCBNOSA-N,Tilarginine acetate,,Treatment of cardiogenic shock,C0036980,Cardiogenic shock,4/11/05,Designated,Not FDA Approved for Orphan Indication,,,,
YTGJWQPHMWSCST-UHFFFAOYSA-N,5483,YTGJWQPHMWSCST-UHFFFAOYSA-N,Tiopronin,Thiola,Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.,"C0010691,C0022650","Cystinuria , Nephrolithiasis",1/17/86,Designated/Approved,,"Indicated for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria with urinary cystine greater than 500 mg/day, who are resistant to treatment with conservative measures of high fluid intake, alkali and diet modification or who have adverse reactions to d-penicillamine.", 08/11/1988 , 08/11/1995 ,
DQHNAVOVODVIMG-RGECMCKFSA-M,5487426,DQHNAVOVODVIMG-RGECMCKFSA-M,Tiotropium bromide,,To improve pulmonary function in conjunction with standard therapy in the management of patients with cystic fibrosis,"C0010674,C1547996","Cystic Fibrosis , Pulmonary Function",1/8/08,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
KPWYNAGOBXLMSE-UHFFFAOYSA-N,9893228,KPWYNAGOBXLMSE-UHFFFAOYSA-N,tipelukast,,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,10/20/14,Designated,Not FDA Approved for Orphan Indication,,,,
UOWZUVNAGUAEQC-UHFFFAOYSA-N,5803,UOWZUVNAGUAEQC-UHFFFAOYSA-N,tiratricol,,Treatment of Monocarboxylate 8 Transporter (MCT8) Deficiency (Allan-Herndon-Dudley-Syndrome),"C0039082,C1420103","Syndrome , MCT8",1/16/19,Designated,Not FDA Approved for Orphan Indication,,,,
ZWUKMNZJRDGCTQ-UHFFFAOYSA-N,114869,ZWUKMNZJRDGCTQ-UHFFFAOYSA-N,Tizanidine HCl,,Treatment of spasticity associated with multiple sclerosis and spinal cord injury.,"C0026769,C0026838,C0037929","Multiple Sclerosis , Spasticity , Spinal Cord Injury",1/31/94,Designated,Not FDA Approved for Orphan Indication,,,,
YEZNLOUZAIOMLT-UHFFFAOYSA-N,610479,YEZNLOUZAIOMLT-UHFFFAOYSA-N,tolfenamic acid,,Treatment of Frontotemporal Dementia,C0338451,Frontotemporal dementia,7/13/16,Designated,Not FDA Approved for Orphan Indication,,,,
YEZNLOUZAIOMLT-UHFFFAOYSA-N,610479,YEZNLOUZAIOMLT-UHFFFAOYSA-N,tolfenamic acid,,Treatment of progressive supranuclear palsy,C0038868,Progressive supranuclear palsy,7/13/16,Designated,Not FDA Approved for Orphan Indication,,,,
XFCLJVABOIYOMF-QPLCGJKRSA-N,3005573,XFCLJVABOIYOMF-QPLCGJKRSA-N,Toremifene,,Treatment of desmoid tumors.,C0079218,desmoid tumors,8/17/93,Designated,Not FDA Approved for Orphan Indication,,,,
HSWLVDBGZCETRH-UHFFFAOYSA-O,132472120,HSWLVDBGZCETRH-UHFFFAOYSA-O,trabedersen,,Treatment of Stage IIB through Stage IV malignant melanoma.,C0025202,Malignant Melanoma,8/22/11,Designated,Not FDA Approved for Orphan Indication,,,,
VLPFTAMPNXLGLX-UHFFFAOYSA-N,10850,VLPFTAMPNXLGLX-UHFFFAOYSA-N,tricaprilin,,Treatment of infantile spasms also known as West's syndrome,"C0037769,C3887898","Infantile spasms , Infantile spasms",10/27/20,Designated,Not FDA Approved for Orphan Indication,,,,
MFBCDACCJCDGBA-UHFFFAOYSA-N,11518241,MFBCDACCJCDGBA-UHFFFAOYSA-N,trifarotene,,Treatment of congenital ichthyosis,C0079154,congenital ichthyosis,6/6/14,Designated,Not FDA Approved for Orphan Indication,,,,
UHWVSEOVJBQKBE-UHFFFAOYSA-N,21109,UHWVSEOVJBQKBE-UHFFFAOYSA-N,trimetazidine,,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,8/7/18,Designated,Not FDA Approved for Orphan Indication,,,,
VGGGPCQERPFHOB-RDBSUJKOSA-N,72172,VGGGPCQERPFHOB-RDBSUJKOSA-N,Ubenimex,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,8/7/20,Designated,Not FDA Approved for Orphan Indication,,,,
QNTNKSLOFHEFPK-UHFFFAOYSA-N,25201759,QNTNKSLOFHEFPK-UHFFFAOYSA-N,ubiquinol,,Treatment of Huntington's Disease,C0020179,Huntington's Disease,4/12/04,Designated,Not FDA Approved for Orphan Indication,,,,
QNTNKSLOFHEFPK-UPTCCGCDSA-N,9962735,QNTNKSLOFHEFPK-UPTCCGCDSA-N,ubiquinol,,Treatment of Huntington's Disease,C0020179,Huntington's Disease,4/12/04,Designated,Not FDA Approved for Orphan Indication,,,,
XSQUKJJJFZCRTK-UHFFFAOYSA-N,1176,XSQUKJJJFZCRTK-UHFFFAOYSA-N,urea,,"Treatment of rare congenital ichthyoses (CHILD syndrome, collodion baby, congenital ichthyosform erythroderma, Conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, KID syndrome, lamellar ichthyosis, Netherton syndrome, neutral lipid storage disease, Sjorgren-Larsson syndrome, trichothiodystrophy, X-linked ichthyosis).","C0011606,C0079153,C0079154,C0079588,C0239849,C0265267,C0265962,C0265962,C0268238,C1955934,C3543867,C3665333","Erythroderma , Epidermolytic hyperkeratosis , Lamellar ichthyosis , X-linked ichthyosis , Harlequin Ichthyosis , Child syndrome , Netherton Syndrome , Netherton Syndrome , Neutral lipid storage disease , Trichothiodystrophy , Collodion Baby , Kid syndrome",11/7/11,Designated,Not FDA Approved for Orphan Indication,,,,
ZDRRIRUAESZNIH-JLSAMJFVSA-N,73759969,ZDRRIRUAESZNIH-JLSAMJFVSA-N,Urofollitropin,Metrodin,For induction of ovulation in patients with polycystic ovarian disease who have an elevated LH/FSH ratio and who have failed to respond to adequate clomiphene citrate therapy.,C0032460,Polycystic Ovarian Disease,11/25/87,Designated/Approved,,, 09/18/1986 , 09/18/1993 ,
ZDRRIRUAESZNIH-BZGUUIOASA-N,75409771,ZDRRIRUAESZNIH-BZGUUIOASA-N,Urofollitropin,Metrodin,For induction of ovulation in patients with polycystic ovarian disease who have an elevated LH/FSH ratio and who have failed to respond to adequate clomiphene citrate therapy.,C0032460,Polycystic Ovarian Disease,11/25/87,Designated/Approved,,, 09/18/1986 , 09/18/1993 ,
ZDRRIRUAESZNIH-UHFFFAOYSA-N,62819,ZDRRIRUAESZNIH-UHFFFAOYSA-N,Urofollitropin,Metrodin,For induction of ovulation in patients with polycystic ovarian disease who have an elevated LH/FSH ratio and who have failed to respond to adequate clomiphene citrate therapy.,C0032460,Polycystic Ovarian Disease,11/25/87,Designated/Approved,,, 09/18/1986 , 09/18/1993 ,
ZDRRIRUAESZNIH-JLSAMJFVSA-N,73759969,ZDRRIRUAESZNIH-JLSAMJFVSA-N,Urofollitropin,,"For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism.","C0022735,C0281947,C3671958","Hypogonadotropic Hypogonadism , pituitary dysfunction , Reproductive failure",12/5/97,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ZDRRIRUAESZNIH-BZGUUIOASA-N,75409771,ZDRRIRUAESZNIH-BZGUUIOASA-N,Urofollitropin,,"For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism.","C0022735,C0281947,C3671958","Hypogonadotropic Hypogonadism , pituitary dysfunction , Reproductive failure",12/5/97,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ZDRRIRUAESZNIH-UHFFFAOYSA-N,62819,ZDRRIRUAESZNIH-UHFFFAOYSA-N,Urofollitropin,,"For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism.","C0022735,C0281947,C3671958","Hypogonadotropic Hypogonadism , pituitary dysfunction , Reproductive failure",12/5/97,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
RUDATBOHQWOJDD-UZVSRGJWSA-N,31401,RUDATBOHQWOJDD-UZVSRGJWSA-N,Ursodiol,URSO 250,Treatment of patients with primary biliary cirrhosis,C0008312,Primary Biliary Cirrhosis,6/20/91,Designated/Approved,,, 12/10/1997 , 12/10/2004 ,
FJCDSQATIJKQKA-UHFFFAOYSA-N,54766013,FJCDSQATIJKQKA-UHFFFAOYSA-N,Vactosertib,,Treatment of gastric cancer,C0024623,Gastric Cancer,9/28/20,Designated,Not FDA Approved for Orphan Indication,,,,
SWXOGPJRIDTIRL-CISAEKETSA-N,133566183,SWXOGPJRIDTIRL-CISAEKETSA-N,vapreotide,,Treatment of esophageal variceal hemorrhage patients with portal hypertension.,"C0014852,C0020541,C0333106","ESOPHAGEAL , Portal Hypertension , variceal hemorrhage",1/10/00,Designated,Not FDA Approved for Orphan Indication,,,,
SWXOGPJRIDTIRL-HFQRKYADSA-N,5311370,SWXOGPJRIDTIRL-HFQRKYADSA-N,vapreotide,,Treatment of esophageal variceal hemorrhage patients with portal hypertension.,"C0014852,C0020541,C0333106","ESOPHAGEAL , Portal Hypertension , variceal hemorrhage",1/10/00,Designated,Not FDA Approved for Orphan Indication,,,,
SWXOGPJRIDTIRL-KTJGOPLGSA-N,70689318,SWXOGPJRIDTIRL-KTJGOPLGSA-N,vapreotide,,Treatment of esophageal variceal hemorrhage patients with portal hypertension.,"C0014852,C0020541,C0333106","ESOPHAGEAL , Portal Hypertension , variceal hemorrhage",1/10/00,Designated,Not FDA Approved for Orphan Indication,,,,
SWXOGPJRIDTIRL-DLRASJFKSA-N,45588099,SWXOGPJRIDTIRL-DLRASJFKSA-N,vapreotide,,Treatment of esophageal variceal hemorrhage patients with portal hypertension.,"C0014852,C0020541,C0333106","ESOPHAGEAL , Portal Hypertension , variceal hemorrhage",1/10/00,Designated,Not FDA Approved for Orphan Indication,,,,
SWXOGPJRIDTIRL-UHFFFAOYSA-N,71306,SWXOGPJRIDTIRL-UHFFFAOYSA-N,vapreotide,,Treatment of esophageal variceal hemorrhage patients with portal hypertension.,"C0014852,C0020541,C0333106","ESOPHAGEAL , Portal Hypertension , variceal hemorrhage",1/10/00,Designated,Not FDA Approved for Orphan Indication,,,,
SWXOGPJRIDTIRL-DOUNNPEJSA-N,6918026,SWXOGPJRIDTIRL-DOUNNPEJSA-N,vapreotide,,Treatment of esophageal variceal hemorrhage patients with portal hypertension.,"C0014852,C0020541,C0333106","ESOPHAGEAL , Portal Hypertension , variceal hemorrhage",1/10/00,Designated,Not FDA Approved for Orphan Indication,,,,
VYUWDIKZJLOZJL-UHFFFAOYSA-N,11638255,VYUWDIKZJLOZJL-UHFFFAOYSA-N,Varbulin,,Treatment of glioblastoma multiforme.,C0017636,Glioblastoma multiforme,11/5/09,Designated,Not FDA Approved for Orphan Indication,,,,
LNOVHERIIMJMDG-XZXLULOTSA-N,46184405,LNOVHERIIMJMDG-XZXLULOTSA-N,vatiquinone,,Treatment of mitochondrial disease,C0751651,Mitochondrial disease,8/10/20,Designated,Not FDA Approved for Orphan Indication,,,,
GPXBXXGIAQBQNI-UHFFFAOYSA-N,42611257,GPXBXXGIAQBQNI-UHFFFAOYSA-N,vemurafenib,,Treatment of anaplastic thyroid carcinoma and advanced papillary thyroid cancer whose tumors harbor a BRAF V600 mutation,"C0027651,C0238461,C0238463","Tumors , Anaplastic thyroid carcinoma , papillary thyroid cancer",11/26/13,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
GPXBXXGIAQBQNI-UHFFFAOYSA-N,42611257,GPXBXXGIAQBQNI-UHFFFAOYSA-N,vemurafenib,,Treatment of patients with non-small cell lung cancer (NSCLC) with BRAF V600 mutation,"C0007131,C3539721","Non-Small Cell Lung Cancer , Non-Small Cell Lung Cancer",9/8/14,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ZVXLKCOOOKREJD-OERAVCCFSA-N,154562176,ZVXLKCOOOKREJD-OERAVCCFSA-N,viltolarsen,VILTEPSO,Treatment of Duchenne Muscular Dystrophy,C0013264,DUCHENNE MUSCULAR DYSTROPHY,1/12/17,Designated/Approved,,VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping, 08/12/2020 , 08/12/2027 ,VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping
RNOAOAWBMHREKO-QFIPXVFZSA-N,135565884,RNOAOAWBMHREKO-QFIPXVFZSA-N,zanubrutinib,,Treatment of nodal marginal zone lymphoma,C0242647,Nodal marginal zone lymphoma,8/24/20,Designated,Not FDA Approved for Orphan Indication,,,,
QPAKKWCQMHUHNI-GQIQPHNSSA-N,86278273,QPAKKWCQMHUHNI-GQIQPHNSSA-N,chlorotoxin,,"Treatment of stage IIb, IIc, III & IV melanoma",C0025202,melanoma,12/2/08,Designated,Not FDA Approved for Orphan Indication,,,,
AMLYAMJWYAIXIA-VWNVYAMZSA-N,176873,AMLYAMJWYAIXIA-VWNVYAMZSA-N,cilengitide,,Treatment of malignant glioma,C0555198,Malignant Glioma,5/27/05,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
CKLPLPZSUQEDRT-WPCRTTGESA-N,44469321,CKLPLPZSUQEDRT-WPCRTTGESA-N,Cipargamin,,Treatment of malaria,C0024530,Malaria,7/27/17,Designated,Not FDA Approved for Orphan Indication,,,,
YKPUWZUDDOIDPM-VURMDHGXSA-N,1548942,YKPUWZUDDOIDPM-VURMDHGXSA-N,civamide,,Treatment of postherpetic neuralgia of the trigeminal nerve,C0032768,Postherpetic neuralgia,12/9/02,Designated,Not FDA Approved for Orphan Indication,,,,
PTOAARAWEBMLNO-KVQBGUIXSA-N,20279,PTOAARAWEBMLNO-KVQBGUIXSA-N,Cladribine,,Treatment of acute myeloid leukemia.,C0023467,Acute myeloid leukemia,7/20/90,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PTOAARAWEBMLNO-KVQBGUIXSA-N,20279,PTOAARAWEBMLNO-KVQBGUIXSA-N,cladribine,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,12/31/90,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PTOAARAWEBMLNO-KVQBGUIXSA-N,20279,PTOAARAWEBMLNO-KVQBGUIXSA-N,Cladribine,,Treatment of the chronic progressive form of multiple sclerosis.,C0026769,Multiple Sclerosis,4/19/94,Designated,Not FDA Approved for Orphan Indication,,,,
VNFPBHJOKIVQEB-UHFFFAOYSA-N,2812,VNFPBHJOKIVQEB-UHFFFAOYSA-N,Clotrimazole,,Treatment of sickle cell disease.,C0002895,Sickle Cell Disease,4/24/95,Designated,Not FDA Approved for Orphan Indication,,,,
VNFPBHJOKIVQEB-UHFFFAOYSA-N,2812,VNFPBHJOKIVQEB-UHFFFAOYSA-N,Clotrimazole,,Topical treatment of children and adults with pouchitis,C0376620,Pouchitis,6/14/05,Designated,Not FDA Approved for Orphan Indication,,,,
BSMCAPRUBJMWDF-KRWDZBQOSA-N,16222096,BSMCAPRUBJMWDF-KRWDZBQOSA-N,cobimetinib,,"Treatment of stage IIb, IIc, III, and IV melanoma with BRAFV600 mutation","C0025202,C4553416","melanoma , IIC",1/31/14,Designated/Approved,,"For the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutation, in combination with vemurafenib. Limitations of Use: COTELLIC is not indicated for treatment of patients with wild-type BRAF melanoma.", 11/10/2015 , 11/10/2022 ,"For the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutation, in combination with vemurafenib. COTELLIC is not indicated for treatment of patients with wild-type BRAF melanoma"
RSGPTDNHQUJVBP-MDTVQASCSA-N,129629077,RSGPTDNHQUJVBP-MDTVQASCSA-N,copper histidinate,,Treatment of Menkes disease,C0022716,Menkes disease,5/14/12,Designated,Not FDA Approved for Orphan Indication,,,,
UUYDYUZBCIHUFZ-MDTVQASCSA-L,151722,UUYDYUZBCIHUFZ-MDTVQASCSA-L,copper histidinate,,Treatment of Menkes disease,C0022716,Menkes disease,5/14/12,Designated,Not FDA Approved for Orphan Indication,,,,
ARUVKPQLZAKDPS-UHFFFAOYSA-L,24462,ARUVKPQLZAKDPS-UHFFFAOYSA-L,copper sulfate,,Treatment of keratoconus,C0022578,Keratoconus,10/26/17,Designated,Not FDA Approved for Orphan Indication,,,,
RCBJUJRVBGYTEO-UHFFFAOYSA-N,71587716,RCBJUJRVBGYTEO-UHFFFAOYSA-N,CT-2584 mesylate,,Treatment of malignant mesothelioma.,C0345967,Malignant mesothelioma,4/16/99,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-SCYOXIPCSA-N,123134263,PMATZTZNYRCHOR-SCYOXIPCSA-N,Cyclosporine,,Prophylaxis of organ rejection in patients receiving allogeneic lung transplant,C0815080,organ rejection,11/25/03,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-AVZWOAAISA-N,122172945,PMATZTZNYRCHOR-AVZWOAAISA-N,Cyclosporine,,Prophylaxis of organ rejection in patients receiving allogeneic lung transplant,C0815080,organ rejection,11/25/03,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-SRFWORPQSA-N,25246316,PMATZTZNYRCHOR-SRFWORPQSA-N,Cyclosporine,,Prophylaxis of organ rejection in patients receiving allogeneic lung transplant,C0815080,organ rejection,11/25/03,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-QVSDIVLPSA-N,5497195,PMATZTZNYRCHOR-QVSDIVLPSA-N,Cyclosporine,,Prophylaxis of organ rejection in patients receiving allogeneic lung transplant,C0815080,organ rejection,11/25/03,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-VJRYSDSKSA-N,24883466,PMATZTZNYRCHOR-VJRYSDSKSA-N,Cyclosporine,,Prophylaxis of organ rejection in patients receiving allogeneic lung transplant,C0815080,organ rejection,11/25/03,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-GNSAQUIPSA-N,62280,PMATZTZNYRCHOR-GNSAQUIPSA-N,Cyclosporine,,Prophylaxis of organ rejection in patients receiving allogeneic lung transplant,C0815080,organ rejection,11/25/03,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-IMVLJIQESA-N,5280754,PMATZTZNYRCHOR-IMVLJIQESA-N,Cyclosporine,,Prophylaxis of organ rejection in patients receiving allogeneic lung transplant,C0815080,organ rejection,11/25/03,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-KMSBSJHKSA-N,6435893,PMATZTZNYRCHOR-KMSBSJHKSA-N,Cyclosporine,,Prophylaxis of organ rejection in patients receiving allogeneic lung transplant,C0815080,organ rejection,11/25/03,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-CGLBZJNRSA-N,5284373,PMATZTZNYRCHOR-CGLBZJNRSA-N,Cyclosporine,,Prophylaxis of organ rejection in patients receiving allogeneic lung transplant,C0815080,organ rejection,11/25/03,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-SCYOXIPCSA-N,123134263,PMATZTZNYRCHOR-SCYOXIPCSA-N,cyclosporine,,Prophylaxis of graft-versus-host disease,C0018133,Graft-Versus-Host Disease,2/17/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-AVZWOAAISA-N,122172945,PMATZTZNYRCHOR-AVZWOAAISA-N,cyclosporine,,Prophylaxis of graft-versus-host disease,C0018133,Graft-Versus-Host Disease,2/17/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-SRFWORPQSA-N,25246316,PMATZTZNYRCHOR-SRFWORPQSA-N,cyclosporine,,Prophylaxis of graft-versus-host disease,C0018133,Graft-Versus-Host Disease,2/17/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-QVSDIVLPSA-N,5497195,PMATZTZNYRCHOR-QVSDIVLPSA-N,cyclosporine,,Prophylaxis of graft-versus-host disease,C0018133,Graft-Versus-Host Disease,2/17/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-VJRYSDSKSA-N,24883466,PMATZTZNYRCHOR-VJRYSDSKSA-N,cyclosporine,,Prophylaxis of graft-versus-host disease,C0018133,Graft-Versus-Host Disease,2/17/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-GNSAQUIPSA-N,62280,PMATZTZNYRCHOR-GNSAQUIPSA-N,cyclosporine,,Prophylaxis of graft-versus-host disease,C0018133,Graft-Versus-Host Disease,2/17/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-IMVLJIQESA-N,5280754,PMATZTZNYRCHOR-IMVLJIQESA-N,cyclosporine,,Prophylaxis of graft-versus-host disease,C0018133,Graft-Versus-Host Disease,2/17/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-KMSBSJHKSA-N,6435893,PMATZTZNYRCHOR-KMSBSJHKSA-N,cyclosporine,,Prophylaxis of graft-versus-host disease,C0018133,Graft-Versus-Host Disease,2/17/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-CGLBZJNRSA-N,5284373,PMATZTZNYRCHOR-CGLBZJNRSA-N,cyclosporine,,Prophylaxis of graft-versus-host disease,C0018133,Graft-Versus-Host Disease,2/17/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
UFULAYFCSOUIOV-UHFFFAOYSA-N,6058,UFULAYFCSOUIOV-UHFFFAOYSA-N,cysteamine,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,9/11/13,Designated,Not FDA Approved for Orphan Indication,,,,
UFULAYFCSOUIOV-UHFFFAOYSA-N,6058,UFULAYFCSOUIOV-UHFFFAOYSA-N,Cysteamine,,Treatment of cystic fibrosis,C0010674,Cystic Fibrosis,9/11/14,Designated,Not FDA Approved for Orphan Indication,,,,
KGPGQDLTDHGEGT-VBZOGQDBSA-N,23724878,KGPGQDLTDHGEGT-VBZOGQDBSA-N,dalbavancin,,Treatment of acute osteomyelitis in children (0 through 16 years of age),C0158371,Acute osteomyelitis,3/30/15,Designated,Not FDA Approved for Orphan Indication,,,,
KGPGQDLTDHGEGT-CUIWZYKSSA-N,133268464,KGPGQDLTDHGEGT-CUIWZYKSSA-N,dalbavancin,,Treatment of acute osteomyelitis in children (0 through 16 years of age),C0158371,Acute osteomyelitis,3/30/15,Designated,Not FDA Approved for Orphan Indication,,,,
KGPGQDLTDHGEGT-JCIKCJKQSA-N,16134410,KGPGQDLTDHGEGT-JCIKCJKQSA-N,dalbavancin,,Treatment of acute osteomyelitis in children (0 through 16 years of age),C0158371,Acute osteomyelitis,3/30/15,Designated,Not FDA Approved for Orphan Indication,,,,
KGPGQDLTDHGEGT-FOPUKGCJSA-N,135659030,KGPGQDLTDHGEGT-FOPUKGCJSA-N,dalbavancin,,Treatment of acute osteomyelitis in children (0 through 16 years of age),C0158371,Acute osteomyelitis,3/30/15,Designated,Not FDA Approved for Orphan Indication,,,,
KGPGQDLTDHGEGT-SZUNQUCBSA-N,16134627,KGPGQDLTDHGEGT-SZUNQUCBSA-N,dalbavancin,,Treatment of acute osteomyelitis in children (0 through 16 years of age),C0158371,Acute osteomyelitis,3/30/15,Designated,Not FDA Approved for Orphan Indication,,,,
NUKYPUAOHBNCPY-UHFFFAOYSA-N,1727,NUKYPUAOHBNCPY-UHFFFAOYSA-N,dalfampridine,Ampyra,Relief of symptoms of multiple sclerosis,C0026769,Multiple Sclerosis,6/2/87,Designated/Approved,,Treatment to improve walking in patients with multiple sclerosis, 01/22/2010 , 01/22/2017 ,
MQJKPEGWNLWLTK-UHFFFAOYSA-N,2955,MQJKPEGWNLWLTK-UHFFFAOYSA-N,Dapsone,,Prophylaxis of toxoplasmosis in severely immunocompromised patients with CD4 counts below 100.,C0040558,Toxoplasmosis,11/7/94,Designated,Not FDA Approved for Orphan Indication,,,,
XAUDJQYHKZQPEU-KVQBGUIXSA-N,451668,XAUDJQYHKZQPEU-KVQBGUIXSA-N,decitabine,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,8/4/06,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
UREBDLICKHMUKA-CXSFZGCWSA-N,5743,UREBDLICKHMUKA-CXSFZGCWSA-N,dexamethasone,,Prevention of Proliferative Vitreoretinopathy (PVR),C0242852,Proliferative vitreoretinopathy,1/26/21,Designated,Not FDA Approved for Orphan Indication,,,,
DPFYBZWSVVKNPZ-SYWJPMBBSA-N,92043573,DPFYBZWSVVKNPZ-SYWJPMBBSA-N,dextran 1,,Treatment of cystic fibrosis,C0010674,Cystic Fibrosis,3/21/03,Designated,Not FDA Approved for Orphan Indication,,,,
LRCZQSDQZJBHAF-PUBGEWHCSA-N,6918473,LRCZQSDQZJBHAF-PUBGEWHCSA-N,DHA-paclitaxel,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,9/25/01,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
AAOVKJBEBIDNHE-UHFFFAOYSA-N,3016,AAOVKJBEBIDNHE-UHFFFAOYSA-N,diazepam,,Treatment of Dravet syndrome,C0751122,Dravet Syndrome,5/23/18,Designated,Not FDA Approved for Orphan Indication,,,,
YLLWQNAEYILHLV-UHFFFAOYSA-N,25014811,YLLWQNAEYILHLV-UHFFFAOYSA-N,diazoxide choline,,Treatment of Prader-Willi Syndrome,C0032897,Prader-Willi Syndrome,5/13/14,Designated,Not FDA Approved for Orphan Indication,,,,
WDJUZGPOPHTGOT-XUDUSOBPSA-N,441207,WDJUZGPOPHTGOT-XUDUSOBPSA-N,digitoxin,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,11/2/01,Designated,Not FDA Approved for Orphan Indication,,,,
JNODQFNWMXFMEV-UHFFFAOYSA-N,197033,JNODQFNWMXFMEV-UHFFFAOYSA-N,dimebon,,Treatment of Huntington's Disease.,C0020179,Huntington's Disease,5/12/09,Designated,Not FDA Approved for Orphan Indication,,,,
SJVQHLPISAIATJ-ZDUSSCGKSA-N,50905713,SJVQHLPISAIATJ-ZDUSSCGKSA-N,duvelisib,,Treatment of T-Cell Lymphoma,C0079772,T-Cell Lymphoma,10/2/19,Designated,Not FDA Approved for Orphan Indication,,,,
SVOQIEJWJCQGDQ-UHFFFAOYSA-N,135449332,SVOQIEJWJCQGDQ-UHFFFAOYSA-N,eltrombopag,Promacta,Treatment of aplastic anemia,C0002874,Aplastic Anemia,11/8/13,Designated/Approved,,Treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy., 08/26/2014 , 08/26/2021 ,Treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.
AXRCEOKUDYDWLF-UHFFFAOYSA-N,176167,AXRCEOKUDYDWLF-UHFFFAOYSA-N,Enzastaurin,,Treatment of glioblastoma multiforme,C0017636,Glioblastoma multiforme,9/19/05,Designated,Not FDA Approved for Orphan Indication,,,,
AOJJSUZBOXZQNB-VTZDEGQISA-N,41867,AOJJSUZBOXZQNB-VTZDEGQISA-N,Epirubicin,Ellence,Treatment of breast cancer.,C0678222,Breast cancer,9/14/99,Designated/Approved,,Component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer., 09/15/1999 , 09/15/2006 ,
HGHOBRRUMWJWCU-FXQIFTODSA-N,219042,HGHOBRRUMWJWCU-FXQIFTODSA-N,Epitalon,,Treatment of retinitis pigmentosa,C0035334,Retinitis Pigmentosa,9/2/10,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
QAMYWGZHLCQOOJ-XXLUYSOPSA-N,122362420,QAMYWGZHLCQOOJ-XXLUYSOPSA-N,eribulin mesylate,Halaven,Treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,5/14/12,Designated/Approved,,Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen, 01/28/2016 , 01/28/2023 ,Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen
QAMYWGZHLCQOOJ-ONAKUIRGSA-N,117590636,QAMYWGZHLCQOOJ-ONAKUIRGSA-N,eribulin mesylate,Halaven,Treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,5/14/12,Designated/Approved,,Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen, 01/28/2016 , 01/28/2023 ,Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen
QAMYWGZHLCQOOJ-SLSRVFANSA-N,146158903,QAMYWGZHLCQOOJ-SLSRVFANSA-N,eribulin mesylate,Halaven,Treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,5/14/12,Designated/Approved,,Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen, 01/28/2016 , 01/28/2023 ,Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen
QAMYWGZHLCQOOJ-UHFFFAOYSA-N,22525136,QAMYWGZHLCQOOJ-UHFFFAOYSA-N,eribulin mesylate,Halaven,Treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,5/14/12,Designated/Approved,,Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen, 01/28/2016 , 01/28/2023 ,Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen
QAMYWGZHLCQOOJ-IJJXRQIPSA-N,74891361,QAMYWGZHLCQOOJ-IJJXRQIPSA-N,eribulin mesylate,Halaven,Treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,5/14/12,Designated/Approved,,Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen, 01/28/2016 , 01/28/2023 ,Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen
QAMYWGZHLCQOOJ-WRNBYXCMSA-N,17755248,QAMYWGZHLCQOOJ-WRNBYXCMSA-N,eribulin mesylate,Halaven,Treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,5/14/12,Designated/Approved,,Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen, 01/28/2016 , 01/28/2023 ,Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen
SUBDBMMJDZJVOS-XMMPIXPASA-N,9579578,SUBDBMMJDZJVOS-XMMPIXPASA-N,esomeprazole,,Treatment of Eosinophilic Esophagitis,C0341106,Eosinophilic esophagitis,5/15/19,Designated,Not FDA Approved for Orphan Indication,,,,
SUBDBMMJDZJVOS-UHFFFAOYSA-N,4594,SUBDBMMJDZJVOS-UHFFFAOYSA-N,esomeprazole,,Treatment of Eosinophilic Esophagitis,C0341106,Eosinophilic esophagitis,5/15/19,Designated,Not FDA Approved for Orphan Indication,,,,
SUBDBMMJDZJVOS-DEOSSOPVSA-N,9568614,SUBDBMMJDZJVOS-DEOSSOPVSA-N,esomeprazole,,Treatment of Eosinophilic Esophagitis,C0341106,Eosinophilic esophagitis,5/15/19,Designated,Not FDA Approved for Orphan Indication,,,,
HKVAMNSJSFKALM-GKUWKFKPSA-N,6442177,HKVAMNSJSFKALM-GKUWKFKPSA-N,everolimus,,Treatment of Waldenstrom macroglobulinemia (also known as lymphoplasmacytic lymphoma),"C0024419,C0334633","Waldenstrom Macroglobulinemia , Lymphoplasmacytic Lymphoma",9/16/10,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
HKVAMNSJSFKALM-GKUWKFKPSA-N,6442177,HKVAMNSJSFKALM-GKUWKFKPSA-N,everolimus,Afinitor,"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)","C0041341,C0205768,C0206633,C0751674,C1832033,C2247022","Tuberous Sclerosis Complex , Subependymal Giant Cell Astrocytoma , Angiomyolipoma , Lymphangioleiomyomatosis , Subependymal Giant Cell Astrocytoma , tuberous sclerosis complex",6/8/09,Designated/Approved,,Treatment of adults with renal angiomyolipoma and tuberous sclerosis complex (TSC) not requiring immediate surgery., 04/26/2012 , 04/26/2019 ,
BFYIZQONLCFLEV-DAELLWKTSA-N,60198,BFYIZQONLCFLEV-DAELLWKTSA-N,Exemestane,Aromasin,Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.,"C0012634,C0678222","Disease , Breast cancer",9/19/91,Designated/Approved,,Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy., 10/21/1999 , 10/21/2006 ,
JOOXLOJCABQBSG-UHFFFAOYSA-N,16722836,JOOXLOJCABQBSG-UHFFFAOYSA-N,Fedratinib,,Treatment of polycythemia vera,C0032463,Polycythemia Vera,3/21/13,Designated,Not FDA Approved for Orphan Indication,,,,
AKJHMTWEGVYYSE-FXILSDISSA-N,5288209,AKJHMTWEGVYYSE-FXILSDISSA-N,fenretinide,,Treatment of peripheral T-cell lymphoma,C0079774,Peripheral T-Cell Lymphoma,9/4/13,Designated,Not FDA Approved for Orphan Indication,,,,
AKJHMTWEGVYYSE-FXILSDISSA-N,5288209,AKJHMTWEGVYYSE-FXILSDISSA-N,fenretinide,,Treatment of Ewing's sarcoma family of tumors.,C0027651,Tumors,2/1/07,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
IPVFGAYTKQKGBM-BYPJNBLXSA-N,50313,IPVFGAYTKQKGBM-BYPJNBLXSA-N,fialuridine,,Adjunctive treatment of chronic active hepatitis B.,C0744831,Chronic active hepatitis B,7/24/92,Designated,Not FDA Approved for Orphan Indication,,,,
DVASNQYQOZHAJN-UHFFFAOYSA-N,41870,DVASNQYQOZHAJN-UHFFFAOYSA-N,Flumecinol,,Treatment of hyperbilirubinemia in newborn infants unresponsive to phototherapy.,C0020433,Hyperbilirubinemia,1/15/85,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
RTHCYVBBDHJXIQ-UHFFFAOYSA-N,3386,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,Fluoxetine,,Treatment of autism.,C0004352,Autism,4/30/99,Designated,Not FDA Approved for Orphan Indication,,,,
WMWTYOKRWGGJOA-CENSZEJFSA-N,444036,WMWTYOKRWGGJOA-CENSZEJFSA-N,fluticasone propionate,,Treatment of eosinophilic esophagitis,C0341106,Eosinophilic esophagitis,12/29/15,Designated,Not FDA Approved for Orphan Indication,,,,
FIDMEHCRMLKKPZ-YSMBQZINSA-N,10186184,FIDMEHCRMLKKPZ-YSMBQZINSA-N,fosbretabulin tromethamine,,Treatment of glioma,C0017638,Glioma,6/8/16,Designated,Not FDA Approved for Orphan Indication,,,,
CZAKJJUNKNPTTO-UHFFFAOYSA-N,135894389,CZAKJJUNKNPTTO-UHFFFAOYSA-N,fosdenopterin,Nulibry,Treatment of molybdenum cofactor deficiency type A (MoCD),C0268119,Molybdenum cofactor deficiency,11/5/09,Designated/Approved,,to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, 02/26/2021 ,  ,
CZAKJJUNKNPTTO-AJFJRRQVSA-N,135463437,CZAKJJUNKNPTTO-AJFJRRQVSA-N,fosdenopterin,Nulibry,Treatment of molybdenum cofactor deficiency type A (MoCD),C0268119,Molybdenum cofactor deficiency,11/5/09,Designated/Approved,,to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, 02/26/2021 ,  ,
UGJMXCAKCUNAIE-UHFFFAOYSA-N,3446,UGJMXCAKCUNAIE-UHFFFAOYSA-N,gabapentin,Gralise,Management of postherpetic neuralgia,C0032768,Postherpetic neuralgia,11/8/10,Designated/Approved,,For the management of postherpetic neuralgia, 01/28/2011 , 01/28/2018 ,
ZXRVKCBLGJOCEE-UHFFFAOYSA-N,3448,ZXRVKCBLGJOCEE-UHFFFAOYSA-N,Gaboxadol,,Treatment of Fragile X syndrome,C0016667,Fragile X Syndrome,10/3/17,Designated,Not FDA Approved for Orphan Indication,,,,
PZBPHYLKIMOZPR-ZWIFOJARSA-K,145994621,PZBPHYLKIMOZPR-ZWIFOJARSA-K,Gallium (68Ga) edotreotide,,Diagnostic for the clinical management of neuroendocrine tumors.,C0206754,Neuroendocrine Tumors,7/1/15,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PZBPHYLKIMOZPR-FIYGWYQWSA-K,71661158,PZBPHYLKIMOZPR-FIYGWYQWSA-K,Gallium (68Ga) edotreotide,,Diagnostic for the clinical management of neuroendocrine tumors.,C0206754,Neuroendocrine Tumors,7/1/15,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
SDUQYLNIPVEERB-QPPQHZFASA-N,60750,SDUQYLNIPVEERB-QPPQHZFASA-N,gemcitabine,,Treatment of cholangiocarcinoma.,C0206698,Cholangiocarcinoma,1/11/16,Designated,Not FDA Approved for Orphan Indication,,,,
BRZYSWJRSDMWLG-JRRILZOYSA-N,134688573,BRZYSWJRSDMWLG-JRRILZOYSA-N,Geneticin,,Treatment of amoebiasis.,C0013370,amoebiasis,6/6/05,Designated,Not FDA Approved for Orphan Indication,,,,
BRZYSWJRSDMWLG-OBOPTQIOSA-N,71684684,BRZYSWJRSDMWLG-OBOPTQIOSA-N,Geneticin,,Treatment of amoebiasis.,C0013370,amoebiasis,6/6/05,Designated,Not FDA Approved for Orphan Indication,,,,
BRZYSWJRSDMWLG-VVNRJQPTSA-N,137967135,BRZYSWJRSDMWLG-VVNRJQPTSA-N,Geneticin,,Treatment of amoebiasis.,C0013370,amoebiasis,6/6/05,Designated,Not FDA Approved for Orphan Indication,,,,
BRZYSWJRSDMWLG-WFDQBLTDSA-N,6710770,BRZYSWJRSDMWLG-WFDQBLTDSA-N,Geneticin,,Treatment of amoebiasis.,C0013370,amoebiasis,6/6/05,Designated,Not FDA Approved for Orphan Indication,,,,
BRZYSWJRSDMWLG-NQRKCNNJSA-N,71308205,BRZYSWJRSDMWLG-NQRKCNNJSA-N,Geneticin,,Treatment of amoebiasis.,C0013370,amoebiasis,6/6/05,Designated,Not FDA Approved for Orphan Indication,,,,
BRZYSWJRSDMWLG-CAXSIQPQSA-N,2733531,BRZYSWJRSDMWLG-CAXSIQPQSA-N,Geneticin,,Treatment of amoebiasis.,C0013370,amoebiasis,6/6/05,Designated,Not FDA Approved for Orphan Indication,,,,
BRZYSWJRSDMWLG-KVXRWBJUSA-N,447379,BRZYSWJRSDMWLG-KVXRWBJUSA-N,Geneticin,,Treatment of amoebiasis.,C0013370,amoebiasis,6/6/05,Designated,Not FDA Approved for Orphan Indication,,,,
BRZYSWJRSDMWLG-DJWUNRQOSA-N,123865,BRZYSWJRSDMWLG-DJWUNRQOSA-N,Geneticin,,Treatment of amoebiasis.,C0013370,amoebiasis,6/6/05,Designated,Not FDA Approved for Orphan Indication,,,,
LZQXMCNBQHANEY-UHFFFAOYSA-N,21195079,LZQXMCNBQHANEY-UHFFFAOYSA-N,glucarpidase,Voraxaze,Treatment of patients at risk of methotrexate toxicity,C0568062,Methotrexate Toxicity,8/19/03,Designated/Approved,,Treatment of toxic (>1 micromole/liter) plasma methotrexate concentrations in patients with delayed methotrexate clearance due to impaired renal function., 01/17/2012 , 01/17/2019 ,
HLNZYALGGXMQQC-WFDKWETCSA-N,138319140,HLNZYALGGXMQQC-WFDKWETCSA-N,granaticin B,,Treatment of Acute Lymphoblastic Leukemia (ALL),"C0023449,C3542401","Acute lymphoblastic leukemia , Acute Lymphoblastic Leukemia",3/7/18,Designated,Not FDA Approved for Orphan Indication,,,,
HLNZYALGGXMQQC-TVASSOHNSA-N,136015147,HLNZYALGGXMQQC-TVASSOHNSA-N,granaticin B,,Treatment of Acute Lymphoblastic Leukemia (ALL),"C0023449,C3542401","Acute lymphoblastic leukemia , Acute Lymphoblastic Leukemia",3/7/18,Designated,Not FDA Approved for Orphan Indication,,,,
HLNZYALGGXMQQC-VHAJSWNUSA-N,136018428,HLNZYALGGXMQQC-VHAJSWNUSA-N,granaticin B,,Treatment of Acute Lymphoblastic Leukemia (ALL),"C0023449,C3542401","Acute lymphoblastic leukemia , Acute Lymphoblastic Leukemia",3/7/18,Designated,Not FDA Approved for Orphan Indication,,,,
INJOMKTZOLKMBF-UHFFFAOYSA-N,3519,INJOMKTZOLKMBF-UHFFFAOYSA-N,guanfacine,,Treatment of fragile X syndrome.,C0016667,Fragile X Syndrome,8/5/99,Designated,Not FDA Approved for Orphan Indication,,,,
JRTRSJGZMRQDHI-UHFFFAOYSA-N,92044406,JRTRSJGZMRQDHI-UHFFFAOYSA-N,Heparin sodium,,Treatment of cystic fibrosis,C0010674,Cystic Fibrosis,6/29/06,Designated,Not FDA Approved for Orphan Indication,,,,
JRTRSJGZMRQDHI-UHFFFAOYSA-N,92044406,JRTRSJGZMRQDHI-UHFFFAOYSA-N,heparin sodium,,Treatment of Cystic Fibrosis,C0010674,Cystic Fibrosis,7/29/19,Designated,Not FDA Approved for Orphan Indication,,,,
WZHKXNSOCOQYQX-XFUHGIIQSA-N,44368295,WZHKXNSOCOQYQX-XFUHGIIQSA-N,His-D-Trp-Ala-Trp-D-Phe-Lys NH2,,For the long term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.,C0015544,growth failure,5/23/90,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
VSNHCAURESNICA-UHFFFAOYSA-N,3657,VSNHCAURESNICA-UHFFFAOYSA-N,hydroxycarbamide (hydroxyurea),Siklos,Treatment of sickle cell disease in patients under 18 years of age,C0002895,Sickle Cell Disease,7/24/13,Designated/Approved,,"To reduce the frequency of painful crises and to reduce the need for blood transfusions in pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crisis", 12/21/2017 , 12/21/2024 ,"To reduce the frequency of painful crises and to reduce the need for blood transfusions in pediatric patients, 2 years of age amd older, with sickle cell anemia with recurrent moderate to severe painful crisis"
XYFPWWZEPKGCCK-GOSISDBHSA-N,24821094,XYFPWWZEPKGCCK-GOSISDBHSA-N,ibrutinib,,Treatment of chronic lymphocytic leukemia (CLL).,C0023434,Chronic Lymphocytic Leukemia,3/27/12,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
XYFPWWZEPKGCCK-GOSISDBHSA-N,24821094,XYFPWWZEPKGCCK-GOSISDBHSA-N,ibrutinib,Imbruvica,Treatment of patients with extranodal marginal zone lymphoma (mucosa associated lymphoid tissue [MALT type] lymphoma),"C0024299,C0242647,C1367654","Lymphoma , marginal zone lymphoma , Marginal zone lymphoma",2/2/16,Designated/Approved,,Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy., 01/18/2017 , 01/18/2024 ,Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.
XYFPWWZEPKGCCK-GOSISDBHSA-N,24821094,XYFPWWZEPKGCCK-GOSISDBHSA-N,ibrutinib,Imbruvica,Treatment of nodal marginal zone lymphoma,C0242647,Nodal marginal zone lymphoma,2/5/15,Designated/Approved,,Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy., 01/18/2017 , 01/18/2024 ,Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.
XYFPWWZEPKGCCK-GOSISDBHSA-N,24821094,XYFPWWZEPKGCCK-GOSISDBHSA-N,ibrutinib,Imbruvica,Treatment of chronic Graft versus Host disease.,C0867389,Chronic Graft Versus Host Disease,6/23/16,Designated/Approved,,Treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy., 08/02/2017 , 08/02/2024 ,Treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.
IHHXIUAEPKVVII-PTKYJSHISA-N,9819903,IHHXIUAEPKVVII-PTKYJSHISA-N,Ibuprofen lysine,NeoProfen,Treatment of patent ductus arteriosus,C0013274,Patent ductus arteriosus,10/29/96,Designated/Approved,,"For closure of a clinically significant patent ductus arteriosus in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective", 04/13/2006 , 04/13/2013 ,
IHHXIUAEPKVVII-UHFFFAOYSA-N,9863332,IHHXIUAEPKVVII-UHFFFAOYSA-N,Ibuprofen lysine,NeoProfen,Treatment of patent ductus arteriosus,C0013274,Patent ductus arteriosus,10/29/96,Designated/Approved,,"For closure of a clinically significant patent ductus arteriosus in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective", 04/13/2006 , 04/13/2013 ,
IHHXIUAEPKVVII-ZSCHJXSPSA-N,9841440,IHHXIUAEPKVVII-ZSCHJXSPSA-N,Ibuprofen lysine,NeoProfen,Treatment of patent ductus arteriosus,C0013274,Patent ductus arteriosus,10/29/96,Designated/Approved,,"For closure of a clinically significant patent ductus arteriosus in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective", 04/13/2006 , 04/13/2013 ,
HIFJCPQKFCZDDL-PNQLYJIOSA-N,134694981,HIFJCPQKFCZDDL-PNQLYJIOSA-N,iloprost,,Treatment of systemic sclerosis,C0036421,Systemic sclerosis,5/9/19,Designated,Not FDA Approved for Orphan Indication,,,,
HIFJCPQKFCZDDL-JYTNZNGZSA-N,91746214,HIFJCPQKFCZDDL-JYTNZNGZSA-N,iloprost,,Treatment of systemic sclerosis,C0036421,Systemic sclerosis,5/9/19,Designated,Not FDA Approved for Orphan Indication,,,,
HIFJCPQKFCZDDL-QSGBCQANSA-N,20838499,HIFJCPQKFCZDDL-QSGBCQANSA-N,iloprost,,Treatment of systemic sclerosis,C0036421,Systemic sclerosis,5/9/19,Designated,Not FDA Approved for Orphan Indication,,,,
HIFJCPQKFCZDDL-GBSCXWAGSA-N,51397006,HIFJCPQKFCZDDL-GBSCXWAGSA-N,iloprost,,Treatment of systemic sclerosis,C0036421,Systemic sclerosis,5/9/19,Designated,Not FDA Approved for Orphan Indication,,,,
HIFJCPQKFCZDDL-NYBPDPFASA-N,54313,HIFJCPQKFCZDDL-NYBPDPFASA-N,iloprost,,Treatment of systemic sclerosis,C0036421,Systemic sclerosis,5/9/19,Designated,Not FDA Approved for Orphan Indication,,,,
HIFJCPQKFCZDDL-QYUAYYPJSA-N,89077401,HIFJCPQKFCZDDL-QYUAYYPJSA-N,iloprost,,Treatment of systemic sclerosis,C0036421,Systemic sclerosis,5/9/19,Designated,Not FDA Approved for Orphan Indication,,,,
HIFJCPQKFCZDDL-CSAIKYROSA-N,53486260,HIFJCPQKFCZDDL-CSAIKYROSA-N,iloprost,,Treatment of systemic sclerosis,C0036421,Systemic sclerosis,5/9/19,Designated,Not FDA Approved for Orphan Indication,,,,
HIFJCPQKFCZDDL-UHFFFAOYSA-N,53394043,HIFJCPQKFCZDDL-UHFFFAOYSA-N,iloprost,,Treatment of systemic sclerosis,C0036421,Systemic sclerosis,5/9/19,Designated,Not FDA Approved for Orphan Indication,,,,
HIFJCPQKFCZDDL-SGSAMSKHSA-N,6435378,HIFJCPQKFCZDDL-SGSAMSKHSA-N,iloprost,,Treatment of systemic sclerosis,C0036421,Systemic sclerosis,5/9/19,Designated,Not FDA Approved for Orphan Indication,,,,
HIFJCPQKFCZDDL-ACWOEMLNSA-N,5311181,HIFJCPQKFCZDDL-ACWOEMLNSA-N,iloprost,,Treatment of systemic sclerosis,C0036421,Systemic sclerosis,5/9/19,Designated,Not FDA Approved for Orphan Indication,,,,
KTUFNOKKBVMGRW-UHFFFAOYSA-N,5291,KTUFNOKKBVMGRW-UHFFFAOYSA-N,imatinib,,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,4/7/10,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
YLMAHDNUQAMNNX-UHFFFAOYSA-N,123596,YLMAHDNUQAMNNX-UHFFFAOYSA-N,imatinib mesylate,Gleevec,Treatment of gastrointestinal stromal tumors,C0238198,Gastrointestinal Stromal Tumors,11/1/01,Designated/Approved,,Treatment of patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST), 02/01/2002 , 02/01/2009 ,
BIXBBIPTYBJTRY-UHFFFAOYSA-N,68791,BIXBBIPTYBJTRY-UHFFFAOYSA-N,Imexon,,Treatment of multiple myeloma.,C0026764,Multiple Myeloma,11/8/96,Designated,Not FDA Approved for Orphan Indication,,,,
GAMYYCRTACQSBR-UHFFFAOYSA-N,67504,GAMYYCRTACQSBR-UHFFFAOYSA-N,Imidazopyridine,,Treatment of Amyotrophic Lateral Sclerosis,C0002736,Amyotrophic Lateral Sclerosis,7/22/19,Designated,Not FDA Approved for Orphan Indication,,,,
HHGRMHMXKPQNGF-SAOVQBGCSA-N,134692690,HHGRMHMXKPQNGF-SAOVQBGCSA-N,inecalcitol,,Treatment of acute myeloid leukemia.,C0023467,Acute myeloid leukemia,8/3/15,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
HHGRMHMXKPQNGF-VTQYNGMESA-N,131954606,HHGRMHMXKPQNGF-VTQYNGMESA-N,inecalcitol,,Treatment of acute myeloid leukemia.,C0023467,Acute myeloid leukemia,8/3/15,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
HHGRMHMXKPQNGF-AAMRAYDJSA-N,146157506,HHGRMHMXKPQNGF-AAMRAYDJSA-N,inecalcitol,,Treatment of acute myeloid leukemia.,C0023467,Acute myeloid leukemia,8/3/15,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
HHGRMHMXKPQNGF-ZKNOEPHOSA-N,53877232,HHGRMHMXKPQNGF-ZKNOEPHOSA-N,inecalcitol,,Treatment of acute myeloid leukemia.,C0023467,Acute myeloid leukemia,8/3/15,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
HHGRMHMXKPQNGF-WEZTXPJVSA-N,9952841,HHGRMHMXKPQNGF-WEZTXPJVSA-N,inecalcitol,,Treatment of acute myeloid leukemia.,C0023467,Acute myeloid leukemia,8/3/15,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
HHGRMHMXKPQNGF-WNSNRMDMSA-N,6915835,HHGRMHMXKPQNGF-WNSNRMDMSA-N,inecalcitol,,Treatment of acute myeloid leukemia.,C0023467,Acute myeloid leukemia,8/3/15,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PDWUPXJEEYOOTR-JRGAVVOBSA-N,71184,PDWUPXJEEYOOTR-JRGAVVOBSA-N,Iobenguane I 131,Azedra Ultratrace,Treatment of neuroendocrine tumors,C0206754,Neuroendocrine Tumors,1/18/06,Designated/Approved,,"AZEDRA is indicated for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy.", 07/30/2018 , 07/30/2025 ,"AZEDRA is indicated for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy."
NICJCIQSJJKZAH-AWEZNQCLSA-N,148189,NICJCIQSJJKZAH-AWEZNQCLSA-N,irofulven,,Treatment of renal cell carcinoma.,C0007134,Renal Cell Carcinoma,7/27/99,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PURKAOJPTOLRMP-UHFFFAOYSA-N,16220172,PURKAOJPTOLRMP-UHFFFAOYSA-N,ivacaftor,Kalydeco,Treatment of patients with cystic fibrosis,C0010674,Cystic Fibrosis,12/20/06,Designated/Approved,,Treatment of cystic fibrosis (CF) in patients age 2 years and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data., 05/17/2017 , 05/17/2024 ,"Treatment of cystic fibrosis (CF) in patients age 2 years and older who have one of the following mutations in the CFTR gene: E56K, P67L, R74W, D110E, D110H, R117C, E193K, L206W, R347H, R352Q, A455E, D579G, S945L, S977F, F1052V, K1060T, A1067T, G1069R, R1070Q, R1070W, F1074L, D1152H, and D1270N."
AUGCSOFQTDKPSO-RGVLZGJSSA-N,16117309,AUGCSOFQTDKPSO-RGVLZGJSSA-N,Ivaltinostat,,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,8/21/20,Designated,Not FDA Approved for Orphan Indication,,,,
WIJZXSAJMHAVGX-DHLKQENFSA-N,71657455,WIJZXSAJMHAVGX-DHLKQENFSA-N,ivosidenib,,Treatment of cholangiocarcinoma,C0206698,Cholangiocarcinoma,4/26/17,Designated,Not FDA Approved for Orphan Indication,,,,
BMLMGCPTLHPWPY-REOHCLBHSA-N,72390,BMLMGCPTLHPWPY-REOHCLBHSA-N,L-2-oxothiazolidine-4-carboxylic acid,,Treatment of adult respiratory distress syndrome.,C0035222,ADULT RESPIRATORY DISTRESS SYNDROME,6/14/94,Designated,Not FDA Approved for Orphan Indication,,,,
BMLMGCPTLHPWPY-UHFFFAOYSA-N,65272,BMLMGCPTLHPWPY-UHFFFAOYSA-N,L-2-oxothiazolidine-4-carboxylic acid,,Treatment of adult respiratory distress syndrome.,C0035222,ADULT RESPIRATORY DISTRESS SYNDROME,6/14/94,Designated,Not FDA Approved for Orphan Indication,,,,
KPYSYYIEGFHWSV-QMMMGPOBSA-N,44602,KPYSYYIEGFHWSV-QMMMGPOBSA-N,L-baclofen,,Treatment of trigeminal neuralgia.,C0040997,Trigeminal Neuralgia,7/13/90,Designated,Not FDA Approved for Orphan Indication,,,,
KPYSYYIEGFHWSV-MRVPVSSYSA-N,44600,KPYSYYIEGFHWSV-MRVPVSSYSA-N,L-baclofen,,Treatment of trigeminal neuralgia.,C0040997,Trigeminal Neuralgia,7/13/90,Designated,Not FDA Approved for Orphan Indication,,,,
LRSYFEZBIMVWRY-VWMHFEHESA-N,44247677,LRSYFEZBIMVWRY-VWMHFEHESA-N,L-ornithine phenylacetate,,Treatment of hyperammonemia and resultant hepatic encephalopathy (HE) in patients with acute liver failure or acute on chronic liver disase,"C0019151,C0162557,C0220994","Hepatic Encephalopathy , Acute liver failure , Hyperammonemia",4/7/10,Designated,Not FDA Approved for Orphan Indication,,,,
FNVKWTCPMNNIND-WDTSGDEMSA-N,71587496,FNVKWTCPMNNIND-WDTSGDEMSA-N,L-tyrosine-L-serine-L-leucine,,Treatment of hepatocellular carcinoma.,C2239176,HEPATOCELLULAR CARCINOMA,9/10/04,Designated,Not FDA Approved for Orphan Indication,,,,
PUDHBTGHUJUUFI-SCTWWAJVSA-N,6918011,PUDHBTGHUJUUFI-SCTWWAJVSA-N,lanreotide acetate,Somatuline Depot,Treatment of neuroendocrine tumors,C0206754,Neuroendocrine Tumors,8/25/11,Designated/Approved,,"Treatment of patients with unresectable,well- or moderately-differentiated locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival", 12/16/2014 , 12/16/2021 ,"Treatment of patients with unresectable,well- or moderately-differentiated locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival"
PUDHBTGHUJUUFI-UHFFFAOYSA-N,71349,PUDHBTGHUJUUFI-UHFFFAOYSA-N,lanreotide acetate,Somatuline Depot,Treatment of neuroendocrine tumors,C0206754,Neuroendocrine Tumors,8/25/11,Designated/Approved,,"Treatment of patients with unresectable,well- or moderately-differentiated locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival", 12/16/2014 , 12/16/2021 ,"Treatment of patients with unresectable,well- or moderately-differentiated locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival"
JWHPPWBIIQMBQC-UHFFFAOYSA-M,23697158,JWHPPWBIIQMBQC-UHFFFAOYSA-M,laquinimod sodium,,Treatment of Huntington's Disease,C0020179,Huntington's Disease,1/31/17,Designated,Not FDA Approved for Orphan Indication,,,,
PHIQHXFUZVPYII-ZCFIWIBFSA-N,10917,PHIQHXFUZVPYII-ZCFIWIBFSA-N,Levocarnitine,Carnitor,Treatment of genetic carnitine deficiency.,C0342788,Carnitine Deficiency,2/28/84,Designated/Approved,,, 04/10/1986 , 04/10/1993 ,
PHIQHXFUZVPYII-ZCFIWIBFSA-N,10917,PHIQHXFUZVPYII-ZCFIWIBFSA-N,levocarnitine,,1. Prevention of secondary carnitine deficiency in valproic acid toxicity 2. Treatment of secondary carnitine deficiency in valproic acid toxicity,"C0600688,C2025219","Toxicity , Secondary carnitine deficiency",11/15/89,Designated,Not FDA Approved for Orphan Indication,,,,
GSDSWSVVBLHKDQ-JTQLQIEISA-N,149096,GSDSWSVVBLHKDQ-JTQLQIEISA-N,Levofloxacin,,Treatment of pulmonary infections due to Pseudomonas aeruginosa and other bacteria in patients with cystic fibrosis patients,"C0004611,C0010674,C0033809,C0876973","Bacteria , Cystic Fibrosis , Pseudomonas aeruginosa , Pulmonary infections",2/27/08,Designated,Not FDA Approved for Orphan Indication,,,,
VVIAGPKUTFNRDU-STQMWFEESA-N,135398559,VVIAGPKUTFNRDU-STQMWFEESA-N,levoleucovorin,Fusilev,For use in combination chemotherapy with the approved agent 5-fluorouracil in the palliative treatment of metastatic adenocarcinoma of the colon and rectum,"C0334277,C0338106","Metastatic adenocarcinoma , adenocarcinoma of the colon",12/18/90,Designated/Approved,,For use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer, 04/29/2011 , 04/29/2018 ,
VWBBRFHSPXRJQD-QNTKWALQSA-L,135564391,VWBBRFHSPXRJQD-QNTKWALQSA-L,levomefolate calcium,,Treatment of megaloblastic anemia caused by folate deficiency,"C0002888,C0016412","Megaloblastic anemia , Folate deficiency",2/10/15,Designated,Not FDA Approved for Orphan Indication,,,,
LKCWBDHBTVXHDL-CAIQVSFASA-N,456591,LKCWBDHBTVXHDL-CAIQVSFASA-N,liposomal amikacin,Arikayce,Treatment of infections caused by non-tuberculous mycobacteria,"C1265234,C3714514","Non-Tuberculous Mycobacteria , Infections",3/25/13,Designated/Approved,,Treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy, 09/28/2018 , 09/28/2025 ,Treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy
APKFDSVGJQXUKY-INPOYWNPSA-N,5280965,APKFDSVGJQXUKY-INPOYWNPSA-N,Liposomal amphotericin B,AmBisome,Treatment of cryptococcal meningitis.,C0085436,Cryptococcal meningitis,12/10/96,Designated/Approved,,Treatment of disseminated cryptococcosis including meningitis., 08/11/1997 , 08/11/2004 ,
JJOFNSLZHKIJEV-UHFFFAOYSA-N,11192129,JJOFNSLZHKIJEV-UHFFFAOYSA-N,Lodoxamide tromethamine,Alomide Ophthalmic Solution,Treatment of vernal keratoconjunctivitis.,C0022577,Vernal keratoconjunctivitis,10/16/91,Designated/Approved,,"Treatment of ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, vernal keratitis.", 09/23/1993 , 09/23/2000 ,
OSPNFKYGOFXGBX-YWWKUQGPSA-N,145722609,OSPNFKYGOFXGBX-YWWKUQGPSA-N,Lucinactant,,Prevention of bronchopulmonary dysplasia in premature infants,C0006287,Bronchopulmonary Dysplasia,5/23/06,Designated,Not FDA Approved for Orphan Indication,,,,
OSPNFKYGOFXGBX-YWWKUQGPSA-N,145722609,OSPNFKYGOFXGBX-YWWKUQGPSA-N,Lucinactant,,Treatment of acute respiratory distress syndrome in adults.,C0035222,Acute respiratory distress syndrome,7/17/95,Designated,Not FDA Approved for Orphan Indication,,,,
STPKWKPURVSAJF-LJEWAXOPSA-N,9831643,STPKWKPURVSAJF-LJEWAXOPSA-N,maralixibat,,Treatment of progressive familial intrahepatic cholestasis,C4551898,Progressive familial intrahepatic cholestasis,9/4/13,Designated,Not FDA Approved for Orphan Indication,,,,
NGWSFRIPKNWYAO-SHTIJGAHSA-N,11347535,NGWSFRIPKNWYAO-SHTIJGAHSA-N,marizomib,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,12/13/13,Designated,Not FDA Approved for Orphan Indication,,,,
WJEOLQLKVOPQFV-UHFFFAOYSA-N,10074640,WJEOLQLKVOPQFV-UHFFFAOYSA-N,masitinib,,Treatment of mastocytosis,C0024899,Mastocytosis,9/14/05,Designated,Not FDA Approved for Orphan Indication,,,,
TXCWBWKVIZGWEQ-UHFFFAOYSA-N,25024769,TXCWBWKVIZGWEQ-UHFFFAOYSA-N,masitinib mesylate,,Treatment of gastric cancer including cancer of the gastroesophageal junction,C0024623,Gastric Cancer,9/14/15,Designated,Not FDA Approved for Orphan Indication,,,,
TXCWBWKVIZGWEQ-UHFFFAOYSA-N,25024769,TXCWBWKVIZGWEQ-UHFFFAOYSA-N,masitinib mesylate,,Treatment of amyotrophic lateral sclerosis.,C0002736,Amyotrophic Lateral Sclerosis,3/18/15,Designated,Not FDA Approved for Orphan Indication,,,,
PSGAAPLEWMOORI-PEINSRQWSA-N,6279,PSGAAPLEWMOORI-PEINSRQWSA-N,Medroxyprogesterone acetate,,Treatment of immune thrombocytopenic purpura.,C0398650,Immune thrombocytopenic purpura,2/22/01,Designated,Not FDA Approved for Orphan Indication,,,,
DRLFMBDRBRZALE-UHFFFAOYSA-N,896,DRLFMBDRBRZALE-UHFFFAOYSA-N,Melatonin,,Prevention of retinopathy of prematurity,C0035344,Retinopathy of Prematurity,4/20/20,Designated,Not FDA Approved for Orphan Indication,,,,
SGDBTWWWUNNDEQ-LBPRGKRZSA-N,460612,SGDBTWWWUNNDEQ-LBPRGKRZSA-N,melphalan,,Treatment of cholangiocarcinoma.,C0206698,Cholangiocarcinoma,7/14/15,Designated,Not FDA Approved for Orphan Indication,,,,
FBOZXECLQNJBKD-ZDUSSCGKSA-N,126941,FBOZXECLQNJBKD-ZDUSSCGKSA-N,methotrexate,,Prevention of proliferative vitreoretinopathy (PVR),C0242852,Proliferative vitreoretinopathy,4/11/18,Designated,Not FDA Approved for Orphan Indication,,,,
BKBBTCORRZMASO-ZOWNYOTGSA-M,24906323,BKBBTCORRZMASO-ZOWNYOTGSA-M,Methotrexate sodium,Methotrexate,Treatment of osteogenic sarcoma.,C0029463,Osteogenic sarcoma,10/21/85,Designated/Approved,,For the use of high dose methotrexate with leucovorin rescue in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor., 04/07/1988 , 04/07/1995 ,
BKBBTCORRZMASO-ZOWNYOTGSA-M,24906323,BKBBTCORRZMASO-ZOWNYOTGSA-M,Methotrexate sodium,Methotrexate,Treatment of osteogenic sarcoma.,C0029463,Osteogenic sarcoma,10/21/85,Designated/Approved,,For the use of high dose methotrexate with leucovorin rescue in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor., 04/07/1988 , 04/07/1995 ,
DASQOOZCTWOQPA-GXKRWWSZSA-L,11329481,DASQOOZCTWOQPA-GXKRWWSZSA-L,Methotrexate sodium,Methotrexate,Treatment of osteogenic sarcoma.,C0029463,Osteogenic sarcoma,10/21/85,Designated/Approved,,For the use of high dose methotrexate with leucovorin rescue in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor., 04/07/1988 , 04/07/1995 ,
VAOCPAMSLUNLGC-UHFFFAOYSA-N,4173,VAOCPAMSLUNLGC-UHFFFAOYSA-N,metronidazole,,Treatment of clostridium difficile infection in pediatric patients (0 through 16 years of age).,C0343386,Clostridium difficile infection,4/5/16,Designated,Not FDA Approved for Orphan Indication,,,,
VAOCPAMSLUNLGC-UHFFFAOYSA-N,4173,VAOCPAMSLUNLGC-UHFFFAOYSA-N,Metronidazole,,Treatment of perioral dermatitis.,C0263449,Perioral Dermatitis,10/24/91,Designated,Not FDA Approved for Orphan Indication,,,,
FJLBFSROUSIWMA-UHFFFAOYSA-N,4174,FJLBFSROUSIWMA-UHFFFAOYSA-N,metyrapone,,Treatment of Cushing's syndrome,C0039082,Syndrome,9/25/12,Designated,Not FDA Approved for Orphan Indication,,,,
VKHAHZOOUSRJNA-GCNJZUOMSA-N,55245,VKHAHZOOUSRJNA-GCNJZUOMSA-N,mifepristone,Korlym,Treatment of the clinical manifestations of endogenous Cushing's syndrone,C0010481,Cushing Syndrome,7/5/07,Designated/Approved,,for the control of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery., 02/17/2012 , 02/17/2019 ,
WTJXVDPDEQKTCV-VQAITOIOSA-N,54685925,WTJXVDPDEQKTCV-VQAITOIOSA-N,Minocycline HCl,,Treatment of chronic malignant pleural effusion.,C0080032,malignant pleural effusion,6/19/92,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
NWIBSHFKIJFRCO-WUDYKRTCSA-N,5746,NWIBSHFKIJFRCO-WUDYKRTCSA-N,mitomycin,Jelmyto,Treatment of upper tract urothelial cell cancers (transitional cell carcinoma of the renal pelvis and ureter),"C1370932,C4087468","carcinoma of the renal pelvis and ureter , Transitional Cell Carcinoma of the Renal Pelvis",9/8/14,Designated/Approved,,JELMYTO is indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC), 04/15/2020 , 04/15/2027 ,Indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC).
AZSRSNUQCUDCGG-UHFFFAOYSA-N,118607832,AZSRSNUQCUDCGG-UHFFFAOYSA-N,mobocertinib,,"Treatment of non-small cell lung cancer with genetic alterations in EGFR including EGFR mutations and/or EGFR gene amplifications, HER2 mutations, or BRAF G466V mutations",C3539721,Non-Small Cell Lung Cancer,12/17/19,Designated,Not FDA Approved for Orphan Indication,,,,
IDIIJJHBXUESQI-DFIJPDEKSA-N,101526,IDIIJJHBXUESQI-DFIJPDEKSA-N,moxifloxacin hydrochloride,,Treatment of tuberculosis,C0041296,Tuberculosis,4/30/14,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
XIKSEDLKDYKPTO-UHFFFAOYSA-N,10038269,XIKSEDLKDYKPTO-UHFFFAOYSA-N,"N-(3,4-dihydroxyphenyl)-3,4-dihydroxybenzamide",,Treatment of AL Amyloidosis,C0268381,AL Amyloidosis,10/15/14,Designated,Not FDA Approved for Orphan Indication,,,,
XPEHHUISIBFLHX-QFWMXSHPSA-N,121439966,XPEHHUISIBFLHX-QFWMXSHPSA-N,"N-(trans-3-(5-((R)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)cyclobutyl)-3-phenylisoxazole-5-carboxamide",,Treatment of cystic fibrosis,C0010674,Cystic Fibrosis,3/7/18,Designated,Not FDA Approved for Orphan Indication,,,,
WXNXCEHXYPACJF-ZETCQYMHSA-N,70912,WXNXCEHXYPACJF-ZETCQYMHSA-N,N-Acetyl-Leucine,,Treatment of Ataxia Telangiectasia,C0004135,Ataxia Telangiectasia,10/2/18,Designated,Not FDA Approved for Orphan Indication,,,,
PWKSKIMOESPYIA-BYPYZUCNSA-N,12035,PWKSKIMOESPYIA-BYPYZUCNSA-N,N-acetylcysteine,,Prevention of ototoxicity caused by platinum-based chemotherapeutic agents used to treat pediatric cancers,"C0006826,C0235280","Cancers , Ototoxicity",7/19/12,Designated,Not FDA Approved for Orphan Indication,,,,
URCVCIZFVQDVPM-UHFFFAOYSA-N,3035714,URCVCIZFVQDVPM-UHFFFAOYSA-N,N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide,,Treatment of neuroblastoma,C0027819,Neuroblastoma,9/30/04,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
YZOQZEXYFLXNKA-UHFFFAOYSA-N,10309114,YZOQZEXYFLXNKA-UHFFFAOYSA-N,"N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide",,Treatment of stages IIB-IV melanoma,C0025202,melanoma,8/13/04,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PCHKPVIQAHNQLW-CQSZACIVSA-N,24958200,PCHKPVIQAHNQLW-CQSZACIVSA-N,niraparib,Zejula,Treatment of ovarian cancer,C4721610,Ovarian Cancer,4/30/10,Designated/Approved,,"ZEJULA is indicated for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy", 04/29/2020 , 04/29/2027 ,Indicated for the maintenance treatment of adult patients with advanced epithelial ovarian cancer who are in a complete or partial response to first-line platinum-based chemotherapy.
PCHKPVIQAHNQLW-CQSZACIVSA-N,24958200,PCHKPVIQAHNQLW-CQSZACIVSA-N,niraparib,Zejula,Treatment of ovarian cancer,C4721610,Ovarian Cancer,4/30/10,Designated/Approved,,"Indicated for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy", 03/27/2017 , 03/27/2024 ,Indicated for maintenance treatment of adult patients with recurrent epithelial ovarian cancer who are in a complete or partial response to platinum-based chemotherapy
MWUXSHHQAYIFBG-UHFFFAOYSA-N,145068,MWUXSHHQAYIFBG-UHFFFAOYSA-N,nitric oxide,,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,12/28/11,Designated,Not FDA Approved for Orphan Indication,,,,
MIMNFCVQODTQDP-NDLVEFNKSA-N,118984458,MIMNFCVQODTQDP-NDLVEFNKSA-N,oblimersen,,"Treatment of advanced malignant melanoma (Stages II,III, IV).",C0025202,Malignant Melanoma,7/31/00,Designated,Not FDA Approved for Orphan Indication,,,,
IBXPAFBDJCXCDW-MHFPCNPESA-A,118984457,IBXPAFBDJCXCDW-MHFPCNPESA-A,oblimersen,,"Treatment of advanced malignant melanoma (Stages II,III, IV).",C0025202,Malignant Melanoma,7/31/00,Designated,Not FDA Approved for Orphan Indication,,,,
GDLPAGOVHZLZEK-JBUFHSOLSA-L,158780,GDLPAGOVHZLZEK-JBUFHSOLSA-L,oglufanide disodium,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,9/24/01,Designated,Not FDA Approved for Orphan Indication,,,,
FDLYAMZZIXQODN-UHFFFAOYSA-N,23725625,FDLYAMZZIXQODN-UHFFFAOYSA-N,olaparib,Lynparza,Treatment of primary peritoneal cancer,C1514428,Primary Peritoneal Cancer,5/15/18,Designated/Approved,,"Lynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either: a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FD", 05/08/2020 , 05/08/2027 ,"LYNPARZA is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinumbased chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by genomic instability."
FDLYAMZZIXQODN-UHFFFAOYSA-N,23725625,FDLYAMZZIXQODN-UHFFFAOYSA-N,olaparib,Lynparza,Treatment of Fallopian Tube Cancer,C0238122,Fallopian Tube Cancer,5/15/18,Designated/Approved,,"Lynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either: a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FD", 05/08/2020 , 05/08/2027 ,"LYNPARZA is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinumbased chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by genomic instability."
FDLYAMZZIXQODN-UHFFFAOYSA-N,23725625,FDLYAMZZIXQODN-UHFFFAOYSA-N,olaparib,Lynparza,Treatment of ovarian cancer,C4721610,Ovarian Cancer,10/16/13,Designated/Approved,,"Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum based chemotherapy. Select patients with gBRCAm advanced epithelial ovarian, fallopian tube or primary peritoneal cancer for therapy based on FDA-approved companion diagnostic for Lynparza.", 12/19/2018 , 12/19/2025 ,Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian cancer who are in complete or partial response to first-line platinum based chemotherapy.
FDLYAMZZIXQODN-UHFFFAOYSA-N,23725625,FDLYAMZZIXQODN-UHFFFAOYSA-N,olaparib,Lynparza,Treatment of Fallopian Tube Cancer,C0238122,Fallopian Tube Cancer,5/15/18,Designated/Approved,,"Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum based chemotherapy. Select patients with gBRCAm advanced epithelial ovarian, fallopian tube or primary peritoneal cancer for therapy based on FDA-approved companion diagnostic for Lynparza.", 12/19/2018 , 12/19/2025 ,Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced fallopian tube cancer who are in complete or partial response to first-line platinum based chemotherapy.
FDLYAMZZIXQODN-UHFFFAOYSA-N,23725625,FDLYAMZZIXQODN-UHFFFAOYSA-N,olaparib,Lynparza,Treatment of ovarian cancer,C4721610,Ovarian Cancer,10/16/13,Designated/Approved,,"Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.", 08/17/2017 , 08/17/2024 ,"Maintenance treatment of adult patients with recurrent epithelial ovarian cancer, who are in a complete or partial response to platinum-based chemotherapy."
QJAGBAPUFWBVSD-UHFFFAOYSA-N,86278354,QJAGBAPUFWBVSD-UHFFFAOYSA-N,olaptesed pegol,,Treatment of glioblastoma in conjunction with radiotherapy.,C0017636,Glioblastoma,8/19/14,Designated,Not FDA Approved for Orphan Indication,,,,
YFGBQHOOROIVKG-FKBYEOEOSA-N,443363,YFGBQHOOROIVKG-FKBYEOEOSA-N,opioid growth factor,,Treatment of liver and intrahepatic bile duct cancer,C0279000,Liver and Intrahepatic Bile Duct Cancer,4/16/13,Designated,Not FDA Approved for Orphan Indication,,,,
KHPXUQMNIQBQEV-UHFFFAOYSA-N,970,KHPXUQMNIQBQEV-UHFFFAOYSA-N,oxaloacetate,,Treatment of gliomas,C0017638,gliomas,7/24/12,Designated,Not FDA Approved for Orphan Indication,,,,
BEZZFPOZAYTVHN-UHFFFAOYSA-N,40854,BEZZFPOZAYTVHN-UHFFFAOYSA-N,oxfendazole,,Treatment of cysticercosis,C0010678,Cysticercosis,8/7/17,Designated,Not FDA Approved for Orphan Indication,,,,
HWXVIOGONBBTBY-ONEGZZNKSA-N,46216796,HWXVIOGONBBTBY-ONEGZZNKSA-N,pacritinib,,"Treatment of primary myelofibrosis (MF), post-polycythemia vera MF, and post-essential thrombocythemia MF","C0001815,C0026987,C0032463,C0040028","Primary Myelofibrosis , Myelofibrosis , Polycythemia Vera , ESSENTIAL THROMBOCYTHEMIA",3/13/08,Designated,Not FDA Approved for Orphan Indication,,,,
FPOHNWQLNRZRFC-ZHACJKMWSA-N,6918837,FPOHNWQLNRZRFC-ZHACJKMWSA-N,panobinostat,,Treatment of Hodgkin's lymphoma,C0019829,hodgkin's lymphoma,9/18/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
QXRSDHAAWVKZLJ-PVYNADRNSA-N,448013,QXRSDHAAWVKZLJ-PVYNADRNSA-N,patupilone,,Treatment of primary fallopian tube cancer.,C0238122,Fallopian Tube Cancer,2/2/10,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
GAQMWPRWVIGRRV-IVDGIBIRSA-N,70683024,GAQMWPRWVIGRRV-IVDGIBIRSA-N,Pegfilgrastim,Neulasta,Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident,C0854467,Myelosuppression,11/20/13,Designated/Approved,,To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome), 11/13/2015 , 11/13/2022 ,To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome)
YBVNFKZSMZGRAD-UHFFFAOYSA-N,8813,YBVNFKZSMZGRAD-UHFFFAOYSA-N,Pentamidine isethionate,Nebupent,Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.,C1535939,Pneumocystis carinii Pneumonia,1/12/88,Designated/Approved,,, 06/15/1989 , 06/15/1996 ,
RZPNFYXFSHGGBE-UHFFFAOYSA-N,2916,RZPNFYXFSHGGBE-UHFFFAOYSA-N,Phosphocysteamine,,Treatment of cystinosis.,C4316899,Cystinosis,9/12/88,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
GMZVRMREEHBGGF-UHFFFAOYSA-N,4843,GMZVRMREEHBGGF-UHFFFAOYSA-N,Piracetam,,Treatment of myoclonus.,C0027066,Myoclonus,10/2/87,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ISWRGOKTTBVCFA-UHFFFAOYSA-N,40632,ISWRGOKTTBVCFA-UHFFFAOYSA-N,pirfenidone,,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,7/31/14,Designated,Not FDA Approved for Orphan Indication,,,,
UUSZLLQJYRSZIS-LXNNNBEUSA-N,9812534,UUSZLLQJYRSZIS-LXNNNBEUSA-N,Plitidepsin,,Treatment of acute lymphoblastic leukemia,C0023449,Acute lymphoblastic leukemia,6/18/04,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ONJQDTZCDSESIW-UHFFFAOYSA-N,656641,ONJQDTZCDSESIW-UHFFFAOYSA-N,polidocanol,,Treatment of congenital venous malformations,C2937220,Venous malformations,2/19/15,Designated,Not FDA Approved for Orphan Indication,,,,
RVGRUAULSDPKGF-UHFFFAOYSA-N,24751,RVGRUAULSDPKGF-UHFFFAOYSA-N,poloxamer 188,,Treatment of Acute Limb Ischemia,C2945695,Limb ischemia,11/8/13,Designated,Not FDA Approved for Orphan Indication,,,,
UVSMNLNDYGZFPF-UHFFFAOYSA-N,134780,UVSMNLNDYGZFPF-UHFFFAOYSA-N,pomalidomide,,Treatment of systemic sclerosis,C0036421,Systemic sclerosis,8/22/13,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
RSQDGTJKZWTAGL-UHFFFAOYSA-N,137321858,RSQDGTJKZWTAGL-UHFFFAOYSA-N,porfimer sodium,,Treatment of malignant mesothelioma,C0345967,Malignant mesothelioma,12/2/11,Designated,Not FDA Approved for Orphan Indication,,,,
ACSROKXFXFNERX-UHFFFAOYSA-N,51711,ACSROKXFXFNERX-UHFFFAOYSA-N,Pramiracetam Sulfate,,For the management of cognitive dysfunction and enhancement of antidepressant activity associated with electroconvulsive therapy.,C0338656,Cognitive Dysfunction,11/4/91,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
DGMKFQYCZXERLX-UHFFFAOYSA-N,4922,DGMKFQYCZXERLX-UHFFFAOYSA-N,Proglumide,,Treatment of gastric cancer,C0024623,Gastric Cancer,7/23/20,Designated,Not FDA Approved for Orphan Indication,,,,
HSUDWURBWSUCOB-IBEPEKEJSA-N,44147881,HSUDWURBWSUCOB-IBEPEKEJSA-N,Protaxel,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,5/21/03,Designated,Not FDA Approved for Orphan Indication,,,,
YKUQEKXHQFYULM-UHFFFAOYSA-N,156867,YKUQEKXHQFYULM-UHFFFAOYSA-N,Pyronaridine tetraphosphate,,Treatment of Malaria,C0024530,Malaria,2/11/20,Designated,Not FDA Approved for Orphan Indication,,,,
GPKJTRJOBQGKQK-UHFFFAOYSA-N,237,GPKJTRJOBQGKQK-UHFFFAOYSA-N,quinacrine,,Treatment of Ebola Infection,C0282687,Ebola Infection,9/10/19,Designated,Not FDA Approved for Orphan Indication,,,,
CVWXJKQAOSCOAB-UHFFFAOYSA-N,24889392,CVWXJKQAOSCOAB-UHFFFAOYSA-N,quizartinib,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,3/18/09,Designated,Not FDA Approved for Orphan Indication,,,,
QFJCIRLUMZQUOT-HPLJOQBZSA-N,5284616,QFJCIRLUMZQUOT-HPLJOQBZSA-N,rapamycin,,Treatment of facial angiofibromas (FA) associated with tuberous sclerosis complex (TSC).,"C0041341,C0265319","Tuberous Sclerosis Complex , Facial angiofibromas",2/24/16,Designated,Not FDA Approved for Orphan Indication,,,,
PTFCDOFLOPIGGS-UHFFFAOYSA-N,32051,PTFCDOFLOPIGGS-UHFFFAOYSA-N,Recombinant human alpha-mannosidase,,Treatment of alpha-mannosidosis,C0024748,alpha-Mannosidosis,2/2/06,Designated,Not FDA Approved for Orphan Indication,,,,
WANIDIGFXJFFEL-SANMLTNESA-N,73051463,WANIDIGFXJFFEL-SANMLTNESA-N,relacorilant,,Treatment of endogenous Cushing syndrome,C0010481,Cushing Syndrome,10/15/18,Designated,Not FDA Approved for Orphan Indication,,,,
VYGQUTWHTHXGQB-FFHKNEKCSA-N,5280531,VYGQUTWHTHXGQB-FFHKNEKCSA-N,Retinol palmitate,,Prevention of bronchopulmonary dysplasia.,C0006287,Bronchopulmonary Dysplasia,8/8/16,Designated,Not FDA Approved for Orphan Indication,,,,
IWUCXVSUMQZMFG-AFCXAGJDSA-N,37542,IWUCXVSUMQZMFG-AFCXAGJDSA-N,ribavirin,,Treatment of hemorrhagic fever with renal syndrome,C0019101,Hemorrhagic Fever with Renal Syndrome,4/12/91,Designated,Not FDA Approved for Orphan Indication,,,,
OWBFCJROIKNMGD-BQYQJAHWSA-N,6918736,OWBFCJROIKNMGD-BQYQJAHWSA-N,rigosertib,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,3/18/11,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
OWBFCJROIKNMGD-BQYQJAHWSA-N,6918736,OWBFCJROIKNMGD-BQYQJAHWSA-N,rigosertib,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,3/16/12,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
FTALBRSUTCGOEG-UHFFFAOYSA-N,5070,FTALBRSUTCGOEG-UHFFFAOYSA-N,Riluzole,Rilutek,Treatment of amyotrophic lateral sclerosis.,C0002736,Amyotrophic Lateral Sclerosis,3/16/93,Designated/Approved,,Treatment of patients with amyotrophic lateral sclerosis. Riluzole extends survival and/or time to tracheostomy., 12/12/1995 , 12/12/2002 ,
WXXSNCNJFUAIDG-UHFFFAOYSA-N,11304743,WXXSNCNJFUAIDG-UHFFFAOYSA-N,riociguat,,Treatment of systemic sclerosis,C0036421,Systemic sclerosis,7/24/14,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
SGOOQMRIPALTEL-UHFFFAOYSA-N,54676478,SGOOQMRIPALTEL-UHFFFAOYSA-N,Roquinimex,,To prolong time to relapse in leukemia patients who have undergone autologous bone marrow transplantation.,C0023418,leukemia,7/1/93,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
VDNLFJGJEQUWRB-UHFFFAOYSA-L,3856851,VDNLFJGJEQUWRB-UHFFFAOYSA-L,Rose bengal disodium,,Treatment of Neuroblastoma,C0027819,Neuroblastoma,11/2/18,Designated,Not FDA Approved for Orphan Indication,,,,
HMABYWSNWIZPAG-UHFFFAOYSA-N,9931954,HMABYWSNWIZPAG-UHFFFAOYSA-N,rucaparib,Rubraca,Treatment of ovarian cancer,C4721610,Ovarian Cancer,7/31/12,Designated/Approved,,As monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies, 12/19/2016 , 12/19/2023 ,As monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies
HFNKQEVNSGCOJV-OAHLLOKOSA-N,25126798,HFNKQEVNSGCOJV-OAHLLOKOSA-N,ruxolitinib,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,8/16/13,Designated,Not FDA Approved for Orphan Indication,,,,
QXWZQTURMXZVHJ-UHFFFAOYSA-N,9913767,QXWZQTURMXZVHJ-UHFFFAOYSA-N,selexipag,Uptravi,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,4/30/10,Designated/Approved,,"For treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH", 12/21/2015 , 12/21/2022 ,"For treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH"
FUZYTVDVLBBXDL-UHFFFAOYSA-N,5113032,FUZYTVDVLBBXDL-UHFFFAOYSA-N,selisistat,,Treatment of Huntington's disease,C0020179,Huntington's Disease,12/7/09,Designated,Not FDA Approved for Orphan Indication,,,,
XIIOFHFUYBLOLW-UHFFFAOYSA-N,134436906,XIIOFHFUYBLOLW-UHFFFAOYSA-N,selpercatinib,RETEVMO,"Treatment of RET fusion-positive or RET mutant thyroid cancers including poorly differentiated thyroid cancer, undifferentiated or anaplastic thyroid cancer, medullary thyroid cancer, and locally advanced or metastatic follicular or papillary thyroid canc","C0238461,C0238462,C0549473,C1337013","anaplastic thyroid cancer , Thyroid cancer, medullary , Thyroid Cancers , Differentiated Thyroid Cancer",11/21/19,Designated/Approved,,RETEVMO is indicated for the treatment of: Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy; Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate), 05/08/2020 , 05/08/2027 ,"For the treatment of: adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy; and, adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)."
CYOHGALHFOKKQC-UHFFFAOYSA-N,10127622,CYOHGALHFOKKQC-UHFFFAOYSA-N,selumetinib,,Treatment of uveal melanoma.,C0220633,Uveal melanoma,4/15/15,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
HDHDTKMUACZDAA-PHNIDTBTSA-N,11993702,HDHDTKMUACZDAA-PHNIDTBTSA-N,setmelanotide,Imcivree,Treatment of leptin receptor deficiency,C3554225,LEPTIN RECEPTOR DEFICIENCY,11/27/17,Designated/Approved,,"Chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).", 11/25/2020 , 11/25/2027 ,"Chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS)."
BNRNXUUZRGQAQC-UHFFFAOYSA-N,135398744,BNRNXUUZRGQAQC-UHFFFAOYSA-N,sildenafil,,Treatment of pediatric (defined as children less than 17 years of age) pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,7/28/11,Designated,Not FDA Approved for Orphan Indication,,,,
KIHYPELVXPAIDH-HNSNBQBZSA-N,44599207,KIHYPELVXPAIDH-HNSNBQBZSA-N,siponimod,,Treatment of dermatomyositis,C0011633,Dermatomyositis,7/10/14,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
QNAZTOHXCZPOSA-UHFFFAOYSA-N,9862248,QNAZTOHXCZPOSA-UHFFFAOYSA-N,sobetirome,,Treatment of X-linked adrenoleukodystrophy,C0162309,X-Linked Adrenoleukodystrophy,4/29/11,Designated,Not FDA Approved for Orphan Indication,,,,
LPXPTNMVRIOKMN-UHFFFAOYSA-M,23668193,LPXPTNMVRIOKMN-UHFFFAOYSA-M,sodium nitrite,,Prevention of ischemia reperfusion injury to donor organ tissue associated with solid organ transplantation,C0035126,ischemia reperfusion injury,9/3/09,Designated,Not FDA Approved for Orphan Indication,,,,
VPZRWNZGLKXFOE-UHFFFAOYSA-M,5258,VPZRWNZGLKXFOE-UHFFFAOYSA-M,Sodium phenylbutyrate,,Treatment of spinal muscular atrophy,C0026847,Spinal Muscular Atrophy,3/20/07,Designated,Not FDA Approved for Orphan Indication,,,,
CUEDNFKBTFCOSV-UZVLBLASSA-L,16683012,CUEDNFKBTFCOSV-UZVLBLASSA-L,Sodium Stibogluconate,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,6/5/17,Designated,Not FDA Approved for Orphan Indication,,,,
NHXLMOGPVYXJNR-HVEUVEBASA-N,44377662,NHXLMOGPVYXJNR-HVEUVEBASA-N,Somatostatin,,Treatment of bleeding esophageal varices.,C0014867,Esophageal Varices,12/22/94,Designated,Not FDA Approved for Orphan Indication,,,,
NHXLMOGPVYXJNR-FMGBKAQLSA-N,44291156,NHXLMOGPVYXJNR-FMGBKAQLSA-N,Somatostatin,,Treatment of bleeding esophageal varices.,C0014867,Esophageal Varices,12/22/94,Designated,Not FDA Approved for Orphan Indication,,,,
NHXLMOGPVYXJNR-FQSIDJEASA-N,71308696,NHXLMOGPVYXJNR-FQSIDJEASA-N,Somatostatin,,Treatment of bleeding esophageal varices.,C0014867,Esophageal Varices,12/22/94,Designated,Not FDA Approved for Orphan Indication,,,,
NHXLMOGPVYXJNR-UYURUMNQSA-N,16161315,NHXLMOGPVYXJNR-UYURUMNQSA-N,Somatostatin,,Treatment of bleeding esophageal varices.,C0014867,Esophageal Varices,12/22/94,Designated,Not FDA Approved for Orphan Indication,,,,
NHXLMOGPVYXJNR-UHFFFAOYSA-N,16129681,NHXLMOGPVYXJNR-UHFFFAOYSA-N,Somatostatin,,Treatment of bleeding esophageal varices.,C0014867,Esophageal Varices,12/22/94,Designated,Not FDA Approved for Orphan Indication,,,,
NHXLMOGPVYXJNR-ATOGVRKGSA-N,16129706,NHXLMOGPVYXJNR-ATOGVRKGSA-N,Somatostatin,,Treatment of bleeding esophageal varices.,C0014867,Esophageal Varices,12/22/94,Designated,Not FDA Approved for Orphan Indication,,,,
VIDRYROWYFWGSY-UHFFFAOYSA-N,66245,VIDRYROWYFWGSY-UHFFFAOYSA-N,Sotalol HCl,Betapace,1. Treatment of life-threatening ventricular tachyarrhythmias 2. Prevention of life treatening ventricular tachyarrhythmias,C3827656,Ventricular Tachyarrhythmias,9/23/88,Designated/Approved,,Treatment of life-threatening ventricular tachyarrhythmias, 10/30/1992 , 10/30/1999 ,
HMHVCUVYZFYAJI-UHFFFAOYSA-N,5356,HMHVCUVYZFYAJI-UHFFFAOYSA-N,sulthiame,,Treatment of patients with benign epilepsy of childhood with centrotemporal spikes (BECTS) also known as rolandic epilepsy,"C0376532,C2363129","rolandic epilepsy , Benign Epilepsy Of Childhood With Centrotemporal Spikes",7/25/13,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
GLXYOFXNKBTMQL-YKCHQESGSA-N,134687212,GLXYOFXNKBTMQL-YKCHQESGSA-N,synthetic preImplantation factor,,Prevention of graft versus host disease,C0018133,GRAFT VERSUS HOST DISEASE,5/8/18,Designated,Not FDA Approved for Orphan Indication,,,,
QJJXYPPXXYFBGM-LFZNUXCKSA-N,445643,QJJXYPPXXYFBGM-LFZNUXCKSA-N,Tacrolimus,,Treatment of vernal keratoconjunctivitis,C0022577,Vernal keratoconjunctivitis,6/3/20,Designated,Not FDA Approved for Orphan Indication,,,,
NSQSAUGJQHDYNO-UHFFFAOYSA-N,66558664,NSQSAUGJQHDYNO-UHFFFAOYSA-N,tazemetostat,,Treatment of chordoma,C0008487,Chordoma,5/23/18,Designated,Not FDA Approved for Orphan Indication,,,,
CILIXQOJUNDIDU-ASQIGDHWSA-N,16139605,CILIXQOJUNDIDU-ASQIGDHWSA-N,Teduglutide,,Prevention of acute graft versus host disease,C0856825,Acute Graft Versus Host Disease,12/8/20,Designated,Not FDA Approved for Orphan Indication,,,,
MRGCZDWBFFUEES-CWBCWDDISA-L,11583399,MRGCZDWBFFUEES-CWBCWDDISA-L,temocillin sodium,,Treatment of pulmonary infections caused by Burkholderia cepacia,"C0085469,C0876973","Burkholderia cepacia , Pulmonary infections",4/21/04,Designated,Not FDA Approved for Orphan Indication,,,,
LYPFDBRUNKHDGX-UHFFFAOYSA-N,60751,LYPFDBRUNKHDGX-UHFFFAOYSA-N,Temoporfin,,"Palliative treatment of recurrent, refractory or second primary squamous cell carcinomas of the head and neck in patients considered to be incurable with surgery or radiotherapy.",C0007137,Squamous Cell Carcinomas,10/28/99,Designated,Not FDA Approved for Orphan Indication,,,,
BPEGJWRSRHCHSN-UHFFFAOYSA-N,5394,BPEGJWRSRHCHSN-UHFFFAOYSA-N,Temozolomide,,Treatment of newly diagnosed high grade glioma,C0555198,High Grade Glioma,10/18/04,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
BPEGJWRSRHCHSN-UHFFFAOYSA-N,5394,BPEGJWRSRHCHSN-UHFFFAOYSA-N,Temozolomide,,Treatment of neuroblastoma,C0027819,Neuroblastoma,8/1/19,Designated,Not FDA Approved for Orphan Indication,,,,
BPEGJWRSRHCHSN-UHFFFAOYSA-N,5394,BPEGJWRSRHCHSN-UHFFFAOYSA-N,temozolomide,,Treatment glioblastoma multiforme in pediatric patients,C0017636,Glioblastoma multiforme,11/25/15,Designated,Not FDA Approved for Orphan Indication,,,,
JOAHPSVPXZTVEP-YXJHDRRASA-N,443951,JOAHPSVPXZTVEP-YXJHDRRASA-N,terguride,,Treatment of systemic sclerosis,C0036421,Systemic sclerosis,5/17/13,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
OGBMKVWORPGQRR-UMXFMPSGSA-N,16133850,OGBMKVWORPGQRR-UMXFMPSGSA-N,Teriparatide,Parathar,Diagnostic agent to assist in establishing the diagnosis in patients presenting with clinical and laboratory evidence of hypocalcemia due to either hypoparathyroidism or pseudohypoparathyroidism.,"C0020598,C0020626,C0033835","Hypocalcemia , Hypoparathyroidism , Pseudohypoparathyroidism",1/9/87,Designated/Approved,,, 12/23/1987 , 12/23/1994 ,
BENFXAYNYRLAIU-QSVFAHTRSA-N,72081,BENFXAYNYRLAIU-QSVFAHTRSA-N,terlipressin,,Treatment of hepatorenal syndrome,C0019212,Hepatorenal Syndrome,11/21/18,Designated,Not FDA Approved for Orphan Indication,,,,
HVXKQKFEHMGHSL-GOOCMWNKSA-N,10458325,HVXKQKFEHMGHSL-GOOCMWNKSA-N,Tesevatinib,,Treatment of patients with autosomal recessive polycystic kidney disease (ARPKD),"C0085548,C1418605","Autosomal Recessive Polycystic Kidney Disease , ARPKD",3/1/16,Designated,Not FDA Approved for Orphan Indication,,,,
MKJIEFSOBYUXJB-UHFFFAOYSA-N,6018,MKJIEFSOBYUXJB-UHFFFAOYSA-N,Tetrabenazine,Xenazine,Treatment of Huntington's disease,C0020179,Huntington's Disease,12/11/97,Designated/Approved,,Treatment of chorea associated with Huntington's disease, 08/15/2008 , 08/15/2015 ,
UEJJHQNACJXSKW-UHFFFAOYSA-N,5426,UEJJHQNACJXSKW-UHFFFAOYSA-N,Thalidomide,,Treatment of primary brain malignancies.,C0006826,MALIGNANCIES,2/27/98,Designated,Not FDA Approved for Orphan Indication,,,,
UEJJHQNACJXSKW-UHFFFAOYSA-N,5426,UEJJHQNACJXSKW-UHFFFAOYSA-N,thalidomide,,1. Treatment of graft versus host disease in patients receiving bone marrow transplantation 2. Prevention of graft versus host disease in patients receiving bone marrow transplantation,C0018133,GRAFT VERSUS HOST DISEASE,9/19/88,Designated,Not FDA Approved for Orphan Indication,,,,
UEJJHQNACJXSKW-UHFFFAOYSA-N,5426,UEJJHQNACJXSKW-UHFFFAOYSA-N,Thalidomide,,"Treatment of severe recurrent aphthous stomatitis in severely, terminally immunocompromised patients.",C2937365,Recurrent aphthous stomatitis,5/1/95,Designated,Not FDA Approved for Orphan Indication,,,,
NZVYCXVTEHPMHE-ZSUJOUNUSA-N,16130571,NZVYCXVTEHPMHE-ZSUJOUNUSA-N,Thymalfasin,,Treatment of hepatocellular carcinoma.,C2239176,HEPATOCELLULAR CARCINOMA,3/6/00,Designated,Not FDA Approved for Orphan Indication,,,,
UGPMCIBIHRSCBV-UHFFFAOYSA-N,45382195,UGPMCIBIHRSCBV-UHFFFAOYSA-N,Thymosin beta 4,,Treatment of epidermolysis bullosa,C0014527,Epidermolysis Bullosa,5/28/04,Designated,Not FDA Approved for Orphan Indication,,,,
JICJBGPOMZQUBB-UHFFFAOYSA-N,68870,JICJBGPOMZQUBB-UHFFFAOYSA-N,tianeptine,,Treatment of Rett syndrome (RTT),C0035372,Rett Syndrome,3/8/18,Designated,Not FDA Approved for Orphan Indication,,,,
PLHJCIYEEKOWNM-HHHXNRCGSA-N,159324,PLHJCIYEEKOWNM-HHHXNRCGSA-N,tipifarnib,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,6/22/17,Designated,Not FDA Approved for Orphan Indication,,,,
RSQGZEAXODVTOL-UHFFFAOYSA-N,23729157,RSQGZEAXODVTOL-UHFFFAOYSA-N,tirasemtiv,,Treatment of amyotrophic lateral sclerosis (ALS),C0002736,Amyotrophic Lateral Sclerosis,3/2/10,Designated,Not FDA Approved for Orphan Indication,,,,
RMDMBHQVNHQDDD-VFWKRBOSSA-L,10287099,RMDMBHQVNHQDDD-VFWKRBOSSA-L,trans sodium crocetinate,,Treatment of brain metastasis,C0220650,brain metastasis,12/3/12,Designated,Not FDA Approved for Orphan Indication,,,,
PHLBKPHSAVXXEF-UHFFFAOYSA-N,5533,PHLBKPHSAVXXEF-UHFFFAOYSA-N,trazodone,,Treatment of Dravet syndrome,C0751122,Dravet Syndrome,8/18/17,Designated,Not FDA Approved for Orphan Indication,,,,
HDTRYLNUVZCQOY-LIZSDCNHSA-N,7427,HDTRYLNUVZCQOY-LIZSDCNHSA-N,trehalose,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,11/18/20,Designated,Not FDA Approved for Orphan Indication,,,,
PAJMKGZZBBTTOY-ZFORQUDYSA-N,6918140,PAJMKGZZBBTTOY-ZFORQUDYSA-N,Treprostinil,,Treatment of Idiopathic Pulmonary Fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,12/8/20,Designated,Not FDA Approved for Orphan Indication,,,,
ZBVJFYPGLGEMIN-UHFFFAOYSA-N,25091037,ZBVJFYPGLGEMIN-UHFFFAOYSA-N,Triptorelin pamoate,,For use in the palliative treatment of advanced ovarian carcinoma of epithelial origin.,C4721610,Ovarian carcinoma,8/10/90,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ZBVJFYPGLGEMIN-IKNXIQPFSA-N,60196291,ZBVJFYPGLGEMIN-IKNXIQPFSA-N,Triptorelin pamoate,,For use in the palliative treatment of advanced ovarian carcinoma of epithelial origin.,C4721610,Ovarian carcinoma,8/10/90,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ZBVJFYPGLGEMIN-OYLNGHKZSA-N,25074469,ZBVJFYPGLGEMIN-OYLNGHKZSA-N,Triptorelin pamoate,,For use in the palliative treatment of advanced ovarian carcinoma of epithelial origin.,C4721610,Ovarian carcinoma,8/10/90,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
BUSXWGRAOZQTEY-SDBXPKJASA-N,11318905,BUSXWGRAOZQTEY-SDBXPKJASA-N,Trofinetide,,Treatment of Rett syndrome,C0035372,Rett Syndrome,2/11/15,Designated,Not FDA Approved for Orphan Indication,,,,
ISAVYTVYFVQUDY-UHFFFAOYSA-N,8814,ISAVYTVYFVQUDY-UHFFFAOYSA-N,Tyloxapol,,Treatment of cystic fibrosis.,C0010674,Cystic Fibrosis,3/8/95,Designated,Not FDA Approved for Orphan Indication,,,,
GWJOFBXSBDVUMH-UHFFFAOYSA-N,16219992,GWJOFBXSBDVUMH-UHFFFAOYSA-N,Tyloxapol,,Treatment of cystic fibrosis.,C0010674,Cystic Fibrosis,3/8/95,Designated,Not FDA Approved for Orphan Indication,,,,
MDYZKJNTKZIUSK-UHFFFAOYSA-N,71388,MDYZKJNTKZIUSK-UHFFFAOYSA-N,Tyloxapol,,Treatment of cystic fibrosis.,C0010674,Cystic Fibrosis,3/8/95,Designated,Not FDA Approved for Orphan Indication,,,,
IUVCFHHAEHNCFT-INIZCTEOSA-N,72950888,IUVCFHHAEHNCFT-INIZCTEOSA-N,umbralisib,Ukoniq,Treatment of nodal marginal zone lymphoma,C0242647,Nodal marginal zone lymphoma,4/11/19,Designated/Approved,,Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen, 02/05/2021 ,  ,
WYQFJHHDOKWSHR-MNOVXSKESA-N,58557659,WYQFJHHDOKWSHR-MNOVXSKESA-N,upadacitinib,,Treatment of pediatric systemic juvenile idiopathic arthritis,C1384600,Systemic juvenile idiopathic arthritis,8/16/17,Designated,Not FDA Approved for Orphan Indication,,,,
JZCILZBQRWUKME-SPOOISQMSA-N,154731995,JZCILZBQRWUKME-SPOOISQMSA-N,valine-valine-ganciclovir,,Treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HSV1 and HSV2.,"C0022568,C0022573","Keratitis , Keratoconjunctivitis",5/21/07,Designated,Not FDA Approved for Orphan Indication,,,,
LNOVHERIIMJMDG-XZXLULOTSA-N,46184405,LNOVHERIIMJMDG-XZXLULOTSA-N,vatiquinone,,Treatment of Rett syndrome,C0035372,Rett Syndrome,11/17/14,Designated,Not FDA Approved for Orphan Indication,,,,
JNAHVYVRKWKWKQ-CYBMUJFWSA-N,11960529,JNAHVYVRKWKWKQ-CYBMUJFWSA-N,veliparib,,Treatment of squamous non-small cell lung cancer,C4509816,Squamous non-small cell lung cancer,11/3/16,Designated,Not FDA Approved for Orphan Indication,,,,
LQBVNQSMGBZMKD-UHFFFAOYSA-N,49846579,LQBVNQSMGBZMKD-UHFFFAOYSA-N,venetoclax,VENCLEXTA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,9/20/12,Designated/Approved,,"VENCLEXTA (venetoclax) indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.", 06/08/2018 , 06/08/2025 ,"For treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), without 17p deletion, who have received at least one prior therapy."
LQBVNQSMGBZMKD-UHFFFAOYSA-N,49846579,LQBVNQSMGBZMKD-UHFFFAOYSA-N,venetoclax,VENCLEXTA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,9/20/12,Designated/Approved,,"Treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy", 04/11/2016 , 04/11/2023 ,"Treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy"
LQBVNQSMGBZMKD-UHFFFAOYSA-N,49846579,LQBVNQSMGBZMKD-UHFFFAOYSA-N,venetoclax,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,8/29/16,Designated,Not FDA Approved for Orphan Indication,,,,
YFHRCLAKZBDRHN-MRXNPFEDSA-N,60199242,YFHRCLAKZBDRHN-MRXNPFEDSA-N,Venglustat,,Treatment of Fabry's disease,C0002986,Fabry's Disease,8/26/14,Designated,Not FDA Approved for Orphan Indication,,,,
HJOCKFVCMLCPTP-UHFFFAOYSA-N,71424,HJOCKFVCMLCPTP-UHFFFAOYSA-N,viloxazine HCL,,Treatment of cataplexy and narcolepsy,C0751362,Cataplexy and narcolepsy,6/11/84,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
KUZYSQSABONDME-QRLOMCMNSA-N,25014653,KUZYSQSABONDME-QRLOMCMNSA-N,vintafolide,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,12/16/13,Designated,Not FDA Approved for Orphan Indication,,,,
VYGQUTWHTHXGQB-FFHKNEKCSA-N,5280531,VYGQUTWHTHXGQB-FFHKNEKCSA-N,vitamin A palmitate,,Prevention of bronchopulmonary dysplasia.,C0006287,Bronchopulmonary Dysplasia,7/14/15,Designated,Not FDA Approved for Orphan Indication,,,,
JESCETIFNOFKEU-SJORKVTESA-N,16046068,JESCETIFNOFKEU-SJORKVTESA-N,vixotrigine,,Treatment of trigeminal neuralgia,C0040997,Trigeminal Neuralgia,7/24/13,Designated,Not FDA Approved for Orphan Indication,,,,
WAEXFXRVDQXREF-UHFFFAOYSA-N,5311,WAEXFXRVDQXREF-UHFFFAOYSA-N,vorinostat,Zolinza,Treatment of T-cell non-Hodgkin's lymphoma,C0079772,T-cell non-Hodgkin's lymphoma,3/16/04,Designated/Approved,,"Treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistant or recurrent disease on or following two systemic therapies.", 10/06/2006 , 10/06/2013 ,
XRASPMIURGNCCH-UHFFFAOYSA-N,68740,XRASPMIURGNCCH-UHFFFAOYSA-N,zoledronic acid,,Treatment of complex regional pain syndrome,C0458219,Complex regional pain syndrome,5/6/13,Designated,Not FDA Approved for Orphan Indication,,,,
VDHAWDNDOKGFTD-MRXNPFEDSA-N,156419,VDHAWDNDOKGFTD-MRXNPFEDSA-N,cinacalcet,Sensipar,"Treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery",C0221002,Primary hyperparathyroidism,4/30/10,Designated/Approved,,"Treatment of hypercalcemia in adult patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy.", 11/21/2014 , 11/21/2021 ,"Treatment of less severe hypercalcemia (serum calcium >11.2 mg/dl and <= 12.5 mg/dl) in adult patients with primary hyperparathyroidism (HPT) for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy."
AUODDLQVRAJAJM-DOPPNGDLSA-N,137705122,AUODDLQVRAJAJM-DOPPNGDLSA-N,Clindamycin hydrochloride,,Treatment of sarcoidosis,C0036202,Sarcoidosis,8/9/06,Designated,Not FDA Approved for Orphan Indication,,,,
AUODDLQVRAJAJM-OKBXBIFFSA-N,134693959,AUODDLQVRAJAJM-OKBXBIFFSA-N,Clindamycin hydrochloride,,Treatment of sarcoidosis,C0036202,Sarcoidosis,8/9/06,Designated,Not FDA Approved for Orphan Indication,,,,
AUODDLQVRAJAJM-PIPVPTKYSA-N,134129519,AUODDLQVRAJAJM-PIPVPTKYSA-N,Clindamycin hydrochloride,,Treatment of sarcoidosis,C0036202,Sarcoidosis,8/9/06,Designated,Not FDA Approved for Orphan Indication,,,,
AUODDLQVRAJAJM-ZSHBVFQLSA-N,86222708,AUODDLQVRAJAJM-ZSHBVFQLSA-N,Clindamycin hydrochloride,,Treatment of sarcoidosis,C0036202,Sarcoidosis,8/9/06,Designated,Not FDA Approved for Orphan Indication,,,,
AUODDLQVRAJAJM-VSPYWEHYSA-N,75534857,AUODDLQVRAJAJM-VSPYWEHYSA-N,Clindamycin hydrochloride,,Treatment of sarcoidosis,C0036202,Sarcoidosis,8/9/06,Designated,Not FDA Approved for Orphan Indication,,,,
AUODDLQVRAJAJM-FWTPQNFYSA-N,46738091,AUODDLQVRAJAJM-FWTPQNFYSA-N,Clindamycin hydrochloride,,Treatment of sarcoidosis,C0036202,Sarcoidosis,8/9/06,Designated,Not FDA Approved for Orphan Indication,,,,
AUODDLQVRAJAJM-XNQAQEGKSA-N,44629924,AUODDLQVRAJAJM-XNQAQEGKSA-N,Clindamycin hydrochloride,,Treatment of sarcoidosis,C0036202,Sarcoidosis,8/9/06,Designated,Not FDA Approved for Orphan Indication,,,,
AUODDLQVRAJAJM-CTEDBMRYSA-N,16219133,AUODDLQVRAJAJM-CTEDBMRYSA-N,Clindamycin hydrochloride,,Treatment of sarcoidosis,C0036202,Sarcoidosis,8/9/06,Designated,Not FDA Approved for Orphan Indication,,,,
AUODDLQVRAJAJM-KBTFJHITSA-N,46781040,AUODDLQVRAJAJM-KBTFJHITSA-N,Clindamycin hydrochloride,,Treatment of sarcoidosis,C0036202,Sarcoidosis,8/9/06,Designated,Not FDA Approved for Orphan Indication,,,,
AUODDLQVRAJAJM-UHFFFAOYSA-N,21872021,AUODDLQVRAJAJM-UHFFFAOYSA-N,Clindamycin hydrochloride,,Treatment of sarcoidosis,C0036202,Sarcoidosis,8/9/06,Designated,Not FDA Approved for Orphan Indication,,,,
AUODDLQVRAJAJM-SVLAMSDMSA-N,5702025,AUODDLQVRAJAJM-SVLAMSDMSA-N,Clindamycin hydrochloride,,Treatment of sarcoidosis,C0036202,Sarcoidosis,8/9/06,Designated,Not FDA Approved for Orphan Indication,,,,
AUODDLQVRAJAJM-GQYOKNPUSA-N,441204,AUODDLQVRAJAJM-GQYOKNPUSA-N,Clindamycin hydrochloride,,Treatment of sarcoidosis,C0036202,Sarcoidosis,8/9/06,Designated,Not FDA Approved for Orphan Indication,,,,
AUODDLQVRAJAJM-PTTDBYGSSA-N,6419884,AUODDLQVRAJAJM-PTTDBYGSSA-N,Clindamycin hydrochloride,,Treatment of sarcoidosis,C0036202,Sarcoidosis,8/9/06,Designated,Not FDA Approved for Orphan Indication,,,,
AUODDLQVRAJAJM-XJQDNNTCSA-N,16051951,AUODDLQVRAJAJM-XJQDNNTCSA-N,Clindamycin hydrochloride,,Treatment of sarcoidosis,C0036202,Sarcoidosis,8/9/06,Designated,Not FDA Approved for Orphan Indication,,,,
WDQPAMHFFCXSNU-UHFFFAOYSA-N,2794,WDQPAMHFFCXSNU-UHFFFAOYSA-N,clofazimine,,Treatment of active tuberculosis,C0041296,Active Tuberculosis,6/25/14,Designated,Not FDA Approved for Orphan Indication,,,,
ZOEFCCMDUURGSE-CQVUSSRSSA-N,16129617,ZOEFCCMDUURGSE-CQVUSSRSSA-N,cosyntropin,,Treatment of infantile spasms.,C3887898,Infantile spasms,8/2/17,Designated,Not FDA Approved for Orphan Indication,,,,
CVSVTCORWBXHQV-UHFFFAOYSA-N,586,CVSVTCORWBXHQV-UHFFFAOYSA-N,Creatine,,Treatment of Huntington's disease,C0020179,Huntington's Disease,10/11/05,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
DYNHJHQFHQTFTP-UHFFFAOYSA-N,10366136,DYNHJHQFHQTFTP-UHFFFAOYSA-N,crenolanib,,Treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,3/18/11,Designated,Not FDA Approved for Orphan Indication,,,,
KTEIFNKAUNYNJU-GFCCVEGCSA-N,11626560,KTEIFNKAUNYNJU-GFCCVEGCSA-N,crizotinib,Xalkori,"Treatment of ALK-positive, MET-positive, or ROS-positive non-small cell lung cancer",C3539721,Non-Small Cell Lung Cancer,9/13/10,Designated/Approved,,Treatment of patients with metastatic NSCLC whose tumors are ROS1-positive, 03/11/2016 , 03/11/2023 ,Treatment of patients with metastatic NSCLC whose tumors are ROS1-positive
CMSMOCZEIVJLDB-UHFFFAOYSA-N,2907,CMSMOCZEIVJLDB-UHFFFAOYSA-N,cyclophosphamide,,Treatment of systemic sclerosis.,C0036421,Systemic sclerosis,6/7/11,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-WIUPBDCUSA-N,132274082,PMATZTZNYRCHOR-WIUPBDCUSA-N,Cyclosporin A,,Treatment of amyotrophic lateral sclerosis and its variants,C0002736,Amyotrophic Lateral Sclerosis,10/29/04,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-ONJQHLSTSA-N,129009974,PMATZTZNYRCHOR-ONJQHLSTSA-N,Cyclosporin A,,Treatment of amyotrophic lateral sclerosis and its variants,C0002736,Amyotrophic Lateral Sclerosis,10/29/04,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-BMGRVWOJSA-N,71306795,PMATZTZNYRCHOR-BMGRVWOJSA-N,Cyclosporin A,,Treatment of amyotrophic lateral sclerosis and its variants,C0002736,Amyotrophic Lateral Sclerosis,10/29/04,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-QVSDIVLPSA-N,5497195,PMATZTZNYRCHOR-QVSDIVLPSA-N,Cyclosporin A,,Treatment of amyotrophic lateral sclerosis and its variants,C0002736,Amyotrophic Lateral Sclerosis,10/29/04,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-WCIOLWJGSA-N,5458585,PMATZTZNYRCHOR-WCIOLWJGSA-N,Cyclosporin A,,Treatment of amyotrophic lateral sclerosis and its variants,C0002736,Amyotrophic Lateral Sclerosis,10/29/04,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-LQJDIJJQSA-N,73896891,PMATZTZNYRCHOR-LQJDIJJQSA-N,Cyclosporin A,,Treatment of amyotrophic lateral sclerosis and its variants,C0002736,Amyotrophic Lateral Sclerosis,10/29/04,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-VPYFBNRVSA-N,49867938,PMATZTZNYRCHOR-VPYFBNRVSA-N,Cyclosporin A,,Treatment of amyotrophic lateral sclerosis and its variants,C0002736,Amyotrophic Lateral Sclerosis,10/29/04,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-VJRYSDSKSA-N,24883466,PMATZTZNYRCHOR-VJRYSDSKSA-N,Cyclosporin A,,Treatment of amyotrophic lateral sclerosis and its variants,C0002736,Amyotrophic Lateral Sclerosis,10/29/04,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-NFOUMSERSA-N,16404350,PMATZTZNYRCHOR-NFOUMSERSA-N,Cyclosporin A,,Treatment of amyotrophic lateral sclerosis and its variants,C0002736,Amyotrophic Lateral Sclerosis,10/29/04,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-UHFFFAOYSA-N,2909,PMATZTZNYRCHOR-UHFFFAOYSA-N,Cyclosporin A,,Treatment of amyotrophic lateral sclerosis and its variants,C0002736,Amyotrophic Lateral Sclerosis,10/29/04,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-IMVLJIQESA-N,5280754,PMATZTZNYRCHOR-IMVLJIQESA-N,Cyclosporin A,,Treatment of amyotrophic lateral sclerosis and its variants,C0002736,Amyotrophic Lateral Sclerosis,10/29/04,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-CGLBZJNRSA-N,5284373,PMATZTZNYRCHOR-CGLBZJNRSA-N,Cyclosporin A,,Treatment of amyotrophic lateral sclerosis and its variants,C0002736,Amyotrophic Lateral Sclerosis,10/29/04,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-RNWFWJGASA-N,138107778,PMATZTZNYRCHOR-RNWFWJGASA-N,cyclosporine A,,Prevention of corneal graft rejection,C0339303,Corneal graft rejection,9/30/08,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-RYZPDLMBSA-N,123134270,PMATZTZNYRCHOR-RYZPDLMBSA-N,cyclosporine A,,Prevention of corneal graft rejection,C0339303,Corneal graft rejection,9/30/08,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-NFOUMSERSA-N,16404350,PMATZTZNYRCHOR-NFOUMSERSA-N,cyclosporine A,,Prevention of corneal graft rejection,C0339303,Corneal graft rejection,9/30/08,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-QVSDIVLPSA-N,5497195,PMATZTZNYRCHOR-QVSDIVLPSA-N,cyclosporine A,,Prevention of corneal graft rejection,C0339303,Corneal graft rejection,9/30/08,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-UHFFFAOYSA-N,2909,PMATZTZNYRCHOR-UHFFFAOYSA-N,cyclosporine A,,Prevention of corneal graft rejection,C0339303,Corneal graft rejection,9/30/08,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-NSJDOISKSA-N,71463825,PMATZTZNYRCHOR-NSJDOISKSA-N,cyclosporine A,,Prevention of corneal graft rejection,C0339303,Corneal graft rejection,9/30/08,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-VPYFBNRVSA-N,49867938,PMATZTZNYRCHOR-VPYFBNRVSA-N,cyclosporine A,,Prevention of corneal graft rejection,C0339303,Corneal graft rejection,9/30/08,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-IMVLJIQESA-N,5280754,PMATZTZNYRCHOR-IMVLJIQESA-N,cyclosporine A,,Prevention of corneal graft rejection,C0339303,Corneal graft rejection,9/30/08,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-CGLBZJNRSA-N,5284373,PMATZTZNYRCHOR-CGLBZJNRSA-N,cyclosporine A,,Prevention of corneal graft rejection,C0339303,Corneal graft rejection,9/30/08,Designated,Not FDA Approved for Orphan Indication,,,,
ZBNZXTGUTAYRHI-UHFFFAOYSA-N,3062316,ZBNZXTGUTAYRHI-UHFFFAOYSA-N,Dasatinib,,Treatment of Noonan syndrome-associated hypertrophic cardiomyopathy,"C0007194,C0028326","Hypertrophic Cardiomyopathy , Noonan Syndrome",10/26/20,Designated,Not FDA Approved for Orphan Indication,,,,
ZBNZXTGUTAYRHI-UHFFFAOYSA-N,3062316,ZBNZXTGUTAYRHI-UHFFFAOYSA-N,dasatinib,Sprycel,Treatment of chronic myelogenous leukemia,C0023473,Chronic myelogenous leukemia,11/28/05,Designated/Approved,,Treatment of pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, 11/09/2017 , 11/09/2024 ,Treatment of pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase
TZXKOCQBRNJULO-UHFFFAOYSA-N,2972,TZXKOCQBRNJULO-UHFFFAOYSA-N,deferiprone,,Treatment of Friedreich's ataxia,C0016719,Friedreich's Ataxia,7/31/08,Designated,Not FDA Approved for Orphan Indication,,,,
OEUUFNIKLCFNLN-LLVKDONJSA-N,135413558,OEUUFNIKLCFNLN-LLVKDONJSA-N,Deferitrin,,Treatment of iron overload,C0282193,Iron Overload,4/14/04,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
FBHSPRKOSMHSIF-GRMWVWQJSA-N,189821,FBHSPRKOSMHSIF-GRMWVWQJSA-N,deflazacort,Emflaza,Treatment of Duchenne muscular dystrophy,C0013264,DUCHENNE MUSCULAR DYSTROPHY,8/16/13,Designated/Approved,,EMFLAZA is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older., 06/07/2019 , 06/07/2026 ,For the treatment of Duchene muscular dystrophy in patients 2 years of age to less than 5 years of age
FBHSPRKOSMHSIF-GRMWVWQJSA-N,189821,FBHSPRKOSMHSIF-GRMWVWQJSA-N,deflazacort,,Treatment of pediatric (0 through 16 years of age) juvenile idiopathis arthritis (JIA) International League of Associations for Rheumatology (ILAR) categories excluding systemic JIA.,"C0003864,C3495559","Arthritis , JIA",10/22/15,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
LFQSCWFLJHTTHZ-UHFFFAOYSA-N,702,LFQSCWFLJHTTHZ-UHFFFAOYSA-N,Dehydrated alcohol,,Treatment of methanol poisoning,C0392621,methanol poisoning,7/10/20,Designated,Not FDA Approved for Orphan Indication,,,,
SSNHGLKFJISNTR-FWUPRJFYSA-N,44148067,SSNHGLKFJISNTR-FWUPRJFYSA-N,delta-9-tetrahydrocannabinol and cannabidiol,,Treatment of complex regional pain syndrome,C0458219,Complex regional pain syndrome,3/7/18,Designated,Not FDA Approved for Orphan Indication,,,,
SSNHGLKFJISNTR-FWUPRJFYSA-N,44148067,SSNHGLKFJISNTR-FWUPRJFYSA-N,delta-9-tetrahydrocannabinol and cannabidiol,,Treatment of Huntington's Disease,C0020179,Huntington's Disease,1/29/19,Designated,Not FDA Approved for Orphan Indication,,,,
BIFMNMPSIYHKDN-FJXQXJEOSA-N,6918223,BIFMNMPSIYHKDN-FJXQXJEOSA-N,dexrazoxane hydrochloride,,Prevention of cardiomyopathy for chilren and adolescents 0 through 16 years of age treated with anthracyclines,C0878544,Cardiomyopathy,8/19/14,Designated,Not FDA Approved for Orphan Indication,,,,
LRCZQSDQZJBHAF-PUBGEWHCSA-N,6918473,LRCZQSDQZJBHAF-PUBGEWHCSA-N,DHA-paclitaxel,,Treatment of adenocarcinoma of the stomach or lower esophagus,C0278701,adenocarcinoma of the stomach,5/1/03,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
TYNLGDBUJLVSMA-UHFFFAOYSA-N,26248,TYNLGDBUJLVSMA-UHFFFAOYSA-N,Diacerein,,Treatment of epidermolysis bullosa,C0014527,Epidermolysis Bullosa,11/2/18,Designated,Not FDA Approved for Orphan Indication,,,,
GDLBFKVLRPITMI-UHFFFAOYSA-N,3019,GDLBFKVLRPITMI-UHFFFAOYSA-N,diazoxide,,Treatment of Prader Willi Syndrome,C0032897,Prader Willi syndrome,12/3/12,Designated,Not FDA Approved for Orphan Indication,,,,
BXZVVICBKDXVGW-NKWVEPMBSA-N,135398739,BXZVVICBKDXVGW-NKWVEPMBSA-N,Dideoxyinosine,,Treatment of acquired immunodeficiency syndrome.,C0021051,Immunodeficiency Syndrome,6/22/88,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
NVKAWKQGWWIWPM-ABEVXSGRSA-N,10635,NVKAWKQGWWIWPM-ABEVXSGRSA-N,Dihydrotestosterone,,Treatment of weight loss in AIDS patients with HIV-associated wasting.,"C0006625,C0019682,C4084774","Wasting , HIV , Weight loss",2/5/96,Designated,Not FDA Approved for Orphan Indication,,,,
MBMBGCFOFBJSGT-KUBAVDMBSA-N,445580,MBMBGCFOFBJSGT-KUBAVDMBSA-N,docosahexaenoic acid,,Treatment of sickle cell disease,C0002895,Sickle Cell Disease,4/27/15,Designated,Not FDA Approved for Orphan Indication,,,,
CTENFNNZBMHDDG-UHFFFAOYSA-N,65340,CTENFNNZBMHDDG-UHFFFAOYSA-N,dopamine hydrochloride,,Prevention of intraventricular hemorrhage in hypotensive premature neonates,"C0151526,C0240059,C0857353","Premature , Intraventricular hemorrhage , Hypotensive",10/24/17,Designated,Not FDA Approved for Orphan Indication,,,,
AVAACINZEOAHHE-VFZPANTDSA-N,73303,AVAACINZEOAHHE-VFZPANTDSA-N,Doripenem,,Treatment of bronchopulmonary infection in patients with cystic fibrosis who are colonized with Pseudomonas aeruginosa or Burkholderia cepacia.,"C0009450,C0010674","Infection , Cystic Fibrosis",7/16/04,Designated,Not FDA Approved for Orphan Indication,,,,
ZUJBBVJXXYRPFS-DYKIIFRCSA-N,71722017,ZUJBBVJXXYRPFS-DYKIIFRCSA-N,dusquetide,,Treatment of macrophage activation syndrome,C1096155,Macrophage Activation Syndrome,8/10/16,Designated,Not FDA Approved for Orphan Indication,,,,
ZJIHMALTJRDNQI-VFQQELCFSA-N,13018787,ZJIHMALTJRDNQI-VFQQELCFSA-N,duvoglustat hydrochloride,,Treatment of Pompe disease,C0017921,Pompe Disease,6/18/07,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
VBGWSQKGUZHFPS-ZVYAWBDLSA-N,129628207,VBGWSQKGUZHFPS-ZVYAWBDLSA-N,ecallantide,Kalbitor,Treatment of angioedema,C0002994,Angioedema,2/4/03,Designated/Approved,,Treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older, 03/28/2014 , 03/28/2021 ,Treatment of acute attacks of hereditary angioedema (HAE) in patients 12 through 15 years of age.
VBGWSQKGUZHFPS-FHVLXVBRSA-N,118984459,VBGWSQKGUZHFPS-FHVLXVBRSA-N,ecallantide,Kalbitor,Treatment of angioedema,C0002994,Angioedema,2/4/03,Designated/Approved,,Treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older, 03/28/2014 , 03/28/2021 ,Treatment of acute attacks of hereditary angioedema (HAE) in patients 12 through 15 years of age.
VBGWSQKGUZHFPS-VGMMZINCSA-N,44152182,VBGWSQKGUZHFPS-VGMMZINCSA-N,ecallantide,Kalbitor,Treatment of angioedema,C0002994,Angioedema,2/4/03,Designated/Approved,,Treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older, 03/28/2014 , 03/28/2021 ,Treatment of acute attacks of hereditary angioedema (HAE) in patients 12 through 15 years of age.
OVXQHPWHMXOFRD-UHFFFAOYSA-M,10547,OVXQHPWHMXOFRD-UHFFFAOYSA-M,echothiophate iodide,,Treatment of Stargardt's disease,C0271093,Stargardt's disease,6/2/14,Designated,Not FDA Approved for Orphan Indication,,,,
JQLBBYLGWHUHRW-KUBAVDMBSA-N,44626120,JQLBBYLGWHUHRW-KUBAVDMBSA-N,Edasalonexent,,Treatment of Duchenne muscular dystrophy,C0013264,DUCHENNE MUSCULAR DYSTROPHY,11/17/14,Designated,Not FDA Approved for Orphan Indication,,,,
VLCYCQAOQCDTCN-UHFFFAOYSA-N,3009,VLCYCQAOQCDTCN-UHFFFAOYSA-N,eflornithine,,Treatment of neuroblastoma,C0027819,Neuroblastoma,11/22/17,Designated,Not FDA Approved for Orphan Indication,,,,
SCVHJVCATBPIHN-SJCJKPOMSA-N,12000240,SCVHJVCATBPIHN-SJCJKPOMSA-N,emricasan,,Treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end stage liver disease,"C0016059,C0023890,C0745744","Fibrosis , Cirrhosis , End Stage Liver Disease",11/20/13,Designated,Not FDA Approved for Orphan Indication,,,,
XSMSNFMDVXXHGJ-UHFFFAOYSA-N,59473233,XSMSNFMDVXXHGJ-UHFFFAOYSA-N,entospletinib,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,6/15/17,Designated,Not FDA Approved for Orphan Indication,,,,
HAYYBYPASCDWEQ-UHFFFAOYSA-N,25141092,HAYYBYPASCDWEQ-UHFFFAOYSA-N,entrectinib,ROZLYTREK,Treatment of NTRK fusion-positive solid tumors,C0280100,solid tumors,7/5/17,Designated/Approved,,"ROZLYTREK is indicated for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have either progressed following treatment or have no satisfactory alternative therapy", 08/15/2019 , 08/15/2026 ,"For the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have either progressed following treatment or have no satisfactory alternative therapy."
FBKMWOJEPMPVTQ-UHFFFAOYSA-N,135564890,FBKMWOJEPMPVTQ-UHFFFAOYSA-N,epacadostat,,Treatment of stage IIB-IV melanoma.,C0025202,melanoma,2/11/16,Designated,Not FDA Approved for Orphan Indication,,,,
PIWHBPJCPCXFEU-UHFFFAOYSA-N,127893,PIWHBPJCPCXFEU-UHFFFAOYSA-N,Epoetin alfa,,Treatment of myelodysplastic syndrome.,C3463824,MYELODYSPLASTIC SYNDROME,12/20/93,Designated,Not FDA Approved for Orphan Indication,,,,
PIWHBPJCPCXFEU-UHFFFAOYSA-N,127893,PIWHBPJCPCXFEU-UHFFFAOYSA-N,Epoetin alfa,Epogen,Treatment of anemia associated with end stage renal disease.,"C0002871,C0022661","Anemia , End stage renal disease",4/10/86,Designated/Approved,,"Treatment of anemia associated with chronic renal failure, including patients on dialysis (end stage renal disesae) and patients not on dialysis", 06/01/1989 , 06/01/1996 ,
QGFORSXNKQLDNO-UHFFFAOYSA-N,65632,QGFORSXNKQLDNO-UHFFFAOYSA-N,erdosteine,,Treatment of bronchiectasis.,C0006267,Bronchiectasis,12/20/13,Designated,Not FDA Approved for Orphan Indication,,,,
GWBBVOVXJZATQQ-UHFFFAOYSA-L,23894,GWBBVOVXJZATQQ-UHFFFAOYSA-L,Etidronate disodium,,Prevention of degenerative metabolic bone disease occurring in patients who require long term (6 months or greater) total parenteral nutrition.,C0005944,Metabolic Bone Disease,5/2/91,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
XJDYQYNYISTAMO-GFDYFVENSA-N,25063260,XJDYQYNYISTAMO-GFDYFVENSA-N,ezatiostat hydrochloride,,Treatment of myelodysplastic syndrome,C3463824,MYELODYSPLASTIC SYNDROME,1/9/13,Designated,Not FDA Approved for Orphan Indication,,,,
NGOGFTYYXHNFQH-UHFFFAOYSA-N,3547,NGOGFTYYXHNFQH-UHFFFAOYSA-N,Fasudil,,Treatment of progressive supranuclear palsy,C0038868,Progressive supranuclear palsy,12/21/20,Designated,Not FDA Approved for Orphan Indication,,,,
WKGXYQFOCVYPAC-UHFFFAOYSA-N,3331,WKGXYQFOCVYPAC-UHFFFAOYSA-N,Felbamate,Felbatol,Treatment of Lennox-Gastaut syndrome.,C0238111,Lennox-Gastaut syndrome,1/24/89,Designated/Approved,,As adjunctive therapy in the treatment of partial and generalized seizures associated with the Lennox-Gastaut syndrome in children., 07/29/1993 , 07/29/2000 ,
AKJHMTWEGVYYSE-FXILSDISSA-N,5288209,AKJHMTWEGVYYSE-FXILSDISSA-N,Fenretinide,,Treatment of Pseudomonas aeruginosa lung infections in cystic fibrosis patients,"C0010674,C0033809,C3714514","Cystic Fibrosis , Pseudomonas aeruginosa , Infections",4/7/10,Designated,Not FDA Approved for Orphan Indication,,,,
ZVGNESXIJDCBKN-DEIWUYIYSA-N,135391138,ZVGNESXIJDCBKN-DEIWUYIYSA-N,fidaxomicin,Dificid,Treatment of pediatric Clostridium difficile infection,C0343386,Clostridium difficile infection,12/13/10,Designated/Approved,,DIFICID is indicated in adult and pediatric patients aged 6 months and older for the treatment of C. difficile-associated diarrhea (CDAD)., 01/24/2020 ,  ,
ZVGNESXIJDCBKN-JMEUZRPYSA-N,132472265,ZVGNESXIJDCBKN-JMEUZRPYSA-N,fidaxomicin,Dificid,Treatment of pediatric Clostridium difficile infection,C0343386,Clostridium difficile infection,12/13/10,Designated/Approved,,DIFICID is indicated in adult and pediatric patients aged 6 months and older for the treatment of C. difficile-associated diarrhea (CDAD)., 01/24/2020 ,  ,
ZVGNESXIJDCBKN-ZJHJTZDTSA-N,131668620,ZVGNESXIJDCBKN-ZJHJTZDTSA-N,fidaxomicin,Dificid,Treatment of pediatric Clostridium difficile infection,C0343386,Clostridium difficile infection,12/13/10,Designated/Approved,,DIFICID is indicated in adult and pediatric patients aged 6 months and older for the treatment of C. difficile-associated diarrhea (CDAD)., 01/24/2020 ,  ,
ZVGNESXIJDCBKN-DBGJUELJSA-N,117590639,ZVGNESXIJDCBKN-DBGJUELJSA-N,fidaxomicin,Dificid,Treatment of pediatric Clostridium difficile infection,C0343386,Clostridium difficile infection,12/13/10,Designated/Approved,,DIFICID is indicated in adult and pediatric patients aged 6 months and older for the treatment of C. difficile-associated diarrhea (CDAD)., 01/24/2020 ,  ,
ZVGNESXIJDCBKN-KFGPIHIUSA-N,70678896,ZVGNESXIJDCBKN-KFGPIHIUSA-N,fidaxomicin,Dificid,Treatment of pediatric Clostridium difficile infection,C0343386,Clostridium difficile infection,12/13/10,Designated/Approved,,DIFICID is indicated in adult and pediatric patients aged 6 months and older for the treatment of C. difficile-associated diarrhea (CDAD)., 01/24/2020 ,  ,
ZVGNESXIJDCBKN-SZYXOGSFSA-N,102580518,ZVGNESXIJDCBKN-SZYXOGSFSA-N,fidaxomicin,Dificid,Treatment of pediatric Clostridium difficile infection,C0343386,Clostridium difficile infection,12/13/10,Designated/Approved,,DIFICID is indicated in adult and pediatric patients aged 6 months and older for the treatment of C. difficile-associated diarrhea (CDAD)., 01/24/2020 ,  ,
ZVGNESXIJDCBKN-VUCVDCOISA-N,91885501,ZVGNESXIJDCBKN-VUCVDCOISA-N,fidaxomicin,Dificid,Treatment of pediatric Clostridium difficile infection,C0343386,Clostridium difficile infection,12/13/10,Designated/Approved,,DIFICID is indicated in adult and pediatric patients aged 6 months and older for the treatment of C. difficile-associated diarrhea (CDAD)., 01/24/2020 ,  ,
ZVGNESXIJDCBKN-UHFFFAOYSA-N,151383,ZVGNESXIJDCBKN-UHFFFAOYSA-N,fidaxomicin,Dificid,Treatment of pediatric Clostridium difficile infection,C0343386,Clostridium difficile infection,12/13/10,Designated/Approved,,DIFICID is indicated in adult and pediatric patients aged 6 months and older for the treatment of C. difficile-associated diarrhea (CDAD)., 01/24/2020 ,  ,
ZVGNESXIJDCBKN-LGPUCNCQSA-N,46174142,ZVGNESXIJDCBKN-LGPUCNCQSA-N,fidaxomicin,Dificid,Treatment of pediatric Clostridium difficile infection,C0343386,Clostridium difficile infection,12/13/10,Designated/Approved,,DIFICID is indicated in adult and pediatric patients aged 6 months and older for the treatment of C. difficile-associated diarrhea (CDAD)., 01/24/2020 ,  ,
ZVGNESXIJDCBKN-UUEYKCAUSA-N,10034073,ZVGNESXIJDCBKN-UUEYKCAUSA-N,fidaxomicin,Dificid,Treatment of pediatric Clostridium difficile infection,C0343386,Clostridium difficile infection,12/13/10,Designated/Approved,,DIFICID is indicated in adult and pediatric patients aged 6 months and older for the treatment of C. difficile-associated diarrhea (CDAD)., 01/24/2020 ,  ,
LLXISKGBWFTGEI-FQEVSTJZSA-N,44224257,LLXISKGBWFTGEI-FQEVSTJZSA-N,filanesib,,Treatment of multiple myeloma.,C0026764,Multiple Myeloma,5/6/14,Designated,Not FDA Approved for Orphan Indication,,,,
SMANXXCATUTDDT-QPJJXVBHSA-N,941361,SMANXXCATUTDDT-QPJJXVBHSA-N,flunarizine,,Treatment of alternating hemiplegia.,C0018991,Hemiplegia,1/6/86,Designated,Not FDA Approved for Orphan Indication,,,,
RTHCYVBBDHJXIQ-UHFFFAOYSA-N,3386,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,Fluoxetine,,Treatment of body dysmorphic disorder in children and adolescents,C0005887,Body dysmorphic disorder,4/14/04,Designated,Not FDA Approved for Orphan Indication,,,,
NHTKGYOMICWFQZ-BBOXMAMFSA-N,134812042,NHTKGYOMICWFQZ-BBOXMAMFSA-N,fosgemcitabine palabenamide,,Treatment of biliary tract cancer,C0750952,Biliary Tract Cancer,6/11/19,Designated,Not FDA Approved for Orphan Indication,,,,
YKGYIDJEEQRWQH-UHFFFAOYSA-N,3447,YKGYIDJEEQRWQH-UHFFFAOYSA-N,Gabexate,,Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis,C0042384,Vasculitis,9/18/20,Designated,Not FDA Approved for Orphan Indication,,,,
PGTVWKLGGCQMBR-FLBATMFCSA-N,6918305,PGTVWKLGGCQMBR-FLBATMFCSA-N,ganaxolone,,Treatment of cyclin-dependent kinase-like 5 (CDKL5) gene-related early-onset infantile epileptic encephalopathy,C0543888,Epileptic encephalopathy,6/28/17,Designated,Not FDA Approved for Orphan Indication,,,,
PGTVWKLGGCQMBR-FLBATMFCSA-N,6918305,PGTVWKLGGCQMBR-FLBATMFCSA-N,ganaxolone,,Treatment of status epilepticus.,C0038220,Status Epilepticus,4/14/16,Designated,Not FDA Approved for Orphan Indication,,,,
IRSCQMHQWWYFCW-UHFFFAOYSA-N,135398740,IRSCQMHQWWYFCW-UHFFFAOYSA-N,ganciclovir,Zirgan,Treatment of acute herpetic keratitis (dendritic and geographic ulcers),"C0019357,C0041582","Herpetic keratitis , Ulcers",3/22/07,Designated/Approved,,Treatment of acute herpetic keratitis (dendritic ulcers), 09/15/2009 , 09/15/2016 ,
SDMBRCRVFFHJKR-UHFFFAOYSA-N,157692,SDMBRCRVFFHJKR-UHFFFAOYSA-N,gemcabene,,Treatment of homozygous familial hypercholesterolemia,C0020445,FAMILIAL HYPERCHOLESTEROLEMIA,2/6/14,Designated,Not FDA Approved for Orphan Indication,,,,
HUCXKZBETONXFO-NJFMWZAGSA-N,5282199,HUCXKZBETONXFO-NJFMWZAGSA-N,Geranylgeranylacetone,,Prevention of post-hepatectomy liver failure,C0085605,Liver Failure,6/16/20,Designated,Not FDA Approved for Orphan Indication,,,,
ZNNLBTZKUZBEKO-UHFFFAOYSA-N,3488,ZNNLBTZKUZBEKO-UHFFFAOYSA-N,Glyburide,,Treatment of severe cerebral edema in patients with acute ischemic stroke,"C0006114,C0948008","Cerebral Edema , Ischemic stroke",1/12/17,Designated,Not FDA Approved for Orphan Indication,,,,
UEAYTGFTNACKMX-VMXHOPILSA-N,9872764,UEAYTGFTNACKMX-VMXHOPILSA-N,H-Leu-Pro-Pro-Ser-Arg-OH,,Treatment of Kaposi sarcoma,C0036220,Kaposi Sarcoma,9/20/12,Designated,Not FDA Approved for Orphan Indication,,,,
HTTJABKRGRZYRN-UHFFFAOYSA-N,772,HTTJABKRGRZYRN-UHFFFAOYSA-N,Heparin,,Treatment of cystic fibrosis,C0010674,Cystic Fibrosis,11/3/05,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
HHXHVIJIIXKSOE-QILQGKCVSA-N,25077993,HHXHVIJIIXKSOE-QILQGKCVSA-N,Histrelin,Supprelin LA,Treatment of central precocious puberty,C0342543,Central Precocious Puberty,11/18/05,Designated/Approved,,Treatment of central precocious puberty, 05/03/2007 , 05/03/2014 ,
VSNHCAURESNICA-UHFFFAOYSA-N,3657,VSNHCAURESNICA-UHFFFAOYSA-N,hydroxyurea,,Treatment of pediatric patients with sickle cell anemia.,C0002895,SICKLE CELL ANEMIA,4/15/05,Designated,Not FDA Approved for Orphan Indication,,,,
ZJVFLBOZORBYFE-UHFFFAOYSA-N,3671,ZJVFLBOZORBYFE-UHFFFAOYSA-N,ibudilast,,Treatment of Krabbe disease,C0023521,Krabbe Disease,6/1/15,Designated,Not FDA Approved for Orphan Indication,,,,
XDXDZDZNSLXDNA-TZNDIEGXSA-N,42890,XDXDZDZNSLXDNA-TZNDIEGXSA-N,Idarubicin,,Treatment of myelodysplastic syndromes.,C3463824,Myelodysplastic Syndromes,12/1/92,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
TVTXCJFHQKSQQM-LJQIRTBHSA-N,53358942,TVTXCJFHQKSQQM-LJQIRTBHSA-N,idasanutlin,,Treatment of polycythemia vera,C0032463,Polycythemia Vera,11/29/17,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
BIXBBIPTYBJTRY-UHFFFAOYSA-N,68791,BIXBBIPTYBJTRY-UHFFFAOYSA-N,imexon,,Treatment of ovarian cancer.,C4721610,Ovarian Cancer,8/12/05,Designated,Not FDA Approved for Orphan Indication,,,,
LWXUIUUOMSMZKJ-KLFWAVJMSA-M,72196309,LWXUIUUOMSMZKJ-KLFWAVJMSA-M,isavuconazonium sulfate,,Treatment of invasive candidiasis/candidemia,"C0877445,C1609535","Candidemia , Invasive Candidiasis",10/20/14,Designated,Not FDA Approved for Orphan Indication,,,,
LWXUIUUOMSMZKJ-KLFWAVJMSA-M,72196309,LWXUIUUOMSMZKJ-KLFWAVJMSA-M,isavuconazonium sulfate,Cresemba,Treatment of zygomycosis,C0043541,Zygomycosis,10/25/13,Designated/Approved,,Treatment of invasive mucormycosis in patients 18 years of age and older, 03/06/2015 , 03/06/2022 ,Treatment of invasive mucormycosis in patients 18 years of age and older
WFKAJVHLWXSISD-UHFFFAOYSA-N,68424,WFKAJVHLWXSISD-UHFFFAOYSA-N,Isobutyramide,,Treatment of beta-hemoglobinopathies and beta-thalassemia syndromes.,"C0005283,C0019045","BETA-THALASSEMIA , Hemoglobinopathies",12/18/92,Designated,Not FDA Approved for Orphan Indication,,,,
KTBSXLIQKWEBRB-UHFFFAOYSA-N,53380437,KTBSXLIQKWEBRB-UHFFFAOYSA-N,itacitinib,,Treatment of graft versus host disease,C0018133,GRAFT VERSUS HOST DISEASE,4/17/17,Designated,Not FDA Approved for Orphan Indication,,,,
ACRHBAYQBXXRTO-OAQYLSRUSA-N,132999,ACRHBAYQBXXRTO-OAQYLSRUSA-N,ivabradine,,Treatment of post-cardiac transplant heart dysfunction,C0340515,heart dysfunction,7/9/18,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PURKAOJPTOLRMP-UHFFFAOYSA-N,16220172,PURKAOJPTOLRMP-UHFFFAOYSA-N,ivacaftor,KALYDECO,Treatment of patients with cystic fibrosis,C0010674,Cystic Fibrosis,12/20/06,Designated/Approved,,KALYDECO is indicated for the treatment of cystic fibrosis (CF) in patients age 4 months and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data, 09/24/2020 , 09/24/2027 ,treatment of cystic fibrosis (CF) in patients age 4 months to less than 6 months who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data
PURKAOJPTOLRMP-UHFFFAOYSA-N,16220172,PURKAOJPTOLRMP-UHFFFAOYSA-N,ivacaftor,Kalydeco,Treatment of patients with cystic fibrosis,C0010674,Cystic Fibrosis,12/20/06,Designated/Approved,,Treatment of cystic fibrosis (CF) in patients age 6 years and older who have a G551D mutation in the CFTR gene., 01/31/2012 , 01/31/2019 ,
BMLMGCPTLHPWPY-REOHCLBHSA-N,72390,BMLMGCPTLHPWPY-REOHCLBHSA-N,L-2-oxothiazolidine-4-carboxylic acid,,Treatment of amyotrophic lateral sclerosis.,C0002736,Amyotrophic Lateral Sclerosis,7/30/96,Designated,Not FDA Approved for Orphan Indication,,,,
BMLMGCPTLHPWPY-UHFFFAOYSA-N,65272,BMLMGCPTLHPWPY-UHFFFAOYSA-N,L-2-oxothiazolidine-4-carboxylic acid,,Treatment of amyotrophic lateral sclerosis.,C0002736,Amyotrophic Lateral Sclerosis,7/30/96,Designated,Not FDA Approved for Orphan Indication,,,,
LKCWBDHBTVXHDL-CAIQVSFASA-N,456591,LKCWBDHBTVXHDL-CAIQVSFASA-N,liposomal amikacin,,Treatment of bronchiectasis in patients with Pseudomonas aeruginosa or other susceptible microbial pathogens,"C0006267,C0033809","Bronchiectasis , Pseudomonas aeruginosa",8/25/09,Designated,Not FDA Approved for Orphan Indication,,,,
APKFDSVGJQXUKY-INPOYWNPSA-N,5280965,APKFDSVGJQXUKY-INPOYWNPSA-N,Liposomal amphotericin B,AmBisome,Treatment of visceral leishmaniasis.,C0023290,Visceral leishmaniasis,12/6/96,Designated/Approved,,Treatment of visceral leishmaniasis., 08/11/1997 , 08/11/2004 ,
APKFDSVGJQXUKY-INPOYWNPSA-N,5280965,APKFDSVGJQXUKY-INPOYWNPSA-N,Liposomal amphotericin B,,Treatment of histoplasmosis.,C0019655,Histoplasmosis,12/10/96,Designated,Not FDA Approved for Orphan Indication,,,,
PPHTXRNHTVLQED-UHFFFAOYSA-N,172997,PPHTXRNHTVLQED-UHFFFAOYSA-N,lixivaptan,,Treatment of autosomal dominant polycystic kidney disease (ADPKD),C0085413,Autosomal dominant polycystic kidney disease,9/18/17,Designated,Not FDA Approved for Orphan Indication,,,,
XTTZERNUQAFMOF-QMMMGPOBSA-N,11658860,XTTZERNUQAFMOF-QMMMGPOBSA-N,lorcaserin,,Treatment of Dravet syndrome,C0751122,Dravet Syndrome,4/17/17,Designated,Not FDA Approved for Orphan Indication,,,,
KKYABQBFGDZVNQ-UHFFFAOYSA-N,11552706,KKYABQBFGDZVNQ-UHFFFAOYSA-N,losmapimod,,Treatment of Facioscapulohumeral muscular dystrophy,C0238288,Facioscapulohumeral muscular dystrophy,1/27/20,Designated,Not FDA Approved for Orphan Indication,,,,
UQRORFVVSGFNRO-XFWSIPNHSA-N,501391,UQRORFVVSGFNRO-XFWSIPNHSA-N,lucerastat,,Treatment of Fabry Disease.,C0002986,Fabry Disease,10/29/15,Designated,Not FDA Approved for Orphan Indication,,,,
OSPNFKYGOFXGBX-YWWKUQGPSA-N,145722609,OSPNFKYGOFXGBX-YWWKUQGPSA-N,Lucinactant,,Treatment of respiratory distress syndrome in premature infants.,C1968593,Respiratory Distress Syndrome In Premature Infants,10/18/95,Designated,Not FDA Approved for Orphan Indication,,,,
YDDMIZRDDREKEP-HWTBNCOESA-N,57327016,YDDMIZRDDREKEP-HWTBNCOESA-N,lurbinectedin,Zepzelca,Treatment of small cell lung cancer (SCLC),"C0149925,C0262584,C3540630","Small Cell Lung Cancer , SCLC , Small Cell Lung Cancer",8/1/18,Designated/Approved,,Zepzelca (lurbinectedin) is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after prior platinum-based chemotherapy., 06/15/2020 , 06/15/2027 ,For the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
KJFBVJALEQWJBS-XUXIUFHCSA-N,471161,KJFBVJALEQWJBS-XUXIUFHCSA-N,maribavir,,Prevention of cytomegalovirus viremia and disease in the populations at risk.,"C0012634,C0877635","Disease , Cytomegalovirus viremia",2/1/07,Designated,Not FDA Approved for Orphan Indication,,,,
WJEOLQLKVOPQFV-UHFFFAOYSA-N,10074640,WJEOLQLKVOPQFV-UHFFFAOYSA-N,masitinib,,Treatment of patients with pancreatic cancer,C0235974,PANCREATIC CANCER,7/21/09,Designated,Not FDA Approved for Orphan Indication,,,,
ZPXSCAKFGYXMGA-UHFFFAOYSA-N,4020,ZPXSCAKFGYXMGA-UHFFFAOYSA-N,mazindol,,Treatment of narcolepsy,C0027404,Narcolepsy,7/6/16,Designated,Not FDA Approved for Orphan Indication,,,,
DRLFMBDRBRZALE-UHFFFAOYSA-N,896,DRLFMBDRBRZALE-UHFFFAOYSA-N,melatonin,,Treatment of neonatal hypoxic ischemic encephalopathy,C3898147,Neonatal Hypoxic Ischemic Encephalopathy,4/12/13,Designated,Not FDA Approved for Orphan Indication,,,,
DRLFMBDRBRZALE-UHFFFAOYSA-N,896,DRLFMBDRBRZALE-UHFFFAOYSA-N,melatonin,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,10/9/19,Designated,Not FDA Approved for Orphan Indication,,,,
SGDBTWWWUNNDEQ-LBPRGKRZSA-N,460612,SGDBTWWWUNNDEQ-LBPRGKRZSA-N,Melphalan,,For use in hyperthermic regional limb perfusion to treat metastatic melanoma of the extremity.,"C0015967,C0278883","hyperthermic , Metastatic melanoma",3/3/92,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
DKHGMERMDICWDU-GHDNBGIDSA-N,5282367,DKHGMERMDICWDU-GHDNBGIDSA-N,menatetrenone,,Treatment of acute promyelocytic leukemia.,C0023487,Acute Promyelocytic Leukemia,11/2/10,Designated,Not FDA Approved for Orphan Indication,,,,
DKHGMERMDICWDU-GHDNBGIDSA-N,5282367,DKHGMERMDICWDU-GHDNBGIDSA-N,menatetrenone,,Treatment of myelodysplastic syndrome.,C3463824,MYELODYSPLASTIC SYNDROME,2/4/11,Designated,Not FDA Approved for Orphan Indication,,,,
KBOPZPXVLCULAV-UHFFFAOYSA-N,4075,KBOPZPXVLCULAV-UHFFFAOYSA-N,mesalamine,,Treatment of pediatric ulcerative colitis,C2931173,Pediatric ulcerative colitis,1/19/10,Designated,Not FDA Approved for Orphan Indication,,,,
CJCSPKMFHVPWAR-JTQLQIEISA-N,38853,CJCSPKMFHVPWAR-JTQLQIEISA-N,methyldopa,,Treatment of type 1 diabetes in DQ8 positive patients with residual beta cell function,C0011854,Type 1 Diabetes,1/12/17,Designated,Not FDA Approved for Orphan Indication,,,,
DDLIGBOFAVUZHB-UHFFFAOYSA-N,4192,DDLIGBOFAVUZHB-UHFFFAOYSA-N,midazolam,,Treatment of nerve agent-induced seizures,C0036572,Seizures,7/24/12,Designated,Not FDA Approved for Orphan Indication,,,,
DDLIGBOFAVUZHB-UHFFFAOYSA-N,4192,DDLIGBOFAVUZHB-UHFFFAOYSA-N,midazolam,,Treatment of bouts of increased seizure activity in selected refractory patients with epilepsy who are on stable regimens of anti-epileptic drugs and who require intermittent use of midazolam,"C0014544,C1148454","Epilepsy , seizure activity",5/8/06,Designated,Not FDA Approved for Orphan Indication,,,,
PQLXHQMOHUQAKB-UHFFFAOYSA-N,3599,PQLXHQMOHUQAKB-UHFFFAOYSA-N,miltefosine,,Treatment of disseminated amebiasis,C0013370,amebiasis,6/19/17,Designated,Not FDA Approved for Orphan Indication,,,,
PQLXHQMOHUQAKB-UHFFFAOYSA-N,3599,PQLXHQMOHUQAKB-UHFFFAOYSA-N,miltefosine,,Treatment of primary amebic encephalitis (PAM),"C0338427,C2931826","Primary amebic encephalitis , PAM",12/6/16,Designated,Not FDA Approved for Orphan Indication,,,,
PQLXHQMOHUQAKB-UHFFFAOYSA-N,3599,PQLXHQMOHUQAKB-UHFFFAOYSA-N,miltefosine,IMPAVIDO,Treatment of leishmaniasis.,C0023281,Leishmaniasis,10/10/06,Designated/Approved,,"Treatment of visceral leishmaniasis due to Leishmania donovani; cutaneous leishmaniasis due to Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis; and mucosal leishmaniasis due to Leishmania braziliensis.", 03/19/2014 , 03/19/2021 ,"Treatment of visceral leishmaniasis due to Leishmania donovani; cutaneous leishmaniasis due to Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis; and mucosal leishmaniasis due to Leishmania braziliensis."
MXWHMTNPTTVWDM-VEPASKNESA-N,76961227,MXWHMTNPTTVWDM-VEPASKNESA-N,Mitoguazone,,"Treatment of diffuse non-Hodgkin's lymphoma, including AIDS-related diffuse non-Hodgkin's lymphoma.","C0001175,C0348394","AIDS , Diffuse non-Hodgkin's lymphoma",3/18/94,Designated,Not FDA Approved for Orphan Indication,,,,
MXWHMTNPTTVWDM-UHFFFAOYSA-N,9991,MXWHMTNPTTVWDM-UHFFFAOYSA-N,Mitoguazone,,"Treatment of diffuse non-Hodgkin's lymphoma, including AIDS-related diffuse non-Hodgkin's lymphoma.","C0001175,C0348394","AIDS , Diffuse non-Hodgkin's lymphoma",3/18/94,Designated,Not FDA Approved for Orphan Indication,,,,
MXWHMTNPTTVWDM-XVVXZDBVSA-N,5363702,MXWHMTNPTTVWDM-XVVXZDBVSA-N,Mitoguazone,,"Treatment of diffuse non-Hodgkin's lymphoma, including AIDS-related diffuse non-Hodgkin's lymphoma.","C0001175,C0348394","AIDS , Diffuse non-Hodgkin's lymphoma",3/18/94,Designated,Not FDA Approved for Orphan Indication,,,,
MXWHMTNPTTVWDM-NXOFHUPFSA-N,5351154,MXWHMTNPTTVWDM-NXOFHUPFSA-N,Mitoguazone,,"Treatment of diffuse non-Hodgkin's lymphoma, including AIDS-related diffuse non-Hodgkin's lymphoma.","C0001175,C0348394","AIDS , Diffuse non-Hodgkin's lymphoma",3/18/94,Designated,Not FDA Approved for Orphan Indication,,,,
JJVZSYKFCOBILL-MKMRYRNGSA-N,91865076,JJVZSYKFCOBILL-MKMRYRNGSA-N,motixafortide,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,9/5/13,Designated,Not FDA Approved for Orphan Indication,,,,
DQCKKXVULJGBQN-XFWGSAIBSA-N,5360515,DQCKKXVULJGBQN-XFWGSAIBSA-N,naltrexone,,Treatment of postherpetic neuralgia,C0032768,Postherpetic neuralgia,2/23/15,Designated,Not FDA Approved for Orphan Indication,,,,
ALWKGYPQUAPLQC-UHFFFAOYSA-N,4456,ALWKGYPQUAPLQC-UHFFFAOYSA-N,neostigmine,,Treatment of acute colonic pseudo-obstruction,C0009377,Colonic Pseudo-Obstruction,3/18/13,Designated,Not FDA Approved for Orphan Indication,,,,
PUUSSSIBPPTKTP-UHFFFAOYSA-N,71237,PUUSSSIBPPTKTP-UHFFFAOYSA-N,neridronate,,"Treatment of complex regional pain syndrome (CRPS-1, CRPS-II, CRPS-NOS)",C0458219,Complex regional pain syndrome,3/25/13,Designated,Not FDA Approved for Orphan Indication,,,,
OUBCNLGXQFSTLU-UHFFFAOYSA-N,115355,OUBCNLGXQFSTLU-UHFFFAOYSA-N,Nitisinone,Orfadin,Treatment of tyrosinemia type 1.,C0268490,Tyrosinemia Type 1,5/16/95,Designated/Approved,,Treatment of hereditary tyrosinemia type 1 in combination with dietary restriction of tyrosine and phenylalanine., 04/22/2016 ,  ,
MWUXSHHQAYIFBG-UHFFFAOYSA-N,145068,MWUXSHHQAYIFBG-UHFFFAOYSA-N,nitric oxide,,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,1/31/17,Designated,Not FDA Approved for Orphan Indication,,,,
MWUXSHHQAYIFBG-UHFFFAOYSA-N,145068,MWUXSHHQAYIFBG-UHFFFAOYSA-N,nitric oxide,,Treatment of persistent pulmonary hypertension in newborns,C1135361,Persistent pulmonary hypertension,6/18/12,Designated/Approved,,GENOSYL is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents., 12/20/2019 ,  ,
MIMNFCVQODTQDP-NDLVEFNKSA-N,118984458,MIMNFCVQODTQDP-NDLVEFNKSA-N,oblimersen,,Treatment of acute myelocytic leukemia,C0023467,Acute myelocytic leukemia,8/28/01,Designated,Not FDA Approved for Orphan Indication,,,,
IBXPAFBDJCXCDW-MHFPCNPESA-A,118984457,IBXPAFBDJCXCDW-MHFPCNPESA-A,oblimersen,,Treatment of acute myelocytic leukemia,C0023467,Acute myelocytic leukemia,8/28/01,Designated,Not FDA Approved for Orphan Indication,,,,
YWQFJNWMWZMXRW-HXUWFJFHSA-N,90445883,YWQFJNWMWZMXRW-HXUWFJFHSA-N,olinciguat,,Treatment of Sickle Cell Disease,C0002895,Sickle Cell Disease,6/4/18,Designated,Not FDA Approved for Orphan Indication,,,,
DUYJMQONPNNFPI-UHFFFAOYSA-N,71496458,DUYJMQONPNNFPI-UHFFFAOYSA-N,osimertinib,Tagrisso,Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer,"C1414313,C3539721","EPIDERMAL GROWTH FACTOR RECEPTOR , Non-Small Cell Lung Cancer",9/4/14,Designated/Approved,,"adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test", 12/18/2020 , 12/18/2027 ,"adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test"
KHPXUQMNIQBQEV-UHFFFAOYSA-N,970,KHPXUQMNIQBQEV-UHFFFAOYSA-N,oxaloacetic acid,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,11/18/15,Designated,Not FDA Approved for Orphan Indication,,,,
QSLJIVKCVHQPLV-PEMPUTJUSA-N,5878,QSLJIVKCVHQPLV-PEMPUTJUSA-N,Oxandrolone,,Adjunctive therapy for AIDS patients suffering from HIV-wasting syndrome.,"C0006625,C0019682","Wasting syndrome , HIV",9/6/91,Designated,Not FDA Approved for Orphan Indication,,,,
HXNFUBHNUDHIGC-UHFFFAOYSA-N,135398752,HXNFUBHNUDHIGC-UHFFFAOYSA-N,Oxypurinol,,Treatment of hyperuricemia in patients intolerant to allopurinol.,C0740394,Hyperuricemia,11/9/98,Designated,Not FDA Approved for Orphan Indication,,,,
XNOPRXBHLZRZKH-DSZYJQQASA-N,439302,XNOPRXBHLZRZKH-DSZYJQQASA-N,oxytocin,,Treatment of Prader-Willi syndrome,C0032897,Prader-Willi Syndrome,6/15/17,Designated,Not FDA Approved for Orphan Indication,,,,
BPKAHTKRCLCHEA-UBFJEZKGSA-N,5281104,BPKAHTKRCLCHEA-UBFJEZKGSA-N,paricalcitol,Zemplar,Treatment of pediatric hyperparathyroidism,C0020502,Hyperparathyroidism,10/27/15,Designated/Approved,,Indicated in adults and pediatric patients 10 years of age and older for the prevention and treatment of secondary hyperparathyroidism associated with Chronic kidney disease (CKD) Stages 3 and 4 and CKD Stage 5 in patients on hemodialysis or peritoneal dialysis, 10/18/2016 , 10/18/2023 ,Indicated in pediatric patients ages 10 -16 years for treatment of secondary hyperparathyroidism associated with Chronic kidney disease (CKD) Stages 3 and 4 and pediatric patients ages 10-16 years for treatment of secondary hyperparathyroidism associated with CKD Stage 5.
ZQPDJCIXJHUERQ-QWRGUYRKSA-N,86677874,ZQPDJCIXJHUERQ-QWRGUYRKSA-N,parsaclisib,,Treatment of nodal marginal zone lymphoma,C0242647,Nodal marginal zone lymphoma,10/7/19,Designated,Not FDA Approved for Orphan Indication,,,,
QXLQZLBNPTZMRK-UHFFFAOYSA-N,436058,QXLQZLBNPTZMRK-UHFFFAOYSA-N,Pegaspargase,Oncaspar; Asparlas,Treatment of acute lymphocytic leukemia.,C0023449,Acute lymphocytic leukemia,10/20/89,Designated/Approved,,Combination chemotherapy for the treatment of patients with acute lymphoblastic leukemia who are hypersensitive to native forms of L-asparaginase., 02/01/1994 , 02/01/2001 ,
DOHVAKFYAHLCJP-UHFFFAOYSA-N,135413525,DOHVAKFYAHLCJP-UHFFFAOYSA-N,Peldesine,,Treatment of cutaneous T-cell lymphoma.,C0079773,cutaneous T-cell lymphoma,10/5/93,Designated,Not FDA Approved for Orphan Indication,,,,
NEYNJQRKHLUJRU-DZUOILHNSA-N,9853654,NEYNJQRKHLUJRU-DZUOILHNSA-N,pentagastrin,,Diagnostic for the management of medullary thyroid cancer,C0238462,medullary thyroid cancer,4/21/20,Designated,Not FDA Approved for Orphan Indication,,,,
CWRVKFFCRWGWCS-UHFFFAOYSA-N,5917,CWRVKFFCRWGWCS-UHFFFAOYSA-N,pentetrazol,,Treatment of idiopathic hypersomnia,C0751757,Idiopathic Hypersomnia,9/9/15,Designated,Not FDA Approved for Orphan Indication,,,,
VPAWVRUHMJVRHU-GYKQLYQFSA-N,9690122,VPAWVRUHMJVRHU-GYKQLYQFSA-N,Perfosfamide,,"For use in the ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.",C0023467,Acute myelogenous leukemia,12/4/89,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
VPAWVRUHMJVRHU-RWNHWRGESA-N,6918238,VPAWVRUHMJVRHU-RWNHWRGESA-N,Perfosfamide,,"For use in the ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.",C0023467,Acute myelogenous leukemia,12/4/89,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
VPAWVRUHMJVRHU-HYORBCNSSA-N,70697640,VPAWVRUHMJVRHU-HYORBCNSSA-N,Perfosfamide,,"For use in the ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.",C0023467,Acute myelogenous leukemia,12/4/89,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
VPAWVRUHMJVRHU-UHFFFAOYSA-N,38347,VPAWVRUHMJVRHU-UHFFFAOYSA-N,Perfosfamide,,"For use in the ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.",C0023467,Acute myelogenous leukemia,12/4/89,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
VPAWVRUHMJVRHU-VGDKGRGNSA-N,9554809,VPAWVRUHMJVRHU-VGDKGRGNSA-N,Perfosfamide,,"For use in the ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.",C0023467,Acute myelogenous leukemia,12/4/89,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
JGSARLDLIJGVTE-MBNYWOFBSA-M,640429,JGSARLDLIJGVTE-MBNYWOFBSA-M,picibanil,,Treatment of patients with lymphatic malformations,C0398368,lymphatic malformations,5/15/09,Designated,Not FDA Approved for Orphan Indication,,,,
JGSARLDLIJGVTE-MBNYWOFBSA-M,640429,JGSARLDLIJGVTE-MBNYWOFBSA-M,picibanil,,Treatment of lymphatic malformations,C0398368,lymphatic malformations,3/17/11,Designated,Not FDA Approved for Orphan Indication,,,,
IIMIOEBMYPRQGU-UHFFFAOYSA-L,177358,IIMIOEBMYPRQGU-UHFFFAOYSA-L,Picoplatin,,Treatment of small cell lung cancer,C3540630,Small Cell Lung Cancer,11/2/05,Designated,Not FDA Approved for Orphan Indication,,,,
KMSKQZKKOZQFFG-MJKUFRJISA-N,137704806,KMSKQZKKOZQFFG-MJKUFRJISA-N,Pirarubicin,,Treatment of osteosarcoma,C0029463,Osteosarcoma,10/29/20,Designated,Not FDA Approved for Orphan Indication,,,,
KMSKQZKKOZQFFG-ULRATTRFSA-N,134692159,KMSKQZKKOZQFFG-ULRATTRFSA-N,Pirarubicin,,Treatment of osteosarcoma,C0029463,Osteosarcoma,10/29/20,Designated,Not FDA Approved for Orphan Indication,,,,
KMSKQZKKOZQFFG-CBFOJMSHSA-N,131750285,KMSKQZKKOZQFFG-CBFOJMSHSA-N,Pirarubicin,,Treatment of osteosarcoma,C0029463,Osteosarcoma,10/29/20,Designated,Not FDA Approved for Orphan Indication,,,,
KMSKQZKKOZQFFG-FQSDZSELSA-N,122173004,KMSKQZKKOZQFFG-FQSDZSELSA-N,Pirarubicin,,Treatment of osteosarcoma,C0029463,Osteosarcoma,10/29/20,Designated,Not FDA Approved for Orphan Indication,,,,
KMSKQZKKOZQFFG-MJTHYZEOSA-N,6712062,KMSKQZKKOZQFFG-MJTHYZEOSA-N,Pirarubicin,,Treatment of osteosarcoma,C0029463,Osteosarcoma,10/29/20,Designated,Not FDA Approved for Orphan Indication,,,,
KMSKQZKKOZQFFG-CBIZWKIZSA-N,45358767,KMSKQZKKOZQFFG-CBIZWKIZSA-N,Pirarubicin,,Treatment of osteosarcoma,C0029463,Osteosarcoma,10/29/20,Designated,Not FDA Approved for Orphan Indication,,,,
KMSKQZKKOZQFFG-NCXNULAVSA-N,6917695,KMSKQZKKOZQFFG-NCXNULAVSA-N,Pirarubicin,,Treatment of osteosarcoma,C0029463,Osteosarcoma,10/29/20,Designated,Not FDA Approved for Orphan Indication,,,,
KMSKQZKKOZQFFG-YHKVCKOMSA-N,3033521,KMSKQZKKOZQFFG-YHKVCKOMSA-N,Pirarubicin,,Treatment of osteosarcoma,C0029463,Osteosarcoma,10/29/20,Designated,Not FDA Approved for Orphan Indication,,,,
KMSKQZKKOZQFFG-UHFFFAOYSA-N,4844,KMSKQZKKOZQFFG-UHFFFAOYSA-N,Pirarubicin,,Treatment of osteosarcoma,C0029463,Osteosarcoma,10/29/20,Designated,Not FDA Approved for Orphan Indication,,,,
KMSKQZKKOZQFFG-YXRRJAAWSA-N,11296583,KMSKQZKKOZQFFG-YXRRJAAWSA-N,Pirarubicin,,Treatment of osteosarcoma,C0029463,Osteosarcoma,10/29/20,Designated,Not FDA Approved for Orphan Indication,,,,
KMSKQZKKOZQFFG-HSUXVGOQSA-N,636397,KMSKQZKKOZQFFG-HSUXVGOQSA-N,Pirarubicin,,Treatment of osteosarcoma,C0029463,Osteosarcoma,10/29/20,Designated,Not FDA Approved for Orphan Indication,,,,
YIQPUIGJQJDJOS-UHFFFAOYSA-N,65015,YIQPUIGJQJDJOS-UHFFFAOYSA-N,plerixafor,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,7/28/11,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
RVGRUAULSDPKGF-UHFFFAOYSA-N,24751,RVGRUAULSDPKGF-UHFFFAOYSA-N,Poloxamer 188,,Treatment of vasospasm in subarachnoid hemorrhage patients following surgical repair of a ruptured cerebral aneurysm.,"C0038525,C0242084","Subarachnoid Hemorrhage , Ruptured cerebral aneurysm",8/5/97,Designated,Not FDA Approved for Orphan Indication,,,,
MRYYMYCQXMFJNE-UHFFFAOYSA-N,136033680,MRYYMYCQXMFJNE-UHFFFAOYSA-N,Poly-ICLC,,Treatment of primary brain tumors.,C0750974,primary brain tumors,3/17/97,Designated,Not FDA Approved for Orphan Indication,,,,
RSQDGTJKZWTAGL-UHFFFAOYSA-N,137321858,RSQDGTJKZWTAGL-UHFFFAOYSA-N,Porfimer sodium,Photofrin,For the photodynamic therapy of patients with primary or recurrent obstructing (either partially or completely) esophageal carcinoma.,C0152018,Esophageal carcinoma,6/6/89,Designated/Approved,,"Photodynamic therapy with PHOTOFRIN for the palliation of patients with completely obstructing esophageal cancer, or of patients with partially obstructing esophageal cancer who cannot be satisfactorily treated with Nd:YAG laser therapy.", 12/27/1995 , 12/27/2002 ,
QEEAPRPFLLJWCF-UHFFFAOYSA-K,13344,QEEAPRPFLLJWCF-UHFFFAOYSA-K,Potassium citrate,Urocit-K,1. Prevention of calcium renal stones in patients with hypocitraturia 2. For avoidance of the complication of calcium stone formation in patients with uric lithiasis.,"C0009566,C0022650,C0023869,C2673444","Complication , renal stones , Lithiasis , Hypocitraturia",11/1/84,Designated/Approved,,Prevention of recurring calcium conating stines associated with a deficiency in the urine., 08/07/1985 , 08/07/1992 ,
RJKFOVLPORLFTN-LEKSSAKUSA-N,5994,RJKFOVLPORLFTN-LEKSSAKUSA-N,progesterone,,For early intervention in the treatment of moderate to severe closed-head traumatic brain injury,C0876926,Traumatic Brain Injury,9/3/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
DJUFPMUQJKWIJB-UHFFFAOYSA-N,107771,DJUFPMUQJKWIJB-UHFFFAOYSA-N,Pyronaridine,,Treatment of Chagas Disease,C0041234,Chagas Disease,10/21/19,Designated,Not FDA Approved for Orphan Indication,,,,
LCTONWCANYUPML-UHFFFAOYSA-M,107735,LCTONWCANYUPML-UHFFFAOYSA-M,Pyruvate,,Treatment of interstitial lung disease.,C0206062,Interstitial lung disease,2/21/01,Designated,Not FDA Approved for Orphan Indication,,,,
NNYBQONXHNTVIJ-QGZVFWFLSA-N,667528,NNYBQONXHNTVIJ-QGZVFWFLSA-N,R-etodolac,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,12/9/02,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
NHTGHBARYWONDQ-UHFFFAOYSA-N,3125,NHTGHBARYWONDQ-UHFFFAOYSA-N,Racemetyrosine,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,7/31/20,Designated,Not FDA Approved for Orphan Indication,,,,
GZUITABIAKMVPG-UHFFFAOYSA-N,5035,GZUITABIAKMVPG-UHFFFAOYSA-N,raloxifene,Evista,Reduction of the risk of breast cancer in postmenopausal women,C0678222,Breast cancer,7/14/05,Designated/Approved,,Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer, 09/13/2007 , 09/13/2014 ,
PRFBWBYKWZVQJF-RRABGKBLSA-M,23668369,PRFBWBYKWZVQJF-RRABGKBLSA-M,recilisib sodium,,Treatment of acute radiation syndrome,C0520799,Acute Radiation Syndrome,9/4/12,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
CKRVBMUJCFKRND-UHFFFAOYSA-N,86287614,CKRVBMUJCFKRND-UHFFFAOYSA-N,Redaporfin,,Treatment of cholangiocarcinoma,C0206698,Cholangiocarcinoma,4/12/17,Designated,Not FDA Approved for Orphan Indication,,,,
FNHKPVJBJVTLMP-UHFFFAOYSA-N,11167602,FNHKPVJBJVTLMP-UHFFFAOYSA-N,Regorafenib,,Treatment of glioblastoma multiforme,C0017636,Glioblastoma multiforme,7/1/19,Designated,Not FDA Approved for Orphan Indication,,,,
RWWYLEGWBNMMLJ-YSOARWBDSA-N,121304016,RWWYLEGWBNMMLJ-YSOARWBDSA-N,remdesivir,,Treatment of coronavirus disease 2019 (COVID-19),C5203670,COVID-19,3/23/20,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
DSDNAKHZNJAGHN-WLJYXNHNSA-N,134688669,DSDNAKHZNJAGHN-WLJYXNHNSA-N,resiniferatoxin,,Treatment of intractable pain at end-stage disease,C0030200,intractable pain,5/13/03,Designated,Not FDA Approved for Orphan Indication,,,,
DSDNAKHZNJAGHN-GGIHZKEUSA-N,44564218,DSDNAKHZNJAGHN-GGIHZKEUSA-N,resiniferatoxin,,Treatment of intractable pain at end-stage disease,C0030200,intractable pain,5/13/03,Designated,Not FDA Approved for Orphan Indication,,,,
DSDNAKHZNJAGHN-YOHYOAFPSA-N,2733497,DSDNAKHZNJAGHN-YOHYOAFPSA-N,resiniferatoxin,,Treatment of intractable pain at end-stage disease,C0030200,intractable pain,5/13/03,Designated,Not FDA Approved for Orphan Indication,,,,
DSDNAKHZNJAGHN-UHFFFAOYSA-N,5148108,DSDNAKHZNJAGHN-UHFFFAOYSA-N,resiniferatoxin,,Treatment of intractable pain at end-stage disease,C0030200,intractable pain,5/13/03,Designated,Not FDA Approved for Orphan Indication,,,,
DSDNAKHZNJAGHN-VQBCBPMFSA-N,6324660,DSDNAKHZNJAGHN-VQBCBPMFSA-N,resiniferatoxin,,Treatment of intractable pain at end-stage disease,C0030200,intractable pain,5/13/03,Designated,Not FDA Approved for Orphan Indication,,,,
DSDNAKHZNJAGHN-IHCAYWNCSA-N,104826,DSDNAKHZNJAGHN-IHCAYWNCSA-N,resiniferatoxin,,Treatment of intractable pain at end-stage disease,C0030200,intractable pain,5/13/03,Designated,Not FDA Approved for Orphan Indication,,,,
DSDNAKHZNJAGHN-MXTYGGKSSA-N,5702546,DSDNAKHZNJAGHN-MXTYGGKSSA-N,resiniferatoxin,,Treatment of intractable pain at end-stage disease,C0030200,intractable pain,5/13/03,Designated,Not FDA Approved for Orphan Indication,,,,
OAKGNIRUXAZDQF-DFZJEWIASA-N,134694917,OAKGNIRUXAZDQF-DFZJEWIASA-N,retaspimycin,,Treatment for gastrointestinal stromal tumor,C0238198,gastrointestinal stromal tumor,8/31/07,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
OAKGNIRUXAZDQF-NTEXKKDHSA-N,131801266,OAKGNIRUXAZDQF-NTEXKKDHSA-N,retaspimycin,,Treatment for gastrointestinal stromal tumor,C0238198,gastrointestinal stromal tumor,8/31/07,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
OAKGNIRUXAZDQF-RYORMVDLSA-N,129894409,OAKGNIRUXAZDQF-RYORMVDLSA-N,retaspimycin,,Treatment for gastrointestinal stromal tumor,C0238198,gastrointestinal stromal tumor,8/31/07,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
OAKGNIRUXAZDQF-BGGMETADSA-N,131861370,OAKGNIRUXAZDQF-BGGMETADSA-N,retaspimycin,,Treatment for gastrointestinal stromal tumor,C0238198,gastrointestinal stromal tumor,8/31/07,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
OAKGNIRUXAZDQF-HTLBVUBBSA-N,66577020,OAKGNIRUXAZDQF-HTLBVUBBSA-N,retaspimycin,,Treatment for gastrointestinal stromal tumor,C0238198,gastrointestinal stromal tumor,8/31/07,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
OAKGNIRUXAZDQF-TXHRRWQRSA-N,11534420,OAKGNIRUXAZDQF-TXHRRWQRSA-N,retaspimycin,,Treatment for gastrointestinal stromal tumor,C0238198,gastrointestinal stromal tumor,8/31/07,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
NZCRJKRKKOLAOJ-WSTNJLQSSA-N,135391139,NZCRJKRKKOLAOJ-WSTNJLQSSA-N,Rifaximin,,treatment of sickle cell disease,C0002895,Sickle Cell Disease,10/28/20,Designated,Not FDA Approved for Orphan Indication,,,,
NZCRJKRKKOLAOJ-UPMLHBPDSA-N,134754219,NZCRJKRKKOLAOJ-UPMLHBPDSA-N,Rifaximin,,treatment of sickle cell disease,C0002895,Sickle Cell Disease,10/28/20,Designated,Not FDA Approved for Orphan Indication,,,,
NZCRJKRKKOLAOJ-VJYREXROSA-N,134754217,NZCRJKRKKOLAOJ-VJYREXROSA-N,Rifaximin,,treatment of sickle cell disease,C0002895,Sickle Cell Disease,10/28/20,Designated,Not FDA Approved for Orphan Indication,,,,
NZCRJKRKKOLAOJ-KPKMWDGOSA-N,101307877,NZCRJKRKKOLAOJ-KPKMWDGOSA-N,Rifaximin,,treatment of sickle cell disease,C0002895,Sickle Cell Disease,10/28/20,Designated,Not FDA Approved for Orphan Indication,,,,
NZCRJKRKKOLAOJ-IEOSPBRCSA-N,66577007,NZCRJKRKKOLAOJ-IEOSPBRCSA-N,Rifaximin,,treatment of sickle cell disease,C0002895,Sickle Cell Disease,10/28/20,Designated,Not FDA Approved for Orphan Indication,,,,
NZCRJKRKKOLAOJ-VXTOCXBKSA-N,42608884,NZCRJKRKKOLAOJ-VXTOCXBKSA-N,Rifaximin,,treatment of sickle cell disease,C0002895,Sickle Cell Disease,10/28/20,Designated,Not FDA Approved for Orphan Indication,,,,
NZCRJKRKKOLAOJ-XWSQLESMSA-N,44384716,NZCRJKRKKOLAOJ-XWSQLESMSA-N,Rifaximin,,treatment of sickle cell disease,C0002895,Sickle Cell Disease,10/28/20,Designated,Not FDA Approved for Orphan Indication,,,,
NZCRJKRKKOLAOJ-IIBMFGDOSA-N,72111,NZCRJKRKKOLAOJ-IIBMFGDOSA-N,Rifaximin,,treatment of sickle cell disease,C0002895,Sickle Cell Disease,10/28/20,Designated,Not FDA Approved for Orphan Indication,,,,
NZCRJKRKKOLAOJ-LXVXMSHWSA-N,71296876,NZCRJKRKKOLAOJ-LXVXMSHWSA-N,Rifaximin,,treatment of sickle cell disease,C0002895,Sickle Cell Disease,10/28/20,Designated,Not FDA Approved for Orphan Indication,,,,
NZCRJKRKKOLAOJ-KOPWYESNSA-N,72698618,NZCRJKRKKOLAOJ-KOPWYESNSA-N,Rifaximin,,treatment of sickle cell disease,C0002895,Sickle Cell Disease,10/28/20,Designated,Not FDA Approved for Orphan Indication,,,,
NZCRJKRKKOLAOJ-CPJOEXDVSA-N,57507834,NZCRJKRKKOLAOJ-CPJOEXDVSA-N,Rifaximin,,treatment of sickle cell disease,C0002895,Sickle Cell Disease,10/28/20,Designated,Not FDA Approved for Orphan Indication,,,,
NZCRJKRKKOLAOJ-UHFFFAOYSA-N,53395233,NZCRJKRKKOLAOJ-UHFFFAOYSA-N,Rifaximin,,treatment of sickle cell disease,C0002895,Sickle Cell Disease,10/28/20,Designated,Not FDA Approved for Orphan Indication,,,,
NZCRJKRKKOLAOJ-HQDKJBBOSA-N,16667733,NZCRJKRKKOLAOJ-HQDKJBBOSA-N,Rifaximin,,treatment of sickle cell disease,C0002895,Sickle Cell Disease,10/28/20,Designated,Not FDA Approved for Orphan Indication,,,,
NZCRJKRKKOLAOJ-LGPAXTBISA-N,46783403,NZCRJKRKKOLAOJ-LGPAXTBISA-N,Rifaximin,,treatment of sickle cell disease,C0002895,Sickle Cell Disease,10/28/20,Designated,Not FDA Approved for Orphan Indication,,,,
NZCRJKRKKOLAOJ-XRCRFVBUSA-N,6436173,NZCRJKRKKOLAOJ-XRCRFVBUSA-N,Rifaximin,,treatment of sickle cell disease,C0002895,Sickle Cell Disease,10/28/20,Designated,Not FDA Approved for Orphan Indication,,,,
LCFFREMLXLZNHE-GBOLQPHISA-N,73388818,LCFFREMLXLZNHE-GBOLQPHISA-N,rilzabrutinib,,Treatment of immune thrombocytopenic purpura (ITP),C0398650,Immune thrombocytopenic purpura,10/15/18,Designated,Not FDA Approved for Orphan Indication,,,,
ASKZRYGFUPSJPN-UHFFFAOYSA-N,118513932,ASKZRYGFUPSJPN-UHFFFAOYSA-N,risdiplam,EVRYSDI,Treatment of spinal muscular atrophy,C0026847,Spinal Muscular Atrophy,1/4/17,Designated/Approved,,treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older, 08/07/2020 , 08/07/2027 ,treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older.
OHRURASPPZQGQM-QPJBHPOGSA-N,154574495,OHRURASPPZQGQM-QPJBHPOGSA-N,romidepsin,Istodax,Treatment of non-Hodgkin T-cell lymphomas,C0079772,T-Cell Lymphomas,9/30/04,Designated/Approved,,Treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy, 06/16/2011 , 06/16/2018 ,
OHRURASPPZQGQM-WOADUJSRSA-N,129905275,OHRURASPPZQGQM-WOADUJSRSA-N,romidepsin,Istodax,Treatment of non-Hodgkin T-cell lymphomas,C0079772,T-Cell Lymphomas,9/30/04,Designated/Approved,,Treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy, 06/16/2011 , 06/16/2018 ,
OHRURASPPZQGQM-OYTWCIJESA-N,123135747,OHRURASPPZQGQM-OYTWCIJESA-N,romidepsin,Istodax,Treatment of non-Hodgkin T-cell lymphomas,C0079772,T-Cell Lymphomas,9/30/04,Designated/Approved,,Treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy, 06/16/2011 , 06/16/2018 ,
OHRURASPPZQGQM-MWQPNCDWSA-N,91110640,OHRURASPPZQGQM-MWQPNCDWSA-N,romidepsin,Istodax,Treatment of non-Hodgkin T-cell lymphomas,C0079772,T-Cell Lymphomas,9/30/04,Designated/Approved,,Treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy, 06/16/2011 , 06/16/2018 ,
OHRURASPPZQGQM-WDCUYUQDSA-N,56840936,OHRURASPPZQGQM-WDCUYUQDSA-N,romidepsin,Istodax,Treatment of non-Hodgkin T-cell lymphomas,C0079772,T-Cell Lymphomas,9/30/04,Designated/Approved,,Treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy, 06/16/2011 , 06/16/2018 ,
OHRURASPPZQGQM-UHFFFAOYSA-N,3425,OHRURASPPZQGQM-UHFFFAOYSA-N,romidepsin,Istodax,Treatment of non-Hodgkin T-cell lymphomas,C0079772,T-Cell Lymphomas,9/30/04,Designated/Approved,,Treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy, 06/16/2011 , 06/16/2018 ,
OHRURASPPZQGQM-QDBHDZETSA-N,57515973,OHRURASPPZQGQM-QDBHDZETSA-N,romidepsin,Istodax,Treatment of non-Hodgkin T-cell lymphomas,C0079772,T-Cell Lymphomas,9/30/04,Designated/Approved,,Treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy, 06/16/2011 , 06/16/2018 ,
OHRURASPPZQGQM-GCCNXGTGSA-N,5352062,OHRURASPPZQGQM-GCCNXGTGSA-N,romidepsin,Istodax,Treatment of non-Hodgkin T-cell lymphomas,C0079772,T-Cell Lymphomas,9/30/04,Designated/Approved,,Treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy, 06/16/2011 , 06/16/2018 ,
YUQCJZVVMQZBFE-JPUFUMQZSA-N,145982170,YUQCJZVVMQZBFE-JPUFUMQZSA-N,roneparstat,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,3/19/15,Designated,Not FDA Approved for Orphan Indication,,,,
BPRHUIZQVSMCRT-VEUZHWNKSA-N,446157,BPRHUIZQVSMCRT-VEUZHWNKSA-N,rosuvastatin,Crestor,For the treatment of pediatric homozygous familial hypercholesterolemia,C0020445,FAMILIAL HYPERCHOLESTEROLEMIA,2/14/14,Designated/Approved,,"An adjunct to diet to reduce LDL-C, Total-C, nonHDL-C and ApoB in children and adolescents 7 to 17 years of age with homozygous familial hypercholesterolemia, either alone or with other lipid-lowering treatments (e.g., LDL apheresis).", 05/27/2016 , 05/27/2023 ,"An adjunct to diet to reduce LDL-C, Total-C, nonHDL-C and ApoB in children and adolescents 7 to 17 years of age with homozygous familial hypercholesterolemia, either alone or with other lipid-lowering treatments (e.g., LDL apheresis)."
NQUUPTGRJYIXSL-YPDXTJLXSA-N,131954443,NQUUPTGRJYIXSL-YPDXTJLXSA-N,rovalpituzumab tesirine,,Treatment of small cell lung cancer,C3540630,Small Cell Lung Cancer,12/22/15,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
VHXNKPBCCMUMSW-FQEVSTJZSA-N,472335,VHXNKPBCCMUMSW-FQEVSTJZSA-N,rubitecan,,Treatment of pediatric patients infected with human immunodeficiency virus and acquired immunodeficiency syndrome,"C0019682,C0021051","Human Immunodeficiency Virus , Immunodeficiency Syndrome",7/17/02,Designated,Not FDA Approved for Orphan Indication,,,,
JFMWPOCYMYGEDM-XFULWGLBSA-N,25127112,JFMWPOCYMYGEDM-XFULWGLBSA-N,ruxolitinib phosphate,Jakafi,Treatment of myelofibrosis,C0026987,myelofibrosis,9/5/08,Designated/Approved,,"Treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis", 11/16/2011 , 11/16/2018 ,
DEVSOMFAQLZNKR-RJRFIUFISA-N,71481097,DEVSOMFAQLZNKR-RJRFIUFISA-N,selinexor,Xpovio,Treatment of multiple myeloma,C0026764,Multiple Myeloma,1/5/15,Designated/Approved,,in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy, 12/18/2020 ,  ,
CYOHGALHFOKKQC-UHFFFAOYSA-N,10127622,CYOHGALHFOKKQC-UHFFFAOYSA-N,selumetinib,,Adjuvant treatment of patients with stage III or stage IV differentiated thyroid cancer.,C1337013,Differentiated Thyroid Cancer,5/10/16,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
BVLCEKWPOSAKSZ-YQMCHIOTSA-N,16132412,BVLCEKWPOSAKSZ-YQMCHIOTSA-N,Sermorelin acetate,,Treatment of AIDS-associated catabolism/weight loss.,"C0001175,C4084774","AIDS , Weight loss",12/5/91,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
HDHDTKMUACZDAA-PHNIDTBTSA-N,11993702,HDHDTKMUACZDAA-PHNIDTBTSA-N,setmelanotide,Imcivree,Treatment of pro-opiomelanocortin (POMC) deficiency due to mutations in the POMC gene,C1337111,POMC,4/4/16,Designated/Approved,,"chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).", 11/25/2020 , 11/25/2027 ,"chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS)."
HDHDTKMUACZDAA-PHNIDTBTSA-N,11993702,HDHDTKMUACZDAA-PHNIDTBTSA-N,setmelanotide,,Treatment of Prader-Willi Syndrome.,C0032897,Prader-Willi Syndrome,9/21/15,Designated,Not FDA Approved for Orphan Indication,,,,
KIHYPELVXPAIDH-HNSNBQBZSA-N,44599207,KIHYPELVXPAIDH-HNSNBQBZSA-N,Siponimod,,Treatment of polymyositis,C0085655,Polymyositis,11/26/13,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
VPZRWNZGLKXFOE-UHFFFAOYSA-M,5258,VPZRWNZGLKXFOE-UHFFFAOYSA-M,sodium phenylbutyrate,,Treatment of maple syrup urine disease,C0024776,Maple Syrup Urine Disease,8/19/14,Designated,Not FDA Approved for Orphan Indication,,,,
VPZRWNZGLKXFOE-UHFFFAOYSA-M,5258,VPZRWNZGLKXFOE-UHFFFAOYSA-M,sodium phenylbutyrate,,Treatment of urea cycle disorders,C0154246,Urea Cycle Disorders,6/6/13,Designated,Not FDA Approved for Orphan Indication,,,,
AKHNMLFCWUSKQB-UHFFFAOYSA-L,24477,AKHNMLFCWUSKQB-UHFFFAOYSA-L,sodium thiosulfate,,Treatment of uremic and non-uremic calciphylaxis,C0006666,Calciphylaxis,11/9/11,Designated,Not FDA Approved for Orphan Indication,,,,
AKHNMLFCWUSKQB-UHFFFAOYSA-L,24477,AKHNMLFCWUSKQB-UHFFFAOYSA-L,sodium thiosulfate,,Prevention of platinum-induced ototoxicity in pediatric patients,C0235280,Ototoxicity,10/13/11,Designated,Not FDA Approved for Orphan Indication,,,,
MLDQJTXFUGDVEO-UHFFFAOYSA-N,216239,MLDQJTXFUGDVEO-UHFFFAOYSA-N,sorafenib,Nexavar,"Treatment of medullary thyroid cancer, anaplastic thyroid cancer, and recurrent or metastatic follicular or papillary thyroid cancer","C0238461,C0238462,C0238463","Cancer, Anaplastic Thyroid , medullary thyroid cancer , papillary thyroid cancer",12/12/11,Designated/Approved,,"Treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DCT) that is refractory to radioactive iodine treatment.", 11/22/2013 , 11/22/2020 ,"Treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DCT) that is refractory to radioactive iodine treatment."
MLDQJTXFUGDVEO-UHFFFAOYSA-N,216239,MLDQJTXFUGDVEO-UHFFFAOYSA-N,sorafenib,,Treatment of desmoid tumors/aggressive fibromatosis,C0079218,desmoid tumors,2/28/19,Designated,Not FDA Approved for Orphan Indication,,,,
MLDQJTXFUGDVEO-UHFFFAOYSA-N,216239,MLDQJTXFUGDVEO-UHFFFAOYSA-N,Sorafenib,,Treatment of stage IIB through stage IV melanoma,C0278883,stage iv melanoma,9/29/06,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
NXQKSXLFSAEQCZ-SFHVURJKSA-N,137278711,NXQKSXLFSAEQCZ-SFHVURJKSA-N,sotorasib,,Treatment of KRAS p.G12C-positive non-small cell lung cancer,C3539721,Non-Small Cell Lung Cancer,5/1/19,Designated,Not FDA Approved for Orphan Indication,,,,
ACTOXUHEUCPTEW-IWJSIHOMSA-N,153274329,ACTOXUHEUCPTEW-IWJSIHOMSA-N,Spiramycin,,For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.,"C0021051,C0030498,C0239055","Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS",10/17/84,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ACTOXUHEUCPTEW-QTKFNTAMSA-N,135391165,ACTOXUHEUCPTEW-QTKFNTAMSA-N,Spiramycin,,For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.,"C0021051,C0030498,C0239055","Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS",10/17/84,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ACTOXUHEUCPTEW-NHYPZVJXSA-N,134717663,ACTOXUHEUCPTEW-NHYPZVJXSA-N,Spiramycin,,For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.,"C0021051,C0030498,C0239055","Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS",10/17/84,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ACTOXUHEUCPTEW-LFIIGWMYSA-N,134715567,ACTOXUHEUCPTEW-LFIIGWMYSA-N,Spiramycin,,For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.,"C0021051,C0030498,C0239055","Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS",10/17/84,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ACTOXUHEUCPTEW-FCCRBRQASA-N,134687906,ACTOXUHEUCPTEW-FCCRBRQASA-N,Spiramycin,,For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.,"C0021051,C0030498,C0239055","Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS",10/17/84,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ACTOXUHEUCPTEW-VRCNPYAISA-N,131674879,ACTOXUHEUCPTEW-VRCNPYAISA-N,Spiramycin,,For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.,"C0021051,C0030498,C0239055","Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS",10/17/84,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ACTOXUHEUCPTEW-SENNIVHBSA-N,129627802,ACTOXUHEUCPTEW-SENNIVHBSA-N,Spiramycin,,For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.,"C0021051,C0030498,C0239055","Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS",10/17/84,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ACTOXUHEUCPTEW-IMDCDJEBSA-N,76324338,ACTOXUHEUCPTEW-IMDCDJEBSA-N,Spiramycin,,For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.,"C0021051,C0030498,C0239055","Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS",10/17/84,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ACTOXUHEUCPTEW-HRAVRIHDSA-N,44629935,ACTOXUHEUCPTEW-HRAVRIHDSA-N,Spiramycin,,For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.,"C0021051,C0030498,C0239055","Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS",10/17/84,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ACTOXUHEUCPTEW-GRWVDKKHSA-N,5353959,ACTOXUHEUCPTEW-GRWVDKKHSA-N,Spiramycin,,For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.,"C0021051,C0030498,C0239055","Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS",10/17/84,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ACTOXUHEUCPTEW-OSLILNPBSA-N,137704528,ACTOXUHEUCPTEW-OSLILNPBSA-N,Spiramycin,,For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.,"C0021051,C0030498,C0239055","Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS",10/17/84,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ACTOXUHEUCPTEW-JNQYENBPSA-N,71729958,ACTOXUHEUCPTEW-JNQYENBPSA-N,Spiramycin,,For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.,"C0021051,C0030498,C0239055","Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS",10/17/84,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ACTOXUHEUCPTEW-OBURPCBNSA-N,5356392,ACTOXUHEUCPTEW-OBURPCBNSA-N,Spiramycin,,For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.,"C0021051,C0030498,C0239055","Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS",10/17/84,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ACTOXUHEUCPTEW-BWHGAVFKSA-N,5284619,ACTOXUHEUCPTEW-BWHGAVFKSA-N,Spiramycin,,For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.,"C0021051,C0030498,C0239055","Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS",10/17/84,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ACTOXUHEUCPTEW-UHFFFAOYSA-N,5266,ACTOXUHEUCPTEW-UHFFFAOYSA-N,Spiramycin,,For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.,"C0021051,C0030498,C0239055","Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS",10/17/84,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ACTOXUHEUCPTEW-BOISPSKTSA-N,5702243,ACTOXUHEUCPTEW-BOISPSKTSA-N,Spiramycin,,For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.,"C0021051,C0030498,C0239055","Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS",10/17/84,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ACTOXUHEUCPTEW-CEUOBAOPSA-N,5289394,ACTOXUHEUCPTEW-CEUOBAOPSA-N,Spiramycin,,For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.,"C0021051,C0030498,C0239055","Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS",10/17/84,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ACTOXUHEUCPTEW-KWBWCIJSSA-N,6440717,ACTOXUHEUCPTEW-KWBWCIJSSA-N,Spiramycin,,For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.,"C0021051,C0030498,C0239055","Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS",10/17/84,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ACTOXUHEUCPTEW-JMRHEKERSA-N,6419898,ACTOXUHEUCPTEW-JMRHEKERSA-N,Spiramycin,,For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.,"C0021051,C0030498,C0239055","Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS",10/17/84,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
FIAFUQMPZJWCLV-UHFFFAOYSA-N,5361,FIAFUQMPZJWCLV-UHFFFAOYSA-N,suramin,,Treatment of human African trypanosomiasis,C0041228,African Trypanosomiasis,1/25/21,Designated,Not FDA Approved for Orphan Indication,,,,
GLXYOFXNKBTMQL-YKCHQESGSA-N,134687212,GLXYOFXNKBTMQL-YKCHQESGSA-N,Synthetic PreImplantation Factor,,Treatment of Acute Radiation Syndrome,C0520799,Acute Radiation Syndrome,12/19/18,Designated,Not FDA Approved for Orphan Indication,,,,
QJJXYPPXXYFBGM-LFZNUXCKSA-N,445643,QJJXYPPXXYFBGM-LFZNUXCKSA-N,tacrolimus,Envarsus XR,Prophylaxis of organ rejection in patients receiving allogeneic kidney transplant,C0815080,organ rejection,12/20/13,Designated/Approved,,ENVARSUS XR is indicated for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants., 12/19/2018 ,  ,
FKCMADOPPWWGNZ-YUMQZZPRSA-N,6918572,FKCMADOPPWWGNZ-YUMQZZPRSA-N,Talabostat,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,3/16/17,Designated,Not FDA Approved for Orphan Indication,,,,
FKCMADOPPWWGNZ-YUMQZZPRSA-N,6918572,FKCMADOPPWWGNZ-YUMQZZPRSA-N,Talabostat,,Treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,1/26/21,Designated,Not FDA Approved for Orphan Indication,,,,
FKCMADOPPWWGNZ-YUMQZZPRSA-N,6918572,FKCMADOPPWWGNZ-YUMQZZPRSA-N,Talabostat,,Treatment of acute myelogenous leukemia,C0023467,Acute myelogenous leukemia,8/21/19,Designated,Not FDA Approved for Orphan Indication,,,,
QFCXANHHBCGMAS-UHFFFAOYSA-N,9808844,QFCXANHHBCGMAS-UHFFFAOYSA-N,telatinib,,Treatment of gastric cancer,C0024623,Gastric Cancer,5/17/10,Designated,Not FDA Approved for Orphan Indication,,,,
NRUKOCRGYNPUPR-CTWARWOPSA-N,137701349,NRUKOCRGYNPUPR-CTWARWOPSA-N,Teniposide,Vumon for injection,Treatment of refractory childhood acute lymphocytic leukemia.,C0023452,Childhood Acute Lymphocytic Leukemia,11/1/84,Designated/Approved,,Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents., 07/14/1992 , 07/14/1999 ,
NRUKOCRGYNPUPR-DYPKOKSYSA-N,134694361,NRUKOCRGYNPUPR-DYPKOKSYSA-N,Teniposide,Vumon for injection,Treatment of refractory childhood acute lymphocytic leukemia.,C0023452,Childhood Acute Lymphocytic Leukemia,11/1/84,Designated/Approved,,Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents., 07/14/1992 , 07/14/1999 ,
NRUKOCRGYNPUPR-VEUOYOFCSA-N,122172961,NRUKOCRGYNPUPR-VEUOYOFCSA-N,Teniposide,Vumon for injection,Treatment of refractory childhood acute lymphocytic leukemia.,C0023452,Childhood Acute Lymphocytic Leukemia,11/1/84,Designated/Approved,,Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents., 07/14/1992 , 07/14/1999 ,
NRUKOCRGYNPUPR-OMLXZSNTSA-N,90659141,NRUKOCRGYNPUPR-OMLXZSNTSA-N,Teniposide,Vumon for injection,Treatment of refractory childhood acute lymphocytic leukemia.,C0023452,Childhood Acute Lymphocytic Leukemia,11/1/84,Designated/Approved,,Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents., 07/14/1992 , 07/14/1999 ,
NRUKOCRGYNPUPR-ANTWWVKXSA-N,54610154,NRUKOCRGYNPUPR-ANTWWVKXSA-N,Teniposide,Vumon for injection,Treatment of refractory childhood acute lymphocytic leukemia.,C0023452,Childhood Acute Lymphocytic Leukemia,11/1/84,Designated/Approved,,Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents., 07/14/1992 , 07/14/1999 ,
NRUKOCRGYNPUPR-DKQCQWADSA-N,129009948,NRUKOCRGYNPUPR-DKQCQWADSA-N,Teniposide,Vumon for injection,Treatment of refractory childhood acute lymphocytic leukemia.,C0023452,Childhood Acute Lymphocytic Leukemia,11/1/84,Designated/Approved,,Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents., 07/14/1992 , 07/14/1999 ,
NRUKOCRGYNPUPR-ZVYBSHBNSA-N,23724511,NRUKOCRGYNPUPR-ZVYBSHBNSA-N,Teniposide,Vumon for injection,Treatment of refractory childhood acute lymphocytic leukemia.,C0023452,Childhood Acute Lymphocytic Leukemia,11/1/84,Designated/Approved,,Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents., 07/14/1992 , 07/14/1999 ,
NRUKOCRGYNPUPR-OQMCATNJSA-N,6708778,NRUKOCRGYNPUPR-OQMCATNJSA-N,Teniposide,Vumon for injection,Treatment of refractory childhood acute lymphocytic leukemia.,C0023452,Childhood Acute Lymphocytic Leukemia,11/1/84,Designated/Approved,,Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents., 07/14/1992 , 07/14/1999 ,
NRUKOCRGYNPUPR-NFIYYIGVSA-N,5284623,NRUKOCRGYNPUPR-NFIYYIGVSA-N,Teniposide,Vumon for injection,Treatment of refractory childhood acute lymphocytic leukemia.,C0023452,Childhood Acute Lymphocytic Leukemia,11/1/84,Designated/Approved,,Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents., 07/14/1992 , 07/14/1999 ,
NRUKOCRGYNPUPR-CRZAWEBOSA-N,275784,NRUKOCRGYNPUPR-CRZAWEBOSA-N,Teniposide,Vumon for injection,Treatment of refractory childhood acute lymphocytic leukemia.,C0023452,Childhood Acute Lymphocytic Leukemia,11/1/84,Designated/Approved,,Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents., 07/14/1992 , 07/14/1999 ,
NRUKOCRGYNPUPR-PSZSYXFXSA-N,34698,NRUKOCRGYNPUPR-PSZSYXFXSA-N,Teniposide,Vumon for injection,Treatment of refractory childhood acute lymphocytic leukemia.,C0023452,Childhood Acute Lymphocytic Leukemia,11/1/84,Designated/Approved,,Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents., 07/14/1992 , 07/14/1999 ,
NRUKOCRGYNPUPR-UHFFFAOYSA-N,5396,NRUKOCRGYNPUPR-UHFFFAOYSA-N,Teniposide,Vumon for injection,Treatment of refractory childhood acute lymphocytic leukemia.,C0023452,Childhood Acute Lymphocytic Leukemia,11/1/84,Designated/Approved,,Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents., 07/14/1992 , 07/14/1999 ,
NRUKOCRGYNPUPR-QBPJDGROSA-N,452548,NRUKOCRGYNPUPR-QBPJDGROSA-N,Teniposide,Vumon for injection,Treatment of refractory childhood acute lymphocytic leukemia.,C0023452,Childhood Acute Lymphocytic Leukemia,11/1/84,Designated/Approved,,Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents., 07/14/1992 , 07/14/1999 ,
HVXKQKFEHMGHSL-GOOCMWNKSA-N,10458325,HVXKQKFEHMGHSL-GOOCMWNKSA-N,tesevatinib,,Treatment of non-small cell lung cancer with epithelial growth factor receptor-activating mutations,C3539721,Non-Small Cell Lung Cancer,8/3/17,Designated,Not FDA Approved for Orphan Indication,,,,
UEJJHQNACJXSKW-UHFFFAOYSA-N,5426,UEJJHQNACJXSKW-UHFFFAOYSA-N,Thalidomide,,"Treatment and prevention of recurrent aphthous ulcers in severely, terminally immunocompromised patients.",C2937365,Recurrent aphthous ulcers,5/15/95,Designated,Not FDA Approved for Orphan Indication,,,,
UEJJHQNACJXSKW-UHFFFAOYSA-N,5426,UEJJHQNACJXSKW-UHFFFAOYSA-N,thalidomide,,Treatment of myelodysplastic syndrome,C3463824,MYELODYSPLASTIC SYNDROME,9/27/04,Designated,Not FDA Approved for Orphan Indication,,,,
PRDJGNVQBVXXEO-UHFFFAOYSA-N,437740,PRDJGNVQBVXXEO-UHFFFAOYSA-N,thioureidobutyronitrile,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,1/20/16,Designated,Not FDA Approved for Orphan Indication,,,,
NZVYCXVTEHPMHE-ZSUJOUNUSA-N,16130571,NZVYCXVTEHPMHE-ZSUJOUNUSA-N,Thymalfasin,,Treatment of DiGeorge anomaly with immune defects.,C0012236,DiGeorge Anomaly,1/8/98,Designated,Not FDA Approved for Orphan Indication,,,,
XNSAINXGIQZQOO-UHFFFAOYSA-N,32281,XNSAINXGIQZQOO-UHFFFAOYSA-N,Thyrotropin alfa,Thyrogen,"Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid",C0007097,Carcinomas,8/3/01,Designated/Approved,,For use as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of metastatic thyroid cancer, 12/14/2007 , 12/14/2014 ,
MIQPIUSUKVNLNT-UHFFFAOYSA-N,4659569,MIQPIUSUKVNLNT-UHFFFAOYSA-N,Tolcapone,,Treatment of transthyretin amyloidosis,C2751492,Transthyretin Amyloidosis,12/24/13,Designated,Not FDA Approved for Orphan Indication,,,,
PPKXEPBICJTCRU-XMZRARIVSA-N,63013,PPKXEPBICJTCRU-XMZRARIVSA-N,Tramadol hydrochloride,,Treatment of painful HIV-associated neuropathy,"C0019682,C0442874","HIV , Neuropathy",1/28/05,Designated,Not FDA Approved for Orphan Indication,,,,
NZHGWWWHIYHZNX-CSKARUKUSA-N,5282230,NZHGWWWHIYHZNX-CSKARUKUSA-N,Tranilast,,For the treatment of maligant glioma,C0017638,Glioma,12/2/03,Designated,Not FDA Approved for Orphan Indication,,,,
HDTRYLNUVZCQOY-LIZSDCNHSA-N,7427,HDTRYLNUVZCQOY-LIZSDCNHSA-N,trehalose,,Treatment of spinal cerebellar ataxia type 3 (also known as SCA3 or Machado Joseph disease),"C0007758,C0024408","Cerebellar Ataxia , SCA3",11/17/14,Designated,Not FDA Approved for Orphan Indication,,,,
HDTRYLNUVZCQOY-LIZSDCNHSA-N,7427,HDTRYLNUVZCQOY-LIZSDCNHSA-N,Trehalose,,Treatment of CLN Batten disease,C0751383,Batten Disease,10/21/20,Designated,Not FDA Approved for Orphan Indication,,,,
PAJMKGZZBBTTOY-ZFORQUDYSA-N,6918140,PAJMKGZZBBTTOY-ZFORQUDYSA-N,treprostinil,,Treatment of Systemic sclerosis,C0036421,Systemic sclerosis,6/8/20,Designated,Not FDA Approved for Orphan Indication,,,,
SHGAZHPCJJPHSC-YCNIQYBTSA-N,444795,SHGAZHPCJJPHSC-YCNIQYBTSA-N,Tretinoin,Vesanoid,Treatment of acute promyelocytic leukemia.,C0023487,Acute Promyelocytic Leukemia,10/24/90,Designated/Approved,,Induction of remission in patients with acute promyelocytic leukemia who are refractory to or unable to tolerate anthracycline based cytotoxic chemotherapeutic regimens., 11/22/1995 , 11/22/2002 ,
HOGVTUZUJGHKPL-HTVVRFAVSA-N,65399,HOGVTUZUJGHKPL-HTVVRFAVSA-N,triciribine,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,2/1/08,Designated,Not FDA Approved for Orphan Indication,,,,
XPVOJYDIBHYVFL-UHFFFAOYSA-N,5458180,XPVOJYDIBHYVFL-UHFFFAOYSA-N,Trientine HCl,Syprine,"Treatment of patients with Wilson's disease who are intolerant, or inadequately responsive to penicillamine.",C0019202,Wilson's Disease,12/24/84,Designated/Approved,,, 11/08/1985 , 11/08/1992 ,
PVHLMTREZMEJCG-GDTLVBQBSA-N,123805,PVHLMTREZMEJCG-GDTLVBQBSA-N,TXA127,,Treament of acute radiation syndrome,C0520799,Acute Radiation Syndrome,10/25/13,Designated,Not FDA Approved for Orphan Indication,,,,
ACTIUHUUMQJHFO-UPTCCGCDSA-N,5281915,ACTIUHUUMQJHFO-UPTCCGCDSA-N,ubidecarenone,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,11/8/17,Designated,Not FDA Approved for Orphan Indication,,,,
ACTIUHUUMQJHFO-UPTCCGCDSA-N,5281915,ACTIUHUUMQJHFO-UPTCCGCDSA-N,ubidecarenone,,Treatment of Epidermolysis Bullosa,C0014527,Epidermolysis Bullosa,4/16/18,Designated,Not FDA Approved for Orphan Indication,,,,
PGAVKCOVUIYSFO-XVFCMESISA-N,6133,PGAVKCOVUIYSFO-XVFCMESISA-N,Uridine 5'-triphosphate,,To facilitate the removal of lung secretions in the treatment of patients with primary ciliary dyskinesia.,C4551720,Primary Ciliary Dyskinesia,6/26/96,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
FJLUJBDSFBGOPL-YOKUEUOXSA-N,44566638,FJLUJBDSFBGOPL-YOKUEUOXSA-N,uttroside B,,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,1/19/21,Designated,Not FDA Approved for Orphan Indication,,,,
MYPYJXKWCTUITO-LYRMYLQWSA-N,14969,MYPYJXKWCTUITO-LYRMYLQWSA-N,vancomycin,,Treatment of endophthalmitis,C0014236,Endophthalmitis,12/27/12,Designated,Not FDA Approved for Orphan Indication,,,,
SWXOGPJRIDTIRL-CISAEKETSA-N,133566183,SWXOGPJRIDTIRL-CISAEKETSA-N,Vapreotide,,Treatment of symptomatic carcinoid tumors,C0007095,Carcinoid Tumors,4/6/04,Designated,Not FDA Approved for Orphan Indication,,,,
SWXOGPJRIDTIRL-HFQRKYADSA-N,5311370,SWXOGPJRIDTIRL-HFQRKYADSA-N,Vapreotide,,Treatment of symptomatic carcinoid tumors,C0007095,Carcinoid Tumors,4/6/04,Designated,Not FDA Approved for Orphan Indication,,,,
SWXOGPJRIDTIRL-KTJGOPLGSA-N,70689318,SWXOGPJRIDTIRL-KTJGOPLGSA-N,Vapreotide,,Treatment of symptomatic carcinoid tumors,C0007095,Carcinoid Tumors,4/6/04,Designated,Not FDA Approved for Orphan Indication,,,,
SWXOGPJRIDTIRL-DLRASJFKSA-N,45588099,SWXOGPJRIDTIRL-DLRASJFKSA-N,Vapreotide,,Treatment of symptomatic carcinoid tumors,C0007095,Carcinoid Tumors,4/6/04,Designated,Not FDA Approved for Orphan Indication,,,,
SWXOGPJRIDTIRL-UHFFFAOYSA-N,71306,SWXOGPJRIDTIRL-UHFFFAOYSA-N,Vapreotide,,Treatment of symptomatic carcinoid tumors,C0007095,Carcinoid Tumors,4/6/04,Designated,Not FDA Approved for Orphan Indication,,,,
SWXOGPJRIDTIRL-DOUNNPEJSA-N,6918026,SWXOGPJRIDTIRL-DOUNNPEJSA-N,Vapreotide,,Treatment of symptomatic carcinoid tumors,C0007095,Carcinoid Tumors,4/6/04,Designated,Not FDA Approved for Orphan Indication,,,,
UWXSAYUXVSFDBQ-CYBMUJFWSA-N,42642648,UWXSAYUXVSFDBQ-CYBMUJFWSA-N,varlitinib,,Treatment of gastric cancer.,C0024623,Gastric Cancer,6/20/16,Designated,Not FDA Approved for Orphan Indication,,,,
LNOVHERIIMJMDG-XZXLULOTSA-N,46184405,LNOVHERIIMJMDG-XZXLULOTSA-N,vatiquinone,,Treatment of Leigh Syndrome,C0023264,Leigh Syndrome,6/4/14,Designated,Not FDA Approved for Orphan Indication,,,,
GPXBXXGIAQBQNI-UHFFFAOYSA-N,42611257,GPXBXXGIAQBQNI-UHFFFAOYSA-N,vemurafenib,Zelboraf,Treatment of patients with IIb to Stage IV melanoma positive for the BRAF(v600) mutation,C0025202,melanoma,12/20/10,Designated/Approved,,Treatment of unresectable or metastatic melanoma with the BRAFV600E mutation as detected by an FDA-approved test., 08/17/2011 , 08/17/2018 ,
LQBVNQSMGBZMKD-UHFFFAOYSA-N,49846579,LQBVNQSMGBZMKD-UHFFFAOYSA-N,venetoclax,VENCLEXTA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,9/20/12,Designated/Approved,,VENCLEXTA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)., 05/15/2019 , 05/15/2026 ,Treatment of previously untreated adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
LQBVNQSMGBZMKD-UHFFFAOYSA-N,49846579,LQBVNQSMGBZMKD-UHFFFAOYSA-N,venetoclax,,Treatment of mantle cell lymphoma,C4721414,Mantle cell lymphoma,8/31/17,Designated,Not FDA Approved for Orphan Indication,,,,
LQBVNQSMGBZMKD-UHFFFAOYSA-N,49846579,LQBVNQSMGBZMKD-UHFFFAOYSA-N,venetoclax,VENCLEXTA,Treatment of acute myeloid leukemia.,C0023467,Acute myeloid leukemia,2/4/16,Designated/Approved,,"VENCLEXTA is indicated in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.", 11/21/2018 , 11/21/2025 ,"VENCLEXTA is indicated in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy."
YFHRCLAKZBDRHN-MRXNPFEDSA-N,60199242,YFHRCLAKZBDRHN-MRXNPFEDSA-N,venglustat,,Treatment of Autosomal Dominant Polycystic Kidney Disease,C0085413,Autosomal dominant polycystic kidney disease,5/1/18,Designated,Not FDA Approved for Orphan Indication,,,,
SQXUKOJKIWCALK-PKLMIRHRSA-N,78425810,SQXUKOJKIWCALK-PKLMIRHRSA-N,venglustat malate,,Treatment of GM2 gangliosidosis,C0268274,GM2 Gangliosidosis,8/13/20,Designated,Not FDA Approved for Orphan Indication,,,,
FWCVZAQENIZVMY-UHFFFAOYSA-N,71602803,FWCVZAQENIZVMY-UHFFFAOYSA-N,Voxelotor,OXBRYTA,Treatment of sickle cell disease (SCD).,"C0002895,C0085298","Sickle Cell Disease , SCD",12/29/15,Designated/Approved,,OXBRYTA is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older., 11/25/2019 , 11/25/2026 ,Indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older.
WREGKURFCTUGRC-POYBYMJQSA-N,24066,WREGKURFCTUGRC-POYBYMJQSA-N,Zalcitabine,,Treatment of AIDS.,C0001175,AIDS,12/9/86,Designated,Not FDA Approved for Orphan Indication,,,,
HBOMLICNUCNMMY-XLPZGREQSA-N,35370,HBOMLICNUCNMMY-XLPZGREQSA-N,zidovudine,Retrovir,Treatment of AIDS,C0001175,AIDS,7/17/85,Designated/Approved,,Management of certain adult patients with symptomatic HIV infection (AIDS and advanced ARC) who have a history of cytologically confirmed Pneumocytis carinii pneumonia (PCP) or an absolute CD4 (T4 helper/induccer) lymphocyte count of less than 200/mm in the peripheral blood before therapy is begun, 03/19/1987 , 03/19/1994 ,
REQQVBGILUTQNN-UHFFFAOYSA-N,90420193,REQQVBGILUTQNN-UHFFFAOYSA-N,Ziritaxestat,,Treatment of systemic sclerosis,C0036421,Systemic sclerosis,1/27/20,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
QGNJRVVDBSJHIZ-AQDFTDIISA-N,10245972,QGNJRVVDBSJHIZ-AQDFTDIISA-N,zuretinol acetate,,Treatment of retinitis pigmentosa,C0035334,Retinitis Pigmentosa,12/2/10,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
MYSWGUAQZAJSOK-UHFFFAOYSA-N,2764,MYSWGUAQZAJSOK-UHFFFAOYSA-N,ciprofloxacin,,The management of bronchiectasis,C0006267,Bronchiectasis,6/1/11,Designated,Not FDA Approved for Orphan Indication,,,,
LXZZYRPGZAFOLE-UHFFFAOYSA-L,5702198,LXZZYRPGZAFOLE-UHFFFAOYSA-L,Cisplatin,,Treatment of anal cancer,C0279637,Anal Cancer,9/6/16,Designated,Not FDA Approved for Orphan Indication,,,,
KDLRVYVGXIQJDK-BVGIQVCNSA-N,129627692,KDLRVYVGXIQJDK-BVGIQVCNSA-N,Clindamycin,,Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.,"C0276527,C1535939","Pneumonia associated with AIDS , Pneumocystis carinii Pneumonia",10/28/88,Designated,Not FDA Approved for Orphan Indication,,,,
KDLRVYVGXIQJDK-NQQGAZBYSA-N,129009913,KDLRVYVGXIQJDK-NQQGAZBYSA-N,Clindamycin,,Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.,"C0276527,C1535939","Pneumonia associated with AIDS , Pneumocystis carinii Pneumonia",10/28/88,Designated,Not FDA Approved for Orphan Indication,,,,
KDLRVYVGXIQJDK-PSUNAQLJSA-N,53245639,KDLRVYVGXIQJDK-PSUNAQLJSA-N,Clindamycin,,Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.,"C0276527,C1535939","Pneumonia associated with AIDS , Pneumocystis carinii Pneumonia",10/28/88,Designated,Not FDA Approved for Orphan Indication,,,,
KDLRVYVGXIQJDK-NKPHASNASA-N,46783762,KDLRVYVGXIQJDK-NKPHASNASA-N,Clindamycin,,Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.,"C0276527,C1535939","Pneumonia associated with AIDS , Pneumocystis carinii Pneumonia",10/28/88,Designated,Not FDA Approved for Orphan Indication,,,,
KDLRVYVGXIQJDK-ZNZDIMKLSA-N,27281318,KDLRVYVGXIQJDK-ZNZDIMKLSA-N,Clindamycin,,Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.,"C0276527,C1535939","Pneumonia associated with AIDS , Pneumocystis carinii Pneumonia",10/28/88,Designated,Not FDA Approved for Orphan Indication,,,,
KDLRVYVGXIQJDK-ZUWRKQLMSA-N,45357041,KDLRVYVGXIQJDK-ZUWRKQLMSA-N,Clindamycin,,Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.,"C0276527,C1535939","Pneumonia associated with AIDS , Pneumocystis carinii Pneumonia",10/28/88,Designated,Not FDA Approved for Orphan Indication,,,,
KDLRVYVGXIQJDK-UHFFFAOYSA-N,2786,KDLRVYVGXIQJDK-UHFFFAOYSA-N,Clindamycin,,Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.,"C0276527,C1535939","Pneumonia associated with AIDS , Pneumocystis carinii Pneumonia",10/28/88,Designated,Not FDA Approved for Orphan Indication,,,,
KDLRVYVGXIQJDK-NOWPCOIGSA-N,29029,KDLRVYVGXIQJDK-NOWPCOIGSA-N,Clindamycin,,Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.,"C0276527,C1535939","Pneumonia associated with AIDS , Pneumocystis carinii Pneumonia",10/28/88,Designated,Not FDA Approved for Orphan Indication,,,,
KDLRVYVGXIQJDK-AWPVFWJPSA-N,446598,KDLRVYVGXIQJDK-AWPVFWJPSA-N,Clindamycin,,Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.,"C0276527,C1535939","Pneumonia associated with AIDS , Pneumocystis carinii Pneumonia",10/28/88,Designated,Not FDA Approved for Orphan Indication,,,,
WDDPHFBMKLOVOX-AYQXTPAHSA-N,119182,WDDPHFBMKLOVOX-AYQXTPAHSA-N,clofarabine,,Treatment of acute myelogenous leukemia,C0023467,Acute myelogenous leukemia,3/14/02,Designated,Not FDA Approved for Orphan Indication,,,,
IAKHMKGGTNLKSZ-INIZCTEOSA-N,6167,IAKHMKGGTNLKSZ-INIZCTEOSA-N,colchicine,Colcrys,Treatment of familial Mediterranean fever,C0031069,Familial Mediterranean Fever,9/25/07,Designated/Approved,,Treatment of familial Mediterranean fever, 07/29/2009 , 07/29/2016 ,
MWYDSXOGIBMAET-UHFFFAOYSA-N,135565596,MWYDSXOGIBMAET-UHFFFAOYSA-N,copanlisib,,Treatment of splenic marginal zone lymphoma,C0349632,Splenic marginal zone lymphoma,2/7/17,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-SCYOXIPCSA-N,123134263,PMATZTZNYRCHOR-SCYOXIPCSA-N,cyclosporine,,Treatment of graft-versus-host disease,C0018133,Graft-Versus-Host Disease,2/17/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-AVZWOAAISA-N,122172945,PMATZTZNYRCHOR-AVZWOAAISA-N,cyclosporine,,Treatment of graft-versus-host disease,C0018133,Graft-Versus-Host Disease,2/17/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-SRFWORPQSA-N,25246316,PMATZTZNYRCHOR-SRFWORPQSA-N,cyclosporine,,Treatment of graft-versus-host disease,C0018133,Graft-Versus-Host Disease,2/17/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-QVSDIVLPSA-N,5497195,PMATZTZNYRCHOR-QVSDIVLPSA-N,cyclosporine,,Treatment of graft-versus-host disease,C0018133,Graft-Versus-Host Disease,2/17/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-VJRYSDSKSA-N,24883466,PMATZTZNYRCHOR-VJRYSDSKSA-N,cyclosporine,,Treatment of graft-versus-host disease,C0018133,Graft-Versus-Host Disease,2/17/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-GNSAQUIPSA-N,62280,PMATZTZNYRCHOR-GNSAQUIPSA-N,cyclosporine,,Treatment of graft-versus-host disease,C0018133,Graft-Versus-Host Disease,2/17/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-IMVLJIQESA-N,5280754,PMATZTZNYRCHOR-IMVLJIQESA-N,cyclosporine,,Treatment of graft-versus-host disease,C0018133,Graft-Versus-Host Disease,2/17/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-KMSBSJHKSA-N,6435893,PMATZTZNYRCHOR-KMSBSJHKSA-N,cyclosporine,,Treatment of graft-versus-host disease,C0018133,Graft-Versus-Host Disease,2/17/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-CGLBZJNRSA-N,5284373,PMATZTZNYRCHOR-CGLBZJNRSA-N,cyclosporine,,Treatment of graft-versus-host disease,C0018133,Graft-Versus-Host Disease,2/17/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
UFULAYFCSOUIOV-UHFFFAOYSA-N,6058,UFULAYFCSOUIOV-UHFFFAOYSA-N,cysteamine,,Treatment of neuronal ceroid lipofuscinoses (Batten disease),"C0027877,C0751383","neuronal ceroid lipofuscinoses , Batten Disease",8/6/08,Designated,Not FDA Approved for Orphan Indication,,,,
UFULAYFCSOUIOV-UHFFFAOYSA-N,6058,UFULAYFCSOUIOV-UHFFFAOYSA-N,cysteamine,,Treatment of Huntington's disease,C0020179,Huntington's Disease,5/9/08,Designated,Not FDA Approved for Orphan Indication,,,,
PMHDSACGRKBACK-UHFFFAOYSA-N,4961254,PMHDSACGRKBACK-UHFFFAOYSA-N,D-amino acid oxidase inhibitor,,Treatment of Friedreich's ataxia (FRDA),C0016719,Friedreich's Ataxia,12/6/17,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
BFSMGDJOXZAERB-UHFFFAOYSA-N,44462760,BFSMGDJOXZAERB-UHFFFAOYSA-N,dabrafenib,,Treatment of malignant glioma with BRAF V600 mutation,C0555198,Malignant Glioma,2/8/16,Designated,Not FDA Approved for Orphan Indication,,,,
LVXJQMNHJWSHET-AATRIKPKSA-N,11511120,LVXJQMNHJWSHET-AATRIKPKSA-N,dacomitinib,VIZIMPRO,"Treatment of non-small cell lung cancer with EGFR, HER2, HER4, or DDR2 mutations.",C3539721,Non-Small Cell Lung Cancer,3/3/15,Designated/Approved,,For the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R, 09/27/2018 , 09/27/2025 ,For the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R
JGDXFQORBMPJGR-YUMQZZPRSA-N,11683005,JGDXFQORBMPJGR-YUMQZZPRSA-N,Darinaparsin,,Treatment of peripheral T-cell lymphoma.,C0079774,Peripheral T-Cell Lymphoma,9/13/10,Designated,Not FDA Approved for Orphan Indication,,,,
BOFQWVMAQOTZIW-UHFFFAOYSA-N,214348,BOFQWVMAQOTZIW-UHFFFAOYSA-N,deferasirox,Exjade; Jadenu Sprinkles,Treatment of chronic iron overload in alpha-thalassemia,"C0002312,C0282193","alpha-Thalassemia , Iron Overload",2/24/15,Designated/Approved,,Treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and a serum ferritin greater than 300 mcg/L., 05/18/2017 ,  ,
JNWFIPVDEINBAI-UHFFFAOYSA-N,135565962,JNWFIPVDEINBAI-UHFFFAOYSA-N,defibrotide,,For the prevention of hepatic veno-occlusive disease.,C0019156,Hepatic Veno-Occlusive Disease,1/8/07,Designated,Not FDA Approved for Orphan Indication,,,,
GFJWACFSUSFUOG-ZJTJBYBXSA-M,23668320,GFJWACFSUSFUOG-ZJTJBYBXSA-M,Dehydroepiandrosterone sulfate sodium,,Treatment of serious burns requiring hospitalization.,C0006434,Burns,1/29/97,Designated,Not FDA Approved for Orphan Indication,,,,
GJKXGJCSJWBJEZ-XRSSZCMZSA-N,25077495,GJKXGJCSJWBJEZ-XRSSZCMZSA-N,Deslorelin,,Treatment of central precocious puberty.,C0342543,Central Precocious Puberty,11/5/87,Designated,Not FDA Approved for Orphan Indication,,,,
MLSVJHOYXJGGTR-GHZYFSNVSA-N,146160431,MLSVJHOYXJGGTR-GHZYFSNVSA-N,Desmopressin acetate,,Treatment of mild hemophilia A and von Willebrand's disease.,"C0042974,C0272324","von Willebrand's Disease , Mild hemophilia A",1/22/91,Designated/Approved,,Treatment of patients with hemophilia A or von Willebrand's disease (type I) whose factor VIII coagulant activity level is greater than 5%., 03/07/1994 , 03/07/2001 ,
MLSVJHOYXJGGTR-COZVRORISA-N,124080868,MLSVJHOYXJGGTR-COZVRORISA-N,Desmopressin acetate,,Treatment of mild hemophilia A and von Willebrand's disease.,"C0042974,C0272324","von Willebrand's Disease , Mild hemophilia A",1/22/91,Designated/Approved,,Treatment of patients with hemophilia A or von Willebrand's disease (type I) whose factor VIII coagulant activity level is greater than 5%., 03/07/1994 , 03/07/2001 ,
MLSVJHOYXJGGTR-MOMGZFCSSA-N,16051969,MLSVJHOYXJGGTR-MOMGZFCSSA-N,Desmopressin acetate,,Treatment of mild hemophilia A and von Willebrand's disease.,"C0042974,C0272324","von Willebrand's Disease , Mild hemophilia A",1/22/91,Designated/Approved,,Treatment of patients with hemophilia A or von Willebrand's disease (type I) whose factor VIII coagulant activity level is greater than 5%., 03/07/1994 , 03/07/2001 ,
MLSVJHOYXJGGTR-UHFFFAOYSA-N,64758,MLSVJHOYXJGGTR-UHFFFAOYSA-N,Desmopressin acetate,,Treatment of mild hemophilia A and von Willebrand's disease.,"C0042974,C0272324","von Willebrand's Disease , Mild hemophilia A",1/22/91,Designated/Approved,,Treatment of patients with hemophilia A or von Willebrand's disease (type I) whose factor VIII coagulant activity level is greater than 5%., 03/07/1994 , 03/07/2001 ,
MLSVJHOYXJGGTR-IFHOVBQLSA-N,9833407,MLSVJHOYXJGGTR-IFHOVBQLSA-N,Desmopressin acetate,,Treatment of mild hemophilia A and von Willebrand's disease.,"C0042974,C0272324","von Willebrand's Disease , Mild hemophilia A",1/22/91,Designated/Approved,,Treatment of patients with hemophilia A or von Willebrand's disease (type I) whose factor VIII coagulant activity level is greater than 5%., 03/07/1994 , 03/07/2001 ,
MKJIEFSOBYUXJB-VFJJUKLQSA-N,73437646,MKJIEFSOBYUXJB-VFJJUKLQSA-N,deutetrabenazine,,Treatment of Tourette syndrome in the pediatric population (defined as 0 through 16 years of age),C0040517,Tourette Syndrome,1/13/15,Designated,Not FDA Approved for Orphan Indication,,,,
FASDKYOPVNHBLU-SSDOTTSWSA-N,59868,FASDKYOPVNHBLU-SSDOTTSWSA-N,dexpramipexole,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,10/11/07,Designated,Not FDA Approved for Orphan Indication,,,,
PIMQWRZWLQKKBJ-SFHVURJKSA-N,46926350,PIMQWRZWLQKKBJ-SFHVURJKSA-N,dinaciclib,,Treatment of chronic lymphocytic leukemia.,C0023434,Chronic Lymphocytic Leukemia,8/25/11,Designated,Not FDA Approved for Orphan Indication,,,,
MBMBGCFOFBJSGT-KUBAVDMBSA-N,445580,MBMBGCFOFBJSGT-KUBAVDMBSA-N,docosahexaenoic acid,,Treatment of short bowel syndrome,C0036992,Short Bowel Syndrome,6/1/15,Designated,Not FDA Approved for Orphan Indication,,,,
FGXWKSZFVQUSTL-UHFFFAOYSA-N,3151,FGXWKSZFVQUSTL-UHFFFAOYSA-N,domperidone,,"Treatment of hypoprolactinemia in breastfeeding mothers, and in some hypoprolactinemic conditions following the use of cabergoline or bromocriptine in mothers who wish to initiate or return to breastfeeding",C0271586,Hypoprolactinemia,9/2/11,Designated,Not FDA Approved for Orphan Indication,,,,
FIITXXIVUIXYMI-RQJHMYQMSA-N,164486,FIITXXIVUIXYMI-RQJHMYQMSA-N,doranidazole,,radiosensitizer to be used during radiation treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,11/30/18,Designated,Not FDA Approved for Orphan Indication,,,,
HWXIGFIVGWUZAO-UHFFFAOYSA-N,50942,HWXIGFIVGWUZAO-UHFFFAOYSA-N,doxofylline,,Treatment of bronchiectasis,C0006267,Bronchiectasis,2/14/14,Designated,Not FDA Approved for Orphan Indication,,,,
AOJJSUZBOXZQNB-TZSSRYMLSA-N,31703,AOJJSUZBOXZQNB-TZSSRYMLSA-N,doxorubicin,,Treatment of hepatocellular carcinoma.,C2239176,HEPATOCELLULAR CARCINOMA,8/25/09,Designated,Not FDA Approved for Orphan Indication,,,,
QELUYTUMUWHWMC-UHFFFAOYSA-N,4021,QELUYTUMUWHWMC-UHFFFAOYSA-N,edaravone,Radicava,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,5/12/15,Designated/Approved,,Treatment of amyotrophic lateral sclerosis (ALS), 05/05/2017 , 05/05/2024 ,Treatment of amyotrophic lateral sclerosis (ALS)
BNFRJXLZYUTIII-UHFFFAOYSA-N,122335,BNFRJXLZYUTIII-UHFFFAOYSA-N,efaproxiral,,Adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with breast cancer,"C0220650,C0678222","brain metastases , Breast cancer",7/28/04,Designated,Not FDA Approved for Orphan Indication,,,,
SFVLTCAESLKEHH-WKAQUBQDSA-N,11764719,SFVLTCAESLKEHH-WKAQUBQDSA-N,elamipretide,,Treatment of Barth syndrome,C0574083,Barth Syndrome,3/22/18,Designated,Not FDA Approved for Orphan Indication,,,,
FJZZPCZKBUKGGU-AUSIDOKSSA-N,23652731,FJZZPCZKBUKGGU-AUSIDOKSSA-N,eliglustat,CERDELGA,Treatment of Type I Gaucher disease,C0017205,Gaucher Disease,9/17/08,Designated/Approved,,"Long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test.", 08/19/2014 , 08/19/2021 ,"Long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test."
JUTBAVRYDAKVGQ-UHFFFAOYSA-N,21133161,JUTBAVRYDAKVGQ-UHFFFAOYSA-N,emeramide,,Treatment of mercury toxicity,C0600688,Toxicity,4/6/12,Designated,Not FDA Approved for Orphan Indication,,,,
CMJCXYNUCSMDBY-ZDUSSCGKSA-N,50922675,CMJCXYNUCSMDBY-ZDUSSCGKSA-N,encorafenib,,Treatment of Stage IIB-IV melanoma positive for BRAF mutation,C0025202,melanoma,11/19/13,Designated,Not FDA Approved for Orphan Indication,,,,
CIBHDGPIOICRGX-ZQCHCGQNSA-N,5311219,CIBHDGPIOICRGX-ZQCHCGQNSA-N,enisoprost,,1. For use with cyclosporine in organ transplant recipients to reduce acute transplant rejection 2. For use in organ transplant patients to diminish the nephrotoxicity induced by cyclosporine.,C0595916,nephrotoxicity,10/20/89,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
CHNUOJQWGUIOLD-NFZZJPOKSA-N,1549120,CHNUOJQWGUIOLD-NFZZJPOKSA-N,epalrestat,,"Treatment of phosphomannomutase-2 deficiency, a congenital disorder of glycosylation",C0282577,Congenital disorder of glycosylation,3/26/20,Designated,Not FDA Approved for Orphan Indication,,,,
MGNVWUDMMXZUDI-UHFFFAOYSA-N,428573,MGNVWUDMMXZUDI-UHFFFAOYSA-N,eprodisate,,Treatment of secondary amyloidosis,C3536715,Secondary amyloidosis,4/6/99,Designated,Not FDA Approved for Orphan Indication,,,,
GTTBEUCJPZQMDZ-UHFFFAOYSA-N,176871,GTTBEUCJPZQMDZ-UHFFFAOYSA-N,Erlotinib Hydrochloride,,Treatment of malignant gliomas,C0555198,malignant gliomas,7/18/03,Designated,Not FDA Approved for Orphan Indication,,,,
AJIPIJNNOJSSQC-NYLIRDPKSA-N,27125,AJIPIJNNOJSSQC-NYLIRDPKSA-N,estetrol,,Treatment of neonatal hypoxic ischemic encephalopathy,C3898147,Neonatal Hypoxic Ischemic Encephalopathy,3/28/19,Designated,Not FDA Approved for Orphan Indication,,,,
RAJWOBJTTGJROA-QJISAEMRSA-N,440114,RAJWOBJTTGJROA-QJISAEMRSA-N,Etiocholanedione,,Treatment of aplastic anemia.,C0002874,Aplastic Anemia,11/3/95,Designated,Not FDA Approved for Orphan Indication,,,,
HKVAMNSJSFKALM-GKUWKFKPSA-N,6442177,HKVAMNSJSFKALM-GKUWKFKPSA-N,everolimus,Afinitor,Treatment of neuroendocrine tumors,C0206754,Neuroendocrine Tumors,2/14/08,Designated/Approved,,"Treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease; and treatment of adult patients with progressive, well-differentiated, non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin, with unresectable, locally advanced or metastatic disease.", 02/26/2016 , 02/26/2023 ,"Treatment of adult patients with progressive, well-differentiated, non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) (excluding pancreatic) or lung origin, with unresectable, locally advanced or metastatic disease."
HTQBXNHDCUEHJF-JHBIHAKISA-N,138394057,HTQBXNHDCUEHJF-JHBIHAKISA-N,exenatide,,Treatment of idiopathic intracranial hypertension,C0033845,Idiopathic Intracranial Hypertension,5/16/17,Designated,Not FDA Approved for Orphan Indication,,,,
HTQBXNHDCUEHJF-URRANESESA-N,56927919,HTQBXNHDCUEHJF-URRANESESA-N,exenatide,,Treatment of idiopathic intracranial hypertension,C0033845,Idiopathic Intracranial Hypertension,5/16/17,Designated,Not FDA Approved for Orphan Indication,,,,
HTQBXNHDCUEHJF-XWLPCZSASA-N,45588096,HTQBXNHDCUEHJF-XWLPCZSASA-N,exenatide,,Treatment of idiopathic intracranial hypertension,C0033845,Idiopathic Intracranial Hypertension,5/16/17,Designated,Not FDA Approved for Orphan Indication,,,,
LFVPBERIVUNMGV-UHFFFAOYSA-N,163751,LFVPBERIVUNMGV-UHFFFAOYSA-N,Fasudil hydrochloride,,Treatment of Corticobasal Syndrome,C0039082,Syndrome,1/7/21,Designated,Not FDA Approved for Orphan Indication,,,,
DBGIVFWFUFKIQN-UHFFFAOYSA-N,3337,DBGIVFWFUFKIQN-UHFFFAOYSA-N,fenfluramine,,Treatment of Lennox-Gastaut syndrome,C0238111,Lennox-Gastaut syndrome,6/19/17,Designated,Not FDA Approved for Orphan Indication,,,,
KKGQTZUTZRNORY-UHFFFAOYSA-N,107970,KKGQTZUTZRNORY-UHFFFAOYSA-N,fingolimod,,Treatment of chronic inflammatory demyelinating polyneuropathy,C0393819,Chronic inflammatory demyelinating polyneuropathy,4/30/10,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
SJZRECIVHVDYJC-UHFFFAOYSA-N,10413,SJZRECIVHVDYJC-UHFFFAOYSA-N,Gamma-hydroxybutyric acid,,"Treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations, and automatic behavior.","C0007384,C0027404,C0233773,C0456511,C1457887","Cataplexy , Narcolepsy , Hypnagogic hallucinations , Sleep Paralysis , Symptoms",1/22/85,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PGTVWKLGGCQMBR-FLBATMFCSA-N,6918305,PGTVWKLGGCQMBR-FLBATMFCSA-N,ganaxolone,,Treatment of Fragile X Syndrome,C0016667,Fragile X Syndrome,12/28/16,Designated,Not FDA Approved for Orphan Indication,,,,
RUPXJRIDSUCQAN-PQNNUJSWSA-N,119058042,RUPXJRIDSUCQAN-PQNNUJSWSA-N,givosiran,GIVLAARI,Treatment of acute hepatic porphyria,C0268328,Acute hepatic porphyria,8/29/16,Designated/Approved,,GIVLAARI is indicated for the treatment of adults with acute hepatic porphyria (AHP)., 11/20/2019 , 11/20/2026 ,Indicated for the treatment of adults with acute hepatic porphyria (AHP).
SFNSLLSYNZWZQG-VQIMIIECSA-N,25166913,SFNSLLSYNZWZQG-VQIMIIECSA-N,Glasdegib,DAURISMO,Treatment of acute myeloid leukemia (AML),C0023467,Acute myeloid leukemia,6/28/17,Designated/Approved,,"DAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are >75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.", 11/21/2018 , 11/21/2025 ,"DAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are >75 years old or who have comorbidities that preclude use of intensive induction chemotherapy."
PSVUJBVBCOISSP-SPFKKGSWSA-N,123628,PSVUJBVBCOISSP-SPFKKGSWSA-N,glufosfamide,,For treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,9/18/06,Designated,Not FDA Approved for Orphan Indication,,,,
ZDXPYRJPNDTMRX-VKHMYHEASA-N,5961,ZDXPYRJPNDTMRX-VKHMYHEASA-N,Glutamine,NutreStore,For use with human growth hormone in the treatment of short bowel syndrome (nutrient malabsorption from the gastrointestinal tract resulting from an inadequate absorptive surface).,"C0024523,C0036992","Malabsorption , Short Bowel Syndrome",3/6/95,Designated/Approved,,Treatment of short bowel syndrome in patients receiving specialized nutritional support when used in conjunction with a recombinant human growth hormone that is approved for this indication., 06/10/2004 , 06/10/2011 ,
ZNNLBTZKUZBEKO-UHFFFAOYSA-N,3488,ZNNLBTZKUZBEKO-UHFFFAOYSA-N,glyburide,,Treatment of acute spinal cord injury,C0878589,acute spinal cord injury,9/29/15,Designated,Not FDA Approved for Orphan Indication,,,,
NTYJJOPFIAHURM-UHFFFAOYSA-N,774,NTYJJOPFIAHURM-UHFFFAOYSA-N,Histamine,,Adjunct to cytokine therapy in the treatment of acute myeloid leukemia.,C0023467,Acute myeloid leukemia,12/15/99,Designated,Not FDA Approved for Orphan Indication,,,,
VSNHCAURESNICA-UHFFFAOYSA-N,3657,VSNHCAURESNICA-UHFFFAOYSA-N,Hydroxyurea,Droxia,Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S.,"C0002895,C0037054","SICKLE CELL ANEMIA , Hemoglobin S",10/1/90,Designated/Approved,,To reduce the frequency of painful crises and to reduce the need for blood transfusions in adult patients with sickle cell anemia with recurrent moderate to severe painful crises (generally at least 3 during the preceding 12 months)., 02/25/1998 , 02/25/2005 ,
XYFPWWZEPKGCCK-GOSISDBHSA-N,24821094,XYFPWWZEPKGCCK-GOSISDBHSA-N,ibrutinib,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,5/16/13,Designated,Not FDA Approved for Orphan Indication,,,,
XYFPWWZEPKGCCK-GOSISDBHSA-N,24821094,XYFPWWZEPKGCCK-GOSISDBHSA-N,ibrutinib,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,6/12/17,Designated,Not FDA Approved for Orphan Indication,,,,
KTUFNOKKBVMGRW-UHFFFAOYSA-N,5291,KTUFNOKKBVMGRW-UHFFFAOYSA-N,imatinib,Gleevec,Treatment of Philadelphia-positive acute lymphoblastic leukemia,C1709527,Philadelphia-positive acute lymphoblastic leukemia,10/11/05,Designated/Approved,,Treatment of adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL), 10/19/2006 , 10/19/2013 ,
YLMAHDNUQAMNNX-UHFFFAOYSA-N,123596,YLMAHDNUQAMNNX-UHFFFAOYSA-N,imatinib mesylate,Gleevec,Treatment of dermatofibrosarcoma protuberans,C0206647,Dermatofibrosarcoma Protuberans,12/19/05,Designated/Approved,,"Treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP)", 10/19/2006 , 10/19/2013 ,
YLMAHDNUQAMNNX-UHFFFAOYSA-N,123596,YLMAHDNUQAMNNX-UHFFFAOYSA-N,Imatinib mesylate,Gleevec,Treatment of myeloproliferative disorders/myelodysplastic syndromes associated with platelet-derived growth factor gene re-arrangements,"C0027022,C0812325,C3463824","Myeloproliferative Disorders , Growth Factor Gene , Myelodysplastic Syndromes",10/5/05,Designated/Approved,,Treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements, 10/19/2006 , 10/19/2013 ,
LVZYXEALRXBLJZ-ISQYCPACSA-N,71587831,LVZYXEALRXBLJZ-ISQYCPACSA-N,imetelstat,,Treatment of myelofibrosis,C0026987,myelofibrosis,6/11/15,Designated,Not FDA Approved for Orphan Indication,,,,
YHTTWXCDIRTOQX-FQJIPJFPSA-N,134611625,YHTTWXCDIRTOQX-FQJIPJFPSA-N,internalized-arginylglycylaspartic acid cyclic peptide,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,1/29/19,Designated,Not FDA Approved for Orphan Indication,,,,
NICJCIQSJJKZAH-AWEZNQCLSA-N,148189,NICJCIQSJJKZAH-AWEZNQCLSA-N,irofulven,,Treatment of ovarian cancer.,C4721610,Ovarian Cancer,7/6/99,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PURKAOJPTOLRMP-UHFFFAOYSA-N,16220172,PURKAOJPTOLRMP-UHFFFAOYSA-N,ivacaftor,Kalydeco,Treatment of patients with cystic fibrosis,C0010674,Cystic Fibrosis,12/20/06,Designated/Approved,,"Treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R; and treatment of CF in patients age 6 years and older who have an R117H mutation in the CFTR gene.", 12/29/2014 , 12/29/2021 ,Treatment of cystic fibrosis (CF) in patients age 6 years and older who have an R117H mutation in the CFTR gene.
PURKAOJPTOLRMP-UHFFFAOYSA-N,16220172,PURKAOJPTOLRMP-UHFFFAOYSA-N,ivacaftor,Kalydeco,Treatment of patients with cystic fibrosis,C0010674,Cystic Fibrosis,12/20/06,Designated/Approved,,treatment of cystic fibrosis (CF) in patients age 4 months and older who have one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data, 12/21/2020 , 12/21/2027 ,"treatment of cystic fibrosis (CF) in patients age 4 months and older who have one of the additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that have been identified as responsive to ivacaftor potentiation based on in vitro data and identified in the approval on December 21, 2020."
JOITUBWXBFATOR-HKBOAZHASA-N,71587904,JOITUBWXBFATOR-HKBOAZHASA-N,L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal,,Treatment of Duchenne and Becker muscular dystrophy,C3542021,Duchenne and Becker Muscular Dystrophy,1/18/06,Designated,Not FDA Approved for Orphan Indication,,,,
AYFVYJQAPQTCCC-GBXIJSLDSA-N,6288,AYFVYJQAPQTCCC-GBXIJSLDSA-N,L-threonine,,Treatment of spasticity associated with familial spastic paraparesis.,"C0026838,C0037771","Spasticity , spastic paraparesis",7/24/92,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
NYNZQNWKBKUAII-KBXCAEBGSA-N,46188928,NYNZQNWKBKUAII-KBXCAEBGSA-N,Larotrectinib,,Treatment of soft tissue sarcoma.,C1261473,Soft tissue sarcoma,8/31/15,Designated,Not FDA Approved for Orphan Indication,,,,
GOTYRUGSSMKFNF-UHFFFAOYSA-N,216326,GOTYRUGSSMKFNF-UHFFFAOYSA-N,lenalidomide,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,1/17/07,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
FWYSMLBETOMXAG-QHCPKHFHSA-N,45138674,FWYSMLBETOMXAG-QHCPKHFHSA-N,letermovir,PREVYMIS,Prevention of human cytomegalovirus viremia and disease in at risk populations,"C0205725,C0877635","Human cytomegalovirus , Cytomegalovirus viremia",12/12/11,Designated/Approved,,Prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT)., 11/08/2017 , 11/08/2024 ,Prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).
IVTMXOXVAHXCHI-YXLMWLKOSA-N,104778,IVTMXOXVAHXCHI-YXLMWLKOSA-N,levodopa and carbidopa,Duopa,Treatment of late stage Parkinson's disease,C0030567,Parkinson's Disease,1/18/00,Designated/Approved,,Treatment of motor flucuations in patients with advanced Parkinson's disease, 01/09/2015 , 01/09/2022 ,Treatment of motor flucuations in patients with advanced Parkinson's disease
LKCWBDHBTVXHDL-CAIQVSFASA-N,456591,LKCWBDHBTVXHDL-CAIQVSFASA-N,liposomal amikacin,,Treatment of bronchopulmonary Pseudomonas aeruginosa infections in cystic fibrosis patients,"C0010674,C0854135","Cystic Fibrosis , Pseudomonas aeruginosa Infections",3/9/06,Designated,Not FDA Approved for Orphan Indication,,,,
OSPNFKYGOFXGBX-YWWKUQGPSA-N,145722609,OSPNFKYGOFXGBX-YWWKUQGPSA-N,Lucinactant,,Treatment of meconium aspiration syndrome in newborn infants,C0025048,of meconium aspiration,7/30/96,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
JGCMEBMXRHSZKX-UHFFFAOYSA-N,16004692,JGCMEBMXRHSZKX-UHFFFAOYSA-N,macitentan,Opsumit,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,9/3/09,Designated/Approved,,"Treatment of pulmonary arterial hypertension (PAH, WHO Group 1) to delay disease progression. Disease progression included: death, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical worsening of PAH (decreased 6-minute walk distance, worsened PAH symptoms and need for additional PAH treatment). Opsumit also reduced hospitalization for PAH.", 10/18/2013 , 10/18/2020 ,"Treatment of pulmonary arterial hypertension (PAH, WHO Group 1) to delay disease progression. Disease progression included: death, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical worsening of PAH (decreased 6-minute walk distance, worsened PAH symptoms and need for additional PAH treatment). Opsumit also reduced hospitalization for PAH."
STPKWKPURVSAJF-LJEWAXOPSA-N,9831643,STPKWKPURVSAJF-LJEWAXOPSA-N,maralixibat,,treatment of biliary atresia,C0005411,Biliary Atresia,10/21/20,Designated,Not FDA Approved for Orphan Indication,,,,
KJFBVJALEQWJBS-XUXIUFHCSA-N,471161,KJFBVJALEQWJBS-XUXIUFHCSA-N,maribavir,,Treatment of clinically significant cytomegalovirus viremia and disease in at-risk patients.,"C0012634,C0877635","Disease , Cytomegalovirus viremia",6/7/11,Designated,Not FDA Approved for Orphan Indication,,,,
RQZAXGRLVPAYTJ-GQFGMJRRSA-N,11683,RQZAXGRLVPAYTJ-GQFGMJRRSA-N,Megestrol acetate,Megace,"Treatment of patients with anorexia, cachexia, or significant weight loss (=/>10% of baseline body weight) and confirmed diagnosis of AIDS.","C0001175,C0006625,C4084774","AIDS , Cachexia , Weight loss",4/13/88,Designated/Approved,,"Treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with a diagnosis of acquired immune deficiency syndrome.", 09/10/1993 , 09/10/2000 ,
DRLFMBDRBRZALE-UHFFFAOYSA-N,896,DRLFMBDRBRZALE-UHFFFAOYSA-N,Melatonin,,Treatment of heat stroke,C0038819,Heat Stroke,4/22/19,Designated,Not FDA Approved for Orphan Indication,,,,
DRLFMBDRBRZALE-UHFFFAOYSA-N,896,DRLFMBDRBRZALE-UHFFFAOYSA-N,melatonin,,Treatment of Acute Radiation Syndrome,C0520799,Acute Radiation Syndrome,10/22/18,Designated,Not FDA Approved for Orphan Indication,,,,
DRLFMBDRBRZALE-UHFFFAOYSA-N,896,DRLFMBDRBRZALE-UHFFFAOYSA-N,melatonin,,Treatment of short bowel syndrome,C0036992,Short Bowel Syndrome,2/14/17,Designated,Not FDA Approved for Orphan Indication,,,,
SGDBTWWWUNNDEQ-LBPRGKRZSA-N,460612,SGDBTWWWUNNDEQ-LBPRGKRZSA-N,melphalan,,Treatment of retinoblastoma,C0035335,Retinoblastoma,11/19/12,Designated,Not FDA Approved for Orphan Indication,,,,
OUUYBRCCFUEMLH-YDALLXLXSA-N,9927978,OUUYBRCCFUEMLH-YDALLXLXSA-N,melphalan hydrochloride,,Treatment of patients with cutaneous melanoma.,C0025202,cutaneous melanoma,11/12/08,Designated,Not FDA Approved for Orphan Indication,,,,
RYKKQQUKJJGFMN-HVDRVSQOSA-N,115198,RYKKQQUKJJGFMN-HVDRVSQOSA-N,metadoxine,,Treatment of Fragile X Syndrome,C0016667,Fragile X Syndrome,12/16/13,Designated,Not FDA Approved for Orphan Indication,,,,
FBOZXECLQNJBKD-ZDUSSCGKSA-N,126941,FBOZXECLQNJBKD-ZDUSSCGKSA-N,Methotrexate,,Treatment of Myasthenia Gravis,C0026896,Myasthenia Gravis,8/28/14,Designated,Not FDA Approved for Orphan Indication,,,,
JVLBPIPGETUEET-GAAHOAFPSA-O,5361918,JVLBPIPGETUEET-GAAHOAFPSA-O,Methylnaltrexone,,Treatment of chronic opioid-induced constipation unresponsive to conventional therapy.,C3160897,Opioid-Induced Constipation,6/17/96,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
VAOCPAMSLUNLGC-UHFFFAOYSA-N,4173,VAOCPAMSLUNLGC-UHFFFAOYSA-N,metronidazole,,Treatment of pouchitis,C0376620,Pouchitis,9/17/08,Designated,Not FDA Approved for Orphan Indication,,,,
NHTGHBARYWONDQ-JTQLQIEISA-N,441350,NHTGHBARYWONDQ-JTQLQIEISA-N,metyrosine,,Treatment of velocardiofacial syndrome associated psychosis.,"C0012236,C0033975","Velocardiofacial Syndrome , Psychosis",7/25/08,Designated,Not FDA Approved for Orphan Indication,,,,
UQRORFVVSGFNRO-UTINFBMNSA-N,51634,UQRORFVVSGFNRO-UTINFBMNSA-N,miglustat,,Treatment of CLN Batten Disease,C0751383,Batten Disease,1/19/21,Designated,Not FDA Approved for Orphan Indication,,,,
UQRORFVVSGFNRO-UTINFBMNSA-N,51634,UQRORFVVSGFNRO-UTINFBMNSA-N,miglustat,Zavesca,Treatment of Gaucher disease.,C0017205,Gaucher Disease,5/29/98,Designated/Approved,,"Treatment of mild to moderate Type I Gaucher disease in adults for whom enzyme replacement therapy is not a therapeutic option (e.g., due to constraints such as allergy, hypersensitivity, or poor venous access).", 07/31/2003 , 07/31/2010 ,
ZHBJMVNZRZUQEP-KIKMAQITSA-L,46203139,ZHBJMVNZRZUQEP-KIKMAQITSA-L,Minnelide,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,2/18/13,Designated,Not FDA Approved for Orphan Indication,,,,
TZRFSLHOCZEXCC-HIVFKXHNSA-A,71301230,TZRFSLHOCZEXCC-HIVFKXHNSA-A,mipomersen,KYNAMRO,Treatment of homozygous familial hypercholesterolemia,C0020445,FAMILIAL HYPERCHOLESTEROLEMIA,5/23/06,Designated/Approved,,"Adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).", 01/29/2013 , 01/29/2020 ,"Adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH)."
NWIBSHFKIJFRCO-WUDYKRTCSA-N,5746,NWIBSHFKIJFRCO-WUDYKRTCSA-N,mitomycin-C,Mitosol,Treatment of refractory glaucoma as an adjunct to surgery,C0017601,Glaucoma,1/8/08,Designated/Approved,,An adjunct to ab externo glaucoma surgery., 02/07/2012 , 02/07/2019 ,
HZQDCMWJEBCWBR-UUOKFMHZSA-N,104762,HZQDCMWJEBCWBR-UUOKFMHZSA-N,Mizoribine,,Treatment of membranous nephropathy,C0017665,membranous nephropathy,11/9/20,Designated,Not FDA Approved for Orphan Indication,,,,
QJYMZHMIZZYHBI-UHFFFAOYSA-N,56841946,QJYMZHMIZZYHBI-UHFFFAOYSA-N,monarsen,,Treatment of myasthenia gravis,C0026896,Myasthenia Gravis,11/14/03,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
FJCDSQATIJKQKA-UHFFFAOYSA-N,54766013,FJCDSQATIJKQKA-UHFFFAOYSA-N,"N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline",,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,6/14/17,Designated,Not FDA Approved for Orphan Indication,,,,
RIIKDGPBTPECSW-UHFFFAOYSA-N,124147085,RIIKDGPBTPECSW-UHFFFAOYSA-N,"N-(tert-butylcarbamoyl)-5-cyano-2-((4'-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)oxy)benzenesulfonamide",,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,3/1/18,Designated,Not FDA Approved for Orphan Indication,,,,
UJCHIZDEQZMODR-BYPYZUCNSA-N,10176265,UJCHIZDEQZMODR-BYPYZUCNSA-N,N-acetyl cysteine amide,,Treatment of retinitis pigmentosa,C0035334,Retinitis Pigmentosa,12/31/13,Designated,Not FDA Approved for Orphan Indication,,,,
LAMIXXKAWNLXOC-INIZCTEOSA-N,6918848,LAMIXXKAWNLXOC-INIZCTEOSA-N,N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide,,Treatment of Schwannoma of the central nervous system,C0027809,Schwannoma,1/13/12,Designated,Not FDA Approved for Orphan Indication,,,,
AKFJWRDCWYYTIG-ZDUSSCGKSA-N,9884642,AKFJWRDCWYYTIG-ZDUSSCGKSA-N,naproxcinod,,Treatment of Duchenne muscular dystrophy.,C0013264,DUCHENNE MUSCULAR DYSTROPHY,3/16/15,Designated,Not FDA Approved for Orphan Indication,,,,
ZBBHBTPTTSWHBA-UHFFFAOYSA-N,4474,ZBBHBTPTTSWHBA-UHFFFAOYSA-N,nicardipine,,Treatment of Pitt-Hopkins Syndrome,C1970431,PITT-HOPKINS SYNDROME,11/26/19,Designated,Not FDA Approved for Orphan Indication,,,,
HYIMSNHJOBLJNT-UHFFFAOYSA-N,4485,HYIMSNHJOBLJNT-UHFFFAOYSA-N,Nifedipine,,Treatment of interstitial cystitis.,C0282488,Interstitial Cystitis,6/13/91,Designated,Not FDA Approved for Orphan Indication,,,,
ARFHIAQFJWUCFH-IZZDOVSWSA-N,6842999,ARFHIAQFJWUCFH-IZZDOVSWSA-N,nifurtimox,LAMPIT,Treatment of Chagas disease (American Typanosomiasis)caused by T. cruzi,C0041234,Chagas Disease,8/5/10,Designated/Approved,,"LAMPIT is indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis), caused by Trypanosoma cruzi", 08/06/2020 , 08/06/2027 ,indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis) caused by Trypanosoma cruzi
HHZIURLSWUIHRB-UHFFFAOYSA-N,644241,HHZIURLSWUIHRB-UHFFFAOYSA-N,nilotinib,Tasigna,Treatment of chronic myelogenous leukemia,C0023473,Chronic myelogenous leukemia,4/27/06,Designated/Approved,,For the use for chronic phase (CP) and accelerated phase (AP) Philadelphia chromosome positive chronic myelogenous leukemia (CML) in adult patients resistant to or intolerant to prior therapy that included imatinib., 10/29/2007 , 10/29/2014 ,
CPMDPSXJELVGJG-UHFFFAOYSA-N,135423438,CPMDPSXJELVGJG-UHFFFAOYSA-N,nintedanib,OFEV,Treatment of systemic sclerosis (including the associated interstitial lung disease).,"C0036421,C0206062","Systemic sclerosis , Interstitial lung disease",7/6/16,Designated/Approved,,OFEV is indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD)., 09/06/2019 , 09/06/2026 ,Indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
YQNQNVDNTFHQSW-UHFFFAOYSA-N,41684,YQNQNVDNTFHQSW-UHFFFAOYSA-N,nitazoxanide,Alinia,Treatment of intestinal giardiasis,C0017536,INTESTINAL GIARDIASIS,2/14/02,Designated/Approved,,Treatment of diarrhea caused by Cryptosporidium parvum and Giardia lamblia, 11/22/2002 , 11/22/2009 ,
YQNQNVDNTFHQSW-UHFFFAOYSA-N,41684,YQNQNVDNTFHQSW-UHFFFAOYSA-N,Nitazoxanide,Alinia,Treatment of cryptosporidiosis.,C0010418,Cryptosporidiosis,12/12/96,Designated/Approved,,Treatment of diarrhea caused by Cryptosporidium parvum and Giardia lamblia, 11/22/2002 , 11/22/2009 ,
MWUXSHHQAYIFBG-UHFFFAOYSA-N,145068,MWUXSHHQAYIFBG-UHFFFAOYSA-N,Nitric oxide,,Diagnosis of sarcoidosis,C0036202,Sarcoidosis,2/16/05,Designated,Not FDA Approved for Orphan Indication,,,,
MWUXSHHQAYIFBG-UHFFFAOYSA-N,145068,MWUXSHHQAYIFBG-UHFFFAOYSA-N,Nitric oxide,,To reduce the risk of chronic lung disease in premature neonates,C0746102,Chronic lung disease,9/27/04,Designated,Not FDA Approved for Orphan Indication,,,,
FDLYAMZZIXQODN-UHFFFAOYSA-N,23725625,FDLYAMZZIXQODN-UHFFFAOYSA-N,olaparib,Lynparza,Treatment of Fallopian Tube Cancer,C0238122,Fallopian Tube Cancer,5/15/18,Designated/Approved,,"Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; and treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.", 08/17/2017 , 08/17/2024 ,Maintenance treatment of adult patients with recurrent fallopian tube cancer who are in a complete or partial response to platinum-based chemotherapy.
SLVOKEOPLJCHCQ-UHFFFAOYSA-O,6710777,SLVOKEOPLJCHCQ-UHFFFAOYSA-O,oleylphosphocholine,,Treatment of leishmaniasis,C0023281,Leishmaniasis,10/25/13,Designated,Not FDA Approved for Orphan Indication,,,,
SLVOKEOPLJCHCQ-SEYXRHQNSA-N,9932595,SLVOKEOPLJCHCQ-SEYXRHQNSA-N,oleylphosphocholine,,Treatment of leishmaniasis,C0023281,Leishmaniasis,10/25/13,Designated,Not FDA Approved for Orphan Indication,,,,
DUYJMQONPNNFPI-UHFFFAOYSA-N,71496458,DUYJMQONPNNFPI-UHFFFAOYSA-N,osimertinib,Tagrisso,Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer,"C1414313,C3539721","EPIDERMAL GROWTH FACTOR RECEPTOR , Non-Small Cell Lung Cancer",9/4/14,Designated/Approved,,"For treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy", 11/13/2015 , 11/13/2022 ,"For treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy"
DUYJMQONPNNFPI-UHFFFAOYSA-N,71496458,DUYJMQONPNNFPI-UHFFFAOYSA-N,osimertinib,Tagrisso,Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer,"C1414313,C3539721","EPIDERMAL GROWTH FACTOR RECEPTOR , Non-Small Cell Lung Cancer",9/4/14,Designated/Approved,,"TAGRISSO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test", 04/18/2018 , 04/18/2025 ,"TAGRISSO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test"
QSLJIVKCVHQPLV-PEMPUTJUSA-N,5878,QSLJIVKCVHQPLV-PEMPUTJUSA-N,Oxandrolone,,Treatment of constitutional delay of growth and puberty.,C0342538,Constitutional delay of growth and puberty,10/5/90,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
SWMNGXODFOCPKQ-BTJKTKAUSA-N,154731101,SWMNGXODFOCPKQ-BTJKTKAUSA-N,Pafuramidine maleate,,Treatment of human African trypanosomiasis (sleeping sickness),C0041228,African Trypanosomiasis,8/31/07,Designated,Not FDA Approved for Orphan Indication,,,,
SWMNGXODFOCPKQ-BTJKTKAUSA-N,154731101,SWMNGXODFOCPKQ-BTJKTKAUSA-N,Pafuramidine maleate,,Treatment of human African trypanosomiasis (sleeping sickness),C0041228,African Trypanosomiasis,8/31/07,Designated,Not FDA Approved for Orphan Indication,,,,
SWMNGXODFOCPKQ-BTJKTKAUSA-N,154731101,SWMNGXODFOCPKQ-BTJKTKAUSA-N,Pafuramidine maleate,,Treatment of human African trypanosomiasis (sleeping sickness),C0041228,African Trypanosomiasis,8/31/07,Designated,Not FDA Approved for Orphan Indication,,,,
SWMNGXODFOCPKQ-BTJKTKAUSA-N,154731101,SWMNGXODFOCPKQ-BTJKTKAUSA-N,pafuramidine maleate,,Treatment of pneumocystis jiroveci pneumonia,C1535939,Pneumocystis jiroveci pneumonia,11/17/06,Designated,Not FDA Approved for Orphan Indication,,,,
SWMNGXODFOCPKQ-BTJKTKAUSA-N,154731101,SWMNGXODFOCPKQ-BTJKTKAUSA-N,pafuramidine maleate,,Treatment of pneumocystis jiroveci pneumonia,C1535939,Pneumocystis jiroveci pneumonia,11/17/06,Designated,Not FDA Approved for Orphan Indication,,,,
SWMNGXODFOCPKQ-BTJKTKAUSA-N,154731101,SWMNGXODFOCPKQ-BTJKTKAUSA-N,pafuramidine maleate,,Treatment of pneumocystis jiroveci pneumonia,C1535939,Pneumocystis jiroveci pneumonia,11/17/06,Designated,Not FDA Approved for Orphan Indication,,,,
FPOHNWQLNRZRFC-ZHACJKMWSA-N,6918837,FPOHNWQLNRZRFC-ZHACJKMWSA-N,Panobinostat,,Treatment of cutaneous T-cell lymphoma,C0079773,cutaneous T-cell lymphoma,9/26/07,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
UOZODPSAJZTQNH-LSWIJEOBSA-N,165580,UOZODPSAJZTQNH-LSWIJEOBSA-N,paromomycin,,Treatment of cutaneous leishmaniasis (Old World and New World),C0023283,Cutaneous leishmaniasis,2/11/15,Designated,Not FDA Approved for Orphan Indication,,,,
ZQPDJCIXJHUERQ-QWRGUYRKSA-N,86677874,ZQPDJCIXJHUERQ-QWRGUYRKSA-N,parsaclisib,,Treatment of mantle cell lymphoma,C4721414,Mantle cell lymphoma,6/12/19,Designated,Not FDA Approved for Orphan Indication,,,,
QXRSDHAAWVKZLJ-PVYNADRNSA-N,448013,QXRSDHAAWVKZLJ-PVYNADRNSA-N,Patupilone,,Treatment of ovarian cancer.,C4721610,Ovarian Cancer,10/4/05,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
HCDMJFOHIXMBOV-UHFFFAOYSA-N,86705695,HCDMJFOHIXMBOV-UHFFFAOYSA-N,Pemigatinib,PEMAZYRE,Treatment of cholangiocarcinoma,C0206698,Cholangiocarcinoma,3/12/18,Designated/Approved,,"PEMAZYRE is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test", 04/17/2020 , 04/17/2027 ,"For the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test."
NEYNJQRKHLUJRU-DZUOILHNSA-N,9853654,NEYNJQRKHLUJRU-DZUOILHNSA-N,pentagastrin,,To aid in the diagnosis of medullary thyroid carcinoma,C0238462,Medullary thyroid carcinoma,5/29/09,Designated,Not FDA Approved for Orphan Indication,,,,
XDRYMKDFEDOLFX-UHFFFAOYSA-N,4735,XDRYMKDFEDOLFX-UHFFFAOYSA-N,pentamidine,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,8/12/13,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
FPVKHBSQESCIEP-JQCXWYLXSA-N,439693,FPVKHBSQESCIEP-JQCXWYLXSA-N,Pentostatin,,Treatment of cutaneous T-cell lymphoma.,C0079773,cutaneous T-cell lymphoma,3/27/98,Designated,Not FDA Approved for Orphan Indication,,,,
UUBHZHZSIKRVIV-KCXSXWJSSA-N,6437836,UUBHZHZSIKRVIV-KCXSXWJSSA-N,peretinoin,,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,9/23/11,Designated,Not FDA Approved for Orphan Indication,,,,
WTWWXOGTJWMJHI-UHFFFAOYSA-N,9873,WTWWXOGTJWMJHI-UHFFFAOYSA-N,Perflubron,,Treatment of acute respiratory distress disease (ARDS) in adults,"C0012634,C0035222,C0748355","Disease , ARDS , Acute respiratory distress",4/26/01,Designated,Not FDA Approved for Orphan Indication,,,,
DDBREPKUVSBGFI-UHFFFAOYSA-N,4763,DDBREPKUVSBGFI-UHFFFAOYSA-N,phenobarbital,,Treatment of neonatal seizures,C0159020,Neonatal seizures,10/25/17,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
IEJSCSAMMLUINT-NRFANRHFSA-N,135430970,IEJSCSAMMLUINT-NRFANRHFSA-N,Plevitrexed,,Treatment of gastric (stomach cancer,C0024623,stomach cancer,5/29/07,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
CPKVUHPKYQGHMW-UHFFFAOYSA-N,410087,CPKVUHPKYQGHMW-UHFFFAOYSA-N,povidone iodine,,Treatment of Endophthalmitis,C0014236,Endophthalmitis,11/30/18,Designated,Not FDA Approved for Orphan Indication,,,,
OGSBUKJUDHAQEA-WMCAAGNKSA-N,148121,OGSBUKJUDHAQEA-WMCAAGNKSA-N,pralatrexate,,Treatment of diffuse large B-cell lymphoma,C1332201,Diffuse Large B-Cell Lymphoma,10/20/08,Designated,Not FDA Approved for Orphan Indication,,,,
RJKFOVLPORLFTN-LEKSSAKUSA-N,5994,RJKFOVLPORLFTN-LEKSSAKUSA-N,progesterone,,Treatment of ocular graft versus host disease,C5203917,Ocular Graft Versus Host Disease,6/3/20,Designated,Not FDA Approved for Orphan Indication,,,,
DGMKFQYCZXERLX-UHFFFAOYSA-N,4922,DGMKFQYCZXERLX-UHFFFAOYSA-N,Proglumide,,Treatment of Chronic Pancreatitis,C0149521,Chronic pancreatitis,9/9/20,Designated,Not FDA Approved for Orphan Indication,,,,
ODUOJXZPIYUATO-UHFFFAOYSA-N,107751,ODUOJXZPIYUATO-UHFFFAOYSA-N,racecadotril,,Treatment of Microvillus inclusion disease,C0341306,Microvillus inclusion disease,4/13/20,Designated,Not FDA Approved for Orphan Indication,,,,
QFJCIRLUMZQUOT-HPLJOQBZSA-N,5284616,QFJCIRLUMZQUOT-HPLJOQBZSA-N,rapamycin,,Treatment of perivascular epithelioid cell tumors (PEComa),C1300127,Perivascular Epithelioid Cell Tumors,12/21/17,Designated,Not FDA Approved for Orphan Indication,,,,
FNHKPVJBJVTLMP-UHFFFAOYSA-N,11167602,FNHKPVJBJVTLMP-UHFFFAOYSA-N,regorafenib,Stivarga,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,6/4/15,Designated/Approved,,Treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with sorafenib., 04/27/2017 , 04/27/2024 ,Treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with sorafenib.
HEBKCHPVOIAQTA-NGQZWQHPSA-N,6912,HEBKCHPVOIAQTA-NGQZWQHPSA-N,ribitol,,Treatment of limb-girdle muscular dystrophy type 2I,C0686353,Limb-girdle muscular dystrophy,1/16/19,Designated,Not FDA Approved for Orphan Indication,,,,
WDZCUPBHRAEYDL-YUUOHQKVSA-N,138404395,WDZCUPBHRAEYDL-YUUOHQKVSA-N,Rifapentine,,Treatment of Mycobacterium avium complex in patients with AIDS.,"C0001175,C0026914","AIDS , Mycobacterium avium Complex",6/9/95,Designated,Not FDA Approved for Orphan Indication,,,,
WDZCUPBHRAEYDL-RDKOBYJASA-N,137235501,WDZCUPBHRAEYDL-RDKOBYJASA-N,Rifapentine,,Treatment of Mycobacterium avium complex in patients with AIDS.,"C0001175,C0026914","AIDS , Mycobacterium avium Complex",6/9/95,Designated,Not FDA Approved for Orphan Indication,,,,
WDZCUPBHRAEYDL-LBJWSYCFSA-N,137091916,WDZCUPBHRAEYDL-LBJWSYCFSA-N,Rifapentine,,Treatment of Mycobacterium avium complex in patients with AIDS.,"C0001175,C0026914","AIDS , Mycobacterium avium Complex",6/9/95,Designated,Not FDA Approved for Orphan Indication,,,,
WDZCUPBHRAEYDL-USLNORDZSA-N,137030254,WDZCUPBHRAEYDL-USLNORDZSA-N,Rifapentine,,Treatment of Mycobacterium avium complex in patients with AIDS.,"C0001175,C0026914","AIDS , Mycobacterium avium Complex",6/9/95,Designated,Not FDA Approved for Orphan Indication,,,,
WDZCUPBHRAEYDL-QFWJEWEWSA-N,135887820,WDZCUPBHRAEYDL-QFWJEWEWSA-N,Rifapentine,,Treatment of Mycobacterium avium complex in patients with AIDS.,"C0001175,C0026914","AIDS , Mycobacterium avium Complex",6/9/95,Designated,Not FDA Approved for Orphan Indication,,,,
WDZCUPBHRAEYDL-FHDUCCPFSA-N,136122663,WDZCUPBHRAEYDL-FHDUCCPFSA-N,Rifapentine,,Treatment of Mycobacterium avium complex in patients with AIDS.,"C0001175,C0026914","AIDS , Mycobacterium avium Complex",6/9/95,Designated,Not FDA Approved for Orphan Indication,,,,
WDZCUPBHRAEYDL-METIDKAPSA-N,135932821,WDZCUPBHRAEYDL-METIDKAPSA-N,Rifapentine,,Treatment of Mycobacterium avium complex in patients with AIDS.,"C0001175,C0026914","AIDS , Mycobacterium avium Complex",6/9/95,Designated,Not FDA Approved for Orphan Indication,,,,
WDZCUPBHRAEYDL-PWXWUWFUSA-N,135925739,WDZCUPBHRAEYDL-PWXWUWFUSA-N,Rifapentine,,Treatment of Mycobacterium avium complex in patients with AIDS.,"C0001175,C0026914","AIDS , Mycobacterium avium Complex",6/9/95,Designated,Not FDA Approved for Orphan Indication,,,,
WDZCUPBHRAEYDL-HJTBMZGUSA-N,135749824,WDZCUPBHRAEYDL-HJTBMZGUSA-N,Rifapentine,,Treatment of Mycobacterium avium complex in patients with AIDS.,"C0001175,C0026914","AIDS , Mycobacterium avium Complex",6/9/95,Designated,Not FDA Approved for Orphan Indication,,,,
WDZCUPBHRAEYDL-BGZYVKEHSA-N,136246610,WDZCUPBHRAEYDL-BGZYVKEHSA-N,Rifapentine,,Treatment of Mycobacterium avium complex in patients with AIDS.,"C0001175,C0026914","AIDS , Mycobacterium avium Complex",6/9/95,Designated,Not FDA Approved for Orphan Indication,,,,
WDZCUPBHRAEYDL-LYDPARFQSA-N,135968625,WDZCUPBHRAEYDL-LYDPARFQSA-N,Rifapentine,,Treatment of Mycobacterium avium complex in patients with AIDS.,"C0001175,C0026914","AIDS , Mycobacterium avium Complex",6/9/95,Designated,Not FDA Approved for Orphan Indication,,,,
WDZCUPBHRAEYDL-NAFQJNKLSA-N,136238508,WDZCUPBHRAEYDL-NAFQJNKLSA-N,Rifapentine,,Treatment of Mycobacterium avium complex in patients with AIDS.,"C0001175,C0026914","AIDS , Mycobacterium avium Complex",6/9/95,Designated,Not FDA Approved for Orphan Indication,,,,
WDZCUPBHRAEYDL-QEDJKGLXSA-N,136073066,WDZCUPBHRAEYDL-QEDJKGLXSA-N,Rifapentine,,Treatment of Mycobacterium avium complex in patients with AIDS.,"C0001175,C0026914","AIDS , Mycobacterium avium Complex",6/9/95,Designated,Not FDA Approved for Orphan Indication,,,,
WDZCUPBHRAEYDL-PRHSTWAZSA-N,135659016,WDZCUPBHRAEYDL-PRHSTWAZSA-N,Rifapentine,,Treatment of Mycobacterium avium complex in patients with AIDS.,"C0001175,C0026914","AIDS , Mycobacterium avium Complex",6/9/95,Designated,Not FDA Approved for Orphan Indication,,,,
WDZCUPBHRAEYDL-GZAUEHORSA-N,135403821,WDZCUPBHRAEYDL-GZAUEHORSA-N,Rifapentine,,Treatment of Mycobacterium avium complex in patients with AIDS.,"C0001175,C0026914","AIDS , Mycobacterium avium Complex",6/9/95,Designated,Not FDA Approved for Orphan Indication,,,,
NZCRJKRKKOLAOJ-WSTNJLQSSA-N,135391139,NZCRJKRKKOLAOJ-WSTNJLQSSA-N,rifaximin,Xifaxan,Treatment of hepatic encephalopathy,C0019151,Hepatic Encephalopathy,2/10/98,Designated/Approved,,Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age, 03/24/2010 , 03/24/2017 ,
NZCRJKRKKOLAOJ-UPMLHBPDSA-N,134754219,NZCRJKRKKOLAOJ-UPMLHBPDSA-N,rifaximin,Xifaxan,Treatment of hepatic encephalopathy,C0019151,Hepatic Encephalopathy,2/10/98,Designated/Approved,,Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age, 03/24/2010 , 03/24/2017 ,
NZCRJKRKKOLAOJ-VJYREXROSA-N,134754217,NZCRJKRKKOLAOJ-VJYREXROSA-N,rifaximin,Xifaxan,Treatment of hepatic encephalopathy,C0019151,Hepatic Encephalopathy,2/10/98,Designated/Approved,,Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age, 03/24/2010 , 03/24/2017 ,
NZCRJKRKKOLAOJ-KPKMWDGOSA-N,101307877,NZCRJKRKKOLAOJ-KPKMWDGOSA-N,rifaximin,Xifaxan,Treatment of hepatic encephalopathy,C0019151,Hepatic Encephalopathy,2/10/98,Designated/Approved,,Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age, 03/24/2010 , 03/24/2017 ,
NZCRJKRKKOLAOJ-IEOSPBRCSA-N,66577007,NZCRJKRKKOLAOJ-IEOSPBRCSA-N,rifaximin,Xifaxan,Treatment of hepatic encephalopathy,C0019151,Hepatic Encephalopathy,2/10/98,Designated/Approved,,Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age, 03/24/2010 , 03/24/2017 ,
NZCRJKRKKOLAOJ-VXTOCXBKSA-N,42608884,NZCRJKRKKOLAOJ-VXTOCXBKSA-N,rifaximin,Xifaxan,Treatment of hepatic encephalopathy,C0019151,Hepatic Encephalopathy,2/10/98,Designated/Approved,,Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age, 03/24/2010 , 03/24/2017 ,
NZCRJKRKKOLAOJ-XWSQLESMSA-N,44384716,NZCRJKRKKOLAOJ-XWSQLESMSA-N,rifaximin,Xifaxan,Treatment of hepatic encephalopathy,C0019151,Hepatic Encephalopathy,2/10/98,Designated/Approved,,Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age, 03/24/2010 , 03/24/2017 ,
NZCRJKRKKOLAOJ-IIBMFGDOSA-N,72111,NZCRJKRKKOLAOJ-IIBMFGDOSA-N,rifaximin,Xifaxan,Treatment of hepatic encephalopathy,C0019151,Hepatic Encephalopathy,2/10/98,Designated/Approved,,Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age, 03/24/2010 , 03/24/2017 ,
NZCRJKRKKOLAOJ-LXVXMSHWSA-N,71296876,NZCRJKRKKOLAOJ-LXVXMSHWSA-N,rifaximin,Xifaxan,Treatment of hepatic encephalopathy,C0019151,Hepatic Encephalopathy,2/10/98,Designated/Approved,,Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age, 03/24/2010 , 03/24/2017 ,
NZCRJKRKKOLAOJ-KOPWYESNSA-N,72698618,NZCRJKRKKOLAOJ-KOPWYESNSA-N,rifaximin,Xifaxan,Treatment of hepatic encephalopathy,C0019151,Hepatic Encephalopathy,2/10/98,Designated/Approved,,Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age, 03/24/2010 , 03/24/2017 ,
NZCRJKRKKOLAOJ-CPJOEXDVSA-N,57507834,NZCRJKRKKOLAOJ-CPJOEXDVSA-N,rifaximin,Xifaxan,Treatment of hepatic encephalopathy,C0019151,Hepatic Encephalopathy,2/10/98,Designated/Approved,,Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age, 03/24/2010 , 03/24/2017 ,
NZCRJKRKKOLAOJ-UHFFFAOYSA-N,53395233,NZCRJKRKKOLAOJ-UHFFFAOYSA-N,rifaximin,Xifaxan,Treatment of hepatic encephalopathy,C0019151,Hepatic Encephalopathy,2/10/98,Designated/Approved,,Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age, 03/24/2010 , 03/24/2017 ,
NZCRJKRKKOLAOJ-HQDKJBBOSA-N,16667733,NZCRJKRKKOLAOJ-HQDKJBBOSA-N,rifaximin,Xifaxan,Treatment of hepatic encephalopathy,C0019151,Hepatic Encephalopathy,2/10/98,Designated/Approved,,Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age, 03/24/2010 , 03/24/2017 ,
NZCRJKRKKOLAOJ-LGPAXTBISA-N,46783403,NZCRJKRKKOLAOJ-LGPAXTBISA-N,rifaximin,Xifaxan,Treatment of hepatic encephalopathy,C0019151,Hepatic Encephalopathy,2/10/98,Designated/Approved,,Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age, 03/24/2010 , 03/24/2017 ,
NZCRJKRKKOLAOJ-XRCRFVBUSA-N,6436173,NZCRJKRKKOLAOJ-XRCRFVBUSA-N,rifaximin,Xifaxan,Treatment of hepatic encephalopathy,C0019151,Hepatic Encephalopathy,2/10/98,Designated/Approved,,Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age, 03/24/2010 , 03/24/2017 ,
DRFDPXKCEWYIAW-UHFFFAOYSA-M,4194514,DRFDPXKCEWYIAW-UHFFFAOYSA-M,risedronate sodium,,Treatment of patients with osteogenesis imperfecta,C0029434,Osteogenesis Imperfecta,12/18/06,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
JUQLTPCYUFPYKE-UHFFFAOYSA-N,5074,JUQLTPCYUFPYKE-UHFFFAOYSA-N,Ritanserin,,Treatment of glioblastoma,C0017636,Glioblastoma,5/11/17,Designated,Not FDA Approved for Orphan Indication,,,,
HYHSBSXUHZOYLX-WDSKDSINSA-M,7059524,HYHSBSXUHZOYLX-WDSKDSINSA-M,S-nitrosoglutathione,,Management of cystic fibrosis patients to improve airway clearance and to improve or stabilize pulmonary function,"C0010674,C1547996","Cystic Fibrosis , Pulmonary Function",5/12/09,Designated,Not FDA Approved for Orphan Indication,,,,
HYHSBSXUHZOYLX-WDSKDSINSA-N,104858,HYHSBSXUHZOYLX-WDSKDSINSA-N,S-nitrosoglutathione,,Management of cystic fibrosis patients to improve airway clearance and to improve or stabilize pulmonary function,"C0010674,C1547996","Cystic Fibrosis , Pulmonary Function",5/12/09,Designated,Not FDA Approved for Orphan Indication,,,,
ULRUOUDIQPERIJ-PQURJYPBSA-N,91668186,ULRUOUDIQPERIJ-PQURJYPBSA-N,sacituzumab govitecan,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,5/29/14,Designated,Not FDA Approved for Orphan Indication,,,,
HKFMQJUJWSFOLY-OAQYLSRUSA-N,6918388,HKFMQJUJWSFOLY-OAQYLSRUSA-N,sarizotan,,Treatment of Rett syndrome.,C0035372,Rett Syndrome,7/7/15,Designated,Not FDA Approved for Orphan Indication,,,,
ZJZDXGQUNVNYQP-MXEXKMKYSA-N,24894654,ZJZDXGQUNVNYQP-MXEXKMKYSA-N,satoreotide tetraxetan,,Management of gastroenteropancreatic neuroendocrine tumors,C0206754,Neuroendocrine Tumors,9/24/14,Designated,Not FDA Approved for Orphan Indication,,,,
JWHYSEDOYMYMNM-QGZVFWFLSA-N,11236126,JWHYSEDOYMYMNM-QGZVFWFLSA-N,seladelpar,,Treatment of primary biliary cholangitis,C0008312,Primary Biliary Cholangitis,11/7/16,Designated,Not FDA Approved for Orphan Indication,,,,
XIIOFHFUYBLOLW-UHFFFAOYSA-N,134436906,XIIOFHFUYBLOLW-UHFFFAOYSA-N,selpercatinib,RETEVMO,Treatment of RET-fusion-positive non-small cell lung cancer,C3539721,Non-Small Cell Lung Cancer,10/30/19,Designated/Approved,,RETEVMO is indicated for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), 05/08/2020 , 05/08/2027 ,For the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC)
VPVOXUSPXFPWBN-VKHMYHEASA-N,135398579,VPVOXUSPXFPWBN-VKHMYHEASA-N,sepiapterin,,Treatment of primary tetrahydrobiopterin deficiency,C0751436,Tetrahydrobiopterin Deficiency,2/19/20,Designated,Not FDA Approved for Orphan Indication,,,,
QFJCIRLUMZQUOT-HPLJOQBZSA-N,5284616,QFJCIRLUMZQUOT-HPLJOQBZSA-N,sirolimus,,Treatment of beta-thalassemia.,C0005283,BETA-THALASSEMIA,6/21/16,Designated,Not FDA Approved for Orphan Indication,,,,
LUPNKHXLFSSUGS-UHFFFAOYSA-M,517326,LUPNKHXLFSSUGS-UHFFFAOYSA-M,Sodium dichloroacetate,,Treatment of severe head injury.,C0018674,HEAD INJURY,6/14/99,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
LUPNKHXLFSSUGS-UHFFFAOYSA-M,517326,LUPNKHXLFSSUGS-UHFFFAOYSA-M,Sodium dichloroacetate,,Treatment of lactic acidosis in patients with severe malaria.,"C0001125,C2747816","LACTIC ACIDOSIS , Severe Malaria",11/10/94,Designated,Not FDA Approved for Orphan Indication,,,,
LUPNKHXLFSSUGS-UHFFFAOYSA-M,517326,LUPNKHXLFSSUGS-UHFFFAOYSA-M,Sodium dichloroacetate,,Treatment of congenital lactic acidosis,C4025276,Congenital lactic acidosis,6/11/90,Designated,Not FDA Approved for Orphan Indication,,,,
LPXPTNMVRIOKMN-UHFFFAOYSA-M,23668193,LPXPTNMVRIOKMN-UHFFFAOYSA-M,sodium nitrite,,Treatment of chlorine gas poisoning,C0017107,Gas Poisoning,1/9/12,Designated,Not FDA Approved for Orphan Indication,,,,
VPZRWNZGLKXFOE-UHFFFAOYSA-M,5258,VPZRWNZGLKXFOE-UHFFFAOYSA-M,sodium phenylbutyrate,,Treatment of urea cycle disorder.,C0154246,urea cycle disorder,1/19/10,Designated,Not FDA Approved for Orphan Indication,,,,
AEQFSUDEHCCHBT-UHFFFAOYSA-M,16760703,AEQFSUDEHCCHBT-UHFFFAOYSA-M,sodium valproate,,Treatment of Wolfram syndrome,C0043207,Wolfram Syndrome,8/5/15,Designated,Not FDA Approved for Orphan Indication,,,,
LKVFMOMQYXIFRK-KSVAIKAXSA-N,91864495,LKVFMOMQYXIFRK-KSVAIKAXSA-N,solnatide,,Treatment of primary graft dysfunction following lung transplantation,C0948031,Primary Graft Dysfunction,2/4/16,Designated,Not FDA Approved for Orphan Indication,,,,
UCTRAOBQFUDCSR-SECBINFHSA-N,10130337,UCTRAOBQFUDCSR-SECBINFHSA-N,Solriamfetol,Sunosi,Treatment of narcolepsy,C0027404,Narcolepsy,8/20/12,Designated/Approved,,SUNOSI is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy, 06/17/2019 , 06/17/2026 ,To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy
PWILYDZRJORZDR-MISYRCLQSA-N,213054,PWILYDZRJORZDR-MISYRCLQSA-N,soraprazan,,Treatment of Stargardt Disease (StD),"C0036916,C1412063","STD , Stargardt disease",12/22/17,Designated,Not FDA Approved for Orphan Indication,,,,
SEEPANYCNGTZFQ-UHFFFAOYSA-N,5215,SEEPANYCNGTZFQ-UHFFFAOYSA-N,Sulfadiazine,,For use in combination with pyrimethamine for the treatment of Toxoplasma gondii encephalitis in patients with and without AIDS.,"C0001175,C0085315","AIDS , toxoplasma gondii encephalitis",3/14/94,Designated/Approved,,"Toxoplasmosis, as adjunctive with pyrimethamine", 07/29/1994 , 07/29/2001 ,
GECHUMIMRBOMGK-UHFFFAOYSA-N,5336,GECHUMIMRBOMGK-UHFFFAOYSA-N,Sulfapyridine,,Treatment of dermatitis herpetiformis.,C0011608,Dermatitis Herpetiformis,9/10/90,Designated,Not FDA Approved for Orphan Indication,,,,
MLKXDPUZXIRXEP-MFOYZWKCSA-N,1548887,MLKXDPUZXIRXEP-MFOYZWKCSA-N,sulindac,,Treatment of retinitis pigmentosa,C0035334,Retinitis Pigmentosa,8/4/20,Designated,Not FDA Approved for Orphan Indication,,,,
FIAFUQMPZJWCLV-UHFFFAOYSA-N,5361,FIAFUQMPZJWCLV-UHFFFAOYSA-N,Suramin,,Treatment of hormone-refractory prostate cancer.,C0376358,Prostate Cancer,5/6/97,Designated,Not FDA Approved for Orphan Indication,,,,
QJJXYPPXXYFBGM-LFZNUXCKSA-N,445643,QJJXYPPXXYFBGM-LFZNUXCKSA-N,tacrolimus,,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,5/4/15,Designated,Not FDA Approved for Orphan Indication,,,,
JCOHXVDKRMWUQP-UHFFFAOYSA-M,23718384,JCOHXVDKRMWUQP-UHFFFAOYSA-M,tasisulam sodium,,Treatment of melanoma stages IIB through IV,C0280209,melanoma stages,9/3/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
XSFPZBUIBYMVEA-CELUQASASA-N,25253377,XSFPZBUIBYMVEA-CELUQASASA-N,telotristat etiprate,Xermelo,Treatment of carcinoid syndrome in patients with neuroendocrine tumors,"C0024586,C0206754","Carcinoid syndrome , Neuroendocrine Tumors",3/9/12,Designated/Approved,,Treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy., 02/28/2017 , 02/28/2024 ,Treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.
JOAHPSVPXZTVEP-YXJHDRRASA-N,443951,JOAHPSVPXZTVEP-YXJHDRRASA-N,terguride,,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,5/2/08,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
BENFXAYNYRLAIU-QSVFAHTRSA-N,72081,BENFXAYNYRLAIU-QSVFAHTRSA-N,terlipressin,,Treatment of Hepatorenal Syndrome,C0019212,Hepatorenal Syndrome,10/29/04,Designated,Not FDA Approved for Orphan Indication,,,,
FEQOLYDPQKHFTD-UHFFFAOYSA-N,46932299,FEQOLYDPQKHFTD-UHFFFAOYSA-N,"tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride",,Treatment of infantile spasms,C3887898,Infantile spasms,6/20/16,Designated,Not FDA Approved for Orphan Indication,,,,
MJUVRTYWUMPBTR-MRXNPFEDSA-N,46199646,MJUVRTYWUMPBTR-MRXNPFEDSA-N,Tezacaftor,,Treatment of cystic fibrosis,C0010674,Cystic Fibrosis,4/24/14,Designated,Not FDA Approved for Orphan Indication,,,,
UEJJHQNACJXSKW-UHFFFAOYSA-N,5426,UEJJHQNACJXSKW-UHFFFAOYSA-N,Thalidomide,,Prevention of graft versus host disease.,C0018133,GRAFT VERSUS HOST DISEASE,3/5/90,Designated,Not FDA Approved for Orphan Indication,,,,
UEJJHQNACJXSKW-UHFFFAOYSA-N,5426,UEJJHQNACJXSKW-UHFFFAOYSA-N,Thalidomide,Thalomid,Treatment of erythema nodosum leprosum.,C0343467,Erythema nodosum leprosum,7/26/95,Designated/Approved,,Acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) and as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrences., 07/16/1998 , 07/16/2005 ,
SOVUOXKZCCAWOJ-HJYUBDRYSA-N,54686904,SOVUOXKZCCAWOJ-HJYUBDRYSA-N,tigecycline,,Treatment of acute myeloid leukemia.,C0023467,Acute myeloid leukemia,10/23/13,Designated,Not FDA Approved for Orphan Indication,,,,
DWGQFQRWFYIINU-UHFFFAOYSA-N,134687437,DWGQFQRWFYIINU-UHFFFAOYSA-N,tinostamustine hydrochloride,,Treatment of T-cell prolymphocytic leukemia,C2363142,T-Cell Prolymphocytic Leukemia,3/15/19,Designated,Not FDA Approved for Orphan Indication,,,,
YTGJWQPHMWSCST-UHFFFAOYSA-N,5483,YTGJWQPHMWSCST-UHFFFAOYSA-N,Tiopronin,Thiola,Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.,"C0010691,C0022650","Cystinuria , Nephrolithiasis",1/17/86,Designated/Approved,,"THIOLA EC is indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 20 kg and greater with severe homozygous cystinuria, who are not responsive to these measures alone.", 06/28/2019 , 06/28/2026 ,
ORYDPOVDJJZGHQ-UHFFFAOYSA-N,135413511,ORYDPOVDJJZGHQ-UHFFFAOYSA-N,tirapazamine,,Treatment of head and neck cancer,C3887461,Head and Neck Cancer,10/23/02,Designated,Not FDA Approved for Orphan Indication,,,,
XFCLJVABOIYOMF-QPLCGJKRSA-N,3005573,XFCLJVABOIYOMF-QPLCGJKRSA-N,Toremifene,Fareston,Hormonal therapy of metastatic carcinoma of the breast.,"C0678222,C1384494","Carcinoma of the Breast , Metastatic Carcinoma",9/19/91,Designated/Approved,,Treatment of metastatic breast cancer in postmenopausal women with estrogen positive or receptor unknown tumors., 05/29/1997 , 05/29/2004 ,
FWFGIHPGRQZWIW-SQNIBIBYSA-N,15547703,FWFGIHPGRQZWIW-SQNIBIBYSA-N,Tosedostat,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,12/10/08,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PKVRCIRHQMSYJX-AIFWHQITSA-N,108150,PKVRCIRHQMSYJX-AIFWHQITSA-N,trabectedin,Yondelis,Treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,9/30/04,Designated/Approved,,For the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen, 10/23/2015 , 10/23/2022 ,For the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen
HSWLVDBGZCETRH-UHFFFAOYSA-O,132472120,HSWLVDBGZCETRH-UHFFFAOYSA-O,trabedersen,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,7/21/09,Designated,Not FDA Approved for Orphan Indication,,,,
NZHGWWWHIYHZNX-CSKARUKUSA-N,5282230,NZHGWWWHIYHZNX-CSKARUKUSA-N,tranilast,,Prevention of scarring following glaucoma filtration surgery,C0017601,Glaucoma,12/23/10,Designated,Not FDA Approved for Orphan Indication,,,,
WBYWAXJHAXSJNI-VOTSOKGWSA-N,444539,WBYWAXJHAXSJNI-VOTSOKGWSA-N,Trans-Cinnamic Acid,,treatment for Niemann-Pick disease Type A and Type B,C0268242,niemann-pick disease type a,11/24/20,Designated,Not FDA Approved for Orphan Indication,,,,
YCPOZVAOBBQLRI-PHDIDXHHSA-N,95839,YCPOZVAOBBQLRI-PHDIDXHHSA-N,Treosulfan,,Treatment of ovarian cancer.,C4721610,Ovarian Cancer,5/16/94,Designated,Not FDA Approved for Orphan Indication,,,,
YCPOZVAOBBQLRI-UHFFFAOYSA-N,9296,YCPOZVAOBBQLRI-UHFFFAOYSA-N,Treosulfan,,Treatment of ovarian cancer.,C4721610,Ovarian Cancer,5/16/94,Designated,Not FDA Approved for Orphan Indication,,,,
YCPOZVAOBBQLRI-WDSKDSINSA-N,9882105,YCPOZVAOBBQLRI-WDSKDSINSA-N,Treosulfan,,Treatment of ovarian cancer.,C4721610,Ovarian Cancer,5/16/94,Designated,Not FDA Approved for Orphan Indication,,,,
WYHIICXRPHEJKI-UHFFFAOYSA-N,71433,WYHIICXRPHEJKI-UHFFFAOYSA-N,trientine hydrochloride,,Treatment of manganism,C0677050,Manganism,11/2/10,Designated,Not FDA Approved for Orphan Indication,,,,
KSERXGMCDHOLSS-LJQANCHMSA-N,11719003,KSERXGMCDHOLSS-LJQANCHMSA-N,Ulixertinib,,Treatment of Stage IIb through Stage IV BRAF mutant melanoma,C0025202,melanoma,6/24/13,Designated,Not FDA Approved for Orphan Indication,,,,
WYQFJHHDOKWSHR-MNOVXSKESA-N,58557659,WYQFJHHDOKWSHR-MNOVXSKESA-N,upadacitinib,,Treatment of pediatric ulcerative colitis,C2931173,Pediatric ulcerative colitis,12/30/19,Designated,Not FDA Approved for Orphan Indication,,,,
RUDATBOHQWOJDD-UZVSRGJWSA-N,31401,RUDATBOHQWOJDD-UZVSRGJWSA-N,ursodiol,,Treatment of cystic fibrosis liver disease,C2827436,Cystic Fibrosis Liver Disease,10/23/07,Designated,Not FDA Approved for Orphan Indication,,,,
AEQFSUDEHCCHBT-UHFFFAOYSA-M,16760703,AEQFSUDEHCCHBT-UHFFFAOYSA-M,Valproate,,Treatment of fragile X syndrome,C0016667,Fragile X Syndrome,5/5/08,Designated,Not FDA Approved for Orphan Indication,,,,
NIJJYAXOARWZEE-UHFFFAOYSA-M,3549980,NIJJYAXOARWZEE-UHFFFAOYSA-M,Valproate,,Treatment of fragile X syndrome,C0016667,Fragile X Syndrome,5/5/08,Designated,Not FDA Approved for Orphan Indication,,,,
NIJJYAXOARWZEE-UHFFFAOYSA-N,3121,NIJJYAXOARWZEE-UHFFFAOYSA-N,Valproate,,Treatment of fragile X syndrome,C0016667,Fragile X Syndrome,5/5/08,Designated,Not FDA Approved for Orphan Indication,,,,
UHTHHESEBZOYNR-UHFFFAOYSA-N,3081361,UHTHHESEBZOYNR-UHFFFAOYSA-N,vandetanib,CAPRELSA(r),"Treatment of patients with follicular thyroid carcinoma, medullary thyroid carcinoma, anaplastic thyroid carcinoma, and locally advanced and metastatic papillary thyroid carcinoma","C0206682,C0238461,C0238462,C0278851","Follicular thyroid carcinoma , Carcinoma, Anaplastic Thyroid , Thyroid carcinoma, medullary , Metastatic papillary thyroid carcinoma",10/21/05,Designated/Approved,,Treatment of asymptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease, 04/06/2011 , 04/06/2018 ,
SECKRCOLJRRGGV-UHFFFAOYSA-N,135400189,SECKRCOLJRRGGV-UHFFFAOYSA-N,vardenafil,,Treatment of Pulmonary Arterial Hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,4/22/19,Designated,Not FDA Approved for Orphan Indication,,,,
UWXSAYUXVSFDBQ-CYBMUJFWSA-N,42642648,UWXSAYUXVSFDBQ-CYBMUJFWSA-N,varlitinib,,treatment of biliary tract cancer,C0750952,Biliary Tract Cancer,8/5/15,Designated,Not FDA Approved for Orphan Indication,,,,
JNAHVYVRKWKWKQ-CYBMUJFWSA-N,11960529,JNAHVYVRKWKWKQ-CYBMUJFWSA-N,veliparib,,Treatment of brain metastases when used in combination with DNA-damaging agents,C0220650,brain metastases,12/17/14,Designated,Not FDA Approved for Orphan Indication,,,,
JNAHVYVRKWKWKQ-CYBMUJFWSA-N,11960529,JNAHVYVRKWKWKQ-CYBMUJFWSA-N,veliparib,,Treatment of glioblastoma multiforme when used in combination with DNA-damaging agents,C0017636,Glioblastoma multiforme,5/9/08,Designated,Not FDA Approved for Orphan Indication,,,,
GPXBXXGIAQBQNI-UHFFFAOYSA-N,42611257,GPXBXXGIAQBQNI-UHFFFAOYSA-N,vemurafenib,Zelboraf,Treatment of Erdheim-Chester Disease,C0878675,Erdheim-Chester Disease,8/2/16,Designated/Approved,,Treatment of patients with Erdheim-Chester Disease with BRAF V600 mutation, 11/06/2017 , 11/06/2024 ,Treatment of patients with Erdheim-Chester Disease with BRAF V600 mutation
NJLRKAMQPVVOIU-IDLGWYNRSA-N,11980904,NJLRKAMQPVVOIU-IDLGWYNRSA-N,verteporfin,,Treatment of chronic or recurrent central serous chorioretinopathy,C0730328,Central Serous Chorioretinopathy,3/9/12,Designated,Not FDA Approved for Orphan Indication,,,,
QCZAWDGAVJMPTA-RNFRBKRXSA-N,117817422,QCZAWDGAVJMPTA-RNFRBKRXSA-N,vorasidenib,,Treatment of glioma,C0017638,Glioma,9/10/18,Designated,Not FDA Approved for Orphan Indication,,,,
WAEXFXRVDQXREF-UHFFFAOYSA-N,5311,WAEXFXRVDQXREF-UHFFFAOYSA-N,vorinostat,,Treatment of mesothelioma,C0025500,Mesothelioma,3/17/04,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
RNOAOAWBMHREKO-QFIPXVFZSA-N,135565884,RNOAOAWBMHREKO-QFIPXVFZSA-N,Zanubrutinib,,Treatment of Waldenstrom's macroglobulinemia,C0024419,Waldenstrom's Macroglobulinemia,6/29/16,Designated,Not FDA Approved for Orphan Indication,,,,
XRASPMIURGNCCH-UHFFFAOYSA-N,68740,XRASPMIURGNCCH-UHFFFAOYSA-N,Zoledronate,"Zometa, Zabel",Treatment of tumor induced hypercalcemia.,"C0020437,C0027651","Hypercalcemia , Tumor",8/18/00,Designated/Approved,,Treatment of hypercalcemia of malignancy., 08/20/2001 , 08/20/2008 ,
VQJFFWJUYDGTQZ-MGUDINDMSA-N,54612642,VQJFFWJUYDGTQZ-MGUDINDMSA-N,Zosuquidar trihydrochloride,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,12/15/05,Designated,Not FDA Approved for Orphan Indication,,,,
IHOVFYSQUDPMCN-XAKVHENESA-N,3036703,IHOVFYSQUDPMCN-XAKVHENESA-N,Zosuquidar trihydrochloride,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,12/15/05,Designated,Not FDA Approved for Orphan Indication,,,,
ZPFVQKPWGDRLHL-ZLYBXYBFSA-N,153997,ZPFVQKPWGDRLHL-ZLYBXYBFSA-N,Zosuquidar trihydrochloride,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,12/15/05,Designated,Not FDA Approved for Orphan Indication,,,,
VXBAJLGYBMTJCY-NSCUHMNNSA-N,16739650,VXBAJLGYBMTJCY-NSCUHMNNSA-N,zotiraciclib,,Treatment of glioma,C0017638,Glioma,11/21/19,Designated,Not FDA Approved for Orphan Indication,,,,
QGNJRVVDBSJHIZ-AQDFTDIISA-N,10245972,QGNJRVVDBSJHIZ-AQDFTDIISA-N,zuretinol acetate,,Treatment of inherited retinal dystrophies caused by confirmed biallelic RPE65 or LRAT mutations,C0854723,Retinal Dystrophies,12/2/10,Designated,Not FDA Approved for Orphan Indication,,,,
PENDGIOBPJLVBT-WNGDBVLYSA-N,146157949,PENDGIOBPJLVBT-WNGDBVLYSA-N,cethromycin,,Prophylactic treatment of patients exposed to inhalation anthrax.,C0155866,Inhalation anthrax,2/28/07,Designated,Not FDA Approved for Orphan Indication,,,,
PENDGIOBPJLVBT-COVUKVLKSA-N,11354711,PENDGIOBPJLVBT-COVUKVLKSA-N,cethromycin,,Prophylactic treatment of patients exposed to inhalation anthrax.,C0155866,Inhalation anthrax,2/28/07,Designated,Not FDA Approved for Orphan Indication,,,,
PENDGIOBPJLVBT-AMXFZXBBSA-N,156417,PENDGIOBPJLVBT-AMXFZXBBSA-N,cethromycin,,Prophylactic treatment of patients exposed to inhalation anthrax.,C0155866,Inhalation anthrax,2/28/07,Designated,Not FDA Approved for Orphan Indication,,,,
PENDGIOBPJLVBT-HMMOOPTJSA-N,5282045,PENDGIOBPJLVBT-HMMOOPTJSA-N,cethromycin,,Prophylactic treatment of patients exposed to inhalation anthrax.,C0155866,Inhalation anthrax,2/28/07,Designated,Not FDA Approved for Orphan Indication,,,,
PENDGIOBPJLVBT-ONLVEXIXSA-N,447451,PENDGIOBPJLVBT-ONLVEXIXSA-N,cethromycin,,Prophylactic treatment of patients exposed to inhalation anthrax.,C0155866,Inhalation anthrax,2/28/07,Designated,Not FDA Approved for Orphan Indication,,,,
PENDGIOBPJLVBT-WNGDBVLYSA-N,146157949,PENDGIOBPJLVBT-WNGDBVLYSA-N,cethromycin,,Prophylactic treatment of tularemia due to Francisella tularensis.,C0041351,Tularemia,9/9/09,Designated,Not FDA Approved for Orphan Indication,,,,
PENDGIOBPJLVBT-COVUKVLKSA-N,11354711,PENDGIOBPJLVBT-COVUKVLKSA-N,cethromycin,,Prophylactic treatment of tularemia due to Francisella tularensis.,C0041351,Tularemia,9/9/09,Designated,Not FDA Approved for Orphan Indication,,,,
PENDGIOBPJLVBT-AMXFZXBBSA-N,156417,PENDGIOBPJLVBT-AMXFZXBBSA-N,cethromycin,,Prophylactic treatment of tularemia due to Francisella tularensis.,C0041351,Tularemia,9/9/09,Designated,Not FDA Approved for Orphan Indication,,,,
PENDGIOBPJLVBT-HMMOOPTJSA-N,5282045,PENDGIOBPJLVBT-HMMOOPTJSA-N,cethromycin,,Prophylactic treatment of tularemia due to Francisella tularensis.,C0041351,Tularemia,9/9/09,Designated,Not FDA Approved for Orphan Indication,,,,
PENDGIOBPJLVBT-ONLVEXIXSA-N,447451,PENDGIOBPJLVBT-ONLVEXIXSA-N,cethromycin,,Prophylactic treatment of tularemia due to Francisella tularensis.,C0041351,Tularemia,9/9/09,Designated,Not FDA Approved for Orphan Indication,,,,
RUDATBOHQWOJDD-BSWAIDMHSA-N,10133,RUDATBOHQWOJDD-BSWAIDMHSA-N,chenodeoxycholic acid,,Treatment of cerebrotendinous xanthomatosis,C0238052,CEREBROTENDINOUS XANTHOMATOSIS,2/12/07,Designated,Not FDA Approved for Orphan Indication,,,,
SGMZJAMFUVOLNK-UHFFFAOYSA-M,6209,SGMZJAMFUVOLNK-UHFFFAOYSA-M,Choline chloride,,Prevention and/or treatment of choline deficiency in patients on long-term parenteral nutrition,C0008412,Choline Deficiency,7/20/06,Designated,Not FDA Approved for Orphan Indication,,,,
SCKYRAXSEDYPSA-UHFFFAOYSA-N,2749,SCKYRAXSEDYPSA-UHFFFAOYSA-N,Ciclopirox,,Treatment of congenital erythropoietic porphyria,C0162530,congenital erythropoietic porphyria,4/17/18,Designated,Not FDA Approved for Orphan Indication,,,,
PTOAARAWEBMLNO-KVQBGUIXSA-N,20279,PTOAARAWEBMLNO-KVQBGUIXSA-N,Cladribine,Leustatin Injection,Treatment of hairy cell leukemia.,C0023443,Hairy Cell Leukemia,11/15/90,Designated/Approved,,, 02/26/1993 , 02/26/2000 ,
STJMRWALKKWQGH-UHFFFAOYSA-N,2783,STJMRWALKKWQGH-UHFFFAOYSA-N,clenbuterol,,Adjunctive therapy with enzyme replacement therapy in the treatment of Pompe disease,C0017921,Pompe Disease,10/27/14,Designated,Not FDA Approved for Orphan Indication,,,,
VNFPBHJOKIVQEB-UHFFFAOYSA-N,2812,VNFPBHJOKIVQEB-UHFFFAOYSA-N,Clotrimazole,,Treatment of Huntington's disease,C0020179,Huntington's Disease,3/13/06,Designated,Not FDA Approved for Orphan Indication,,,,
ZCIGNRJZKPOIKD-CQXVEOKZSA-N,25151504,ZCIGNRJZKPOIKD-CQXVEOKZSA-N,cobicistat,Tybost,Treatment of human immunodeficiency virus type 1 (HIV-1) infection in pediatric patients,"C0009450,C0019704","Infection , Human immunodeficiency virus type 1",6/15/17,Designated/Approved,,TYBOST is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir in combination with other antiretroviral agents in the treatment of HIV-1 infection in pediatric patients weighing at least 35 kg, 08/22/2019 , 08/22/2026 ,Indicated to increase systemic exposure of atazanavir in combination with other antiretroviral agents in the treatment of HIV-1 infection in pediatric patients weighing at least 35 kg.
NNUHKSNTEOVPHV-UHFFFAOYSA-N,145994613,NNUHKSNTEOVPHV-UHFFFAOYSA-N,cobomarsen,,Treatment of T-cell lymphoma,C0079772,T-Cell Lymphoma,7/21/20,Designated,Not FDA Approved for Orphan Indication,,,,
NNUHKSNTEOVPHV-XHZCTNOISA-N,126480232,NNUHKSNTEOVPHV-XHZCTNOISA-N,cobomarsen,,Treatment of T-cell lymphoma,C0079772,T-Cell Lymphoma,7/21/20,Designated,Not FDA Approved for Orphan Indication,,,,
WDOGQTQEKVLZIJ-WAYWQWQTSA-L,21159388,WDOGQTQEKVLZIJ-WAYWQWQTSA-L,Combretastatin A4 phosphate,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,5/8/06,Designated,Not FDA Approved for Orphan Indication,,,,
WDOGQTQEKVLZIJ-WAYWQWQTSA-N,5351387,WDOGQTQEKVLZIJ-WAYWQWQTSA-N,Combretastatin A4 phosphate,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,5/8/06,Designated,Not FDA Approved for Orphan Indication,,,,
MWYDSXOGIBMAET-UHFFFAOYSA-N,135565596,MWYDSXOGIBMAET-UHFFFAOYSA-N,copanlisib,ALIQOPA,Treatment of follicular lymphoma,C0024301,follicular lymphoma,2/5/15,Designated/Approved,,Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies, 09/14/2017 , 09/14/2024 ,Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies
MWYDSXOGIBMAET-UHFFFAOYSA-N,135565596,MWYDSXOGIBMAET-UHFFFAOYSA-N,copanlisib,,Treatment of nodal marginal zone lymphoma,C0242647,Nodal marginal zone lymphoma,2/7/17,Designated,Not FDA Approved for Orphan Indication,,,,
OFEZSBMBBKLLBJ-BAJZRUMYSA-N,6303,OFEZSBMBBKLLBJ-BAJZRUMYSA-N,Cordycepin,,Treatment of TdT-positive acute lymphocytic leukemia,C0023449,Acute lymphocytic leukemia,7/5/07,Designated,Not FDA Approved for Orphan Indication,,,,
MTSXPVSZJVNPBE-OCOINPOZSA-M,16218873,MTSXPVSZJVNPBE-OCOINPOZSA-M,corifungin,,Treatment of amebic meningoencephalitis.,C0487784,Amebic Meningoencephalitis,8/22/11,Designated,Not FDA Approved for Orphan Indication,,,,
ZYGHJZDHTFUPRJ-UHFFFAOYSA-N,323,ZYGHJZDHTFUPRJ-UHFFFAOYSA-N,Coumarin,,Treatment of renal cell carcinoma.,C0007134,Renal Cell Carcinoma,12/22/94,Designated,Not FDA Approved for Orphan Indication,,,,
CVSVTCORWBXHQV-UHFFFAOYSA-N,586,CVSVTCORWBXHQV-UHFFFAOYSA-N,creatine,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,2/12/02,Designated,Not FDA Approved for Orphan Indication,,,,
DYNHJHQFHQTFTP-UHFFFAOYSA-N,10366136,DYNHJHQFHQTFTP-UHFFFAOYSA-N,crenolanib,,"Treatment of gastric cancer, including cancer of the gastroesophageal junction","C0006826,C0024623","Cancer , Gastric Cancer",10/21/19,Designated,Not FDA Approved for Orphan Indication,,,,
ARQUTWAXTHJROR-UHFFFAOYSA-N,18435899,ARQUTWAXTHJROR-UHFFFAOYSA-N,crenolanib besylate,,Treatment of malignant glioma,C0555198,Malignant Glioma,12/20/10,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-SCYOXIPCSA-N,123134263,PMATZTZNYRCHOR-SCYOXIPCSA-N,Cyclosporine,,Treatment of acute rejection in patients requiring allogenic lung transplants,C3273245,Acute Rejection,11/25/03,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-AVZWOAAISA-N,122172945,PMATZTZNYRCHOR-AVZWOAAISA-N,Cyclosporine,,Treatment of acute rejection in patients requiring allogenic lung transplants,C3273245,Acute Rejection,11/25/03,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-SRFWORPQSA-N,25246316,PMATZTZNYRCHOR-SRFWORPQSA-N,Cyclosporine,,Treatment of acute rejection in patients requiring allogenic lung transplants,C3273245,Acute Rejection,11/25/03,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-QVSDIVLPSA-N,5497195,PMATZTZNYRCHOR-QVSDIVLPSA-N,Cyclosporine,,Treatment of acute rejection in patients requiring allogenic lung transplants,C3273245,Acute Rejection,11/25/03,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-VJRYSDSKSA-N,24883466,PMATZTZNYRCHOR-VJRYSDSKSA-N,Cyclosporine,,Treatment of acute rejection in patients requiring allogenic lung transplants,C3273245,Acute Rejection,11/25/03,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-GNSAQUIPSA-N,62280,PMATZTZNYRCHOR-GNSAQUIPSA-N,Cyclosporine,,Treatment of acute rejection in patients requiring allogenic lung transplants,C3273245,Acute Rejection,11/25/03,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-IMVLJIQESA-N,5280754,PMATZTZNYRCHOR-IMVLJIQESA-N,Cyclosporine,,Treatment of acute rejection in patients requiring allogenic lung transplants,C3273245,Acute Rejection,11/25/03,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-KMSBSJHKSA-N,6435893,PMATZTZNYRCHOR-KMSBSJHKSA-N,Cyclosporine,,Treatment of acute rejection in patients requiring allogenic lung transplants,C3273245,Acute Rejection,11/25/03,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-CGLBZJNRSA-N,5284373,PMATZTZNYRCHOR-CGLBZJNRSA-N,Cyclosporine,,Treatment of acute rejection in patients requiring allogenic lung transplants,C3273245,Acute Rejection,11/25/03,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-RNWFWJGASA-N,138107778,PMATZTZNYRCHOR-RNWFWJGASA-N,cyclosporine A,,Treatment of herpes simplex virus stromal keratitis,"C0319157,C1318020","virus , Stromal keratitis",4/9/08,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-RYZPDLMBSA-N,123134270,PMATZTZNYRCHOR-RYZPDLMBSA-N,cyclosporine A,,Treatment of herpes simplex virus stromal keratitis,"C0319157,C1318020","virus , Stromal keratitis",4/9/08,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-NFOUMSERSA-N,16404350,PMATZTZNYRCHOR-NFOUMSERSA-N,cyclosporine A,,Treatment of herpes simplex virus stromal keratitis,"C0319157,C1318020","virus , Stromal keratitis",4/9/08,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-QVSDIVLPSA-N,5497195,PMATZTZNYRCHOR-QVSDIVLPSA-N,cyclosporine A,,Treatment of herpes simplex virus stromal keratitis,"C0319157,C1318020","virus , Stromal keratitis",4/9/08,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-UHFFFAOYSA-N,2909,PMATZTZNYRCHOR-UHFFFAOYSA-N,cyclosporine A,,Treatment of herpes simplex virus stromal keratitis,"C0319157,C1318020","virus , Stromal keratitis",4/9/08,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-NSJDOISKSA-N,71463825,PMATZTZNYRCHOR-NSJDOISKSA-N,cyclosporine A,,Treatment of herpes simplex virus stromal keratitis,"C0319157,C1318020","virus , Stromal keratitis",4/9/08,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-VPYFBNRVSA-N,49867938,PMATZTZNYRCHOR-VPYFBNRVSA-N,cyclosporine A,,Treatment of herpes simplex virus stromal keratitis,"C0319157,C1318020","virus , Stromal keratitis",4/9/08,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-IMVLJIQESA-N,5280754,PMATZTZNYRCHOR-IMVLJIQESA-N,cyclosporine A,,Treatment of herpes simplex virus stromal keratitis,"C0319157,C1318020","virus , Stromal keratitis",4/9/08,Designated,Not FDA Approved for Orphan Indication,,,,
PMATZTZNYRCHOR-CGLBZJNRSA-N,5284373,PMATZTZNYRCHOR-CGLBZJNRSA-N,cyclosporine A,,Treatment of herpes simplex virus stromal keratitis,"C0319157,C1318020","virus , Stromal keratitis",4/9/08,Designated,Not FDA Approved for Orphan Indication,,,,
UWFYSQMTEOIJJG-FDTZYFLXSA-N,9880,UWFYSQMTEOIJJG-FDTZYFLXSA-N,Cyproterone acetate,,Treatment of severe hirsutism.,C0019572,Hirsutism,10/26/84,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ZBNZXTGUTAYRHI-UHFFFAOYSA-N,3062316,ZBNZXTGUTAYRHI-UHFFFAOYSA-N,Dasatinib,Sprycel,Treatment of Philadelphia-positive acute lymphoblastic leukemia,C1709527,Philadelphia-positive acute lymphoblastic leukemia,11/18/05,Designated/Approved,,SPRYCEL (dasatinib) is indicated for the treatment of pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy., 12/21/2018 , 12/21/2025 ,SPRYCEL (dasatinib) is indicated for the treatment of pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.
FWLMVFUGMHIOAA-UHFFFAOYSA-N,25117126,FWLMVFUGMHIOAA-UHFFFAOYSA-N,defactinib,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,2/12/15,Designated,Not FDA Approved for Orphan Indication,,,,
TZXKOCQBRNJULO-UHFFFAOYSA-N,2972,TZXKOCQBRNJULO-UHFFFAOYSA-N,deferiprone,Ferriprox,Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy,"C0018939,C0282193","Hematologic Disorders , Iron Overload",12/12/01,Designated/Approved,,Ferriprox (deferiprone) is indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate., 05/19/2020 ,  ,
TZXKOCQBRNJULO-UHFFFAOYSA-N,2972,TZXKOCQBRNJULO-UHFFFAOYSA-N,deferiprone,Ferriprox,Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy,"C0018939,C0282193","Hematologic Disorders , Iron Overload",12/12/01,Designated/Approved,,Treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate, 10/14/2011 , 10/14/2018 ,
LFQSCWFLJHTTHZ-UHFFFAOYSA-N,702,LFQSCWFLJHTTHZ-UHFFFAOYSA-N,dehydrated alcohol,,Treatment of trigeminal neuralgia,C0040997,Trigeminal Neuralgia,3/16/12,Designated,Not FDA Approved for Orphan Indication,,,,
LFQSCWFLJHTTHZ-UHFFFAOYSA-N,702,LFQSCWFLJHTTHZ-UHFFFAOYSA-N,dehydrated alcohol,Ablysinol,Treatment of hypertrophic obstructive cardiomyopathy,C4551472,Hypertrophic obstructive cardiomyopathy,9/11/13,Designated/Approved,,ABLYSINOL is indicated to induce controlled cardiac septal infarction to improve exercise capacity in adults with symptomatic hypertrophic obstructive cardiomyopathy who are not candidates for surgical myectomy., 06/21/2018 , 06/21/2025 ,ABLYSINOL is indicated to induce controlled cardiac septal infarction to improve exercise capacity in adults with symptomatic hypertrophic obstructive cardiomyopathy who are not candidates for surgical myectomy.
FMGSKLZLMKYGDP-USOAJAOKSA-N,5881,FMGSKLZLMKYGDP-USOAJAOKSA-N,Dehydroepiandrosterone,,Treatment of systemic lupus erythematosus (SLE) and the reduction in the use of steroids in steroid-dependent SLE patients.,"C0014060,C0024141","SLE , SYSTEMIC LUPUS ERYTHEMATOSUS",7/13/94,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
CYQFCXCEBYINGO-IAGOWNOFSA-N,16078,CYQFCXCEBYINGO-IAGOWNOFSA-N,delta-9-tetrahydrocannabinol,,Treatment of Hepatocellular Carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,11/27/19,Designated,Not FDA Approved for Orphan Indication,,,,
SSNHGLKFJISNTR-FWUPRJFYSA-N,44148067,SSNHGLKFJISNTR-FWUPRJFYSA-N,delta-9-tetrahydrocannabinol and cannabidiol,,Treatment of Epidermolysis Bullosa,C0014527,Epidermolysis Bullosa,4/14/20,Designated,Not FDA Approved for Orphan Indication,,,,
LMBWSYZSUOEYSN-UHFFFAOYSA-M,28343,LMBWSYZSUOEYSN-UHFFFAOYSA-M,Diethyldithiocarbamate,,Treatment of AIDS.,C0001175,AIDS,4/3/86,Designated,Not FDA Approved for Orphan Indication,,,,
IAZDPXIOMUYVGZ-UHFFFAOYSA-N,679,IAZDPXIOMUYVGZ-UHFFFAOYSA-N,Dimethylsulfoxide,,Topical treatment for the prevention of soft tissue injury following extravastion of cytotoxic drugs.,C0037578,SOFT TISSUE INJURY,4/15/97,Designated,Not FDA Approved for Orphan Indication,,,,
XLZOVRYBVCMCGL-BPNVQINPSA-L,49867944,XLZOVRYBVCMCGL-BPNVQINPSA-L,Disufenton sodium,,Treatment of malignant glioma,C0555198,Malignant Glioma,8/14/20,Designated,Not FDA Approved for Orphan Indication,,,,
XLZOVRYBVCMCGL-BPNVQINPSA-L,49867944,XLZOVRYBVCMCGL-BPNVQINPSA-L,Disufenton sodium,,Treatment of malignant glioma,C0555198,Malignant Glioma,8/14/20,Designated,Not FDA Approved for Orphan Indication,,,,
CYQFCXCEBYINGO-IAGOWNOFSA-N,16078,CYQFCXCEBYINGO-IAGOWNOFSA-N,Dronabinol,Marinol,For the stimulation of appetite and prevention of weight loss in patients with a confirmed diagnosis of AIDS.,"C0001175,C4084774","AIDS , Weight loss",1/15/91,Designated/Approved,,Treatment of anorexia associated with weight loss in patients with AIDS., 12/22/1992 , 12/22/1999 ,
SJVQHLPISAIATJ-ZDUSSCGKSA-N,50905713,SJVQHLPISAIATJ-ZDUSSCGKSA-N,duvelisib,COPIKTRA,Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma,"C0023434,C0855095","Chronic Lymphocytic Leukemia , Small Lymphocytic Lymphoma",4/15/13,Designated/Approved,,Treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies, 09/24/2018 , 09/24/2025 ,Treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies
SJVQHLPISAIATJ-ZDUSSCGKSA-N,50905713,SJVQHLPISAIATJ-ZDUSSCGKSA-N,duvelisib,COPIKTRA,Treatment of follicular lymphoma,C0024301,follicular lymphoma,8/1/13,Designated/Approved,,Treatment of adult patients with relapsed or refractory follicular lymphoma after at least two prior therapies, 09/24/2018 , 09/24/2025 ,Treatment of adult patients with relapsed or refractory follicular lymphoma after at least two prior therapies
AUJXLBOHYWTPFV-BLWRDSOESA-N,138402870,AUJXLBOHYWTPFV-BLWRDSOESA-N,echinomycin,,Treatment of acute myeloid leukemia.,C0023467,Acute myeloid leukemia,5/21/15,Designated,Not FDA Approved for Orphan Indication,,,,
AUJXLBOHYWTPFV-UJILECMYSA-N,134692670,AUJXLBOHYWTPFV-UJILECMYSA-N,echinomycin,,Treatment of acute myeloid leukemia.,C0023467,Acute myeloid leukemia,5/21/15,Designated,Not FDA Approved for Orphan Indication,,,,
AUJXLBOHYWTPFV-LDUXBRJQSA-N,91826096,AUJXLBOHYWTPFV-LDUXBRJQSA-N,echinomycin,,Treatment of acute myeloid leukemia.,C0023467,Acute myeloid leukemia,5/21/15,Designated,Not FDA Approved for Orphan Indication,,,,
AUJXLBOHYWTPFV-MADNPERPSA-N,6917949,AUJXLBOHYWTPFV-MADNPERPSA-N,echinomycin,,Treatment of acute myeloid leukemia.,C0023467,Acute myeloid leukemia,5/21/15,Designated,Not FDA Approved for Orphan Indication,,,,
AUJXLBOHYWTPFV-MXGHYKICSA-N,23724556,AUJXLBOHYWTPFV-MXGHYKICSA-N,echinomycin,,Treatment of acute myeloid leukemia.,C0023467,Acute myeloid leukemia,5/21/15,Designated,Not FDA Approved for Orphan Indication,,,,
AUJXLBOHYWTPFV-RQLJINDISA-N,44448250,AUJXLBOHYWTPFV-RQLJINDISA-N,echinomycin,,Treatment of acute myeloid leukemia.,C0023467,Acute myeloid leukemia,5/21/15,Designated,Not FDA Approved for Orphan Indication,,,,
AUJXLBOHYWTPFV-CVLRASHMSA-N,458034,AUJXLBOHYWTPFV-CVLRASHMSA-N,echinomycin,,Treatment of acute myeloid leukemia.,C0023467,Acute myeloid leukemia,5/21/15,Designated,Not FDA Approved for Orphan Indication,,,,
AUJXLBOHYWTPFV-VITLIGDRSA-N,6857732,AUJXLBOHYWTPFV-VITLIGDRSA-N,echinomycin,,Treatment of acute myeloid leukemia.,C0023467,Acute myeloid leukemia,5/21/15,Designated,Not FDA Approved for Orphan Indication,,,,
AUJXLBOHYWTPFV-UHFFFAOYSA-N,3197,AUJXLBOHYWTPFV-UHFFFAOYSA-N,echinomycin,,Treatment of acute myeloid leukemia.,C0023467,Acute myeloid leukemia,5/21/15,Designated,Not FDA Approved for Orphan Indication,,,,
JAZBEHYOTPTENJ-JLNKQSITSA-N,446284,JAZBEHYOTPTENJ-JLNKQSITSA-N,eicosapentaenoic acid,,Treatment of familial adenomatous polyposis,C0032580,Familial Adenomatous Polyposis,3/8/11,Designated,Not FDA Approved for Orphan Indication,,,,
AFLFKFHDSCQHOL-IZZDOVSWSA-N,9864881,AFLFKFHDSCQHOL-IZZDOVSWSA-N,elafibranor,,Treatment of Primary Biliary Cholangitis,C0008312,Primary Biliary Cholangitis,7/25/19,Designated,Not FDA Approved for Orphan Indication,,,,
SFVLTCAESLKEHH-WKAQUBQDSA-N,11764719,SFVLTCAESLKEHH-WKAQUBQDSA-N,elamipretide,,Treatment of Lebers Hereditary Optic Neuropathy,C3887709,Optic Neuropathy,4/2/18,Designated,Not FDA Approved for Orphan Indication,,,,
JFSOSUNPIXJCIX-UHFFFAOYSA-N,3025067,JFSOSUNPIXJCIX-UHFFFAOYSA-N,eltoprazine HCl,,Treatment of levodopa-induced dyskinesia associated with Parkinson's disease.,"C0013384,C0030567","Dyskinesia , Parkinson's Disease",2/8/16,Designated,Not FDA Approved for Orphan Indication,,,,
ZVVAINSYJGRDTR-TYLGTTGKSA-N,60767,ZVVAINSYJGRDTR-TYLGTTGKSA-N,Enadoline hydrochloride,,Treatment of severe head injury.,C0018674,HEAD INJURY,1/28/97,Designated,Not FDA Approved for Orphan Indication,,,,
LMHIPJMTZHDKEW-XQYLJSSYSA-N,21158562,LMHIPJMTZHDKEW-XQYLJSSYSA-N,epoprostenol,Flolan,Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.,"C0042373,C0264936","Vascular Disease , Secondary pulmonary hypertension",3/22/99,Designated/Approved,,0, 04/14/2000 , 04/14/2007 ,
WHVPOEPABJZBBY-XQYLJSSYSA-N,67548346,WHVPOEPABJZBBY-XQYLJSSYSA-N,epoprostenol,Flolan,Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.,"C0042373,C0264936","Vascular Disease , Secondary pulmonary hypertension",3/22/99,Designated/Approved,,0, 04/14/2000 , 04/14/2007 ,
LMHIPJMTZHDKEW-XQYLJSSYSA-M,6364626,LMHIPJMTZHDKEW-XQYLJSSYSA-M,epoprostenol,Flolan,Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.,"C0042373,C0264936","Vascular Disease , Secondary pulmonary hypertension",3/22/99,Designated/Approved,,0, 04/14/2000 , 04/14/2007 ,
KAQKFAOMNZTLHT-OZUDYXHBSA-N,5282411,KAQKFAOMNZTLHT-OZUDYXHBSA-N,epoprostenol,Flolan,Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.,"C0042373,C0264936","Vascular Disease , Secondary pulmonary hypertension",3/22/99,Designated/Approved,,0, 04/14/2000 , 04/14/2007 ,
ANIAZGVDEUQPRI-ZJQCGQFWSA-N,71511839,ANIAZGVDEUQPRI-ZJQCGQFWSA-N,etelcalcetide,,Treatment of pediatric hyperparathyroidism,C0020502,Hyperparathyroidism,5/31/17,Designated,Not FDA Approved for Orphan Indication,,,,
HZAXFHJVJLSVMW-UHFFFAOYSA-N,700,HZAXFHJVJLSVMW-UHFFFAOYSA-N,ethanolamine,,Prophylactic use in pediatric patients (age 0 through 16 years) with esophageal varices that are at risk of bleeding to obliterate varices and to prevent bleeding,"C0014867,C0042345","Esophageal Varices , Varices",1/17/14,Designated,Not FDA Approved for Orphan Indication,,,,
CLQRMSBSMHXMMC-UHFFFAOYSA-N,153980,CLQRMSBSMHXMMC-UHFFFAOYSA-N,"Ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate",,Treatment of Crohn's disease.,C0010346,Crohn's Disease,5/13/98,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
SSQPWTVBQMWLSZ-AAQCHOMXSA-N,9831415,SSQPWTVBQMWLSZ-AAQCHOMXSA-N,Ethyl eicosapentaenoate,,Treatment of Huntington's disease.,C0020179,Huntington's Disease,4/6/00,Designated,Not FDA Approved for Orphan Indication,,,,
GWBBVOVXJZATQQ-UHFFFAOYSA-L,23894,GWBBVOVXJZATQQ-UHFFFAOYSA-L,Etidronate disodium,Didronel,Treatment of hypercalcemia of malignancy inadequately managed by dietary modification and/or oral hydration.,C0149911,Hypercalcemia of malignancy,3/21/86,Designated/Approved,,, 04/21/1987 , 04/21/1994 ,
SELCJVNOEBVTAC-UHFFFAOYSA-N,71300725,SELCJVNOEBVTAC-UHFFFAOYSA-N,etirinotecan pegol,,Treatment of ovarian cancer.,C4721610,Ovarian Cancer,4/18/11,Designated,Not FDA Approved for Orphan Indication,,,,
SELCJVNOEBVTAC-HLDPIHRNSA-N,56935717,SELCJVNOEBVTAC-HLDPIHRNSA-N,etirinotecan pegol,,Treatment of ovarian cancer.,C4721610,Ovarian Cancer,4/18/11,Designated,Not FDA Approved for Orphan Indication,,,,
HKVAMNSJSFKALM-GKUWKFKPSA-N,6442177,HKVAMNSJSFKALM-GKUWKFKPSA-N,everolimus,,Treatment of diffuse large B-cell lymphoma,C1332201,Diffuse Large B-Cell Lymphoma,6/2/14,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
JOOXLOJCABQBSG-UHFFFAOYSA-N,16722836,JOOXLOJCABQBSG-UHFFFAOYSA-N,Fedratinib,INREBIC,Treatment of secondary and primary myelofibrosis,C0001815,Primary Myelofibrosis,5/18/09,Designated/Approved,,INREBIC is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF)., 08/16/2019 , 08/16/2026 ,For the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).
AKJHMTWEGVYYSE-FXILSDISSA-N,5288209,AKJHMTWEGVYYSE-FXILSDISSA-N,fenretinide,,Treatment of cutaneous T-cell lymphoma,C0079773,cutaneous T-cell lymphoma,12/19/17,Designated,Not FDA Approved for Orphan Indication,,,,
BFENHEAPFWQJFL-BTJKTKAUSA-N,131801100,BFENHEAPFWQJFL-BTJKTKAUSA-N,filgotinib maleate,,Treatment of pediatric Crohn's disease,C2931133,Pediatric Crohn's disease,7/18/17,Designated,Not FDA Approved for Orphan Indication,,,,
GHASVSINZRGABV-UHFFFAOYSA-N,3385,GHASVSINZRGABV-UHFFFAOYSA-N,Fluorouracil,,"For use in combination with interferon alpha-2a, recombinant, for the treatment of advanced colorectal carcinoma.",C5206582,Advanced Colorectal Carcinoma,4/18/90,Designated,Not FDA Approved for Orphan Indication,,,,
GHASVSINZRGABV-UHFFFAOYSA-N,3385,GHASVSINZRGABV-UHFFFAOYSA-N,Fluorouracil,,For use in combination with leucovorin for therapy of metastatic adenocarcinoma of the colon and rectum.,"C0334277,C0338106","Metastatic adenocarcinoma , adenocarcinoma of the colon",2/6/89,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
RIKMMFOAQPJVMX-UHFFFAOYSA-N,3406,RIKMMFOAQPJVMX-UHFFFAOYSA-N,Fomepizole,,Treatment of acetaminophen overdose,C0572025,Acetaminophen overdose,3/2/21,Designated,Not FDA Approved for Orphan Indication,,,,
RIKMMFOAQPJVMX-UHFFFAOYSA-N,3406,RIKMMFOAQPJVMX-UHFFFAOYSA-N,fomepizole,Antizole,Treatment of methanol or ethylene glycol poisoning.,C0413194,Ethylene glycol poisoning,12/22/88,Designated/Approved,,"As an antidote to ethylene glycol (antifreeze) poisoning, or for use in suspected ethylene glycol ingestion.", 12/04/1997 , 12/04/2004 ,
SJZRECIVHVDYJC-UHFFFAOYSA-N,10413,SJZRECIVHVDYJC-UHFFFAOYSA-N,Gamma-hydroxybutyric acid,,Treatment of idiopathic hypersomnia,C0751757,Idiopathic Hypersomnia,7/31/19,Designated,Not FDA Approved for Orphan Indication,,,,
SFNSLLSYNZWZQG-VQIMIIECSA-N,25166913,SFNSLLSYNZWZQG-VQIMIIECSA-N,glasdegib,,Treatment of myelodysplastic syndrome,C3463824,MYELODYSPLASTIC SYNDROME,10/20/17,Designated,Not FDA Approved for Orphan Indication,,,,
FHEAIOHRHQGZPC-KIWGSFCNSA-N,3081884,FHEAIOHRHQGZPC-KIWGSFCNSA-N,glatiramer acetate,,Treatment of amyotrophic lateral sclerosis (ALS).,C0002736,Amyotrophic Lateral Sclerosis,11/14/07,Designated,Not FDA Approved for Orphan Indication,,,,
PEDCQBHIVMGVHV-UHFFFAOYSA-N,753,PEDCQBHIVMGVHV-UHFFFAOYSA-N,Glyceol,,To decrease intracranial hypertension and/or alleviate cerebral edema in patients who may benefit from osmotherapy.,"C0006114,C0151740","Cerebral Edema , Intracranial Hypertension",2/22/90,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
YUFWAVFNITUSHI-UHFFFAOYSA-N,56927696,YUFWAVFNITUSHI-UHFFFAOYSA-N,Guanethidine monosulfate,,Treatment of moderate to severe reflex sympathetic dystrophy and causalgia.,"C0007462,C0034931","Causalgia , Reflex Sympathetic Dystrophy",1/6/86,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ACGDKVXYNVEAGU-UHFFFAOYSA-N,3518,ACGDKVXYNVEAGU-UHFFFAOYSA-N,Guanethidine monosulfate,,Treatment of moderate to severe reflex sympathetic dystrophy and causalgia.,"C0007462,C0034931","Causalgia , Reflex Sympathetic Dystrophy",1/6/86,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
YUFWAVFNITUSHI-UHFFFAOYSA-N,56927696,YUFWAVFNITUSHI-UHFFFAOYSA-N,Guanethidine monosulfate,,Treatment of moderate to severe reflex sympathetic dystrophy and causalgia.,"C0007462,C0034931","Causalgia , Reflex Sympathetic Dystrophy",1/6/86,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
JYGXADMDTFJGBT-VWUMJDOOSA-N,5754,JYGXADMDTFJGBT-VWUMJDOOSA-N,Hydrocortisone,ALKINDI SPRINKLE,Treatment of pediatric adrenal insufficiency (0 through 16 years of age).,C0001623,Adrenal Insufficiency,5/13/15,Designated/Approved,,ALKINDI SPRINKLE is indicated as replacement therapy in pediatric patients with adrenocortical insufficiency, 09/29/2020 ,  ,
SPCMQFLNOVTUBM-UHFFFAOYSA-N,60150609,SPCMQFLNOVTUBM-UHFFFAOYSA-N,hydromethylthionine mesylate,,Treatment of frontotemporal dementia,C0338451,Frontotemporal dementia,11/20/18,Designated,Not FDA Approved for Orphan Indication,,,,
DQOCFCZRZOAIBN-BYFNXCQMSA-M,152743320,DQOCFCZRZOAIBN-BYFNXCQMSA-M,Hydroxocobalamin,Cyanokit,Treatment of acute cyanide poisoning,C0238080,Cyanide poisoning,11/25/03,Designated/Approved,,Treatment on known or suspected cyanide poisoning, 12/15/2006 , 12/15/2013 ,
YOZNUFWCRFCGIH-UHFFFAOYSA-K,146014417,YOZNUFWCRFCGIH-UHFFFAOYSA-K,Hydroxocobalamin,Cyanokit,Treatment of acute cyanide poisoning,C0238080,Cyanide poisoning,11/25/03,Designated/Approved,,Treatment on known or suspected cyanide poisoning, 12/15/2006 , 12/15/2013 ,
ITFLMCXLENHUAD-PYFZXISVSA-L,134820153,ITFLMCXLENHUAD-PYFZXISVSA-L,Hydroxocobalamin,Cyanokit,Treatment of acute cyanide poisoning,C0238080,Cyanide poisoning,11/25/03,Designated/Approved,,Treatment on known or suspected cyanide poisoning, 12/15/2006 , 12/15/2013 ,
ITFLMCXLENHUAD-WZHZPDAFSA-M,129893562,ITFLMCXLENHUAD-WZHZPDAFSA-M,Hydroxocobalamin,Cyanokit,Treatment of acute cyanide poisoning,C0238080,Cyanide poisoning,11/25/03,Designated/Approved,,Treatment on known or suspected cyanide poisoning, 12/15/2006 , 12/15/2013 ,
RHYVGCKRBKDRDX-UHFFFAOYSA-L,126480146,RHYVGCKRBKDRDX-UHFFFAOYSA-L,Hydroxocobalamin,Cyanokit,Treatment of acute cyanide poisoning,C0238080,Cyanide poisoning,11/25/03,Designated/Approved,,Treatment on known or suspected cyanide poisoning, 12/15/2006 , 12/15/2013 ,
TUMIEHFYGNUNBB-JJUQEKPGSA-L,71774773,TUMIEHFYGNUNBB-JJUQEKPGSA-L,Hydroxocobalamin,Cyanokit,Treatment of acute cyanide poisoning,C0238080,Cyanide poisoning,11/25/03,Designated/Approved,,Treatment on known or suspected cyanide poisoning, 12/15/2006 , 12/15/2013 ,
DQOCFCZRZOAIBN-WZHZPDAFSA-L,16056828,DQOCFCZRZOAIBN-WZHZPDAFSA-L,Hydroxocobalamin,Cyanokit,Treatment of acute cyanide poisoning,C0238080,Cyanide poisoning,11/25/03,Designated/Approved,,Treatment on known or suspected cyanide poisoning, 12/15/2006 , 12/15/2013 ,
DQOCFCZRZOAIBN-JLKASCPDSA-L,6474319,DQOCFCZRZOAIBN-JLKASCPDSA-L,Hydroxocobalamin,Cyanokit,Treatment of acute cyanide poisoning,C0238080,Cyanide poisoning,11/25/03,Designated/Approved,,Treatment on known or suspected cyanide poisoning, 12/15/2006 , 12/15/2013 ,
DQOCFCZRZOAIBN-AZCDKEHOSA-L,146156970,DQOCFCZRZOAIBN-AZCDKEHOSA-L,Hydroxocobalamin,Cyanokit,Treatment of acute cyanide poisoning,C0238080,Cyanide poisoning,11/25/03,Designated/Approved,,Treatment on known or suspected cyanide poisoning, 12/15/2006 , 12/15/2013 ,
DQOCFCZRZOAIBN-UVKKECPRSA-L,24892771,DQOCFCZRZOAIBN-UVKKECPRSA-L,Hydroxocobalamin,Cyanokit,Treatment of acute cyanide poisoning,C0238080,Cyanide poisoning,11/25/03,Designated/Approved,,Treatment on known or suspected cyanide poisoning, 12/15/2006 , 12/15/2013 ,
ITFLMCXLENHUAD-WZHZPDAFSA-L,70678542,ITFLMCXLENHUAD-WZHZPDAFSA-L,Hydroxocobalamin,Cyanokit,Treatment of acute cyanide poisoning,C0238080,Cyanide poisoning,11/25/03,Designated/Approved,,Treatment on known or suspected cyanide poisoning, 12/15/2006 , 12/15/2013 ,
DQOCFCZRZOAIBN-PMEYKKDOSA-L,50935334,DQOCFCZRZOAIBN-PMEYKKDOSA-L,Hydroxocobalamin,Cyanokit,Treatment of acute cyanide poisoning,C0238080,Cyanide poisoning,11/25/03,Designated/Approved,,Treatment on known or suspected cyanide poisoning, 12/15/2006 , 12/15/2013 ,
DQOCFCZRZOAIBN-WZHZPDAFSA-L,16056828,DQOCFCZRZOAIBN-WZHZPDAFSA-L,Hydroxocobalamin,Cyanokit,Treatment of acute cyanide poisoning,C0238080,Cyanide poisoning,11/25/03,Designated/Approved,,Treatment on known or suspected cyanide poisoning, 12/15/2006 , 12/15/2013 ,
DQOCFCZRZOAIBN-IQFXPAJWSA-L,45357193,DQOCFCZRZOAIBN-IQFXPAJWSA-L,Hydroxocobalamin,Cyanokit,Treatment of acute cyanide poisoning,C0238080,Cyanide poisoning,11/25/03,Designated/Approved,,Treatment on known or suspected cyanide poisoning, 12/15/2006 , 12/15/2013 ,
YOZNUFWCRFCGIH-WZHZPDAFSA-K,44475014,YOZNUFWCRFCGIH-WZHZPDAFSA-K,Hydroxocobalamin,Cyanokit,Treatment of acute cyanide poisoning,C0238080,Cyanide poisoning,11/25/03,Designated/Approved,,Treatment on known or suspected cyanide poisoning, 12/15/2006 , 12/15/2013 ,
DQOCFCZRZOAIBN-WZHZPDAFSA-L,16056828,DQOCFCZRZOAIBN-WZHZPDAFSA-L,Hydroxocobalamin,Cyanokit,Treatment of acute cyanide poisoning,C0238080,Cyanide poisoning,11/25/03,Designated/Approved,,Treatment on known or suspected cyanide poisoning, 12/15/2006 , 12/15/2013 ,
DQOCFCZRZOAIBN-BYFNXCQMSA-M,152743320,DQOCFCZRZOAIBN-BYFNXCQMSA-M,Hydroxocobalamin,,Treatment of acute cyanide poisoning,C0238080,Cyanide poisoning,9/22/00,Designated,Not FDA Approved for Orphan Indication,,,,
YOZNUFWCRFCGIH-UHFFFAOYSA-K,146014417,YOZNUFWCRFCGIH-UHFFFAOYSA-K,Hydroxocobalamin,,Treatment of acute cyanide poisoning,C0238080,Cyanide poisoning,9/22/00,Designated,Not FDA Approved for Orphan Indication,,,,
ITFLMCXLENHUAD-PYFZXISVSA-L,134820153,ITFLMCXLENHUAD-PYFZXISVSA-L,Hydroxocobalamin,,Treatment of acute cyanide poisoning,C0238080,Cyanide poisoning,9/22/00,Designated,Not FDA Approved for Orphan Indication,,,,
ITFLMCXLENHUAD-WZHZPDAFSA-M,129893562,ITFLMCXLENHUAD-WZHZPDAFSA-M,Hydroxocobalamin,,Treatment of acute cyanide poisoning,C0238080,Cyanide poisoning,9/22/00,Designated,Not FDA Approved for Orphan Indication,,,,
RHYVGCKRBKDRDX-UHFFFAOYSA-L,126480146,RHYVGCKRBKDRDX-UHFFFAOYSA-L,Hydroxocobalamin,,Treatment of acute cyanide poisoning,C0238080,Cyanide poisoning,9/22/00,Designated,Not FDA Approved for Orphan Indication,,,,
TUMIEHFYGNUNBB-JJUQEKPGSA-L,71774773,TUMIEHFYGNUNBB-JJUQEKPGSA-L,Hydroxocobalamin,,Treatment of acute cyanide poisoning,C0238080,Cyanide poisoning,9/22/00,Designated,Not FDA Approved for Orphan Indication,,,,
DQOCFCZRZOAIBN-WZHZPDAFSA-L,16056828,DQOCFCZRZOAIBN-WZHZPDAFSA-L,Hydroxocobalamin,,Treatment of acute cyanide poisoning,C0238080,Cyanide poisoning,9/22/00,Designated,Not FDA Approved for Orphan Indication,,,,
DQOCFCZRZOAIBN-JLKASCPDSA-L,6474319,DQOCFCZRZOAIBN-JLKASCPDSA-L,Hydroxocobalamin,,Treatment of acute cyanide poisoning,C0238080,Cyanide poisoning,9/22/00,Designated,Not FDA Approved for Orphan Indication,,,,
DQOCFCZRZOAIBN-AZCDKEHOSA-L,146156970,DQOCFCZRZOAIBN-AZCDKEHOSA-L,Hydroxocobalamin,,Treatment of acute cyanide poisoning,C0238080,Cyanide poisoning,9/22/00,Designated,Not FDA Approved for Orphan Indication,,,,
DQOCFCZRZOAIBN-UVKKECPRSA-L,24892771,DQOCFCZRZOAIBN-UVKKECPRSA-L,Hydroxocobalamin,,Treatment of acute cyanide poisoning,C0238080,Cyanide poisoning,9/22/00,Designated,Not FDA Approved for Orphan Indication,,,,
ITFLMCXLENHUAD-WZHZPDAFSA-L,70678542,ITFLMCXLENHUAD-WZHZPDAFSA-L,Hydroxocobalamin,,Treatment of acute cyanide poisoning,C0238080,Cyanide poisoning,9/22/00,Designated,Not FDA Approved for Orphan Indication,,,,
DQOCFCZRZOAIBN-PMEYKKDOSA-L,50935334,DQOCFCZRZOAIBN-PMEYKKDOSA-L,Hydroxocobalamin,,Treatment of acute cyanide poisoning,C0238080,Cyanide poisoning,9/22/00,Designated,Not FDA Approved for Orphan Indication,,,,
DQOCFCZRZOAIBN-WZHZPDAFSA-L,16056828,DQOCFCZRZOAIBN-WZHZPDAFSA-L,Hydroxocobalamin,,Treatment of acute cyanide poisoning,C0238080,Cyanide poisoning,9/22/00,Designated,Not FDA Approved for Orphan Indication,,,,
DQOCFCZRZOAIBN-IQFXPAJWSA-L,45357193,DQOCFCZRZOAIBN-IQFXPAJWSA-L,Hydroxocobalamin,,Treatment of acute cyanide poisoning,C0238080,Cyanide poisoning,9/22/00,Designated,Not FDA Approved for Orphan Indication,,,,
YOZNUFWCRFCGIH-WZHZPDAFSA-K,44475014,YOZNUFWCRFCGIH-WZHZPDAFSA-K,Hydroxocobalamin,,Treatment of acute cyanide poisoning,C0238080,Cyanide poisoning,9/22/00,Designated,Not FDA Approved for Orphan Indication,,,,
DQOCFCZRZOAIBN-WZHZPDAFSA-L,16056828,DQOCFCZRZOAIBN-WZHZPDAFSA-L,Hydroxocobalamin,,Treatment of acute cyanide poisoning,C0238080,Cyanide poisoning,9/22/00,Designated,Not FDA Approved for Orphan Indication,,,,
OXVFDZYQLGRLCD-UHFFFAOYSA-N,4147757,OXVFDZYQLGRLCD-UHFFFAOYSA-N,hydroxypioglitazone,,Treatment of X-linked adrenoleukodystrophy,C0162309,X-Linked Adrenoleukodystrophy,1/30/17,Designated,Not FDA Approved for Orphan Indication,,,,
DOMWKUIIPQCAJU-LJHIYBGHSA-N,169870,DOMWKUIIPQCAJU-LJHIYBGHSA-N,hydroxyprogesterone caproate,Makena,Prevention of preterm birth in singleton pregnancies,C0151526,Preterm Birth,1/25/07,Designated/Approved,,To reduce the risk of preterm birth in women with singleton pregnancy who have a history of singleton spontaneous preterm birth, 02/03/2011 , 02/03/2018 ,
VSNHCAURESNICA-UHFFFAOYSA-N,3657,VSNHCAURESNICA-UHFFFAOYSA-N,Hydroxyurea,,Treatment of sickle cell anemia in pediatric patients,C0002895,SICKLE CELL ANEMIA,3/2/17,Designated,Not FDA Approved for Orphan Indication,,,,
YDOIFHVUBCIUHF-UHFFFAOYSA-N,3663,YDOIFHVUBCIUHF-UHFFFAOYSA-N,hypericin,,Treatment of cutaneous T-cell lymphoma,C0079773,cutaneous T-cell lymphoma,2/7/00,Designated,Not FDA Approved for Orphan Indication,,,,
XYFPWWZEPKGCCK-GOSISDBHSA-N,24821094,XYFPWWZEPKGCCK-GOSISDBHSA-N,ibrutinib,Imbruvica,Treatment of mantle cell lymphoma,C4721414,Mantle cell lymphoma,12/3/12,Designated/Approved,,Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, 11/13/2013 , 11/13/2020 ,Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy
XYFPWWZEPKGCCK-GOSISDBHSA-N,24821094,XYFPWWZEPKGCCK-GOSISDBHSA-N,ibrutinib,,"Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma","C0024623,C1332166","Gastric Cancer , Gastroesophageal Junction Adenocarcinoma",2/1/18,Designated,Not FDA Approved for Orphan Indication,,,,
DUGMCDWNXXFHDE-VZYDHVRKSA-N,6450830,DUGMCDWNXXFHDE-VZYDHVRKSA-N,ibutamoren mesylate,,Treatment of growth hormone deficiency,C3714796,Growth hormone deficiency,6/15/17,Designated,Not FDA Approved for Orphan Indication,,,,
JGPMMRGNQUBGND-UHFFFAOYSA-N,3686,JGPMMRGNQUBGND-UHFFFAOYSA-N,idebenone,,"Treatment of mitochondrial myopathy, encephalopathy, lactic acidosis with stroke-like episodes syndrome (MELAS)","C0001125,C0039082,C0085584,C0162670,C0162671,C1857287","LACTIC ACIDOSIS , Syndrome , Encephalopathy , MITOCHONDRIAL MYOPATHY , MELAS , Stroke-like episodes",5/22/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
IFSDAJWBUCMOAH-HNNXBMFYSA-N,11625818,IFSDAJWBUCMOAH-HNNXBMFYSA-N,idelalisib,,Treatment of splenic marginal zone lymphoma,C0349632,Splenic marginal zone lymphoma,10/15/13,Designated,Not FDA Approved for Orphan Indication,,,,
KTUFNOKKBVMGRW-UHFFFAOYSA-N,5291,KTUFNOKKBVMGRW-UHFFFAOYSA-N,Imatinib,,Treatment of Pulmonary Arterial Hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,12/21/20,Designated,Not FDA Approved for Orphan Indication,,,,
YLMAHDNUQAMNNX-UHFFFAOYSA-N,123596,YLMAHDNUQAMNNX-UHFFFAOYSA-N,Imatinib mesylate,Gleevec,Treatment of idiopathic hypereosinophilic syndrome including acute and chronic eosinophilic leukemia,"C0206141,C0346421","Idiopathic Hypereosinophilic Syndrome , Chronic eosinophilic leukemia",8/25/05,Designated/Approved,,Treatment of adult patients with hypereosinophic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFR} fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFR} fusion kinase negative or unknown, 10/19/2006 , 10/19/2013 ,
YLMAHDNUQAMNNX-UHFFFAOYSA-N,123596,YLMAHDNUQAMNNX-UHFFFAOYSA-N,imatinib mesylate,,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,6/15/20,Designated,Not FDA Approved for Orphan Indication,,,,
LVZYXEALRXBLJZ-ISQYCPACSA-N,71587831,LVZYXEALRXBLJZ-ISQYCPACSA-N,imetelstat,,Treatment of myelodysplastic syndrome,C3463824,MYELODYSPLASTIC SYNDROME,12/23/15,Designated,Not FDA Approved for Orphan Indication,,,,
ZADWXFSZEAPBJS-SNVBAGLBSA-N,405012,ZADWXFSZEAPBJS-SNVBAGLBSA-N,indoximod,,Treatment of Stage IIB to IV melanoma,C0025202,melanoma,10/26/17,Designated,Not FDA Approved for Orphan Indication,,,,
HHGRMHMXKPQNGF-SAOVQBGCSA-N,134692690,HHGRMHMXKPQNGF-SAOVQBGCSA-N,Inecalcitol,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,5/14/14,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
HHGRMHMXKPQNGF-VTQYNGMESA-N,131954606,HHGRMHMXKPQNGF-VTQYNGMESA-N,Inecalcitol,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,5/14/14,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
HHGRMHMXKPQNGF-AAMRAYDJSA-N,146157506,HHGRMHMXKPQNGF-AAMRAYDJSA-N,Inecalcitol,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,5/14/14,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
HHGRMHMXKPQNGF-ZKNOEPHOSA-N,53877232,HHGRMHMXKPQNGF-ZKNOEPHOSA-N,Inecalcitol,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,5/14/14,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
HHGRMHMXKPQNGF-WEZTXPJVSA-N,9952841,HHGRMHMXKPQNGF-WEZTXPJVSA-N,Inecalcitol,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,5/14/14,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
HHGRMHMXKPQNGF-WNSNRMDMSA-N,6915835,HHGRMHMXKPQNGF-WNSNRMDMSA-N,Inecalcitol,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,5/14/14,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
YLDCUKJMEKGGFI-QCSRICIXSA-N,135449284,YLDCUKJMEKGGFI-QCSRICIXSA-N,Inosine pranobex,,Treatment of subacute sclerosing panencephalitis.,C0038522,Subacute Sclerosing Panencephalitis,9/20/88,Designated,Not FDA Approved for Orphan Indication,,,,
PDWUPXJEEYOOTR-IUAIQHPESA-N,135326,PDWUPXJEEYOOTR-IUAIQHPESA-N,Iobenguane I 123,AdreView,For the diagnosis of pheochromocytomas,C0031511,Pheochromocytomas,12/1/06,Designated/Approved,,To be used in the detection of primary or metastatic pheochromocytomas or neuroblastomas as an adjunct to other diagnostic tests, 09/19/2008 , 09/19/2015 ,
SHGAZHPCJJPHSC-XFYACQKRSA-N,5282379,SHGAZHPCJJPHSC-XFYACQKRSA-N,isotretinoin,,Treatment of congenital ichthyosis,C0079154,congenital ichthyosis,4/10/14,Designated,Not FDA Approved for Orphan Indication,,,,
PURKAOJPTOLRMP-UHFFFAOYSA-N,16220172,PURKAOJPTOLRMP-UHFFFAOYSA-N,ivacaftor,Kalydeco,Treatment of patients with cystic fibrosis,C0010674,Cystic Fibrosis,12/20/06,Designated/Approved,,KALYDECO is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients age 6 months and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data, 04/29/2019 , 04/29/2026 ,For the treatment of cystic fibrosis (CF) in patients age 6 months to less than 12 months who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data
AUGCSOFQTDKPSO-RGVLZGJSSA-N,16117309,AUGCSOFQTDKPSO-RGVLZGJSSA-N,Ivaltinostat,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,1/8/21,Designated,Not FDA Approved for Orphan Indication,,,,
WIJZXSAJMHAVGX-DHLKQENFSA-N,71657455,WIJZXSAJMHAVGX-DHLKQENFSA-N,ivosidenib,TIBSOVO,Treatment of acute myeloid leukemia (AML),C0023467,Acute myeloid leukemia,6/9/15,Designated/Approved,,TIBSOVO is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test., 07/20/2018 , 07/20/2025 ,Indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test
WIJZXSAJMHAVGX-DHLKQENFSA-N,71657455,WIJZXSAJMHAVGX-DHLKQENFSA-N,ivosidenib,TIBSOVO,Treatment of acute myeloid leukemia (AML),C0023467,Acute myeloid leukemia,6/9/15,Designated/Approved,,TIBSOVO is indicated for the treatment of newly-diagnosed acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in adult patients who are >= 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy., 05/02/2019 , 05/02/2026 ,TIBSOVO is indicated for the treatment of newly-diagnosed acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in adult patients who are >= 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
ZCVMWBYGMWKGHF-UHFFFAOYSA-N,3827,ZCVMWBYGMWKGHF-UHFFFAOYSA-N,ketotifen,,Treatment of mastocytosis,C0024899,Mastocytosis,2/25/15,Designated,Not FDA Approved for Orphan Indication,,,,
RHGKLRLOHDJJDR-BYPYZUCNSA-N,9750,RHGKLRLOHDJJDR-BYPYZUCNSA-N,L-citrulline,,Treatment of sickle cell disease,C0002895,Sickle Cell Disease,10/7/20,Designated,Not FDA Approved for Orphan Indication,,,,
DSBPAFWXMCKFIM-BSOLPCOYSA-N,9844677,DSBPAFWXMCKFIM-BSOLPCOYSA-N,L-threonyl-L-prolyl-L-prolyl-L-threonine,,Treatment of neuropathic pain associated with spinal cord injury,"C0027796,C0037929","Neuropathic Pain , Spinal Cord Injury",4/26/05,Designated,Not FDA Approved for Orphan Indication,,,,
JVTAAEKCZFNVCJ-UHFFFAOYSA-N,612,JVTAAEKCZFNVCJ-UHFFFAOYSA-N,Lactic acid,,"Treatment of severe aphthous stomatitis in severely, terminally immunocompromised patients.",C0038363,Aphthous Stomatitis,6/29/99,Designated,Not FDA Approved for Orphan Indication,,,,
PVCULFYROUOVGJ-UHFFFAOYSA-N,3081349,PVCULFYROUOVGJ-UHFFFAOYSA-N,Laromustine,,Treatment of acute myelogenous leukemia,C0023467,Acute myelogenous leukemia,3/27/14,Designated,Not FDA Approved for Orphan Indication,,,,
NYNZQNWKBKUAII-KBXCAEBGSA-N,46188928,NYNZQNWKBKUAII-KBXCAEBGSA-N,larotrectinib,VITRAKVI,Treatment of solid tumors with NTRK-fusion proteins,C0280100,solid tumors,5/9/17,Designated/Approved,,VITRAKVI is indicated for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity; and have no satisfactory alternative treatments or that have progressed following treatment., 11/26/2018 , 11/26/2025 ,VITRAKVI is indicated for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity; and have no satisfactory alternative treatments or that have progressed following treatment.
GOTYRUGSSMKFNF-UHFFFAOYSA-N,216326,GOTYRUGSSMKFNF-UHFFFAOYSA-N,lenalidomide,Revlimid,Treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue,C2200312,marginal zone lymphoma of mucosa-associated lymphoid tissue,4/29/15,Designated/Approved,,"REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL).", 05/28/2019 , 05/28/2026 ,In combination with a rituximab product for the treatment of adult patients with previously treated extranodal marginal zone lymphoma
GOTYRUGSSMKFNF-UHFFFAOYSA-N,216326,GOTYRUGSSMKFNF-UHFFFAOYSA-N,lenalidomide,Revlimid,Treatment of myelodysplastic syndromes,C3463824,Myelodysplastic Syndromes,1/29/04,Designated/Approved,,Treatment of patients with transfusion dependant anemia due to low or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5 q cytogenetic abnormality with or without additional cytogenetic abnormalities, 12/27/2005 , 12/27/2012 ,
PHIQHXFUZVPYII-ZCFIWIBFSA-N,10917,PHIQHXFUZVPYII-ZCFIWIBFSA-N,Levocarnitine,,Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.,"C0022661,C0342788","End stage renal disease , Carnitine Deficiency",11/24/86,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PHIQHXFUZVPYII-ZCFIWIBFSA-N,10917,PHIQHXFUZVPYII-ZCFIWIBFSA-N,Levocarnitine,,Treatment of zidovudine-induced mitochondrial myopathy.,C0162670,MITOCHONDRIAL MYOPATHY,4/7/97,Designated,Not FDA Approved for Orphan Indication,,,,
PKCDDUHJAFVJJB-UHFFFAOYSA-N,11640390,PKCDDUHJAFVJJB-UHFFFAOYSA-N,linsitinib,,Treatment of adrenocortical carcinoma,C0206686,Adrenocortical carcinoma,3/9/12,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
DHMTURDWPRKSOA-RUZDIDTESA-N,148195,DHMTURDWPRKSOA-RUZDIDTESA-N,lonafarnib,ZOKINVY,Treatment of Hutchinson-Gilford progeria syndrome and progeroid laminopathies,C0033300,Hutchinson-Gilford Progeria Syndrome,4/18/11,Designated/Approved,,in patients 12 months of age and older with a body surface area (BSA) of 0.39 m2 and above (1) to reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS); and (2) for the treatment of processing-deficient Progeroid Laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation or homozygous or compound heterozygous ZMPSTE24 mutations, 11/20/2020 , 11/20/2027 ,in patients 12 months of age and older with a body surface area (BSA) of 0.39 m2 and above: (1) to reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS); and (2) for the treatment of processing-deficient Progeroid Laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation or homozygous or compound heterozygous ZMPSTE24 mutations
IIXWYSCJSQVBQM-LLVKDONJSA-N,71731823,IIXWYSCJSQVBQM-LLVKDONJSA-N,Lorlatinib,LORBRENA,Treatment of anaplastic lymphoma kinase (ALK)-positive or ROS1-positive non-small cell lung cancer,C3539721,Non-Small Cell Lung Cancer,6/23/15,Designated/Approved,,LORBRENA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or alectinib as the first ALK inhibitor therapy for metastatic disease; or ceritinib as the first ALK inhibitor therapy for metastatic disease., 11/02/2018 , 11/02/2025 ,LORBRENA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or alectinib as the first ALK inhibitor therapy for metastatic disease; or ceritinib as the first ALK inhibitor therapy for metastatic disease.
PSIFNNKUMBGKDQ-UHFFFAOYSA-N,3961,PSIFNNKUMBGKDQ-UHFFFAOYSA-N,Losartan,,Treatment of epidermolysis bullosa,C0014527,Epidermolysis Bullosa,1/29/19,Designated,Not FDA Approved for Orphan Indication,,,,
UFSKUSARDNFIRC-UHFFFAOYSA-N,16678941,UFSKUSARDNFIRC-UHFFFAOYSA-N,Lumacaftor,,Treatment of Subarachnoid Hemorrhage,C0038525,Subarachnoid Hemorrhage,9/9/20,Designated,Not FDA Approved for Orphan Indication,,,,
CRXRROKIRDSTAH-ZUDQWMAJSA-L,134687480,CRXRROKIRDSTAH-ZUDQWMAJSA-L,magnesium lysinate bis eicosapentaenoate,,Treatment of familial adenomatous polyposis.,C0032580,Familial Adenomatous Polyposis,12/23/15,Designated,Not FDA Approved for Orphan Indication,,,,
ZPXSCAKFGYXMGA-UHFFFAOYSA-N,4020,ZPXSCAKFGYXMGA-UHFFFAOYSA-N,Mazindol,,Treatment of Duchenne muscular dystrophy.,C0013264,DUCHENNE MUSCULAR DYSTROPHY,12/8/86,Designated,Not FDA Approved for Orphan Indication,,,,
DRLFMBDRBRZALE-UHFFFAOYSA-N,896,DRLFMBDRBRZALE-UHFFFAOYSA-N,Melatonin,,Treatment of primary intracerebral hemorrhage,C2937358,Intracerebral Hemorrhage,1/22/20,Designated,Not FDA Approved for Orphan Indication,,,,
DRLFMBDRBRZALE-UHFFFAOYSA-N,896,DRLFMBDRBRZALE-UHFFFAOYSA-N,melatonin,,Treatment of subarachnoid hemorrhage,C0038525,Subarachnoid Hemorrhage,3/28/18,Designated,Not FDA Approved for Orphan Indication,,,,
DRLFMBDRBRZALE-UHFFFAOYSA-N,896,DRLFMBDRBRZALE-UHFFFAOYSA-N,melatonin,,Treatment of necrotizing enterocolitis,C0014356,Enterocolitis,1/25/17,Designated,Not FDA Approved for Orphan Indication,,,,
ZRVUJXDFFKFLMG-UHFFFAOYSA-N,54677470,ZRVUJXDFFKFLMG-UHFFFAOYSA-N,meloxicam,Mobic,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,11/22/02,Designated/Approved,,For relief of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients 2 years of age or older, 08/11/2005 , 08/11/2012 ,
SGDBTWWWUNNDEQ-LBPRGKRZSA-N,460612,SGDBTWWWUNNDEQ-LBPRGKRZSA-N,melphalan,,Treatment of Stage IIB through IV melanoma,C0025202,melanoma,11/19/12,Designated,Not FDA Approved for Orphan Indication,,,,
OUUYBRCCFUEMLH-YDALLXLXSA-N,9927978,OUUYBRCCFUEMLH-YDALLXLXSA-N,melphalan hydrochloride,,Treatment of patients with hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,9/26/13,Designated,Not FDA Approved for Orphan Indication,,,,
OUUYBRCCFUEMLH-YDALLXLXSA-N,9927978,OUUYBRCCFUEMLH-YDALLXLXSA-N,melphalan hydrochloride,,Treatment of patients with ocular (uveal) melanoma.,C0025202,melanoma,11/12/08,Designated,Not FDA Approved for Orphan Indication,,,,
QHADVLVFMKEIIP-UHFFFAOYSA-N,44603533,QHADVLVFMKEIIP-UHFFFAOYSA-N,merestinib,,Treatment of biliary tract cancer,C0750952,Biliary Tract Cancer,4/10/17,Designated,Not FDA Approved for Orphan Indication,,,,
HBNPJJILLOYFJU-VMPREFPWSA-N,60663,HBNPJJILLOYFJU-VMPREFPWSA-N,mibefradil,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,10/16/08,Designated,Not FDA Approved for Orphan Indication,,,,
MGCQZNBCJBRZDT-UHFFFAOYSA-N,18340,MGCQZNBCJBRZDT-UHFFFAOYSA-N,Midodrine HCl,Amatine,Treatment of patients with symptomatic orthostatic hypotension.,C0020651,ORTHOSTATIC HYPOTENSION,6/21/85,Designated/Approved,,Treatment of symptomatic orthostatic hypotension., 09/06/1996 , 09/06/2003 ,
NWIBSHFKIJFRCO-WUDYKRTCSA-N,5746,NWIBSHFKIJFRCO-WUDYKRTCSA-N,Mitomycin-C,,Treatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery.,C0017601,Glaucoma,8/20/93,Designated,Not FDA Approved for Orphan Indication,,,,
ZVHNDZWQTBEVRY-UHFFFAOYSA-N,25062766,ZVHNDZWQTBEVRY-UHFFFAOYSA-N,momelotinib,,Treatment of myelofibrosis,C0026987,myelofibrosis,8/5/10,Designated,Not FDA Approved for Orphan Indication,,,,
RTGDFNSFWBGLEC-SYZQJQIISA-N,5281078,RTGDFNSFWBGLEC-SYZQJQIISA-N,Mycophenolate mofetil,,Treatment of pemphigus vulgaris,C0030809,Pemphigus Vulgaris,5/26/06,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PTKRPOIHIOAMPP-UHFFFAOYSA-N,73334909,PTKRPOIHIOAMPP-UHFFFAOYSA-N,N-(3-fluorobenzyl)-2-(5-(4-morpholinophenyl) pyridin-2-yl) Acetamide Besylate,,Treatment of gliomas,C0017638,gliomas,11/26/13,Designated,Not FDA Approved for Orphan Indication,,,,
RWHUEXWOYVBUCI-UHFFFAOYSA-N,25077649,RWHUEXWOYVBUCI-UHFFFAOYSA-N,Nafarelin acetate,Synarel Nasal Solution,Treatment of central precocious puberty.,C0342543,Central Precocious Puberty,7/20/88,Designated/Approved,,Treatment of central precocious puberty (gonadotropin-dependent precocious puberty) in children of both sexes., 02/26/1992 , 02/26/1999 ,
FSBTYDWUUWLHBD-UHFFFAOYSA-N,25084011,FSBTYDWUUWLHBD-UHFFFAOYSA-N,Nafarelin acetate,Synarel Nasal Solution,Treatment of central precocious puberty.,C0342543,Central Precocious Puberty,7/20/88,Designated/Approved,,Treatment of central precocious puberty (gonadotropin-dependent precocious puberty) in children of both sexes., 02/26/1992 , 02/26/1999 ,
GUJYDLHACHDKAJ-UHFFFAOYSA-N,25077648,GUJYDLHACHDKAJ-UHFFFAOYSA-N,Nafarelin acetate,Synarel Nasal Solution,Treatment of central precocious puberty.,C0342543,Central Precocious Puberty,7/20/88,Designated/Approved,,Treatment of central precocious puberty (gonadotropin-dependent precocious puberty) in children of both sexes., 02/26/1992 , 02/26/1999 ,
FSBTYDWUUWLHBD-UDXTWCDOSA-N,25079425,FSBTYDWUUWLHBD-UDXTWCDOSA-N,Nafarelin acetate,Synarel Nasal Solution,Treatment of central precocious puberty.,C0342543,Central Precocious Puberty,7/20/88,Designated/Approved,,Treatment of central precocious puberty (gonadotropin-dependent precocious puberty) in children of both sexes., 02/26/1992 , 02/26/1999 ,
GUJYDLHACHDKAJ-CFWZQLQRSA-N,25079036,GUJYDLHACHDKAJ-CFWZQLQRSA-N,Nafarelin acetate,Synarel Nasal Solution,Treatment of central precocious puberty.,C0342543,Central Precocious Puberty,7/20/88,Designated/Approved,,Treatment of central precocious puberty (gonadotropin-dependent precocious puberty) in children of both sexes., 02/26/1992 , 02/26/1999 ,
IXOXBSCIXZEQEQ-UHTZMRCNSA-N,3011155,IXOXBSCIXZEQEQ-UHTZMRCNSA-N,nelarabine,Arranon,Treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma,"C0023449,C0278721,C1961102","Acute lymphoblastic leukemia , Lymphoblastic Lymphoma , Acute Lymphoblastic Leukemia",8/10/04,Designated/Approved,,Treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens, 10/28/2005 , 10/28/2012 ,
NQDJXKOVJZTUJA-UHFFFAOYSA-N,4463,NQDJXKOVJZTUJA-UHFFFAOYSA-N,nevirapine,,Prevention of HIV infection in pediatric patients under the age of 16 years,C0019693,HIV infection,11/25/09,Designated,Not FDA Approved for Orphan Indication,,,,
CPMDPSXJELVGJG-UHFFFAOYSA-N,135423438,CPMDPSXJELVGJG-UHFFFAOYSA-N,nintedanib,OFEV,Treatment of patients with idiopathic pulmonary fibrosis.,C1800706,Idiopathic Pulmonary Fibrosis,6/29/11,Designated/Approved,,Treatment of idiopathic pulmonary fibrosis, 10/15/2014 , 10/15/2021 ,Treatment of idiopathic pulmonary fibrosis
OUBCNLGXQFSTLU-UHFFFAOYSA-N,115355,OUBCNLGXQFSTLU-UHFFFAOYSA-N,nitisinone,,Treatment of alkaptonuria,C0002066,Alkaptonuria,10/19/01,Designated,Not FDA Approved for Orphan Indication,,,,
MWUXSHHQAYIFBG-UHFFFAOYSA-N,145068,MWUXSHHQAYIFBG-UHFFFAOYSA-N,Nitric oxide,,Treatment of acute respiratory distress syndrome in adults.,C0035222,Acute respiratory distress syndrome,7/10/95,Designated,Not FDA Approved for Orphan Indication,,,,
WWFDJIVIDXJAQR-FFWSQMGZSA-N,131801471,WWFDJIVIDXJAQR-FFWSQMGZSA-N,nusinersen,Spinraza,Treatment of spinal muscular atrophy,C0026847,Spinal Muscular Atrophy,4/18/11,Designated/Approved,,Treatment of spinal muscular atrophy in pediatric and adult patients, 12/23/2016 , 12/23/2023 ,Treatment of spinal muscular atrophy in pediatric and adult patients
ZVAGBRFUYHSUHA-XEKNBVSESA-N,122362431,ZVAGBRFUYHSUHA-XEKNBVSESA-N,Obatoclax mesylate,,Treatment of myelofibrosis,C0026987,myelofibrosis,12/1/06,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ZVAGBRFUYHSUHA-QUIKYCSHSA-N,56843157,ZVAGBRFUYHSUHA-QUIKYCSHSA-N,Obatoclax mesylate,,Treatment of myelofibrosis,C0026987,myelofibrosis,12/1/06,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ZVAGBRFUYHSUHA-UHFFFAOYSA-N,70700268,ZVAGBRFUYHSUHA-UHFFFAOYSA-N,Obatoclax mesylate,,Treatment of myelofibrosis,C0026987,myelofibrosis,12/1/06,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ZVAGBRFUYHSUHA-CFWFSBERSA-N,16727411,ZVAGBRFUYHSUHA-CFWFSBERSA-N,Obatoclax mesylate,,Treatment of myelofibrosis,C0026987,myelofibrosis,12/1/06,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ZVAGBRFUYHSUHA-RKMKAUCSSA-N,71816154,ZVAGBRFUYHSUHA-RKMKAUCSSA-N,Obatoclax mesylate,,Treatment of myelofibrosis,C0026987,myelofibrosis,12/1/06,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ZVAGBRFUYHSUHA-VLJPQPJMSA-N,46930996,ZVAGBRFUYHSUHA-VLJPQPJMSA-N,Obatoclax mesylate,,Treatment of myelofibrosis,C0026987,myelofibrosis,12/1/06,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ZVAGBRFUYHSUHA-LZOXOEDVSA-N,16681698,ZVAGBRFUYHSUHA-LZOXOEDVSA-N,Obatoclax mesylate,,Treatment of myelofibrosis,C0026987,myelofibrosis,12/1/06,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
GSDSWSVVBLHKDQ-UHFFFAOYSA-N,4583,GSDSWSVVBLHKDQ-UHFFFAOYSA-N,Ofloxacin,Ocuflox Ophthalmic Solution,Treatment of bacterial corneal ulcers.,C0010043,corneal ulcers,4/18/91,Designated/Approved,,Treatment of bacterial corneal ulcers., 05/22/1996 , 05/22/2003 ,
BOWVQLFMWHZBEF-KTKRTIGZSA-N,5283454,BOWVQLFMWHZBEF-KTKRTIGZSA-N,Oleoylethanolamide,,Treatment of Prader-Willi syndrome,C0032897,Prader-Willi Syndrome,6/8/17,Designated,Not FDA Approved for Orphan Indication,,,,
SUFPWYYDCOKDLL-UHFFFAOYSA-N,91885568,SUFPWYYDCOKDLL-UHFFFAOYSA-N,olorofim,,Treatment of coccidioidomycosis,C0009186,Coccidioidomycosis,3/11/20,Designated,Not FDA Approved for Orphan Indication,,,,
RJCWBNBKOKFWNY-IDPLTSGASA-N,71811910,RJCWBNBKOKFWNY-IDPLTSGASA-N,omaveloxolone,,Treatment of Friedreich's Ataxia,C0016719,Friedreich's Ataxia,6/19/17,Designated,Not FDA Approved for Orphan Indication,,,,
QLMMOGWZCFQAPU-UHFFFAOYSA-N,6419718,QLMMOGWZCFQAPU-UHFFFAOYSA-N,omigapil,,Treatment of congenital muscular dystrophy.,C0699743,Congenital muscular dystrophy,6/24/08,Designated,Not FDA Approved for Orphan Indication,,,,
SWZXEVABPLUDIO-WSZYKNRRSA-N,25067547,SWZXEVABPLUDIO-WSZYKNRRSA-N,oprozomib,,Treatment of Waldenstrom's macroglobulinemia,C0024419,Waldenstrom's Macroglobulinemia,8/25/14,Designated,Not FDA Approved for Orphan Indication,,,,
DRMCATBEKSVAPL-BNTLRKBRSA-N,9887053,DRMCATBEKSVAPL-BNTLRKBRSA-N,Oxaliplatin,,Treatment of ovarian cancer.,C4721610,Ovarian Cancer,10/6/92,Designated,Not FDA Approved for Orphan Indication,,,,
QSLJIVKCVHQPLV-PEMPUTJUSA-N,5878,QSLJIVKCVHQPLV-PEMPUTJUSA-N,Oxandrolone,,Treatment of moderate/severe acute alcoholic hepatitis in the presence of moderate protein calorie malnutrition.,"C0001306,C0033677","Acute alcoholic hepatitis , protein calorie malnutrition",3/18/94,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
XRVDGNKRPOAQTN-FQEVSTJZSA-N,52938427,XRVDGNKRPOAQTN-FQEVSTJZSA-N,ozanimod,,Treatment of pediatric Crohns disease,C0010346,Crohns Disease,11/1/17,Designated,Not FDA Approved for Orphan Indication,,,,
BKCJZNIZRWYHBN-UHFFFAOYSA-N,100427,BKCJZNIZRWYHBN-UHFFFAOYSA-N,Palifosfamide,,Treatment of soft tissue sarcomas,C1261473,Soft Tissue Sarcomas,5/5/08,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
GHILNKWBALQPDP-UHFFFAOYSA-N,134168328,GHILNKWBALQPDP-UHFFFAOYSA-N,Paltusotine,,Treatment of acromegaly,C0001206,Acromegaly,7/7/20,Designated,Not FDA Approved for Orphan Indication,,,,
XQYZDYMELSJDRZ-UHFFFAOYSA-N,4680,XQYZDYMELSJDRZ-UHFFFAOYSA-N,papaverine,,Treatment of mesenteric ischemia,C1412000,Mesenteric Ischemia,8/3/17,Designated,Not FDA Approved for Orphan Indication,,,,
LGWACEZVCMBSKW-UHFFFAOYSA-N,57384863,LGWACEZVCMBSKW-UHFFFAOYSA-N,Paxalisib,,Treatment of malignant glioma,C0555198,Malignant Glioma,8/21/20,Designated,Not FDA Approved for Orphan Indication,,,,
QXLQZLBNPTZMRK-UHFFFAOYSA-N,436058,QXLQZLBNPTZMRK-UHFFFAOYSA-N,Pegaspargase,Oncaspar; Asparlas,Treatment of acute lymphocytic leukemia.,C0023449,Acute lymphocytic leukemia,10/20/89,Designated/Approved,,ASPARLAS is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years., 12/20/2018 ,  ,
ZCTCZKWJFTYNMZ-WKUCUCPSSA-J,135564527,ZCTCZKWJFTYNMZ-WKUCUCPSSA-J,pemetrexed disodium,Alimta,Treatment of malignant pleural mesothelioma,C0812413,Malignant Pleural Mesothelioma,8/28/01,Designated/Approved,,Treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery, 02/04/2004 , 02/04/2011 ,
PSXPIRGEVYHPKP-GXKRWWSZSA-N,135544142,PSXPIRGEVYHPKP-GXKRWWSZSA-N,pemetrexed disodium,Alimta,Treatment of malignant pleural mesothelioma,C0812413,Malignant Pleural Mesothelioma,8/28/01,Designated/Approved,,Treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery, 02/04/2004 , 02/04/2011 ,
NYDXNILOWQXUOF-GXKRWWSZSA-M,136253316,NYDXNILOWQXUOF-GXKRWWSZSA-M,pemetrexed disodium,Alimta,Treatment of malignant pleural mesothelioma,C0812413,Malignant Pleural Mesothelioma,8/28/01,Designated/Approved,,Treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery, 02/04/2004 , 02/04/2011 ,
QJVSMHJWAOSBMD-MYXYZBIASA-L,135564751,QJVSMHJWAOSBMD-MYXYZBIASA-L,pemetrexed disodium,Alimta,Treatment of malignant pleural mesothelioma,C0812413,Malignant Pleural Mesothelioma,8/28/01,Designated/Approved,,Treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery, 02/04/2004 , 02/04/2011 ,
WBXPDJSOTKVWSJ-ZDUSSCGKSA-N,135410875,WBXPDJSOTKVWSJ-ZDUSSCGKSA-N,pemetrexed disodium,Alimta,Treatment of malignant pleural mesothelioma,C0812413,Malignant Pleural Mesothelioma,8/28/01,Designated/Approved,,Treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery, 02/04/2004 , 02/04/2011 ,
NYDXNILOWQXUOF-GXKRWWSZSA-L,135413520,NYDXNILOWQXUOF-GXKRWWSZSA-L,pemetrexed disodium,Alimta,Treatment of malignant pleural mesothelioma,C0812413,Malignant Pleural Mesothelioma,8/28/01,Designated/Approved,,Treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery, 02/04/2004 , 02/04/2011 ,
DDBREPKUVSBGFI-UHFFFAOYSA-N,4763,DDBREPKUVSBGFI-UHFFFAOYSA-N,phenobarbital,,Treatment of neonatal seizures,C0159020,Neonatal seizures,10/2/19,Designated,Not FDA Approved for Orphan Indication,,,,
WRLGYAWRGXKSKG-UHFFFAOYSA-M,23674889,WRLGYAWRGXKSKG-UHFFFAOYSA-M,phenobarbital sodium,,Treatment of neonatal seizures,C0159020,Neonatal seizures,2/27/20,Designated,Not FDA Approved for Orphan Indication,,,,
WLJVXDMOQOGPHL-UHFFFAOYSA-N,999,WLJVXDMOQOGPHL-UHFFFAOYSA-N,Phenylacetate,,"For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.","C1578499,C4684861","Radiation Therapy , Recurrent Malignant Glioma",3/6/98,Designated,Not FDA Approved for Orphan Indication,,,,
WLJVXDMOQOGPHL-UHFFFAOYSA-M,4409936,WLJVXDMOQOGPHL-UHFFFAOYSA-M,Phenylacetate,,"For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.","C1578499,C4684861","Radiation Therapy , Recurrent Malignant Glioma",3/6/98,Designated,Not FDA Approved for Orphan Indication,,,,
ISWRGOKTTBVCFA-UHFFFAOYSA-N,40632,ISWRGOKTTBVCFA-UHFFFAOYSA-N,pirfenidone,ESBRIET,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,3/5/04,Designated/Approved,,Treatment of idiopathic pulmonary fibrosis, 10/15/2014 , 10/15/2021 ,Treatment of idiopathic pulmonary fibrosis
HRHKSTOGXBBQCB-VFWICMBZSA-N,13116,HRHKSTOGXBBQCB-VFWICMBZSA-N,Porfiromycin,,Treatment of cervical cancer.,C4048328,cervical cancer,3/13/97,Designated,Not FDA Approved for Orphan Indication,,,,
RAGOYPUPXAKGKH-XAKZXMRKSA-N,468595,RAGOYPUPXAKGKH-XAKZXMRKSA-N,posaconazole,,Treatment of invasive aspergillosis,C0238013,Invasive aspergillosis,10/4/16,Designated,Not FDA Approved for Orphan Indication,,,,
OGSBUKJUDHAQEA-WMCAAGNKSA-N,148121,OGSBUKJUDHAQEA-WMCAAGNKSA-N,pralatrexate,Folotyn,Treatment of T-cell lymphoma,C0079772,T-Cell Lymphoma,7/20/06,Designated/Approved,,Treatment of patients with relapsed or refractory peripheral T-cell lymphoma, 09/24/2009 , 09/24/2016 ,
JALHGCPDPSNJNY-UHFFFAOYSA-N,10158453,JALHGCPDPSNJNY-UHFFFAOYSA-N,prasugrel hydrochloride,,Treatment of sickle cell disease,C0002895,Sickle Cell Disease,5/26/15,Designated,Not FDA Approved for Orphan Indication,,,,
ZLHZLMOSPGACSZ-NSHDSACASA-N,456199,ZLHZLMOSPGACSZ-NSHDSACASA-N,Pretomanid,Pretomanid,Treatment of tuberculosis,C0041296,Tuberculosis,7/5/07,Designated/Approved,,"Pretomanid tablet is indicated, as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary extensively drug resistant (XDR) or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB).", 08/14/2019 , 08/14/2026 ,As part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary extensively drug resistant (XDR) or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB).
UKUYYHVRVSDDQG-UBXFZUKZSA-N,86566352,UKUYYHVRVSDDQG-UBXFZUKZSA-N,Pro-Pro-Thr-Val-Pro-Thr-Arg,,Treatment of xeroderma pigmentosum,C0043346,Xeroderma Pigmentosum,7/27/17,Designated,Not FDA Approved for Orphan Indication,,,,
DGMKFQYCZXERLX-UHFFFAOYSA-N,4922,DGMKFQYCZXERLX-UHFFFAOYSA-N,Proglumide,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,6/16/20,Designated,Not FDA Approved for Orphan Indication,,,,
YKUQEKXHQFYULM-UHFFFAOYSA-N,156867,YKUQEKXHQFYULM-UHFFFAOYSA-N,pyronaridine tetraphosphate,,Treatment of Ebola infection,C0282687,Ebola Infection,2/28/19,Designated,Not FDA Approved for Orphan Indication,,,,
WANIDIGFXJFFEL-SANMLTNESA-N,73051463,WANIDIGFXJFFEL-SANMLTNESA-N,relacorilant,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,9/27/18,Designated,Not FDA Approved for Orphan Indication,,,,
LNFCWEXGZIEGJW-TXSVMFMRSA-O,78318119,LNFCWEXGZIEGJW-TXSVMFMRSA-O,Rezafungin,,Treatment of candidemia and invasive candidiasis infections caused by susceptible Candida spp.,"C0877445,C1609535","Candidemia , Invasive Candidiasis",2/8/16,Designated,Not FDA Approved for Orphan Indication,,,,
IXSVOCGZBUJEPI-HTQYORAHSA-N,135431094,IXSVOCGZBUJEPI-HTQYORAHSA-N,Rifalazil,,Treatment of pulmonary tuberculosis.,C0041327,Pulmonary tuberculosis,4/13/99,Designated,Not FDA Approved for Orphan Indication,,,,
WXXSNCNJFUAIDG-UHFFFAOYSA-N,11304743,WXXSNCNJFUAIDG-UHFFFAOYSA-N,riociguat,Adempas,Treatment of pulmonary arterial hypertension.,C3203102,PULMONARY ARTERIAL HYPERTENSION,9/19/13,Designated/Approved,,"Treatment of adults with pulmonary arterial hypertension (PAH) WHO Group 1, to improve exercise capacity, WHO functional class and to delay clinical worsening.", 10/08/2013 , 10/08/2020 ,"Treatment of adults with pulmonary arterial hypertension (PAH) WHO Group 1, to improve exercise capacity, WHO functional class and to delay clinical worsening."
WXXSNCNJFUAIDG-UHFFFAOYSA-N,11304743,WXXSNCNJFUAIDG-UHFFFAOYSA-N,riociguat,Adempas,Treatment of chronic thromboembolic pulmonary hypertension,C2363973,Chronic thromboembolic pulmonary hypertension,9/19/13,Designated/Approved,,"Treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) WHO Group 4, after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class", 10/08/2013 , 10/08/2020 ,"Treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) WHO Group 4, after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class"
HUFOZJXAKZVRNJ-UHFFFAOYSA-N,57335384,HUFOZJXAKZVRNJ-UHFFFAOYSA-N,rociletinib,,Treatment of non-small cell lung cancer and mutations in the epidermal growth factor receptor,"C1414313,C3539721","EPIDERMAL GROWTH FACTOR RECEPTOR , Non-Small Cell Lung Cancer",5/14/13,Designated,Not FDA Approved for Orphan Indication,,,,
XIJXHOVKJAXCGJ-XLPZGREQSA-N,9840777,XIJXHOVKJAXCGJ-XLPZGREQSA-N,ropidoxuridine,,Radiosensitizer to be used during radiation treatment of glioma,C0017638,Glioma,5/19/16,Designated,Not FDA Approved for Orphan Indication,,,,
VDNLFJGJEQUWRB-UHFFFAOYSA-L,3856851,VDNLFJGJEQUWRB-UHFFFAOYSA-L,Rose Bengal Disodium,,Treatment of metastatic melanoma,C0278883,Metastatic melanoma,12/21/06,Designated,Not FDA Approved for Orphan Indication,,,,
HMABYWSNWIZPAG-UHFFFAOYSA-N,9931954,HMABYWSNWIZPAG-UHFFFAOYSA-N,rucaparib,Rubraca,Treatment of ovarian cancer,C4721610,Ovarian Cancer,7/31/12,Designated/Approved,,"For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.", 04/06/2018 , 04/06/2025 ,For the maintenance treatment of adult patients with recurrent epithelial ovarian cancer who are in complete or partial response to platinum-based chemotherapy.
HFNKQEVNSGCOJV-OAHLLOKOSA-N,25126798,HFNKQEVNSGCOJV-OAHLLOKOSA-N,ruxolitinib,JAKAFI,Treatment of graft versus host disease,C0018133,GRAFT VERSUS HOST DISEASE,11/3/16,Designated/Approved,,Treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older., 05/24/2019 , 05/24/2026 ,Treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older.
JFMWPOCYMYGEDM-XFULWGLBSA-N,25127112,JFMWPOCYMYGEDM-XFULWGLBSA-N,ruxolitinib phosphate,,Treatment of essential thrombocythemia,C0040028,ESSENTIAL THROMBOCYTHEMIA,3/22/10,Designated,Not FDA Approved for Orphan Indication,,,,
FNKQXYHWGSIFBK-RPDRRWSUSA-N,135398654,FNKQXYHWGSIFBK-RPDRRWSUSA-N,sapropterin,Kuvan,Treatment of hyperphenylalaninemia,C0751435,Hyperphenylalaninemia,1/29/04,Designated/Approved,,Indicated to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU). Kuvan is to be used in conjunction with a Phe-restricted diet., 12/13/2007 , 12/13/2014 ,
UJYFZCVPOSZDMK-YPPDDXJESA-L,121000421,UJYFZCVPOSZDMK-YPPDDXJESA-L,saroglitazar magnesium,,Treatment of Primary Biliary Cholangitis,C0008312,Primary Biliary Cholangitis,1/26/21,Designated,Not FDA Approved for Orphan Indication,,,,
RGYQPQARIQKJKH-UHFFFAOYSA-N,58496428,RGYQPQARIQKJKH-UHFFFAOYSA-N,Setanaxib,,treatment of primary biliary cholangitis,C0008312,Primary Biliary Cholangitis,10/16/20,Designated,Not FDA Approved for Orphan Indication,,,,
MUOKSQABCJCOPU-UHFFFAOYSA-N,24748573,MUOKSQABCJCOPU-UHFFFAOYSA-N,Silmitasertib,,Treatment of cholangiocarcinoma,C0206698,Cholangiocarcinoma,12/22/16,Designated,Not FDA Approved for Orphan Indication,,,,
QFJCIRLUMZQUOT-HPLJOQBZSA-N,5284616,QFJCIRLUMZQUOT-HPLJOQBZSA-N,sirolimus,Rapamune,Treatment of lymphangioleiomyomatosis,C0751674,Lymphangioleiomyomatosis,10/31/12,Designated/Approved,,Treatment of lymphangioleiomyomatosis (LAM), 05/28/2015 , 05/28/2022 ,Treatment of lymphangioleiomyomatosis (LAM)
LUPNKHXLFSSUGS-UHFFFAOYSA-M,517326,LUPNKHXLFSSUGS-UHFFFAOYSA-M,sodium dichloroacetate,,For pulmonary arterial hypertension.,C3203102,PULMONARY ARTERIAL HYPERTENSION,11/29/10,Designated,Not FDA Approved for Orphan Indication,,,,
LPXPTNMVRIOKMN-UHFFFAOYSA-M,23668193,LPXPTNMVRIOKMN-UHFFFAOYSA-M,sodium nitrite,,Treatment of cyanide poisoning,C0238080,Cyanide poisoning,4/18/07,Designated,Not FDA Approved for Orphan Indication,,,,
LPXPTNMVRIOKMN-UHFFFAOYSA-M,23668193,LPXPTNMVRIOKMN-UHFFFAOYSA-M,sodium nitrite,,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,7/8/08,Designated,Not FDA Approved for Orphan Indication,,,,
VPZRWNZGLKXFOE-UHFFFAOYSA-M,5258,VPZRWNZGLKXFOE-UHFFFAOYSA-M,sodium phenylbutyrate,,"Treatment for sickling disorders, which include S-S hemoglobinopathy, S-C hemoglobinopathy, and S-thalassemia hemoglobinopathy.","C0019045,C0039730","Hemoglobinopathy , Thalassemia",7/2/92,Designated,Not FDA Approved for Orphan Indication,,,,
UPUIQOIQVMNQAP-UHFFFAOYSA-M,23665770,UPUIQOIQVMNQAP-UHFFFAOYSA-M,Sodium tetradecyl sulfate,,Treatment of bleeding esophageal varices.,C0014867,Esophageal Varices,6/10/86,Designated,Not FDA Approved for Orphan Indication,,,,
AKHNMLFCWUSKQB-UHFFFAOYSA-L,24477,AKHNMLFCWUSKQB-UHFFFAOYSA-L,sodium thiosulfate,,Treatment of calciphylaxis,C0006666,Calciphylaxis,11/19/12,Designated,Not FDA Approved for Orphan Indication,,,,
NHXLMOGPVYXJNR-HVEUVEBASA-N,44377662,NHXLMOGPVYXJNR-HVEUVEBASA-N,Somatostatin,,"Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or pancreas.",C0423772,Cutaneous Fistulas,6/20/88,Designated,Not FDA Approved for Orphan Indication,,,,
NHXLMOGPVYXJNR-FMGBKAQLSA-N,44291156,NHXLMOGPVYXJNR-FMGBKAQLSA-N,Somatostatin,,"Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or pancreas.",C0423772,Cutaneous Fistulas,6/20/88,Designated,Not FDA Approved for Orphan Indication,,,,
NHXLMOGPVYXJNR-FQSIDJEASA-N,71308696,NHXLMOGPVYXJNR-FQSIDJEASA-N,Somatostatin,,"Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or pancreas.",C0423772,Cutaneous Fistulas,6/20/88,Designated,Not FDA Approved for Orphan Indication,,,,
NHXLMOGPVYXJNR-UYURUMNQSA-N,16161315,NHXLMOGPVYXJNR-UYURUMNQSA-N,Somatostatin,,"Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or pancreas.",C0423772,Cutaneous Fistulas,6/20/88,Designated,Not FDA Approved for Orphan Indication,,,,
NHXLMOGPVYXJNR-UHFFFAOYSA-N,16129681,NHXLMOGPVYXJNR-UHFFFAOYSA-N,Somatostatin,,"Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or pancreas.",C0423772,Cutaneous Fistulas,6/20/88,Designated,Not FDA Approved for Orphan Indication,,,,
NHXLMOGPVYXJNR-ATOGVRKGSA-N,16129706,NHXLMOGPVYXJNR-ATOGVRKGSA-N,Somatostatin,,"Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or pancreas.",C0423772,Cutaneous Fistulas,6/20/88,Designated,Not FDA Approved for Orphan Indication,,,,
WRFHGDPIDHPWIQ-UHFFFAOYSA-N,10257882,WRFHGDPIDHPWIQ-UHFFFAOYSA-N,sparsentan,,Treatment of Focal Segmental Glomerulosclerosis,C0017668,Focal segmental glomerulosclerosis,1/5/15,Designated,Not FDA Approved for Orphan Indication,,,,
LXMSZDCAJNLERA-ZHYRCANASA-N,5833,LXMSZDCAJNLERA-ZHYRCANASA-N,spironolactone,,Use in pediatric patients with primary hyperaldosteronism,C1384514,Primary Hyperaldosteronism,5/22/14,Designated,Not FDA Approved for Orphan Indication,,,,
QJJXYPPXXYFBGM-LFZNUXCKSA-N,445643,QJJXYPPXXYFBGM-LFZNUXCKSA-N,tacrolimus,,Treatment of hemorrhagic cystitis,C0085692,Hemorrhagic cystitis,7/6/12,Designated,Not FDA Approved for Orphan Indication,,,,
QJJXYPPXXYFBGM-LFZNUXCKSA-N,445643,QJJXYPPXXYFBGM-LFZNUXCKSA-N,Tacrolimus,Prograf,Prophylaxis of organ rejection in patients receiving heart transplants.,C0815080,organ rejection,6/6/05,Designated/Approved,,Prophylaxis of organ rejection in patients receiving allogenic heart transplants., 03/29/2006 , 03/29/2013 ,
JACAAXNEHGBPOQ-LLVKDONJSA-N,164509,JACAAXNEHGBPOQ-LLVKDONJSA-N,talampanel,,Treatment of glioma,C0017638,Glioma,2/17/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
NSQSAUGJQHDYNO-UHFFFAOYSA-N,66558664,NSQSAUGJQHDYNO-UHFFFAOYSA-N,tazemetostat,,Treatment of follicular lymphoma,C0024301,follicular lymphoma,11/14/17,Designated/Approved,,TAZVERIK (tazemetostat) is indicated for: the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies; and the treatment of adult patients with R/R FL who have no satisfactory alternative treatment options., 06/18/2020 ,  ,
HDXDQPRPFRKGKZ-INIZCTEOSA-N,86291103,HDXDQPRPFRKGKZ-INIZCTEOSA-N,tenalisib,,Treatment of Cutaneous T-Cell Lymphoma,C0079773,cutaneous T-cell lymphoma,4/4/18,Designated,Not FDA Approved for Orphan Indication,,,,
SCTJKHUUZLXJIP-RUZDIDTESA-N,23628250,SCTJKHUUZLXJIP-RUZDIDTESA-N,tenofovir exalidex,,Treatment of pediatric chronic hepatitis B infection (age 0 through 11 years of age),"C0019163,C0524909","Hepatitis B infection , chronic hepatitis b",2/20/18,Designated,Not FDA Approved for Orphan Indication,,,,
OGBMKVWORPGQRR-UMXFMPSGSA-N,16133850,OGBMKVWORPGQRR-UMXFMPSGSA-N,Teriparatide,,Treatment of idiopathic osteoporosis.,C0158447,Idiopathic osteoporosis,10/28/99,Designated,Not FDA Approved for Orphan Indication,,,,
MUMGGOZAMZWBJJ-DYKIIFRCSA-N,6013,MUMGGOZAMZWBJJ-DYKIIFRCSA-N,Testosterone,,Treatment of weight loss in AIDS patients with HIV-associated wasting.,"C0006625,C0019682,C4084774","Wasting , HIV , Weight loss",2/5/96,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
UEJJHQNACJXSKW-UHFFFAOYSA-N,5426,UEJJHQNACJXSKW-UHFFFAOYSA-N,Thalidomide,,Treatment of graft versus host disease.,C0018133,GRAFT VERSUS HOST DISEASE,3/5/90,Designated,Not FDA Approved for Orphan Indication,,,,
UEJJHQNACJXSKW-UHFFFAOYSA-N,5426,UEJJHQNACJXSKW-UHFFFAOYSA-N,Thalidomide,,Treatment of the clinical manifestations of mycobacterial infection caused by Mycobacterium tuberculosis and non-tuberculous mycobacteria.,"C0026918,C0041296,C1265234","Mycobacterial infection , Infection caused by Mycobacterium tuberculosis , Non-Tuberculous Mycobacteria",1/12/93,Designated,Not FDA Approved for Orphan Indication,,,,
BSVYJQAWONIOOU-UHFFFAOYSA-N,33958,BSVYJQAWONIOOU-UHFFFAOYSA-N,tilorone dihydrochloride,,Treatment of Ebola infection,C0282687,Ebola Infection,2/7/18,Designated,Not FDA Approved for Orphan Indication,,,,
DMAHZCZCPVOYGS-ZLSDMPCXSA-L,135565472,DMAHZCZCPVOYGS-ZLSDMPCXSA-L,tin ethyl etiopurpurin,,Treatment of basal cell carcinoma nevus syndrome (BCCNS),"C0007117,C0027962","Basal cell carcinoma , Nevus",1/16/18,Designated,Not FDA Approved for Orphan Indication,,,,
HJLSLZFTEKNLFI-UHFFFAOYSA-N,5479,HJLSLZFTEKNLFI-UHFFFAOYSA-N,tinidazole,Tindamax,Treatment of giardiasis,C0017536,Giardiasis,4/18/02,Designated/Approved,,Treatment of giardiasis caused by G. duodenalis (also termed G. lamblia) in both adults and pediatric patients older than three years of age, 05/17/2004 , 05/17/2011 ,
PLHJCIYEEKOWNM-HHHXNRCGSA-N,159324,PLHJCIYEEKOWNM-HHHXNRCGSA-N,Tipifarnib,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,7/6/04,Designated,Not FDA Approved for Orphan Indication,,,,
NLVFBUXFDBBNBW-PBSUHMDJSA-N,36294,NLVFBUXFDBBNBW-PBSUHMDJSA-N,Tobramycin,,Treatment of bronchiectasis patients infected with Pseudomonas aeruginosa.,C0006267,Bronchiectasis,6/18/99,Designated,Not FDA Approved for Orphan Indication,,,,
KJADKKWYZYXHBB-XBWDGYHZSA-N,5284627,KJADKKWYZYXHBB-XBWDGYHZSA-N,Topiramate,Topamax,Treatment of Lennox-Gastaut syndrome.,C0238111,Lennox-Gastaut syndrome,11/25/92,Designated/Approved,,As adjunctive therapy in patients two years and older with siezures associated with Lennox-Gastaut syndrome., 08/28/2001 , 08/28/2008 ,
PKVRCIRHQMSYJX-AIFWHQITSA-N,108150,PKVRCIRHQMSYJX-AIFWHQITSA-N,trabectedin,,Treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,3/29/05,Designated,Not FDA Approved for Orphan Indication,,,,
HSWLVDBGZCETRH-UHFFFAOYSA-O,132472120,HSWLVDBGZCETRH-UHFFFAOYSA-O,trabedersen,,Treatment of malignant glioma,C0555198,Malignant Glioma,6/5/02,Designated,Not FDA Approved for Orphan Indication,,,,
NQPDXQQQCQDHHW-UHFFFAOYSA-N,50248,NQPDXQQQCQDHHW-UHFFFAOYSA-N,triclabendazole,,Treatment of fascioliasis,C0015652,Fascioliasis,6/27/16,Designated,Not FDA Approved for Orphan Indication,,,,
ZCJXQWYMBJYJNB-UHFFFAOYSA-N,336805,ZCJXQWYMBJYJNB-UHFFFAOYSA-N,Trimetrexate glucuronate,Neutrexin,Treatment of Pneumocystis carinii pneumonia in AIDS patients.,C1535939,Pneumocystis carinii Pneumonia,5/15/86,Designated/Approved,,"Concurrent leucovorin administration as an alternative therapy for the treatment of moderate to severe PCP in immunocompromised patients who are intolerant of, or are refractory to, trimethoprim sulfamethoxazole.", 12/17/1993 , 12/17/2000 ,
ZCJXQWYMBJYJNB-LRDBBFHQSA-N,54949,ZCJXQWYMBJYJNB-LRDBBFHQSA-N,Trimetrexate glucuronate,Neutrexin,Treatment of Pneumocystis carinii pneumonia in AIDS patients.,C1535939,Pneumocystis carinii Pneumonia,5/15/86,Designated/Approved,,"Concurrent leucovorin administration as an alternative therapy for the treatment of moderate to severe PCP in immunocompromised patients who are intolerant of, or are refractory to, trimethoprim sulfamethoxazole.", 12/17/1993 , 12/17/2000 ,
ZBVJFYPGLGEMIN-UHFFFAOYSA-N,25091037,ZBVJFYPGLGEMIN-UHFFFAOYSA-N,triptorelin pamoate,Triptodur,Treatment of central precocious puberty,C0342543,Central Precocious Puberty,8/20/12,Designated/Approved,,Treatment of pediatric patients 2 years of age and older with central precocious puberty, 06/29/2017 , 06/29/2024 ,Treatment of pediatric patients 2 years of age and older with central precocious puberty
ZBVJFYPGLGEMIN-IKNXIQPFSA-N,60196291,ZBVJFYPGLGEMIN-IKNXIQPFSA-N,triptorelin pamoate,Triptodur,Treatment of central precocious puberty,C0342543,Central Precocious Puberty,8/20/12,Designated/Approved,,Treatment of pediatric patients 2 years of age and older with central precocious puberty, 06/29/2017 , 06/29/2024 ,Treatment of pediatric patients 2 years of age and older with central precocious puberty
ZBVJFYPGLGEMIN-OYLNGHKZSA-N,25074469,ZBVJFYPGLGEMIN-OYLNGHKZSA-N,triptorelin pamoate,Triptodur,Treatment of central precocious puberty,C0342543,Central Precocious Puberty,8/20/12,Designated/Approved,,Treatment of pediatric patients 2 years of age and older with central precocious puberty, 06/29/2017 , 06/29/2024 ,Treatment of pediatric patients 2 years of age and older with central precocious puberty
BUSXWGRAOZQTEY-SDBXPKJASA-N,11318905,BUSXWGRAOZQTEY-SDBXPKJASA-N,Trofinetide,,Treatment of Fragile X Syndrome,C0016667,Fragile X Syndrome,10/23/13,Designated,Not FDA Approved for Orphan Indication,,,,
LQCLVBQBTUVCEQ-DURLPPERSA-N,133562799,LQCLVBQBTUVCEQ-DURLPPERSA-N,Troleandomycin,,Treatment of severe steroid-requiring asthma.,C0004096,Asthma,9/21/89,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
LQCLVBQBTUVCEQ-ISONCDLBSA-N,146158448,LQCLVBQBTUVCEQ-ISONCDLBSA-N,Troleandomycin,,Treatment of severe steroid-requiring asthma.,C0004096,Asthma,9/21/89,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
LQCLVBQBTUVCEQ-BFKGUNNCSA-N,6713914,LQCLVBQBTUVCEQ-BFKGUNNCSA-N,Troleandomycin,,Treatment of severe steroid-requiring asthma.,C0004096,Asthma,9/21/89,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
LQCLVBQBTUVCEQ-CLPGKMRCSA-N,5289436,LQCLVBQBTUVCEQ-CLPGKMRCSA-N,Troleandomycin,,Treatment of severe steroid-requiring asthma.,C0004096,Asthma,9/21/89,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
LQCLVBQBTUVCEQ-UHFFFAOYSA-N,418931,LQCLVBQBTUVCEQ-UHFFFAOYSA-N,Troleandomycin,,Treatment of severe steroid-requiring asthma.,C0004096,Asthma,9/21/89,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
LQCLVBQBTUVCEQ-RFHKDOLOSA-N,6708521,LQCLVBQBTUVCEQ-RFHKDOLOSA-N,Troleandomycin,,Treatment of severe steroid-requiring asthma.,C0004096,Asthma,9/21/89,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
LQCLVBQBTUVCEQ-MCQAQMIOSA-N,5284630,LQCLVBQBTUVCEQ-MCQAQMIOSA-N,Troleandomycin,,Treatment of severe steroid-requiring asthma.,C0004096,Asthma,9/21/89,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
LQCLVBQBTUVCEQ-GSELTXNRSA-N,17675,LQCLVBQBTUVCEQ-GSELTXNRSA-N,Troleandomycin,,Treatment of severe steroid-requiring asthma.,C0004096,Asthma,9/21/89,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
LQCLVBQBTUVCEQ-QTFUVMRISA-N,202225,LQCLVBQBTUVCEQ-QTFUVMRISA-N,Troleandomycin,,Treatment of severe steroid-requiring asthma.,C0004096,Asthma,9/21/89,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
RXRGZNYSEHTMHC-BQBZGAKWSA-N,454194,RXRGZNYSEHTMHC-BQBZGAKWSA-N,Troxacitabine,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,4/4/05,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
SDEAXTCZPQIFQM-UHFFFAOYSA-N,51039094,SDEAXTCZPQIFQM-UHFFFAOYSA-N,tucatinib,,Treatment of breast cancer patients with brain metastases.,"C0220650,C0678222","brain metastases , Breast cancer",6/5/17,Designated/Approved,,"TUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.", 04/17/2020 , 04/17/2027 ,"For use in combination with trastuzumab and capecitabine for treatment of adult patients with metastatic HER2-positive breast cancer and brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting."
SDEAXTCZPQIFQM-UHFFFAOYSA-N,51039094,SDEAXTCZPQIFQM-UHFFFAOYSA-N,tucatinib,,Treatment of HER2+ colorectal cancer,C0009404,Colorectal Cancer,9/18/17,Designated,Not FDA Approved for Orphan Indication,,,,
IUVCFHHAEHNCFT-INIZCTEOSA-N,72950888,IUVCFHHAEHNCFT-INIZCTEOSA-N,umbralisib,Ukoniq,Treatment of splenic marginal zone lymphoma,C0349632,Splenic marginal zone lymphoma,4/11/19,Designated/Approved,,treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen, 02/05/2021 ,  ,
PGAVKCOVUIYSFO-XVFCMESISA-N,6133,PGAVKCOVUIYSFO-XVFCMESISA-N,Uridine 5'-triphosphate,,Treatment of cystic fibrosis.,C0010674,Cystic Fibrosis,12/4/95,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
GEJDGVNQKABXKG-CFKGEZKQSA-N,24795069,GEJDGVNQKABXKG-CFKGEZKQSA-N,valbenazine,,Treatment of pediatric patients with Tourette syndrome (TS).,C0040517,Tourette Syndrome,10/19/17,Designated,Not FDA Approved for Orphan Indication,,,,
ZYTXTXAMMDTYDQ-DGEXFFLYSA-N,3035000,ZYTXTXAMMDTYDQ-DGEXFFLYSA-N,vamorolone,,Treatment of Duchenne muscular dystrophy,C0013264,DUCHENNE MUSCULAR DYSTROPHY,12/2/11,Designated,Not FDA Approved for Orphan Indication,,,,
VBUWHHLIZKOSMS-RIWXPGAOSA-N,53314964,VBUWHHLIZKOSMS-RIWXPGAOSA-N,Vasoactive intestinal peptide,,Treatment of Acute Respiratory Distress Syndrome.,C0035222,Acute respiratory distress syndrome,3/9/01,Designated,Not FDA Approved for Orphan Indication,,,,
LQBVNQSMGBZMKD-UHFFFAOYSA-N,49846579,LQBVNQSMGBZMKD-UHFFFAOYSA-N,Venetoclax,,Treatment for small cell lung cancer,C3540630,Small Cell Lung Cancer,11/5/20,Designated,Not FDA Approved for Orphan Indication,,,,
LQBVNQSMGBZMKD-UHFFFAOYSA-N,49846579,LQBVNQSMGBZMKD-UHFFFAOYSA-N,Venetoclax,,Treatment of myelodysplastic syndromes,C3463824,Myelodysplastic Syndromes,6/12/19,Designated,Not FDA Approved for Orphan Indication,,,,
YFHRCLAKZBDRHN-MRXNPFEDSA-N,60199242,YFHRCLAKZBDRHN-MRXNPFEDSA-N,venglustat,,Treatment of Gaucher disease,C0017205,Gaucher Disease,9/11/14,Designated,Not FDA Approved for Orphan Indication,,,,
SXNJFOWDRLKDSF-XKHVUIRMSA-N,10461508,SXNJFOWDRLKDSF-XKHVUIRMSA-N,volasertib,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,4/14/14,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
SXNJFOWDRLKDSF-XKHVUIRMSA-N,10461508,SXNJFOWDRLKDSF-XKHVUIRMSA-N,Volasertib,,treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,10/8/20,Designated,Not FDA Approved for Orphan Indication,,,,
WAEXFXRVDQXREF-UHFFFAOYSA-N,5311,WAEXFXRVDQXREF-UHFFFAOYSA-N,vorinostat,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,6/12/03,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
RNOAOAWBMHREKO-QFIPXVFZSA-N,135565884,RNOAOAWBMHREKO-QFIPXVFZSA-N,Zanubrutinib,,Treatment of chronic lymphocytic leukemia.,C0023434,Chronic Lymphocytic Leukemia,7/20/16,Designated,Not FDA Approved for Orphan Indication,,,,
RNOAOAWBMHREKO-QFIPXVFZSA-N,135565884,RNOAOAWBMHREKO-QFIPXVFZSA-N,zanubrutinib,BRUKINSA,Treatment of mantle cell lymphoma,C4721414,Mantle cell lymphoma,6/23/16,Designated/Approved,,BRUKINSA is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy., 11/14/2019 , 11/14/2026 ,Indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
RNOAOAWBMHREKO-QFIPXVFZSA-N,135565884,RNOAOAWBMHREKO-QFIPXVFZSA-N,zanubrutinib,,Treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue,C2200312,marginal zone lymphoma of mucosa-associated lymphoid tissue,8/24/20,Designated,Not FDA Approved for Orphan Indication,,,,
RNOAOAWBMHREKO-QFIPXVFZSA-N,135565884,RNOAOAWBMHREKO-QFIPXVFZSA-N,zanubrutinib,,Treatment of splenic marginal zone lymphoma,C0349632,Splenic marginal zone lymphoma,8/24/20,Designated,Not FDA Approved for Orphan Indication,,,,
CFMRIVODIXTERW-BDTNDASRSA-N,11553430,CFMRIVODIXTERW-BDTNDASRSA-N,"[(1S,2S,5S)-2-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-6,6-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanol",,Prevention of proliferative vitreoretinopathy,C0242852,Proliferative vitreoretinopathy,4/13/20,Designated,Not FDA Approved for Orphan Indication,,,,
RUDATBOHQWOJDD-BSWAIDMHSA-N,10133,RUDATBOHQWOJDD-BSWAIDMHSA-N,chenodiol,Chenix,"For patients with radiolucent stones in well opacifying gallbladders, in whom elective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age",C0442893,Systemic disease,9/21/84,Designated/Approved,,, 07/28/1983 , 07/28/1990 ,
ICKFFNBDFNZJSX-UHFFFAOYSA-N,25295,ICKFFNBDFNZJSX-UHFFFAOYSA-N,chloropyramine,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,10/22/10,Designated,Not FDA Approved for Orphan Indication,,,,
QPAKKWCQMHUHNI-GQIQPHNSSA-N,86278273,QPAKKWCQMHUHNI-GQIQPHNSSA-N,Chlorotoxin,,Treatment of malignant glioma,C0555198,Malignant Glioma,12/18/07,Designated,Not FDA Approved for Orphan Indication,,,,
VDHAWDNDOKGFTD-MRXNPFEDSA-N,156419,VDHAWDNDOKGFTD-MRXNPFEDSA-N,cinacalcet,,Treatment of secondary hyperparathyroidism (HPT) in pediatric patients with chronic kidney disease receiving dialysis,"C0020503,C1384672,C1561643","Secondary hyperparathyroidism , HPT , Chronic Kidney Disease",9/7/16,Designated,Not FDA Approved for Orphan Indication,,,,
YASYEJJMZJALEJ-UHFFFAOYSA-N,22230,YASYEJJMZJALEJ-UHFFFAOYSA-N,citric acid monohydrate,,Treatment of acute-on-chronic liver failure,C3850141,Acute-On-Chronic Liver Failure,6/21/17,Designated,Not FDA Approved for Orphan Indication,,,,
CJXAEXPPLWQRFR-UHFFFAOYSA-N,2782,CJXAEXPPLWQRFR-UHFFFAOYSA-N,clemizole,,Treatment of Dravet syndrome,C0751122,Dravet Syndrome,4/19/17,Designated,Not FDA Approved for Orphan Indication,,,,
WDDPHFBMKLOVOX-AYQXTPAHSA-N,119182,WDDPHFBMKLOVOX-AYQXTPAHSA-N,clofarabine,Clolar,Treatment of acute lymphoblastic leukemia,C0023449,Acute lymphoblastic leukemia,2/7/02,Designated/Approved,,Treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens, 12/28/2004 , 12/28/2011 ,
WDQPAMHFFCXSNU-UHFFFAOYSA-N,2794,WDQPAMHFFCXSNU-UHFFFAOYSA-N,Clofazimine,Lamprene,"Treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum.","C0023348,C0343467","Lepromatous leprosy , Erythema nodosum leprosum",6/11/84,Designated/Approved,,, 12/15/1986 , 12/15/1993 ,
GJSURZIOUXUGAL-UHFFFAOYSA-N,2803,GJSURZIOUXUGAL-UHFFFAOYSA-N,Clonidine,Duraclon,"For continous epidural administration as adjunctive therapy with intraspinal opiates for the treatment of pain in cancer patients tolerant to, or unresponsive to, intraspinal opiates.","C0006826,C0030193","Cancer , Pain",1/24/89,Designated/Approved,,In combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone., 10/02/1996 , 10/02/2003 ,
IAKHMKGGTNLKSZ-INIZCTEOSA-N,6167,IAKHMKGGTNLKSZ-INIZCTEOSA-N,Colchicine,,Treatment of Behcet's Syndrome,C0004943,Behcet Syndrome,9/25/07,Designated,Not FDA Approved for Orphan Indication,,,,
UOMKBIIXHQIERR-UHFFFAOYSA-N,38072,UOMKBIIXHQIERR-UHFFFAOYSA-N,cridanimod,,Treatment of progesterone receptor negative endometrial cancer in conjunction with progesterone therapy.,C0476089,Endometrial Cancer,1/12/11,Designated,Not FDA Approved for Orphan Indication,,,,
KTEIFNKAUNYNJU-GFCCVEGCSA-N,11626560,KTEIFNKAUNYNJU-GFCCVEGCSA-N,crizotinib,,Treatment of neuroblastoma,C0027819,Neuroblastoma,10/31/12,Designated,Not FDA Approved for Orphan Indication,,,,
AMHZIUVRYRVYBA-UHFFFAOYSA-N,2896,AMHZIUVRYRVYBA-UHFFFAOYSA-N,cyclocreatine,,Treatment of creatine transporter deficiency,C1845862,Creatine transporter deficiency,6/18/12,Designated,Not FDA Approved for Orphan Indication,,,,
CMSMOCZEIVJLDB-UHFFFAOYSA-N,2907,CMSMOCZEIVJLDB-UHFFFAOYSA-N,cyclophosphamide,,Prevention of graft versus host disease following allogeneic hematopoietic stem cell transplant,C0018133,GRAFT VERSUS HOST DISEASE,6/17/11,Designated,Not FDA Approved for Orphan Indication,,,,
USSIQXCVUWKGNF-KRWDZBQOSA-N,643985,USSIQXCVUWKGNF-KRWDZBQOSA-N,d-methadone,,Treatment of postherpetic neuralgia,C0032768,Postherpetic neuralgia,6/2/16,Designated,Not FDA Approved for Orphan Indication,,,,
BFSMGDJOXZAERB-UHFFFAOYSA-N,44462760,BFSMGDJOXZAERB-UHFFFAOYSA-N,dabrafenib,TAFINLAR,Treatment BRAF V600 mutation positive Stage IIB through IV melanoma,C0025202,melanoma,1/12/11,Designated/Approved,,Treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA approved test., 05/29/2013 , 05/29/2020 ,Treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA approved test.
KSRLIXGNPXAZHD-DFPPEFKWSA-N,136675526,KSRLIXGNPXAZHD-DFPPEFKWSA-N,dantrolene sodium,,Treatment of Wolfram Syndrome,C0043207,Wolfram Syndrome,2/17/16,Designated,Not FDA Approved for Orphan Indication,,,,
KSRLIXGNPXAZHD-DFPPEFKWSA-N,136675526,KSRLIXGNPXAZHD-DFPPEFKWSA-N,dantrolene sodium,,Treatment of Wolfram Syndrome,C0043207,Wolfram Syndrome,2/17/16,Designated,Not FDA Approved for Orphan Indication,,,,
KSRLIXGNPXAZHD-DFPPEFKWSA-M,71563341,KSRLIXGNPXAZHD-DFPPEFKWSA-M,dantrolene sodium,,Treatment of Wolfram Syndrome,C0043207,Wolfram Syndrome,2/17/16,Designated,Not FDA Approved for Orphan Indication,,,,
OZOMQRBLCMDCEG-CHHVJCJISA-M,5353563,OZOMQRBLCMDCEG-CHHVJCJISA-M,dantrolene sodium,,Treatment of Wolfram Syndrome,C0043207,Wolfram Syndrome,2/17/16,Designated,Not FDA Approved for Orphan Indication,,,,
OZOMQRBLCMDCEG-VIZOYTHASA-M,6604728,OZOMQRBLCMDCEG-VIZOYTHASA-M,dantrolene sodium,,Treatment of Wolfram Syndrome,C0043207,Wolfram Syndrome,2/17/16,Designated,Not FDA Approved for Orphan Indication,,,,
KSRLIXGNPXAZHD-HAZZGOGXSA-N,23707296,KSRLIXGNPXAZHD-HAZZGOGXSA-N,dantrolene sodium,,Treatment of Wolfram Syndrome,C0043207,Wolfram Syndrome,2/17/16,Designated,Not FDA Approved for Orphan Indication,,,,
BDZCLIOURDFSFQ-HAZZGOGXSA-N,16219293,BDZCLIOURDFSFQ-HAZZGOGXSA-N,dantrolene sodium,,Treatment of Wolfram Syndrome,C0043207,Wolfram Syndrome,2/17/16,Designated,Not FDA Approved for Orphan Indication,,,,
LTWQNYPDAUSXBC-CDJGKPBYSA-L,9568637,LTWQNYPDAUSXBC-CDJGKPBYSA-L,dantrolene sodium,,Treatment of Wolfram Syndrome,C0043207,Wolfram Syndrome,2/17/16,Designated,Not FDA Approved for Orphan Indication,,,,
KSRLIXGNPXAZHD-UHFFFAOYSA-M,32731,KSRLIXGNPXAZHD-UHFFFAOYSA-M,dantrolene sodium,,Treatment of Wolfram Syndrome,C0043207,Wolfram Syndrome,2/17/16,Designated,Not FDA Approved for Orphan Indication,,,,
KSRLIXGNPXAZHD-HAZZGOGXSA-M,13271066,KSRLIXGNPXAZHD-HAZZGOGXSA-M,dantrolene sodium,,Treatment of Wolfram Syndrome,C0043207,Wolfram Syndrome,2/17/16,Designated,Not FDA Approved for Orphan Indication,,,,
KSRLIXGNPXAZHD-DFPPEFKWSA-M,71563341,KSRLIXGNPXAZHD-DFPPEFKWSA-M,dantrolene sodium,,Treatment of Wolfram Syndrome,C0043207,Wolfram Syndrome,2/17/16,Designated,Not FDA Approved for Orphan Indication,,,,
KSRLIXGNPXAZHD-HAZZGOGXSA-M,13271066,KSRLIXGNPXAZHD-HAZZGOGXSA-M,dantrolene sodium,,Treatment of Wolfram Syndrome,C0043207,Wolfram Syndrome,2/17/16,Designated,Not FDA Approved for Orphan Indication,,,,
DWLTUUXCVGVRAV-XWRHUKJGSA-N,9832404,DWLTUUXCVGVRAV-XWRHUKJGSA-N,davunetide,,Treatment of Activity-Dependent Neuroprotective Protein (ADNP) Syndrome,"C0039082,C1423715","Syndrome , ADNP",2/22/18,Designated,Not FDA Approved for Orphan Indication,,,,
XAUDJQYHKZQPEU-KVQBGUIXSA-N,451668,XAUDJQYHKZQPEU-KVQBGUIXSA-N,decitabine,,Treatment of chronic myelogenous leukemia.,C0023473,Chronic myelogenous leukemia,3/8/99,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
TZXKOCQBRNJULO-UHFFFAOYSA-N,2972,TZXKOCQBRNJULO-UHFFFAOYSA-N,deferiprone,,Treatment of neurodegeneration with brain iron accumulation (NBIA),C5194180,Iron accumulation,6/15/17,Designated,Not FDA Approved for Orphan Indication,,,,
TZXKOCQBRNJULO-UHFFFAOYSA-N,2972,TZXKOCQBRNJULO-UHFFFAOYSA-N,deferiprone,,Treatment of superficial siderosis,C0037061,Siderosis,9/1/11,Designated,Not FDA Approved for Orphan Indication,,,,
JNWFIPVDEINBAI-UHFFFAOYSA-N,135565962,JNWFIPVDEINBAI-UHFFFAOYSA-N,defibrotide,Defitelio,For the treatment of hepatic veno-occlusive disease,C0019156,Hepatic Veno-Occlusive Disease,5/21/03,Designated/Approved,,"For the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT).", 03/30/2016 , 03/30/2023 ,"For the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT)."
VQODGRNSFPNSQE-CXSFZGCWSA-N,9400,VQODGRNSFPNSQE-CXSFZGCWSA-N,dexamethasone phosphate,,Treatment of corneal graft rejection.,C0339303,Corneal graft rejection,12/2/08,Designated,Not FDA Approved for Orphan Indication,,,,
SSQJFGMEZBFMNV-PMACEKPBSA-N,107778,SSQJFGMEZBFMNV-PMACEKPBSA-N,dexanabinol,,For the attenuation or amelioration of the long-term neurological sequelae associated with moderate and severe traumatic brain injury,"C0543419,C0876926","Sequelae , Traumatic Brain Injury",8/11/04,Designated,Not FDA Approved for Orphan Indication,,,,
DPFYBZWSVVKNPZ-AQWIXGDGSA-N,71315856,DPFYBZWSVVKNPZ-AQWIXGDGSA-N,Dextran 70,,Treatment of recurrent corneal erosion unresponsive to conventional therapy.,C0155119,Recurrent corneal erosion,3/5/90,Designated,Not FDA Approved for Orphan Indication,,,,
LRCZQSDQZJBHAF-PUBGEWHCSA-N,6918473,LRCZQSDQZJBHAF-PUBGEWHCSA-N,DHA-paclitaxel,,Treatment of metastatic malignant melanoma,C0860594,Metastatic malignant melanoma,10/10/02,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
GJQPMPFPNINLKP-UHFFFAOYSA-N,3038,GJQPMPFPNINLKP-UHFFFAOYSA-N,dichlorphenamide,,Treatment of primary periodic paralyses,C0522224,Paralyses,9/2/10,Designated/Approved,,"Treatment of primary hyperkalemic periodic paralysis, primary hypokalemic period paralysis, and related variants", 08/07/2015 , 08/07/2022 ,"Treatment of primary hyperkalemic periodic paralysis, primary hypokalemic period paralysis, and related variants"
WYQPLTPSGFELIB-JTQPXKBDSA-N,443936,WYQPLTPSGFELIB-JTQPXKBDSA-N,difluprednate,Durezol,Treatment of endogenous and traumatic anterior uveitis and panuveitis.,"C0030343,C4325554","Panuveitis , Traumatic anterior uveitis",9/30/08,Designated/Approved,,Treatment of endogenous anterior uveitis, 06/13/2012 , 06/13/2019 ,
WDJUZGPOPHTGOT-XUDUSOBPSA-N,441207,WDJUZGPOPHTGOT-XUDUSOBPSA-N,digitoxin,,Treatment of cystic fibrosis,C0010674,Cystic Fibrosis,5/27/05,Designated,Not FDA Approved for Orphan Indication,,,,
GZSOSUNBTXMUFQ-YFAPSIMESA-N,5281613,GZSOSUNBTXMUFQ-YFAPSIMESA-N,diosmin,,Treatment of systemic sclerosis,C0036421,Systemic sclerosis,5/15/18,Designated,Not FDA Approved for Orphan Indication,,,,
DNUXJWBKTMJNEP-JVSLBXKQSA-N,131842305,DNUXJWBKTMJNEP-JVSLBXKQSA-N,Disaccharide tripeptide glycerol dipalmitoyl,,Treatment of pulmonary and hepatic metastases in patients with colorectal adenocarcinoma.,"C0494165,C1319315","hepatic metastases , Colorectal Adenocarcinoma",3/1/90,Designated,Not FDA Approved for Orphan Indication,,,,
XWHPUCFOTRBMGS-UHFFFAOYSA-L,23724874,XWHPUCFOTRBMGS-UHFFFAOYSA-L,Disodium clodronate tetrahydrate,,Treatment of increased bone resorption due to malignancy.,C0006826,Malignancy,3/5/90,Designated,Not FDA Approved for Orphan Indication,,,,
VLCYCQAOQCDTCN-UHFFFAOYSA-N,3009,VLCYCQAOQCDTCN-UHFFFAOYSA-N,eflornithine,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,12/14/16,Designated,Not FDA Approved for Orphan Indication,,,,
VKDGNNYJFSHYKD-UHFFFAOYSA-N,57004,VKDGNNYJFSHYKD-UHFFFAOYSA-N,Eflornithine HCl,,Treatment of Pneumocystis carinii pneumonia in AIDS patients.,C1535939,Pneumocystis carinii Pneumonia,4/18/86,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
VKDGNNYJFSHYKD-UHFFFAOYSA-N,57004,VKDGNNYJFSHYKD-UHFFFAOYSA-N,eflornithine HCL,,Treatment of gastric cancer,C0024623,Gastric Cancer,4/7/15,Designated,Not FDA Approved for Orphan Indication,,,,
VKDGNNYJFSHYKD-UHFFFAOYSA-N,57004,VKDGNNYJFSHYKD-UHFFFAOYSA-N,Eflornithine HCl,Ornidyl,Treatment of Trypanosoma brucei gambiense infection (sleeping sickness).,"C0009450,C0041218,C0041228","Infection , Trypanosoma brucei gambiense , Sleeping sickness",4/23/86,Designated/Approved,,, 11/28/1990 , 11/28/1997 ,
FLFGNMFWNBOBGE-FNNZEKJRSA-N,6438895,FLFGNMFWNBOBGE-FNNZEKJRSA-N,elacytarabine,,Treatment of acute myeloid leukemia (AML),C0023467,Acute myeloid leukemia,6/18/08,Designated,Not FDA Approved for Orphan Indication,,,,
SVOQIEJWJCQGDQ-UHFFFAOYSA-N,135449332,SVOQIEJWJCQGDQ-UHFFFAOYSA-N,eltrombopag,Promacta,Treatment of aplastic anemia,C0002874,Aplastic Anemia,11/8/13,Designated/Approved,,PROMACTA is indicated in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia., 11/16/2018 , 11/16/2025 ,PROMACTA is indicated in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia.
PIWHBPJCPCXFEU-UHFFFAOYSA-N,127893,PIWHBPJCPCXFEU-UHFFFAOYSA-N,Epoetin alfa,Epogen,Treatment of anemia associated with HIV infection or HIV treatment.,"C0002871,C0019693","Anemia , HIV infection",7/1/91,Designated/Approved,,Treatment of AZT-induced anemia in HIV infected patients., 12/31/1990 , 12/31/1997 ,
HKVAMNSJSFKALM-GKUWKFKPSA-N,6442177,HKVAMNSJSFKALM-GKUWKFKPSA-N,everolimus,,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,7/23/12,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
HKVAMNSJSFKALM-GKUWKFKPSA-N,6442177,HKVAMNSJSFKALM-GKUWKFKPSA-N,everolimus,Afinitor,Treatment of neuroendocrine tumors,C0206754,Neuroendocrine Tumors,2/14/08,Designated/Approved,,0, 05/05/2011 , 05/05/2018 ,
WSEVKKHALHSUMB-RYVRVIGHSA-N,129012199,WSEVKKHALHSUMB-RYVRVIGHSA-N,exendin-(9-39),,Treatment of congential hyperinsulinenic hypoglycemia and other causes of hyperinsulinemic hypoglycemia in adults and children,"C0020615,C3888018","Hypoglycemia , Hyperinsulinemic Hypoglycemia",6/1/11,Designated,Not FDA Approved for Orphan Indication,,,,
MVGSNCBCUWPVDA-MFOYZWKCSA-N,5472495,MVGSNCBCUWPVDA-MFOYZWKCSA-N,Exisulind,,For the suppression and control of colonic adenomatous polyps in the inherited disease adenomatous polyposis coli.,"C0032580,C0206677","Adenomatous Polyposis Coli , Adenomatous Polyps",2/14/94,Designated,Not FDA Approved for Orphan Indication,,,,
BFENHEAPFWQJFL-BTJKTKAUSA-N,131801100,BFENHEAPFWQJFL-BTJKTKAUSA-N,filgotinib maleate,,Treatment of pediatric ulcerative colitis (UC),"C0009324,C2931173","Ulcerative Colitis , Pediatric ulcerative colitis",10/5/17,Designated,Not FDA Approved for Orphan Indication,,,,
CPEUVMUXAHMANV-UHFFFAOYSA-N,35802,CPEUVMUXAHMANV-UHFFFAOYSA-N,flubendazole,,"Treatment of lymphatic filariasis caused by nematodes of the family Filariodidea, in children and adults.",C0013884,Lymphatic Filariasis,1/23/14,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
SMANXXCATUTDDT-QPJJXVBHSA-N,941361,SMANXXCATUTDDT-QPJJXVBHSA-N,flunarizine,,Treatment of alternating hemiplegia,C0018991,Hemiplegia,6/24/13,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
GKDRMWXFWHEQQT-UHFFFAOYSA-N,11671467,GKDRMWXFWHEQQT-UHFFFAOYSA-N,fostamatinib,,Treatment of autoimmune hemolytic anemia (AIHA),C0002880,Autoimmune hemolytic anemia,1/31/18,Designated,Not FDA Approved for Orphan Indication,,,,
TZDUHAJSIBHXDL-UHFFFAOYSA-N,9883933,TZDUHAJSIBHXDL-UHFFFAOYSA-N,gabapentin enacarbil,Horizant,Treatment of postherpetic neuralgia,C0032768,Postherpetic neuralgia,6/7/11,Designated/Approved,,Management of postherpetic neuralgia in adults., 06/06/2012 , 06/06/2019 ,
SDUQYLNIPVEERB-QPPQHZFASA-N,60750,SDUQYLNIPVEERB-QPPQHZFASA-N,Gemcitabine,,Treatment of cholangiocarcinoma,C0206698,Cholangiocarcinoma,5/18/20,Designated,Not FDA Approved for Orphan Indication,,,,
YALNUENQHAQXEA-UHFFFAOYSA-N,9804992,YALNUENQHAQXEA-UHFFFAOYSA-N,Givinostat,,Treatment of polycythemia vera (PV),C0032463,Polycythemia Vera,9/28/17,Designated,Not FDA Approved for Orphan Indication,,,,
YALNUENQHAQXEA-UHFFFAOYSA-N,9804992,YALNUENQHAQXEA-UHFFFAOYSA-N,givinostat,,Treatment of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy,"C0013264,C0917713","DUCHENNE MUSCULAR DYSTROPHY , Becker Muscular Dystrophy",4/12/13,Designated,Not FDA Approved for Orphan Indication,,,,
ZNNLBTZKUZBEKO-UHFFFAOYSA-N,3488,ZNNLBTZKUZBEKO-UHFFFAOYSA-N,glyburide,,Treatment of acute subarachnoid hemorrhage,C0038525,Subarachnoid Hemorrhage,2/8/16,Designated,Not FDA Approved for Orphan Indication,,,,
QBKSWRVVCFFDOT-UHFFFAOYSA-N,3503,QBKSWRVVCFFDOT-UHFFFAOYSA-N,Gossypol,,Treatment of cancer of the adrenal cortex.,C0206686,cancer of the adrenal cortex,10/22/90,Designated,Not FDA Approved for Orphan Indication,,,,
GUWXKKAWLCENJA-WGWHJZDNSA-N,135564655,GUWXKKAWLCENJA-WGWHJZDNSA-N,guadecitabine,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,9/29/15,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
AXSPHUWXYSZPBG-UHFFFAOYSA-N,55361,AXSPHUWXYSZPBG-UHFFFAOYSA-N,gusperimus trihydrochloride,,Treatment of Wegener's granulomatosis,C3495801,Wegener's Granulomatosis,6/29/11,Designated,Not FDA Approved for Orphan Indication,,,,
LVASCWIMLIKXLA-CABCVRRESA-N,456390,LVASCWIMLIKXLA-CABCVRRESA-N,Halofuginone,,Treatment of systemic sclerosis.,C0036421,Systemic sclerosis,2/7/00,Designated,Not FDA Approved for Orphan Indication,,,,
LVASCWIMLIKXLA-UHFFFAOYSA-N,62894,LVASCWIMLIKXLA-UHFFFAOYSA-N,Halofuginone,,Treatment of systemic sclerosis.,C0036421,Systemic sclerosis,2/7/00,Designated,Not FDA Approved for Orphan Indication,,,,
LVASCWIMLIKXLA-LSDHHAIUSA-N,400772,LVASCWIMLIKXLA-LSDHHAIUSA-N,Halofuginone,,Treatment of systemic sclerosis.,C0036421,Systemic sclerosis,2/7/00,Designated,Not FDA Approved for Orphan Indication,,,,
DHZIAGCFFSRULK-UHFFFAOYSA-H,91667962,DHZIAGCFFSRULK-UHFFFAOYSA-H,hexasodium phytate,,Treatment of calciphylaxis,C0006666,Calciphylaxis,12/2/12,Designated,Not FDA Approved for Orphan Indication,,,,
HYFHYPWGAURHIV-PWNJXPRTSA-N,71296925,HYFHYPWGAURHIV-PWNJXPRTSA-N,homoharringtonine,,Treatment for chronic myelogenous leukemia,C0023473,Chronic myelogenous leukemia,2/8/02,Designated,Not FDA Approved for Orphan Indication,,,,
HYFHYPWGAURHIV-RZCBTRPQSA-N,56841046,HYFHYPWGAURHIV-RZCBTRPQSA-N,homoharringtonine,,Treatment for chronic myelogenous leukemia,C0023473,Chronic myelogenous leukemia,2/8/02,Designated,Not FDA Approved for Orphan Indication,,,,
HYFHYPWGAURHIV-BRXDYEKISA-N,5458297,HYFHYPWGAURHIV-BRXDYEKISA-N,homoharringtonine,,Treatment for chronic myelogenous leukemia,C0023473,Chronic myelogenous leukemia,2/8/02,Designated,Not FDA Approved for Orphan Indication,,,,
HYFHYPWGAURHIV-JCNWCSDUSA-N,45356872,HYFHYPWGAURHIV-JCNWCSDUSA-N,homoharringtonine,,Treatment for chronic myelogenous leukemia,C0023473,Chronic myelogenous leukemia,2/8/02,Designated,Not FDA Approved for Orphan Indication,,,,
HYFHYPWGAURHIV-ZEDNPHJLSA-N,72332,HYFHYPWGAURHIV-ZEDNPHJLSA-N,homoharringtonine,,Treatment for chronic myelogenous leukemia,C0023473,Chronic myelogenous leukemia,2/8/02,Designated,Not FDA Approved for Orphan Indication,,,,
HYFHYPWGAURHIV-UHFFFAOYSA-N,3628,HYFHYPWGAURHIV-UHFFFAOYSA-N,homoharringtonine,,Treatment for chronic myelogenous leukemia,C0023473,Chronic myelogenous leukemia,2/8/02,Designated,Not FDA Approved for Orphan Indication,,,,
HYFHYPWGAURHIV-JFIAXGOJSA-N,285033,HYFHYPWGAURHIV-JFIAXGOJSA-N,homoharringtonine,,Treatment for chronic myelogenous leukemia,C0023473,Chronic myelogenous leukemia,2/8/02,Designated,Not FDA Approved for Orphan Indication,,,,
BVOZFCOTOYGLGD-VPQOAABJSA-N,24847767,BVOZFCOTOYGLGD-VPQOAABJSA-N,hyaluronic acid,,Treatment of emphysema due to alpha1-antitrypsin deficiency.,C0034067,Emphysema,1/18/17,Designated,Not FDA Approved for Orphan Indication,,,,
RPTUSVTUFVMDQK-UHFFFAOYSA-N,3637,RPTUSVTUFVMDQK-UHFFFAOYSA-N,Hydralazine,,Treatment of severe intrapartum hypertension (diastolic blood pressure greater than or equal to 110 or systolic blood pressure greater than or equal to 160) associated with severe preeclampsia/eclampsia of pregnancy,"C0013537,C0341950,C1963138","Eclampsia , Severe Preeclampsia , Hypertension",4/9/04,Designated,Not FDA Approved for Orphan Indication,,,,
YDOIFHVUBCIUHF-UHFFFAOYSA-N,3663,YDOIFHVUBCIUHF-UHFFFAOYSA-N,Hypericin,,Treatment of glioblastoma multiforme.,C0017636,Glioblastoma multiforme,8/3/00,Designated,Not FDA Approved for Orphan Indication,,,,
XYFPWWZEPKGCCK-GOSISDBHSA-N,24821094,XYFPWWZEPKGCCK-GOSISDBHSA-N,ibrutinib,,Treatment of diffuse large B-cell lymphoma,C1332201,Diffuse Large B-Cell Lymphoma,10/23/13,Designated,Not FDA Approved for Orphan Indication,,,,
ZJVFLBOZORBYFE-UHFFFAOYSA-N,3671,ZJVFLBOZORBYFE-UHFFFAOYSA-N,ibudilast,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,10/6/16,Designated,Not FDA Approved for Orphan Indication,,,,
QURWXBZNHXJZBE-UAULPJDASA-N,137705994,QURWXBZNHXJZBE-UAULPJDASA-N,icatibant,,Treatment of burn patients hospitalized with burn-induced edema,C0013604,Edema,5/5/04,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
QURWXBZNHXJZBE-JNFYKTHFSA-N,90488794,QURWXBZNHXJZBE-JNFYKTHFSA-N,icatibant,,Treatment of burn patients hospitalized with burn-induced edema,C0013604,Edema,5/5/04,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
QURWXBZNHXJZBE-UHFFFAOYSA-N,14724482,QURWXBZNHXJZBE-UHFFFAOYSA-N,icatibant,,Treatment of burn patients hospitalized with burn-induced edema,C0013604,Edema,5/5/04,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
QURWXBZNHXJZBE-MCDGZUPGSA-N,71364,QURWXBZNHXJZBE-MCDGZUPGSA-N,icatibant,,Treatment of burn patients hospitalized with burn-induced edema,C0013604,Edema,5/5/04,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
QURWXBZNHXJZBE-SKXRKSCCSA-N,6918173,QURWXBZNHXJZBE-SKXRKSCCSA-N,icatibant,,Treatment of burn patients hospitalized with burn-induced edema,C0013604,Edema,5/5/04,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
XDXDZDZNSLXDNA-TZNDIEGXSA-N,42890,XDXDZDZNSLXDNA-TZNDIEGXSA-N,Idarubicin,,Treatment of chronic myelogenous leukemia.,C0023473,Chronic myelogenous leukemia,12/2/92,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
IFSDAJWBUCMOAH-HNNXBMFYSA-N,11625818,IFSDAJWBUCMOAH-HNNXBMFYSA-N,idelalisib,,Treatment of lymphoplasmacytic lymphoma with or without Walenstrom's macroglobulinemia,"C0024419,C0334633","lymphoplasmacytic lymphoma , Lymphoplasmacytic Lymphoma",9/26/13,Designated,Not FDA Approved for Orphan Indication,,,,
HOMGKSMUEGBAAB-UHFFFAOYSA-N,3690,HOMGKSMUEGBAAB-UHFFFAOYSA-N,ifosfamide,,Treatment of soft tissue and bone sarcomas,C0029463,bone sarcomas,8/7/85,Designated,Not FDA Approved for Orphan Indication,,,,
HIFJCPQKFCZDDL-PNQLYJIOSA-N,134694981,HIFJCPQKFCZDDL-PNQLYJIOSA-N,iloprost,,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,4/6/12,Designated,Not FDA Approved for Orphan Indication,,,,
HIFJCPQKFCZDDL-JYTNZNGZSA-N,91746214,HIFJCPQKFCZDDL-JYTNZNGZSA-N,iloprost,,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,4/6/12,Designated,Not FDA Approved for Orphan Indication,,,,
HIFJCPQKFCZDDL-QSGBCQANSA-N,20838499,HIFJCPQKFCZDDL-QSGBCQANSA-N,iloprost,,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,4/6/12,Designated,Not FDA Approved for Orphan Indication,,,,
HIFJCPQKFCZDDL-GBSCXWAGSA-N,51397006,HIFJCPQKFCZDDL-GBSCXWAGSA-N,iloprost,,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,4/6/12,Designated,Not FDA Approved for Orphan Indication,,,,
HIFJCPQKFCZDDL-NYBPDPFASA-N,54313,HIFJCPQKFCZDDL-NYBPDPFASA-N,iloprost,,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,4/6/12,Designated,Not FDA Approved for Orphan Indication,,,,
HIFJCPQKFCZDDL-QYUAYYPJSA-N,89077401,HIFJCPQKFCZDDL-QYUAYYPJSA-N,iloprost,,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,4/6/12,Designated,Not FDA Approved for Orphan Indication,,,,
HIFJCPQKFCZDDL-CSAIKYROSA-N,53486260,HIFJCPQKFCZDDL-CSAIKYROSA-N,iloprost,,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,4/6/12,Designated,Not FDA Approved for Orphan Indication,,,,
HIFJCPQKFCZDDL-UHFFFAOYSA-N,53394043,HIFJCPQKFCZDDL-UHFFFAOYSA-N,iloprost,,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,4/6/12,Designated,Not FDA Approved for Orphan Indication,,,,
HIFJCPQKFCZDDL-SGSAMSKHSA-N,6435378,HIFJCPQKFCZDDL-SGSAMSKHSA-N,iloprost,,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,4/6/12,Designated,Not FDA Approved for Orphan Indication,,,,
HIFJCPQKFCZDDL-ACWOEMLNSA-N,5311181,HIFJCPQKFCZDDL-ACWOEMLNSA-N,iloprost,,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,4/6/12,Designated,Not FDA Approved for Orphan Indication,,,,
KTUFNOKKBVMGRW-UHFFFAOYSA-N,5291,KTUFNOKKBVMGRW-UHFFFAOYSA-N,Imatinib,Gleevec,Treatment of chronic myelogenous leukemia,C0023473,Chronic myelogenous leukemia,1/31/01,Designated/Approved,,"Treatment of patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy", 05/10/2001 , 05/10/2008 ,
YLMAHDNUQAMNNX-UHFFFAOYSA-N,123596,YLMAHDNUQAMNNX-UHFFFAOYSA-N,Imatinib mesylate,Gleevec,Treatment of systemic mastocytosis without the D816V c-kit mutation,C0221013,Systemic mastocytosis,9/9/05,Designated/Approved,,Treatment of adult patients with aggressive mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown, 10/19/2006 , 10/19/2013 ,
BIXBBIPTYBJTRY-UHFFFAOYSA-N,68791,BIXBBIPTYBJTRY-UHFFFAOYSA-N,Imexon,,Treatment of pancreatic adenocarcinoma,C0281361,Pancreatic adenocarcinoma,11/1/03,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
BIXBBIPTYBJTRY-UHFFFAOYSA-N,68791,BIXBBIPTYBJTRY-UHFFFAOYSA-N,Imexon,,Treatment of metastatic malignant melanoma,C0860594,Metastatic malignant melanoma,8/3/01,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
KZIMLUFVKJLCCH-UHFFFAOYSA-N,9942657,KZIMLUFVKJLCCH-UHFFFAOYSA-N,imidazolyl ethanamide pentandioic acid,,Treatment of Acute Radiation Syndrome,C0520799,Acute Radiation Syndrome,9/17/18,Designated,Not FDA Approved for Orphan Indication,,,,
PDWUPXJEEYOOTR-JRGAVVOBSA-N,71184,PDWUPXJEEYOOTR-JRGAVVOBSA-N,iobenguane I 131,,Treatment of neuroendocrine tumors,C0206754,Neuroendocrine Tumors,7/5/07,Designated,Not FDA Approved for Orphan Indication,,,,
NMHJRGCKGFRFAQ-ZKFIMABGSA-N,450505,NMHJRGCKGFRFAQ-ZKFIMABGSA-N,Iobenguane Sulfate I 131,,For use as a diagnostic adjunct in patients with pheochromocytoma.,C0031511,Pheochromocytoma,11/14/84,Designated/Approved/Withdrawn,,Adjunctive diagnostic agent in the localization of primary or metastatic pheochromocytomas., 03/25/1994 , 03/25/2001 ,
XNACDNPGABUBFR-GNPGNDBSSA-N,76971242,XNACDNPGABUBFR-GNPGNDBSSA-N,Iobenguane Sulfate I 131,,For use as a diagnostic adjunct in patients with pheochromocytoma.,C0031511,Pheochromocytoma,11/14/84,Designated/Approved/Withdrawn,,Adjunctive diagnostic agent in the localization of primary or metastatic pheochromocytomas., 03/25/1994 , 03/25/2001 ,
GRZXWCHAXNAUHY-NSISKUIASA-N,24788740,GRZXWCHAXNAUHY-NSISKUIASA-N,Ipatasertib,,For the treatment of gastric cancer including cancer of the gastro-esophageal junction.,C0024623,Gastric Cancer,4/30/14,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
WFKAJVHLWXSISD-UHFFFAOYSA-N,68424,WFKAJVHLWXSISD-UHFFFAOYSA-N,Isobutyramide,,Treatment of sickle cell disease and beta thalassemia.,"C0002895,C0005283","Sickle Cell Disease , beta Thalassemia",5/25/94,Designated,Not FDA Approved for Orphan Indication,,,,
PURKAOJPTOLRMP-UHFFFAOYSA-N,16220172,PURKAOJPTOLRMP-UHFFFAOYSA-N,ivacaftor,Kalydeco,Treatment of patients with cystic fibrosis,C0010674,Cystic Fibrosis,12/20/06,Designated/Approved,,"Treatment of cystic fibrosis (CF) in patients age 2 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R ; and treatment of CF in patients age 2 years and older who have an R117H mutation in the CFTR gene.", 03/17/2015 , 03/17/2022 ,"Treatment of cystic fibrosis (CF) in patients ages 2 to less than 6 years who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, and R117H."
XMAYWYJOQHXEEK-ZZHFZYNASA-N,73951506,XMAYWYJOQHXEEK-ZZHFZYNASA-N,Ketoconazole,,For use with cyclosporine A to diminish the nephrotoxicity induced by cyclosporine in organ transplantation.,C0595916,nephrotoxicity,3/27/91,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
XMAYWYJOQHXEEK-ANWICMFUSA-N,16757695,XMAYWYJOQHXEEK-ANWICMFUSA-N,Ketoconazole,,For use with cyclosporine A to diminish the nephrotoxicity induced by cyclosporine in organ transplantation.,C0595916,nephrotoxicity,3/27/91,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
XMAYWYJOQHXEEK-NASUQTAISA-N,5702077,XMAYWYJOQHXEEK-NASUQTAISA-N,Ketoconazole,,For use with cyclosporine A to diminish the nephrotoxicity induced by cyclosporine in organ transplantation.,C0595916,nephrotoxicity,3/27/91,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
XMAYWYJOQHXEEK-UHFFFAOYSA-N,3823,XMAYWYJOQHXEEK-UHFFFAOYSA-N,Ketoconazole,,For use with cyclosporine A to diminish the nephrotoxicity induced by cyclosporine in organ transplantation.,C0595916,nephrotoxicity,3/27/91,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
XMAYWYJOQHXEEK-ZEQKJWHPSA-N,47576,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,Ketoconazole,,For use with cyclosporine A to diminish the nephrotoxicity induced by cyclosporine in organ transplantation.,C0595916,nephrotoxicity,3/27/91,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
XMAYWYJOQHXEEK-OZXSUGGESA-N,456201,XMAYWYJOQHXEEK-OZXSUGGESA-N,Ketoconazole,,For use with cyclosporine A to diminish the nephrotoxicity induced by cyclosporine in organ transplantation.,C0595916,nephrotoxicity,3/27/91,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
LDCYZAJDBXYCGN-VIFPVBQESA-N,439280,LDCYZAJDBXYCGN-VIFPVBQESA-N,L-5-hydroxytryptophan,,Treatment of tetrahydrobiopterin deficiency.,C0751436,Tetrahydrobiopterin Deficiency,1/20/99,Designated,Not FDA Approved for Orphan Indication,,,,
KPYSYYIEGFHWSV-QMMMGPOBSA-N,44602,KPYSYYIEGFHWSV-QMMMGPOBSA-N,L-baclofen,,Treatment of trigeminal neuralgia,C0040997,Trigeminal Neuralgia,1/6/98,Designated,Not FDA Approved for Orphan Indication,,,,
KPYSYYIEGFHWSV-MRVPVSSYSA-N,44600,KPYSYYIEGFHWSV-MRVPVSSYSA-N,L-baclofen,,Treatment of trigeminal neuralgia,C0040997,Trigeminal Neuralgia,1/6/98,Designated,Not FDA Approved for Orphan Indication,,,,
KPYSYYIEGFHWSV-QMMMGPOBSA-N,44602,KPYSYYIEGFHWSV-QMMMGPOBSA-N,L-baclofen,,Treatment of spasticity associated with spinal cord injury or multiple sclerosis.,"C0026769,C0026838,C0037929","Multiple Sclerosis , Spasticity , Spinal Cord Injury",12/17/91,Designated,Not FDA Approved for Orphan Indication,,,,
KPYSYYIEGFHWSV-MRVPVSSYSA-N,44600,KPYSYYIEGFHWSV-MRVPVSSYSA-N,L-baclofen,,Treatment of spasticity associated with spinal cord injury or multiple sclerosis.,"C0026769,C0026838,C0037929","Multiple Sclerosis , Spasticity , Spinal Cord Injury",12/17/91,Designated,Not FDA Approved for Orphan Indication,,,,
RHGKLRLOHDJJDR-BYPYZUCNSA-N,9750,RHGKLRLOHDJJDR-BYPYZUCNSA-N,L-citrulline,,Prevention of clinical sequelae of acute lung injury induced by cardiopulmonary bypass in pediatric patients,C0242488,Acute Lung Injury,1/9/17,Designated,Not FDA Approved for Orphan Indication,,,,
SHZGCJCMOBCMKK-DHVFOXMCSA-N,17106,SHZGCJCMOBCMKK-DHVFOXMCSA-N,L-fucose,,Treatment of Congenital Disorder of Glycosylation IIc,C0282577,Congenital disorder of glycosylation,1/14/19,Designated,Not FDA Approved for Orphan Indication,,,,
AYFVYJQAPQTCCC-GBXIJSLDSA-N,6288,AYFVYJQAPQTCCC-GBXIJSLDSA-N,L-threonine,,Treatment of amyotrophic lateral sclerosis.,C0002736,Amyotrophic Lateral Sclerosis,2/6/89,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
GOTYRUGSSMKFNF-UHFFFAOYSA-N,216326,GOTYRUGSSMKFNF-UHFFFAOYSA-N,lenalidomide,Revlimid,Treatment of multiple myeloma,C0026764,Multiple Myeloma,9/20/01,Designated/Approved,,REVLIMID in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM)., 02/17/2015 , 02/17/2022 ,For use in combination with dexamethasone for the treatment of patients with multiple myeloma who have not received at least one prior therapy (first-line therapy).
GOTYRUGSSMKFNF-UHFFFAOYSA-N,216326,GOTYRUGSSMKFNF-UHFFFAOYSA-N,lenalidomide,Revlimid,Treatment of multiple myeloma,C0026764,Multiple Myeloma,9/20/01,Designated/Approved,,"Treatment of multiple myeloma (MM), as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT)", 02/22/2017 , 02/22/2024 ,"Treatment of multiple myeloma (MM), as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT)"
FIBJDTSHOUXTKV-UHFFFAOYSA-N,139600825,FIBJDTSHOUXTKV-UHFFFAOYSA-N,Lepirudin,Refluden,Treatment of heparin-associated thrombocytopenia type II.,C0040034,Thrombocytopenia,2/13/97,Designated/Approved,,For anticoagulation in patients with heparin-induced thrombocytopenia and associated thromboembolic disease in order to prevent further thromboembolic complications., 03/06/1998 , 03/06/2005 ,
FIBJDTSHOUXTKV-BRHMIFOHSA-N,118856773,FIBJDTSHOUXTKV-BRHMIFOHSA-N,Lepirudin,Refluden,Treatment of heparin-associated thrombocytopenia type II.,C0040034,Thrombocytopenia,2/13/97,Designated/Approved,,For anticoagulation in patients with heparin-induced thrombocytopenia and associated thromboembolic disease in order to prevent further thromboembolic complications., 03/06/1998 , 03/06/2005 ,
UIARLYUEJFELEN-LROUJFHJSA-N,126565,UIARLYUEJFELEN-LROUJFHJSA-N,lestaurtinib,,Treatment of Philadelphia-negative classic myeloproliferative disorders,C0027022,Myeloproliferative Disorders,9/3/09,Designated,Not FDA Approved for Orphan Indication,,,,
VVIAGPKUTFNRDU-ABLWVSNPSA-L,135823198,VVIAGPKUTFNRDU-ABLWVSNPSA-L,Leucovorin calcium,,For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.,C4721579,Metastatic colorectal cancer,6/23/88,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
KVUAALJSMIVURS-ZEDZUCNESA-N,135436482,KVUAALJSMIVURS-ZEDZUCNESA-N,Leucovorin calcium,,For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.,C4721579,Metastatic colorectal cancer,6/23/88,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
DZNHRKNLTYYMQA-ZIGBGYJWSA-N,135738681,DZNHRKNLTYYMQA-ZIGBGYJWSA-N,Leucovorin calcium,,For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.,C4721579,Metastatic colorectal cancer,6/23/88,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
KVUAALJSMIVURS-ZEDZUCNESA-L,135883785,KVUAALJSMIVURS-ZEDZUCNESA-L,Leucovorin calcium,,For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.,C4721579,Metastatic colorectal cancer,6/23/88,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
KVUAALJSMIVURS-ZEDZUCNESA-L,135883785,KVUAALJSMIVURS-ZEDZUCNESA-L,Leucovorin calcium,,For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.,C4721579,Metastatic colorectal cancer,6/23/88,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PHIQHXFUZVPYII-ZCFIWIBFSA-N,10917,PHIQHXFUZVPYII-ZCFIWIBFSA-N,Levocarnitine,,Treatment of pediatric cardiomyopathy.,C0878544,Cardiomyopathy,11/22/93,Designated,Not FDA Approved for Orphan Indication,,,,
CZGVOBIGEBDYTP-VSGBNLITSA-N,53492727,CZGVOBIGEBDYTP-VSGBNLITSA-N,linerixibat,,Treatment of Primary Biliary Cholangitis,C0008312,Primary Biliary Cholangitis,9/18/19,Designated,Not FDA Approved for Orphan Indication,,,,
MBBCVAKAJPKAKM-UHFFFAOYSA-N,9853053,MBBCVAKAJPKAKM-UHFFFAOYSA-N,lomitapide,,Treatment of Familial Chylomicronemia,C0023817,Familial Chylomicronemia,3/3/11,Designated,Not FDA Approved for Orphan Indication,,,,
VDCRFBBZFHHYGT-IOSLPCCCSA-N,135410906,VDCRFBBZFHHYGT-IOSLPCCCSA-N,Loxoribine,,Treatment of common variable immunodeficiency.,C2936664,Common Variable Immunodeficiency,2/24/92,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
JGCMEBMXRHSZKX-UHFFFAOYSA-N,16004692,JGCMEBMXRHSZKX-UHFFFAOYSA-N,macitentan,,Treatment of idiopathic pulmonary fibrosis.,C1800706,Idiopathic Pulmonary Fibrosis,4/14/09,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PBUUPFTVAPUWDE-HSLMEMBISA-N,5362269,PBUUPFTVAPUWDE-HSLMEMBISA-N,Mafosfamide,,Treatment of neoplastic meningitis,C0220654,neoplastic meningitis,1/21/03,Designated,Not FDA Approved for Orphan Indication,,,,
PBUUPFTVAPUWDE-UGZDLDLSSA-N,76968809,PBUUPFTVAPUWDE-UGZDLDLSSA-N,Mafosfamide,,Treatment of neoplastic meningitis,C0220654,neoplastic meningitis,1/21/03,Designated,Not FDA Approved for Orphan Indication,,,,
PBUUPFTVAPUWDE-UHFFFAOYSA-N,104746,PBUUPFTVAPUWDE-UHFFFAOYSA-N,Mafosfamide,,Treatment of neoplastic meningitis,C0220654,neoplastic meningitis,1/21/03,Designated,Not FDA Approved for Orphan Indication,,,,
WJEOLQLKVOPQFV-UHFFFAOYSA-N,10074640,WJEOLQLKVOPQFV-UHFFFAOYSA-N,masitinib,,Treatment of malignant gastrointestinal stromal tumors,C0238198,Gastrointestinal Stromal Tumors,4/20/05,Designated,Not FDA Approved for Orphan Indication,,,,
OPXLLQIJSORQAM-UHFFFAOYSA-N,4030,OPXLLQIJSORQAM-UHFFFAOYSA-N,mebendazole,VERMOX 500 mg chewable tablets,"Treatment of single or mixed gastrointestinal infestations by Trichuris trichiura (whipworm), Ascaris lumbricoides (large roundworm), and Ancylostoma duodenale and Nectar americanus (hookworm).",C0040954,whipworm,9/3/14,Designated/Approved,,treatment of patients one year of age and older withgastrointestinal infections caused by Ascaris lumbricoides (roundworm) and Trichuris trichiura (whipworm), 10/19/2016 ,  ,
DRLFMBDRBRZALE-UHFFFAOYSA-N,896,DRLFMBDRBRZALE-UHFFFAOYSA-N,Melatonin,,Treatment of retinopathy of prematurity,C0035344,Retinopathy of Prematurity,4/20/20,Designated,Not FDA Approved for Orphan Indication,,,,
DRLFMBDRBRZALE-UHFFFAOYSA-N,896,DRLFMBDRBRZALE-UHFFFAOYSA-N,melatonin,,Treatment of perinatal asphyxia,C0559477,Perinatal asphyxia,3/8/18,Designated,Not FDA Approved for Orphan Indication,,,,
DRLFMBDRBRZALE-UHFFFAOYSA-N,896,DRLFMBDRBRZALE-UHFFFAOYSA-N,melatonin,,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,2/28/19,Designated,Not FDA Approved for Orphan Indication,,,,
YQZNKYXGZSVEHI-VXKWHMMOSA-N,9935639,YQZNKYXGZSVEHI-VXKWHMMOSA-N,melphalan flufenamide,Pepaxto,"Treatment of plasma cell myeloma, also referred to as multiple myeloma",C0026764,Plasma cell myeloma,3/16/15,Designated/Approved,,"Treatment (in combination with dexamethasone) of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD-38 directed monoclonal antibody.", 02/26/2021 ,  ,
DMJNNHOOLUXYBV-PQTSNVLCSA-N,441130,DMJNNHOOLUXYBV-PQTSNVLCSA-N,Meropenem,,"Management of acute pulmonary exacerbations, in cystic fibrosis patients, due to respiratory tract infection with susceptible organisms.","C0010674,C0035243","Cystic Fibrosis , Respiratory Tract Infection",4/27/00,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
XZWYZXLIPXDOLR-UHFFFAOYSA-N,4091,XZWYZXLIPXDOLR-UHFFFAOYSA-N,metformin,,Treatment of progressive myoclonus epilepsy type 2 (Lafora disease),"C0751778,C0751783","progressive myoclonus epilepsy , Lafora Disease",12/14/17,Designated,Not FDA Approved for Orphan Indication,,,,
FBOZXECLQNJBKD-ZDUSSCGKSA-N,126941,FBOZXECLQNJBKD-ZDUSSCGKSA-N,methotrexate,,Treatment of juvenile rheumatoid arthritis.,C3495559,Juvenile rheumatoid arthritis,8/23/93,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
DDLIGBOFAVUZHB-UHFFFAOYSA-N,4192,DDLIGBOFAVUZHB-UHFFFAOYSA-N,midazolam,,Treatment of status epilepticus,C0038220,Status Epilepticus,1/30/18,Designated,Not FDA Approved for Orphan Indication,,,,
BMGQWWVMWDBQGC-IIFHNQTCSA-N,9829523,BMGQWWVMWDBQGC-IIFHNQTCSA-N,midostaurin,Rydapt,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,7/7/09,Designated/Approved,,"Treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.", 04/28/2017 , 04/28/2024 ,"Treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation."
BMGQWWVMWDBQGC-IIFHNQTCSA-N,9829523,BMGQWWVMWDBQGC-IIFHNQTCSA-N,midostaurin,Rydapt,Treatment of mastocytosis,C0024899,Mastocytosis,4/30/10,Designated/Approved,,"Treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL)", 04/28/2017 , 04/28/2024 ,"Treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL)"
VKHAHZOOUSRJNA-GCNJZUOMSA-N,55245,VKHAHZOOUSRJNA-GCNJZUOMSA-N,Mifepristone,,Treatment of Cushing's syndrome secondary to ectopic ACTH secretion,"C0001231,C0039082","Ectopic ACTH secretion , Syndrome",2/7/05,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PZRHRDRVRGEVNW-UHFFFAOYSA-N,4197,PZRHRDRVRGEVNW-UHFFFAOYSA-N,milrinone,,Treatment of right heart failure (RHF) in left ventricular assist device (LVAD) patients,C0235527,Right heart failure,1/8/18,Designated,Not FDA Approved for Orphan Indication,,,,
PQLXHQMOHUQAKB-UHFFFAOYSA-N,3599,PQLXHQMOHUQAKB-UHFFFAOYSA-N,miltefosine,,Treatment of granulomatous amebic encephalitis (GAE),C0338428,Granulomatous amebic encephalitis,6/19/17,Designated,Not FDA Approved for Orphan Indication,,,,
PQLXHQMOHUQAKB-UHFFFAOYSA-N,3599,PQLXHQMOHUQAKB-UHFFFAOYSA-N,miltefosine,,Topical treatment of cutaneous lymphoma encompassing cutaneous manifestations of T-cell lymphoma and B-cell lymphoma,"C0079731,C0079772,C1276146","B-Cell Lymphoma , T-Cell Lymphoma , Cutaneous lymphoma",3/18/09,Designated,Not FDA Approved for Orphan Indication,,,,
XAYGBKHKBBXDAK-UHFFFAOYSA-N,59634741,XAYGBKHKBBXDAK-UHFFFAOYSA-N,Mitapivat,,Treatment of thalassemia,C0039730,Thalassemia,6/8/20,Designated,Not FDA Approved for Orphan Indication,,,,
NWIBSHFKIJFRCO-WUDYKRTCSA-N,5746,NWIBSHFKIJFRCO-WUDYKRTCSA-N,mitomycin,,Prevention of recurrence of pterygium after its surgical excision.,C1867441,Pterygium,1/13/11,Designated,Not FDA Approved for Orphan Indication,,,,
KKZJGLLVHKMTCM-UHFFFAOYSA-N,4212,KKZJGLLVHKMTCM-UHFFFAOYSA-N,Mitoxantrone,Novantrone,Treatment of secondary-progressive multiple sclerosis.,C0393665,Progressive multiple sclerosis,8/13/99,Designated/Approved,,"Reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly adnormal between relapses).", 10/13/2000 , 10/13/2007 ,
KKZJGLLVHKMTCM-UHFFFAOYSA-N,4212,KKZJGLLVHKMTCM-UHFFFAOYSA-N,Mitoxantrone,Novantrone,Treatment of hormone refractory prostate cancer.,C1328504,Hormone refractory prostate cancer,8/21/96,Designated/Approved,,In combination with corticosteroids as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer., 11/13/1996 , 11/13/2003 ,
HRNLUBSXIHFDHP-UHFFFAOYSA-N,9865515,HRNLUBSXIHFDHP-UHFFFAOYSA-N,Mocetinostat,,Treatment of myelodysplastic syndrome,C3463824,MYELODYSPLASTIC SYNDROME,6/12/14,Designated,Not FDA Approved for Orphan Indication,,,,
ABASMUXUCSQFKC-PKEKLUKKSA-N,121490254,ABASMUXUCSQFKC-PKEKLUKKSA-N,mongersen,,Treatment of pediatric Crohn's disease,C2931133,Pediatric Crohn's disease,7/20/15,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
GHBFNMLVSPCDGN-UHFFFAOYSA-N,3033877,GHBFNMLVSPCDGN-UHFFFAOYSA-N,Monooctanoin,Moctanin,For dissolution of cholesterol gallstones retained in the common bile duct.,C0856727,Cholesterol gallstones,5/30/84,Designated/Approved,,, 10/31/1985 , 10/31/1992 ,
JJVZSYKFCOBILL-MKMRYRNGSA-N,91865076,JJVZSYKFCOBILL-MKMRYRNGSA-N,motixafortide,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,2/1/19,Designated,Not FDA Approved for Orphan Indication,,,,
YZBLFMPOMVTDJY-JLOCULIASA-N,154825546,YZBLFMPOMVTDJY-JLOCULIASA-N,moxidectin,,Treatment of onchocerciasis volvulus in children and adults,"C0029001,C0042961","Onchocerciasis , Volvulus",9/29/10,Designated/Approved,,Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older, 06/13/2018 , 06/13/2025 ,Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older
YZBLFMPOMVTDJY-HFVHDGGLSA-N,153640463,YZBLFMPOMVTDJY-HFVHDGGLSA-N,moxidectin,,Treatment of onchocerciasis volvulus in children and adults,"C0029001,C0042961","Onchocerciasis , Volvulus",9/29/10,Designated/Approved,,Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older, 06/13/2018 , 06/13/2025 ,Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older
YZBLFMPOMVTDJY-IRFODQMOSA-N,131954608,YZBLFMPOMVTDJY-IRFODQMOSA-N,moxidectin,,Treatment of onchocerciasis volvulus in children and adults,"C0029001,C0042961","Onchocerciasis , Volvulus",9/29/10,Designated/Approved,,Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older, 06/13/2018 , 06/13/2025 ,Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older
YZBLFMPOMVTDJY-LRWNSQJFSA-N,139031013,YZBLFMPOMVTDJY-LRWNSQJFSA-N,moxidectin,,Treatment of onchocerciasis volvulus in children and adults,"C0029001,C0042961","Onchocerciasis , Volvulus",9/29/10,Designated/Approved,,Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older, 06/13/2018 , 06/13/2025 ,Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older
YZBLFMPOMVTDJY-XHQXRQCGSA-N,91885488,YZBLFMPOMVTDJY-XHQXRQCGSA-N,moxidectin,,Treatment of onchocerciasis volvulus in children and adults,"C0029001,C0042961","Onchocerciasis , Volvulus",9/29/10,Designated/Approved,,Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older, 06/13/2018 , 06/13/2025 ,Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older
YZBLFMPOMVTDJY-AMFIFCOJSA-N,86287400,YZBLFMPOMVTDJY-AMFIFCOJSA-N,moxidectin,,Treatment of onchocerciasis volvulus in children and adults,"C0029001,C0042961","Onchocerciasis , Volvulus",9/29/10,Designated/Approved,,Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older, 06/13/2018 , 06/13/2025 ,Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older
YZBLFMPOMVTDJY-UBOCAARVSA-N,9604461,YZBLFMPOMVTDJY-UBOCAARVSA-N,moxidectin,,Treatment of onchocerciasis volvulus in children and adults,"C0029001,C0042961","Onchocerciasis , Volvulus",9/29/10,Designated/Approved,,Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older, 06/13/2018 , 06/13/2025 ,Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older
YZBLFMPOMVTDJY-KAAHEXRMSA-N,137701808,YZBLFMPOMVTDJY-KAAHEXRMSA-N,moxidectin,,Treatment of onchocerciasis volvulus in children and adults,"C0029001,C0042961","Onchocerciasis , Volvulus",9/29/10,Designated/Approved,,Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older, 06/13/2018 , 06/13/2025 ,Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older
YZBLFMPOMVTDJY-UHFFFAOYSA-N,72728820,YZBLFMPOMVTDJY-UHFFFAOYSA-N,moxidectin,,Treatment of onchocerciasis volvulus in children and adults,"C0029001,C0042961","Onchocerciasis , Volvulus",9/29/10,Designated/Approved,,Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older, 06/13/2018 , 06/13/2025 ,Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older
YZBLFMPOMVTDJY-RWJZGKSFSA-N,71312368,YZBLFMPOMVTDJY-RWJZGKSFSA-N,moxidectin,,Treatment of onchocerciasis volvulus in children and adults,"C0029001,C0042961","Onchocerciasis , Volvulus",9/29/10,Designated/Approved,,Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older, 06/13/2018 , 06/13/2025 ,Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older
YZBLFMPOMVTDJY-DSNUORPKSA-N,6436009,YZBLFMPOMVTDJY-DSNUORPKSA-N,moxidectin,,Treatment of onchocerciasis volvulus in children and adults,"C0029001,C0042961","Onchocerciasis , Volvulus",9/29/10,Designated/Approved,,Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older, 06/13/2018 , 06/13/2025 ,Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older
YZBLFMPOMVTDJY-BFPKLJSTSA-N,9571036,YZBLFMPOMVTDJY-BFPKLJSTSA-N,moxidectin,,Treatment of onchocerciasis volvulus in children and adults,"C0029001,C0042961","Onchocerciasis , Volvulus",9/29/10,Designated/Approved,,Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older, 06/13/2018 , 06/13/2025 ,Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older
YZBLFMPOMVTDJY-CBYMMZEQSA-N,16760141,YZBLFMPOMVTDJY-CBYMMZEQSA-N,moxidectin,,Treatment of onchocerciasis volvulus in children and adults,"C0029001,C0042961","Onchocerciasis , Volvulus",9/29/10,Designated/Approved,,Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older, 06/13/2018 , 06/13/2025 ,Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older
YZBLFMPOMVTDJY-LSGXYNIPSA-N,9832912,YZBLFMPOMVTDJY-LSGXYNIPSA-N,moxidectin,,Treatment of onchocerciasis volvulus in children and adults,"C0029001,C0042961","Onchocerciasis , Volvulus",9/29/10,Designated/Approved,,Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older, 06/13/2018 , 06/13/2025 ,Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older
CDAISMWEOUEBRE-UHFFFAOYSA-N,892,CDAISMWEOUEBRE-UHFFFAOYSA-N,myo-inositol,,Prevention of retinopathy of prematurity in preterm infants at risk for developing retinopathy of prematurity,C0035344,Retinopathy of Prematurity,4/7/05,Designated,Not FDA Approved for Orphan Indication,,,,
PWKSKIMOESPYIA-BYPYZUCNSA-N,12035,PWKSKIMOESPYIA-BYPYZUCNSA-N,N-acetylcysteine,,Treatment of apnea of prematurity,C0475715,Apnea of prematurity,10/21/10,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
OVRNDRQMDRJTHS-UHFFFAOYSA-N,899,OVRNDRQMDRJTHS-UHFFFAOYSA-N,N-Acetylglucosamine,,Treatment for Duchenne Muscular Dystrophy,C0013264,DUCHENNE MUSCULAR DYSTROPHY,9/23/20,Designated,Not FDA Approved for Orphan Indication,,,,
OVRNDRQMDRJTHS-RTRLPJTCSA-N,439174,OVRNDRQMDRJTHS-RTRLPJTCSA-N,N-Acetylglucosamine,,Treatment for Duchenne Muscular Dystrophy,C0013264,DUCHENNE MUSCULAR DYSTROPHY,9/23/20,Designated,Not FDA Approved for Orphan Indication,,,,
OVRNDRQMDRJTHS-FMDGEEDCSA-N,24139,OVRNDRQMDRJTHS-FMDGEEDCSA-N,N-Acetylglucosamine,,Treatment for Duchenne Muscular Dystrophy,C0013264,DUCHENNE MUSCULAR DYSTROPHY,9/23/20,Designated,Not FDA Approved for Orphan Indication,,,,
ACPCMBPQKQTAQY-UHFFFAOYSA-N,67027333,ACPCMBPQKQTAQY-UHFFFAOYSA-N,N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N1-(2-fluoro-5-methylphenyl) urea,,Treatment of acute myelogenous leukemia,C0023467,Acute myelogenous leukemia,10/23/07,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
MQQNFDZXWVTQEH-UHFFFAOYSA-N,4413,MQQNFDZXWVTQEH-UHFFFAOYSA-N,Nafamostat,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,5/11/20,Designated,Not FDA Approved for Orphan Indication,,,,
UZHSEJADLWPNLE-GRGSLBFTSA-N,5284596,UZHSEJADLWPNLE-GRGSLBFTSA-N,naloxone,,Topical treatment of pruritus associated with mycosis fungoides,"C0026948,C0033774","Mycosis Fungoides , Pruritus",11/23/10,Designated,Not FDA Approved for Orphan Indication,,,,
NPAGDVCDWIYMMC-IZPLOLCNSA-N,9904,NPAGDVCDWIYMMC-IZPLOLCNSA-N,nandrolone,,Treatment of limb-girdle muscular dystrophy,C0686353,Limb-girdle muscular dystrophy,12/4/19,Designated,Not FDA Approved for Orphan Indication,,,,
IXOXBSCIXZEQEQ-UHTZMRCNSA-N,3011155,IXOXBSCIXZEQEQ-UHTZMRCNSA-N,nelarabine,,Treatment of chronic lymphocytic leukemia.,C0023434,Chronic Lymphocytic Leukemia,9/2/99,Designated,Not FDA Approved for Orphan Indication,,,,
QAGYKUNXZHXKMR-HKWSIXNMSA-N,64143,QAGYKUNXZHXKMR-HKWSIXNMSA-N,nelfinavir,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,2/14/17,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
JLEBZPBDRKPWTD-TURQNECASA-O,439924,JLEBZPBDRKPWTD-TURQNECASA-O,nicotinamide riboside,,"Treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome (MELAS)","C0001125,C0039082,C0162671,C1852373,C1857287","LACTIC ACIDOSIS , Syndrome , MELAS , Mitochondrial encephalopathy , Stroke-like episodes",1/25/17,Designated,Not FDA Approved for Orphan Indication,,,,
CPMDPSXJELVGJG-UHFFFAOYSA-N,135423438,CPMDPSXJELVGJG-UHFFFAOYSA-N,Nintedanib,,Treatment of mesothelioma,C0025500,Mesothelioma,12/12/16,Designated,Not FDA Approved for Orphan Indication,,,,
YQNQNVDNTFHQSW-UHFFFAOYSA-N,41684,YQNQNVDNTFHQSW-UHFFFAOYSA-N,nitazoxanide,,Treatment for intestinal amebiasis,C0013370,Intestinal Amebiasis,10/23/01,Designated,Not FDA Approved for Orphan Indication,,,,
MWUXSHHQAYIFBG-UHFFFAOYSA-N,145068,MWUXSHHQAYIFBG-UHFFFAOYSA-N,Nitric oxide,,Treatment of non-tuberculosis mycobacterial (NTM) infections,"C0041296,C1265234,C3714514","Tuberculosis , NTM , Infections",9/26/17,Designated,Not FDA Approved for Orphan Indication,,,,
MWUXSHHQAYIFBG-UHFFFAOYSA-N,145068,MWUXSHHQAYIFBG-UHFFFAOYSA-N,nitric oxide,,Use in combination with a drug delivery device for acute treatment of sickle cell vaso-occlusive crisis (pain crises),"C0030193,C0231224,C0750151","Pain , crises , Vaso-Occlusive Crisis",9/5/08,Designated,Not FDA Approved for Orphan Indication,,,,
MWUXSHHQAYIFBG-UHFFFAOYSA-N,145068,MWUXSHHQAYIFBG-UHFFFAOYSA-N,nitric oxide,,Treatment of non-tuberculous mycobacterial lung disease,"C0024115,C0041296","Lung Disease , Tuberculous",6/5/18,Designated,Not FDA Approved for Orphan Indication,,,,
AKNNEGZIBPJZJG-MSOLQXFVSA-N,275196,AKNNEGZIBPJZJG-MSOLQXFVSA-N,noscapine,,Treatment of amyotrophic lateral sclerosis.,C0002736,Amyotrophic Lateral Sclerosis,12/29/15,Designated,Not FDA Approved for Orphan Indication,,,,
DEQANNDTNATYII-JPZSUCLZSA-N,138107728,DEQANNDTNATYII-JPZSUCLZSA-N,Octreotide,Sandostatin LAR,Treatment of acromegaly.,C0001206,Acromegaly,8/24/98,Designated/Approved,,Reduction of growth hormone and IGF-1 (somatomedin C) in acromegaly., 11/25/1998 , 11/25/2005 ,
DEQANNDTNATYII-LIXSYSMXSA-N,44311916,DEQANNDTNATYII-LIXSYSMXSA-N,Octreotide,Sandostatin LAR,Treatment of acromegaly.,C0001206,Acromegaly,8/24/98,Designated/Approved,,Reduction of growth hormone and IGF-1 (somatomedin C) in acromegaly., 11/25/1998 , 11/25/2005 ,
DEQANNDTNATYII-XOEBDJBESA-N,90488715,DEQANNDTNATYII-XOEBDJBESA-N,Octreotide,Sandostatin LAR,Treatment of acromegaly.,C0001206,Acromegaly,8/24/98,Designated/Approved,,Reduction of growth hormone and IGF-1 (somatomedin C) in acromegaly., 11/25/1998 , 11/25/2005 ,
DEQANNDTNATYII-FLDZURHUSA-N,86289069,DEQANNDTNATYII-FLDZURHUSA-N,Octreotide,Sandostatin LAR,Treatment of acromegaly.,C0001206,Acromegaly,8/24/98,Designated/Approved,,Reduction of growth hormone and IGF-1 (somatomedin C) in acromegaly., 11/25/1998 , 11/25/2005 ,
DEQANNDTNATYII-MEUDYGGUSA-N,44420813,DEQANNDTNATYII-MEUDYGGUSA-N,Octreotide,Sandostatin LAR,Treatment of acromegaly.,C0001206,Acromegaly,8/24/98,Designated/Approved,,Reduction of growth hormone and IGF-1 (somatomedin C) in acromegaly., 11/25/1998 , 11/25/2005 ,
DEQANNDTNATYII-RRCPSWKPSA-N,6400441,DEQANNDTNATYII-RRCPSWKPSA-N,Octreotide,Sandostatin LAR,Treatment of acromegaly.,C0001206,Acromegaly,8/24/98,Designated/Approved,,Reduction of growth hormone and IGF-1 (somatomedin C) in acromegaly., 11/25/1998 , 11/25/2005 ,
DEQANNDTNATYII-UHFFFAOYSA-N,383414,DEQANNDTNATYII-UHFFFAOYSA-N,Octreotide,Sandostatin LAR,Treatment of acromegaly.,C0001206,Acromegaly,8/24/98,Designated/Approved,,Reduction of growth hormone and IGF-1 (somatomedin C) in acromegaly., 11/25/1998 , 11/25/2005 ,
DEQANNDTNATYII-OULOTJBUSA-N,448601,DEQANNDTNATYII-OULOTJBUSA-N,Octreotide,Sandostatin LAR,Treatment of acromegaly.,C0001206,Acromegaly,8/24/98,Designated/Approved,,Reduction of growth hormone and IGF-1 (somatomedin C) in acromegaly., 11/25/1998 , 11/25/2005 ,
FDLYAMZZIXQODN-UHFFFAOYSA-N,23725625,FDLYAMZZIXQODN-UHFFFAOYSA-N,olaparib,Lynparza,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,10/11/18,Designated/Approved,,Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza., 12/27/2019 , 12/27/2026 ,Indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.
FDLYAMZZIXQODN-UHFFFAOYSA-N,23725625,FDLYAMZZIXQODN-UHFFFAOYSA-N,olaparib,Lynparza,Treatment of ovarian cancer,C4721610,Ovarian Cancer,10/16/13,Designated/Approved,,Indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy, 12/19/2014 , 12/19/2021 ,Use as monotherapy for patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy
TZKBVRDEOITLRB-UHFFFAOYSA-N,51038269,TZKBVRDEOITLRB-UHFFFAOYSA-N,olverembatinib,,Treatment of chronic myeloid leukemia,C0023473,Chronic myeloid leukemia,4/22/20,Designated,Not FDA Approved for Orphan Indication,,,,
RJCWBNBKOKFWNY-IDPLTSGASA-N,71811910,RJCWBNBKOKFWNY-IDPLTSGASA-N,omaveloxolone,,Treatment of stage IIb through IV malignant melanoma,C0025202,Malignant Melanoma,9/5/17,Designated,Not FDA Approved for Orphan Indication,,,,
MZPVEMOYADUARK-UHFFFAOYSA-N,91667513,MZPVEMOYADUARK-UHFFFAOYSA-N,Orelabrutinib,,Treatment of Mantle Cell Lymphoma,C4721414,Mantle cell lymphoma,12/30/20,Designated,Not FDA Approved for Orphan Indication,,,,
UQCNKQCJZOAFTQ-ISWURRPUSA-N,5284604,UQCNKQCJZOAFTQ-ISWURRPUSA-N,Oxymorphone,,For relief of severe intractable pain in narcotic-tolerant patients.,C0030200,intractable pain,3/19/85,Designated,Not FDA Approved for Orphan Indication,,,,
XRVDGNKRPOAQTN-FQEVSTJZSA-N,52938427,XRVDGNKRPOAQTN-FQEVSTJZSA-N,ozanimod,,Treatment of pediatric (0 through 16 years of age) ulcerative colitis,C0009324,Ulcerative Colitis,12/29/15,Designated,Not FDA Approved for Orphan Indication,,,,
RCINICONZNJXQF-MZXODVADSA-N,36314,RCINICONZNJXQF-MZXODVADSA-N,Paclitaxel,,Treatment of AIDS-related Kaposi's sarcoma.,C0276535,AIDS-related Kaposi's sarcoma,4/15/97,Designated,Not FDA Approved for Orphan Indication,,,,
YTFHCXIPDIHOIA-DHZHZOJOSA-N,10295295,YTFHCXIPDIHOIA-DHZHZOJOSA-N,palovarotene,,Treatment of multiple osteochondromas,C0015306,MULTIPLE OSTEOCHONDROMAS,11/6/17,Designated,Not FDA Approved for Orphan Indication,,,,
ZQPDJCIXJHUERQ-QWRGUYRKSA-N,86677874,ZQPDJCIXJHUERQ-QWRGUYRKSA-N,parsaclisib,,Treatment of splenic marginal zone lymphoma,C0349632,Splenic marginal zone lymphoma,9/10/19,Designated,Not FDA Approved for Orphan Indication,,,,
ZQPDJCIXJHUERQ-QWRGUYRKSA-N,86677874,ZQPDJCIXJHUERQ-QWRGUYRKSA-N,Parsaclisib,,Treatment of Follicular Lymphoma,C0024301,follicular lymphoma,9/25/19,Designated,Not FDA Approved for Orphan Indication,,,,
ZQPDJCIXJHUERQ-QWRGUYRKSA-N,86677874,ZQPDJCIXJHUERQ-QWRGUYRKSA-N,parsaclisib,,Treatment of extranodal marginal zone lymphoma,C1367654,Marginal zone lymphoma,10/9/19,Designated,Not FDA Approved for Orphan Indication,,,,
NPOCDVAOUKODSQ-ZDUSSCGKSA-N,86278362,NPOCDVAOUKODSQ-ZDUSSCGKSA-N,pegvaliase-pqpz,PALYNZIQ,Treatment of hyperphenylalaninemia,C0751435,Hyperphenylalaninemia,3/8/95,Designated/Approved,,Palynziq is indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management, 05/24/2018 , 05/24/2025 ,Palynziq is indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management
HCDMJFOHIXMBOV-UHFFFAOYSA-N,86705695,HCDMJFOHIXMBOV-UHFFFAOYSA-N,Pemigatinib,,"Treatment of myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2","C0014457,C0027651","Eosinophilia , Neoplasms",8/21/19,Designated,Not FDA Approved for Orphan Indication,,,,
XDRYMKDFEDOLFX-UHFFFAOYSA-N,4735,XDRYMKDFEDOLFX-UHFFFAOYSA-N,pentamidine,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,9/13/10,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
YBVNFKZSMZGRAD-UHFFFAOYSA-N,8813,YBVNFKZSMZGRAD-UHFFFAOYSA-N,Pentamidine isethionate,,Treatment of Pneumocystis carinii pneumonia.,C1535939,Pneumocystis carinii Pneumonia,10/29/84,Designated,Not FDA Approved for Orphan Indication,,,,
YBVNFKZSMZGRAD-UHFFFAOYSA-N,8813,YBVNFKZSMZGRAD-UHFFFAOYSA-N,Pentamidine isethionate,Pentam 300,Treatment of Pneumocystis carinii pneumonia.,C1535939,Pneumocystis carinii Pneumonia,2/28/84,Designated/Approved,,, 10/16/1984 , 10/16/1991 ,
CWRVKFFCRWGWCS-UHFFFAOYSA-N,5917,CWRVKFFCRWGWCS-UHFFFAOYSA-N,pentetrazol,,Treatment of narcolepsy,C0027404,Narcolepsy,3/16/17,Designated,Not FDA Approved for Orphan Indication,,,,
FPVKHBSQESCIEP-JQCXWYLXSA-N,439693,FPVKHBSQESCIEP-JQCXWYLXSA-N,Pentostatin,,Treatment of patients with chronic lymphocytic leukemia.,C0023434,Chronic Lymphocytic Leukemia,1/29/91,Designated,Not FDA Approved for Orphan Indication,,,,
YEHCICAEULNIGD-MZMPZRCHSA-N,47811,YEHCICAEULNIGD-MZMPZRCHSA-N,Pergolide,,Treatment of Tourette's syndrome.,C0040517,Tourette's Syndrome,11/20/97,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
JDZOTSLZMQDFLG-BTJKTKAUSA-N,5284439,JDZOTSLZMQDFLG-BTJKTKAUSA-N,perhexiline maleate,,Treatment of moderate to severe symptomatic hypertrophic cardiomyopathy,C0007194,Hypertrophic Cardiomyopathy,6/14/12,Designated,Not FDA Approved for Orphan Indication,,,,
ISWRGOKTTBVCFA-UHFFFAOYSA-N,40632,ISWRGOKTTBVCFA-UHFFFAOYSA-N,pirfenidone,,Treatment of Unclassifiable-interstitial lung disease,C0206062,Interstitial lung disease,3/11/20,Designated,Not FDA Approved for Orphan Indication,,,,
KQOXLKOJHVFTRN-UHFFFAOYSA-N,1684,KQOXLKOJHVFTRN-UHFFFAOYSA-N,pleconaril,,Treatment of symptomatic enteroviral infection in the neonate,"C0014378,C0854706","Enteroviral infection , infection in the neonate",12/22/14,Designated,Not FDA Approved for Orphan Indication,,,,
VAZJLPXFVQHDFB-UHFFFAOYSA-N,20977,VAZJLPXFVQHDFB-UHFFFAOYSA-N,polyhexanide,,Treatment of Acanthamoeba keratitis,C0000880,Acanthamoeba Keratitis,11/6/17,Designated,Not FDA Approved for Orphan Indication,,,,
RSQDGTJKZWTAGL-UHFFFAOYSA-N,137321858,RSQDGTJKZWTAGL-UHFFFAOYSA-N,Porfimer sodium,,Treatment of cholangiocarcinoma,C0206698,Cholangiocarcinoma,11/18/04,Designated,Not FDA Approved for Orphan Indication,,,,
GBLBJPZSROAGMF-SIYOEGHHSA-N,129073603,GBLBJPZSROAGMF-SIYOEGHHSA-N,pralsetinib,GAVRETO,"Treatment of rearranged during transfection (RET)-rearranged non-small cell lung cancer (NSCLC), JAK1/2-positive NSCLC, or TRKC-positive NSCLC.","C0007131,C0694890,C3539721","Non-Small Cell Lung Cancer , rearranged during transfection , Non-Small Cell Lung Cancer",4/11/18,Designated/Approved,,treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test, 09/04/2020 , 09/04/2027 ,treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test
FASDKYOPVNHBLU-ZETCQYMHSA-N,119570,FASDKYOPVNHBLU-ZETCQYMHSA-N,pramipexole,,Treatment of Tourette's syndrome in pediatric patients,C0040517,Tourette's Syndrome,1/31/08,Designated,Not FDA Approved for Orphan Indication,,,,
GJOHLWZHWQUKAU-UHFFFAOYSA-N,6135,GJOHLWZHWQUKAU-UHFFFAOYSA-N,Primaquine phosphate,,For use in combination with clindamycin hydrochloride in the treatment of Pneumocystis carinii pneumonia associated with AIDS.,"C0276527,C1535939","Pneumonia associated with AIDS , Pneumocystis carinii Pneumonia",7/23/93,Designated,Not FDA Approved for Orphan Indication,,,,
DERJYEZSLHIUKF-UHFFFAOYSA-N,9703,DERJYEZSLHIUKF-UHFFFAOYSA-N,Procarbazine HCl,,Treatment of malignant glioma,C0555198,Malignant Glioma,8/8/06,Designated,Not FDA Approved for Orphan Indication,,,,
WKSAUQYGYAYLPV-UHFFFAOYSA-N,4993,WKSAUQYGYAYLPV-UHFFFAOYSA-N,pyrimethamine,,Treatment of GM-2 gangliosidoses (Tay-Sachs disease and Sandhoff disease).,"C0017083,C0036161,C0039373","Gangliosidoses , Sandhoff Disease , Tay-Sachs Disease",8/16/11,Designated,Not FDA Approved for Orphan Indication,,,,
FNHKPVJBJVTLMP-UHFFFAOYSA-N,11167602,FNHKPVJBJVTLMP-UHFFFAOYSA-N,regorafenib,Stivarga,Treatment gastrointestinal stromal tumors,C0238198,Gastrointestinal Stromal Tumors,1/12/11,Designated/Approved,,"Treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.", 02/25/2013 , 02/25/2020 ,"Treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate."
MQXWPWOCXGARRK-UHFFFAOYSA-N,67454400,MQXWPWOCXGARRK-UHFFFAOYSA-N,Reldesemtiv,,Treatment of Amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,12/11/19,Designated,Not FDA Approved for Orphan Indication,,,,
PWOQRKCAHTVFLB-UHFFFAOYSA-N,22420,PWOQRKCAHTVFLB-UHFFFAOYSA-N,Revimmune,,Treatment of autoimmune hemolytic anemia.,C0002880,Autoimmune hemolytic anemia,2/18/11,Designated,Not FDA Approved for Orphan Indication,,,,
BUROJSBIWGDYCN-MWBWAFHZSA-N,137704508,BUROJSBIWGDYCN-MWBWAFHZSA-N,ridaforolimus,,Treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,8/12/05,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
BUROJSBIWGDYCN-BPIPWEEESA-N,137303705,BUROJSBIWGDYCN-BPIPWEEESA-N,ridaforolimus,,Treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,8/12/05,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
BUROJSBIWGDYCN-GAFNQWMWSA-N,133268486,BUROJSBIWGDYCN-GAFNQWMWSA-N,ridaforolimus,,Treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,8/12/05,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
BUROJSBIWGDYCN-AFTOUBNRSA-N,87423409,BUROJSBIWGDYCN-AFTOUBNRSA-N,ridaforolimus,,Treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,8/12/05,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
BUROJSBIWGDYCN-QSRQGROMSA-N,86289926,BUROJSBIWGDYCN-QSRQGROMSA-N,ridaforolimus,,Treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,8/12/05,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
BUROJSBIWGDYCN-OZFXDLPUSA-N,74787553,BUROJSBIWGDYCN-OZFXDLPUSA-N,ridaforolimus,,Treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,8/12/05,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
BUROJSBIWGDYCN-QVXCGEACSA-N,71308311,BUROJSBIWGDYCN-QVXCGEACSA-N,ridaforolimus,,Treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,8/12/05,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
BUROJSBIWGDYCN-UHFFFAOYSA-N,71433797,BUROJSBIWGDYCN-UHFFFAOYSA-N,ridaforolimus,,Treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,8/12/05,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
BUROJSBIWGDYCN-QHPXJTPRSA-N,25199957,BUROJSBIWGDYCN-QHPXJTPRSA-N,ridaforolimus,,Treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,8/12/05,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
BUROJSBIWGDYCN-GAUTUEMISA-N,11520894,BUROJSBIWGDYCN-GAUTUEMISA-N,ridaforolimus,,Treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,8/12/05,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
GROMEQPXDKRRIE-UHFFFAOYSA-N,9799487,GROMEQPXDKRRIE-UHFFFAOYSA-N,rimeporide,,Treatment of Duchenne muscular dystrophy,C0013264,DUCHENNE MUSCULAR DYSTROPHY,9/19/17,Designated,Not FDA Approved for Orphan Indication,,,,
KNUXHTWUIVMBBY-JRJYXWDASA-N,135537060,KNUXHTWUIVMBBY-JRJYXWDASA-N,Rintatolimod,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,12/17/20,Designated,Not FDA Approved for Orphan Indication,,,,
VDNLFJGJEQUWRB-UHFFFAOYSA-L,3856851,VDNLFJGJEQUWRB-UHFFFAOYSA-L,rose bengal disodium,,Treatment of hepatocellular carcinoma.,C2239176,HEPATOCELLULAR CARCINOMA,4/18/11,Designated,Not FDA Approved for Orphan Indication,,,,
FZVMMANVVHMVBM-OIXLVLAFSA-N,70693548,FZVMMANVVHMVBM-OIXLVLAFSA-N,rusalatide acetate,,Treatment of acute radiation syndrome (ARS),C0520799,Acute Radiation Syndrome,9/7/17,Designated,Not FDA Approved for Orphan Indication,,,,
AHMIRVCNZZUANP-LPBAWZRYSA-N,91668177,AHMIRVCNZZUANP-LPBAWZRYSA-N,rusalatide acetate,,Treatment of acute radiation syndrome (ARS),C0520799,Acute Radiation Syndrome,9/7/17,Designated,Not FDA Approved for Orphan Indication,,,,
KQXDHUJYNAXLNZ-XQSDOZFQSA-N,3085092,KQXDHUJYNAXLNZ-XQSDOZFQSA-N,Salinomycin,,Treatment of small cell lung cancer,C3540630,Small Cell Lung Cancer,12/12/19,Designated,Not FDA Approved for Orphan Indication,,,,
GMBQZIIUCVWOCD-WWASVFFGSA-N,92095,GMBQZIIUCVWOCD-WWASVFFGSA-N,sarsasapogenin,,Treatment of amyotrophic lateral sclerosis (ALS),C0002736,Amyotrophic Lateral Sclerosis,6/18/04,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
BVLCEKWPOSAKSZ-YQMCHIOTSA-N,16132412,BVLCEKWPOSAKSZ-YQMCHIOTSA-N,Sermorelin acetate,,Adjunct to gonadotropin therapy in the induction of ovulation in women with anovulatory or oligo-ovulatory infertility who fail to ovulate in response to adequate treatment with clomiphene citrate alone and gonadotropin therapy alone.,"C0021359,C0429468","Infertility , Anovulatory",2/13/90,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
QFJCIRLUMZQUOT-HPLJOQBZSA-N,5284616,QFJCIRLUMZQUOT-HPLJOQBZSA-N,sirolimus,,Treatment of angiofibroma associated with tuberous sclerosis,"C0041341,C0206731","Tuberous Sclerosis , Angiofibroma",5/17/17,Designated,Not FDA Approved for Orphan Indication,,,,
BTGNGJJLZOIYID-UHFFFAOYSA-N,107706,BTGNGJJLZOIYID-UHFFFAOYSA-N,Sivelestat,,Treatment of Acute Radiation Syndrome,C0520799,Acute Radiation Syndrome,1/27/21,Designated,Not FDA Approved for Orphan Indication,,,,
BTGNGJJLZOIYID-UHFFFAOYSA-N,107706,BTGNGJJLZOIYID-UHFFFAOYSA-N,sivelestat,,Treatment of gastric cancer,C0024623,Gastric Cancer,6/5/20,Designated,Not FDA Approved for Orphan Indication,,,,
QUMMZNCRRKUJLQ-ZMGJSDJYSA-M,71680544,QUMMZNCRRKUJLQ-ZMGJSDJYSA-M,"Sodium (4Z,7Z,10R,11E,13E,15Z,17S,19Z) 10,17-dihydroxy-docosa-4,7,11,13,15,19-hexaenoate",,Prevention of retinopathy of prematurity,C0035344,Retinopathy of Prematurity,3/30/20,Designated,Not FDA Approved for Orphan Indication,,,,
UKLNMMHNWFDKNT-UHFFFAOYSA-M,23668197,UKLNMMHNWFDKNT-UHFFFAOYSA-M,sodium chlorite,,For slowing the progression of amyotrophic lateral sclerosis.,C0002736,Amyotrophic Lateral Sclerosis,8/22/11,Designated,Not FDA Approved for Orphan Indication,,,,
LPXPTNMVRIOKMN-UHFFFAOYSA-M,23668193,LPXPTNMVRIOKMN-UHFFFAOYSA-M,sodium nitrite,,Prevention of vasospasm associated with subarachnoid hemorrhage,C0038525,Subarachnoid Hemorrhage,1/17/07,Designated,Not FDA Approved for Orphan Indication,,,,
LPXPTNMVRIOKMN-UHFFFAOYSA-M,23668193,LPXPTNMVRIOKMN-UHFFFAOYSA-M,Sodium Nitrite,,Treatment of Sickle Cell Disease,C0002895,Sickle Cell Disease,3/25/20,Designated,Not FDA Approved for Orphan Indication,,,,
XYGBKMMCQDZQOZ-UHFFFAOYSA-M,23663870,XYGBKMMCQDZQOZ-UHFFFAOYSA-M,sodium oxybate,Xyrem,Treatment of narcolepsy.,C0027404,Narcolepsy,11/7/94,Designated/Approved,,Treatment of excessive daytime sleepiness in patients with narcolepsy, 11/18/2005 , 11/18/2012 ,
VPZRWNZGLKXFOE-UHFFFAOYSA-M,5258,VPZRWNZGLKXFOE-UHFFFAOYSA-M,Sodium phenylbutyrate,,"For use as an adjuct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.",C4684861,Recurrent Malignant Glioma,4/24/98,Designated,Not FDA Approved for Orphan Indication,,,,
AKHNMLFCWUSKQB-UHFFFAOYSA-L,24477,AKHNMLFCWUSKQB-UHFFFAOYSA-L,Sodium Thiosulfate,,Treatment of uremic and non-uremic calciphylaxis,C0006666,Calciphylaxis,2/16/12,Designated,Not FDA Approved for Orphan Indication,,,,
AEQFSUDEHCCHBT-UHFFFAOYSA-M,16760703,AEQFSUDEHCCHBT-UHFFFAOYSA-M,sodium valproate,,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,3/9/20,Designated,Not FDA Approved for Orphan Indication,,,,
GCQYYIHYQMVWLT-HQNLTJAPSA-N,5282192,GCQYYIHYQMVWLT-HQNLTJAPSA-N,Sorivudine,,Treatment of herpes zoster (shingles) in immunocompromised patients,"C0019360,C4553551","Zoster , Shingles",11/9/95,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ACTRVOBWPAIOHC-XIXRPRMCSA-N,2724354,ACTRVOBWPAIOHC-XIXRPRMCSA-N,Succimer,,Treatment of mercury intoxication.,C0728899,Intoxication,3/22/91,Designated,Not FDA Approved for Orphan Indication,,,,
ACTRVOBWPAIOHC-XIXRPRMCSA-N,2724354,ACTRVOBWPAIOHC-XIXRPRMCSA-N,Succimer,Chemet capsules,Treatment of lead poisoning in children.,C0149921,lead poisoning in children,5/9/84,Designated/Approved,,, 01/30/1991 , 01/30/1998 ,
QJJXYPPXXYFBGM-LFZNUXCKSA-N,445643,QJJXYPPXXYFBGM-LFZNUXCKSA-N,tacrolimus,,Treatment of pulmonary arterial hypertension.,C3203102,PULMONARY ARTERIAL HYPERTENSION,3/16/15,Designated,Not FDA Approved for Orphan Indication,,,,
WOXKDUGGOYFFRN-IIBYNOLFSA-N,110635,WOXKDUGGOYFFRN-IIBYNOLFSA-N,tadalafil,,Treatment of Duchenne Muscular Dystrophy (DMD),C0013264,DUCHENNE MUSCULAR DYSTROPHY,5/4/15,Designated,Not FDA Approved for Orphan Indication,,,,
TXEIIPDJKFWEEC-UHFFFAOYSA-N,11001318,TXEIIPDJKFWEEC-UHFFFAOYSA-N,tafamidis,,Treatment of familial amyloid polyneuropathy,C0206245,Familial Amyloid Polyneuropathy,5/23/06,Designated,Not FDA Approved for Orphan Indication,,,,
NYQPLPNEESYGNO-IBGZPJMESA-N,130731,NYQPLPNEESYGNO-IBGZPJMESA-N,Talotrexin,,Treatment of acute lymphoblastic leukemia,C0023449,Acute lymphoblastic leukemia,5/8/06,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
MUTNCGKQJGXKEM-UHFFFAOYSA-N,108143,MUTNCGKQJGXKEM-UHFFFAOYSA-N,Tamibarotene,,Treatment of acute promyelocytic leukemia (APL).,"C0023487,C1859592","Acute Promyelocytic Leukemia , APL",10/11/07,Designated,Not FDA Approved for Orphan Indication,,,,
PTOIAAWZLUQTIO-GXFFZTMASA-N,10220503,PTOIAAWZLUQTIO-GXFFZTMASA-N,tasimelteon,Hetlioz LQ,Treatment of the sleep disorder in Smith-Magenis syndrome associated with diurnal melatonin secretion.,"C0795864,C0851578","Smith-Magenis syndrome , Sleep disorder",4/30/10,Designated/Approved,,Treatment of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in pediatric patients 3 to 15 years of age, 12/01/2020 , 12/01/2027 ,Treatment of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in pediatric patients 3 to 15 years of age
NSQSAUGJQHDYNO-UHFFFAOYSA-N,66558664,NSQSAUGJQHDYNO-UHFFFAOYSA-N,tazemetostat,,Treatment of mesothelioma,C0025500,Mesothelioma,9/28/17,Designated,Not FDA Approved for Orphan Indication,,,,
NSQSAUGJQHDYNO-UHFFFAOYSA-N,66558664,NSQSAUGJQHDYNO-UHFFFAOYSA-N,tazemetostat,,Treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,6/15/17,Designated/Approved,,TAZVERIK is indicated for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection., 01/23/2020 , 01/23/2027 ,
CSKDFZIMJXRJGH-VWLPUNTISA-N,16124688,CSKDFZIMJXRJGH-VWLPUNTISA-N,tecovirimat,,post exposure prophylaxis against smallpox,C0037356,smallpox,12/18/06,Designated,Not FDA Approved for Orphan Indication,,,,
CSKDFZIMJXRJGH-VWLPUNTISA-N,16124688,CSKDFZIMJXRJGH-VWLPUNTISA-N,tecovirimat,TPOXX,Treatment of smallpox,C0037356,smallpox,12/27/06,Designated/Approved,,TPOXX is indicated for the treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 13 kg., 07/13/2018 , 07/13/2025 ,TPOXX is indicated for the treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 13 kg.
OGBMKVWORPGQRR-UMXFMPSGSA-N,16133850,OGBMKVWORPGQRR-UMXFMPSGSA-N,teriparatide,,Treatment of hypoparathyroidism,C0020626,Hypoparathyroidism,4/18/14,Designated,Not FDA Approved for Orphan Indication,,,,
BENFXAYNYRLAIU-QSVFAHTRSA-N,72081,BENFXAYNYRLAIU-QSVFAHTRSA-N,terlipressin,,Treatment of ascites due to all etiologies except cancer,C0003962,Ascites,9/8/16,Designated,Not FDA Approved for Orphan Indication,,,,
MODVSQKJJIBWPZ-VLLPJHQWSA-N,6918574,MODVSQKJJIBWPZ-VLLPJHQWSA-N,tesetaxel,,Treatment of gastric cancer,C0024623,Gastric Cancer,12/22/08,Designated,Not FDA Approved for Orphan Indication,,,,
MODVSQKJJIBWPZ-VLLPJHQWSA-N,6918574,MODVSQKJJIBWPZ-VLLPJHQWSA-N,tesetaxel,,"Treatment of stages IIB, IIC, III, and stage IV melanoma","C0278883,C4521788,C4553416","stage iv melanoma , IIB , IIC",11/21/08,Designated,Not FDA Approved for Orphan Indication,,,,
MKJIEFSOBYUXJB-UHFFFAOYSA-N,6018,MKJIEFSOBYUXJB-UHFFFAOYSA-N,tetrabenazine,,"Treatment of Tourette's Syndrome in school-age children, ages 5-16",C0040517,Tourette's Syndrome,7/1/09,Designated,Not FDA Approved for Orphan Indication,,,,
UEJJHQNACJXSKW-UHFFFAOYSA-N,5426,UEJJHQNACJXSKW-UHFFFAOYSA-N,Thalidomide,thalomid,Treatment of multiple myeloma,C0026764,Multiple Myeloma,10/14/98,Designated/Approved,,Treatment of patients with newly diagnosed multiple myeloma, 05/25/2006 , 05/25/2013 ,
UEJJHQNACJXSKW-UHFFFAOYSA-N,5426,UEJJHQNACJXSKW-UHFFFAOYSA-N,Thalidomide,,Treatment of Kaposi's sarcoma.,C0036220,Kaposi's Sarcoma,7/29/98,Designated,Not FDA Approved for Orphan Indication,,,,
UEJJHQNACJXSKW-UHFFFAOYSA-N,5426,UEJJHQNACJXSKW-UHFFFAOYSA-N,Thalidomide,,Treatment of Crohn's disease.,C0010346,Crohn's Disease,4/6/99,Designated,Not FDA Approved for Orphan Indication,,,,
UEJJHQNACJXSKW-UHFFFAOYSA-N,5426,UEJJHQNACJXSKW-UHFFFAOYSA-N,Thalidomide,,Treatment of HIV-associated wasting syndrome.,C0019682,HIV,3/11/96,Designated,Not FDA Approved for Orphan Indication,,,,
JTVPZMFULRWINT-UHFFFAOYSA-N,5467,JTVPZMFULRWINT-UHFFFAOYSA-N,Tiapride,,Treatment of Tourette's syndrome.,C0040517,Tourette's Syndrome,4/21/98,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PPKXEPBICJTCRU-XMZRARIVSA-N,63013,PPKXEPBICJTCRU-XMZRARIVSA-N,Tramadol hydrochloride,,Management of postherpetic neuralgia,C0032768,Postherpetic neuralgia,4/26/05,Designated,Not FDA Approved for Orphan Indication,,,,
RMDMBHQVNHQDDD-VFWKRBOSSA-L,10287099,RMDMBHQVNHQDDD-VFWKRBOSSA-L,trans sodium crocetinate,,Treatment of glioblastoma in conjunction with radiotherapy,C0017636,Glioblastoma,7/21/11,Designated,Not FDA Approved for Orphan Indication,,,,
PAJMKGZZBBTTOY-ZFORQUDYSA-N,6918140,PAJMKGZZBBTTOY-ZFORQUDYSA-N,treprostinil,Remodulin;Orenitram,Treatment of pulmonary arterial hypertension.,C3203102,PULMONARY ARTERIAL HYPERTENSION,6/4/97,Designated/Approved,,Orenitram is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity., 12/20/2013 , 12/20/2020 ,For treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity.
PAJMKGZZBBTTOY-ZFORQUDYSA-N,6918140,PAJMKGZZBBTTOY-ZFORQUDYSA-N,treprostinil,Remodulin;Orenitram,Treatment of pulmonary arterial hypertension.,C3203102,PULMONARY ARTERIAL HYPERTENSION,6/4/97,Designated/Approved,,Treatment of pulmonary arterial hypertension., 05/21/2002 , 05/21/2009 ,
SHGAZHPCJJPHSC-YCNIQYBTSA-N,444795,SHGAZHPCJJPHSC-YCNIQYBTSA-N,Tretinoin,,Treatment of acute and chronic leukemia.,C1279296,Chronic leukemia,1/14/93,Designated,Not FDA Approved for Orphan Indication,,,,
URLYINUFLXOMHP-HTVVRFAVSA-N,43860,URLYINUFLXOMHP-HTVVRFAVSA-N,Triciribine phosphate,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,4/24/17,Designated,Not FDA Approved for Orphan Indication,,,,
NQPDXQQQCQDHHW-UHFFFAOYSA-N,50248,NQPDXQQQCQDHHW-UHFFFAOYSA-N,triclabendazole,Egaten,Treatment of fascioliasis,C0015652,Fascioliasis,4/17/17,Designated/Approved,,EGATEN is indicated for the treatment of fascioliasis in patients 6 years of age and older., 02/13/2019 , 02/13/2026 ,EGATEN is indicated for the treatment of fascioliasis in patients 6 years of age and older.
OKHMDSCYUWAQPT-UHFFFAOYSA-N,71434,OKHMDSCYUWAQPT-UHFFFAOYSA-N,trientine tetrahydrochloride,,treatment of Wilsons disease,C0019202,Wilsons Disease,3/10/16,Designated,Not FDA Approved for Orphan Indication,,,,
ZCJXQWYMBJYJNB-UHFFFAOYSA-N,336805,ZCJXQWYMBJYJNB-UHFFFAOYSA-N,Trimetrexate glucuronate,,Treatment of pancreatic adenocarcinoma.,C0281361,Pancreatic adenocarcinoma,7/25/85,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
ZCJXQWYMBJYJNB-LRDBBFHQSA-N,54949,ZCJXQWYMBJYJNB-LRDBBFHQSA-N,Trimetrexate glucuronate,,Treatment of pancreatic adenocarcinoma.,C0281361,Pancreatic adenocarcinoma,7/25/85,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
VGGGPCQERPFHOB-RDBSUJKOSA-N,72172,VGGGPCQERPFHOB-RDBSUJKOSA-N,Ubenimex,,Treatment of Chronic Myeloid Leukemia,C0023473,Chronic myeloid leukemia,3/8/21,Designated,Not FDA Approved for Orphan Indication,,,,
VGGGPCQERPFHOB-RDBSUJKOSA-N,72172,VGGGPCQERPFHOB-RDBSUJKOSA-N,Ubenimex,,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,6/12/20,Designated,Not FDA Approved for Orphan Indication,,,,
IYFNEFQTYQPVOC-UHFFFAOYSA-N,135413547,IYFNEFQTYQPVOC-UHFFFAOYSA-N,udenafil,,Treatment of single ventricle congenital heart disease with Fontan physiology,"C0152021,C0152424","Congenital heart disease , Single ventricle",8/31/15,Designated,Not FDA Approved for Orphan Indication,,,,
WYQFJHHDOKWSHR-MNOVXSKESA-N,58557659,WYQFJHHDOKWSHR-MNOVXSKESA-N,upadacitinib,,Treatment of pediatric (aged 0 through 16 years) juvenile idiopathic arthritis (JIA) ILAR categories excluding systemic JIA,"C3495559,C3714757","juvenile idiopathic arthritis , Juvenile idiopathic arthritis",9/18/15,Designated,Not FDA Approved for Orphan Indication,,,,
HUASEDVYRABWCV-NDEPHWFRSA-N,90937527,HUASEDVYRABWCV-NDEPHWFRSA-N,upamostat,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,10/16/17,Designated,Not FDA Approved for Orphan Indication,,,,
HUASEDVYRABWCV-UHFFFAOYSA-N,72754524,HUASEDVYRABWCV-UHFFFAOYSA-N,upamostat,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,10/16/17,Designated,Not FDA Approved for Orphan Indication,,,,
HUASEDVYRABWCV-NDEPHWFRSA-N,90937527,HUASEDVYRABWCV-NDEPHWFRSA-N,upamostat,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,10/16/17,Designated,Not FDA Approved for Orphan Indication,,,,
HUASEDVYRABWCV-NDEPHWFRSA-N,90937527,HUASEDVYRABWCV-NDEPHWFRSA-N,upamostat,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,10/16/17,Designated,Not FDA Approved for Orphan Indication,,,,
ZOCKGBMQLCSHFP-KQRAQHLDSA-N,454216,ZOCKGBMQLCSHFP-KQRAQHLDSA-N,Valrubicin,Valstar,Treatment of carcinoma in situ of the urinary bladder.,C4551642,Carcinoma in situ of the Urinary Bladder,5/23/94,Designated/Approved,,For intravesical therapy of BCG-refractory carcinoma in situ of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality., 09/25/1998 , 09/25/2005 ,
SWXOGPJRIDTIRL-CISAEKETSA-N,133566183,SWXOGPJRIDTIRL-CISAEKETSA-N,vapreotide,,Treatment of gastrointestinal and pancreatic fistulas.,C0030290,Pancreatic Fistulas,1/10/00,Designated,Not FDA Approved for Orphan Indication,,,,
SWXOGPJRIDTIRL-HFQRKYADSA-N,5311370,SWXOGPJRIDTIRL-HFQRKYADSA-N,vapreotide,,Treatment of gastrointestinal and pancreatic fistulas.,C0030290,Pancreatic Fistulas,1/10/00,Designated,Not FDA Approved for Orphan Indication,,,,
SWXOGPJRIDTIRL-KTJGOPLGSA-N,70689318,SWXOGPJRIDTIRL-KTJGOPLGSA-N,vapreotide,,Treatment of gastrointestinal and pancreatic fistulas.,C0030290,Pancreatic Fistulas,1/10/00,Designated,Not FDA Approved for Orphan Indication,,,,
SWXOGPJRIDTIRL-DLRASJFKSA-N,45588099,SWXOGPJRIDTIRL-DLRASJFKSA-N,vapreotide,,Treatment of gastrointestinal and pancreatic fistulas.,C0030290,Pancreatic Fistulas,1/10/00,Designated,Not FDA Approved for Orphan Indication,,,,
SWXOGPJRIDTIRL-UHFFFAOYSA-N,71306,SWXOGPJRIDTIRL-UHFFFAOYSA-N,vapreotide,,Treatment of gastrointestinal and pancreatic fistulas.,C0030290,Pancreatic Fistulas,1/10/00,Designated,Not FDA Approved for Orphan Indication,,,,
SWXOGPJRIDTIRL-DOUNNPEJSA-N,6918026,SWXOGPJRIDTIRL-DOUNNPEJSA-N,vapreotide,,Treatment of gastrointestinal and pancreatic fistulas.,C0030290,Pancreatic Fistulas,1/10/00,Designated,Not FDA Approved for Orphan Indication,,,,
SWXOGPJRIDTIRL-CISAEKETSA-N,133566183,SWXOGPJRIDTIRL-CISAEKETSA-N,vapreotide,,Treatment of acromegaly,C0001206,Acromegaly,11/4/03,Designated,Not FDA Approved for Orphan Indication,,,,
SWXOGPJRIDTIRL-HFQRKYADSA-N,5311370,SWXOGPJRIDTIRL-HFQRKYADSA-N,vapreotide,,Treatment of acromegaly,C0001206,Acromegaly,11/4/03,Designated,Not FDA Approved for Orphan Indication,,,,
SWXOGPJRIDTIRL-KTJGOPLGSA-N,70689318,SWXOGPJRIDTIRL-KTJGOPLGSA-N,vapreotide,,Treatment of acromegaly,C0001206,Acromegaly,11/4/03,Designated,Not FDA Approved for Orphan Indication,,,,
SWXOGPJRIDTIRL-DLRASJFKSA-N,45588099,SWXOGPJRIDTIRL-DLRASJFKSA-N,vapreotide,,Treatment of acromegaly,C0001206,Acromegaly,11/4/03,Designated,Not FDA Approved for Orphan Indication,,,,
SWXOGPJRIDTIRL-UHFFFAOYSA-N,71306,SWXOGPJRIDTIRL-UHFFFAOYSA-N,vapreotide,,Treatment of acromegaly,C0001206,Acromegaly,11/4/03,Designated,Not FDA Approved for Orphan Indication,,,,
SWXOGPJRIDTIRL-DOUNNPEJSA-N,6918026,SWXOGPJRIDTIRL-DOUNNPEJSA-N,vapreotide,,Treatment of acromegaly,C0001206,Acromegaly,11/4/03,Designated,Not FDA Approved for Orphan Indication,,,,
BHLXTPHDSZUFHR-UHFFFAOYSA-N,155815,BHLXTPHDSZUFHR-UHFFFAOYSA-N,Varespladib,,Treatment of snakebite,C0037379,Snakebite,3/25/19,Designated,Not FDA Approved for Orphan Indication,,,,
XZZUHXILQXLTGV-UHFFFAOYSA-M,23674730,XZZUHXILQXLTGV-UHFFFAOYSA-M,varespladib sodium,,Prevention of acute chest syndrome in at-risk patients with sickle cell disease,"C0002895,C0742343","Sickle Cell Disease , Acute Chest Syndrome",11/19/07,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
VBUWHHLIZKOSMS-UHFFFAOYSA-N,16129679,VBUWHHLIZKOSMS-UHFFFAOYSA-N,Vasoactive intestinal polypeptide,,Treatment of acute esophageal food impaction.,C1695984,Esophageal food impaction,6/23/93,Designated,Not FDA Approved for Orphan Indication,,,,
LNOVHERIIMJMDG-XZXLULOTSA-N,46184405,LNOVHERIIMJMDG-XZXLULOTSA-N,vatiquinone,,Treatment of pontocerebellar hypoplasia,C0266468,Pontocerebellar Hypoplasia,10/18/17,Designated,Not FDA Approved for Orphan Indication,,,,
GPXBXXGIAQBQNI-UHFFFAOYSA-N,42611257,GPXBXXGIAQBQNI-UHFFFAOYSA-N,vemurafenib,,Treatment of hairy cell leukemia (HCL).,C0023443,Hairy Cell Leukemia,8/26/14,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,
PJDFLNIOAUIZSL-UHFFFAOYSA-N,5665,PJDFLNIOAUIZSL-UHFFFAOYSA-N,vigabatrin,Sabril,Treatment of infantile spasms.,C3887898,Infantile spasms,6/12/00,Designated/Approved,,For infantile spasms (IS) - 1 month to 2 years of age., 08/21/2009 , 08/21/2016 ,
WREGKURFCTUGRC-POYBYMJQSA-N,24066,WREGKURFCTUGRC-POYBYMJQSA-N,Zalcitabine,Hivid,Treatment of AIDS.,C0001175,AIDS,6/28/88,Designated/Approved,,Combination therapy with zidovudine is indicated for the treatment of adult patients with advanced HIV infection (CD4 count < 300) who have demonstrated malignant clinical or immunologic deterioration., 06/19/1992 , 06/19/1999 ,